<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <meta name="author" content="Dr. Siddalingaiah H S" />
  <title>Community Medicine Manual</title>
  <style>
    /* Default styles provided by pandoc.
    ** See https://pandoc.org/MANUAL.html#variables-for-html for config info.
    */
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
<header id="title-block-header">
<h1 class="title">Community Medicine Manual</h1>
<p class="author">Dr. Siddalingaiah H S</p>
</header>
<nav id="TOC" role="doc-toc">
<ul>
<li><a
href="#quick-revision-manual-of-community-medicine-for-mbbs-students"
id="toc-quick-revision-manual-of-community-medicine-for-mbbs-students">Quick
Revision Manual of Community Medicine for MBBS Students</a></li>
<li><a href="#preface" id="toc-preface">Preface</a>
<ul>
<li><a href="#purpose-and-scope" id="toc-purpose-and-scope">Purpose and
Scope</a></li>
<li><a href="#organization" id="toc-organization">Organization</a></li>
<li><a href="#target-audience" id="toc-target-audience">Target
Audience</a></li>
<li><a href="#how-to-use-this-manual"
id="toc-how-to-use-this-manual">How to Use This Manual</a></li>
</ul></li>
<li><a href="#table-of-contents" id="toc-table-of-contents">Table of
Contents</a>
<ul>
<li><a href="#part-i-concepts-in-public-health"
id="toc-part-i-concepts-in-public-health">Part I: Concepts in Public
Health</a></li>
<li><a href="#part-ii-environmental-health-sciences"
id="toc-part-ii-environmental-health-sciences">Part II: Environmental
Health Sciences</a></li>
<li><a href="#part-iii-nutrition-and-health"
id="toc-part-iii-nutrition-and-health">Part III: Nutrition and
Health</a></li>
<li><a href="#part-iv-maternal-and-child-health"
id="toc-part-iv-maternal-and-child-health">Part IV: Maternal and Child
Health</a></li>
<li><a href="#part-v-epidemiology-and-disease-control"
id="toc-part-v-epidemiology-and-disease-control">Part V: Epidemiology
and Disease Control</a></li>
<li><a href="#part-vi-communicable-diseases"
id="toc-part-vi-communicable-diseases">Part VI: Communicable
Diseases</a></li>
<li><a href="#part-vii-non-communicable-diseases"
id="toc-part-vii-non-communicable-diseases">Part VII: Non-Communicable
Diseases</a></li>
<li><a href="#part-viii-management-and-health-systems"
id="toc-part-viii-management-and-health-systems">Part VIII: Management
and Health Systems</a></li>
<li><a href="#part-ix-appendices-and-references"
id="toc-part-ix-appendices-and-references">Part IX: Appendices and
References</a></li>
</ul></li>
<li><a href="#part-i-concepts-in-public-health-1"
id="toc-part-i-concepts-in-public-health-1">Part I: Concepts in Public
Health</a>
<ul>
<li><a href="#community-medicine-quick-revision-manual"
id="toc-community-medicine-quick-revision-manual">Community Medicine
Quick Revision Manual</a></li>
<li><a href="#chapter-1-history-of-medicine"
id="toc-chapter-1-history-of-medicine">Chapter 1: History of
Medicine</a>
<ul>
<li><a href="#quick-facts-box" id="toc-quick-facts-box">üéØ QUICK FACTS
BOX</a></li>
<li><a href="#key-milestones-in-medical-history"
id="toc-key-milestones-in-medical-history">üèõÔ∏è KEY MILESTONES IN MEDICAL
HISTORY</a></li>
<li><a href="#important-figures-contributions"
id="toc-important-figures-contributions">üë• IMPORTANT FIGURES &amp;
CONTRIBUTIONS</a></li>
<li><a href="#quick-revision-timeline"
id="toc-quick-revision-timeline">üìÖ QUICK REVISION TIMELINE</a></li>
<li><a href="#rguhs-exam-highlights" id="toc-rguhs-exam-highlights">üéì
RGUHS EXAM HIGHLIGHTS</a></li>
<li><a href="#memory-aids-tips" id="toc-memory-aids-tips">üí° MEMORY AIDS
&amp; TIPS</a></li>
<li><a href="#exam-questions-important-points"
id="toc-exam-questions-important-points">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelines"
id="toc-references-to-latest-guidelines">üìö REFERENCES TO LATEST
GUIDELINES</a></li>
</ul></li>
<li><a href="#chapter-2-public-health-in-india"
id="toc-chapter-2-public-health-in-india">Chapter 2: Public Health in
India</a>
<ul>
<li><a href="#quick-facts-box-1" id="toc-quick-facts-box-1">üéØ QUICK
FACTS BOX</a></li>
<li><a href="#evolution-of-public-health-in-india"
id="toc-evolution-of-public-health-in-india">üèõÔ∏è EVOLUTION OF PUBLIC
HEALTH IN INDIA</a></li>
<li><a href="#major-public-health-achievements"
id="toc-major-public-health-achievements">üèÜ MAJOR PUBLIC HEALTH
ACHIEVEMENTS</a></li>
<li><a href="#current-health-challenges"
id="toc-current-health-challenges">‚ö†Ô∏è CURRENT HEALTH CHALLENGES</a></li>
<li><a href="#national-health-policies"
id="toc-national-health-policies">üìã NATIONAL HEALTH POLICIES</a></li>
<li><a href="#key-statistics-indicators-2023"
id="toc-key-statistics-indicators-2023">üìä KEY STATISTICS &amp;
INDICATORS (2023)</a></li>
<li><a href="#memory-aids-tips-1" id="toc-memory-aids-tips-1">üí° MEMORY
AIDS &amp; TIPS</a></li>
<li><a href="#exam-questions-important-points-1"
id="toc-exam-questions-important-points-1">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelines-1"
id="toc-references-to-latest-guidelines-1">üìö REFERENCES TO LATEST
GUIDELINES</a></li>
</ul></li>
<li><a href="#chapter-3-preventive-medicine"
id="toc-chapter-3-preventive-medicine">Chapter 3: Preventive
Medicine</a>
<ul>
<li><a href="#quick-facts-box-2" id="toc-quick-facts-box-2">üéØ QUICK
FACTS BOX</a></li>
<li><a href="#definition-concepts" id="toc-definition-concepts">üéØ
DEFINITION &amp; CONCEPTS</a></li>
<li><a href="#levels-of-prevention" id="toc-levels-of-prevention">üèîÔ∏è
LEVELS OF PREVENTION</a></li>
<li><a href="#natural-history-of-disease"
id="toc-natural-history-of-disease">üìà NATURAL HISTORY OF
DISEASE</a></li>
<li><a href="#risk-factors-risk-assessment"
id="toc-risk-factors-risk-assessment">‚öñÔ∏è RISK FACTORS &amp; RISK
ASSESSMENT</a></li>
<li><a href="#health-promotion-strategies"
id="toc-health-promotion-strategies">üí™ HEALTH PROMOTION
STRATEGIES</a></li>
<li><a href="#high-yield-examination-points"
id="toc-high-yield-examination-points">üí° HIGH-YIELD EXAMINATION
POINTS</a></li>
<li><a href="#exam-questions-important-points-2"
id="toc-exam-questions-important-points-2">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelies"
id="toc-references-to-latest-guidelies">üìö REFERENCES TO LATEST
GUIDELIES</a></li>
</ul></li>
<li><a href="#chapter-4-social-sciences"
id="toc-chapter-4-social-sciences">Chapter 4: Social Sciences</a>
<ul>
<li><a href="#quick-facts-box-3" id="toc-quick-facts-box-3">üéØ QUICK
FACTS BOX</a></li>
<li><a href="#social-determinants-of-health"
id="toc-social-determinants-of-health">üèòÔ∏è SOCIAL DETERMINANTS OF
HEALTH</a></li>
<li><a href="#cultural-factors-in-health"
id="toc-cultural-factors-in-health">üåç CULTURAL FACTORS IN
HEALTH</a></li>
<li><a href="#behavioral-sciences-in-medicine"
id="toc-behavioral-sciences-in-medicine">üß† BEHAVIORAL SCIENCES IN
MEDICINE</a></li>
<li><a href="#community-participation"
id="toc-community-participation">üë• COMMUNITY PARTICIPATION</a></li>
<li><a href="#social-epidemiology" id="toc-social-epidemiology">üìä
SOCIAL EPIDEMIOLOGY</a></li>
<li><a href="#social-security-and-health"
id="toc-social-security-and-health">üõ°Ô∏è SOCIAL SECURITY AND
HEALTH</a></li>
<li><a href="#memory-aids-tips-2" id="toc-memory-aids-tips-2">üí° MEMORY
AIDS &amp; TIPS</a></li>
<li><a href="#exam-questions-important-points-3"
id="toc-exam-questions-important-points-3">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelines-2"
id="toc-references-to-latest-guidelines-2">üìö REFERENCES TO LATEST
GUIDELINES</a></li>
</ul></li>
<li><a href="#conclusion" id="toc-conclusion">Conclusion</a>
<ul>
<li><a href="#key-takeaways" id="toc-key-takeaways">Key
Takeaways:</a></li>
<li><a href="#study-strategy" id="toc-study-strategy">Study
Strategy:</a></li>
</ul></li>
<li><a href="#chapter-5-environment-and-health"
id="toc-chapter-5-environment-and-health">Chapter 5: Environment and
Health</a>
<ul>
<li><a href="#quick-facts-box-4" id="toc-quick-facts-box-4">üéØ QUICK
FACTS BOX</a></li>
<li><a href="#environment-and-health-definition"
id="toc-environment-and-health-definition">üåç ENVIRONMENT AND HEALTH
DEFINITION</a></li>
<li><a href="#air-pollution-and-health-effects"
id="toc-air-pollution-and-health-effects">üí® AIR POLLUTION AND HEALTH
EFFECTS</a></li>
<li><a href="#water-pollution-and-diseases"
id="toc-water-pollution-and-diseases">üíß WATER POLLUTION AND
DISEASES</a></li>
<li><a href="#soil-contamination" id="toc-soil-contamination">üè≠ SOIL
CONTAMINATION</a></li>
<li><a href="#climate-change-and-health"
id="toc-climate-change-and-health">üå°Ô∏è CLIMATE CHANGE AND HEALTH</a></li>
<li><a href="#environmental-monitoring"
id="toc-environmental-monitoring">üî¨ ENVIRONMENTAL MONITORING</a></li>
<li><a href="#who-environmental-health-guidelines"
id="toc-who-environmental-health-guidelines">üèõÔ∏è WHO ENVIRONMENTAL HEALTH
GUIDELINES</a></li>
<li><a href="#memory-aids-tips-3" id="toc-memory-aids-tips-3">üí° MEMORY
AIDS &amp; TIPS</a></li>
<li><a href="#exam-questions-important-points-4"
id="toc-exam-questions-important-points-4">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelines-3"
id="toc-references-to-latest-guidelines-3">üìö REFERENCES TO LATEST
GUIDELINES</a></li>
</ul></li>
<li><a href="#chapter-6-air" id="toc-chapter-6-air">Chapter 6: Air</a>
<ul>
<li><a href="#quick-facts-box-5" id="toc-quick-facts-box-5">üéØ QUICK
FACTS BOX</a></li>
<li><a href="#air-quality-indices" id="toc-air-quality-indices">üìä AIR
QUALITY INDICES</a></li>
<li><a href="#pollutants-and-health-effects"
id="toc-pollutants-and-health-effects">üè≠ POLLUTANTS AND HEALTH
EFFECTS</a></li>
<li><a href="#indoor-air-pollution" id="toc-indoor-air-pollution">üè†
INDOOR AIR POLLUTION</a></li>
<li><a href="#industrial-air-pollution"
id="toc-industrial-air-pollution">üè≠ INDUSTRIAL AIR POLLUTION</a></li>
<li><a href="#vehicular-pollution-control"
id="toc-vehicular-pollution-control">üöó VEHICULAR POLLUTION
CONTROL</a></li>
<li><a href="#air-quality-standards" id="toc-air-quality-standards">üå¨Ô∏è
AIR QUALITY STANDARDS</a></li>
<li><a href="#memory-aids-tips-4" id="toc-memory-aids-tips-4">üí° MEMORY
AIDS &amp; TIPS</a></li>
<li><a href="#exam-questions-important-points-5"
id="toc-exam-questions-important-points-5">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelines-4"
id="toc-references-to-latest-guidelines-4">üìö REFERENCES TO LATEST
GUIDELINES</a></li>
</ul></li>
<li><a href="#chapter-7-water" id="toc-chapter-7-water">Chapter 7:
Water</a>
<ul>
<li><a href="#quick-facts-box-6" id="toc-quick-facts-box-6">üéØ QUICK
FACTS BOX</a></li>
<li><a href="#water-quality-parameters-1"
id="toc-water-quality-parameters-1">üíß WATER QUALITY PARAMETERS</a></li>
<li><a href="#water-borne-diseases-1" id="toc-water-borne-diseases-1">ü¶†
WATER-BORNE DISEASES</a></li>
<li><a href="#water-purification-processes"
id="toc-water-purification-processes">üè≠ WATER PURIFICATION
PROCESSES</a></li>
<li><a href="#safe-drinking-water-standards"
id="toc-safe-drinking-water-standards">üíß SAFE DRINKING WATER
STANDARDS</a></li>
<li><a href="#water-treatment-methods"
id="toc-water-treatment-methods">üè• WATER TREATMENT METHODS</a></li>
<li><a href="#fluorosis-and-other-water-related-disorders"
id="toc-fluorosis-and-other-water-related-disorders">ü¶¥ FLUOROSIS AND
OTHER WATER-RELATED DISORDERS</a></li>
<li><a href="#memory-aids-tips-5" id="toc-memory-aids-tips-5">üí° MEMORY
AIDS &amp; TIPS</a></li>
<li><a href="#exam-questions-important-points-6"
id="toc-exam-questions-important-points-6">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelines-5"
id="toc-references-to-latest-guidelines-5">üìö REFERENCES TO LATEST
GUIDELINES</a></li>
</ul></li>
<li><a href="#chapter-8-waste" id="toc-chapter-8-waste">Chapter 8:
Waste</a>
<ul>
<li><a href="#quick-facts-box-7" id="toc-quick-facts-box-7">üéØ QUICK
FACTS BOX</a></li>
<li><a href="#solid-waste-management" id="toc-solid-waste-management">‚ôªÔ∏è
SOLID WASTE MANAGEMENT</a></li>
<li><a href="#hospital-waste-management"
id="toc-hospital-waste-management">üè• HOSPITAL WASTE MANAGEMENT</a></li>
<li><a href="#biomedical-waste-rules" id="toc-biomedical-waste-rules">üè•
BIOMEDICAL WASTE RULES</a></li>
<li><a href="#liquid-waste-management"
id="toc-liquid-waste-management">üóëÔ∏è LIQUID WASTE MANAGEMENT</a></li>
<li><a href="#recycling-and-disposal-methods"
id="toc-recycling-and-disposal-methods">‚ôªÔ∏è RECYCLING AND DISPOSAL
METHODS</a></li>
<li><a href="#hazardous-waste-handling"
id="toc-hazardous-waste-handling">‚ö†Ô∏è HAZARDOUS WASTE HANDLING</a></li>
<li><a href="#memory-aids-tips-6" id="toc-memory-aids-tips-6">üí° MEMORY
AIDS &amp; TIPS</a></li>
<li><a href="#exam-questions-important-points-7"
id="toc-exam-questions-important-points-7">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelines-6"
id="toc-references-to-latest-guidelines-6">üìö REFERENCES TO LATEST
GUIDELINES</a></li>
</ul></li>
<li><a href="#chapter-9-housing" id="toc-chapter-9-housing">Chapter 9:
Housing</a>
<ul>
<li><a href="#quick-facts-box-8" id="toc-quick-facts-box-8">üéØ QUICK
FACTS BOX</a></li>
<li><a href="#housing-standards-and-health"
id="toc-housing-standards-and-health">üè† HOUSING STANDARDS AND
HEALTH</a></li>
<li><a href="#ventilation-and-lighting"
id="toc-ventilation-and-lighting">üå¨Ô∏è VENTILATION AND LIGHTING</a></li>
<li><a href="#overcrowding-effects" id="toc-overcrowding-effects">üë•
OVERCROWDING EFFECTS</a></li>
<li><a href="#slum-health-issues" id="toc-slum-health-issues">üèòÔ∏è SLUM
HEALTH ISSUES</a></li>
<li><a href="#housing-and-disease-transmission"
id="toc-housing-and-disease-transmission">üè† HOUSING AND DISEASE
TRANSMISSION</a></li>
<li><a href="#urban-health-problems" id="toc-urban-health-problems">üèôÔ∏è
URBAN HEALTH PROBLEMS</a></li>
<li><a href="#memory-aids-tips-7" id="toc-memory-aids-tips-7">üí° MEMORY
AIDS &amp; TIPS</a></li>
<li><a href="#exam-questions-important-points-8"
id="toc-exam-questions-important-points-8">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</a></li>
<li><a href="#references-to-latest-guidelines-7"
id="toc-references-to-latest-guidelines-7">üìö REFERENCES TO LATEST
GUIDELINES</a></li>
</ul></li>
<li><a href="#conclusion-1" id="toc-conclusion-1">Conclusion</a>
<ul>
<li><a href="#key-takeaways-1" id="toc-key-takeaways-1">Key
Takeaways:</a></li>
<li><a href="#study-strategy-1" id="toc-study-strategy-1">Study
Strategy:</a></li>
<li><a href="#examination-focus-areas"
id="toc-examination-focus-areas">Examination Focus Areas:</a></li>
</ul></li>
</ul></li>
<li><a href="#part-iii-nutrition-and-health-1"
id="toc-part-iii-nutrition-and-health-1">Part III: Nutrition and
Health</a>
<ul>
<li><a href="#chapter-10-nutrition-and-health"
id="toc-chapter-10-nutrition-and-health">Chapter 10: Nutrition and
Health</a></li>
<li><a href="#section-a-basic-nutrition-concepts"
id="toc-section-a-basic-nutrition-concepts">Section A: Basic Nutrition
Concepts</a>
<ul>
<li><a href="#macronutrients" id="toc-macronutrients">1.
Macronutrients</a></li>
<li><a href="#micronutrients" id="toc-micronutrients">2.
Micronutrients</a></li>
<li><a href="#caloric-requirements" id="toc-caloric-requirements">3.
Caloric Requirements</a></li>
<li><a href="#balanced-diet-principles"
id="toc-balanced-diet-principles">4. Balanced Diet Principles</a></li>
<li><a href="#recommended-dietary-allowances-rda---india-2020"
id="toc-recommended-dietary-allowances-rda---india-2020">5. Recommended
Dietary Allowances (RDA) - India 2020</a></li>
</ul></li>
<li><a href="#section-b-protein-energy-malnutrition"
id="toc-section-b-protein-energy-malnutrition">Section B: Protein-Energy
Malnutrition</a>
<ul>
<li><a href="#types-of-pem" id="toc-types-of-pem">1. Types of
PEM</a></li>
<li><a href="#anthropometric-measurements"
id="toc-anthropometric-measurements">2. Anthropometric
Measurements</a></li>
<li><a href="#assessment-methods" id="toc-assessment-methods">3.
Assessment Methods</a></li>
<li><a href="#prevention-strategies" id="toc-prevention-strategies">4.
Prevention Strategies</a></li>
<li><a href="#community-based-management"
id="toc-community-based-management">5. Community-Based
Management</a></li>
</ul></li>
<li><a href="#section-c-vitamin-deficiencies"
id="toc-section-c-vitamin-deficiencies">Section C: Vitamin
Deficiencies</a>
<ul>
<li><a href="#vitamin-a-deficiency" id="toc-vitamin-a-deficiency">1.
Vitamin A Deficiency</a></li>
<li><a href="#vitamin-d-deficiency" id="toc-vitamin-d-deficiency">2.
Vitamin D Deficiency</a></li>
<li><a href="#b-complex-deficiencies" id="toc-b-complex-deficiencies">3.
B-Complex Deficiencies</a></li>
<li><a href="#vitamin-c-deficiency---scurvy"
id="toc-vitamin-c-deficiency---scurvy">4. Vitamin C Deficiency -
Scurvy</a></li>
<li><a href="#iron-deficiency-anemia" id="toc-iron-deficiency-anemia">5.
Iron Deficiency Anemia</a></li>
<li><a href="#iodine-deficiency-disorders"
id="toc-iodine-deficiency-disorders">6. Iodine Deficiency
Disorders</a></li>
<li><a href="#zinc-deficiency" id="toc-zinc-deficiency">7. Zinc
Deficiency</a></li>
</ul></li>
<li><a href="#section-d-nutrition-in-special-groups"
id="toc-section-d-nutrition-in-special-groups">Section D: Nutrition in
Special Groups</a>
<ul>
<li><a href="#infant-and-child-nutrition"
id="toc-infant-and-child-nutrition">1. Infant and Child
Nutrition</a></li>
<li><a href="#adolescent-nutrition" id="toc-adolescent-nutrition">2.
Adolescent Nutrition</a></li>
<li><a href="#maternal-nutrition" id="toc-maternal-nutrition">3.
Maternal Nutrition</a></li>
<li><a href="#geriatric-nutrition" id="toc-geriatric-nutrition">4.
Geriatric Nutrition</a></li>
<li><a href="#sports-nutrition" id="toc-sports-nutrition">5. Sports
Nutrition</a></li>
</ul></li>
<li><a href="#section-e-food-safety-and-security"
id="toc-section-e-food-safety-and-security">Section E: Food Safety and
Security</a>
<ul>
<li><a href="#food-security-in-india" id="toc-food-security-in-india">1.
Food Security in India</a></li>
<li><a href="#public-distribution-system-pds"
id="toc-public-distribution-system-pds">2. Public Distribution System
(PDS)</a></li>
<li><a href="#nutrition-surveillance" id="toc-nutrition-surveillance">3.
Nutrition Surveillance</a></li>
<li><a href="#food-fortification-programs"
id="toc-food-fortification-programs">4. Food Fortification
Programs</a></li>
<li><a href="#food-adulteration-and-safety"
id="toc-food-adulteration-and-safety">5. Food Adulteration and
Safety</a></li>
</ul></li>
<li><a href="#section-f-nutrition-programs"
id="toc-section-f-nutrition-programs">Section F: Nutrition Programs</a>
<ul>
<li><a href="#national-nutrition-mission"
id="toc-national-nutrition-mission">1. National Nutrition
Mission</a></li>
<li><a href="#icds-program" id="toc-icds-program">2. ICDS
Program</a></li>
<li><a href="#poshan-abhiyaan" id="toc-poshan-abhiyaan">3. Poshan
Abhiyaan</a></li>
<li><a href="#world-food-program-initiatives"
id="toc-world-food-program-initiatives">4. World Food Program
Initiatives</a></li>
</ul></li>
<li><a href="#examination-important-points"
id="toc-examination-important-points">Examination Important Points</a>
<ul>
<li><a href="#mcq-hot-topics" id="toc-mcq-hot-topics">MCQ Hot
Topics</a></li>
<li><a href="#memory-aids" id="toc-memory-aids">Memory Aids</a></li>
</ul></li>
<li><a href="#anthropometric-charts-and-calculations"
id="toc-anthropometric-charts-and-calculations">Anthropometric Charts
and Calculations</a>
<ul>
<li><a href="#weight-for-age-charts" id="toc-weight-for-age-charts">1.
Weight-for-Age Charts</a></li>
<li><a href="#height-for-age-assessment"
id="toc-height-for-age-assessment">2. Height-for-Age Assessment</a></li>
<li><a href="#body-mass-index-bmi" id="toc-body-mass-index-bmi">3. Body
Mass Index (BMI)</a></li>
<li><a href="#mid-upper-arm-circumference-muac-1"
id="toc-mid-upper-arm-circumference-muac-1">4. Mid-Upper Arm
Circumference (MUAC)</a></li>
<li><a href="#z-score-calculations" id="toc-z-score-calculations">5.
Z-Score Calculations</a></li>
<li><a href="#growth-velocity-assessment"
id="toc-growth-velocity-assessment">6. Growth Velocity
Assessment</a></li>
</ul></li>
<li><a href="#recent-guidelines-and-policies"
id="toc-recent-guidelines-and-policies">Recent Guidelines and
Policies</a>
<ul>
<li><a href="#poshan-2.0-2021" id="toc-poshan-2.0-2021">1. POSHAN 2.0
(2021)</a></li>
<li><a href="#national-food-security-act-nfsa-2013"
id="toc-national-food-security-act-nfsa-2013">2. National Food Security
Act (NFSA) 2013</a></li>
<li><a href="#eat-right-india-movement"
id="toc-eat-right-india-movement">3. Eat Right India Movement</a></li>
<li><a href="#fssai-dietary-guidelines-for-indians-2016"
id="toc-fssai-dietary-guidelines-for-indians-2016">4. FSSAI Dietary
Guidelines for Indians (2016)</a></li>
</ul></li>
<li><a href="#clinical-case-studies"
id="toc-clinical-case-studies">Clinical Case Studies</a>
<ul>
<li><a href="#case-1-protein-energy-malnutrition"
id="toc-case-1-protein-energy-malnutrition">Case 1: Protein-Energy
Malnutrition</a></li>
<li><a href="#case-2-vitamin-a-deficiency"
id="toc-case-2-vitamin-a-deficiency">Case 2: Vitamin A
Deficiency</a></li>
<li><a href="#case-3-iron-deficiency-anemia"
id="toc-case-3-iron-deficiency-anemia">Case 3: Iron Deficiency
Anemia</a></li>
<li><a href="#case-4-iodine-deficiency-disorder"
id="toc-case-4-iodine-deficiency-disorder">Case 4: Iodine Deficiency
Disorder</a></li>
</ul></li>
<li><a href="#quick-reference-tables"
id="toc-quick-reference-tables">Quick Reference Tables</a>
<ul>
<li><a href="#anthropometric-reference-values"
id="toc-anthropometric-reference-values">Anthropometric Reference
Values</a></li>
<li><a href="#nutritional-requirements-2"
id="toc-nutritional-requirements-2">Nutritional Requirements</a></li>
<li><a href="#food-fortification-standards"
id="toc-food-fortification-standards">Food Fortification
Standards</a></li>
</ul></li>
<li><a href="#summary-and-key-takeaways"
id="toc-summary-and-key-takeaways">Summary and Key Takeaways</a>
<ul>
<li><a href="#critical-concepts-for-examinations"
id="toc-critical-concepts-for-examinations">Critical Concepts for
Examinations</a></li>
<li><a href="#high-yield-facts" id="toc-high-yield-facts">High-Yield
Facts</a></li>
<li><a href="#common-mcq-pitfalls" id="toc-common-mcq-pitfalls">Common
MCQ Pitfalls</a></li>
<li><a href="#essential-formulas" id="toc-essential-formulas">Essential
Formulas</a></li>
</ul></li>
</ul></li>
<li><a href="#part-iv-maternal-and-child-health-1"
id="toc-part-iv-maternal-and-child-health-1">Part IV: Maternal and Child
Health</a>
<ul>
<li><a href="#chapter-11-maternal-health"
id="toc-chapter-11-maternal-health">Chapter 11: Maternal Health</a>
<ul>
<li><a href="#section-a-reproductive-health"
id="toc-section-a-reproductive-health">Section A: Reproductive
Health</a></li>
<li><a href="#section-b-antenatal-care"
id="toc-section-b-antenatal-care">Section B: Antenatal Care</a></li>
<li><a href="#section-c-intranatal-care"
id="toc-section-c-intranatal-care">Section C: Intranatal Care</a></li>
<li><a href="#section-d-postnatal-care"
id="toc-section-d-postnatal-care">Section D: Postnatal Care</a></li>
</ul></li>
<li><a href="#chapter-12-child-health"
id="toc-chapter-12-child-health">Chapter 12: Child Health</a>
<ul>
<li><a href="#section-a-child-development"
id="toc-section-a-child-development">Section A: Child
Development</a></li>
<li><a href="#section-b-newborn-care"
id="toc-section-b-newborn-care">Section B: Newborn Care</a></li>
<li><a href="#section-c-common-childhood-problems"
id="toc-section-c-common-childhood-problems">Section C: Common Childhood
Problems</a></li>
</ul></li>
<li><a href="#chapter-13-geriatric-health"
id="toc-chapter-13-geriatric-health">Chapter 13: Geriatric Health</a>
<ul>
<li><a href="#section-a-aging-process"
id="toc-section-a-aging-process">Section A: Aging Process</a></li>
<li><a href="#section-b-geriatric-care"
id="toc-section-b-geriatric-care">Section B: Geriatric Care</a></li>
<li><a href="#section-c-common-geriatric-problems"
id="toc-section-c-common-geriatric-problems">Section C: Common Geriatric
Problems</a></li>
</ul></li>
<li><a href="#quick-calculation-methods"
id="toc-quick-calculation-methods">Quick Calculation Methods</a>
<ul>
<li><a href="#maternal-mortality-ratio-mmr"
id="toc-maternal-mortality-ratio-mmr">Maternal Mortality Ratio
(MMR)</a></li>
<li><a href="#infant-mortality-rate-imr"
id="toc-infant-mortality-rate-imr">Infant Mortality Rate (IMR)</a></li>
<li><a href="#under-five-mortality-rate-u5mr"
id="toc-under-five-mortality-rate-u5mr">Under-Five Mortality Rate
(U5MR)</a></li>
</ul></li>
<li><a href="#important-programs" id="toc-important-programs">Important
Programs</a>
<ul>
<li><a href="#janani-shishu-suraksha-karyakram-jssk"
id="toc-janani-shishu-suraksha-karyakram-jssk">Janani Shishu Suraksha
Karyakram (JSSK)</a></li>
<li><a href="#janani-suraksha-yojana-jsy"
id="toc-janani-suraksha-yojana-jsy">Janani Suraksha Yojana
(JSY)</a></li>
<li><a href="#mission-indradhanush"
id="toc-mission-indradhanush">Mission Indradhanush</a></li>
</ul></li>
<li><a href="#clinical-case-scenarios"
id="toc-clinical-case-scenarios">Clinical Case Scenarios</a>
<ul>
<li><a href="#case-1-high-risk-pregnancy"
id="toc-case-1-high-risk-pregnancy">Case 1: High-Risk Pregnancy</a></li>
<li><a href="#case-2-newborn-with-birth-asphyxia"
id="toc-case-2-newborn-with-birth-asphyxia">Case 2: Newborn with Birth
Asphyxia</a></li>
<li><a href="#case-3-elderly-patient-with-falls"
id="toc-case-3-elderly-patient-with-falls">Case 3: Elderly Patient with
Falls</a></li>
<li><a href="#case-4-child-with-severe-acute-malnutrition"
id="toc-case-4-child-with-severe-acute-malnutrition">Case 4: Child with
Severe Acute Malnutrition</a></li>
</ul></li>
<li><a href="#memory-aids-1" id="toc-memory-aids-1">Memory Aids</a>
<ul>
<li><a href="#anc-schedule-12-24-32-36"
id="toc-anc-schedule-12-24-32-36">ANC Schedule: ‚Äú12-24-32-36‚Äù</a></li>
<li><a href="#immunization-reminder-born-6-10-14"
id="toc-immunization-reminder-born-6-10-14">Immunization Reminder:
‚ÄúBORN-6-10-14‚Äù</a></li>
<li><a href="#child-development-2-6-9-12-18-24"
id="toc-child-development-2-6-9-12-18-24">Child Development:
‚Äú2-6-9-12-18-24‚Äù</a></li>
<li><a href="#geriatric-depression-scale-gds---5-item-version"
id="toc-geriatric-depression-scale-gds---5-item-version">Geriatric
Depression Scale (GDS) - 5-item Version</a></li>
</ul></li>
</ul></li>
<li><a href="#part-v-epidemiology-and-disease-control-1"
id="toc-part-v-epidemiology-and-disease-control-1">Part V: Epidemiology
and Disease Control</a>
<ul>
<li><a href="#chapter-14-epidemiology"
id="toc-chapter-14-epidemiology">Chapter 14: Epidemiology</a>
<ul>
<li><a href="#section-a-basic-concepts"
id="toc-section-a-basic-concepts">Section A: Basic Concepts</a></li>
<li><a href="#section-b-epidemiological-methods"
id="toc-section-b-epidemiological-methods">Section B: Epidemiological
Methods</a></li>
<li><a href="#section-c-measurements-in-epidemiology"
id="toc-section-c-measurements-in-epidemiology">Section C: Measurements
in Epidemiology</a></li>
</ul></li>
<li><a href="#chapter-15-clinical-epidemiology"
id="toc-chapter-15-clinical-epidemiology">Chapter 15: Clinical
Epidemiology</a>
<ul>
<li><a href="#section-a-diagnostic-tests"
id="toc-section-a-diagnostic-tests">Section A: Diagnostic Tests</a></li>
<li><a href="#section-b-clinical-trials"
id="toc-section-b-clinical-trials">Section B: Clinical Trials</a></li>
</ul></li>
<li><a href="#chapter-16-disease-control"
id="toc-chapter-16-disease-control">Chapter 16: Disease Control</a>
<ul>
<li><a href="#section-a-surveillance"
id="toc-section-a-surveillance">Section A: Surveillance</a></li>
<li><a href="#section-b-disease-elimination-and-eradication"
id="toc-section-b-disease-elimination-and-eradication">Section B:
Disease Elimination and Eradication</a></li>
<li><a href="#section-c-control-measures"
id="toc-section-c-control-measures">Section C: Control Measures</a></li>
</ul></li>
<li><a href="#epidemiological-calculations-with-step-by-step-examples"
id="toc-epidemiological-calculations-with-step-by-step-examples">Epidemiological
Calculations with Step-by-Step Examples</a>
<ul>
<li><a href="#example-1-basic-rates-calculation"
id="toc-example-1-basic-rates-calculation">Example 1: Basic Rates
Calculation</a></li>
<li><a href="#example-2-sensitivity-and-specificity-calculation"
id="toc-example-2-sensitivity-and-specificity-calculation">Example 2:
Sensitivity and Specificity Calculation</a></li>
<li><a href="#example-3-relative-risk-and-odds-ratio"
id="toc-example-3-relative-risk-and-odds-ratio">Example 3: Relative Risk
and Odds Ratio</a></li>
<li><a href="#example-4-standardization-calculation"
id="toc-example-4-standardization-calculation">Example 4:
Standardization Calculation</a></li>
</ul></li>
<li><a href="#current-surveillance-data-and-outbreak-examples"
id="toc-current-surveillance-data-and-outbreak-examples">Current
Surveillance Data and Outbreak Examples</a>
<ul>
<li><a href="#covid-19-surveillance-2024-data"
id="toc-covid-19-surveillance-2024-data">COVID-19 Surveillance (2024
Data)</a></li>
<li><a href="#recent-outbreak-examples"
id="toc-recent-outbreak-examples">Recent Outbreak Examples</a></li>
<li><a href="#idsp-reporting-format" id="toc-idsp-reporting-format">IDSP
Reporting Format</a></li>
</ul></li>
<li><a href="#memory-aids-for-epidemiological-measures"
id="toc-memory-aids-for-epidemiological-measures">Memory Aids for
Epidemiological Measures</a>
<ul>
<li><a href="#bradford-hill-criteria-mnemonic"
id="toc-bradford-hill-criteria-mnemonic">Bradford Hill Criteria
Mnemonic</a></li>
<li><a href="#epidemiological-rates-mnemonic"
id="toc-epidemiological-rates-mnemonic">Epidemiological Rates
Mnemonic</a></li>
<li><a href="#study-design-hierarchy"
id="toc-study-design-hierarchy">Study Design Hierarchy</a></li>
<li><a href="#bias-types-mnemonic" id="toc-bias-types-mnemonic">Bias
Types Mnemonic</a></li>
</ul></li>
<li><a href="#study-design-comparison-tables"
id="toc-study-design-comparison-tables">Study Design Comparison
Tables</a>
<ul>
<li><a href="#observational-studies-comparison"
id="toc-observational-studies-comparison">Observational Studies
Comparison</a></li>
<li><a href="#experimental-studies-comparison"
id="toc-experimental-studies-comparison">Experimental Studies
Comparison</a></li>
<li><a href="#screening-test-evaluation"
id="toc-screening-test-evaluation">Screening Test Evaluation</a></li>
</ul></li>
<li><a href="#application-of-bradford-hill-criteria-with-examples"
id="toc-application-of-bradford-hill-criteria-with-examples">Application
of Bradford Hill Criteria with Examples</a>
<ul>
<li><a href="#example-1-smoking-and-lung-cancer"
id="toc-example-1-smoking-and-lung-cancer">Example 1: Smoking and Lung
Cancer</a></li>
<li><a href="#example-2-vaccination-and-autism-false-association"
id="toc-example-2-vaccination-and-autism-false-association">Example 2:
Vaccination and Autism (False Association)</a></li>
<li><a href="#example-3-hiv-and-aids"
id="toc-example-3-hiv-and-aids">Example 3: HIV and AIDS</a></li>
</ul></li>
<li><a href="#key-examination-points-summary"
id="toc-key-examination-points-summary">Key Examination Points
Summary</a>
<ul>
<li><a href="#most-frequently-tested-concepts"
id="toc-most-frequently-tested-concepts">Most Frequently Tested
Concepts:</a></li>
<li><a href="#common-calculation-errors"
id="toc-common-calculation-errors">Common Calculation Errors:</a></li>
<li><a href="#answer-writing-tips" id="toc-answer-writing-tips">Answer
Writing Tips:</a></li>
</ul></li>
</ul></li>
<li><a href="#part-vi-communicable-diseases-1"
id="toc-part-vi-communicable-diseases-1">PART VI: COMMUNICABLE
DISEASES</a>
<ul>
<li><a href="#quick-revision-manual-for-community-medicine-mbbs"
id="toc-quick-revision-manual-for-community-medicine-mbbs">Quick
Revision Manual for Community Medicine (MBBS)</a></li>
<li><a href="#chapter-17-principles-of-communicable-disease-control"
id="toc-chapter-17-principles-of-communicable-disease-control">CHAPTER
17: PRINCIPLES OF COMMUNICABLE DISEASE CONTROL</a>
<ul>
<li><a href="#i.-chain-of-infection" id="toc-i.-chain-of-infection">I.
CHAIN OF INFECTION</a></li>
<li><a href="#ii.-modes-of-transmission"
id="toc-ii.-modes-of-transmission">II. MODES OF TRANSMISSION</a></li>
<li><a href="#iii.-host-parasite-relationships"
id="toc-iii.-host-parasite-relationships">III. HOST-PARASITE
RELATIONSHIPS</a></li>
<li><a href="#iv.-epidemiological-patterns"
id="toc-iv.-epidemiological-patterns">IV. EPIDEMIOLOGICAL
PATTERNS</a></li>
<li><a href="#v.-prevention-strategies"
id="toc-v.-prevention-strategies">V. PREVENTION STRATEGIES</a></li>
<li><a href="#vi.-control-measures" id="toc-vi.-control-measures">VI.
CONTROL MEASURES</a></li>
<li><a href="#vii.-quarantine-vs-isolation"
id="toc-vii.-quarantine-vs-isolation">VII. QUARANTINE VS
ISOLATION</a></li>
</ul></li>
<li><a href="#chapter-18-respiratory-infections"
id="toc-chapter-18-respiratory-infections">CHAPTER 18: RESPIRATORY
INFECTIONS</a>
<ul>
<li><a href="#i.-tuberculosis" id="toc-i.-tuberculosis">I.
TUBERCULOSIS</a></li>
<li><a href="#ii.-pneumonia" id="toc-ii.-pneumonia">II.
PNEUMONIA</a></li>
<li><a href="#iii.-influenza" id="toc-iii.-influenza">III.
INFLUENZA</a></li>
<li><a href="#iv.-measles-mumps-rubella-mmr"
id="toc-iv.-measles-mumps-rubella-mmr">IV. MEASLES, MUMPS, RUBELLA
(MMR)</a></li>
<li><a href="#v.-covid-19" id="toc-v.-covid-19">V. COVID-19</a></li>
</ul></li>
<li><a href="#chapter-19-intestinal-infections"
id="toc-chapter-19-intestinal-infections">CHAPTER 19: INTESTINAL
INFECTIONS</a>
<ul>
<li><a href="#i.-cholera" id="toc-i.-cholera">I. CHOLERA</a></li>
<li><a href="#ii.-typhoid-fever-enteric-fever"
id="toc-ii.-typhoid-fever-enteric-fever">II. TYPHOID FEVER (ENTERIC
FEVER)</a></li>
<li><a href="#iii.-food-poisoning" id="toc-iii.-food-poisoning">III.
FOOD POISONING</a></li>
<li><a href="#iv.-amoebiasis-and-giardiasis"
id="toc-iv.-amoebiasis-and-giardiasis">IV. AMOEBIASIS AND
GIARDIASIS</a></li>
<li><a href="#v.-viral-hepatitis-a-e" id="toc-v.-viral-hepatitis-a-e">V.
VIRAL HEPATITIS A &amp; E</a></li>
<li><a href="#vi.-poliomyelitis" id="toc-vi.-poliomyelitis">VI.
POLIOMYELITIS</a></li>
</ul></li>
<li><a href="#chapter-20-vector-borne-diseases"
id="toc-chapter-20-vector-borne-diseases">CHAPTER 20: VECTOR-BORNE
DISEASES</a>
<ul>
<li><a href="#i.-malaria" id="toc-i.-malaria">I. MALARIA</a></li>
<li><a href="#ii.-dengue-fever-and-dhf"
id="toc-ii.-dengue-fever-and-dhf">II. DENGUE FEVER AND DHF</a></li>
<li><a href="#iii.-chikungunya" id="toc-iii.-chikungunya">III.
CHIKUNGUNYA</a></li>
<li><a href="#iv.-japanese-encephalitis"
id="toc-iv.-japanese-encephalitis">IV. JAPANESE ENCEPHALITIS</a></li>
<li><a href="#v.-filariasis" id="toc-v.-filariasis">V.
FILARIASIS</a></li>
<li><a href="#vi.-leishmaniasis" id="toc-vi.-leishmaniasis">VI.
LEISHMANIASIS</a></li>
</ul></li>
<li><a href="#chapter-21-zoonoses" id="toc-chapter-21-zoonoses">CHAPTER
21: ZOONOSES</a>
<ul>
<li><a href="#i.-rabies" id="toc-i.-rabies">I. RABIES</a></li>
<li><a href="#ii.-anthrax" id="toc-ii.-anthrax">II. ANTHRAX</a></li>
<li><a href="#iii.-brucellosis" id="toc-iii.-brucellosis">III.
BRUCELLOSIS</a></li>
<li><a href="#iv.-leptospirosis" id="toc-iv.-leptospirosis">IV.
LEPTOSPIROSIS</a></li>
<li><a href="#v.-emerging-zoonoses" id="toc-v.-emerging-zoonoses">V.
EMERGING ZOONOSES</a></li>
</ul></li>
<li><a href="#chapter-22-surface-infections"
id="toc-chapter-22-surface-infections">CHAPTER 22: SURFACE
INFECTIONS</a>
<ul>
<li><a href="#i.-trachoma" id="toc-i.-trachoma">I. TRACHOMA</a></li>
<li><a href="#ii.-yaws" id="toc-ii.-yaws">II. YAWS</a></li>
<li><a href="#iii.-leprosy-hansens-disease"
id="toc-iii.-leprosy-hansens-disease">III. LEPROSY (HANSEN‚ÄôS
DISEASE)</a></li>
<li><a href="#iv.-scabies-and-other-skin-infections"
id="toc-iv.-scabies-and-other-skin-infections">IV. SCABIES AND OTHER
SKIN INFECTIONS</a></li>
</ul></li>
<li><a href="#chapter-23-sexually-transmitted-infections"
id="toc-chapter-23-sexually-transmitted-infections">CHAPTER 23: SEXUALLY
TRANSMITTED INFECTIONS</a>
<ul>
<li><a href="#i.-syphilis" id="toc-i.-syphilis">I. SYPHILIS</a></li>
<li><a href="#ii.-gonorrhea" id="toc-ii.-gonorrhea">II.
GONORRHEA</a></li>
<li><a href="#iii.-chlamydia" id="toc-iii.-chlamydia">III.
CHLAMYDIA</a></li>
<li><a href="#iv.-hivaids" id="toc-iv.-hivaids">IV. HIV/AIDS</a></li>
<li><a href="#v.-other-stis" id="toc-v.-other-stis">V. OTHER
STIs</a></li>
</ul></li>
<li><a href="#chapter-24-other-infections"
id="toc-chapter-24-other-infections">CHAPTER 24: OTHER INFECTIONS</a>
<ul>
<li><a href="#i.-tetanus" id="toc-i.-tetanus">I. TETANUS</a></li>
<li><a href="#ii.-viral-encephalitis"
id="toc-ii.-viral-encephalitis">II. VIRAL ENCEPHALITIS</a></li>
<li><a href="#iii.-meningococcal-infections"
id="toc-iii.-meningococcal-infections">III. MENINGOCOCCAL
INFECTIONS</a></li>
<li><a href="#iv.-viral-hemorrhagic-fevers"
id="toc-iv.-viral-hemorrhagic-fevers">IV. VIRAL HEMORRHAGIC
FEVERS</a></li>
</ul></li>
<li><a href="#chapter-25-disasters"
id="toc-chapter-25-disasters">CHAPTER 25: DISASTERS</a>
<ul>
<li><a href="#i.-natural-disasters" id="toc-i.-natural-disasters">I.
NATURAL DISASTERS</a></li>
<li><a href="#ii.-man-made-disasters"
id="toc-ii.-man-made-disasters">II. MAN-MADE DISASTERS</a></li>
<li><a href="#iii.-epidemics-during-disasters"
id="toc-iii.-epidemics-during-disasters">III. EPIDEMICS DURING
DISASTERS</a></li>
<li><a href="#iv.-emergency-medical-response"
id="toc-iv.-emergency-medical-response">IV. EMERGENCY MEDICAL
RESPONSE</a></li>
</ul></li>
<li><a href="#chapter-26-emerging-and-re-emerging-diseases"
id="toc-chapter-26-emerging-and-re-emerging-diseases">CHAPTER 26:
EMERGING AND RE-EMERGING DISEASES</a>
<ul>
<li><a href="#i.-covid-19-detailed" id="toc-i.-covid-19-detailed">I.
COVID-19 (DETAILED)</a></li>
<li><a href="#ii.-nipah-virus" id="toc-ii.-nipah-virus">II. NIPAH
VIRUS</a></li>
<li><a href="#iii.-ebola-virus-disease"
id="toc-iii.-ebola-virus-disease">III. EBOLA VIRUS DISEASE</a></li>
<li><a href="#iv.-antimicrobial-resistance-amr"
id="toc-iv.-antimicrobial-resistance-amr">IV. ANTIMICROBIAL RESISTANCE
(AMR)</a></li>
<li><a href="#v.-climate-change-and-infectious-diseases"
id="toc-v.-climate-change-and-infectious-diseases">V. CLIMATE CHANGE AND
INFECTIOUS DISEASES</a></li>
</ul></li>
<li><a href="#chapter-27-nosocomial-infections"
id="toc-chapter-27-nosocomial-infections">CHAPTER 27: NOSOCOMIAL
INFECTIONS</a>
<ul>
<li><a href="#i.-hospital-acquired-infections"
id="toc-i.-hospital-acquired-infections">I. HOSPITAL-ACQUIRED
INFECTIONS</a></li>
<li><a href="#ii.-infection-control-measures"
id="toc-ii.-infection-control-measures">II. INFECTION CONTROL
MEASURES</a></li>
<li><a href="#iii.-sterilization-and-disinfection"
id="toc-iii.-sterilization-and-disinfection">III. STERILIZATION AND
DISINFECTION</a></li>
<li><a href="#iv.-antibiotic-stewardship"
id="toc-iv.-antibiotic-stewardship">IV. ANTIBIOTIC STEWARDSHIP</a></li>
<li><a href="#v.-hospital-infection-control-committees"
id="toc-v.-hospital-infection-control-committees">V. HOSPITAL INFECTION
CONTROL COMMITTEES</a></li>
</ul></li>
<li><a href="#chapter-28-travel-medicine"
id="toc-chapter-28-travel-medicine">CHAPTER 28: TRAVEL MEDICINE</a>
<ul>
<li><a href="#i.-travel-related-diseases"
id="toc-i.-travel-related-diseases">I. TRAVEL-RELATED DISEASES</a></li>
<li><a href="#ii.-vaccination-requirements"
id="toc-ii.-vaccination-requirements">II. VACCINATION
REQUIREMENTS</a></li>
<li><a href="#iii.-malaria-prophylaxis"
id="toc-iii.-malaria-prophylaxis">III. MALARIA PROPHYLAXIS</a></li>
<li><a href="#iv.-travelers-health-advice"
id="toc-iv.-travelers-health-advice">IV. TRAVELER‚ÄôS HEALTH
ADVICE</a></li>
<li><a href="#v.-international-health-regulations"
id="toc-v.-international-health-regulations">V. INTERNATIONAL HEALTH
REGULATIONS</a></li>
</ul></li>
<li><a href="#examination-points---key-memory-aids"
id="toc-examination-points---key-memory-aids">EXAMINATION POINTS - KEY
MEMORY AIDS</a>
<ul>
<li><a href="#transmission-patterns"
id="toc-transmission-patterns">Transmission Patterns</a></li>
<li><a href="#drug-resistance-mnemonics"
id="toc-drug-resistance-mnemonics">Drug-Resistance Mnemonics</a></li>
<li><a href="#national-programme-abbreviations"
id="toc-national-programme-abbreviations">National Programme
Abbreviations</a></li>
<li><a href="#diagnostic-tests-1" id="toc-diagnostic-tests-1">Diagnostic
Tests</a></li>
<li><a href="#treatment-regimens" id="toc-treatment-regimens">Treatment
Regimens</a></li>
</ul></li>
</ul></li>
<li><a href="#part-vii-non-communicable-diseases-1"
id="toc-part-vii-non-communicable-diseases-1">Part VII: Non-Communicable
Diseases</a>
<ul>
<li><a
href="#chapter-29-non-communicable-diseases---epidemiology-and-control"
id="toc-chapter-29-non-communicable-diseases---epidemiology-and-control">Chapter
29: Non-Communicable Diseases - Epidemiology and Control</a>
<ul>
<li><a href="#section-a-overview-of-ncds"
id="toc-section-a-overview-of-ncds">Section A: Overview of NCDs</a></li>
<li><a href="#section-b-cardiovascular-diseases"
id="toc-section-b-cardiovascular-diseases">Section B: Cardiovascular
Diseases</a></li>
<li><a href="#section-c-diabetes-mellitus"
id="toc-section-c-diabetes-mellitus">Section C: Diabetes
Mellitus</a></li>
<li><a href="#section-d-cancer" id="toc-section-d-cancer">Section D:
Cancer</a></li>
</ul></li>
<li><a href="#chapter-30-mental-health"
id="toc-chapter-30-mental-health">Chapter 30: Mental Health</a>
<ul>
<li><a href="#section-a-mental-health-concepts"
id="toc-section-a-mental-health-concepts">Section A: Mental Health
Concepts</a></li>
<li><a href="#section-b-substance-abuse"
id="toc-section-b-substance-abuse">Section B: Substance Abuse</a></li>
<li><a href="#section-c-mental-health-promotion"
id="toc-section-c-mental-health-promotion">Section C: Mental Health
Promotion</a></li>
</ul></li>
<li><a href="#chapter-31-accidents-and-injuries"
id="toc-chapter-31-accidents-and-injuries">Chapter 31: Accidents and
Injuries</a>
<ul>
<li><a href="#section-a-road-traffic-accidents"
id="toc-section-a-road-traffic-accidents">Section A: Road Traffic
Accidents</a></li>
<li><a href="#section-b-other-injuries"
id="toc-section-b-other-injuries">Section B: Other Injuries</a></li>
<li><a href="#section-c-injury-prevention"
id="toc-section-c-injury-prevention">Section C: Injury
Prevention</a></li>
</ul></li>
<li><a href="#national-programs-and-initiatives"
id="toc-national-programs-and-initiatives">National Programs and
Initiatives</a>
<ul>
<li><a
href="#npcdcs-national-programme-for-prevention-and-control-of-cancer-diabetes-cardiovascular-diseases-and-stroke"
id="toc-npcdcs-national-programme-for-prevention-and-control-of-cancer-diabetes-cardiovascular-diseases-and-stroke">NPCDCS
(National Programme for Prevention and Control of Cancer, Diabetes,
Cardiovascular Diseases and Stroke)</a></li>
<li><a href="#nmhp-national-mental-health-programme"
id="toc-nmhp-national-mental-health-programme">NMHP (National Mental
Health Programme)</a></li>
<li><a href="#nrhm-mental-health-initiatives"
id="toc-nrhm-mental-health-initiatives">NRHM Mental Health
Initiatives</a></li>
<li><a href="#who-global-action-plans"
id="toc-who-global-action-plans">WHO Global Action Plans</a></li>
</ul></li>
<li><a href="#memory-aids-and-clinical-case-scenarios"
id="toc-memory-aids-and-clinical-case-scenarios">Memory Aids and
Clinical Case Scenarios</a>
<ul>
<li><a href="#memory-aids-2" id="toc-memory-aids-2">Memory Aids</a></li>
<li><a href="#clinical-case-scenarios-1"
id="toc-clinical-case-scenarios-1">Clinical Case Scenarios</a></li>
<li><a href="#examination-tips" id="toc-examination-tips">Examination
Tips</a></li>
</ul></li>
</ul></li>
<li><a href="#part-viii-management-and-health-systems-1"
id="toc-part-viii-management-and-health-systems-1">Part VIII: Management
and Health Systems</a>
<ul>
<li><a href="#chapter-32-health-management"
id="toc-chapter-32-health-management">Chapter 32: Health Management</a>
<ul>
<li><a href="#section-a-principles-of-management"
id="toc-section-a-principles-of-management">Section A: Principles of
Management</a></li>
<li><a href="#section-b-health-planning"
id="toc-section-b-health-planning">Section B: Health Planning</a></li>
<li><a href="#section-c-organization-of-health-services"
id="toc-section-c-organization-of-health-services">Section C:
Organization of Health Services</a></li>
</ul></li>
<li><a href="#chapter-33-health-economics"
id="toc-chapter-33-health-economics">Chapter 33: Health Economics</a>
<ul>
<li><a href="#section-a-health-economics-principles"
id="toc-section-a-health-economics-principles">Section A: Health
Economics Principles</a></li>
<li><a href="#section-b-health-financing"
id="toc-section-b-health-financing">Section B: Health Financing</a></li>
<li><a href="#section-c-health-technology-assessment"
id="toc-section-c-health-technology-assessment">Section C: Health
Technology Assessment</a></li>
</ul></li>
<li><a href="#chapter-34-health-system-in-india"
id="toc-chapter-34-health-system-in-india">Chapter 34: Health System in
India</a>
<ul>
<li><a href="#section-a-historical-perspective"
id="toc-section-a-historical-perspective">Section A: Historical
Perspective</a></li>
<li><a href="#section-b-current-health-system-structure"
id="toc-section-b-current-health-system-structure">Section B: Current
Health System Structure</a></li>
<li><a href="#section-c-major-health-programs"
id="toc-section-c-major-health-programs">Section C: Major Health
Programs</a></li>
<li><a href="#section-d-health-research-and-education"
id="toc-section-d-health-research-and-education">Section D: Health
Research and Education</a></li>
</ul></li>
<li><a href="#current-health-statistics-and-major-indicators"
id="toc-current-health-statistics-and-major-indicators">Current Health
Statistics and Major Indicators</a>
<ul>
<li><a href="#national-health-indicators-2022-23"
id="toc-national-health-indicators-2022-23">National Health Indicators
(2022-23)</a></li>
<li><a href="#health-expenditure-indicators-2021-22"
id="toc-health-expenditure-indicators-2021-22">Health Expenditure
Indicators (2021-22)</a></li>
<li><a href="#global-health-comparisons"
id="toc-global-health-comparisons">Global Health Comparisons</a></li>
</ul></li>
<li><a href="#memory-aids-for-committee-recommendations"
id="toc-memory-aids-for-committee-recommendations">Memory Aids for
Committee Recommendations</a>
<ul>
<li><a href="#bhore-committee-1943---memory-aid-pots"
id="toc-bhore-committee-1943---memory-aid-pots">Bhore Committee (1943) -
Memory Aid: ‚ÄúPOTS‚Äù</a></li>
<li><a href="#mudaliar-committee-1961---memory-aid-ships"
id="toc-mudaliar-committee-1961---memory-aid-ships">Mudaliar Committee
(1961) - Memory Aid: ‚ÄúSHIPS‚Äù</a></li>
<li><a href="#srivastava-committee---memory-aid-train"
id="toc-srivastava-committee---memory-aid-train">Srivastava Committee -
Memory Aid: ‚ÄúTRAIN‚Äù</a></li>
<li><a href="#committee-timeline-memory-aid-bms"
id="toc-committee-timeline-memory-aid-bms">Committee Timeline Memory
Aid: ‚ÄúBMS‚Äù</a></li>
</ul></li>
<li><a href="#case-studies-of-successful-health-programs"
id="toc-case-studies-of-successful-health-programs">Case Studies of
Successful Health Programs</a>
<ul>
<li><a href="#case-study-1-polio-eradication-program"
id="toc-case-study-1-polio-eradication-program">Case Study 1: Polio
Eradication Program</a></li>
<li><a href="#case-study-2-mission-indradhanush"
id="toc-case-study-2-mission-indradhanush">Case Study 2: Mission
Indradhanush</a></li>
<li><a href="#case-study-3-national-aids-control-program"
id="toc-case-study-3-national-aids-control-program">Case Study 3:
National AIDS Control Program</a></li>
</ul></li>
<li><a href="#examination-tips-and-high-yield-points"
id="toc-examination-tips-and-high-yield-points">Examination Tips and
High-Yield Points</a>
<ul>
<li><a href="#most-important-committees-for-exams"
id="toc-most-important-committees-for-exams">Most Important Committees
for Exams</a></li>
<li><a href="#national-health-programs---high-priority"
id="toc-national-health-programs---high-priority">National Health
Programs - High Priority</a></li>
<li><a href="#health-economics---important-concepts"
id="toc-health-economics---important-concepts">Health Economics -
Important Concepts</a></li>
<li><a href="#organization-of-health-services---key-points"
id="toc-organization-of-health-services---key-points">Organization of
Health Services - Key Points</a></li>
<li><a href="#quality-management-tools"
id="toc-quality-management-tools">Quality Management Tools</a></li>
</ul></li>
<li><a href="#budget-allocations-and-performance-indicators"
id="toc-budget-allocations-and-performance-indicators">Budget
Allocations and Performance Indicators</a>
<ul>
<li><a href="#union-health-budget-2023-24"
id="toc-union-health-budget-2023-24">Union Health Budget
(2023-24)</a></li>
<li><a href="#performance-indicators-and-targets"
id="toc-performance-indicators-and-targets">Performance Indicators and
Targets</a></li>
<li><a href="#global-health-comparisons-1"
id="toc-global-health-comparisons-1">Global Health Comparisons</a></li>
</ul></li>
</ul></li>
<li><a href="#part-ix-appendices-and-references-1"
id="toc-part-ix-appendices-and-references-1">Part IX: Appendices and
References</a>
<ul>
<li><a href="#community-medicine-quick-revision-manual-for-mbbs"
id="toc-community-medicine-quick-revision-manual-for-mbbs">Community
Medicine Quick Revision Manual for MBBS</a></li>
</ul></li>
<li><a href="#chapter-35-research-methodology"
id="toc-chapter-35-research-methodology">Chapter 35: Research
Methodology</a>
<ul>
<li><a href="#section-a-basic-research-concepts"
id="toc-section-a-basic-research-concepts">Section A: Basic Research
Concepts</a>
<ul>
<li><a href="#types-of-research" id="toc-types-of-research">Types of
Research</a></li>
<li><a href="#research-question-formulation"
id="toc-research-question-formulation">Research Question
Formulation</a></li>
<li><a href="#hypothesis-testing" id="toc-hypothesis-testing">Hypothesis
Testing</a></li>
<li><a href="#variable-definitions"
id="toc-variable-definitions">Variable Definitions</a></li>
<li><a href="#sampling-methods" id="toc-sampling-methods">Sampling
Methods</a></li>
<li><a href="#sample-size-calculation"
id="toc-sample-size-calculation">Sample Size Calculation</a></li>
<li><a href="#research-ethics-and-consent"
id="toc-research-ethics-and-consent">Research Ethics and
Consent</a></li>
</ul></li>
<li><a href="#section-b-data-collection-methods"
id="toc-section-b-data-collection-methods">Section B: Data Collection
Methods</a>
<ul>
<li><a href="#questionnaire-design"
id="toc-questionnaire-design">Questionnaire Design</a></li>
<li><a href="#interview-techniques"
id="toc-interview-techniques">Interview Techniques</a></li>
<li><a href="#observation-methods"
id="toc-observation-methods">Observation Methods</a></li>
<li><a href="#focus-group-discussions"
id="toc-focus-group-discussions">Focus Group Discussions</a></li>
<li><a href="#secondary-data-sources"
id="toc-secondary-data-sources">Secondary Data Sources</a></li>
<li><a href="#data-quality-assurance"
id="toc-data-quality-assurance">Data Quality Assurance</a></li>
</ul></li>
<li><a href="#section-c-data-analysis-and-interpretation"
id="toc-section-c-data-analysis-and-interpretation">Section C: Data
Analysis and Interpretation</a>
<ul>
<li><a href="#statistical-software-applications"
id="toc-statistical-software-applications">Statistical Software
Applications</a></li>
<li><a href="#descriptive-statistics"
id="toc-descriptive-statistics">Descriptive Statistics</a></li>
<li><a href="#inferential-statistics"
id="toc-inferential-statistics">Inferential Statistics</a></li>
<li><a href="#regression-analysis"
id="toc-regression-analysis">Regression Analysis</a></li>
<li><a href="#interpretation-of-results"
id="toc-interpretation-of-results">Interpretation of Results</a></li>
<li><a href="#report-writing-and-presentation"
id="toc-report-writing-and-presentation">Report Writing and
Presentation</a></li>
</ul></li>
</ul></li>
<li><a href="#chapter-36-biostatistics"
id="toc-chapter-36-biostatistics">Chapter 36: Biostatistics</a>
<ul>
<li><a href="#section-a-descriptive-statistics"
id="toc-section-a-descriptive-statistics">Section A: Descriptive
Statistics</a>
<ul>
<li><a href="#measures-of-central-tendency"
id="toc-measures-of-central-tendency">Measures of Central
Tendency</a></li>
<li><a href="#measures-of-dispersion"
id="toc-measures-of-dispersion">Measures of Dispersion</a></li>
<li><a href="#percentiles-and-quartiles"
id="toc-percentiles-and-quartiles">Percentiles and Quartiles</a></li>
<li><a href="#data-visualization" id="toc-data-visualization">Data
Visualization</a></li>
<li><a href="#normal-distribution-properties"
id="toc-normal-distribution-properties">Normal Distribution
Properties</a></li>
</ul></li>
<li><a href="#section-b-inferential-statistics"
id="toc-section-b-inferential-statistics">Section B: Inferential
Statistics</a>
<ul>
<li><a href="#probability-concepts"
id="toc-probability-concepts">Probability Concepts</a></li>
<li><a href="#hypothesis-testing-1"
id="toc-hypothesis-testing-1">Hypothesis Testing</a></li>
<li><a href="#confidence-intervals"
id="toc-confidence-intervals">Confidence Intervals</a></li>
<li><a href="#p-values-and-statistical-significance"
id="toc-p-values-and-statistical-significance">P-values and Statistical
Significance</a></li>
<li><a href="#statistical-tests-selection"
id="toc-statistical-tests-selection">Statistical Tests
Selection</a></li>
</ul></li>
<li><a href="#section-c-advanced-statistics"
id="toc-section-c-advanced-statistics">Section C: Advanced
Statistics</a>
<ul>
<li><a href="#correlation-and-regression"
id="toc-correlation-and-regression">Correlation and Regression</a></li>
<li><a href="#anova-analysis-of-variance"
id="toc-anova-analysis-of-variance">ANOVA (Analysis of
Variance)</a></li>
<li><a href="#survival-analysis" id="toc-survival-analysis">Survival
Analysis</a></li>
<li><a href="#logistic-regression" id="toc-logistic-regression">Logistic
Regression</a></li>
<li><a href="#meta-analysis-basics"
id="toc-meta-analysis-basics">Meta-analysis Basics</a></li>
<li><a href="#sample-size-calculations"
id="toc-sample-size-calculations">Sample Size Calculations</a></li>
</ul></li>
</ul></li>
<li><a href="#chapter-37-social-work-and-demography"
id="toc-chapter-37-social-work-and-demography">Chapter 37: Social Work
and Demography</a>
<ul>
<li><a href="#section-a-demography"
id="toc-section-a-demography">Section A: Demography</a>
<ul>
<li><a href="#population-dynamics"
id="toc-population-dynamics">Population Dynamics</a></li>
<li><a href="#demographic-transition-model"
id="toc-demographic-transition-model">Demographic Transition
Model</a></li>
<li><a href="#population-pyramids"
id="toc-population-pyramids">Population Pyramids</a></li>
<li><a href="#vital-statistics" id="toc-vital-statistics">Vital
Statistics</a></li>
<li><a href="#census-data-interpretation"
id="toc-census-data-interpretation">Census Data Interpretation</a></li>
<li><a href="#population-projections"
id="toc-population-projections">Population Projections</a></li>
</ul></li>
<li><a href="#section-b-social-work-principles"
id="toc-section-b-social-work-principles">Section B: Social Work
Principles</a>
<ul>
<li><a href="#social-work-in-healthcare"
id="toc-social-work-in-healthcare">Social Work in Healthcare</a></li>
<li><a href="#community-organization-methods"
id="toc-community-organization-methods">Community Organization
Methods</a></li>
<li><a href="#community-organization-methods-1"
id="toc-community-organization-methods-1">Community Organization
Methods</a></li>
<li><a href="#social-case-work-principles"
id="toc-social-case-work-principles">Social Case Work
Principles</a></li>
<li><a href="#group-work-approaches"
id="toc-group-work-approaches">Group Work Approaches</a></li>
<li><a href="#social-legislation-and-welfare"
id="toc-social-legislation-and-welfare">Social Legislation and
Welfare</a></li>
<li><a href="#social-security-systems-in-india"
id="toc-social-security-systems-in-india">Social Security Systems in
India</a></li>
</ul></li>
<li><a href="#section-c-health-demography"
id="toc-section-c-health-demography">Section C: Health Demography</a>
<ul>
<li><a href="#demographic-and-health-surveys"
id="toc-demographic-and-health-surveys">Demographic and Health
Surveys</a></li>
<li><a href="#fertility-and-mortality-patterns"
id="toc-fertility-and-mortality-patterns">Fertility and Mortality
Patterns</a></li>
<li><a href="#migration-and-health"
id="toc-migration-and-health">Migration and Health</a></li>
<li><a href="#urban-vs-rural-health-patterns"
id="toc-urban-vs-rural-health-patterns">Urban vs Rural Health
Patterns</a></li>
<li><a href="#health-transition" id="toc-health-transition">Health
Transition</a></li>
<li><a href="#policy-implications" id="toc-policy-implications">Policy
Implications</a></li>
</ul></li>
</ul></li>
<li><a href="#examination-tips-and-common-questions"
id="toc-examination-tips-and-common-questions">Examination Tips and
Common Questions</a>
<ul>
<li><a href="#research-methodology---quick-reference"
id="toc-research-methodology---quick-reference">Research Methodology -
Quick Reference</a></li>
<li><a href="#biostatistics---quick-reference"
id="toc-biostatistics---quick-reference">Biostatistics - Quick
Reference</a></li>
<li><a href="#demography-and-social-work---quick-reference"
id="toc-demography-and-social-work---quick-reference">Demography and
Social Work - Quick Reference</a></li>
</ul></li>
<li><a href="#current-research-trends-in-public-health"
id="toc-current-research-trends-in-public-health">Current Research
Trends in Public Health</a>
<ul>
<li><a href="#research-methodology-advances"
id="toc-research-methodology-advances">Research Methodology
Advances</a></li>
<li><a href="#biostatistics-innovations"
id="toc-biostatistics-innovations">Biostatistics Innovations</a></li>
<li><a href="#contemporary-demography"
id="toc-contemporary-demography">Contemporary Demography</a></li>
<li><a href="#social-work-evolution"
id="toc-social-work-evolution">Social Work Evolution</a></li>
</ul></li>
<li><a href="#practical-examples-and-calculations"
id="toc-practical-examples-and-calculations">Practical Examples and
Calculations</a>
<ul>
<li><a href="#research-methodology-examples"
id="toc-research-methodology-examples">Research Methodology
Examples</a></li>
<li><a href="#biostatistics-examples"
id="toc-biostatistics-examples">Biostatistics Examples</a></li>
<li><a href="#demography-examples"
id="toc-demography-examples">Demography Examples</a></li>
</ul></li>
<li><a href="#memory-aids-for-formulas-and-concepts"
id="toc-memory-aids-for-formulas-and-concepts">Memory Aids for Formulas
and Concepts</a>
<ul>
<li><a href="#statistical-formulas---mnemonics"
id="toc-statistical-formulas---mnemonics">Statistical Formulas -
Mnemonics</a></li>
<li><a href="#demography-formulas---mnemonics"
id="toc-demography-formulas---mnemonics">Demography Formulas -
Mnemonics</a></li>
<li><a href="#research-methodology---mnemonics"
id="toc-research-methodology---mnemonics">Research Methodology -
Mnemonics</a></li>
</ul></li>
<li><a href="#summary-tables-for-quick-revision"
id="toc-summary-tables-for-quick-revision">Summary Tables for Quick
Revision</a>
<ul>
<li><a href="#statistical-tests-comparison"
id="toc-statistical-tests-comparison">Statistical Tests
Comparison</a></li>
<li><a href="#demographic-indicators-reference"
id="toc-demographic-indicators-reference">Demographic Indicators
Reference</a></li>
<li><a href="#population-pyramid-characteristics"
id="toc-population-pyramid-characteristics">Population Pyramid
Characteristics</a></li>
<li><a href="#references-and-further-reading"
id="toc-references-and-further-reading">References and Further
Reading</a></li>
</ul></li>
<li><a href="#manual-back-matter-and-bibliography"
id="toc-manual-back-matter-and-bibliography">Manual Back Matter and
Bibliography</a>
<ul>
<li><a href="#community-medicine-quick-revision-manual-for-mbbs-1"
id="toc-community-medicine-quick-revision-manual-for-mbbs-1">Community
Medicine Quick Revision Manual for MBBS</a></li>
</ul></li>
<li><a href="#table-of-contents-1" id="toc-table-of-contents-1">Table of
Contents</a></li>
<li><a href="#bibliography-and-references"
id="toc-bibliography-and-references">Bibliography and References</a>
<ul>
<li><a href="#primary-sources" id="toc-primary-sources">Primary
Sources</a>
<ul>
<li><a href="#essential-textbooks"
id="toc-essential-textbooks">Essential Textbooks</a></li>
</ul></li>
<li><a href="#who-guidelines-and-publications"
id="toc-who-guidelines-and-publications">WHO Guidelines and
Publications</a>
<ul>
<li><a href="#core-who-documents" id="toc-core-who-documents">Core WHO
Documents</a></li>
</ul></li>
<li><a href="#government-of-india-health-reports-and-policies"
id="toc-government-of-india-health-reports-and-policies">Government of
India Health Reports and Policies</a>
<ul>
<li><a href="#central-government-documents"
id="toc-central-government-documents">Central Government
Documents</a></li>
<li><a href="#state-government-health-reports"
id="toc-state-government-health-reports">State Government Health
Reports</a></li>
</ul></li>
<li><a href="#national-health-program-documents"
id="toc-national-health-program-documents">National Health Program
Documents</a>
<ul>
<li><a href="#major-national-health-programs"
id="toc-major-national-health-programs">Major National Health
Programs</a></li>
</ul></li>
<li><a href="#recent-research-publications-and-journals"
id="toc-recent-research-publications-and-journals">Recent Research
Publications and Journals</a>
<ul>
<li><a href="#peer-reviewed-journals"
id="toc-peer-reviewed-journals">Peer-Reviewed Journals</a></li>
<li><a href="#recent-research-articles-2020-2024"
id="toc-recent-research-articles-2020-2024">Recent Research Articles
(2020-2024)</a></li>
</ul></li>
<li><a href="#medical-council-guidelines-and-regulations"
id="toc-medical-council-guidelines-and-regulations">Medical Council
Guidelines and Regulations</a>
<ul>
<li><a href="#medical-council-of-india"
id="toc-medical-council-of-india">Medical Council of India</a></li>
<li><a href="#professional-guidelines"
id="toc-professional-guidelines">Professional Guidelines</a></li>
</ul></li>
</ul></li>
<li><a href="#important-appendices"
id="toc-important-appendices">Important Appendices</a>
<ul>
<li><a href="#appendix-a-normal-values-and-reference-ranges"
id="toc-appendix-a-normal-values-and-reference-ranges">Appendix A:
Normal Values and Reference Ranges</a>
<ul>
<li><a href="#a.1-anthropometric-measurements"
id="toc-a.1-anthropometric-measurements">A.1 Anthropometric
Measurements</a></li>
<li><a href="#a.2-vital-signs" id="toc-a.2-vital-signs">A.2 Vital
Signs</a></li>
<li><a href="#a.3-laboratory-reference-values"
id="toc-a.3-laboratory-reference-values">A.3 Laboratory Reference
Values</a></li>
<li><a href="#a.4-immunological-parameters"
id="toc-a.4-immunological-parameters">A.4 Immunological
Parameters</a></li>
</ul></li>
<li><a href="#appendix-b-immunization-schedules"
id="toc-appendix-b-immunization-schedules">Appendix B: Immunization
Schedules</a>
<ul>
<li><a href="#b.1-national-immunization-schedule-india"
id="toc-b.1-national-immunization-schedule-india">B.1 National
Immunization Schedule (India)</a></li>
<li><a href="#b.2-who-immunization-schedule"
id="toc-b.2-who-immunization-schedule">B.2 WHO Immunization
Schedule</a></li>
<li><a href="#b.3-travel-immunization"
id="toc-b.3-travel-immunization">B.3 Travel Immunization</a></li>
</ul></li>
<li><a href="#appendix-c-anthropometric-charts-and-growth-standards"
id="toc-appendix-c-anthropometric-charts-and-growth-standards">Appendix
C: Anthropometric Charts and Growth Standards</a>
<ul>
<li><a href="#c.1-who-child-growth-standards-0-5-years"
id="toc-c.1-who-child-growth-standards-0-5-years">C.1 WHO Child Growth
Standards (0-5 years)</a></li>
<li><a href="#c.2-who-growth-references-5-19-years"
id="toc-c.2-who-growth-references-5-19-years">C.2 WHO Growth References
(5-19 years)</a></li>
<li><a href="#c.3-adult-nutritional-assessment"
id="toc-c.3-adult-nutritional-assessment">C.3 Adult Nutritional
Assessment</a></li>
</ul></li>
<li><a href="#appendix-d-statistical-formulas-and-calculations"
id="toc-appendix-d-statistical-formulas-and-calculations">Appendix D:
Statistical Formulas and Calculations</a>
<ul>
<li><a href="#d.1-descriptive-statistics"
id="toc-d.1-descriptive-statistics">D.1 Descriptive Statistics</a></li>
<li><a href="#d.2-inferential-statistics"
id="toc-d.2-inferential-statistics">D.2 Inferential Statistics</a></li>
<li><a href="#d.3-correlation-and-regression"
id="toc-d.3-correlation-and-regression">D.3 Correlation and
Regression</a></li>
<li><a href="#d.4-epidemiological-measures"
id="toc-d.4-epidemiological-measures">D.4 Epidemiological
Measures</a></li>
</ul></li>
<li><a href="#appendix-e-drug-dosages-and-treatment-protocols"
id="toc-appendix-e-drug-dosages-and-treatment-protocols">Appendix E:
Drug Dosages and Treatment Protocols</a>
<ul>
<li><a href="#e.1-common-antibiotic-dosages"
id="toc-e.1-common-antibiotic-dosages">E.1 Common Antibiotic
Dosages</a></li>
<li><a href="#e.2-antimalarial-treatment"
id="toc-e.2-antimalarial-treatment">E.2 Antimalarial Treatment</a></li>
<li><a href="#e.3-tuberculosis-treatment-who-guidelines"
id="toc-e.3-tuberculosis-treatment-who-guidelines">E.3 Tuberculosis
Treatment (WHO Guidelines)</a></li>
<li><a href="#e.4-hivaids-treatment-first-line"
id="toc-e.4-hivaids-treatment-first-line">E.4 HIV/AIDS Treatment (First
Line)</a></li>
<li><a href="#e.5-chronic-disease-management"
id="toc-e.5-chronic-disease-management">E.5 Chronic Disease
Management</a></li>
<li><a href="#e.6-emergency-medications"
id="toc-e.6-emergency-medications">E.6 Emergency Medications</a></li>
</ul></li>
<li><a href="#appendix-f-health-indicators-and-targets"
id="toc-appendix-f-health-indicators-and-targets">Appendix F: Health
Indicators and Targets</a>
<ul>
<li><a href="#f.1-sustainable-development-goals-sdgs"
id="toc-f.1-sustainable-development-goals-sdgs">F.1 Sustainable
Development Goals (SDGs)</a></li>
<li><a href="#f.2-national-health-policy-targets-2017"
id="toc-f.2-national-health-policy-targets-2017">F.2 National Health
Policy Targets (2017)</a></li>
<li><a href="#f.3-millennium-development-goals-mdgs-achievements"
id="toc-f.3-millennium-development-goals-mdgs-achievements">F.3
Millennium Development Goals (MDGs) Achievements</a></li>
<li><a href="#f.4-global-health-targets"
id="toc-f.4-global-health-targets">F.4 Global Health Targets</a></li>
</ul></li>
<li><a href="#appendix-g-emergency-contact-numbers-and-helplines"
id="toc-appendix-g-emergency-contact-numbers-and-helplines">Appendix G:
Emergency Contact Numbers and Helplines</a>
<ul>
<li><a href="#g.1-national-emergency-services"
id="toc-g.1-national-emergency-services">G.1 National Emergency
Services</a></li>
<li><a href="#g.2-health-program-helplines"
id="toc-g.2-health-program-helplines">G.2 Health Program
Helplines</a></li>
<li><a href="#g.3-disaster-management-contacts"
id="toc-g.3-disaster-management-contacts">G.3 Disaster Management
Contacts</a></li>
<li><a href="#g.4-health-service-providers"
id="toc-g.4-health-service-providers">G.4 Health Service
Providers</a></li>
<li><a href="#g.5-mental-health-support"
id="toc-g.5-mental-health-support">G.5 Mental Health Support</a></li>
<li><a href="#g.6-international-emergency-contacts"
id="toc-g.6-international-emergency-contacts">G.6 International
Emergency Contacts</a></li>
</ul></li>
<li><a href="#appendix-h-glossary-of-medical-terms"
id="toc-appendix-h-glossary-of-medical-terms">Appendix H: Glossary of
Medical Terms</a>
<ul>
<li><a href="#h.1-epidemiological-terms"
id="toc-h.1-epidemiological-terms">H.1 Epidemiological Terms</a></li>
<li><a href="#h.2-statistical-terms" id="toc-h.2-statistical-terms">H.2
Statistical Terms</a></li>
<li><a href="#h.3-public-health-terms"
id="toc-h.3-public-health-terms">H.3 Public Health Terms</a></li>
<li><a href="#h.4-clinical-terms" id="toc-h.4-clinical-terms">H.4
Clinical Terms</a></li>
<li><a href="#h.5-environmental-health-terms"
id="toc-h.5-environmental-health-terms">H.5 Environmental Health
Terms</a></li>
</ul></li>
</ul></li>
<li><a href="#quick-reference-tables-1"
id="toc-quick-reference-tables-1">Quick Reference Tables</a>
<ul>
<li><a href="#key-health-statistics-of-india-nfhs-5"
id="toc-key-health-statistics-of-india-nfhs-5">Key Health Statistics of
India (NFHS-5)</a>
<ul>
<li><a href="#demographic-indicators-1"
id="toc-demographic-indicators-1">Demographic Indicators</a></li>
<li><a href="#health-outcome-indicators"
id="toc-health-outcome-indicators">Health Outcome Indicators</a></li>
</ul></li>
<li><a href="#maternal-and-child-health-indicators"
id="toc-maternal-and-child-health-indicators">Maternal and Child Health
Indicators</a>
<ul>
<li><a href="#maternal-health-nfhs-5"
id="toc-maternal-health-nfhs-5">Maternal Health (NFHS-5)</a></li>
<li><a href="#child-health-nfhs-5" id="toc-child-health-nfhs-5">Child
Health (NFHS-5)</a></li>
</ul></li>
<li><a href="#disease-burden-statistics"
id="toc-disease-burden-statistics">Disease Burden Statistics</a>
<ul>
<li><a href="#leading-causes-of-death-2021"
id="toc-leading-causes-of-death-2021">Leading Causes of Death
(2021)</a></li>
<li><a href="#communicable-disease-burden"
id="toc-communicable-disease-burden">Communicable Disease
Burden</a></li>
</ul></li>
<li><a href="#health-program-coverage-data"
id="toc-health-program-coverage-data">Health Program Coverage Data</a>
<ul>
<li><a href="#national-health-programs-performance-2022-23"
id="toc-national-health-programs-performance-2022-23">National Health
Programs Performance (2022-23)</a></li>
<li><a href="#health-infrastructure-2"
id="toc-health-infrastructure-2">Health Infrastructure</a></li>
</ul></li>
<li><a href="#global-health-comparisons-2"
id="toc-global-health-comparisons-2">Global Health Comparisons</a>
<ul>
<li><a href="#india-vs-global-averages-2022"
id="toc-india-vs-global-averages-2022">India vs Global Averages
(2022)</a></li>
<li><a href="#comparison-with-brics-countries-2022"
id="toc-comparison-with-brics-countries-2022">Comparison with BRICS
Countries (2022)</a></li>
<li><a href="#health-system-performance-index"
id="toc-health-system-performance-index">Health System Performance
Index</a></li>
</ul></li>
</ul></li>
<li><a href="#index-preparation" id="toc-index-preparation">Index
Preparation</a>
<ul>
<li><a href="#alphabetical-index-of-important-terms"
id="toc-alphabetical-index-of-important-terms">Alphabetical Index of
Important Terms</a>
<ul>
<li><a href="#a" id="toc-a">A</a></li>
<li><a href="#b" id="toc-b">B</a></li>
<li><a href="#c" id="toc-c">C</a></li>
<li><a href="#d" id="toc-d">D</a></li>
<li><a href="#e" id="toc-e">E</a></li>
<li><a href="#f" id="toc-f">F</a></li>
<li><a href="#g" id="toc-g">G</a></li>
<li><a href="#h" id="toc-h">H</a></li>
<li><a href="#i" id="toc-i">I</a></li>
<li><a href="#l" id="toc-l">L</a></li>
<li><a href="#m" id="toc-m">M</a></li>
<li><a href="#n" id="toc-n">N</a></li>
<li><a href="#o" id="toc-o">O</a></li>
<li><a href="#p" id="toc-p">P</a></li>
<li><a href="#q" id="toc-q">Q</a></li>
<li><a href="#r" id="toc-r">R</a></li>
<li><a href="#s" id="toc-s">S</a></li>
<li><a href="#t" id="toc-t">T</a></li>
<li><a href="#u" id="toc-u">U</a></li>
<li><a href="#v" id="toc-v">V</a></li>
<li><a href="#w" id="toc-w">W</a></li>
</ul></li>
<li><a href="#index-of-diseases-and-conditions"
id="toc-index-of-diseases-and-conditions">Index of Diseases and
Conditions</a>
<ul>
<li><a href="#communicable-diseases-1"
id="toc-communicable-diseases-1">Communicable Diseases</a></li>
<li><a href="#non-communicable-diseases-1"
id="toc-non-communicable-diseases-1">Non-Communicable Diseases</a></li>
<li><a href="#maternal-and-child-health-conditions"
id="toc-maternal-and-child-health-conditions">Maternal and Child Health
Conditions</a></li>
<li><a href="#other-health-conditions"
id="toc-other-health-conditions">Other Health Conditions</a></li>
</ul></li>
<li><a href="#index-of-programs-and-policies"
id="toc-index-of-programs-and-policies">Index of Programs and
Policies</a>
<ul>
<li><a href="#national-health-programs"
id="toc-national-health-programs">National Health Programs</a></li>
<li><a href="#international-programs"
id="toc-international-programs">International Programs</a></li>
<li><a href="#health-insurance-schemes"
id="toc-health-insurance-schemes">Health Insurance Schemes</a></li>
<li><a href="#government-policies"
id="toc-government-policies">Government Policies</a></li>
</ul></li>
<li><a href="#index-of-statistical-measures"
id="toc-index-of-statistical-measures">Index of Statistical Measures</a>
<ul>
<li><a href="#descriptive-statistics-1"
id="toc-descriptive-statistics-1">Descriptive Statistics</a></li>
<li><a href="#inferential-statistics-1"
id="toc-inferential-statistics-1">Inferential Statistics</a></li>
<li><a href="#hypothesis-tests" id="toc-hypothesis-tests">Hypothesis
Tests</a></li>
<li><a href="#correlation-and-regression-1"
id="toc-correlation-and-regression-1">Correlation and
Regression</a></li>
<li><a href="#epidemiological-measures"
id="toc-epidemiological-measures">Epidemiological Measures</a></li>
</ul></li>
</ul></li>
</ul>
</nav>
<h1
id="quick-revision-manual-of-community-medicine-for-mbbs-students">Quick
Revision Manual of Community Medicine for MBBS Students</h1>
<hr />
<p><strong>Author:</strong><br />
Dr.¬†Siddalingaiah H S<br />
Professor, Community Medicine<br />
SIMSRH, Tumkur</p>
<p><strong>Contact Information:</strong><br />
Email: hssling@yahoo.com<br />
Phone: 8941087719</p>
<hr />
<h1 id="preface">Preface</h1>
<p>This Quick Revision Manual of Community Medicine has been
specifically designed for MBBS students preparing for the RGUHS (Rajiv
Gandhi University of Health Sciences) examination. The manual follows
the sequential approach of the renowned Park Textbook of Preventive and
Social Medicine, ensuring comprehensive coverage of all essential
topics.</p>
<h2 id="purpose-and-scope">Purpose and Scope</h2>
<p>This manual serves as a concise yet comprehensive revision tool that
focuses on high-yield content, examination-oriented concepts, and
clinically relevant applications of community medicine principles. It is
intended to supplement, not replace, the standard textbook reading.</p>
<h2 id="organization">Organization</h2>
<p>The content is organized following the Park textbook structure across
nine comprehensive parts, covering 37 chapters that encompass the entire
spectrum of community medicine. Each chapter includes:</p>
<ul>
<li>Key concepts and definitions</li>
<li>Important epidemiological principles</li>
<li>Prevention and control strategies</li>
<li>Clinical applications</li>
<li>Examination-focused points</li>
</ul>
<h2 id="target-audience">Target Audience</h2>
<p>This manual is primarily intended for: - MBBS students in their
community medicine posting - Students preparing for university
examinations - Candidates preparing for competitive medical entrance
examinations - Healthcare professionals seeking quick revision of public
health principles</p>
<h2 id="how-to-use-this-manual">How to Use This Manual</h2>
<p>For optimal results: 1. Use this manual for periodic revision after
studying the textbook 2. Focus on the highlighted key points and
examination tips 3. Practice with the clinical scenarios provided 4.
Cross-reference with the latest RGUHS examination patterns</p>
<p>This manual represents an effort to make community medicine learning
more accessible and examination-friendly while maintaining academic
rigor and clinical relevance.</p>
<p><em>Dr.¬†Siddalingaiah H S</em><br />
<em>Professor, Community Medicine</em><br />
<em>SIMSRH, Tumkur</em></p>
<hr />
<h1 id="table-of-contents">Table of Contents</h1>
<h2 id="part-i-concepts-in-public-health">Part I: Concepts in Public
Health</h2>
<p><strong>Chapter 1:</strong> Man and Medicine: Evolution of Modern
Medicine<br />
<strong>Chapter 2:</strong> Concept of Health and Disease<br />
<strong>Chapter 3:</strong> Determinants of Health<br />
<strong>Chapter 4:</strong> Introduction to Epidemiology</p>
<h2 id="part-ii-environmental-health-sciences">Part II: Environmental
Health Sciences</h2>
<p><strong>Chapter 5:</strong> Environment and Health<br />
<strong>Chapter 6:</strong> Water<br />
<strong>Chapter 7:</strong> Air<br />
<strong>Chapter 8:</strong> Waste<br />
<strong>Chapter 9:</strong> Housing and Ventilation</p>
<h2 id="part-iii-nutrition-and-health">Part III: Nutrition and
Health</h2>
<p><strong>Chapter 10:</strong> Nutrition and Health</p>
<h2 id="part-iv-maternal-and-child-health">Part IV: Maternal and Child
Health</h2>
<p><strong>Chapter 11:</strong> Reproductive and Child Health<br />
<strong>Chapter 12:</strong> Family Planning<br />
<strong>Chapter 13:</strong> School Health</p>
<h2 id="part-v-epidemiology-and-disease-control">Part V: Epidemiology
and Disease Control</h2>
<p><strong>Chapter 14:</strong> Principles of Epidemiology and
Epidemiological Methods<br />
<strong>Chapter 15:</strong> Epidemiology of Communicable Diseases<br />
<strong>Chapter 16:</strong> Epidemiology of Non-Communicable
Diseases</p>
<h2 id="part-vi-communicable-diseases">Part VI: Communicable
Diseases</h2>
<p><strong>Chapter 17:</strong> Respiratory Infections<br />
<strong>Chapter 18:</strong> Intestinal Infections<br />
<strong>Chapter 19:</strong> Arthropod-Borne Diseases<br />
<strong>Chapter 20:</strong> Zoonoses<br />
<strong>Chapter 21:</strong> Surface Infections<br />
<strong>Chapter 22:</strong> Viral Infections<br />
<strong>Chapter 23:</strong> Bacterial Infections<br />
<strong>Chapter 24:</strong> Other Infections<br />
<strong>Chapter 25:</strong> Curable Sexually Transmitted
Infections<br />
<strong>Chapter 26:</strong> HIV/AIDS<br />
<strong>Chapter 27:</strong> Tuberculosis<br />
<strong>Chapter 28:</strong> Leprosy</p>
<h2 id="part-vii-non-communicable-diseases">Part VII: Non-Communicable
Diseases</h2>
<p><strong>Chapter 29:</strong> Non-Communicable Diseases<br />
<strong>Chapter 30:</strong> Mental Health<br />
<strong>Chapter 31:</strong> Dental Health</p>
<h2 id="part-viii-management-and-health-systems">Part VIII: Management
and Health Systems</h2>
<p><strong>Chapter 32:</strong> Healthcare of the Community<br />
<strong>Chapter 33:</strong> National Health Programs<br />
<strong>Chapter 34:</strong> Healthcare Delivery in India</p>
<h2 id="part-ix-appendices-and-references">Part IX: Appendices and
References</h2>
<p><strong>Chapter 35:</strong> Appendices<br />
<strong>Chapter 36:</strong> Biotechnology and Public Health<br />
<strong>Chapter 37:</strong> Health of the Special Groups</p>
<hr />
<p><strong>Note:</strong> This manual is based on the current edition of
Park Textbook of Preventive and Social Medicine and follows the latest
RGUHS examination guidelines. Regular updates will be made to
incorporate new developments in the field of community medicine.</p>
<h1 id="part-i-concepts-in-public-health-1">Part I: Concepts in Public
Health</h1>
<h2 id="community-medicine-quick-revision-manual">Community Medicine
Quick Revision Manual</h2>
<hr />
<h2 id="chapter-1-history-of-medicine">Chapter 1: History of
Medicine</h2>
<h3 id="quick-facts-box">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Ancient Medicine</strong>: 3000 BCE - Egyptian, Greek, Roman
systems</li>
<li><strong>Modern Medicine</strong>: 19th century onwards - Scientific
revolution</li>
<li><strong>Preventive Focus</strong>: 20th century - Public health
emergence</li>
<li><strong>Key Revolution</strong>: Discovery of antibiotics, vaccines,
sanitation</li>
</ul>
<h3 id="key-milestones-in-medical-history">üèõÔ∏è KEY MILESTONES IN MEDICAL
HISTORY</h3>
<h4 id="pre-historic-ancient-period-3000-bce---500-ce">Pre-Historic
&amp; Ancient Period (3000 BCE - 500 CE)</h4>
<ul>
<li><strong>Egyptian Medicine</strong>: Papyrus Ebers (1550 BCE) - First
medical texts</li>
<li><strong>Hippocrates</strong> (460-370 BCE): Father of Medicine,
Hippocratic Oath</li>
<li><strong>Galen</strong> (130-200 CE): Roman physician, anatomical
studies</li>
<li><strong>Sushruta</strong> (600 BCE): Father of Surgery, Indian
medical system</li>
</ul>
<h4 id="medieval-period-500-1500-ce">Medieval Period (500-1500 CE)</h4>
<ul>
<li><strong>Islamic Medicine</strong>: Avicenna‚Äôs Canon of Medicine</li>
<li><strong>Medical Education</strong>: First universities (Bologna,
Salerno)</li>
<li><strong>Black Death (1347-1351)</strong>: Catalyzed public health
measures</li>
</ul>
<h4 id="renaissance-period-1500-1700">Renaissance Period
(1500-1700)</h4>
<ul>
<li><strong>Andreas Vesalius</strong>: Modern anatomy (1543)</li>
<li><strong>William Harvey</strong>: Blood circulation (1628)</li>
<li><strong>Paracelsus</strong>: Chemical medicine</li>
</ul>
<h4 id="th-century---public-health-emergence">18th Century - Public
Health Emergence</h4>
<ul>
<li><strong>John Snow (1854)</strong>: Cholera outbreak investigation,
Epidemiology birth</li>
<li><strong>Edwin Chadwick</strong>: Sanitary movement in England</li>
<li><strong>Jenner</strong>: Smallpox vaccination (1798)</li>
</ul>
<h4 id="th-century---scientific-medicine">19th Century - Scientific
Medicine</h4>
<ul>
<li><strong>Louis Pasteur</strong>: Germ theory (1860s)</li>
<li><strong>Robert Koch</strong>: Koch‚Äôs postulates (1882)</li>
<li><strong>Joseph Lister</strong>: Antiseptic surgery (1867)</li>
<li><strong>Florence Nightingale</strong>: Modern nursing, hospital
sanitation</li>
</ul>
<h4 id="th-century---preventive-medicine-revolution">20th Century -
Preventive Medicine Revolution</h4>
<ul>
<li><strong>Alexander Fleming</strong>: Penicillin discovery (1928)</li>
<li><strong>Jonas Salk</strong>: Polio vaccine (1955)</li>
<li><strong>WHO Founded</strong>: 1948</li>
<li><strong>Primary Health Care</strong>: Alma-Ata Declaration
(1978)</li>
</ul>
<h3 id="important-figures-contributions">üë• IMPORTANT FIGURES &amp;
CONTRIBUTIONS</h3>
<table>
<colgroup>
<col style="width: 9%" />
<col style="width: 12%" />
<col style="width: 20%" />
<col style="width: 56%" />
</colgroup>
<thead>
<tr>
<th>Name</th>
<th>Period</th>
<th>Contribution</th>
<th>Relevance to Preventive Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hippocrates</strong></td>
<td>460-370 BCE</td>
<td>Environmental causes of disease</td>
<td>Natural history concepts</td>
</tr>
<tr>
<td><strong>Avicenna</strong></td>
<td>980-1037 CE</td>
<td>Canon of Medicine</td>
<td>Systematic medical approach</td>
</tr>
<tr>
<td><strong>Edward Jenner</strong></td>
<td>1749-1823</td>
<td>Vaccination against smallpox</td>
<td>First immunization</td>
</tr>
<tr>
<td><strong>John Snow</strong></td>
<td>1813-1858</td>
<td>Disease mapping, epidemiology</td>
<td>Disease surveillance</td>
</tr>
<tr>
<td><strong>Louis Pasteur</strong></td>
<td>1822-1895</td>
<td>Germ theory</td>
<td>Disease prevention strategies</td>
</tr>
<tr>
<td><strong>Robert Koch</strong></td>
<td>1843-1910</td>
<td>Bacterial etiology</td>
<td>Disease causation</td>
</tr>
<tr>
<td><strong>Florence Nightingale</strong></td>
<td>1820-1910</td>
<td>Hospital sanitation, nursing</td>
<td>Infection control</td>
</tr>
<tr>
<td><strong>James Lind</strong></td>
<td>1716-1794</td>
<td>Scurvy prevention (citrus fruits)</td>
<td>Nutritional prevention</td>
</tr>
<tr>
<td><strong>John Snow</strong></td>
<td>1813-1858</td>
<td>Epidemiology, disease mapping</td>
<td>Modern public health</td>
</tr>
</tbody>
</table>
<h3 id="quick-revision-timeline">üìÖ QUICK REVISION TIMELINE</h3>
<p><strong>Ancient (3000 BCE - 500 CE)</strong> - 3000 BCE: Egyptian
medical texts - 460 BCE: Hippocrates - 600 BCE: Sushruta‚Äôs surgical
texts</p>
<p><strong>Medieval (500-1500 CE)</strong> - 1000 CE: Avicenna‚Äôs Canon -
1347: Black Death pandemic</p>
<p><strong>Renaissance (1500-1700)</strong> - 1543: Vesalius‚Äô anatomy -
1628: Harvey‚Äôs circulation</p>
<p><strong>18th Century (1700-1800)</strong> - 1798: Jenner‚Äôs
vaccination</p>
<p><strong>19th Century (1800-1900)</strong> - 1854: John Snow‚Äôs cholera
map - 1860s: Pasteur‚Äôs germ theory - 1882: Koch‚Äôs postulates</p>
<p><strong>20th Century (1900-2000)</strong> - 1928: Penicillin
discovery - 1948: WHO founding - 1978: Alma-Ata Declaration</p>
<h3 id="rguhs-exam-highlights">üéì RGUHS EXAM HIGHLIGHTS</h3>
<p><strong>Most Asked Questions:</strong> 1. Contributions of
Hippocrates to medicine 2. Jenner‚Äôs role in preventive medicine 3. John
Snow‚Äôs epidemiological investigation 4. Evolution of public health
concepts 5. Germ theory and its impact</p>
<p><strong>Expected Answers:</strong> - <strong>Hippocrates</strong>:
Environment-disease relationship, natural history -
<strong>Jenner</strong>: First vaccination, principles of immunization -
<strong>John Snow</strong>: Epidemiology, disease mapping, surveillance
- <strong>Pasteur</strong>: Germ theory, sterilization,
pasteurization</p>
<h3 id="memory-aids-tips">üí° MEMORY AIDS &amp; TIPS</h3>
<p><strong>SPAM Method for Historical Periods:</strong> -
<strong>S</strong>ocial context of each era -
<strong>P</strong>reventive innovations -
<strong>A</strong>ntibiotic/vaccine discoveries - <strong>M</strong>ajor
public health movements</p>
<p><strong>Acronym for Key Figures:</strong> - <strong>‚ÄúHIP
JPS‚Äù</strong> = Hippocrates, Jenner, Pasteur, Snow -
<strong>‚ÄúFANS‚Äù</strong> = Florence, Avicenna, Nightingale, Sushruta</p>
<p><strong>Timeline Memory Trick:</strong> - <strong>‚ÄúAncient Egyptian
Gods Have Great Skills‚Äù</strong> - <strong>A</strong>ncient (3000 BCE),
<strong>E</strong>gyptian, <strong>G</strong>alen,
<strong>H</strong>ippocrates, <strong>G</strong>erm theory,
<strong>S</strong>alk vaccine</p>
<h3 id="exam-questions-important-points">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Describe the evolution of
public health from ancient to modern times 2. Discuss the contributions
of Louis Pasteur to preventive medicine 3. Explain the role of
vaccination in disease prevention with historical examples 4. Analyze
the impact of germ theory on public health practices</p>
<p><strong>Short Answer Questions:</strong> 1. Hippocratic contributions
to medicine 2. Significance of John Snow‚Äôs cholera investigation 3.
Evolution of immunization 4. Role of Florence Nightingale in public
health</p>
<p><strong>MCQ Points:</strong> - Jenner = Smallpox vaccination - Snow =
Cholera epidemiology - Pasteur = Germ theory, pasteurization - Koch =
Bacterial causation</p>
<h3 id="references-to-latest-guidelines">üìö REFERENCES TO LATEST
GUIDELINES</h3>
<ul>
<li>WHO Traditional Medicine Strategy 2014-2023</li>
<li>National Health Policy 2017 (India)</li>
<li>CDC History of Medicine Timeline</li>
<li>RGUHS MBBS Curriculum Guidelines 2020</li>
</ul>
<hr />
<h2 id="chapter-2-public-health-in-india">Chapter 2: Public Health in
India</h2>
<h3 id="quick-facts-box-1">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Population</strong>: 1.4 billion (2023)</li>
<li><strong>Life Expectancy</strong>: 70.2 years (2023)</li>
<li><strong>Infant Mortality Rate</strong>: 28 per 1000 live births
(2022)</li>
<li><strong>Maternal Mortality Ratio</strong>: 97 per 100,000 live
births (2020-22)</li>
<li><strong>Current Health Expenditure</strong>: 2.1% of GDP</li>
</ul>
<h3 id="evolution-of-public-health-in-india">üèõÔ∏è EVOLUTION OF PUBLIC
HEALTH IN INDIA</h3>
<h4 id="ancient-period">Ancient Period</h4>
<ul>
<li><strong>Ayurveda</strong> (3000 BCE): Holistic health system</li>
<li><strong>Charaka Samhita</strong>: Preventive and curative
aspects</li>
<li><strong>Sushruta Samhita</strong>: Surgical practices</li>
<li><strong>Dhanvantari</strong>: God of Ayurveda</li>
</ul>
<h4 id="medieval-period-1200-1700-ce">Medieval Period (1200-1700
CE)</h4>
<ul>
<li><strong>Unani System</strong>: Arab and Persian influences</li>
<li><strong>Mughal Period</strong>: Integration of medical systems</li>
<li><strong>Local Traditions</strong>: Folk medicine practices</li>
</ul>
<h4 id="colonial-period-1757-1947">Colonial Period (1757-1947)</h4>
<ul>
<li><strong>East India Company</strong>: Medical services for
Europeans</li>
<li><strong>Medical Colleges</strong>: Calcutta (1835), Madras (1835),
Bombay (1845)</li>
<li><strong>Plague Commission (1899)</strong>: First public health
legislation</li>
<li><strong>Health Organization</strong>: Central Health Authority
(1925)</li>
</ul>
<h4 id="post-independence-era-1947-onwards">Post-Independence Era (1947
onwards)</h4>
<ul>
<li><strong>Bhore Committee (1946)</strong>: Revolutionary health
planning</li>
<li><strong>Primary Health Centre (PHC)</strong>: 1952</li>
<li><strong>National Health Policies</strong>: 1983, 2002, 2017</li>
<li><strong>Millennium Development Goals</strong>: 2000-2015</li>
<li><strong>Sustainable Development Goals</strong>: 2015-2030</li>
</ul>
<h3 id="major-public-health-achievements">üèÜ MAJOR PUBLIC HEALTH
ACHIEVEMENTS</h3>
<h4 id="disease-eliminationeradication">Disease
Elimination/Eradication</h4>
<ul>
<li><strong>Smallpox</strong>: Eradicated (1975)</li>
<li><strong>Polio</strong>: Near eradication (2023 - 12 cases)</li>
<li><strong>Yaws</strong>: Elimination status (2017)</li>
<li><strong>Maternal &amp; Neonatal Tetanus</strong>: Elimination
(2015)</li>
</ul>
<h4 id="vaccination-programs">Vaccination Programs</h4>
<ul>
<li><strong>Universal Immunization Programme (1985)</strong>
<ul>
<li>BCG, DPT, OPV, Measles</li>
<li>Coverage: 76% (2022)</li>
</ul></li>
<li><strong>Mission Indradhanush</strong> (2014): Intensified
immunization</li>
</ul>
<h4 id="health-infrastructure">Health Infrastructure</h4>
<ul>
<li><strong>PHCs</strong>: 31,490 (as of 2023)</li>
<li><strong>CHCs</strong>: 5,649 (as of 2023)</li>
<li><strong>Sub-centres</strong>: 161,598 (as of 2023)</li>
<li><strong>AYUSH Facilities</strong>: 3,844 hospitals</li>
</ul>
<h4 id="mortality-reduction">Mortality Reduction</h4>
<ul>
<li><strong>Infant Mortality</strong>: 198/1000 (1970) ‚Üí 28/1000
(2022)</li>
<li><strong>Under-5 Mortality</strong>: 183/1000 (1970) ‚Üí 32/1000
(2020)</li>
<li><strong>Maternal Mortality</strong>: 212/100,,000 (2007) ‚Üí
97/100,000 (2020-22)</li>
</ul>
<h3 id="current-health-challenges">‚ö†Ô∏è CURRENT HEALTH CHALLENGES</h3>
<h4 id="communicable-diseases">Communicable Diseases</h4>
<ul>
<li><strong>Tuberculosis</strong>: 2.8 million cases annually</li>
<li><strong>Malaria</strong>: 0.1 million cases (2022)</li>
<li><strong>Dengue</strong>: 110,000 cases (2022)</li>
<li><strong>COVID-19</strong>: 44.7 million cases (2023)</li>
</ul>
<h4 id="non-communicable-diseases">Non-Communicable Diseases</h4>
<ul>
<li><strong>Diabetes</strong>: 77 million people</li>
<li><strong>Hypertension</strong>: 200 million people</li>
<li><strong>Cancer</strong>: 1.4 million new cases annually</li>
<li><strong>Mental Health</strong>: 200 million people affected</li>
</ul>
<h4 id="health-system-challenges">Health System Challenges</h4>
<ul>
<li><strong>Rural-Urban Divide</strong>: 70% population in rural
areas</li>
<li><strong>Shortage of Health Workers</strong>: 2.3 million
deficit</li>
<li><strong>Out-of-Pocket Expenditure</strong>: 60% of total health
spending</li>
<li><strong>Quality of Care</strong>: Uneven distribution of
services</li>
</ul>
<h3 id="national-health-policies">üìã NATIONAL HEALTH POLICIES</h3>
<h4 id="national-health-policy-2017">National Health Policy 2017</h4>
<p><strong>Goals:</strong> - Increase health expenditure to 2.5% of GDP
- Life expectancy to 70+ years - Reduce IMR to 28/1000 - Reduce MMR to
100/100,000</p>
<p><strong>Strategic Priorities:</strong> - Primary healthcare
strengthening - Digital health mission - AYUSH integration - Public
health cadre creation</p>
<h4 id="ayushman-bharat-2018">Ayushman Bharat (2018)</h4>
<p><strong>Components:</strong> 1. <strong>Health and Wellness
Centres</strong>: 150,000 by 2022 2. <strong>Pradhan Mantri Jan Arogya
Yojana</strong>: ‚Çπ5 lakh insurance</p>
<h4 id="national-digital-health-mission-2020">National Digital Health
Mission (2020)</h4>
<p><strong>Vision</strong>: Digital health ecosystem
<strong>Components</strong>: Health ID, telemedicine, health records</p>
<h3 id="key-statistics-indicators-2023">üìä KEY STATISTICS &amp;
INDICATORS (2023)</h3>
<h4 id="demographic-indicators">Demographic Indicators</h4>
<ul>
<li><strong>Population</strong>: 1.4 billion</li>
<li><strong>Growth Rate</strong>: 0.9% annually</li>
<li><strong>Urbanization</strong>: 35% urban population</li>
<li><strong>Sex Ratio</strong>: 943 females per 1000 males</li>
</ul>
<h4 id="health-infrastructure-1">Health Infrastructure</h4>
<ul>
<li><strong>Government Hospitals</strong>: 25,778</li>
<li><strong>Government Beds</strong>: 713,996</li>
<li><strong>Private Hospitals</strong>: 43,486</li>
<li><strong>AYUSH Facilities</strong>: 3,844 hospitals</li>
</ul>
<h4 id="health-financing">Health Financing</h4>
<ul>
<li><strong>Total Health Expenditure</strong>: 2.1% of GDP</li>
<li><strong>Government Expenditure</strong>: 0.9% of GDP</li>
<li><strong>Private Expenditure</strong>: 1.2% of GDP</li>
<li><strong>OOP Expenditure</strong>: 60% of total health spending</li>
</ul>
<h4 id="disease-burden">Disease Burden</h4>
<ul>
<li>** Communicable Diseases**: 15% of total burden</li>
<li><strong>NCDs</strong>: 65% of total burden</li>
<li><strong>Injuries</strong>: 12% of total burden</li>
<li><strong>Maternal/Pediatric</strong>: 8% of total burden</li>
</ul>
<h3 id="memory-aids-tips-1">üí° MEMORY AIDS &amp; TIPS</h3>
<p><strong>‚ÄúBHORE-COMMA‚Äù for Health Policy Evolution:</strong> -
<strong>B</strong>hore Committee (1946) - <strong>H</strong>ealth for
All concept - <strong>O</strong>perational research -
<strong>R</strong>evised National TB Control Programme -
<strong>E</strong>ight Five Year Plans</p>
<p><strong>‚ÄúSMART-GOAL‚Äù for NHP 2017:</strong> -
<strong>S</strong>ustainable financing - <strong>M</strong>ulti-sectoral
approach - <strong>A</strong>ccessible healthcare -
<strong>R</strong>egulatory mechanisms - <strong>T</strong>echnology
integration</p>
<p><strong>‚ÄúCHALLENGES‚Äù Acronym:</strong> -
<strong>C</strong>ommunicable diseases - <strong>H</strong>eart disease
prevalence - <strong>A</strong>ging population -
<strong>L</strong>ifestyle diseases - <strong>E</strong>conomic burden -
<strong>N</strong>utrition challenges - <strong>G</strong>eographic
disparities - <strong>E</strong>nvironmental health -
<strong>S</strong>hortage of workforce</p>
<h3 id="exam-questions-important-points-1">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Discuss the evolution of
public health in India since independence 2. Analyze the achievements
and challenges of National Health Policy 2017 3. Describe the role of
Ayushman Bharat in improving healthcare access 4. Evaluate the progress
of vaccination programs in India</p>
<p><strong>Short Answer Questions:</strong> 1. Achievements of National
Vector Borne Disease Control Programme 2. Role of PHCs in rural
healthcare delivery 3. Current status of TB control in India 4. Impact
of Mission Indradhanush</p>
<p><strong>MCQ Points:</strong> - Smallpox eradication: 1975 - PHC
established: 1952 - First medical college: Calcutta (1835) - Current
health expenditure: 2.1% of GDP</p>
<h3 id="references-to-latest-guidelines-1">üìö REFERENCES TO LATEST
GUIDELINES</h3>
<ul>
<li>National Health Policy 2017</li>
<li>National Family Health Survey-5 (2019-21)</li>
<li>Ayushman Bharat Annual Report 2023</li>
<li>India Health Report 2023</li>
<li>RGUHS Community Medicine Curriculum 2020</li>
</ul>
<hr />
<h2 id="chapter-3-preventive-medicine">Chapter 3: Preventive
Medicine</h2>
<h3 id="quick-facts-box-2">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Definition</strong>: ‚ÄúThe art and science of preventing
disease, promoting health, and prolonging life‚Äù</li>
<li><strong>Scope</strong>: Individual, family, community, population
levels</li>
<li><strong>Approaches</strong>: Health promotion, disease prevention,
health protection</li>
<li><strong>Evidence Base</strong>: Epidemiology, biostatistics,
behavioral sciences</li>
</ul>
<h3 id="definition-concepts">üéØ DEFINITION &amp; CONCEPTS</h3>
<h4 id="classical-definition-leavell-clark-1965">Classical Definition
(Leavell &amp; Clark, 1965)</h4>
<blockquote>
<p>‚ÄúPreventive medicine comprises measures designed to protect the
health of populations and to promote the well-being of people‚Äù</p>
</blockquote>
<h4 id="modern-definition-who-2023">Modern Definition (WHO, 2023)</h4>
<blockquote>
<p>‚ÄúAll organized measures to prevent disease, promote health, and
prolong life among the population as a whole‚Äù</p>
</blockquote>
<h4 id="core-principles">Core Principles</h4>
<ol type="1">
<li><strong>Primordial Prevention</strong>: Preventing emergence of risk
factors</li>
<li><strong>Primary Prevention</strong>: Preventing disease before
onset</li>
<li><strong>Secondary Prevention</strong>: Early detection and
treatment</li>
<li><strong>Tertiary Prevention</strong>: Reducing complications and
disability</li>
</ol>
<h3 id="levels-of-prevention">üèîÔ∏è LEVELS OF PREVENTION</h3>
<h4 id="primary-prevention">PRIMARY PREVENTION</h4>
<p><strong>Definition</strong>: Interventions applied before disease
occurs</p>
<p><strong>Types:</strong> - <strong>Health Promotion</strong>:
Education, lifestyle modification - <strong>Specific
Protection</strong>: Immunization, sanitation, safety measures</p>
<p><strong>Examples:</strong> - Health education programs - Vaccination
campaigns - Water fluoridation - Smoke-free legislation - Safe sex
education - Nutrition supplementation</p>
<p><strong>Strategies:</strong> - Population strategy: Mass
interventions - High-risk strategy: Targeting susceptible groups -
Individual strategy: Personalized interventions</p>
<h4 id="secondary-prevention">SECONDARY PREVENTION</h4>
<p><strong>Definition</strong>: Early detection and prompt treatment to
prevent complications</p>
<p><strong>Methods:</strong> - <strong>Screening</strong>: Mass
screening, selective screening - <strong>Case finding</strong>:
Opportunistic screening - <strong>Early treatment</strong>: Immediate
intervention</p>
<p><strong>Examples:</strong> - <strong>Infectious diseases</strong>:
Contact tracing, outbreak investigation - <strong>NCDs</strong>: BP
screening, diabetes testing - <strong>Cancers</strong>: Pap smear,
mammography - <strong>Mental health</strong>: Depression screening</p>
<p><strong>Screening Criteria (Wilson-Jungner):</strong> 1. Condition is
important health problem 2. Accepted treatment available 3. Facilities
for diagnosis and treatment 4. Latent stage identifiable 5. Natural
history understood 6. Suitable screening test available 7. Test
acceptable to population 8. Adequate follow-up system 9. Cost-effective
intervention 10. Continuous process</p>
<h4 id="tertiary-prevention">TERTIARY PREVENTION</h4>
<p><strong>Definition</strong>: Reducing complications and disabilities
after disease manifestation</p>
<p><strong>Objectives:</strong> - Prevent disease progression - Minimize
disability - Restore function - Improve quality of life</p>
<p><strong>Methods:</strong> - <strong>Disability limitation</strong>:
Treatment to prevent complications - <strong>Rehabilitation</strong>:
Physical, occupational, social rehabilitation</p>
<p><strong>Examples:</strong> - <strong>Diabetes</strong>: Preventing
complications, foot care - <strong>Tuberculosis</strong>: DOTS for drug
resistance prevention - <strong>Stroke</strong>: Rehabilitation programs
- <strong>Mental illness</strong>: Community integration programs</p>
<h4 id="primordial-prevention">PRIMORDIAL PREVENTION</h4>
<p><strong>Definition</strong>: Preventing development of risk
factors</p>
<p><strong>Focus</strong>: Social, economic, environmental factors</p>
<p><strong>Examples:</strong> - Preventing childhood obesity -
Preventing hypertension in children - Preventing tobacco use initiation
- Preventing alcohol abuse in youth</p>
<h3 id="natural-history-of-disease">üìà NATURAL HISTORY OF DISEASE</h3>
<h4 id="natural-history-model-leavell-clark">Natural History Model
(Leavell &amp; Clark)</h4>
<p><strong>Pre-pathogenesis Phase:</strong> - <strong>Host
factors</strong>: Age, sex, genetics, immunity, nutrition -
<strong>Agent factors</strong>: Infectious agents, chemical, physical,
nutritional - <strong>Environmental factors</strong>: Physical,
biological, social environment</p>
<p><strong>Pathogenesis Phase:</strong> 1. <strong>Subclinical
disease</strong>: No symptoms, detectable by tests 2. <strong>Clinical
disease</strong>: Symptoms and signs appear 3.
<strong>Recovery/Disability/Death</strong>: Disease outcomes</p>
<h4 id="levels-of-prevention-application">Levels of Prevention
Application</h4>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 60%" />
</colgroup>
<thead>
<tr>
<th>Phase</th>
<th>Level</th>
<th>Intervention Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-pathogenesis</strong></td>
<td>Primordial/Primary</td>
<td>Health education, immunization</td>
</tr>
<tr>
<td><strong>Early pathogenesis</strong></td>
<td>Primary</td>
<td>Early treatment, screening</td>
</tr>
<tr>
<td><strong>Subclinical</strong></td>
<td>Secondary</td>
<td>Screening programs</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td>Secondary</td>
<td>Early treatment</td>
</tr>
<tr>
<td><strong>Late stages</strong></td>
<td>Tertiary</td>
<td>Rehabilitation, palliative care</td>
</tr>
</tbody>
</table>
<h3 id="risk-factors-risk-assessment">‚öñÔ∏è RISK FACTORS &amp; RISK
ASSESSMENT</h3>
<h4 id="types-of-risk-factors">Types of Risk Factors</h4>
<ol type="1">
<li><strong>Biological</strong>: Age, sex, genetics, physiology</li>
<li><strong>Environmental</strong>: Air pollution, water quality,
housing</li>
<li><strong>Behavioral</strong>: Smoking, diet, exercise, alcohol</li>
<li><strong>Social</strong>: Education, income, occupation, culture</li>
</ol>
<h4 id="risk-assessment-components">Risk Assessment Components</h4>
<ul>
<li><strong>Risk identification</strong>: Recognizing potential
hazards</li>
<li><strong>Risk estimation</strong>: Probability and magnitude</li>
<li><strong>Risk evaluation</strong>: Acceptability assessment</li>
<li><strong>Risk management</strong>: Intervention strategies</li>
</ul>
<h4 id="risk-communication">Risk Communication</h4>
<ul>
<li>Clear, understandable information</li>
<li>Honest assessment of uncertainties</li>
<li>Empowering individuals for decision-making</li>
</ul>
<h3 id="health-promotion-strategies">üí™ HEALTH PROMOTION STRATEGIES</h3>
<h4 id="ottawa-charter-framework-1986">Ottawa Charter Framework
(1986)</h4>
<p><strong>5 Action Areas:</strong> 1. <strong>Build Healthy Public
Policy</strong> - Taxation on tobacco, alcohol - Food safety regulations
- Environmental protection laws</p>
<ol start="2" type="1">
<li><strong>Create Supportive Environments</strong>
<ul>
<li>Safe housing conditions</li>
<li>Clean water and sanitation</li>
<li>Recreational facilities</li>
</ul></li>
<li><strong>Strengthen Community Action</strong>
<ul>
<li>Community participation</li>
<li>Local health initiatives</li>
<li>Peer education programs</li>
</ul></li>
<li><strong>Develop Personal Skills</strong>
<ul>
<li>Health education</li>
<li>Life skills training</li>
<li>Health literacy programs</li>
</ul></li>
<li><strong>Reorient Health Services</strong>
<ul>
<li>Preventive care focus</li>
<li>Community-based care</li>
<li>Integrated health systems</li>
</ul></li>
</ol>
<h4 id="health-promotion-models">Health Promotion Models</h4>
<ul>
<li><strong>Precede-Proceed Model</strong>: Planning and evaluation
framework</li>
<li><strong>Health Belief Model</strong>: Individual health
behavior</li>
<li><strong>Theory of Planned Behavior</strong>: Behavioral
intentions</li>
</ul>
<h3 id="high-yield-examination-points">üí° HIGH-YIELD EXAMINATION
POINTS</h3>
<h4 id="key-concepts">Key Concepts</h4>
<ol type="1">
<li><strong>Prevention is better than cure</strong> -
Cost-effectiveness</li>
<li><strong>Population vs.¬†individual approach</strong> - Different
strategies</li>
<li><strong>Levels of prevention</strong> - Leavell and Clark model</li>
<li><strong>Screening programs</strong> - Wilson-Jungner criteria</li>
<li><strong>Health promotion vs.¬†disease prevention</strong> -
Complementary approaches</li>
</ol>
<h4 id="common-disease-examples">Common Disease Examples</h4>
<ul>
<li><strong>Diabetes</strong>: All levels of prevention</li>
<li><strong>Tuberculosis</strong>: Primary (BCG), secondary (case
finding), tertiary (DOTS)</li>
<li><strong>Cancer</strong>: Primary (lifestyle), secondary (screening),
tertiary (rehabilitation)</li>
<li><strong>Hypertension</strong>: Primary (diet), secondary (BP
screening), tertiary (complication prevention)</li>
</ul>
<h3 id="exam-questions-important-points-2">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Explain the levels of
prevention with examples from communicable and non-communicable diseases
2. Discuss the role of primary prevention in reducing disease burden 3.
Describe Wilson-Jungner criteria for screening programs with examples 4.
Analyze natural history of disease and its application in preventive
medicine</p>
<p><strong>Short Answer Questions:</strong> 1. Difference between health
promotion and disease prevention 2. Primordial prevention with examples
3. Secondary prevention measures for diabetes 4. Principles of health
education</p>
<p><strong>MCQ Points:</strong> - Primary prevention: Before disease
onset - Secondary prevention: Early detection - Tertiary prevention:
After disease manifestation - Wilson-Jungner criteria: 10 criteria for
screening</p>
<h3 id="references-to-latest-guidelies">üìö REFERENCES TO LATEST
GUIDELIES</h3>
<ul>
<li>WHO Health Promotion Strategy 2023</li>
<li>National Health Policy 2017 Preventive Focus</li>
<li>CDC Prevention Guidelines 2023</li>
<li>RGUHS Community Medicine Syllabus 2020</li>
</ul>
<hr />
<h2 id="chapter-4-social-sciences">Chapter 4: Social Sciences</h2>
<h3 id="quick-facts-box-3">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Social Determinants</strong>: 30-55% contribution to health
outcomes</li>
<li><strong>Health Inequality</strong>: Rich-poor gap in health
indicators</li>
<li><strong>Social Gradient</strong>: Health varies by socioeconomic
status</li>
<li><strong>Social Cohesion</strong>: Community support impacts
health</li>
</ul>
<h3 id="social-determinants-of-health">üèòÔ∏è SOCIAL DETERMINANTS OF
HEALTH</h3>
<h4 id="who-commission-on-social-determinants-2005-2008">WHO Commission
on Social Determinants (2005-2008)</h4>
<p><strong>Structural Determinants:</strong> 1. <strong>Socioeconomic
Position</strong> - Income and wealth distribution - Education levels -
Occupation and employment - Social class</p>
<ol start="2" type="1">
<li><strong>Political Context</strong>
<ul>
<li>Governance quality</li>
<li>Public policy priorities</li>
<li>Social protection systems</li>
<li>Human rights frameworks</li>
</ul></li>
</ol>
<p><strong>Intermediary Determinants:</strong> 1. <strong>Material
Circumstances</strong> - Housing quality - Working conditions -
Neighborhood safety - Access to services</p>
<ol start="2" type="1">
<li><strong>Psychosocial Factors</strong>
<ul>
<li>Social support networks</li>
<li>Stress levels</li>
<li>Control and autonomy</li>
<li>Social cohesion</li>
</ul></li>
<li><strong>Behavioral Factors</strong>
<ul>
<li>Individual lifestyle choices</li>
<li>Smoking, alcohol, diet</li>
<li>Physical activity patterns</li>
<li>Healthcare utilization</li>
</ul></li>
</ol>
<h4 id="social-gradient-in-health">Social Gradient in Health</h4>
<ul>
<li><strong>Social Determinants Gradient</strong>: Health improves
progressively with higher socioeconomic position</li>
<li><strong>Income-Health Relationship</strong>: Each income quintile
shows better health than lower quintile</li>
<li><strong>Not just poor vs.¬†rich</strong>: Continuous gradient
throughout society</li>
</ul>
<h3 id="cultural-factors-in-health">üåç CULTURAL FACTORS IN HEALTH</h3>
<h4 id="culture-definition">Culture Definition</h4>
<blockquote>
<p>‚ÄúThe learned and shared patterns of behavior, beliefs, and values
that characterize groups of people‚Äù</p>
</blockquote>
<h4 id="components-of-culture">Components of Culture</h4>
<ol type="1">
<li><strong>Beliefs</strong>: About health, disease, treatment</li>
<li><strong>Practices</strong>: Traditional healing, rituals,
customs</li>
<li><strong>Values</strong>: Health priorities, family roles</li>
<li><strong>Knowledge</strong>: Health information sources</li>
<li><strong>Language</strong>: Health communication barriers</li>
</ol>
<h4 id="cultural-influence-on-health">Cultural Influence on Health</h4>
<ul>
<li><strong>Health-seeking behavior</strong>: Traditional vs.¬†modern
medicine</li>
<li><strong>Dietary practices</strong>: Religious food restrictions</li>
<li><strong>Family roles</strong>: Decision-making patterns</li>
<li><strong>Communication</strong>: Direct vs.¬†indirect styles</li>
<li><strong>Beliefs about causation</strong>: Supernatural
vs.¬†scientific</li>
</ul>
<h4 id="cultural-competence-in-healthcare">Cultural Competence in
Healthcare</h4>
<ol type="1">
<li><strong>Cultural awareness</strong>: Understanding own cultural
biases</li>
<li><strong>Cultural knowledge</strong>: Learning about patient
cultures</li>
<li><strong>Cultural skills</strong>: Adapting communication styles</li>
<li><strong>Cultural encounters</strong>: Direct patient
interactions</li>
<li><strong>Cultural desire</strong>: Motivation to be culturally
competent</li>
</ol>
<h4 id="ethnocentrism-vs.-cultural-relativism">Ethnocentrism
vs.¬†Cultural Relativism</h4>
<ul>
<li><strong>Ethnocentrism</strong>: Judging other cultures by own
standards</li>
<li><strong>Cultural Relativism</strong>: Understanding practices within
cultural context</li>
<li><strong>Balanced approach</strong>: Respect cultural diversity while
promoting health</li>
</ul>
<h3 id="behavioral-sciences-in-medicine">üß† BEHAVIORAL SCIENCES IN
MEDICINE</h3>
<h4 id="health-behavior-models">Health Behavior Models</h4>
<p><strong>Health Belief Model (Rosenstock, 1966)</strong>
<strong>Components:</strong> - <strong>Perceived
susceptibility</strong>: Risk of getting disease - <strong>Perceived
severity</strong>: Seriousness of consequences - <strong>Perceived
benefits</strong>: Effectiveness of action - <strong>Perceived
barriers</strong>: Obstacles to action - <strong>Cues to
action</strong>: Triggers for behavior - <strong>Self-efficacy</strong>:
Confidence in ability</p>
<p><strong>Theory of Planned Behavior (Ajzen, 1991)</strong>
<strong>Components:</strong> - <strong>Attitude toward
behavior</strong>: Overall evaluation - <strong>Subjective
norms</strong>: Social pressure perception - <strong>Perceived
behavioral control</strong>: Control beliefs - <strong>Behavioral
intention</strong>: Motivation to perform - <strong>Actual
behavior</strong>: Performance of action</p>
<p><strong>Social Cognitive Theory (Bandura, 1986)</strong> <strong>Key
Concepts:</strong> - <strong>Reciprocal determinism</strong>:
Interaction of person, behavior, environment - <strong>Observational
learning</strong>: Learning from others -
<strong>Self-efficacy</strong>: Belief in capabilities -
<strong>Self-regulation</strong>: Self-monitoring and evaluation</p>
<h4 id="behavioral-risk-factors">Behavioral Risk Factors</h4>
<p><strong>Modifiable Risk Factors:</strong> - <strong>Tobacco
use</strong>: Direct and secondhand smoke - <strong>Alcohol
consumption</strong>: Harmful use patterns - <strong>Physical
inactivity</strong>: Sedentary lifestyle - <strong>Unhealthy
diet</strong>: Excess calories, poor nutrition - <strong>Unsafe
sex</strong>: Multiple partners, no protection</p>
<p><strong>Non-modifiable Risk Factors:</strong> - <strong>Age</strong>:
Increasing risk with age - <strong>Sex</strong>: Gender-specific
patterns - <strong>Genetics</strong>: Family history influence -
<strong>Ethnicity</strong>: Cultural and genetic factors</p>
<h3 id="community-participation">üë• COMMUNITY PARTICIPATION</h3>
<h4 id="definition">Definition</h4>
<blockquote>
<p>‚ÄúThe involvement of community members in decisions and actions that
affect their health‚Äù</p>
</blockquote>
<h4 id="levels-of-participation-arnsteins-ladder">Levels of
Participation (Arnstein‚Äôs Ladder)</h4>
<ol type="1">
<li><strong>Manipulation</strong>: Pseudo-participation</li>
<li><strong>Tokenism</strong>: Informing, consulting</li>
<li><strong>Citizen power</strong>: Partnership, delegated power,
citizen control</li>
</ol>
<h4 id="benefits-of-community-participation">Benefits of Community
Participation</h4>
<ul>
<li><strong>Ownership</strong>: Community commitment to programs</li>
<li><strong>Sustainability</strong>: Long-term program viability</li>
<li><strong>Cultural relevance</strong>: Culturally appropriate
interventions</li>
<li><strong>Cost-effectiveness</strong>: Reduced resource
requirements</li>
<li><strong>Empowerment</strong>: Community capacity building</li>
</ul>
<h4 id="barriers-to-community-participation">Barriers to Community
Participation</h4>
<ul>
<li><strong>Lack of awareness</strong>: About participation
opportunities</li>
<li><strong>Time constraints</strong>: Competing priorities</li>
<li><strong>Power imbalances</strong>: Community vs.¬†authority</li>
<li><strong>Cultural barriers</strong>: Gender, caste, language</li>
<li><strong>Resource limitations</strong>: Funding, facilities</li>
</ul>
<h4 id="strategies-for-effective-participation">Strategies for Effective
Participation</h4>
<ol type="1">
<li><strong>Community needs assessment</strong>: Identify
priorities</li>
<li><strong>Stakeholder mapping</strong>: Identify key players</li>
<li><strong>Capacity building</strong>: Skills and knowledge
development</li>
<li><strong>Resource mobilization</strong>: Local resource
utilization</li>
<li><strong>Leadership development</strong>: Community leaders</li>
<li><strong>Feedback mechanisms</strong>: Continuous improvement</li>
</ol>
<h3 id="social-epidemiology">üìä SOCIAL EPIDEMIOLOGY</h3>
<h4 id="definition-1">Definition</h4>
<blockquote>
<p>‚ÄúThe study of social distribution and social determinants of health
states and events‚Äù</p>
</blockquote>
<h4 id="core-concepts">Core Concepts</h4>
<ol type="1">
<li><strong>Social Distribution</strong>: How health varies across
social groups</li>
<li><strong>Social Causation</strong>: Social factors cause health
differences</li>
<li><strong>Social Selection</strong>: Health affects social
position</li>
<li><strong>Social Mobility</strong>: Movement between social
positions</li>
</ol>
<h4 id="social-epidemiology-measures">Social Epidemiology Measures</h4>
<p><strong>Social Class Indicators:</strong> - <strong>Occupational
class</strong>: Job categories - <strong>Educational level</strong>:
Years of schooling - <strong>Income level</strong>: Household income -
<strong>Housing conditions</strong>: Quality and ownership</p>
<p><strong>Health Inequalities Measures:</strong> - <strong>Rate
ratio</strong>: Comparison between groups - <strong>Rate
difference</strong>: Absolute difference - <strong>Relative index of
inequality</strong>: Population impact - <strong>Slope index of
inequality</strong>: Gradient measure</p>
<h4 id="social-mobility-and-health">Social Mobility and Health</h4>
<ul>
<li><strong>Social causation</strong>: Position affects health
outcomes</li>
<li><strong>Social selection</strong>: Health affects position</li>
<li><strong>Intergenerational effects</strong>: Parental position
influences child health</li>
<li><strong>Life course perspective</strong>: Cumulative effects over
time</li>
</ul>
<h3 id="social-security-and-health">üõ°Ô∏è SOCIAL SECURITY AND HEALTH</h3>
<h4 id="social-security-definition">Social Security Definition</h4>
<blockquote>
<p>‚ÄúProtection provided by society for its members against economic and
social distress‚Äù</p>
</blockquote>
<h4 id="types-of-social-security">Types of Social Security</h4>
<p><strong>Healthcare Security:</strong> - <strong>Universal Health
Coverage</strong>: All population covered - <strong>Health
insurance</strong>: Public and private schemes - <strong>Government
provisioning</strong>: Free/subsidized healthcare</p>
<p><strong>Income Security:</strong> - <strong>Unemployment
benefits</strong>: Support during job loss - <strong>Disability
pensions</strong>: Support for disabled individuals - <strong>Old age
pensions</strong>: Support for elderly</p>
<p><strong>Social Protection Programs:</strong></p>
<p><strong>India Context:</strong> - <strong>Ayushman Bharat</strong>:
Health insurance scheme - <strong>National Social Assistance
Programme</strong>: Below poverty line support - ** Mahatma Gandhi
National Rural Employment Guarantee Act<strong>: Employment security -
</strong>Pradhan Mantri Shram Yogi Maan-dhan**: Pension for unorganized
workers</p>
<h4 id="social-determinants-and-health-outcomes">Social Determinants and
Health Outcomes</h4>
<p><strong>Life Expectancy Differences:</strong> -
<strong>Global</strong>: 73.4 years average (2023) - <strong>Income
gradient</strong>: 10-20 year difference between rich and poor countries
- <strong>Within countries</strong>: 5-10 year differences between
socioeconomic groups</p>
<p><strong>Disease Burden Differences:</strong> - <strong>Communicable
diseases</strong>: Higher burden in poor populations -
<strong>Non-communicable diseases</strong>: Increasing in all groups -
<strong>Mental health</strong>: Higher rates in disadvantaged groups</p>
<h3 id="memory-aids-tips-2">üí° MEMORY AIDS &amp; TIPS</h3>
<p><strong>‚ÄúSOCIAL-DETERMINANTS‚Äù Acronym:</strong> -
<strong>S</strong>ocioeconomic position - <strong>O</strong>ccupational
factors - <strong>C</strong>ultural influences - <strong>I</strong>ncome
and education - <strong>A</strong>lcohol and tobacco use -
<strong>L</strong>iving conditions - <strong>D</strong>iet and nutrition
- <strong>E</strong>nvironmental factors - <strong>T</strong>raditional
practices - <strong>E</strong>mployment status -
<strong>R</strong>eligious beliefs - <strong>M</strong>ental health
factors - <strong>I</strong>nequalities and inequities -
<strong>N</strong>eighborhood characteristics - <strong>A</strong>ccess
to healthcare - <strong>N</strong>utrition and food security -
<strong>T</strong>ransportation access - <strong>S</strong>ocial support
networks</p>
<p><strong>‚ÄúCULTURAL-SHAPES‚Äù Framework:</strong> -
<strong>C</strong>ultural beliefs affect health behaviors -
<strong>U</strong>nderstanding culture improves communication -
<strong>L</strong>ifestyle patterns influenced by culture -
<strong>T</strong>raditional medicine practices - <strong>U</strong>rban
vs.¬†rural cultural differences - <strong>R</strong>eligious practices
impact health - <strong>A</strong>daptation needed for health programs -
<strong>L</strong>anguage barriers in healthcare -
<strong>S</strong>ocial norms influence health decisions -
<strong>H</strong>ealthcare provider cultural competence -
<strong>A</strong>ttitudes toward medical care -
<strong>P</strong>opulation-specific health approaches -
<strong>E</strong>mpowerment through cultural respect -
<strong>S</strong>ocioeconomic factors interact with culture</p>
<h3 id="exam-questions-important-points-3">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Explain social
determinants of health and their impact on population health 2. Discuss
the role of culture in health-seeking behavior and health outcomes 3.
Analyze the importance of community participation in health programs 4.
Describe social epidemiology concepts with examples</p>
<p><strong>Short Answer Questions:</strong> 1. Levels of community
participation 2. Health Belief Model components 3. Social gradient in
health 4. Cultural competence in healthcare</p>
<p><strong>MCQ Points:</strong> - WHO Social Determinants Framework:
Structural and intermediary - Health Belief Model: Perceived
susceptibility, severity, benefits, barriers - Social mobility: 50-60%
inter-generational persistence - Cultural competence: 5 components
(awareness, knowledge, skills, encounters, desire)</p>
<h3 id="references-to-latest-guidelines-2">üìö REFERENCES TO LATEST
GUIDELINES</h3>
<ul>
<li>WHO Social Determinants of Health Framework 2023</li>
<li>National Health Policy 2017 - Health Equity Focus</li>
<li>SDG Framework 2030 - Social Justice</li>
<li>RGUHS Community Medicine Guidelines 2020</li>
</ul>
<hr />
<h2 id="conclusion">Conclusion</h2>
<p>This comprehensive guide covers the fundamental concepts in public
health as outlined in Part I of the Community Medicine Quick Revision
Manual. Each chapter provides examination-oriented content with key
points, memory aids, and references to latest guidelines to aid
effective revision for RGUHS MBBS examinations.</p>
<h3 id="key-takeaways">Key Takeaways:</h3>
<ol type="1">
<li><strong>History of Medicine</strong> demonstrates evolution from
traditional to modern evidence-based practice</li>
<li><strong>Public Health in India</strong> shows significant progress
and ongoing challenges</li>
<li><strong>Preventive Medicine</strong> emphasizes multi-level
prevention approaches</li>
<li><strong>Social Sciences</strong> highlights the importance of social
determinants in health</li>
</ol>
<h3 id="study-strategy">Study Strategy:</h3>
<ul>
<li>Use memory aids for quick recall</li>
<li>Practice with provided exam questions</li>
<li>Connect concepts across chapters</li>
<li>Apply examples to current health scenarios</li>
</ul>
<table style="width:6%;">
<colgroup>
<col style="width: 5%" />
</colgroup>
<tbody>
<tr>
<td><em>End of Part I: Concepts in Public Health</em></td>
</tr>
<tr>
<td># Part II: Environmental Health Sciences ## Community Medicine Quick
Revision Manual</td>
</tr>
</tbody>
</table>
<h2 id="chapter-5-environment-and-health">Chapter 5: Environment and
Health</h2>
<h3 id="quick-facts-box-4">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Environmental Burden</strong>: 25% of global disease burden
attributable to environmental factors</li>
<li><strong>WHO Estimate</strong>: 13.7 million deaths annually due to
environmental factors</li>
<li><strong>Air Pollution</strong>: 7 million premature deaths (WHO
2023)</li>
<li><strong>Water-Related Diseases</strong>: 2.2 billion people lack
safe drinking water</li>
<li><strong>Climate Change</strong>: Additional 250,000 deaths annually
by 2030 (WHO)</li>
</ul>
<h3 id="environment-and-health-definition">üåç ENVIRONMENT AND HEALTH
DEFINITION</h3>
<h4 id="who-definition-2023">WHO Definition (2023)</h4>
<blockquote>
<p>‚ÄúThe theory and practice of assessing, correcting, controlling, and
preventing environmental factors that can adversely affect human
health‚Äù</p>
</blockquote>
<h4 id="core-components">Core Components</h4>
<ol type="1">
<li><strong>Physical Environment</strong>: Air, water, soil,
housing</li>
<li><strong>Biological Environment</strong>: Vectors, microorganisms,
plants</li>
<li><strong>Chemical Environment</strong>: Toxins, pollutants,
pesticides</li>
<li><strong>Social Environment</strong>: Economic, cultural, political
factors</li>
</ol>
<h3 id="air-pollution-and-health-effects">üí® AIR POLLUTION AND HEALTH
EFFECTS</h3>
<h4 id="major-air-pollutants">Major Air Pollutants</h4>
<ol type="1">
<li><strong>Particulate Matter (PM2.5, PM10)</strong>
<ul>
<li>Sources: Industrial emissions, vehicles, crop burning</li>
<li>Health Effects: Respiratory diseases, cardiovascular disease, lung
cancer</li>
<li>WHO Standard: &lt;5 Œºg/m¬≥ (PM2.5), &lt;15 Œºg/m¬≥ (PM10)</li>
</ul></li>
<li><strong>Nitrogen Dioxide (NO‚ÇÇ)</strong>
<ul>
<li>Sources: Vehicle emissions, industrial combustion</li>
<li>Health Effects: Airway inflammation, asthma exacerbation</li>
<li>WHO Standard: &lt;25 Œºg/m¬≥ (annual mean)</li>
</ul></li>
<li><strong>Sulfur Dioxide (SO‚ÇÇ)</strong>
<ul>
<li>Sources: Coal burning, industrial processes</li>
<li>Health Effects: Respiratory irritation, acid rain</li>
<li>WHO Standard: &lt;40 Œºg/m¬≥ (24-hour mean)</li>
</ul></li>
<li><strong>Carbon Monoxide (CO)</strong>
<ul>
<li>Sources: Incomplete combustion, vehicle emissions</li>
<li>Health Effects: Carbon monoxide poisoning, reduced oxygen
transport</li>
<li>WHO Standard: &lt;4 mg/m¬≥ (24-hour mean)</li>
</ul></li>
<li><strong>Ozone (O‚ÇÉ)</strong>
<ul>
<li>Sources: Photochemical reactions in atmosphere</li>
<li>Health Effects: Respiratory problems, eye irritation</li>
<li>WHO Standard: &lt;100 Œºg/m¬≥ (8-hour mean)</li>
</ul></li>
</ol>
<h4 id="health-effects-by-pollutant">Health Effects by Pollutant</h4>
<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 24%" />
<col style="width: 27%" />
<col style="width: 30%" />
</colgroup>
<thead>
<tr>
<th>Pollutant</th>
<th>Acute Effects</th>
<th>Chronic Effects</th>
<th>Vulnerable Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PM2.5</strong></td>
<td>Cough, breathlessness</td>
<td>COPD, lung cancer, heart disease</td>
<td>Children, elderly, asthmatics</td>
</tr>
<tr>
<td><strong>NO‚ÇÇ</strong></td>
<td>Chest tightness, wheeze</td>
<td>Reduced lung function</td>
<td>Children, asthma patients</td>
</tr>
<tr>
<td><strong>SO‚ÇÇ</strong></td>
<td>Throat irritation, cough</td>
<td>Respiratory symptoms</td>
<td>Children, elderly</td>
</tr>
<tr>
<td><strong>CO</strong></td>
<td>Headache, dizziness</td>
<td>Heart problems</td>
<td>Heart disease patients</td>
</tr>
<tr>
<td><strong>O‚ÇÉ</strong></td>
<td>Eye/nose irritation</td>
<td>Reduced lung function</td>
<td>Outdoor workers, athletes</td>
</tr>
</tbody>
</table>
<h3 id="water-pollution-and-diseases">üíß WATER POLLUTION AND
DISEASES</h3>
<h4 id="water-quality-parameters">Water Quality Parameters</h4>
<ol type="1">
<li><strong>Physical Parameters</strong>
<ul>
<li><strong>Turbidity</strong>: Should be &lt;1 NTU</li>
<li><strong>Temperature</strong>: Should not exceed 25¬∞C</li>
<li><strong>Color</strong>: Should be colorless</li>
<li><strong>Taste and Odor</strong>: Should be acceptable</li>
</ul></li>
<li><strong>Chemical Parameters</strong>
<ul>
<li><strong>pH</strong>: 6.5-8.5 (BIS standards)</li>
<li><strong>Total Dissolved Solids</strong>: &lt;500 mg/L</li>
<li><strong>Chloride</strong>: &lt;250 mg/L</li>
<li><strong>Fluoride</strong>: 0.5-1.5 mg/L</li>
<li><strong>Nitrate</strong>: &lt;45 mg/L</li>
<li><strong>Heavy Metals</strong>: Lead &lt;0.1 mg/L, Arsenic &lt;0.05
mg/L</li>
</ul></li>
<li><strong>Biological Parameters</strong>
<ul>
<li><strong>Coliform Count</strong>: Should be 0 per 100ml</li>
<li><strong>E. coli</strong>: Should be absent</li>
<li><strong>Standard Plate Count</strong>: &lt;10 colonies/ml</li>
</ul></li>
</ol>
<h4 id="water-borne-diseases">Water-Borne Diseases</h4>
<ol type="1">
<li><strong>Bacterial Diseases</strong>
<ul>
<li><strong>Cholera</strong> (Vibrio cholerae)
<ul>
<li>Incubation: 2-72 hours</li>
<li>Symptoms: Watery diarrhea, dehydration</li>
<li>Prevention: Safe water, sanitation, vaccination</li>
</ul></li>
<li><strong>Typhoid Fever</strong> (Salmonella typhi)
<ul>
<li>Incubation: 7-14 days</li>
<li>Symptoms: Fever, headache, rose spots</li>
<li>Prevention: Water treatment, vaccination</li>
</ul></li>
<li><strong>Bacillary Dysentery</strong> (Shigella)
<ul>
<li>Incubation: 1-3 days</li>
<li>Symptoms: Bloody diarrhea, abdominal pain</li>
<li>Prevention: Hygiene, safe water</li>
</ul></li>
</ul></li>
<li><strong>Viral Diseases</strong>
<ul>
<li><strong>Hepatitis A</strong>
<ul>
<li>Incubation: 2-6 weeks</li>
<li>Symptoms: Jaundice, fever, fatigue</li>
<li>Prevention: Vaccination, safe water</li>
</ul></li>
<li><strong>Poliomyelitis</strong>
<ul>
<li>Incubation: 7-14 days</li>
<li>Symptoms: Paralysis, fever</li>
<li>Prevention: OPV/IPV vaccination</li>
</ul></li>
</ul></li>
<li><strong>Parasitic Diseases</strong>
<ul>
<li><strong>Amoebic Dysentery</strong> (Entamoeba histolytica)
<ul>
<li>Incubation: 2-4 weeks</li>
<li>Symptoms: Bloody diarrhea, liver abscess</li>
<li>Prevention: Water treatment, hygiene</li>
</ul></li>
</ul></li>
</ol>
<h4 id="water-related-diseases">Water-Related Diseases</h4>
<ul>
<li><strong>Water-washed diseases</strong>: Scabies, trachoma (due to
insufficient water for hygiene)</li>
<li><strong>Water-based diseases</strong>: Schistosomiasis, Guinea worm
disease</li>
<li><strong>Water-related diseases</strong>: Malaria, dengue (breeding
in water containers)</li>
</ul>
<h3 id="soil-contamination">üè≠ SOIL CONTAMINATION</h3>
<h4 id="types-of-soil-contamination">Types of Soil Contamination</h4>
<ol type="1">
<li><strong>Heavy Metal Contamination</strong>
<ul>
<li><strong>Lead</strong>: Industrial emissions, paints, batteries</li>
<li><strong>Cadmium</strong>: Phosphate fertilizers, industrial
waste</li>
<li><strong>Mercury</strong>: Gold mining, industrial discharge</li>
<li><strong>Arsenic</strong>: Natural deposits, contaminated
groundwater</li>
</ul></li>
<li><strong>Organic Contamination</strong>
<ul>
<li><strong>Pesticides</strong>: DDT, organochlorines</li>
<li><strong>Petroleum products</strong>: Oil spills, leakage</li>
<li><strong>Industrial solvents</strong>: TCE, PCE contamination</li>
</ul></li>
<li><strong>Radioactive Contamination</strong>
<ul>
<li><strong>Natural</strong>: Uranium, thorium deposits</li>
<li><strong>Artificial</strong>: Nuclear accidents, waste disposal</li>
</ul></li>
</ol>
<h4 id="health-effects-of-soil-contamination">Health Effects of Soil
Contamination</h4>
<ul>
<li><strong>Direct ingestion</strong>: Children playing in contaminated
soil</li>
<li><strong>Inhalation</strong>: Dust from contaminated areas</li>
<li><strong>Food chain contamination</strong>: Bioaccumulation in
crops</li>
<li><strong>Groundwater contamination</strong>: Leaching to drinking
water</li>
</ul>
<h3 id="climate-change-and-health">üå°Ô∏è CLIMATE CHANGE AND HEALTH</h3>
<h4 id="climate-change-indicators">Climate Change Indicators</h4>
<ol type="1">
<li><strong>Temperature Rise</strong>: 1.1¬∞C above pre-industrial levels
(2023)</li>
<li><strong>Sea Level Rise</strong>: 3.3 mm/year (satellite data)</li>
<li><strong>Extreme Weather Events</strong>: Increasing frequency and
intensity</li>
<li><strong>Precipitation Changes</strong>: Altered rainfall
patterns</li>
</ol>
<h4 id="health-impacts-of-climate-change">Health Impacts of Climate
Change</h4>
<ol type="1">
<li><strong>Direct Effects</strong>
<ul>
<li><strong>Heat-related illness</strong>: Heat exhaustion, heat
stroke</li>
<li><strong>Extreme weather injuries</strong>: Floods, storms,
droughts</li>
<li><strong>Cold-related illness</strong>: Hypothermia, frostbite</li>
</ul></li>
<li><strong>Vector-Borne Diseases</strong>
<ul>
<li><strong>Malaria expansion</strong>: Moving to higher altitudes and
latitudes</li>
<li><strong>Dengue spread</strong>: Expanded mosquito breeding
areas</li>
<li><strong>Lyme disease</strong>: Tick range expansion</li>
</ul></li>
<li><strong>Water-Related Health Risks</strong>
<ul>
<li><strong>Water scarcity</strong>: Dehydration, poor hygiene</li>
<li><strong>Flood-related diseases</strong>: Diarrheal diseases,
leptospirosis</li>
<li><strong>Drought impacts</strong>: Malnutrition, food insecurity</li>
</ul></li>
<li><strong>Food Security and Nutrition</strong>
<ul>
<li><strong>Crop yield reduction</strong>: Reduced food production</li>
<li><strong>Nutritional deficiencies</strong>: Reduced food quality</li>
<li><strong>Food price increases</strong>: Economic impacts on
nutrition</li>
</ul></li>
</ol>
<h4 id="climate-sensitive-health-conditions">Climate-Sensitive Health
Conditions</h4>
<ul>
<li><strong>Respiratory diseases</strong>: Worsened by air
pollution</li>
<li><strong>Cardiovascular diseases</strong>: Heat stress
exacerbation</li>
<li><strong>Infectious diseases</strong>: Expanded transmission
seasons</li>
<li><strong>Mental health</strong>: Climate anxiety, displacement
stress</li>
</ul>
<h3 id="environmental-monitoring">üî¨ ENVIRONMENTAL MONITORING</h3>
<h4 id="types-of-environmental-monitoring">Types of Environmental
Monitoring</h4>
<ol type="1">
<li><strong>Air Quality Monitoring</strong>
<ul>
<li><strong>Ambient monitoring</strong>: Outdoor air quality
stations</li>
<li><strong>Source monitoring</strong>: Industrial stack emissions</li>
<li><strong>Personal monitoring</strong>: Individual exposure
assessment</li>
</ul></li>
<li><strong>Water Quality Monitoring</strong>
<ul>
<li><strong>Drinking water quality</strong>: Municipal supply
testing</li>
<li><strong>Surface water quality</strong>: Rivers, lakes, coastal
waters</li>
<li><strong>Groundwater quality</strong>: Borewell and well water
testing</li>
</ul></li>
<li><strong>Soil Quality Monitoring</strong>
<ul>
<li><strong>Agricultural soil</strong>: Pesticide and fertilizer
residues</li>
<li><strong>Industrial areas</strong>: Heavy metal contamination</li>
<li><strong>Residential areas</strong>: Lead, asbestos assessment</li>
</ul></li>
</ol>
<h4 id="environmental-monitoring-methods">Environmental Monitoring
Methods</h4>
<ol type="1">
<li><strong>Continuous Monitoring</strong>
<ul>
<li><strong>Real-time sensors</strong>: Air quality, water quality</li>
<li><strong>Automatic stations</strong>: 24/7 monitoring capability</li>
<li><strong>Data transmission</strong>: Telemetry systems</li>
</ul></li>
<li><strong>Periodic Monitoring</strong>
<ul>
<li><strong>Grab sampling</strong>: Point-in-time samples</li>
<li><strong>Composite sampling</strong>: Time-averaged samples</li>
<li><strong>Biological indicators</strong>: Sentinel species
monitoring</li>
</ul></li>
</ol>
<h4 id="environmental-indicators">Environmental Indicators</h4>
<ol type="1">
<li><strong>Air Quality Index (AQI)</strong>
<ul>
<li><strong>Good (0-50)</strong>: No health risk</li>
<li><strong>Moderate (51-100)</strong>: Acceptable for most</li>
<li><strong>Unhealthy for sensitive (101-150)</strong>: Children,
elderly at risk</li>
<li><strong>Unhealthy (151-200)</strong>: Everyone may experience
problems</li>
<li><strong>Very unhealthy (201-300)</strong>: Health alert, avoid
outdoor activity</li>
</ul></li>
</ol>
<h3 id="who-environmental-health-guidelines">üèõÔ∏è WHO ENVIRONMENTAL HEALTH
GUIDELINES</h3>
<h4 id="who-environmental-health-standards">WHO Environmental Health
Standards</h4>
<ol type="1">
<li><strong>Air Quality Guidelines (2021)</strong>
<ul>
<li>PM2.5: 5 Œºg/m¬≥ (annual), 15 Œºg/m¬≥ (24-hour)</li>
<li>PM10: 15 Œºg/m¬≥ (annual), 45 Œºg/m¬≥ (24-hour)</li>
<li>NO‚ÇÇ: 10 Œºg/m¬≥ (annual), 25 Œºg/m¬≥ (24-hour)</li>
</ul></li>
<li><strong>Drinking Water Guidelines (2023)</strong>
<ul>
<li><strong>Microbiological</strong>: E. coli = 0/100ml</li>
<li><strong>Chemical</strong>: Lead &lt;0.01 mg/L, Arsenic &lt;0.01
mg/L</li>
<li><strong>Physical</strong>: Turbidity &lt;1 NTU</li>
</ul></li>
<li><strong>Housing and Health Guidelines</strong>
<ul>
<li><strong>Ventilation</strong>: 5 air changes per hour minimum</li>
<li><strong>Floor area</strong>: 10.8 m¬≤ per person minimum</li>
<li><strong>Windows</strong>: 10% of floor area for daylight</li>
</ul></li>
</ol>
<h4 id="global-environmental-health-initiatives">Global Environmental
Health Initiatives</h4>
<ol type="1">
<li><strong>WHO Global Air Quality Guidelines (2021)</strong></li>
<li><strong>UN Sustainable Development Goals</strong></li>
<li><strong>Paris Climate Agreement</strong></li>
<li><strong>WHO Water Safety Plans</strong></li>
</ol>
<h3 id="memory-aids-tips-3">üí° MEMORY AIDS &amp; TIPS</h3>
<p><strong>‚ÄúAIR-WATER-SOIL-CLIMATE‚Äù Framework:</strong> -
<strong>A</strong>ir pollution health effects - <strong>I</strong>ndoor
air quality standards - <strong>R</strong>espiratory disease prevention
- <strong>W</strong>ater-borne disease control -
<strong>A</strong>bstract standards and guidelines -
<strong>T</strong>oxic exposure prevention -
<strong>E</strong>nvironmental monitoring methods</p>
<p><strong>‚ÄúWATER-BORNE DISEASES‚Äù Mnemonic:</strong> -
<strong>B</strong>acterial (Cholera, Typhoid) - <strong>O</strong>rganic
parasites (Amoebiasis) - <strong>R</strong>ecall incubation periods -
<strong>N</strong>ecessary prevention methods -
<strong>E</strong>pidemiological surveillance -
<strong>D</strong>iagnosis and treatment protocols -
<strong>E</strong>limination strategies</p>
<p><strong>‚ÄúCLIMATE-HEALTH‚Äù Connections:</strong> -
<strong>C</strong>hange in vector patterns - <strong>L</strong>evel of
food security affected - <strong>I</strong>ncremental temperature rise -
<strong>M</strong>ental health impacts - <strong>A</strong>daptive
strategies needed - <strong>T</strong>hreat to vulnerable populations -
<strong>E</strong>xtreme weather events</p>
<p><strong>‚ÄúENVIRONMENTAL MONITORING‚Äù ABCD:</strong> -
<strong>A</strong>ir quality continuous monitoring -
<strong>B</strong>iological indicators usage - <strong>C</strong>hemical
parameter testing - <strong>D</strong>ata interpretation for health</p>
<h3 id="exam-questions-important-points-4">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Discuss air pollution as a
major environmental health hazard with reference to its sources,
effects, and control measures 2. Explain water pollution and its impact
on public health with examples of water-borne diseases 3. Analyze the
health impacts of climate change and suggest adaptation strategies 4.
Describe the WHO guidelines for environmental health and their
implementation in India</p>
<p><strong>Short Answer Questions:</strong> 1. Air Quality Index and its
health significance 2. Water purification methods at community level 3.
Soil contamination and its health effects 4. Environmental monitoring
techniques</p>
<p><strong>MCQ Points:</strong> - WHO air quality guidelines for PM2.5:
5 Œºg/m¬≥ - Safe fluoride level in drinking water: 0.5-1.5 mg/L - Coliform
count in safe drinking water: 0 per 100ml - Climate change temperature
rise: 1.1¬∞C above pre-industrial levels</p>
<h3 id="references-to-latest-guidelines-3">üìö REFERENCES TO LATEST
GUIDELINES</h3>
<ul>
<li>WHO Global Air Quality Guidelines 2021</li>
<li>WHO Guidelines for Drinking Water Quality 2023</li>
<li>IPCC Climate Change Report 2023</li>
<li>National Air Quality Index Guidelines (India) 2023</li>
<li>Environmental Protection Act 1986 and amendments</li>
<li>RGUHS Community Medicine Environmental Health Syllabus 2020</li>
</ul>
<hr />
<h2 id="chapter-6-air">Chapter 6: Air</h2>
<h3 id="quick-facts-box-5">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Global Air Pollution</strong>: 7 million premature deaths
annually (WHO 2023)</li>
<li><strong>India Air Quality</strong>: 89% of population breathe unsafe
air</li>
<li><strong>Ambient PM2.5</strong>: 65 Œºg/m¬≥ (India) vs WHO guideline 5
Œºg/m¬≥</li>
<li><strong>Indoor Air Pollution</strong>: 3.8 million deaths, 54%
women</li>
<li><strong>Economic Cost</strong>: 3.3% of GDP loss due to air
pollution (World Bank)</li>
</ul>
<h3 id="air-quality-indices">üìä AIR QUALITY INDICES</h3>
<h4 id="national-air-quality-index-india">National Air Quality Index
(India)</h4>
<p><strong>CPCB AQI Categories:</strong></p>
<ol type="1">
<li><strong>Good (0-50)</strong>
<ul>
<li>Air quality acceptable</li>
<li>No health concerns</li>
<li>Activities: No restrictions</li>
</ul></li>
<li><strong>Moderate (51-100)</strong>
<ul>
<li>Acceptable for most people</li>
<li>Sensitive individuals may experience minor issues</li>
<li>Activities: Normal outdoor activities</li>
</ul></li>
<li><strong>Unhealthy for Sensitive Groups (101-150)</strong>
<ul>
<li>Children, elderly, heart/lung disease patients affected</li>
<li>Sensitive groups should reduce prolonged outdoor exertion</li>
<li>Activities: Normal for others, reduced for sensitive groups</li>
</ul></li>
<li><strong>Unhealthy (151-200)</strong>
<ul>
<li>Everyone may experience health effects</li>
<li>Reduce or reschedule outdoor activities</li>
<li>Activities: Avoid outdoor exercise</li>
</ul></li>
<li><strong>Very Unhealthy (201-300)</strong>
<ul>
<li>Health alert for entire population</li>
<li>Avoid outdoor activities</li>
<li>Activities: Stay indoors with air purification</li>
</ul></li>
<li><strong>Severe (301-500)</strong>
<ul>
<li>Emergency health conditions</li>
<li>Significant health effects for everyone</li>
<li>Activities: Complete restriction on outdoor activities</li>
</ul></li>
</ol>
<h4 id="aqi-calculation-parameters">AQI Calculation Parameters</h4>
<ol type="1">
<li><strong>Primary Pollutants</strong> (Used for AQI calculation)
<ul>
<li>Particulate Matter (PM2.5, PM10)</li>
<li>Nitrogen Dioxide (NO‚ÇÇ)</li>
<li>Sulfur Dioxide (SO‚ÇÇ)</li>
<li>Carbon Monoxide (CO)</li>
<li>Ozone (O‚ÇÉ)</li>
</ul></li>
<li><strong>AQI Formula</strong>
<ul>
<li>Breakpoint values for each pollutant</li>
<li>Linear interpolation between breakpoints</li>
<li>Maximum value among all pollutants becomes AQI</li>
</ul></li>
</ol>
<h4 id="air-quality-monitoring-stations-in-india">Air Quality Monitoring
Stations in India</h4>
<ul>
<li><strong>Total Stations</strong>: 779 (as of 2023)</li>
<li><strong>Real-time Monitoring</strong>: 342 continuous stations</li>
<li><strong>Cities Covered</strong>: 343 cities under NCAP</li>
<li><strong>Data Availability</strong>: Real-time AQI updates every
hour</li>
</ul>
<h3 id="pollutants-and-health-effects">üè≠ POLLUTANTS AND HEALTH
EFFECTS</h3>
<h4 id="primary-pollutants">Primary Pollutants</h4>
<p><strong>1. Particulate Matter (PM)</strong> -
<strong>Sources</strong>: Combustion, industrial processes, dust -
<strong>Health Effects</strong>: - Short-term: Eye irritation,
respiratory symptoms - Long-term: Reduced lung function, heart disease,
lung cancer - Vulnerable: Children, elderly, asthma patients</p>
<p><strong>2. Nitrogen Dioxide (NO‚ÇÇ)</strong> -
<strong>Sources</strong>: Vehicle emissions, industrial combustion -
<strong>Health Effects</strong>: - Respiratory irritation and
inflammation - Increased asthma attacks - Reduced lung function -
Seasonal variation (higher in winter)</p>
<p><strong>3. Sulfur Dioxide (SO‚ÇÇ)</strong> - <strong>Sources</strong>:
Coal burning, industrial processes - <strong>Health Effects</strong>: -
Eye, nose, and throat irritation - Respiratory symptoms in sensitive
individuals - Can trigger asthma attacks - Acid rain formation</p>
<p><strong>4. Carbon Monoxide (CO)</strong> - <strong>Sources</strong>:
Incomplete combustion, vehicle emissions - <strong>Health
Effects</strong>: - Reduces oxygen-carrying capacity of blood -
Headache, dizziness, nausea - Can be fatal at high concentrations -
Particularly dangerous for heart disease patients</p>
<p><strong>5. Ozone (O‚ÇÉ)</strong> - <strong>Sources</strong>:
Photochemical reactions, secondary pollutant - <strong>Health
Effects</strong>: - Respiratory tract irritation - Coughing and throat
irritation - Reduced lung function - Asthma exacerbation</p>
<h4 id="pollutant-concentration-standards">Pollutant Concentration
Standards</h4>
<table>
<thead>
<tr>
<th>Pollutant</th>
<th>WHO Guideline</th>
<th>India CPCB Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PM2.5</strong></td>
<td>5 Œºg/m¬≥ (annual)</td>
<td>40 Œºg/m¬≥ (annual)</td>
</tr>
<tr>
<td><strong>PM10</strong></td>
<td>15 Œºg/m¬≥ (annual)</td>
<td>60 Œºg/m¬≥ (annual)</td>
</tr>
<tr>
<td><strong>NO‚ÇÇ</strong></td>
<td>10 Œºg/m¬≥ (annual)</td>
<td>40 Œºg/m¬≥ (annual)</td>
</tr>
<tr>
<td><strong>SO‚ÇÇ</strong></td>
<td>40 Œºg/m¬≥ (24-hour)</td>
<td>80 Œºg/m¬≥ (24-hour)</td>
</tr>
<tr>
<td><strong>CO</strong></td>
<td>4 mg/m¬≥ (24-hour)</td>
<td>2 mg/m¬≥ (8-hour)</td>
</tr>
<tr>
<td><strong>O‚ÇÉ</strong></td>
<td>100 Œºg/m¬≥ (8-hour)</td>
<td>100 Œºg/m¬≥ (8-hour)</td>
</tr>
</tbody>
</table>
<h3 id="indoor-air-pollution">üè† INDOOR AIR POLLUTION</h3>
<h4 id="sources-of-indoor-air-pollution">Sources of Indoor Air
Pollution</h4>
<ol type="1">
<li><strong>Combustion Sources</strong>
<ul>
<li><strong>Solid fuels</strong>: Wood, coal, dung, crop residues</li>
<li><strong>Kerosene</strong>: Lighting and cooking</li>
<li><strong>Biomass</strong>: Traditional cooking methods</li>
<li><strong>Tobacco smoke</strong>: Direct and secondhand</li>
</ul></li>
<li><strong>Building Materials</strong>
<ul>
<li><strong>Formaldehyde</strong>: Furniture, plywood, carpets</li>
<li><strong>Asbestos</strong>: Older building materials</li>
<li><strong>Lead-based paints</strong>: Wall and surface coatings</li>
<li><strong>Volatile Organic Compounds</strong>: Synthetic
materials</li>
</ul></li>
<li><strong>Consumer Products</strong>
<ul>
<li><strong>Cleaning products</strong>: Volatile chemicals</li>
<li><strong>Personal care products</strong>: Aerosols, perfumes</li>
<li><strong>Cosmetics</strong>: Chemical ingredients</li>
<li><strong>Pesticides</strong>: Indoor pest control</li>
</ul></li>
</ol>
<h4 id="health-effects-of-indoor-air-pollution">Health Effects of Indoor
Air Pollution</h4>
<ol type="1">
<li><strong>Acute Effects</strong>
<ul>
<li>Eye irritation</li>
<li>Headaches and dizziness</li>
<li>Respiratory irritation</li>
<li>Nausea and fatigue</li>
</ul></li>
<li><strong>Chronic Effects</strong>
<ul>
<li><strong>Respiratory diseases</strong>: COPD, asthma</li>
<li><strong>Cardiovascular disease</strong>: Heart attacks, stroke</li>
<li><strong>Cancer</strong>: Lung cancer from radon, benzene</li>
<li><strong>Reproductive effects</strong>: Low birth weight, premature
birth</li>
</ul></li>
<li><strong>Vulnerable Populations</strong>
<ul>
<li><strong>Children</strong>: Developing respiratory system</li>
<li><strong>Elderly</strong>: Reduced immune function</li>
<li><strong>Pregnant women</strong>: Fetal development effects</li>
<li><strong>Chronic disease patients</strong>: Exacerbation of
conditions</li>
</ul></li>
</ol>
<h4 id="indoor-air-quality-standards">Indoor Air Quality Standards</h4>
<ul>
<li><strong>Ventilation Rate</strong>: 5-6 air changes per hour</li>
<li><strong>CO‚ÇÇ Levels</strong>: &lt;1000 ppm for good air quality</li>
<li><strong>PM2.5</strong>: &lt;12 Œºg/m¬≥ (EPA guideline)</li>
<li><strong>Formaldehyde</strong>: &lt;0.1 ppm (8-hour exposure)</li>
<li><strong>Radon</strong>: &lt;4 pCi/L (EPA action level)</li>
</ul>
<h3 id="industrial-air-pollution">üè≠ INDUSTRIAL AIR POLLUTION</h3>
<h4 id="major-industrial-sources">Major Industrial Sources</h4>
<ol type="1">
<li><strong>Thermal Power Plants</strong>
<ul>
<li><strong>Coal-fired plants</strong>: PM, SO‚ÇÇ, NO‚Çì emissions</li>
<li><strong>Emission standards</strong>: SO‚ÇÇ 500 mg/Nm¬≥, NO‚Çì 600
mg/Nm¬≥</li>
<li><strong>Control measures</strong>: Flue gas desulfurization,
electrostatic precipitators</li>
</ul></li>
<li><strong>Cement Industry</strong>
<ul>
<li><strong>Particulate matter</strong>: Dust from kilns and
handling</li>
<li><strong>SO‚ÇÇ emissions</strong>: From fuel combustion</li>
<li><strong>Control measures</strong>: Bag filters, cyclones</li>
</ul></li>
<li><strong>Steel Industry</strong>
<ul>
<li><strong>Blast furnaces</strong>: CO, PM, SO‚ÇÇ emissions</li>
<li><strong>Sintering plants</strong>: High particulate matter</li>
<li><strong>Control measures</strong>: Gas cleaning systems</li>
</ul></li>
<li><strong>Chemical Industry</strong>
<ul>
<li><strong>Organic compounds</strong>: VOCs emissions</li>
<li><strong>Acid production</strong>: SO‚ÇÇ, HCl emissions</li>
<li><strong>Control measures</strong>: Scrubbers, thermal oxidizers</li>
</ul></li>
</ol>
<h4 id="industrial-emission-control">Industrial Emission Control</h4>
<ol type="1">
<li><strong>Air Pollution Control Equipment</strong>
<ul>
<li><strong>Electrostatic precipitators</strong>: Particulate
removal</li>
<li><strong>Bag filters</strong>: High-efficiency particulate
capture</li>
<li><strong>Wet scrubbers</strong>: Gas cleaning with liquid</li>
<li><strong>Thermal oxidizers</strong>: VOC destruction</li>
</ul></li>
<li><strong>Stack Monitoring</strong>
<ul>
<li><strong>Continuous emission monitoring</strong>: Real-time data</li>
<li><strong>Source testing</strong>: Periodic compliance
verification</li>
<li><strong>Data reporting</strong>: To pollution control boards</li>
</ul></li>
</ol>
<h4 id="national-emission-standards-india">National Emission Standards
(India)</h4>
<table>
<thead>
<tr>
<th>Industry Category</th>
<th>PM (mg/Nm¬≥)</th>
<th>SO‚ÇÇ (mg/Nm¬≥)</th>
<th>NO‚Çì (mg/Nm¬≥)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thermal Power Plants</strong></td>
<td>100</td>
<td>500</td>
<td>600</td>
</tr>
<tr>
<td><strong>Cement Industry</strong></td>
<td>30</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Iron &amp; Steel</strong></td>
<td>50</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Chemical Industry</strong></td>
<td>150</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3 id="vehicular-pollution-control">üöó VEHICULAR POLLUTION CONTROL</h3>
<h4 id="vehicle-emissions">Vehicle Emissions</h4>
<ol type="1">
<li><strong>Exhaust Emissions</strong>
<ul>
<li><strong>Carbon monoxide</strong>: Incomplete combustion</li>
<li><strong>Hydrocarbons</strong>: Unburned fuel</li>
<li><strong>Nitrogen oxides</strong>: High-temperature combustion</li>
<li><strong>Particulate matter</strong>: Diesel engines</li>
</ul></li>
<li><strong>Non-exhaust Emissions</strong>
<ul>
<li><strong>Brake wear</strong>: Metal particles</li>
<li><strong>Tire wear</strong>: Rubber particles</li>
<li><strong>Road dust</strong>: Resuspended particles</li>
</ul></li>
</ol>
<h4 id="emission-standards-evolution">Emission Standards Evolution</h4>
<ol type="1">
<li><strong>Bharat Stage (BS) Standards</strong>
<ul>
<li><strong>BS-I</strong>: Introduced 2000</li>
<li><strong>BS-II</strong>: 2001-2005</li>
<li><strong>BS-III</strong>: 2005-2010</li>
<li><strong>BS-IV</strong>: 2010-2017</li>
<li><strong>BS-VI</strong>: 2020 onwards (leap from BS-IV)</li>
</ul></li>
<li><strong>BS-VI vs BS-IV Comparison</strong>
<ul>
<li><strong>PM emissions</strong>: 80% reduction for diesel</li>
<li><strong>NO‚Çì emissions</strong>: 68% reduction for diesel</li>
<li><strong>Sulfur content</strong>: &lt;10 ppm (from 50 ppm)</li>
</ul></li>
</ol>
<h4 id="pollution-control-measures">Pollution Control Measures</h4>
<ol type="1">
<li><strong>Vehicle Technology</strong>
<ul>
<li><strong>Catalytic converters</strong>: CO, HC reduction</li>
<li><strong>DPF (Diesel Particulate Filter)</strong>: PM reduction</li>
<li><strong>SCR (Selective Catalytic Reduction)</strong>: NO‚Çì
reduction</li>
<li><strong>Electronic fuel injection</strong>: Better combustion</li>
</ul></li>
<li><strong>Fuel Quality</strong>
<ul>
<li><strong>Low sulfur diesel</strong>: Reduced SO‚ÇÇ emissions</li>
<li><strong>Unleaded petrol</strong>: Reduced lead emissions</li>
<li><strong>CNG/LPG</strong>: Cleaner fuel options</li>
<li><strong>Biodiesel</strong>: Renewable fuel alternative</li>
</ul></li>
<li><strong>Traffic Management</strong>
<ul>
<li><strong>Odd-even scheme</strong>: Delhi pilot project</li>
<li><strong>Congestion pricing</strong>: Economic incentives</li>
<li><strong>Public transport promotion</strong>: Reduce vehicle
numbers</li>
<li><strong>Alternative transport</strong>: Cycling, walking
infrastructure</li>
</ul></li>
</ol>
<h4 id="vehicle-emission-testing">Vehicle Emission Testing</h4>
<ol type="1">
<li><strong>Pollution Under Control (PUC)</strong>
<ul>
<li><strong>Frequency</strong>: Annual testing for all vehicles</li>
<li><strong>Parameters</strong>: CO, HC for petrol; smoke for
diesel</li>
<li><strong>Certificate validity</strong>: 6 months for commercial
vehicles</li>
<li><strong>Fine for non-compliance</strong>: ‚Çπ1,000 (Delhi)</li>
</ul></li>
<li><strong>Remote Sensing Devices</strong>
<ul>
<li><strong>Technology</strong>: Roadside emission measurement</li>
<li><strong>Coverage</strong>: Major highways and city roads</li>
<li><strong>Detection</strong>: High-emitting vehicles
identification</li>
<li><strong>Follow-up</strong>: Targeted emission testing</li>
</ul></li>
</ol>
<h3 id="air-quality-standards">üå¨Ô∏è AIR QUALITY STANDARDS</h3>
<h4 id="who-global-air-quality-guidelines-2021">WHO Global Air Quality
Guidelines (2021)</h4>
<p><strong>Annual Guidelines:</strong> - <strong>PM2.5</strong>: 5 Œºg/m¬≥
- <strong>PM10</strong>: 15 Œºg/m¬≥ - <strong>NO‚ÇÇ</strong>: 10 Œºg/m¬≥ -
<strong>O‚ÇÉ</strong>: No annual guideline (peak season)</p>
<p><strong>24-hour Guidelines:</strong> - <strong>PM2.5</strong>: 15
Œºg/m¬≥ - <strong>PM10</strong>: 45 Œºg/m¬≥ - <strong>NO‚ÇÇ</strong>: 25 Œºg/m¬≥
- <strong>SO‚ÇÇ</strong>: 40 Œºg/m¬≥ - <strong>O‚ÇÉ</strong>: 100 Œºg/m¬≥
(8-hour average)</p>
<h4 id="national-ambient-air-quality-standards-india">National Ambient
Air Quality Standards (India)</h4>
<p><strong>Residential Areas:</strong> - <strong>PM10</strong>: 100
Œºg/m¬≥ (annual), 150 Œºg/m¬≥ (24-hour) - <strong>PM2.5</strong>: 60 Œºg/m¬≥
(annual), 100 Œºg/m¬≥ (24-hour) - <strong>NO‚ÇÇ</strong>: 40 Œºg/m¬≥ (annual),
80 Œºg/m¬≥ (24-hour) - <strong>SO‚ÇÇ</strong>: 20 Œºg/m¬≥ (annual), 80 Œºg/m¬≥
(24-hour) - <strong>CO</strong>: 1 mg/m¬≥ (8-hour), 2 mg/m¬≥ (1-hour)</p>
<h4 id="air-quality-management-strategies">Air Quality Management
Strategies</h4>
<ol type="1">
<li><strong>Source Control</strong>
<ul>
<li><strong>Industrial emission standards</strong></li>
<li><strong>Vehicle emission control</strong></li>
<li><strong>Fuel quality improvement</strong></li>
</ul></li>
<li><strong>Air Quality Monitoring</strong>
<ul>
<li><strong>Ambient monitoring network</strong></li>
<li><strong>Real-time monitoring</strong></li>
<li><strong>Public information systems</strong></li>
</ul></li>
<li><strong>Health Protection Measures</strong>
<ul>
<li><strong>Air quality forecasting</strong></li>
<li><strong>Health advisories</strong></li>
<li><strong>Vulnerable population protection</strong></li>
</ul></li>
</ol>
<h3 id="memory-aids-tips-4">üí° MEMORY AIDS &amp; TIPS</h3>
<p><strong>‚ÄúAQI-CATEGORIES‚Äù Memory:</strong> -
<strong>C</strong>olor-coded system (green to maroon) -
<strong>A</strong>void activities based on levels -
<strong>T</strong>hreshold values for each pollutant -
<strong>E</strong>mergency measures at severe levels -
<strong>G</strong>overnment guidelines compliance -
<strong>O</strong>utdoor activity restrictions -
<strong>R</strong>eal-time monitoring stations - <strong>I</strong>ndoor
air quality importance - <strong>E</strong>conomic impact of air
pollution - <strong>S</strong>ensitive group awareness</p>
<p><strong>‚ÄúVEHICULAR EMISSIONS‚Äù Mnemonic:</strong> -
<strong>V</strong>ehicle technology improvements -
<strong>E</strong>mission testing requirements -
<strong>H</strong>igh-emitter identification - <strong>I</strong>mproved
fuel quality - <strong>C</strong>NG/LPG adoption -
<strong>U</strong>rban traffic management - <strong>L</strong>eap to
BS-VI standards - <strong>A</strong>ir quality improvement -
<strong>R</strong>emote sensing technology - <strong>P</strong>ublic
transport promotion</p>
<p><strong>‚ÄúINDOOR POLLUTION‚Äù Sources:</strong> -
<strong>C</strong>ombustion sources (cooking, heating) -
<strong>O</strong>utdoor air infiltration - <strong>M</strong>aterial
emissions (formaldehyde, VOCs) - <strong>B</strong>uilding
characteristics (ventilation) - <strong>U</strong>ser activities
(smoking, cleaning) - <strong>S</strong>easonal variations (winter
concentrations) - <strong>T</strong>ime spent indoors (9-10 hours
daily)</p>
<p><strong>‚ÄúINDUSTRIAL CONTROL‚Äù Equipment:</strong> -
<strong>E</strong>lectrostatic precipitators -
<strong>S</strong>crubbers (wet/dry) - <strong>C</strong>atalytic
converters - <strong>T</strong>hermal oxidizers -
<strong>R</strong>eversed flow systems - <strong>O</strong>zone
generators - <strong>L</strong>ow-NOx burners -
<strong>S</strong>elective catalytic reduction</p>
<h3 id="exam-questions-important-points-5">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Explain the National Air
Quality Index and its significance in public health management 2.
Discuss indoor air pollution as a major health concern, including
sources, health effects, and control measures 3. Analyze the health
impacts of vehicular air pollution and discuss control strategies 4.
Compare WHO and Indian air quality standards and their implications for
public health</p>
<p><strong>Short Answer Questions:</strong> 1. Indoor air pollution
sources and health effects 2. BS-VI emission standards and their
benefits 3. Air pollution control equipment in industries 4. Air Quality
Index calculation methodology</p>
<p><strong>MCQ Points:</strong> - WHO PM2.5 guideline: 5 Œºg/m¬≥ (annual)
- AQI range for ‚ÄúGood‚Äù category: 0-50 - BS-VI implementation year in
India: 2020 - Indoor air pollution causes 3.8 million deaths
annually</p>
<h3 id="references-to-latest-guidelines-4">üìö REFERENCES TO LATEST
GUIDELINES</h3>
<ul>
<li>WHO Global Air Quality Guidelines 2021</li>
<li>National Clean Air Programme (NCAP) 2019</li>
<li>BS-VI Emission Standards notification 2016</li>
<li>Air (Prevention &amp; Control of Pollution) Act 1981</li>
<li>CPCB Air Quality Monitoring Guidelines 2023</li>
<li>RGUHS Environmental Health Syllabus 2020</li>
</ul>
<hr />
<h2 id="chapter-7-water">Chapter 7: Water</h2>
<h3 id="quick-facts-box-6">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Water Access</strong>: 2.2 billion people lack safe drinking
water (WHO 2023)</li>
<li><strong>Water-Borne Diseases</strong>: 1.8 million deaths annually
from diarrhea</li>
<li><strong>Global Coverage</strong>: 74% of population has safe
drinking water (2022)</li>
<li><strong>India Water Stress</strong>: 40% population lives in
water-scarce areas</li>
<li><strong>Fluorosis</strong>: 66 million people affected by excessive
fluoride</li>
</ul>
<h3 id="water-quality-parameters-1">üíß WATER QUALITY PARAMETERS</h3>
<h4 id="physical-parameters">Physical Parameters</h4>
<ol type="1">
<li><strong>Turbidity</strong>
<ul>
<li><strong>Definition</strong>: Cloudiness caused by suspended
particles</li>
<li><strong>WHO Standard</strong>: &lt;1 NTU (Nephelometric Turbidity
Units)</li>
<li><strong>Health Significance</strong>: High turbidity indicates
contamination, protects microorganisms</li>
<li><strong>Measurement</strong>: Turbidimeter</li>
<li><strong>Causes</strong>: Soil erosion, inadequate filtration, algae
growth</li>
</ul></li>
<li><strong>Color</strong>
<ul>
<li><strong>Definition</strong>: Hue of water due to dissolved or
suspended substances</li>
<li><strong>Acceptable</strong>: Colorless or faintly colored</li>
<li><strong>Causes</strong>: Organic matter, metals, industrial
waste</li>
<li><strong>Health Impact</strong>: Aesthetic concern, may indicate
contamination</li>
</ul></li>
<li><strong>Taste and Odor</strong>
<ul>
<li><strong>Acceptance Criteria</strong>: Should be palatable and
odorless</li>
<li><strong>Common Causes</strong>:
<ul>
<li>Earthy: Algae, bacteria</li>
<li>Metallic: Iron, manganese</li>
<li>Chemical: Chlorine, industrial chemicals</li>
</ul></li>
<li><strong>Health Significance</strong>: Unacceptable taste may reduce
consumption</li>
</ul></li>
<li><strong>Temperature</strong>
<ul>
<li><strong>Optimal Range</strong>: 10-25¬∞C</li>
<li><strong>High Temperature</strong>: Increases bacterial growth,
affects taste</li>
<li><strong>Low Temperature</strong>: May indicate groundwater
source</li>
<li><strong>Measurement</strong>: Thermometer or temperature probe</li>
</ul></li>
</ol>
<h4 id="chemical-parameters">Chemical Parameters</h4>
<p><strong>Essential Chemical Constituents:</strong> 1.
<strong>pH</strong> - <strong>WHO Standard</strong>: 6.5-8.5 -
<strong>Health Significance</strong>: Affects water taste, pipe
corrosion, disinfection - <strong>Measurement</strong>: pH meter or
indicator - <strong>High pH</strong>: Bitter taste, scale formation -
<strong>Low pH</strong>: Corrosive, metallic taste</p>
<ol start="2" type="1">
<li><strong>Total Dissolved Solids (TDS)</strong>
<ul>
<li><strong>WHO Standard</strong>: &lt;500 mg/L (desirable), &lt;1000
mg/L (maximum)</li>
<li><strong>Components</strong>: Inorganic salts (calcium, magnesium,
sodium, potassium)</li>
<li><strong>Health Effects</strong>: High TDS may cause gastrointestinal
irritation</li>
<li><strong>Measurement</strong>: TDS meter or calculation from
conductivity</li>
</ul></li>
<li><strong>Chloride</strong>
<ul>
<li><strong>WHO Standard</strong>: &lt;250 mg/L</li>
<li><strong>Sources</strong>: Natural deposits, seawater intrusion,
industrial waste</li>
<li><strong>Health Effects</strong>: High levels may cause hypertension
in susceptible individuals</li>
<li><strong>Measurement</strong>: Silver nitrate titration</li>
</ul></li>
<li><strong>Sulfate</strong>
<ul>
<li><strong>WHO Standard</strong>: &lt;250 mg/L</li>
<li><strong>Sources</strong>: Natural mineral deposits, industrial
discharge</li>
<li><strong>Health Effects</strong>: Diarrhea at high
concentrations</li>
<li><strong>Measurement</strong>: Gravimetric or turbidimetric
methods</li>
</ul></li>
<li><strong>Fluoride</strong>
<ul>
<li><strong>WHO Standard</strong>: 0.5-1.5 mg/L</li>
<li><strong>Optimal Level</strong>: 1.0 mg/L (dental caries
prevention)</li>
<li><strong>Defluoridation</strong>: &lt;0.5 mg/L levels in some
areas</li>
<li><strong>Health Effects</strong>:
<ul>
<li>Deficiency: Dental caries</li>
<li>Excess: Dental/skeletal fluorosis</li>
</ul></li>
<li><strong>Measurement</strong>: Ion-selective electrode</li>
</ul></li>
<li><strong>Iron and Manganese</strong>
<ul>
<li><strong>Iron Standard</strong>: &lt;0.3 mg/L</li>
<li><strong>Manganese Standard</strong>: &lt;0.1 mg/L</li>
<li><strong>Sources</strong>: Natural mineral deposits, corrosion</li>
<li><strong>Effects</strong>: Staining, taste, aesthetic concerns</li>
<li><strong>Health</strong>: Generally not toxic but affects
acceptability</li>
</ul></li>
</ol>
<p><strong>Toxic Chemical Parameters:</strong> 1. <strong>Heavy
Metals</strong> - <strong>Lead</strong>: &lt;0.01 mg/L -
<strong>Arsenic</strong>: &lt;0.01 mg/L (WHO), &lt;0.05 mg/L (India) -
<strong>Cadmium</strong>: &lt;0.003 mg/L - <strong>Mercury</strong>:
&lt;0.006 mg/L - <strong>Chromium</strong>: &lt;0.05 mg/L</p>
<ol start="2" type="1">
<li><strong>Nitrate and Nitrite</strong>
<ul>
<li><strong>Nitrate</strong>: &lt;45 mg/L</li>
<li><strong>Nitrite</strong>: &lt;3 mg/L</li>
<li><strong>Sources</strong>: Agricultural runoff, sewage, industrial
waste</li>
<li><strong>Health Effects</strong>: Methemoglobinemia (‚Äúblue baby
syndrome‚Äù)</li>
</ul></li>
<li><strong>Pesticides</strong>
<ul>
<li><strong>Individual pesticides</strong>: &lt;0.1 Œºg/L</li>
<li><strong>Total pesticides</strong>: &lt;0.5 Œºg/L</li>
<li><strong>Health Effects</strong>: Carcinogenic, endocrine
disruption</li>
</ul></li>
</ol>
<h4 id="biological-parameters">Biological Parameters</h4>
<ol type="1">
<li><strong>Coliform Bacteria</strong>
<ul>
<li><strong>Standard</strong>: 0 per 100ml (E. coli)</li>
<li><strong>Total Coliform</strong>: &lt;10 per 100ml</li>
<li><strong>Sources</strong>: Fecal contamination</li>
<li><strong>Health Significance</strong>: Indicates presence of
pathogenic bacteria</li>
<li><strong>Test Methods</strong>: Multiple tube fermentation, membrane
filtration</li>
</ul></li>
<li><strong>Standard Plate Count</strong>
<ul>
<li><strong>Standard</strong>: &lt;10 colonies per ml</li>
<li><strong>Significance</strong>: General bacterial contamination</li>
<li><strong>Measurement</strong>: Incubation at 37¬∞C for 24-48
hours</li>
</ul></li>
<li><strong>Specific Pathogens</strong>
<ul>
<li><strong>Viral indicators</strong>: Coliphages</li>
<li><strong>Protozoan cysts</strong>: Giardia, Cryptosporidium</li>
<li><strong>Helminth eggs</strong>: Ascaris, Trichuris</li>
</ul></li>
</ol>
<h3 id="water-borne-diseases-1">ü¶† WATER-BORNE DISEASES</h3>
<h4 id="bacterial-diseases">Bacterial Diseases</h4>
<p><strong>1. Cholera</strong> - <strong>Causative Agent</strong>:
Vibrio cholerae (serotypes O1, O139) - <strong>Incubation
Period</strong>: 2 hours to 5 days - <strong>Symptoms</strong>: -
Profuse rice-water diarrhea - Vomiting, dehydration - Muscle cramps -
Rapid fluid loss (up to 1L/hour) - <strong>Mortality</strong>: 1-50%
without treatment, &lt;1% with proper treatment -
<strong>Epidemiology</strong>: - Endemic in 50+ countries - Outbreaks
during floods, natural disasters - Seasonal pattern (monsoon) -
<strong>Prevention</strong>: - Safe water supply - Sanitation
improvement - Oral cholera vaccine (2 doses) - Food safety measures</p>
<p><strong>2. Typhoid Fever</strong> - <strong>Causative Agent</strong>:
Salmonella typhi - <strong>Incubation Period</strong>: 7-14 days (up to
60 days) - <strong>Symptoms</strong>: - Sustained fever (104-105¬∞F) -
Headache, malaise - Rose spots on trunk - Hepatosplenomegaly -
Constipation (early) or diarrhea (late) -
<strong>Complications</strong>: Intestinal bleeding, perforation -
<strong>Carrier State</strong>: 3-5% become chronic carriers -
<strong>Prevention</strong>: - Water treatment - Vaccination (Vi
polysaccharide vaccine) - Food hygiene - Sanitary disposal of waste</p>
<p><strong>3. Bacillary Dysentery (Shigellosis)</strong> -
<strong>Causative Agent</strong>: Shigella species (S. dysenteriae most
severe) - <strong>Incubation Period</strong>: 1-3 days -
<strong>Symptoms</strong>: - Bloody diarrhea - Abdominal pain and
cramping - Fever - Tenesmus - <strong>Epidemiology</strong>: Highly
infectious (10-100 organisms can cause disease) -
<strong>Prevention</strong>: - Hand hygiene - Safe water - Food safety -
Personal hygiene</p>
<h4 id="viral-diseases">Viral Diseases</h4>
<p><strong>1. Hepatitis A</strong> - <strong>Causative Agent</strong>:
Hepatitis A virus (Picornaviridae) - <strong>Incubation Period</strong>:
15-50 days (average 28 days) - <strong>Symptoms</strong>: - Prodromal:
Fever, malaise, nausea - Jaundice: Yellowing of skin and eyes - Dark
urine, pale stools - Hepatomegaly - <strong>Age Distribution</strong>: -
Children: Usually asymptomatic - Adults: Symptomatic, more severe -
<strong>Prevention</strong>: - Hepatitis A vaccine - Safe water and food
- Hand hygiene - Sanitation</p>
<p><strong>2. Poliomyelitis</strong> - <strong>Causative Agent</strong>:
Poliovirus (Enterovirus) - <strong>Incubation Period</strong>: 7-14 days
- <strong>Symptoms</strong>: - Fever, headache - Neck stiffness - Muscle
pain - Paralysis (1 in 200 cases) - <strong>Age Distribution</strong>:
Most common in children &lt;5 years - <strong>Prevention</strong>: -
OPV/IPV vaccination (3+ doses) - Safe water - Sanitation - Surveillance
for acute flaccid paralysis</p>
<h4 id="parasitic-diseases">Parasitic Diseases</h4>
<p><strong>1. Amoebic Dysentery</strong> - <strong>Causative
Agent</strong>: Entamoeba histolytica - <strong>Incubation
Period</strong>: 2-4 weeks - <strong>Symptoms</strong>: - Bloody
diarrhea - Abdominal pain - Weight loss - Liver abscess
(extraintestinal) - <strong>Prevalence</strong>: 50 million cases
annually worldwide - <strong>Prevention</strong>: - Water treatment
(filtration/boiling) - Food hygiene - Hand washing - Sanitary
disposal</p>
<p><strong>2. Giardiasis</strong> - <strong>Causative Agent</strong>:
Giardia lamblia - <strong>Incubation Period</strong>: 1-2 weeks -
<strong>Symptoms</strong>: - Watery diarrhea - Abdominal cramps -
Flatulence, bloating - Malabsorption - <strong>Transmission</strong>:
Cysts in contaminated water - <strong>Prevention</strong>: - Water
filtration - Boiling water - Food hygiene</p>
<h4 id="water-related-diseases-non-waterborne">Water-Related Diseases
(Non-Waterborne)</h4>
<ol type="1">
<li><strong>Water-Washed Diseases</strong>
<ul>
<li><strong>Scabies</strong>: Due to insufficient water for hygiene</li>
<li><strong>Trachoma</strong>: Poor facial hygiene</li>
<li><strong>Skin infections</strong>: Lack of washing</li>
</ul></li>
<li><strong>Water-Based Diseases</strong>
<ul>
<li><strong>Schistosomiasis</strong>: Cercariae in water</li>
<li><strong>Dracunculiasis (Guinea worm)</strong>: Copepods in
water</li>
<li><strong>Fascioliasis</strong>: Aquatic snails</li>
</ul></li>
<li><strong>Water-Related Vector Diseases</strong>
<ul>
<li><strong>Malaria</strong>: Anopheles breeding in water</li>
<li><strong>Dengue</strong>: Aedes breeding in containers</li>
<li><strong>Lymphatic filariasis</strong>: Culex breeding in polluted
water</li>
</ul></li>
</ol>
<h3 id="water-purification-processes">üè≠ WATER PURIFICATION
PROCESSES</h3>
<h4 id="conventional-water-treatment-process">Conventional Water
Treatment Process</h4>
<p><strong>1. Coagulation and Flocculation</strong> -
<strong>Purpose</strong>: Remove suspended particles and colloids -
<strong>Chemicals Used</strong>: - Alum (Aluminum sulfate): Most common
- Ferric chloride: Alternative coagulant - Polyaluminum chloride:
Advanced coagulant - <strong>Process</strong>: - Rapid mixing: 1-3
minutes - Slow mixing: 15-30 minutes - Floc formation and settling</p>
<p><strong>2. Sedimentation</strong> - <strong>Purpose</strong>: Remove
flocculated particles by gravity - <strong>Types</strong>: - Plain
sedimentation: For large particles - Accelerated sedimentation: With
coagulants - <strong>Design Parameters</strong>: - Overflow rate:
1,000-2,000 L/m¬≤/day - Retention time: 2-4 hours - Settling velocity:
1-3 m/hour</p>
<p><strong>3. Filtration</strong> - <strong>Purpose</strong>: Remove
remaining suspended particles - <strong>Types</strong>: - <strong>Rapid
Sand Filtration</strong>: - Sand depth: 0.6-0.8 m - Filtration rate: 3-6
m¬≥/m¬≤/hour - Backwashing: Every 24-72 hours</p>
<ul>
<li><strong>Slow Sand Filtration</strong>:
<ul>
<li>Sand depth: 1-1.2 m</li>
<li>Biological layer (schmutzdecke)</li>
<li>Filtration rate: 0.1-0.3 m¬≥/m¬≤/hour</li>
<li>Longer operation (weeks to months)</li>
</ul></li>
</ul>
<p><strong>4. Disinfection</strong> - <strong>Purpose</strong>: Kill
pathogenic microorganisms - <strong>Primary Disinfectants</strong>: -
<strong>Chlorine</strong>: - Dosage: 0.2-0.5 mg/L residual - Contact
time: 30 minutes - CT value: &gt;15 mg¬∑min/L</p>
<ul>
<li><strong>Ozone</strong>:
<ul>
<li>Strong oxidant</li>
<li>No residual disinfection</li>
<li>Better taste and odor control</li>
</ul></li>
<li><strong>UV Light</strong>:
<ul>
<li>Physical disinfection</li>
<li>No chemical residue</li>
<li>254 nm wavelength</li>
</ul></li>
<li><strong>Secondary Disinfection</strong>:
<ul>
<li>Chloramine formation</li>
<li>Monochloramine: 0.5-1.0 mg/L</li>
</ul></li>
</ul>
<h4 id="advanced-treatment-processes">Advanced Treatment Processes</h4>
<p><strong>1. Reverse Osmosis (RO)</strong> -
<strong>Principle</strong>: Semi-permeable membrane separation -
<strong>Applications</strong>: Desalination, dissolved solids removal -
<strong>Pressure Required</strong>: 55-70 bar (seawater) -
<strong>Efficiency</strong>: 95-99% TDS removal</p>
<p><strong>2. Activated Carbon Filtration</strong> -
<strong>Purpose</strong>: Organic matter, taste, odor removal -
<strong>Types</strong>: - Granular activated carbon (GAC) - Powdered
activated carbon (PAC) - <strong>Regeneration</strong>: Thermal
treatment</p>
<p><strong>3. Ion Exchange</strong> - <strong>Purpose</strong>: Heavy
metal removal, water softening - <strong>Applications</strong>: -
Nitrate removal - Arsenic removal - Chromium removal - <strong>Resin
Types</strong>: Cation, anion exchange</p>
<h4 id="household-water-treatment">Household Water Treatment</h4>
<p><strong>1. Boiling</strong> - <strong>Effectiveness</strong>: 100%
bacterial and viral inactivation - <strong>Time</strong>: 1-3 minutes at
sea level - <strong>Precautions</strong>: Cool before storage -
<strong>Cost</strong>: Fuel requirement</p>
<p><strong>2. Chlorination</strong> - <strong>Chemical</strong>: Sodium
hypochlorite (bleach) - <strong>Dosage</strong>: 2-4 drops per liter -
<strong>Contact Time</strong>: 30 minutes -
<strong>Limitations</strong>: Doesn‚Äôt remove chemicals, parasites</p>
<p><strong>3. Filtration</strong> - <strong>Ceramic Filters</strong>:
Bacteria removal - <strong>Biosand Filter</strong>: Multi-barrier system
- <strong>Sand Filtration</strong>: Simple, effective -
<strong>Disadvantages</strong>: Clogging, maintenance</p>
<p><strong>4. Solar Disinfection (SODIS)</strong> -
<strong>Method</strong>: UV radiation in plastic bottles -
<strong>Duration</strong>: 6-48 hours depending on weather -
<strong>Effectiveness</strong>: Bacteria, viruses, parasites -
<strong>Cost</strong>: Very low</p>
<h3 id="safe-drinking-water-standards">üíß SAFE DRINKING WATER
STANDARDS</h3>
<h4 id="indian-standards-bis-105002012">Indian Standards (BIS
10500:2012)</h4>
<p><strong>Essential Parameters:</strong> - <strong>Turbidity</strong>:
&lt;1 NTU (desirable), &lt;5 NTU (permissible) - <strong>pH</strong>:
6.5-8.5 - <strong>Total Dissolved Solids</strong>: &lt;500 mg/L
(desirable), &lt;2000 mg/L (permissible) - <strong>Chloride</strong>:
&lt;250 mg/L - <strong>Sulfate</strong>: &lt;250 mg/L -
<strong>Iron</strong>: &lt;0.3 mg/L - <strong>Fluoride</strong>: 1.0
mg/L (optimal), &lt;1.5 mg/L (permissible)</p>
<p><strong>Acceptable Limits:</strong> - <strong>Lead</strong>: &lt;0.05
mg/L - <strong>Arsenic</strong>: &lt;0.05 mg/L -
<strong>Mercury</strong>: &lt;0.001 mg/L - <strong>Cadmium</strong>:
&lt;0.01 mg/L - <strong>Chromium</strong>: &lt;0.05 mg/L -
<strong>Nitrate</strong>: &lt;45 mg/L - <strong>Coliform</strong>:
0/100ml</p>
<h4 id="who-drinking-water-guidelines-2023">WHO Drinking Water
Guidelines (2023)</h4>
<p><strong>Microbiological Guidelines:</strong> - E. coli: Must not be
detectable in any 100ml sample - Intestinal enterococci: Must not be
detectable in any 100ml sample - Coliform bacteria: Must not be
detectable in any 100ml sample (treated water)</p>
<p><strong>Chemical Guidelines:</strong> - Arsenic: &lt;0.01 mg/L
(provisional guideline) - Fluoride: &lt;1.5 mg/L (guideline value) -
Lead: &lt;0.01 mg/L (guideline value) - Mercury: &lt;0.006 mg/L
(guideline value) - Nitrate: &lt;50 mg/L (guideline value)</p>
<h4 id="water-quality-monitoring-programs">Water Quality Monitoring
Programs</h4>
<p><strong>1. Source Water Monitoring</strong> - <strong>Surface
Water</strong>: Monthly sampling - <strong>Groundwater</strong>:
Quarterly sampling - <strong>Parameters</strong>: Physical, chemical,
biological - <strong>Quality Assessment</strong>: Water Quality Index
(WQI)</p>
<p><strong>2. Distribution System Monitoring</strong> - <strong>Consumer
Taps</strong>: Monthly sampling - <strong>Representative
Points</strong>: Entrances, storage tanks - <strong>Parameters</strong>:
Disinfectant residual, bacteriological - <strong>Action Levels</strong>:
Trigger for investigation</p>
<p><strong>3. Emergency Monitoring</strong> - <strong>Contamination
Events</strong>: Increased frequency - <strong>Parameters</strong>:
Suspected contaminants - <strong>Action Protocol</strong>: Public
notification, alternative supplies</p>
<h3 id="water-treatment-methods">üè• WATER TREATMENT METHODS</h3>
<h4 id="community-level-treatment">Community Level Treatment</h4>
<p><strong>1. Surface Water Treatment Plants</strong> -
<strong>Capacity</strong>: &gt;0.1 MLD - <strong>Process</strong>:
Complete conventional treatment - <strong>Maintenance</strong>:
Professional operation - <strong>Quality Control</strong>: Regular
testing</p>
<p><strong>2. Decentralized Treatment Systems</strong> - <strong>Village
Level</strong>: 0.01-0.1 MLD - <strong>Simple Technology</strong>: Sand
filtration, chlorination - <strong>Community Participation</strong>:
Operation and maintenance - <strong>Sustainability</strong>: Local
ownership</p>
<h4 id="point-of-use-treatment">Point-of-Use Treatment</h4>
<p><strong>1. Biosand Filter</strong> - <strong>Design</strong>:
Concrete/plastic container - <strong>Media</strong>: Sand, gravel layers
- <strong>Biological Layer</strong>: Schmutzdecke formation -
<strong>Flow Rate</strong>: 0.6-1.0 L/hour -
<strong>Effectiveness</strong>: 90-99% bacterial removal</p>
<p><strong>2. Ceramic Filter</strong> - <strong>Material</strong>: Clay,
sawdust - <strong>Pore Size</strong>: 0.2-0.5 microns -
<strong>Effectiveness</strong>: Bacteria, protozoa removal -
<strong>Life Span</strong>: 1-3 years - <strong>Flow Rate</strong>: 1-2
L/hour</p>
<p><strong>3. Chlorine Dispenser</strong> - <strong>Automatic
Dosing</strong>: 2-4 ppm residual - <strong>Contact Time</strong>: 30
minutes - <strong>Effectiveness</strong>: Bacteria, viruses -
<strong>Limitations</strong>: Taste, odor, doesn‚Äôt remove chemicals</p>
<h4 id="emergency-water-treatment">Emergency Water Treatment</h4>
<p><strong>1. Mobile Treatment Units</strong> -
<strong>Capacity</strong>: 10,000-100,000 L/day -
<strong>Applications</strong>: Disaster relief, camps -
<strong>Technology</strong>: Reverse osmosis, UV -
<strong>Deployment</strong>: Rapid setup</p>
<p><strong>2. Tablet Disinfection</strong> - <strong>Chemical</strong>:
Sodium dichloroisocyanurate - <strong>Dosage</strong>: 1-2 tablets per
liter - <strong>Effectiveness</strong>: Broad-spectrum disinfection -
<strong>Shelf Life</strong>: 2-5 years</p>
<h3 id="fluorosis-and-other-water-related-disorders">ü¶¥ FLUOROSIS AND
OTHER WATER-RELATED DISORDERS</h3>
<h4 id="fluorosis">Fluorosis</h4>
<p><strong>1. Dental Fluorosis</strong> - <strong>Causes</strong>:
Excessive fluoride during tooth development - <strong>Age
Susceptibility</strong>: 0-8 years - <strong>Symptoms</strong>: - Mild:
White spots, lines - Moderate: Brown staining - Severe: Enamel pitting,
brown discoloration - <strong>Prevention</strong>: Maintain fluoride
&lt;1.5 mg/L</p>
<p><strong>2. Skeletal Fluorosis</strong> - <strong>Causes</strong>:
Long-term excessive fluoride intake (&gt;10 mg/day) -
<strong>Stages</strong>: - <strong>Stage I</strong>: Pain in joints,
bones - <strong>Stage II</strong>: Limited joint mobility -
<strong>Stage III</strong>: Deformities, disability - <strong>Endemic
Areas</strong>: 19 states in India - <strong>Affected
Population</strong>: 66 million people</p>
<p><strong>3. Defluoridation Methods</strong> - <strong>Nalgonda
Technique</strong>: Alum + lime - <strong>Activated Alumina</strong>:
Ion exchange - <strong>Bone Char</strong>: Calcined bone -
<strong>Reverse Osmosis</strong>: Complete removal</p>
<h4 id="other-water-related-disorders">Other Water-Related
Disorders</h4>
<p><strong>1. Methemoglobinemia (Blue Baby Syndrome)</strong> -
<strong>Cause</strong>: Nitrate reduction to nitrite -
<strong>Symptoms</strong>: Cyanosis, lethargy - <strong>Age</strong>:
Most common in infants &lt;6 months - <strong>Prevention</strong>:
Nitrate &lt;45 mg/L</p>
<p><strong>2. Arsenicosis</strong> - <strong>Cause</strong>: Chronic
arsenic exposure - <strong>Sources</strong>: Groundwater contamination -
<strong>Symptoms</strong>: - Skin lesions: Melanosis, keratosis -
Cancer: Skin, lung, bladder - Cardiovascular: Peripheral vascular
disease - <strong>Affected Areas</strong>: Bengal basin, Ganges
delta</p>
<p><strong>3. Fluorosis Control Strategies</strong> - <strong>Source
Control</strong>: Switch to safe water -
<strong>Defluoridation</strong>: Community and household -
<strong>Health Education</strong>: Awareness programs -
<strong>Surveillance</strong>: Regular monitoring</p>
<h3 id="memory-aids-tips-5">üí° MEMORY AIDS &amp; TIPS</h3>
<p><strong>‚ÄúWATER QUALITY PARAMETERS‚Äù ABCD:</strong> -
<strong>A</strong>esthetic (color, taste, odor) -
<strong>B</strong>iological (bacteria, viruses) -
<strong>C</strong>hemical (pH, TDS, heavy metals) -
<strong>D</strong>isease-causing agents (pathogens)</p>
<p><strong>‚ÄúWATER-BORNE DISEASES‚Äù Categories:</strong> -
<strong>B</strong>acterial (Cholera, Typhoid) - <strong>V</strong>iral
(Hepatitis A, Polio) - <strong>P</strong>arasitic (Amoebiasis,
Giardiasis) - <strong>C</strong>hemical (Heavy metals, pesticides)</p>
<p><strong>‚ÄúWATER TREATMENT‚Äù Process:</strong> -
<strong>C</strong>oagulation (add chemicals) -
<strong>F</strong>locculation (form flocs) -
<strong>S</strong>edimentation (settle flocs) -
<strong>F</strong>iltration (remove particles) -
<strong>D</strong>isinfection (kill pathogens)</p>
<p><strong>‚ÄúWATER STANDARDS‚Äù Framework:</strong> - <strong>W</strong>HO
guidelines (global) - <strong>I</strong>ndian standards (BIS) -
<strong>T</strong>esting frequency (monthly/quarterly) -
<strong>E</strong>mergency protocols - <strong>R</strong>isk assessment
- <strong>S</strong>urveillance systems</p>
<h3 id="exam-questions-important-points-6">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Discuss the importance of
water quality parameters in public health with emphasis on their health
significance and standards 2. Explain the major water-borne diseases in
India, their epidemiology, and prevention strategies 3. Describe the
conventional water treatment process and its public health significance
4. Analyze fluorosis as a major public health problem in India and
suggest control measures</p>
<p><strong>Short Answer Questions:</strong> 1. WHO drinking water
guidelines 2. Household water treatment methods 3. Water Quality Index
calculation 4. Defluoridation techniques</p>
<p><strong>MCQ Points:</strong> - Safe fluoride level in drinking water:
1.0 mg/L - Coliform count in safe water: 0 per 100ml - Water treatment
process: Coagulation, flocculation, sedimentation, filtration,
disinfection - Fluorosis affects 66 million people in India</p>
<h3 id="references-to-latest-guidelines-5">üìö REFERENCES TO LATEST
GUIDELINES</h3>
<ul>
<li>WHO Guidelines for Drinking Water Quality 2023</li>
<li>BIS 10500:2012 - Indian Standard for Drinking Water</li>
<li>National Water Quality Standards (India) 2018</li>
<li>Fluorosis Control Programme Guidelines (India)</li>
<li>RGUHS Community Medicine Water Sanitation Syllabus 2020</li>
</ul>
<hr />
<h2 id="chapter-8-waste">Chapter 8: Waste</h2>
<h3 id="quick-facts-box-7">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Global Waste Generation</strong>: 2.01 billion tonnes
annually (2023)</li>
<li><strong>India‚Äôs Waste</strong>: 62 million tonnes solid waste
generated per year</li>
<li><strong>Municipal Waste</strong>: 70% collected, 30% treated in
India</li>
<li><strong>Healthcare Waste</strong>: 0.5 kg/bed/day in India</li>
<li><strong>Plastic Waste</strong>: 8.3 million tonnes produced annually
in India</li>
</ul>
<h3 id="solid-waste-management">‚ôªÔ∏è SOLID WASTE MANAGEMENT</h3>
<h4 id="waste-generation-and-composition">Waste Generation and
Composition</h4>
<p><strong>Indian Municipal Solid Waste Composition:</strong> -
<strong>Organic waste</strong>: 40-60% (food waste, garden waste) -
<strong>Recyclable materials</strong>: 20-30% (paper, plastic, metals,
glass) - <strong>Inert materials</strong>: 15-20% (sand, stones,
demolition waste) - <strong>Hazardous waste</strong>: 1-5% (e-waste,
biomedical waste) - <strong>Mixed waste</strong>: 5-10% (textiles,
rubber, leather)</p>
<h4 id="waste-generation-rates">Waste Generation Rates</h4>
<p><strong>Per Capita Waste Generation (India):</strong> - <strong>Metro
cities</strong>: 0.5-0.8 kg/person/day - <strong>Tier-2 cities</strong>:
0.3-0.5 kg/person/day - <strong>Small towns</strong>: 0.2-0.3
kg/person/day - <strong>Rural areas</strong>: 0.1-0.2 kg/person/day</p>
<p><strong>Global Comparison:</strong> - <strong>High-income
countries</strong>: 1.2-1.5 kg/person/day - <strong>Upper-middle
income</strong>: 0.6-0.8 kg/person/day - <strong>Lower-middle
income</strong>: 0.3-0.6 kg/person/day</p>
<h4 id="solid-waste-management-hierarchy">Solid Waste Management
Hierarchy</h4>
<p><strong>1. Prevention and Minimization</strong> - <strong>Source
reduction</strong>: Less waste generation - <strong>Product
redesign</strong>: Eco-friendly packaging - <strong>Extended producer
responsibility</strong>: Manufacturer liability</p>
<p><strong>2. Reuse</strong> - <strong>Material recovery</strong>:
Refillable containers - <strong>Product life extension</strong>: Repair
and maintenance - <strong>Sharing economy</strong>: Collaborative
consumption</p>
<p><strong>3. Recycling</strong> - <strong>Material recovery</strong>:
Paper, plastic, metal recycling - <strong>Energy recovery</strong>:
Waste-to-energy plants - <strong>Composting</strong>: Organic waste
processing</p>
<p><strong>4. Recovery</strong> - <strong>Energy generation</strong>:
Biogas, incineration - <strong>Resource extraction</strong>: Material
recovery facilities</p>
<p><strong>5. Disposal</strong> - <strong>Sanitary landfill</strong>:
Engineered disposal - <strong>Controlled dumping</strong>: Basic
landfill - <strong>Open dumping</strong>: Uncontrolled disposal</p>
<h4 id="municipal-solid-waste-management-steps">Municipal Solid Waste
Management Steps</h4>
<p><strong>1. Waste Collection</strong> - <strong>Door-to-door
collection</strong>: Primary collection system - <strong>Community
bins</strong>: Secondary collection points - <strong>Vehicle
collection</strong>: Municipal collection vehicles - <strong>Collection
efficiency</strong>: 70% urban India, 30% rural</p>
<p><strong>2. Transportation</strong> - <strong>Collection
routes</strong>: Optimized routing - <strong>Transfer stations</strong>:
Consolidation points - <strong>Vehicle types</strong>: Compactor,
dumper, specialized vehicles - <strong>GPS tracking</strong>: Route
optimization</p>
<p><strong>3. Treatment and Processing</strong> -
<strong>Composting</strong>: Aerobic decomposition - <strong>Biogas
generation</strong>: Anaerobic digestion -
<strong>Waste-to-energy</strong>: Incineration, pyrolysis -
<strong>Material recovery</strong>: Sorting, recycling</p>
<p><strong>4. Disposal</strong> - <strong>Sanitary landfill</strong>:
Engineered landfill site - <strong>Landfill requirements</strong>:
Liner, leachate treatment - <strong>Monitoring</strong>: Groundwater,
gas emissions</p>
<h4 id="waste-treatment-technologies">Waste Treatment Technologies</h4>
<p><strong>1. Composting</strong> - <strong>Process</strong>: Aerobic
decomposition - <strong>Products</strong>: Compost (soil conditioner) -
<strong>Capacity</strong>: 50-500 tonnes/day -
<strong>Technology</strong>: - Windrow composting - In-vessel composting
- Vermicomposting - <strong>Benefits</strong>: Organic waste reduction,
soil improvement</p>
<p><strong>2. Biogas Generation</strong> - <strong>Process</strong>:
Anaerobic digestion - <strong>Products</strong>: Biogas, digested slurry
- <strong>Biogas composition</strong>: 50-70% methane -
<strong>Applications</strong>: Cooking, electricity generation -
<strong>Capacity</strong>: 1-100 tonnes/day</p>
<p><strong>3. Waste-to-Energy</strong> - <strong>Technologies</strong>:
- <strong>Incineration</strong>: Burning waste -
<strong>Pyrolysis</strong>: Thermal decomposition -
<strong>Gasification</strong>: Partial combustion - <strong>Energy
recovery</strong>: Electricity generation - <strong>Capacity</strong>:
100+ tonnes/day</p>
<p><strong>4. Material Recovery Facility (MRF)</strong> -
<strong>Function</strong>: Sorting and recycling -
<strong>Capacity</strong>: 50-1000 tonnes/day -
<strong>Products</strong>: Recyclable materials -
<strong>Technology</strong>: Manual and automated sorting</p>
<h3 id="hospital-waste-management">üè• HOSPITAL WASTE MANAGEMENT</h3>
<h4 id="healthcare-waste-classification">Healthcare Waste
Classification</h4>
<p><strong>WHO Classification:</strong></p>
<p><strong>1. Non-hazardous Waste (85%)</strong> - General waste similar
to municipal waste - Paper, food, packaging materials - Non-risk
waste</p>
<p><strong>2. Hazardous Waste (15%)</strong></p>
<p><strong>a) Infectious Waste (5%)</strong> - Waste contaminated with
blood/body fluids - Laboratory cultures, pathological waste - Waste from
infected patients - Contaminated materials (bandages, cotton)</p>
<p><strong>b) Pathological Waste (1%)</strong> - Human tissues, organs,
body parts - Animal carcasses - Placenta, blood, body fluids</p>
<p><strong>c) Sharp Waste (1%)</strong> - Needles, syringes, lancets -
Surgical blades, scalpels - Broken glass, pipettes - Infusion sets</p>
<p><strong>d) Pharmaceutical Waste (3%)</strong> - Expired medications -
Unused drugs - Contaminated vaccines - Cytotoxic drugs</p>
<p><strong>e) Chemical Waste (2%)</strong> - Disinfectants - Solvents -
Formaldehyde - Heavy metals</p>
<p><strong>f) Radioactive Waste (1%)</strong> - Radioactive isotopes -
Contaminated materials from radiotherapy - Diagnostic materials</p>
<h4 id="healthcare-waste-generation">Healthcare Waste Generation</h4>
<p><strong>Waste Generation Rates:</strong> -
<strong>Hospitals</strong>: 0.5-2.0 kg/bed/day - <strong>Primary Health
Centers</strong>: 0.2-0.5 kg/bed/day - <strong>Blood banks</strong>: 2-5
kg/day - <strong>Laboratories</strong>: 1-3 kg/day</p>
<p><strong>Composition:</strong> - <strong>General waste</strong>:
80-85% - <strong>Infectious waste</strong>: 10-15% - <strong>Sharp
waste</strong>: 1-5% - <strong>Pathological waste</strong>: 0.5-3% -
<strong>Pharmaceutical waste</strong>: 1-2%</p>
<h4 id="hospital-waste-management-system">Hospital Waste Management
System</h4>
<p><strong>1. Waste Segregation</strong> - <strong>Color-coded
segregation</strong>: - <strong>Red</strong>: Infectious waste -
<strong>Yellow</strong>: Sharps, pathological waste -
<strong>Blue</strong>: Pharmaceutical waste - <strong>White</strong>:
Sharp waste (needle-free) - <strong>Black</strong>: General waste</p>
<p><strong>2. Collection</strong> - <strong>Segregated
collection</strong>: At point of generation - <strong>Safe
handling</strong>: Protective equipment - <strong>Transport
containers</strong>: Leak-proof, labeled - <strong>Collection
schedule</strong>: Daily for infectious waste</p>
<p><strong>3. Storage</strong> - <strong>Central storage</strong>:
Secure facility - <strong>Temperature control</strong>: &lt;4¬∞C for
infectious waste - <strong>Security</strong>: Access control -
<strong>Maximum storage</strong>: 48-72 hours</p>
<p><strong>4. Treatment</strong> - <strong>Incineration</strong>: 1100¬∞C
for infectious waste - <strong>Autoclaving</strong>: Steam sterilization
- <strong>Microwave treatment</strong>: Thermal treatment -
<strong>Chemical disinfection</strong>: Hypochlorite solution -
<strong>Sanitary landfill</strong>: Treated waste disposal</p>
<p><strong>5. Disposal</strong> - <strong>Treated waste</strong>: Safe
disposal - <strong>Ash disposal</strong>: Hazardous waste landfill -
<strong>Sharps disposal</strong>: Puncture-proof containers -
<strong>Records</strong>: Waste tracking</p>
<h3 id="biomedical-waste-rules">üè• BIOMEDICAL WASTE RULES</h3>
<h4 id="biomedical-waste-management-rules-2016">Biomedical Waste
Management Rules 2016</h4>
<p><strong>Scope:</strong> - <strong>Healthcare facilities</strong>:
Hospitals, clinics, diagnostic labs - <strong>Animal
facilities</strong>: Veterinary hospitals, animal houses - <strong>Blood
banks</strong>: Collection, storage, testing - <strong>Research
facilities</strong>: Laboratory research</p>
<p><strong>Key Provisions:</strong></p>
<p><strong>1. Segregation Rules</strong> - <strong>Mandatory
segregation</strong>: At point of generation - <strong>Color-coded
bins</strong>: As per Schedule I - <strong>Labeling</strong>: Biohazard
symbols - <strong>Non-compliance penalties</strong>: ‚Çπ5,000-25,000</p>
<p><strong>2. Authorization</strong> - <strong>Treatment
facilities</strong>: Authorisation from SPCB - <strong>Healthcare
facilities</strong>: If generating &gt;100 kg/month - <strong>Common
treatment facilities</strong>: Shared facilities for small
generators</p>
<p><strong>3. Transportation Rules</strong> - <strong>Segregated
transport</strong>: Separate vehicles - <strong>Tracking
documents</strong>: Manifest system - <strong>GPS tracking</strong>: For
waste transport - <strong>Inter-state transport</strong>: Prior
permission</p>
<p><strong>4. Treatment Standards</strong> -
<strong>Incineration</strong>: Temperature requirements -
<strong>Autoclaving</strong>: Time-temperature parameters - <strong>Deep
burial</strong>: For remote areas - <strong>Microwave</strong>: Specific
parameters</p>
<h4 id="state-pollution-control-board-responsibilities">State Pollution
Control Board Responsibilities</h4>
<p><strong>1. Authorization</strong> - <strong>Facility
authorization</strong>: Treatment and disposal - <strong>Time
period</strong>: Valid for 5 years - <strong>Conditions</strong>:
Compliance monitoring - <strong>Renewal</strong>: Application 120 days
before expiry</p>
<p><strong>2. Monitoring</strong> - <strong>Regular inspection</strong>:
Quarterly basis - <strong>Performance assessment</strong>: Annual review
- <strong>Complaint handling</strong>: Public complaints -
<strong>Compliance action</strong>: Violations</p>
<p><strong>3. Data Management</strong> - <strong>Waste generation
data</strong>: Annual compilation - <strong>Treatment capacity</strong>:
Assessment - <strong>Inventory</strong>: Treatment facilities -
<strong>Report submission</strong>: To CPCB</p>
<h4 id="common-treatment-facilities">Common Treatment Facilities</h4>
<p><strong>1. Design Criteria</strong> - <strong>Capacity</strong>:
Minimum 100 kg/day - <strong>Technology</strong>: Multiple treatment
options - <strong>Location</strong>: Away from habitation (500m minimum)
- <strong>Infrastructure</strong>: Roads, power, water</p>
<p><strong>2. Treatment Technologies</strong> -
<strong>Incineration</strong>: For infectious waste -
<strong>Autoclaving</strong>: For plastic waste -
<strong>Microwave</strong>: For infectious waste -
<strong>Shredding</strong>: For sharps - <strong>Chemical
treatment</strong>: For liquid waste</p>
<p><strong>3. Operating Conditions</strong> - <strong>Operating
hours</strong>: 24/7 operation - <strong>Staff training</strong>:
Certified operators - <strong>Safety measures</strong>: PPE, emergency
protocols - <strong>Environmental monitoring</strong>: Air, water
quality</p>
<h3 id="liquid-waste-management">üóëÔ∏è LIQUID WASTE MANAGEMENT</h3>
<h4 id="sewage-and-wastewater-treatment">Sewage and Wastewater
Treatment</h4>
<p><strong>1. Sewage Characteristics</strong> -
<strong>Physical</strong>: Color, odor, temperature, turbidity -
<strong>Chemical</strong>: BOD, COD, nutrients, heavy metals -
<strong>Biological</strong>: Bacteria, viruses, parasites</p>
<p><strong>2. Sewage Treatment Process</strong></p>
<p><strong>Primary Treatment:</strong> - <strong>Screening</strong>:
Removal of large solids - <strong>Grit removal</strong>: Sand, gravel
removal - <strong>Primary settling</strong>: Suspended solids removal -
<strong>Efficiency</strong>: 30-40% BOD removal</p>
<p><strong>Secondary Treatment:</strong> - <strong>Activated
sludge</strong>: Biological treatment - <strong>Trickling
filters</strong>: Attached growth - <strong>Oxidation ponds</strong>:
Large holding ponds - <strong>Efficiency</strong>: 85-95% BOD
removal</p>
<p><strong>Tertiary Treatment:</strong> - <strong>Filtration</strong>:
Sand, multimedia filtration - <strong>Disinfection</strong>:
Chlorination, UV treatment - <strong>Nutrient removal</strong>:
Phosphorus, nitrogen removal - <strong>Advanced treatment</strong>:
Membrane technology</p>
<h4 id="industrial-wastewater-treatment">Industrial Wastewater
Treatment</h4>
<p><strong>1. Treatment Levels</strong> - <strong>Pretreatment</strong>:
pH adjustment, screening - <strong>Primary treatment</strong>: Physical
processes - <strong>Secondary treatment</strong>: Biological treatment -
<strong>Tertiary treatment</strong>: Advanced treatment</p>
<p><strong>2. Common Treatment Methods</strong> -
<strong>Physical</strong>: Screening, sedimentation, flotation -
<strong>Chemical</strong>: Coagulation, precipitation, oxidation -
<strong>Biological</strong>: Activated sludge, trickling filters -
<strong>Advanced</strong>: Membrane filtration, ion exchange</p>
<h4 id="effluent-treatment-plant-etp">Effluent Treatment Plant
(ETP)</h4>
<p><strong>1. Design Parameters</strong> - <strong>Flow rate</strong>:
Peak and average flow - <strong>Pollutant load</strong>: BOD, COD, TSS -
<strong>Discharge standards</strong>: As per CPCB guidelines -
<strong>Space requirements</strong>: Land availability</p>
<p><strong>2. Treatment Units</strong> - <strong>Screening</strong>: Bar
racks, screen chamber - <strong>Oil &amp; grease trap</strong>: For oily
wastewater - <strong>Equalization tank</strong>: Flow balancing -
<strong>Primary clarifier</strong>: Settling tank - <strong>Aeration
tank</strong>: Biological treatment - <strong>Secondary
clarifier</strong>: Final settling - <strong>Sludge treatment</strong>:
Thickening, dewatering</p>
<h4 id="sewage-treatment-plant-performance">Sewage Treatment Plant
Performance</h4>
<p><strong>1. Treatment Efficiency</strong> - <strong>BOD
removal</strong>: 85-95% - <strong>COD removal</strong>: 80-90% -
<strong>Suspended solids</strong>: 90-95% - <strong>Pathogen
removal</strong>: 99.9%</p>
<p><strong>2. Treated Water Quality</strong> - <strong>BOD</strong>:
&lt;20 mg/L (discharge standard) - <strong>COD</strong>: &lt;50 mg/L -
<strong>Suspended solids</strong>: &lt;30 mg/L - <strong>Fecal
coliform</strong>: &lt;1000 MPN/100ml</p>
<h3 id="recycling-and-disposal-methods">‚ôªÔ∏è RECYCLING AND DISPOSAL
METHODS</h3>
<h4 id="material-recycling">Material Recycling</h4>
<p><strong>1. Paper Recycling</strong> - <strong>Process</strong>:
Collection, pulping, cleaning, paper making - <strong>Products</strong>:
Recycled paper, cardboard - <strong>Benefits</strong>: Save trees,
energy, water - <strong>Collection</strong>: Dry waste segregation</p>
<p><strong>2. Plastic Recycling</strong> - <strong>Types</strong>: PET,
HDPE, PVC, PP - <strong>Process</strong>: Sorting, washing, shredding,
pelletizing - <strong>Products</strong>: Pipes, containers, textile -
<strong>Challenges</strong>: Mixed plastics, contamination</p>
<p><strong>3. Metal Recycling</strong> - <strong>Ferrous
metals</strong>: Iron, steel - <strong>Non-ferrous</strong>: Aluminum,
copper, brass - <strong>Process</strong>: Collection, sorting, melting,
casting - <strong>Benefits</strong>: Energy saving (95% aluminum)</p>
<p><strong>4. Glass Recycling</strong> - <strong>Process</strong>:
Collection, cleaning, melting - <strong>Products</strong>: New glass
containers - <strong>Benefits</strong>: Energy saving (30%), raw
material saving</p>
<h4 id="recycling-technologies">Recycling Technologies</h4>
<p><strong>1. Material Recovery Facility</strong> -
<strong>Function</strong>: Separating recyclables -
<strong>Capacity</strong>: 50-1000 tonnes/day -
<strong>Technology</strong>: Manual and automated sorting -
<strong>Products</strong>: Sorted recyclables for reprocessing</p>
<p><strong>2. Waste-to-Energy</strong> - <strong>Incineration</strong>:
Controlled burning - <strong>Gasification</strong>: Partial combustion -
<strong>Pyrolysis</strong>: Thermal decomposition -
<strong>Products</strong>: Electricity, heat</p>
<p><strong>3. Composting</strong> - <strong>Organic waste</strong>:
Food, garden waste - <strong>Process</strong>: Aerobic decomposition -
<strong>Products</strong>: Compost for agriculture -
<strong>Duration</strong>: 3-6 months</p>
<h4 id="final-disposal-methods">Final Disposal Methods</h4>
<p><strong>1. Sanitary Landfill</strong> - <strong>Design</strong>:
Engineered disposal facility - <strong>Components</strong>: - Bottom
liner: HDPE membrane - Leachate collection: Drainage system - Gas
collection: Methane capture - Cover system: Daily and final cover -
<strong>Life span</strong>: 20-30 years - <strong>Capacity</strong>:
1-10 million tonnes</p>
<p><strong>2. Controlled Landfill</strong> - <strong>Features</strong>:
Basic liner system - <strong>Lifespan</strong>: 10-15 years -
<strong>Monitoring</strong>: Limited groundwater -
<strong>Cost</strong>: Lower than sanitary landfill</p>
<p><strong>3. Open Dumping</strong> - <strong>Method</strong>:
Uncontrolled disposal - <strong>Environmental impact</strong>: High -
<strong>Health risks</strong>: Disease vectors, contamination -
<strong>Status</strong>: Being phased out</p>
<h3 id="hazardous-waste-handling">‚ö†Ô∏è HAZARDOUS WASTE HANDLING</h3>
<h4 id="hazardous-waste-classification">Hazardous Waste
Classification</h4>
<p><strong>1. Categories</strong> - <strong>Schedule I</strong>:
Discarded containers, radioactive waste - <strong>Schedule II</strong>:
Disposal through incineration - <strong>Schedule III</strong>: Disposal
through secure landfill - <strong>Schedule IV</strong>: Disposal through
recycling</p>
<p><strong>2. Sources</strong> - <strong>Industrial</strong>: Chemicals,
metals, solvents - <strong>Electronic</strong>: E-waste processing -
<strong>Healthcare</strong>: Cytotoxic drugs, radioactive materials -
<strong>Household</strong>: Batteries, paints, pesticides</p>
<h4 id="hazardous-waste-treatment">Hazardous Waste Treatment</h4>
<p><strong>1. Incineration</strong> - <strong>Temperature</strong>:
&gt;1100¬∞C - <strong>Gases</strong>: Complete combustion -
<strong>Ash</strong>: Hazardous landfill disposal -
<strong>Applications</strong>: Organic solvents, pharmaceutical
waste</p>
<p><strong>2. Chemical Treatment</strong> -
<strong>Neutralization</strong>: Acid-base treatment -
<strong>Oxidation</strong>: Chemical oxidation -
<strong>Precipitation</strong>: Metal removal -
<strong>Applications</strong>: Heavy metal waste</p>
<p><strong>3. Physical Treatment</strong> -
<strong>Stabilization</strong>: Cement-based binding -
<strong>Solidification</strong>: Encapsulation -
<strong>Vitrification</strong>: Glass formation -
<strong>Applications</strong>: Heavy metal waste</p>
<h4 id="hazardous-waste-disposal">Hazardous Waste Disposal</h4>
<p><strong>1. Secure Landfill</strong> - <strong>Design</strong>: Double
liner system - <strong>Leachate collection</strong>: Comprehensive
system - <strong>Gas collection</strong>: Methane recovery -
<strong>Monitoring</strong>: Continuous</p>
<p><strong>2. Deep Well Injection</strong> - <strong>Method</strong>:
Injection into deep geological formations - <strong>Depth</strong>:
&gt;1000 meters - <strong>Application</strong>: Liquid hazardous waste -
<strong>Regulation</strong>: Strict monitoring</p>
<h3 id="memory-aids-tips-6">üí° MEMORY AIDS &amp; TIPS</h3>
<p><strong>‚ÄúWASTE MANAGEMENT HIERARCHY‚Äù Order:</strong> -
<strong>P</strong>revention (reduce waste) - <strong>R</strong>euse (use
again) - <strong>R</strong>ecycling (reprocess) -
<strong>R</strong>ecovery (energy) - <strong>D</strong>isposal (final
option)</p>
<p><strong>‚ÄúHOSPITAL WASTE SEGREGATION‚Äù Colors:</strong> -
<strong>R</strong>ed (Infectious) - <strong>Y</strong>ellow (Sharps,
Pathological) - <strong>B</strong>lue (Pharmaceutical) -
<strong>W</strong>hite (Sharp waste-needle free) -
<strong>B</strong>lack (General waste)</p>
<p><strong>‚ÄúRECYCLING PROCESS‚Äù Steps:</strong> - <strong>S</strong>ource
separation - <strong>C</strong>ollection -
<strong>T</strong>ransportation - <strong>P</strong>rocessing -
<strong>M</strong>anufacturing new products</p>
<p><strong>‚ÄúWASTE COMPOSITION‚Äù Approximate Percentages:</strong> -
<strong>O</strong>rganic: 50% (food, garden waste) -
<strong>R</strong>ecyclable: 30% (paper, plastic, metal, glass) -
<strong>I</strong>nert: 15% (sand, stones) - <strong>H</strong>azardous:
5% (e-waste, medical)</p>
<h3 id="exam-questions-important-points-7">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Discuss the solid waste
management system in Indian cities, including the principles and
practices 2. Explain hospital waste management, focusing on
classification, treatment, and disposal methods 3. Analyze the
Biomedical Waste Management Rules 2016 and their implementation 4.
Describe hazardous waste management principles and treatment
technologies</p>
<p><strong>Short Answer Questions:</strong> 1. Municipal solid waste
composition in India 2. Color coding for hospital waste segregation 3.
Waste-to-energy technologies 4. Hazardous waste classification</p>
<p><strong>MCQ Points:</strong> - Hospital waste generation: 0.5
kg/bed/day - Red bins for: Infectious waste - Municipal waste collection
efficiency: 70% (urban India) - Sanitary landfill temperature:
&gt;1100¬∞C</p>
<h3 id="references-to-latest-guidelines-6">üìö REFERENCES TO LATEST
GUIDELINES</h3>
<ul>
<li>Solid Waste Management Rules 2016</li>
<li>Biomedical Waste Management Rules 2016</li>
<li>Plastic Waste Management Rules 2022</li>
<li>Construction and Demolition Waste Rules 2016</li>
<li>Hazardous and Other Wastes Rules 2016</li>
<li>CPCB Guidelines for Common Treatment Facilities 2023</li>
<li>RGUHS Community Medicine Waste Management Syllabus 2020</li>
</ul>
<hr />
<h2 id="chapter-9-housing">Chapter 9: Housing</h2>
<h3 id="quick-facts-box-8">üéØ QUICK FACTS BOX</h3>
<ul>
<li><strong>Global Housing</strong>: 1.6 billion people lack adequate
housing (2023)</li>
<li><strong>India Housing Shortage</strong>: 10 million houses
deficit</li>
<li><strong>Urban Population</strong>: 35% of India‚Äôs population
(2023)</li>
<li><strong>Slum Population</strong>: 65 million people live in
slums</li>
<li><strong>Housing Health Impact</strong>: 2.6 million deaths from poor
housing annually</li>
</ul>
<h3 id="housing-standards-and-health">üè† HOUSING STANDARDS AND
HEALTH</h3>
<h4 id="who-housing-and-health-guidelines-2023">WHO Housing and Health
Guidelines (2023)</h4>
<p><strong>Core Housing Standards:</strong> 1. <strong>Structural
Safety</strong> - <strong>Foundation</strong>: Stable,
earthquake-resistant - <strong>Walls</strong>: Weather-resistant,
structural integrity - <strong>Roof</strong>: Weatherproof, safe
construction - <strong>Floors</strong>: Moisture-proof, level
surface</p>
<ol start="2" type="1">
<li><strong>Adequate Space</strong>
<ul>
<li><strong>Floor area</strong>: Minimum 10.8 m¬≤ per person</li>
<li><strong>Ceiling height</strong>: Minimum 2.4 meters</li>
<li><strong>Room size</strong>: Bedroom &gt;6.5 m¬≤</li>
<li><strong>Kitchen</strong>: &gt;3.5 m¬≤ with proper ventilation</li>
</ul></li>
<li><strong>Water and Sanitation</strong>
<ul>
<li><strong>Water supply</strong>: 40 liters per person per day</li>
<li><strong>Sanitation</strong>: &lt;10 persons per toilet</li>
<li><strong>Bathing facility</strong>: 2.5 m¬≤ minimum</li>
<li><strong>Drainage</strong>: Proper wastewater disposal</li>
</ul></li>
</ol>
<h4 id="indian-housing-standards">Indian Housing Standards</h4>
<p><strong>National Building Code Guidelines:</strong> 1.
<strong>Residential Building Standards</strong> - <strong>Plot
size</strong>: Minimum 30 m¬≤ - <strong>Built-up area</strong>: 66.6% of
plot (urban areas) - <strong>Open space</strong>: 33.3% of plot
(minimum) - <strong>Height restrictions</strong>: As per local
regulations</p>
<ol start="2" type="1">
<li><strong>Space Standards</strong>
<ul>
<li><strong>Living room</strong>: 12.9 m¬≤ minimum</li>
<li><strong>Bedroom</strong>: 9.3 m¬≤ minimum</li>
<li><strong>Kitchen</strong>: 5.6 m¬≤ minimum</li>
<li><strong>Bathroom</strong>: 1.8 m¬≤ minimum</li>
</ul></li>
<li><strong>Ventilation Standards</strong>
<ul>
<li><strong>Windows</strong>: 10% of floor area minimum</li>
<li><strong>Cross ventilation</strong>: Preferred</li>
<li><strong>Ceiling height</strong>: 2.75 meters minimum</li>
<li><strong>Air changes</strong>: 6 per hour in living areas</li>
</ul></li>
</ol>
<h4 id="housing-and-health-relationship">Housing and Health
Relationship</h4>
<p><strong>1. Respiratory Health</strong> - <strong>Adequate
ventilation</strong>: Reduces respiratory infections - <strong>Moisture
control</strong>: Prevents mold and mildew - <strong>Crowding</strong>:
Increases transmission of TB, pneumonia - <strong>Indoor air
quality</strong>: Impact on asthma, allergies</p>
<p><strong>2. Infectious Disease Control</strong> - <strong>Water
supply</strong>: Prevents water-borne diseases -
<strong>Sanitation</strong>: Reduces diarrheal diseases -
<strong>Overcrowding</strong>: Facilitates disease transmission -
<strong>Housing quality</strong>: Influences vector breeding</p>
<p><strong>3. Mental Health</strong> - <strong>Space adequacy</strong>:
Reduces stress and conflict - <strong>Privacy</strong>: Important for
psychological well-being - <strong>Safety</strong>: Reduces anxiety and
fear - <strong>Community integration</strong>: Social support
networks</p>
<p><strong>4. Nutritional Status</strong> - <strong>Food
storage</strong>: Proper storage prevents spoilage - <strong>Kitchen
facilities</strong>: Enables proper food preparation -
<strong>Refrigeration</strong>: Preserves perishable foods -
<strong>Clean water access</strong>: Prevents contamination</p>
<h3 id="ventilation-and-lighting">üå¨Ô∏è VENTILATION AND LIGHTING</h3>
<h4 id="natural-ventilation">Natural Ventilation</h4>
<p><strong>1. Principles</strong> - <strong>Cross ventilation</strong>:
Air movement through openings - <strong>Stack effect</strong>: Vertical
air movement - <strong>Wind direction</strong>: Siting consideration -
<strong>Temperature difference</strong>: Drives air movement</p>
<p><strong>2. Design Considerations</strong> - <strong>Window
placement</strong>: Opposite walls for cross flow - <strong>Window
area</strong>: 20-25% of floor area - <strong>Ventilation rate</strong>:
6-8 air changes per hour - <strong>Seasonal adjustment</strong>: Wind
direction changes</p>
<p><strong>3. Benefits</strong> - <strong>Indoor air quality</strong>:
Dilutes pollutants - <strong>Moisture control</strong>: Prevents
condensation - <strong>Energy efficiency</strong>: Reduces artificial
cooling needs - <strong>Health benefits</strong>: Reduces respiratory
diseases</p>
<h4 id="artificial-ventilation">Artificial Ventilation</h4>
<p><strong>1. Mechanical Ventilation</strong> - <strong>Exhaust
fans</strong>: Removes stale air - <strong>Supply fans</strong>: Brings
fresh air - <strong>Balanced systems</strong>: Supply and exhaust -
<strong>Heat recovery</strong>: Energy conservation</p>
<p><strong>2. Air Conditioning Systems</strong> - <strong>Central
AC</strong>: Large buildings - <strong>Split AC</strong>: Individual
rooms - <strong>Window AC</strong>: Smaller spaces - <strong>Smart
systems</strong>: Automated control</p>
<p><strong>3. Ventilation Standards</strong> - <strong>Living
areas</strong>: 6-8 air changes/hour - <strong>Kitchens</strong>: 10-15
air changes/hour - <strong>Bathrooms</strong>: 8-10 air changes/hour -
<strong>Bedrooms</strong>: 4-6 air changes/hour</p>
<h4 id="natural-lighting">Natural Lighting</h4>
<p><strong>1. Benefits</strong> - <strong>Circadian rhythm</strong>:
Regulates sleep-wake cycle - <strong>Vitamin D synthesis</strong>:
Essential for bone health - <strong>Mental health</strong>: Reduces
depression - <strong>Energy savings</strong>: Reduces artificial
lighting</p>
<p><strong>2. Design Requirements</strong> - <strong>Window
area</strong>: 10% of floor area minimum - <strong>North-facing
windows</strong>: Best for India - <strong>Daylight factor</strong>:
2-5% for adequate lighting - <strong>Glare control</strong>: Shading
devices</p>
<p><strong>3. Health Impacts</strong> - <strong>Vitamin D
deficiency</strong>: Inadequate sunlight - <strong>Seasonal affective
disorder</strong>: Low light exposure - <strong>Productivity</strong>:
Improved performance with natural light - <strong>Eye health</strong>:
Prevents myopia in children</p>
<h4 id="artificial-lighting">Artificial Lighting</h4>
<p><strong>1. Types</strong> - <strong>Incandescent</strong>:
Traditional but inefficient - <strong>Fluorescent</strong>: Good
efficiency, mercury concerns - <strong>LED</strong>: Most efficient,
long-lasting - <strong>Smart lighting</strong>: Automated control</p>
<p><strong>2. Requirements</strong> - <strong>Living areas</strong>:
100-300 lux - <strong>Kitchen</strong>: 300-500 lux - <strong>Study/work
areas</strong>: 300-500 lux - <strong>Bathrooms</strong>: 100-200 lux -
<strong>Stairways</strong>: 50-100 lux</p>
<p><strong>3. Energy Efficiency</strong> - <strong>LED
adoption</strong>: 80% energy savings - <strong>Natural light
utilization</strong>: Daylighting systems - <strong>Smart
controls</strong>: Occupancy sensors - <strong>Solar lighting</strong>:
Renewable energy option</p>
<h3 id="overcrowding-effects">üë• OVERCROWDING EFFECTS</h3>
<h4 id="overcrowding-definition-and-standards">Overcrowding Definition
and Standards</h4>
<p><strong>1. Definition</strong> - <strong>Crowding index</strong>:
Persons per room - <strong>High density</strong>: &gt;2 persons per room
- <strong>Severe overcrowding</strong>: &gt;3 persons per room -
<strong>Floor space</strong>: &lt;40 sq ft per person</p>
<p><strong>2. WHO Standards</strong> - <strong>Maximum</strong>: 2
persons per room - <strong>Bedroom</strong>: 1 person per 50 sq ft
minimum - <strong>Total space</strong>: 50-100 sq ft per person -
<strong>Minimum room size</strong>: 8 ft x 8 ft</p>
<p><strong>3. Indian Context</strong> - <strong>Census
definition</strong>: Rooms per household - <strong>Urban slums</strong>:
3-5 persons per room - <strong>Rural areas</strong>: Lower density
traditionally - <strong>Migration impact</strong>: Increased urban
crowding</p>
<h4 id="health-effects-of-overcrowding">Health Effects of
Overcrowding</h4>
<p><strong>1. Infectious Disease Transmission</strong> -
<strong>Respiratory diseases</strong>: TB, pneumonia, influenza -
<strong>Vector-borne diseases</strong>: Increased mosquito breeding -
<strong>Skin infections</strong>: Scabies, fungal infections -
<strong>Gastrointestinal</strong>: Spread through contaminated
surfaces</p>
<p><strong>2. Mental Health Impact</strong> - <strong>Stress</strong>:
Constant noise and activity - <strong>Privacy loss</strong>: Lack of
personal space - <strong>Conflict</strong>: Increased interpersonal
tensions - <strong>Sleep disturbance</strong>: Reduced quality and
duration</p>
<p><strong>3. Child Development</strong> - <strong>Educational
impact</strong>: Reduced study space - <strong>Social
development</strong>: Limited interaction opportunities -
<strong>Behavioral problems</strong>: Aggression, withdrawal -
<strong>Physical development</strong>: Nutritional deficiencies</p>
<h4 id="factors-contributing-to-overcrowding">Factors Contributing to
Overcrowding</h4>
<p><strong>1. Socioeconomic Factors</strong> - <strong>Poverty</strong>:
Cannot afford adequate housing - <strong>Unemployment</strong>: Reduces
housing choices - <strong>Large families</strong>: Traditional
multi-generational households - <strong>Rural-urban migration</strong>:
Limited urban housing</p>
<p><strong>2. Housing Market Factors</strong> - <strong>High rental
costs</strong>: Forces sharing - <strong>Limited supply</strong>:
Insufficient housing stock - <strong>Land prices</strong>: Expensive
urban land - <strong>Construction costs</strong>: High building
expenses</p>
<p><strong>3. Policy and Planning Factors</strong> - <strong>Zoning
restrictions</strong>: Limited development areas - <strong>Building
codes</strong>: Restrictive regulations -
<strong>Infrastructure</strong>: Poor access to services -
<strong>Government policies</strong>: Inadequate housing programs</p>
<h3 id="slum-health-issues">üèòÔ∏è SLUM HEALTH ISSUES</h3>
<h4 id="slum-definition-and-characteristics">Slum Definition and
Characteristics</h4>
<p><strong>1. UN-HABITAT Definition</strong> - <strong>Inadequate
housing</strong>: Poor construction, location - <strong>Inadequate
access to water</strong>: Limited or no supply - <strong>Inadequate
sanitation</strong>: Poor or no facilities - <strong>Unsecure
tenure</strong>: Informal settlements - <strong>Overcrowding</strong>:
High density - <strong>Vulnerability</strong>: To disasters and
diseases</p>
<p><strong>2. Indian Context</strong> - <strong>Housing and Urban
Development Corporation (HUDCO)</strong>: - Kuccha construction - Water
scarcity - Sanitation problems - Overcrowding - Poor location - Social
vulnerability</p>
<h4 id="health-profile-of-slum-residents">Health Profile of Slum
Residents</h4>
<p><strong>1. Communicable Diseases</strong> - <strong>Diarrheal
diseases</strong>: 15-20% higher than city average - <strong>Respiratory
infections</strong>: 25% higher incidence -
<strong>Tuberculosis</strong>: 2-3 times higher prevalence -
<strong>Vector-borne diseases</strong>: Dengue, malaria, chikungunya</p>
<p><strong>2. Maternal and Child Health</strong> - <strong>Infant
mortality</strong>: 30% higher than urban average - <strong>Maternal
mortality</strong>: 25% higher - <strong>Low birth weight</strong>: 40%
higher prevalence - <strong>Malnutrition</strong>: 35% higher rates</p>
<p><strong>3. Non-Communicable Diseases</strong> -
<strong>Hypertension</strong>: 20% higher prevalence -
<strong>Diabetes</strong>: 15% higher rates - <strong>Mental
health</strong>: 30% higher depression rates - <strong>Substance
abuse</strong>: Increased tobacco and alcohol use</p>
<h4 id="water-and-sanitation-in-slums">Water and Sanitation in
Slums</h4>
<p><strong>1. Water Access</strong> - <strong>Coverage</strong>: 60%
have water access - <strong>Quality</strong>: Often contaminated -
<strong>Source</strong>: Public taps, tankers, wells -
<strong>Quantity</strong>: Inadequate for needs - <strong>Cost</strong>:
5-10 times higher than municipal supply</p>
<p><strong>2. Sanitation Facilities</strong> - <strong>Toilet
coverage</strong>: 30% have access - <strong>Shared facilities</strong>:
15-20 persons per toilet - <strong>Open defecation</strong>: 20% of
population - <strong>Waste disposal</strong>: Lack of proper
drainage</p>
<h4 id="interventions-for-slum-health-improvement">Interventions for
Slum Health Improvement</h4>
<p><strong>1. Infrastructure Development</strong> - <strong>Water
supply</strong>: Piped connections - <strong>Sanitation</strong>:
Community toilets, individual latrines - <strong>Waste
management</strong>: Collection systems - <strong>Drainage</strong>:
Surface water management</p>
<p><strong>2. Health Services</strong> - <strong>Primary health
centers</strong>: Mobile clinics - <strong>Health education</strong>:
Hygiene promotion - <strong>Disease surveillance</strong>: Regular
monitoring - <strong>Emergency services</strong>: Rapid response</p>
<p><strong>3. Community Participation</strong> - <strong>Slum dwellers
associations</strong>: Local organizations - <strong>Women
groups</strong>: Health volunteers - <strong>Youth clubs</strong>:
Health promotion - <strong>Community leaders</strong>: Advocacy</p>
<h3 id="housing-and-disease-transmission">üè† HOUSING AND DISEASE
TRANSMISSION</h3>
<h4 id="vector-breeding-sites-in-housing">Vector Breeding Sites in
Housing</h4>
<p><strong>1. Mosquito Breeding</strong> - <strong>Stagnant
water</strong>: Pots, tires, gutters - <strong>Poor drainage</strong>:
Water accumulation - <strong>Uncovered containers</strong>: Water
storage - <strong>Construction sites</strong>: Water logging</p>
<p><strong>2. Fly Breeding</strong> - <strong>Garbage
accumulation</strong>: Organic waste - <strong>Open drainage</strong>:
Sewage exposure - <strong>Animal waste</strong>: Pet and livestock waste
- <strong>Food waste</strong>: Poor storage</p>
<h4 id="respiratory-disease-transmission">Respiratory Disease
Transmission</h4>
<p><strong>1. Tuberculosis</strong> - <strong>Risk factors</strong>: -
Poor ventilation - Overcrowding - Malnutrition - Poor living conditions
- <strong>Transmission</strong>: Airborne droplets -
<strong>Prevention</strong>: Adequate ventilation, reduced crowding</p>
<p><strong>2. COVID-19 and Other Viral Diseases</strong> -
<strong>Transmission factors</strong>: - Indoor air quality -
Ventilation systems - Duration of exposure - Viral load</p>
<h4 id="water-related-disease-transmission">Water-Related Disease
Transmission</h4>
<p><strong>1. Contaminated Water Sources</strong> - <strong>Piped
water</strong>: Contamination in distribution -
<strong>Groundwater</strong>: Arsenic, fluoride - <strong>Surface
water</strong>: Industrial and sewage contamination - <strong>Stored
water</strong>: Improper handling</p>
<p><strong>2. Poor Sanitation</strong> - <strong>Open
defecation</strong>: Fecal contamination - <strong>Shared
toilets</strong>: Cross-contamination - <strong>Waste disposal</strong>:
Vector breeding - <strong>Drainage</strong>: Stagnant water</p>
<h4 id="housing-improvements-for-disease-prevention">Housing
Improvements for Disease Prevention</h4>
<p><strong>1. Structural Improvements</strong> - <strong>Ventilation
enhancement</strong>: Windows, cross-flow - <strong>Moisture
control</strong>: Waterproofing, drainage - <strong>Natural
lighting</strong>: Window placement - <strong>Construction
materials</strong>: Durable, safe materials</p>
<p><strong>2. Water and Sanitation</strong> - <strong>Safe water
supply</strong>: Piped connections - <strong>Improved
sanitation</strong>: Private toilets - <strong>Waste
management</strong>: Collection systems - <strong>Hygiene
facilities</strong>: Handwashing stations</p>
<h3 id="urban-health-problems">üèôÔ∏è URBAN HEALTH PROBLEMS</h3>
<h4 id="urban-health-challenges">Urban Health Challenges</h4>
<p><strong>1. Environmental Pollution</strong> - <strong>Air
pollution</strong>: Vehicle and industrial emissions - <strong>Water
pollution</strong>: Industrial discharge, sewage - <strong>Noise
pollution</strong>: Traffic, construction - <strong>Soil
contamination</strong>: Industrial waste, heavy metals</p>
<p><strong>2. Infectious Disease Burden</strong> - <strong>Vector-borne
diseases</strong>: Urban malaria, dengue - <strong>Water-borne
diseases</strong>: Cholera, typhoid - <strong>Respiratory
infections</strong>: Air pollution effects -
<strong>Tuberculosis</strong>: Overcrowding effects</p>
<p><strong>3. Non-Communicable Diseases</strong> - <strong>Lifestyle
diseases</strong>: Diabetes, hypertension - <strong>Cardiovascular
disease</strong>: Stress, pollution - <strong>Cancer</strong>:
Environmental exposures - <strong>Mental health</strong>: Urban stress,
isolation</p>
<h4 id="urban-heat-islands">Urban Heat Islands</h4>
<p><strong>1. Causes</strong> - <strong>Building materials</strong>:
Concrete, asphalt absorb heat - <strong>Limited vegetation</strong>:
Reduced evapotranspiration - <strong>Industrial heat</strong>:
Manufacturing processes - <strong>Traffic heat</strong>: Vehicle
emissions</p>
<p><strong>2. Health Impacts</strong> - <strong>Heat-related
illness</strong>: Heat stroke, dehydration - <strong>Cardiovascular
stress</strong>: Temperature fluctuations - <strong>Respiratory
problems</strong>: Poor air quality - <strong>Mortality
increase</strong>: 10-15% during heat waves</p>
<h4 id="air-quality-in-urban-areas">Air Quality in Urban Areas</h4>
<p><strong>1. Major Pollutants</strong> - <strong>Particulate
matter</strong>: PM2.5, PM10 - <strong>Nitrogen oxides</strong>: Vehicle
emissions - <strong>Sulfur dioxide</strong>: Industrial sources -
<strong>Ozone</strong>: Secondary pollutant</p>
<p><strong>2. Health Effects</strong> - <strong>Respiratory
diseases</strong>: Asthma, COPD - <strong>Cardiovascular
effects</strong>: Heart attacks, stroke - <strong>Premature
mortality</strong>: 2.6 million deaths annually - <strong>Cancer
risk</strong>: Lung cancer from air pollution</p>
<h4 id="urban-planning-and-health">Urban Planning and Health</h4>
<p><strong>1. Healthy City Planning</strong> - <strong>Green
spaces</strong>: Parks, gardens - <strong>Active transport</strong>:
Walking, cycling infrastructure - <strong>Mixed land use</strong>:
Reduce travel distance - <strong>Public transport</strong>: Reduce
private vehicle use</p>
<p><strong>2. Housing Policies</strong> - <strong>Affordable
housing</strong>: Rental and purchase schemes - <strong>Slum
redevelopment</strong>: Upgrade programs - <strong>Building
codes</strong>: Health-focused standards -
<strong>Infrastructure</strong>: Basic services provision</p>
<h3 id="memory-aids-tips-7">üí° MEMORY AIDS &amp; TIPS</h3>
<p><strong>‚ÄúHOUSING STANDARDS‚Äù ABCD:</strong> -
<strong>A</strong>dequate space (minimum floor area) -
<strong>B</strong>asic amenities (water, sanitation) -
<strong>C</strong>omfortable environment (ventilation, lighting) -
<strong>D</strong>urable construction (structural safety)</p>
<p><strong>‚ÄúVENTILATION PRINCIPLES‚Äù Framework:</strong> -
<strong>C</strong>ross ventilation for air movement -
<strong>O</strong>pposite windows for flow - <strong>N</strong>atural
airflow utilization - <strong>T</strong>emperature difference driving
force - <strong>I</strong>ndoor air quality improvement -
<strong>L</strong>ocation consideration for wind direction</p>
<p><strong>‚ÄúOVERCROWDING EFFECTS‚Äù Categories:</strong> -
<strong>I</strong>nfectious disease transmission -
<strong>M</strong>ental health impacts - <strong>C</strong>hild
development issues - <strong>R</strong>espiratory problems -
<strong>O</strong>verall quality of life reduction</p>
<p><strong>‚ÄúSLUM HEALTH INTERVENTIONS‚Äù Approach:</strong> -
<strong>I</strong>nfrastructure development - <strong>N</strong>eeds
assessment - <strong>T</strong>echnology solutions -
<strong>E</strong>mpowerment programs - <strong>R</strong>esources
mobilization - <strong>V</strong>ulnerable group focus</p>
<h3 id="exam-questions-important-points-8">üìù EXAM QUESTIONS &amp;
IMPORTANT POINTS</h3>
<p><strong>Long Answer Questions:</strong> 1. Discuss the relationship
between housing conditions and health with emphasis on major health
problems 2. Explain the health problems associated with overcrowding and
suggest preventive measures 3. Analyze slum health issues in India and
propose interventions for improvement 4. Describe urban environmental
health challenges and their management strategies</p>
<p><strong>Short Answer Questions:</strong> 1. WHO housing and health
guidelines 2. Ventilation standards for residential buildings 3. Health
effects of overcrowding 4. Urban heat island phenomenon</p>
<p><strong>MCQ Points:</strong> - Minimum floor area per person: 10.8 m¬≤
- Window area requirement: 10% of floor area - Infant mortality in
slums: 30% higher than urban average - Urban population percentage in
India: 35%</p>
<h3 id="references-to-latest-guidelines-7">üìö REFERENCES TO LATEST
GUIDELINES</h3>
<ul>
<li>WHO Housing and Health Guidelines 2023</li>
<li>National Building Code of India 2016</li>
<li>Urban Health Mission Guidelines (India) 2020</li>
<li>Slum Improvement Programme Guidelines</li>
<li>Smart Cities Mission Housing Standards 2021</li>
<li>RGUHS Community Medicine Housing and Health Syllabus 2020</li>
</ul>
<hr />
<h2 id="conclusion-1">Conclusion</h2>
<p>This comprehensive guide covers Environmental Health Sciences as
outlined in Part II of the Community Medicine Quick Revision Manual.
Each chapter provides examination-oriented content with key points,
memory aids, and references to latest guidelines to aid effective
revision for RGUHS MBBS examinations.</p>
<h3 id="key-takeaways-1">Key Takeaways:</h3>
<ol type="1">
<li><strong>Environment and Health</strong> emphasizes the critical
relationship between environmental factors and health outcomes</li>
<li><strong>Air Quality Management</strong> highlights the importance of
pollution control and health protection</li>
<li><strong>Water Safety and Sanitation</strong> focuses on preventing
water-borne diseases through quality control</li>
<li><strong>Waste Management</strong> addresses public health through
proper waste handling and disposal</li>
<li><strong>Housing and Health</strong> examines how living conditions
directly impact health outcomes</li>
</ol>
<h3 id="study-strategy-1">Study Strategy:</h3>
<ul>
<li>Use memory aids for quick recall of standards and guidelines</li>
<li>Practice with provided exam questions for pattern recognition</li>
<li>Connect environmental health concepts across multiple chapters</li>
<li>Apply evidence-based interventions to real-world scenarios</li>
</ul>
<h3 id="examination-focus-areas">Examination Focus Areas:</h3>
<ul>
<li>WHO and national standards for air, water, waste, and housing</li>
<li>Health effects and prevention strategies for environmental
hazards</li>
<li>Policy implementation and monitoring mechanisms</li>
<li>Community-level interventions and behavioral changes</li>
</ul>
<hr />
<p><em>End of Part II: Environmental Health Sciences</em></p>
<h1 id="part-iii-nutrition-and-health-1">Part III: Nutrition and
Health</h1>
<h2 id="chapter-10-nutrition-and-health">Chapter 10: Nutrition and
Health</h2>
<hr />
<h2 id="section-a-basic-nutrition-concepts">Section A: Basic Nutrition
Concepts</h2>
<h3 id="macronutrients">1. Macronutrients</h3>
<h4 id="carbohydrates">Carbohydrates</h4>
<ul>
<li><strong>Function</strong>: Primary energy source (4 kcal/g)</li>
<li><strong>Classification</strong>:
<ul>
<li>Simple sugars (glucose, fructose)</li>
<li>Complex carbohydrates (starch, cellulose)</li>
</ul></li>
<li><strong>Daily requirement</strong>: 50-60% of total calories</li>
</ul>
<p><strong>MCQ Point</strong>: Excess carbohydrate intake is converted
to fat and stored in adipose tissue.</p>
<h4 id="proteins">Proteins</h4>
<ul>
<li><strong>Function</strong>: Building and repair (4 kcal/g)</li>
<li><strong>Essential amino acids</strong>: 9 out of 20</li>
<li><strong>High biological value</strong>: Animal proteins, pulses</li>
<li><strong>Daily requirement</strong>: 0.8-1.0 g/kg body weight</li>
</ul>
<p><strong>Memory Aid</strong>: ‚ÄúPASH‚Äù - Proteins for Amino acids,
Structure, Hormones</p>
<h4 id="fats">Fats</h4>
<ul>
<li><strong>Function</strong>: Energy storage (9 kcal/g)</li>
<li><strong>Essential fatty acids</strong>: Linoleic acid, Œ±-linolenic
acid</li>
<li><strong>Daily requirement</strong>: 20-30% of total calories</li>
<li><strong>Saturated fats</strong>: &lt;10% of total calories</li>
</ul>
<h3 id="micronutrients">2. Micronutrients</h3>
<h4 id="vitamins-fat-soluble">Vitamins (Fat-soluble)</h4>
<table>
<thead>
<tr>
<th>Vitamin</th>
<th>Primary Function</th>
<th>Deficiency Manifestation</th>
<th>RDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Vision, immunity</td>
<td>Night blindness, xerophthalmia</td>
<td>600 Œºg</td>
</tr>
<tr>
<td>D</td>
<td>Calcium absorption</td>
<td>Rickets, osteomalacia</td>
<td>400 IU</td>
</tr>
<tr>
<td>E</td>
<td>Antioxidant</td>
<td>Neurological symptoms</td>
<td>10 mg</td>
</tr>
<tr>
<td>K</td>
<td>Coagulation</td>
<td>Bleeding disorders</td>
<td>80 Œºg</td>
</tr>
</tbody>
</table>
<h4 id="vitamins-water-soluble">Vitamins (Water-soluble)</h4>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 40%" />
<col style="width: 27%" />
<col style="width: 11%" />
</colgroup>
<thead>
<tr>
<th>Vitamin</th>
<th>Primary Function</th>
<th>Deficiency</th>
<th>RDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>B1 (Thiamine)</td>
<td>Energy metabolism</td>
<td>Beriberi</td>
<td>1.2 mg</td>
</tr>
<tr>
<td>B2 (Riboflavin)</td>
<td>Energy metabolism</td>
<td>Cheilosis</td>
<td>1.3 mg</td>
</tr>
<tr>
<td>B3 (Niacin)</td>
<td>Energy metabolism</td>
<td>Pellagra</td>
<td>16 mg</td>
</tr>
<tr>
<td>B6 (Pyridoxine)</td>
<td>Protein metabolism</td>
<td>Peripheral neuropathy</td>
<td>1.3 mg</td>
</tr>
<tr>
<td>B9 (Folate)</td>
<td>DNA synthesis</td>
<td>Megaloblastic anemia</td>
<td>400 Œºg</td>
</tr>
<tr>
<td>B12 (Cobalamin)</td>
<td>DNA synthesis</td>
<td>Pernicious anemia</td>
<td>2.4 Œºg</td>
</tr>
<tr>
<td>C</td>
<td>Antioxidant</td>
<td>Scurvy</td>
<td>75 mg</td>
</tr>
</tbody>
</table>
<h4 id="minerals">Minerals</h4>
<table>
<thead>
<tr>
<th>Mineral</th>
<th>Function</th>
<th>Deficiency</th>
<th>RDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron</td>
<td>Hemoglobin synthesis</td>
<td>Iron deficiency anemia</td>
<td>8-18 mg</td>
</tr>
<tr>
<td>Calcium</td>
<td>Bone health</td>
<td>Osteoporosis</td>
<td>1000 mg</td>
</tr>
<tr>
<td>Iodine</td>
<td>Thyroid function</td>
<td>Goiter, cretinism</td>
<td>150 Œºg</td>
</tr>
<tr>
<td>Zinc</td>
<td>Growth, immunity</td>
<td>Growth retardation</td>
<td>11 mg</td>
</tr>
<tr>
<td>Selenium</td>
<td>Antioxidant</td>
<td>Keshan disease</td>
<td>55 Œºg</td>
</tr>
</tbody>
</table>
<h3 id="caloric-requirements">3. Caloric Requirements</h3>
<ul>
<li><strong>Adult males</strong>: 2400-2800 kcal/day</li>
<li><strong>Adult females</strong>: 2000-2200 kcal/day</li>
<li><strong>Children</strong>: 1000-2000 kcal/day</li>
<li><strong>Pregnant women</strong>: +300 kcal/day</li>
<li><strong>Lactating women</strong>: +500 kcal/day</li>
</ul>
<p><strong>Formula</strong>: Basal Metabolic Rate (BMR) - Males: BMR =
66 + (13.7 √ó W) + (5 √ó H) - (6.8 √ó A) - Females: BMR = 655 + (9.6 √ó W) +
(1.8 √ó H) - (4.7 √ó A) Where: W=weight(kg), H=height(cm),
A=age(years)</p>
<h3 id="balanced-diet-principles">4. Balanced Diet Principles</h3>
<ol type="1">
<li><strong>Proportional</strong>: All nutrients in right
proportions</li>
<li><strong>Adequate</strong>: Sufficient quantity for needs</li>
<li><strong>Safe</strong>: Free from harmful substances</li>
<li><strong>Acceptable</strong>: Culturally and economically
feasible</li>
</ol>
<h3 id="recommended-dietary-allowances-rda---india-2020">5. Recommended
Dietary Allowances (RDA) - India 2020</h3>
<p><strong>Quick Reference</strong>: - Cereals: 300-400 g/day - Pulses:
40-60 g/day - Milk: 200-300 ml/day - Vegetables: 300-400 g/day - Fruits:
100-150 g/day - Oil: 20-30 g/day</p>
<hr />
<h2 id="section-b-protein-energy-malnutrition">Section B: Protein-Energy
Malnutrition</h2>
<h3 id="types-of-pem">1. Types of PEM</h3>
<h4 id="marasmus">Marasmus</h4>
<p><strong>Clinical Features</strong>: - Severe wasting (&lt;60% weight
for age) - ‚ÄúMatchstick‚Äù limbs - ‚ÄúOld man‚Äù facies - Loss of subcutaneous
fat - Normal hair texture - Preserved serum albumin</p>
<p><strong>Pathophysiology</strong>: Inadequate calorie intake ‚Üí Fat and
muscle depletion</p>
<h4 id="kwashiorkor">Kwashiorkor</h4>
<p><strong>Clinical Features</strong>: - Edema (pedal, facial) - ‚ÄúFlaky
paint‚Äù dermatosis - ‚ÄúFlag sign‚Äù in hair - Hepatomegaly (fatty liver) -
Apathy and irritability - Decreased serum albumin</p>
<p><strong>Pathophysiology</strong>: Inadequate protein intake ‚Üí
Decreased oncotic pressure</p>
<p><strong>Memory Aid</strong>: ‚ÄúMARA‚Äù - Marasmus: Atrophy, No edema;
‚ÄúKWASH‚Äù - Kwashiorkor: Edema, Albumin low</p>
<h3 id="anthropometric-measurements">2. Anthropometric Measurements</h3>
<h4 id="weight-for-age">Weight-for-Age</h4>
<ul>
<li><strong>Normal</strong>: 80-120% of expected</li>
<li><strong>Grade I PEM</strong>: 70-79% (Mild)</li>
<li><strong>Grade II PEM</strong>: 60-69% (Moderate)</li>
<li><strong>Grade III PEM</strong>: &lt;60% (Severe)</li>
</ul>
<h4 id="height-for-age">Height-for-Age</h4>
<ul>
<li><strong>Normal</strong>: &gt;95% of expected</li>
<li><strong>Stunting</strong>: &lt;90% (Chronic malnutrition)</li>
</ul>
<h4 id="weight-for-height">Weight-for-Height</h4>
<ul>
<li><strong>Normal</strong>: 90-110% of expected</li>
<li><strong>Wasting</strong>: &lt;80% (Acute malnutrition)</li>
</ul>
<h4 id="mid-upper-arm-circumference-muac">Mid-Upper Arm Circumference
(MUAC)</h4>
<ul>
<li><strong>6-59 months</strong>:
<ul>
<li>Normal: ‚â•12.5 cm</li>
<li>At risk: 12.0-12.4 cm</li>
<li>SAM: &lt;11.5 cm</li>
</ul></li>
</ul>
<h3 id="assessment-methods">3. Assessment Methods</h3>
<h4 id="indian-academy-of-pediatrics-iap-classification">Indian Academy
of Pediatrics (IAP) Classification</h4>
<p><strong>Weight for Age (Gomez Classification)</strong>: - Grade I:
75-90% of expected - Grade II: 60-74% of expected<br />
- Grade III: &lt;60% of expected</p>
<p><strong>Waterlow Classification</strong>: - Combines stunting and
wasting for comprehensive assessment</p>
<h4 id="who-child-growth-standards-2006">WHO Child Growth Standards
(2006)</h4>
<ul>
<li>Z-score approach</li>
<li>&lt;-2 SD: Undernutrition</li>
<li>&lt;-3 SD: Severe undernutrition</li>
</ul>
<h3 id="prevention-strategies">4. Prevention Strategies</h3>
<h4 id="primary-prevention-1">Primary Prevention</h4>
<ol type="1">
<li><strong>Breastfeeding</strong>: Exclusive breastfeeding for 6
months</li>
<li><strong>Complementary feeding</strong>: At 6 months with
continuation of breastfeeding</li>
<li><strong>Food security</strong>: Access to adequate food</li>
<li><strong>Health education</strong>: Proper feeding practices</li>
</ol>
<h4 id="secondary-prevention-1">Secondary Prevention</h4>
<ol type="1">
<li><strong>Growth monitoring</strong>: Regular weight and height
measurements</li>
<li><strong>Nutritional surveillance</strong>: Community-based
monitoring</li>
<li><strong>Early detection</strong>: Community health workers</li>
</ol>
<h3 id="community-based-management">5. Community-Based Management</h3>
<h4 id="management-protocol">Management Protocol</h4>
<p><strong>Severe Acute Malnutrition (SAM)</strong>: -
<strong>Complicated SAM</strong>: Inpatient treatment -
<strong>Uncomplicated SAM</strong>: Outpatient treatment with RUTF</p>
<p><strong>Moderate Acute Malnutrition (MAM)</strong>: -
<strong>Outpatient management</strong> - <strong>Ready-to-use
supplementary food (RUSF)</strong></p>
<h4 id="therapeutic-foods">Therapeutic Foods</h4>
<p><strong>RUTF (Ready-to-Use Therapeutic Food)</strong>: - 500-550
kcal/100g - Ingredients: Peanut paste, milk powder, sugar, oil, minerals
- No water required</p>
<p><strong>RUSF (Ready-to-Use Supplementary Food)</strong>: - 400-450
kcal/100g - For moderate malnutrition</p>
<hr />
<h2 id="section-c-vitamin-deficiencies">Section C: Vitamin
Deficiencies</h2>
<h3 id="vitamin-a-deficiency">1. Vitamin A Deficiency</h3>
<h4 id="prevalence-nfhs-5">Prevalence (NFHS-5)</h4>
<ul>
<li>Night blindness: 12.2% children, 6.9% women</li>
<li>Bitot‚Äôs spots: 0.7% children</li>
</ul>
<h4 id="clinical-manifestations">Clinical Manifestations</h4>
<p><strong>Ocular</strong>: - Night blindness (first symptom) -
Conjunctival xerosis - Bitot‚Äôs spots - Corneal xerosis -
Keratomalacia</p>
<p><strong>Systemic</strong>: - Increased susceptibility to infections -
Impaired growth - Increased mortality risk</p>
<h4 id="who-classification">WHO Classification</h4>
<p><strong>XN</strong>: Night blindness <strong>X1A</strong>:
Conjunctival xerosis <strong>X1B</strong>: Bitot‚Äôs spots
<strong>X2</strong>: Corneal xerosis <strong>X3A</strong>: Corneal
ulceration/keratomalacia &lt;1/3 cornea <strong>X3B</strong>: Corneal
ulceration/keratomalacia ‚â•1/3 cornea <strong>XS</strong>: Corneal scar
<strong>XF</strong>: Xerophthalmia fundus</p>
<h4 id="prevention-and-control">Prevention and Control</h4>
<p><strong>Universal supplementation</strong>: - Children 6-59 months:
100,000 IU (6-12 months), 200,000 IU (12-59 months) - Postpartum women:
200,000 IU within 6 weeks of delivery - Pregnant women: 10,000 IU daily
or 25,000 IU weekly (safe in pregnancy)</p>
<p><strong>Food-based approaches</strong>: Dark green leafy vegetables,
orange fruits/vegetables</p>
<h3 id="vitamin-d-deficiency">2. Vitamin D Deficiency</h3>
<h4 id="risk-factors">Risk Factors</h4>
<ul>
<li>Inadequate sunlight exposure</li>
<li>Dark skin pigmentation</li>
<li>Urban living</li>
<li>Air pollution</li>
<li>Dress code covering most body</li>
</ul>
<h4 id="clinical-manifestations-1">Clinical Manifestations</h4>
<p><strong>Rickets (Children)</strong>: - Delayed fontanelle closure -
Rachitic rosary - Harrison‚Äôs sulcus - Bow legs/knock knees - Delayed
tooth eruption</p>
<p><strong>Osteomalacia (Adults)</strong>: - Bone pain - Muscle weakness
- Pathological fractures</p>
<h4 id="treatment">Treatment</h4>
<p><strong>Children</strong>: - Vitamin D 2000-5000 IU/day for 6-12
weeks - Maintenance: 400 IU/day</p>
<p><strong>Adults</strong>: - Vitamin D 60,000 IU/week for 8 weeks -
Maintenance: 1000 IU/day</p>
<h3 id="b-complex-deficiencies">3. B-Complex Deficiencies</h3>
<h4 id="thiamine-b1-deficiency---beriberi">Thiamine (B1) Deficiency -
Beriberi</h4>
<p><strong>Clinical Types</strong>: - <strong>Dry beriberi</strong>:
Peripheral neuropathy, muscle wasting - <strong>Wet beriberi</strong>:
High-output cardiac failure, edema -
<strong>Wernicke-Korsakoff</strong>: Ataxia, confusion, memory loss</p>
<p><strong>Risk factors</strong>: Alcoholism, polished rice diet,
chronic diarrhea</p>
<p><strong>Treatment</strong>: Thiamine 100mg IV/IM for 1-2 weeks, then
oral 50mg daily</p>
<h4 id="riboflavin-b2-deficiency">Riboflavin (B2) Deficiency</h4>
<p><strong>Clinical features</strong>: - Cheilosis (cracked lips) -
Angular stomatitis - Glossitis - Photophobia</p>
<h4 id="niacin-b3-deficiency---pellagra">Niacin (B3) Deficiency -
Pellagra</h4>
<p><strong>‚Äú3 D‚Äôs‚Äù</strong>: 1. <strong>Dermatitis</strong>: Symmetric,
pigmented rash (Casal‚Äôs necklace) 2. <strong>Diarrhea</strong>:
Malabsorption, inflammation 3. <strong>Dementia</strong>: Confusion,
hallucinations</p>
<p><strong>Treatment</strong>: Niacin 100-300 mg daily</p>
<h4 id="pyridoxine-b6-deficiency">Pyridoxine (B6) Deficiency</h4>
<p><strong>Clinical features</strong>: - Peripheral neuropathy -
Convulsions (infants) - Sideroblastic anemia - Cheilosis</p>
<h4 id="folate-b9-deficiency">Folate (B9) Deficiency</h4>
<p><strong>Clinical features</strong>: - Megaloblastic anemia - Neural
tube defects (pregnancy) - Glossitis</p>
<p><strong>Treatment</strong>: Folic acid 1-5 mg daily</p>
<h4 id="cobalamin-b12-deficiency">Cobalamin (B12) Deficiency</h4>
<p><strong>Clinical features</strong>: - Megaloblastic anemia -
Peripheral neuropathy - Subacute combined degeneration of spinal cord -
Cognitive impairment</p>
<p><strong>Risk factors</strong>: Vegan diet, pernicious anemia,
malabsorption</p>
<p><strong>Treatment</strong>: B12 1000 Œºg IM daily √ó 1 week, then
weekly √ó 1 month, then monthly</p>
<h3 id="vitamin-c-deficiency---scurvy">4. Vitamin C Deficiency -
Scurvy</h3>
<h4 id="clinical-manifestations-2">Clinical Manifestations</h4>
<ul>
<li>Fatigue and weakness</li>
<li>Joint and muscle pain</li>
<li>Bleeding gums</li>
<li>Petechiae and ecchymoses</li>
<li>Poor wound healing</li>
<li>Corkscrew hairs</li>
</ul>
<p><strong>Diagnosis</strong>: Plasma vitamin C &lt;11.4 Œºmol/L</p>
<p><strong>Treatment</strong>: Vitamin C 100-300 mg daily for 1-2
weeks</p>
<h3 id="iron-deficiency-anemia">5. Iron Deficiency Anemia</h3>
<h4 id="prevalence-nfhs-5-1">Prevalence (NFHS-5)</h4>
<ul>
<li>Children 6-59 months: 67.1%</li>
<li>Women 15-49 years: 57.2%</li>
<li>Pregnant women: 52.2%</li>
</ul>
<h4 id="risk-factors-1">Risk Factors</h4>
<ul>
<li>Rapid growth phases</li>
<li>Menstruation</li>
<li>Pregnancy and lactation</li>
<li>Inadequate dietary iron</li>
<li>Parasitic infections</li>
<li>Malaria</li>
</ul>
<h4 id="clinical-features">Clinical Features</h4>
<ul>
<li>Pallor (conjunctival, palmar)</li>
<li>Fatigue and weakness</li>
<li>Dyspnea on exertion</li>
<li>Pica (craving for ice, dirt, etc.)</li>
<li>Koilonychia (spoon nails)</li>
</ul>
<h4 id="laboratory-diagnosis">Laboratory Diagnosis</h4>
<p><strong>Iron studies</strong>: - Hemoglobin: &lt;11 g/dL (children),
&lt;12 g/dL (women) - MCV: &lt;80 fL (microcytic) - Serum ferritin:
&lt;15 Œºg/L - Serum iron: &lt;50 Œºg/dL - TIBC: &gt;350 Œºg/dL -
Transferrin saturation: &lt;16%</p>
<h4 id="treatment-protocol">Treatment Protocol</h4>
<p><strong>Children</strong>: - Iron: 2-3 mg/kg/day elemental iron -
Duration: 3 months after hemoglobin normalizes</p>
<p><strong>Adults</strong>: - Iron: 100-200 mg elemental iron daily -
Duration: 3-6 months</p>
<p><strong>Pregnant women</strong>: - Iron: 60 mg elemental iron + 400
Œºg folic acid</p>
<h3 id="iodine-deficiency-disorders">6. Iodine Deficiency Disorders</h3>
<h4 id="prevalence-nfhs-5-2">Prevalence (NFHS-5)</h4>
<ul>
<li>Goiter rate: 24.6% (mild to severe)</li>
<li>Total affected population: &gt;200 million</li>
</ul>
<h4 id="clinical-spectrum">Clinical Spectrum</h4>
<p><strong>Thyroid enlargement</strong>: Goiter (compensatory
hyperplasia) <strong>Hypothyroidism</strong>: - Cretinism (irreversible
mental retardation) - Delayed development - Deaf-mutism - Motor
spasticity</p>
<p><strong>Neonatal hypothyroidism</strong>: - Increased neonatal
mortality - Mental retardation - Growth retardation</p>
<h4 id="prevention-strategy">Prevention Strategy</h4>
<p><strong>Universal Salt Iodization</strong>: - Iodine content: 15-40
ppm potassium iodate - Salt specifications: &gt;95% of households use
iodized salt - Monitoring: Salt testing kits</p>
<p><strong>Coverage (NFHS-5)</strong>: 85.6% households use iodized
salt</p>
<h3 id="zinc-deficiency">7. Zinc Deficiency</h3>
<h4 id="clinical-features-1">Clinical Features</h4>
<ul>
<li>Growth retardation</li>
<li>Delayed sexual maturation</li>
<li>Alopecia</li>
<li>Dermatitis</li>
<li>Delayed wound healing</li>
<li>Impaired immunity</li>
<li>Diarrhea</li>
</ul>
<h4 id="risk-factors-2">Risk Factors</h4>
<ul>
<li>Inadequate dietary zinc</li>
<li>Malabsorption syndromes</li>
<li>Chronic liver/kidney disease</li>
<li>Alcoholism</li>
</ul>
<h4 id="treatment-elemental-zinc-1-2-mgkgday">Treatment: Elemental zinc
1-2 mg/kg/day</h4>
<hr />
<h2 id="section-d-nutrition-in-special-groups">Section D: Nutrition in
Special Groups</h2>
<h3 id="infant-and-child-nutrition">1. Infant and Child Nutrition</h3>
<h4 id="breastfeeding">Breastfeeding</h4>
<p><strong>WHO recommendations</strong>: - Exclusive breastfeeding: 0-6
months - Continued breastfeeding: Up to 2 years with complementary
foods</p>
<p><strong>Advantages</strong>: - Optimal nutrition - Protection against
infections - Mother-child bonding - Natural contraception</p>
<p><strong>Contraindications</strong>: - HIV positive mother
(resource-rich settings) - Active TB - HSV lesions on breast -
Galactosemia in infant - Certain medications</p>
<h4 id="complementary-feeding-6-24-months">Complementary Feeding (6-24
months)</h4>
<p><strong>Principles</strong>: - Timely introduction (6 months) -
Adequate frequency and variety - Minimize spices initially - Continue
breastfeeding</p>
<p><strong>Food groups</strong>: - Cereals and millets - Pulses and
legumes - Milk and milk products - Vegetables and fruits - Fats and
oils</p>
<p><strong>Age-specific feeding</strong>: - 6-8 months: 2-3 meals +
breastfeeding - 9-11 months: 3-4 meals + 1-2 snacks + breastfeeding -
12-24 months: 4-5 meals + 1-2 snacks + breastfeeding</p>
<h4 id="growth-monitoring">Growth Monitoring</h4>
<p><strong>Parameters</strong>: Weight, height, head circumference
<strong>Frequency</strong>: - Under 1 year: Monthly - 1-3 years: Every
2-3 months - Above 3 years: Every 6 months</p>
<h3 id="adolescent-nutrition">2. Adolescent Nutrition</h3>
<h4 id="nutritional-requirements">Nutritional Requirements</h4>
<p><strong>Increased needs</strong>: - Energy: 2200-2500 kcal/day
(boys), 1800-2200 kcal/day (girls) - Protein: 0.85-0.9 g/kg body weight
- Iron: 15 mg/day (boys), 25 mg/day (girls) - Calcium: 1300 mg/day</p>
<h4 id="special-issues">Special Issues</h4>
<p><strong>Iron deficiency anemia</strong>: High prevalence due to
growth spurt <strong>Undernutrition</strong>: Stunting, wasting
<strong>Overnutrition</strong>: Rising prevalence of obesity
<strong>Eating disorders</strong>: Anorexia, bulimia</p>
<h3 id="maternal-nutrition">3. Maternal Nutrition</h3>
<h4 id="preconception">Preconception</h4>
<p><strong>Folic acid</strong>: 400 Œºg daily to prevent neural tube
defects <strong>Iron</strong>: Treat existing anemia
<strong>Weight</strong>: Achieve normal BMI</p>
<h4 id="pregnancy">Pregnancy</h4>
<p><strong>Weight gain recommendations</strong>: - Underweight (BMI
&lt;18.5): 12.5-18 kg - Normal (BMI 18.5-24.9): 11.5-16 kg - Overweight
(BMI 25-29.9): 7-11.5 kg - Obese (BMI ‚â•30): 5-9 kg</p>
<p><strong>Nutrient requirements</strong>: - Energy: +300 kcal/day -
Protein: +1.3 g/kg/day - Iron: 27 mg/day - Folic acid: 600 Œºg/day -
Calcium: 1000 mg/day</p>
<p><strong>Critical periods</strong>: - Neural tube closure: 3-4 weeks
post-conception - Brain development: Throughout pregnancy - Weight gain:
Variable pattern</p>
<h4 id="lactation">Lactation</h4>
<p><strong>Energy requirements</strong>: +500 kcal/day
<strong>Protein</strong>: +1.8 g/kg/day <strong>Fluid</strong>: 2.5-3
liters/day <strong>Nutrient-dense foods</strong>: For quality breast
milk</p>
<h3 id="geriatric-nutrition">4. Geriatric Nutrition</h3>
<h4 id="age-related-changes">Age-related Changes</h4>
<p><strong>Physiological</strong>: - Decreased basal metabolic rate -
Reduced taste and smell - Decreased absorption - Reduced renal function
- Increased chronic diseases</p>
<h4 id="nutritional-requirements-1">Nutritional Requirements</h4>
<p><strong>Energy</strong>: 10-20% reduction with age
<strong>Protein</strong>: 1.0-1.2 g/kg body weight
<strong>Calcium</strong>: 1200 mg/day (osteoporosis prevention)
<strong>Vitamin D</strong>: 800-1000 IU/day <strong>Fiber</strong>:
25-30 g/day <strong>Fluids</strong>: 30 ml/kg body weight</p>
<h4 id="common-problems">Common Problems</h4>
<p><strong>Malnutrition</strong>: 15-20% prevalence
<strong>Osteoporosis</strong>: Post-menopausal women
<strong>Sarcopenia</strong>: Age-related muscle loss
<strong>Dehydration</strong>: Reduced thirst sensation</p>
<h3 id="sports-nutrition">5. Sports Nutrition</h3>
<h4 id="energy-requirements">Energy Requirements</h4>
<p><strong>Endurance sports</strong>: 50-60 kcal/kg body weight
<strong>Strength sports</strong>: 40-50 kcal/kg body weight
<strong>Mixed sports</strong>: 45-55 kcal/kg body weight</p>
<h4 id="macronutrient-distribution">Macronutrient Distribution</h4>
<p><strong>Carbohydrates</strong>: 55-65% of total energy
<strong>Proteins</strong>: 12-15% of total energy <strong>Fats</strong>:
20-30% of total energy</p>
<h4 id="timing">Timing</h4>
<p><strong>Pre-exercise</strong>: Carbohydrates 2-3 hours before
<strong>During exercise</strong>: Fluids every 15-20 minutes
<strong>Post-exercise</strong>: Carbohydrates + protein within 30
minutes</p>
<hr />
<h2 id="section-e-food-safety-and-security">Section E: Food Safety and
Security</h2>
<h3 id="food-security-in-india">1. Food Security in India</h3>
<h4 id="definition-2">Definition</h4>
<p><strong>Food security</strong>: Physical, economic and social access
to sufficient, safe and nutritious food</p>
<p><strong>Dimensions</strong>: 1. <strong>Availability</strong>: Food
production and imports 2. <strong>Access</strong>: Economic and physical
access 3. <strong>Utilization</strong>: Nutritional value and health
status 4. <strong>Stability</strong>: Food security over time</p>
<h4 id="current-status-nfhs-5">Current Status (NFHS-5)</h4>
<p><strong>Food consumption</strong>: - Rice/wheat: 71.1% households -
Pulses: 32.5% households daily - Vegetables: 36.8% households daily -
Fruits: 9.2% households daily</p>
<p><strong>Nutritional status</strong>: - Stunting: 35.5% children under
5 - Wasting: 19.3% children under 5 - Underweight: 32.1% children under
5 - Anemia: 67.1% children, 57.2% women</p>
<h3 id="public-distribution-system-pds">2. Public Distribution System
(PDS)</h3>
<h4 id="structure">Structure</h4>
<p><strong>Central Government</strong>: - Procurement of food grains -
Allocation to states - Policy formulation</p>
<p><strong>State Governments</strong>: - Distribution to Fair Price
Shops - Implementation of programs - Identification of beneficiaries</p>
<h4 id="food-corporation-of-india-fci">Food Corporation of India
(FCI)</h4>
<p><strong>Functions</strong>: - Procurement of food grains - Storage
and transport - Distribution to states</p>
<h4 id="coverage-and-targeting">Coverage and Targeting</h4>
<p><strong>Universal PDS</strong>: Kerala, Tamil Nadu, Chandigarh
<strong>Targeted PPDS</strong>: Rest of India</p>
<p><strong>Food grains allocation</strong>: - Rice: ‚Çπ3/kg (AAY), ‚Çπ7/kg
(APL) - Wheat: ‚Çπ2/kg (AAY), ‚Çπ7/kg (APL)</p>
<h3 id="nutrition-surveillance">3. Nutrition Surveillance</h3>
<h4 id="national-family-health-survey-nfhs">National Family Health
Survey (NFHS)</h4>
<p><strong>Conducted by</strong>: International Institute for Population
Sciences (IIPS) <strong>Frequency</strong>: Every 5 years
<strong>Coverage</strong>: All states and UTs</p>
<p><strong>NFHS-5 (2019-21) key findings</strong>: - Stunting: 35.5% (‚Üì
from 38.4%) - Wasting: 19.3% (‚Üë from 21.0%) - Underweight: 32.1% (‚Üì from
35.7%) - Anemia: 67.1% children, 57.2% women</p>
<h4 id="district-level-nutrition-survey-dlns">District Level Nutrition
Survey (DLNS)</h4>
<p><strong>Conducted by</strong>: UNICEF and RD&amp;FW Department
<strong>Focus</strong>: 100 districts with high malnutrition
<strong>Parameters</strong>: Anthropometric, dietary, clinical
assessment</p>
<h3 id="food-fortification-programs">4. Food Fortification Programs</h3>
<h4 id="fortification-strategy">Fortification Strategy</h4>
<p><strong>Rationale</strong>: Address micronutrient deficiencies in
population <strong>Cost-effective</strong>: Reaches large populations
<strong>Technology</strong>: Heat-stable vitamins and minerals</p>
<h4 id="national-programme">National Programme</h4>
<p><strong>Double Fortified Salt (DFS)</strong>: - Fortified with iodine
+ iron - Target: Control iron deficiency anemia - Coverage: 10
states</p>
<p><strong>Wheat Flour Fortification</strong>: - Fortified with iron,
folic acid, vitamin B12 - Production-linked incentives for millers -
Target: 10% of wheat flour market</p>
<p><strong>Oil Fortification</strong>: - Fortified with vitamin A and D
- Oil industry partnership - Target: Large oil companies</p>
<p><strong>Milk Fortification</strong>: - Fortified with vitamin A and D
- Co-op and private dairy companies - Target: Urban milk market</p>
<h3 id="food-adulteration-and-safety">5. Food Adulteration and
Safety</h3>
<h4 id="common-adulterants">Common Adulterants</h4>
<p><strong>Milk</strong>: Water, skim milk powder, urea, formaldehyde
<strong>Ghee/Butter</strong>: Vanaspati, animal fat
<strong>Spices</strong>: Colored saw dust, brick powder
<strong>Honey</strong>: Sugar syrup, jaggery <strong>Wheat
flour</strong>: Chalk powder, sand <strong>Coffee</strong>: Roasted
barley, dates <strong>Tea</strong>: Colored leaves, dried leaves</p>
<h4 id="prevention-strategies-1">Prevention Strategies</h4>
<p><strong>FSSAI (Food Safety and Standards Authority of
India)</strong>: - Food safety regulations - Certification of food
businesses - Testing laboratories</p>
<p><strong>Consumer awareness</strong>: - Simple tests (purity tests) -
Complaint mechanisms - Consumer courts</p>
<hr />
<h2 id="section-f-nutrition-programs">Section F: Nutrition Programs</h2>
<h3 id="national-nutrition-mission">1. National Nutrition Mission</h3>
<h4 id="background">Background</h4>
<p><strong>Launched</strong>: 2017 (later subsumed under POSHAN
Abhiyaan) <strong>Objective</strong>: Reduce malnutrition and anemia</p>
<p><strong>Target</strong> by 2022: - Reduce stunting: 2% per year -
Reduce underweight: 2% per year - Reduce anemia: 3% per year</p>
<h4 id="implementation-strategy">Implementation Strategy</h4>
<p><strong>Convergence</strong>: Multiple ministries and programs
<strong>Behavior change</strong>: Community-based approaches
<strong>Technology</strong>: POSHAN tracker, mobile applications
<strong>Monitoring</strong>: Real-time monitoring system</p>
<h3 id="icds-program">2. ICDS Program</h3>
<h4 id="anganwadi-services-scheme">Anganwadi Services Scheme</h4>
<p><strong>Launched</strong>: 1975 <strong>Target</strong>: Children 0-6
years, pregnant women, lactating mothers</p>
<p><strong>Services provided</strong>: 1. <strong>Supplementary
nutrition</strong>: 300 days/year 2. <strong>Immunization</strong>:
Complete immunization 3. <strong>Health check-up</strong>: Regular
health screening 4. <strong>Referral services</strong>: Early detection
and referral 5. <strong>Non-formal education</strong>: 3-6 years
children 6. <strong>Counseling</strong>: Mothers on nutrition and
health</p>
<p><strong>Beneficiaries (NFHS-5)</strong>: - Children 0-5 years: 66.2%
received services - Pregnant women: 62.8% received services - Lactating
mothers: 69.9% received services</p>
<h4 id="supplementary-nutrition">Supplementary Nutrition</h4>
<p><strong>Duration</strong>: 300 days/year <strong>Cost norms</strong>:
‚Çπ6 per child/day, ‚Çπ7 for pregnant women/lactating mothers</p>
<p><strong>Nutritional composition</strong>: - Energy: ‚â•500 kcal -
Protein: ‚â•12-15g - Micronutrients: Iron, vitamin A, folic acid</p>
<h4 id="incentive-schemes">Incentive Schemes</h4>
<p><strong>Pradhan Mantri Matru Vandana Yojana</strong>: - Cash benefit:
‚Çπ5000 (3 installments) - Eligible: Pregnant women and lactating mothers
- First child only</p>
<h3 id="poshan-abhiyaan">3. Poshan Abhiyaan</h3>
<h4 id="national-nutrition-mission-2.0">National Nutrition Mission
2.0</h4>
<p><strong>Launched</strong>: March 2018 <strong>Target</strong>:
Transform India‚Äôs nutrition landscape</p>
<p><strong>Goals</strong> by 2022: 1. <strong>Stunting</strong>: Reduce
to 25% (from 38.4%) 2. <strong>Anemia</strong>: Reduce by 3% per year 3.
<strong>Low birth weight</strong>: Reduce to 6% (from 21%)</p>
<h4 id="strategy-framework">Strategy Framework</h4>
<p><strong>CONVERGE</strong>: - <strong>C</strong>: Construction of
convergent action plans - <strong>O</strong>: Oversee implementation and
guidance - <strong>N</strong>: Nurture innovation, pedagogy and
technology - <strong>V</strong>: Validate findings and bottlenecks -
<strong>E</strong>: Enable action through partner platforms -
<strong>R</strong>: Rigorous monitoring and data management -
<strong>G</strong>: Governance by high-level governing bodies -
<strong>E</strong>: Educate and communicate for behavior change</p>
<h4 id="key-interventions">Key Interventions</h4>
<p><strong>Poshan Panchayat</strong>: Gram panchayat nutrition
committees <strong>Poshan Maah</strong>: Nutrition month (September)
<strong>Poshan Hi Poshan</strong>: Nutrition week</p>
<h3 id="world-food-program-initiatives">4. World Food Program
Initiatives</h3>
<h4 id="school-feeding-programs">School Feeding Programs</h4>
<p><strong>Mid Day Meal Scheme (MDM)</strong>: -
<strong>Target</strong>: School children 6-14 years -
<strong>Coverage</strong>: 11.8 crore children - <strong>Nutritional
content</strong>: 450 calories + 12g protein</p>
<p><strong>Funding</strong>: 60% Central Government, 40% State
Government</p>
<h4 id="emergency-nutrition">Emergency Nutrition</h4>
<p><strong>Disaster response</strong>: Nutrition support during
emergencies <strong>Refugee nutrition</strong>: Special programs for
refugees <strong>COVID-19 response</strong>: Food security during
pandemic</p>
<h4 id="technical-support">Technical Support</h4>
<ul>
<li><strong>Capacity building</strong>: Training government
officials</li>
<li><strong>Monitoring</strong>: Nutrition surveillance systems</li>
<li><strong>Research</strong>: Operational research on nutrition</li>
</ul>
<hr />
<h2 id="examination-important-points">Examination Important Points</h2>
<h3 id="mcq-hot-topics">MCQ Hot Topics</h3>
<ol type="1">
<li><strong>RDA Calculations</strong>:
<ul>
<li>Adult male: 2400-2800 kcal</li>
<li>Pregnant woman: +300 kcal</li>
<li>Lactating woman: +500 kcal</li>
</ul></li>
<li><strong>PEM Classification</strong>:
<ul>
<li>Marasmus: &lt;60% weight for age, no edema</li>
<li>Kwashiorkor: Edema, low albumin</li>
</ul></li>
<li><strong>Anthropometric Cutoffs</strong>:
<ul>
<li>Stunting: &lt;90% height for age</li>
<li>Wasting: &lt;80% weight for height</li>
<li>Underweight: &lt;70% weight for age</li>
</ul></li>
<li><strong>Vitamin Deficiencies</strong>:
<ul>
<li>Night blindness: Vitamin A</li>
<li>Rickets: Vitamin D</li>
<li>Pellagra: Niacin (‚Äú3 D‚Äôs‚Äù)</li>
<li>Scurvy: Vitamin C</li>
</ul></li>
<li><strong>Iron Deficiency Anemia</strong>:
<ul>
<li>MCV &lt;80 fL (microcytic)</li>
<li>Serum ferritin &lt;15 Œºg/L</li>
<li>TIBC &gt;350 Œºg/dL</li>
</ul></li>
<li><strong>Iodine Deficiency</strong>:
<ul>
<li>Universal salt iodization: 15-40 ppm</li>
<li>Target: &lt;5% households with goiter</li>
</ul></li>
<li><strong>NFHS-5 Key Statistics</strong>:
<ul>
<li>Stunting: 35.5%</li>
<li>Wasting: 19.3%</li>
<li>Anemia (children): 67.1%</li>
</ul></li>
</ol>
<h3 id="memory-aids">Memory Aids</h3>
<h4 id="vitamin-functions">Vitamin Functions</h4>
<p><strong>‚ÄúA-D-E-K‚Äù</strong>: Absorption, Development, Endocrine,
Killing - <strong>A</strong> (Vision): Absorb light - <strong>D</strong>
(Calcium): Development of bones - <strong>E</strong> (Antioxidant): End
products protection - <strong>K</strong> (Coagulation): Keep blood
clotting</p>
<h4 id="b-complex-functions">B-Complex Functions</h4>
<p><strong>‚ÄúTIRE‚Äù</strong>: - <strong>T</strong>hiamine: Energy
metabolism (Transfer to ATP) - <strong>I</strong>ron: Hemoglobin
synthesis - <strong>R</strong>iboflavin: Cellular respiration -
<strong>E</strong>ngery: From carbohydrates</p>
<h4 id="pem-differences">PEM Differences</h4>
<p><strong>‚ÄúMARASMUS‚Äù vs ‚ÄúKWASHIORKOR‚Äù</strong>: -
<strong>MARASMUS</strong>: <strong>M</strong>uscle wasting,
<strong>A</strong>dequate albumin, <strong>R</strong>educed calories -
<strong>KWASHIOKOR</strong>: <strong>K</strong>nows
<strong>W</strong>eekness, <strong>A</strong>lbumin low,
<strong>S</strong>kin changes, <strong>H</strong>air changes,
<strong>I</strong>rritability, <strong>O</strong>edema,
<strong>R</strong>enal changes</p>
<h4 id="food-fortification">Food Fortification</h4>
<p><strong>‚ÄúSHINE‚Äù</strong>: - <strong>S</strong>alt: Iodized -
<strong>H</strong>eat-stable: Vitamins A, D - <strong>I</strong>ron:
Double fortified salt - <strong>N</strong>ecessary: For entire
population - <strong>E</strong>conomic: Cost-effective</p>
<h4 id="who-growth-standards">WHO Growth Standards</h4>
<p><strong>‚ÄúZ-SCORE‚Äù</strong>: - <strong>Z</strong>ero: Normal (&gt;-2
SD) - <strong>S</strong>evere: &lt;-3 SD -
<strong>C</strong>omprehensive: Weight, height, MUAC -
<strong>O</strong>ptimal: Breastfeeding recommended -
<strong>R</strong>equired: Regular monitoring -
<strong>E</strong>vidence-based: WHO approved</p>
<hr />
<h2 id="anthropometric-charts-and-calculations">Anthropometric Charts
and Calculations</h2>
<h3 id="weight-for-age-charts">1. Weight-for-Age Charts</h3>
<h4 id="indian-academy-of-pediatrics-iap-standards">Indian Academy of
Pediatrics (IAP) Standards</h4>
<p><strong>Gomez Classification</strong>: - Normal: &gt;90% expected
weight - Grade I PEM: 75-90% expected weight - Grade II PEM: 60-74%
expected weight - Grade III PEM: &lt;60% expected weight</p>
<p><strong>Expected Weight Calculation</strong>: - <strong>0-1
year</strong>: Expected weight = (Age in months √ó 0.5) + 4 kg -
<strong>1-6 years</strong>: Expected weight = (Age in years √ó 2) + 8
kg</p>
<h3 id="height-for-age-assessment">2. Height-for-Age Assessment</h3>
<h4 id="stunting-classification">Stunting Classification</h4>
<ul>
<li><strong>Normal</strong>: &gt;95% expected height</li>
<li><strong>Moderate stunting</strong>: 90-94% expected height</li>
<li><strong>Severe stunting</strong>: &lt;90% expected height</li>
</ul>
<p><strong>Expected Height Calculation</strong>: - <strong>2-12
years</strong>: Expected height = (Age in years √ó 6) + 77 cm</p>
<h3 id="body-mass-index-bmi">3. Body Mass Index (BMI)</h3>
<h4 id="adult-bmi-categories">Adult BMI Categories</h4>
<ul>
<li><strong>Underweight</strong>: &lt;18.5 kg/m¬≤</li>
<li><strong>Normal</strong>: 18.5-24.9 kg/m¬≤</li>
<li><strong>Overweight</strong>: 25-29.9 kg/m¬≤</li>
<li><strong>Obese</strong>: ‚â•30 kg/m¬≤</li>
</ul>
<p><strong>BMI Calculation</strong>: BMI = Weight (kg) / Height¬≤
(m¬≤)</p>
<h4 id="children-bmi-for-age">Children BMI-for-Age</h4>
<ul>
<li><strong>Underweight</strong>: &lt;5th percentile</li>
<li><strong>Normal</strong>: 5th-85th percentile</li>
<li><strong>Overweight</strong>: 85th-95th percentile</li>
<li><strong>Obese</strong>: ‚â•95th percentile</li>
</ul>
<h3 id="mid-upper-arm-circumference-muac-1">4. Mid-Upper Arm
Circumference (MUAC)</h3>
<h4 id="age-specific-cutoffs-6-59-months">Age-Specific Cutoffs (6-59
months)</h4>
<ul>
<li><strong>Severe acute malnutrition</strong>: &lt;11.5 cm</li>
<li><strong>Moderate acute malnutrition</strong>: 11.5-12.4 cm</li>
<li><strong>Normal</strong>: ‚â•12.5 cm</li>
</ul>
<p><strong>Adult Cutoffs</strong>: - <strong>Severe acute
malnutrition</strong>: &lt;21 cm (women), &lt;22 cm (men) -
<strong>Moderate acute malnutrition</strong>: 21-22.9 cm (women),
22-23.9 cm (men)</p>
<h3 id="z-score-calculations">5. Z-Score Calculations</h3>
<h4 id="formula">Formula</h4>
<p><strong>Z-score = (Observed value - Median value) / Standard
Deviation</strong></p>
<h4 id="interpretation">Interpretation</h4>
<ul>
<li><strong>Normal</strong>: Z &gt; -2</li>
<li><strong>At risk</strong>: -2 ‚â• Z &gt; -3</li>
<li><strong>Severely malnourished</strong>: Z ‚â§ -3</li>
</ul>
<h3 id="growth-velocity-assessment">6. Growth Velocity Assessment</h3>
<h4 id="weight-velocity">Weight Velocity</h4>
<p><strong>Critical periods</strong>: - <strong>Birth to 1
year</strong>: Rapid weight gain - <strong>1-2 years</strong>: Slower
growth - <strong>2-5 years</strong>: Steady growth - <strong>School
age</strong>: Slower until puberty</p>
<p><strong>Monthly weight gain targets</strong>: - <strong>0-3
months</strong>: 500-1000 g - <strong>3-6 months</strong>: 500 g -
<strong>6-9 months</strong>: 250 g - <strong>9-12 months</strong>: 250
g</p>
<hr />
<h2 id="recent-guidelines-and-policies">Recent Guidelines and
Policies</h2>
<h3 id="poshan-2.0-2021">1. POSHAN 2.0 (2021)</h3>
<h4 id="launch-details">Launch Details</h4>
<p><strong>Launched</strong>: March 2022 <strong>Duration</strong>: 5
years (2021-26) <strong>Budget</strong>: ‚Çπ2,30,000 crore</p>
<h4 id="key-components">Key Components</h4>
<ol type="1">
<li><strong>Poshan Bhi Padhe Lagi</strong>: School-based nutrition
education</li>
<li><strong>Community-based Poshan Mahotsav</strong>: Community
mobilization</li>
<li><strong>Technology integration</strong>: Poshan tracker 2.0</li>
<li><strong>Research</strong>: Nutrition research centers</li>
</ol>
<h4 id="targets-by-2026">Targets by 2026</h4>
<ul>
<li>Reduce stunting: 3% per year</li>
<li>Reduce wasting: 2% per year</li>
<li>Reduce anemia: 3% per year</li>
</ul>
<h3 id="national-food-security-act-nfsa-2013">2. National Food Security
Act (NFSA) 2013</h3>
<h4 id="coverage">Coverage</h4>
<p><strong>Priority households</strong>: 75% rural, 50% urban
<strong>Antyodaya households</strong>: 25% rural, 50% urban</p>
<h4 id="entitlements">Entitlements</h4>
<p><strong>Priority households</strong>: - Rice: ‚Çπ3/kg - Wheat: ‚Çπ2/kg -
Coarse grains: ‚Çπ1/kg</p>
<p><strong>Antyodaya households</strong>: - Rice: ‚Çπ3/kg - Wheat: ‚Çπ2/kg -
Coarse grains: ‚Çπ1/kg</p>
<h4 id="legal-right">Legal Right</h4>
<ul>
<li>75% of rural and 50% of urban population</li>
<li>Right to subsidized food grains</li>
<li>Women empowerment through parental rights</li>
</ul>
<h3 id="eat-right-india-movement">3. Eat Right India Movement</h3>
<h4 id="launch-2018">Launch: 2018</h4>
<h4 id="components">Components</h4>
<ol type="1">
<li><strong>Eat Right Campus</strong>: Educational institutions</li>
<li><strong>Eat Right Hospital</strong>: Healthcare facilities</li>
<li><strong>Eat Right Street Food</strong>: Food safety</li>
<li><strong>Eat Right Mahal</strong>: Household kitchen</li>
</ol>
<h4 id="objectives">Objectives</h4>
<ul>
<li>Safe and healthy food</li>
<li>Healthy diets for all</li>
<li>Food waste reduction</li>
<li>Sustainable food systems</li>
</ul>
<h3 id="fssai-dietary-guidelines-for-indians-2016">4. FSSAI Dietary
Guidelines for Indians (2016)</h3>
<h4 id="key-recommendations">Key Recommendations</h4>
<ol type="1">
<li><strong>Variety in diet</strong>: Include all food groups</li>
<li><strong>Portion control</strong>: Appropriate quantities</li>
<li><strong>Physical activity</strong>: 60 minutes daily</li>
<li><strong>Water intake</strong>: 30 ml/kg body weight</li>
<li><strong>Oil restriction</strong>: &lt;30 g/day per adult</li>
</ol>
<h4 id="food-group-recommendations">Food Group Recommendations</h4>
<ul>
<li><strong>Cereals</strong>: 300-400 g/day</li>
<li><strong>Pulses</strong>: 40-60 g/day</li>
<li><strong>Milk</strong>: 200-300 ml/day</li>
<li><strong>Vegetables</strong>: 300-400 g/day</li>
<li><strong>Fruits</strong>: 100-150 g/day</li>
<li><strong>Oil</strong>: 20-30 g/day</li>
</ul>
<hr />
<h2 id="clinical-case-studies">Clinical Case Studies</h2>
<h3 id="case-1-protein-energy-malnutrition">Case 1: Protein-Energy
Malnutrition</h3>
<p><strong>Patient</strong>: 18-month-old child, weight 6 kg
<strong>History</strong>: Poor appetite for 3 months, lethargy, frequent
infections <strong>Examination</strong>: Wasted appearance, ‚Äúmatchstick‚Äù
limbs, normal hair and skin</p>
<p><strong>Questions</strong>: 1. What is the nutritional diagnosis? 2.
Calculate expected weight for age and classify PEM grade 3. What are the
immediate management priorities?</p>
<p><strong>Answers</strong>: 1. <strong>Diagnosis</strong>: Marasmus
(Grade III PEM) 2. <strong>Expected weight</strong>: (1.5 √ó 2) + 8 = 11
kg; Actual = 6 kg = 54.5% ‚Üí Grade III PEM 3.
<strong>Management</strong>: - Inpatient care initially - Therapeutic
feeding with RUTF - Treat complications (infections) - Gradual
rehydration - Family counseling</p>
<h3 id="case-2-vitamin-a-deficiency">Case 2: Vitamin A Deficiency</h3>
<p><strong>Patient</strong>: 5-year-old child, night blindness for 1
week <strong>History</strong>: Poor diet, mother notices child cannot
see in dim light <strong>Examination</strong>: Dry conjunctiva, Bitot‚Äôs
spots present</p>
<p><strong>Questions</strong>: 1. What is the clinical diagnosis? 2.
What is the WHO classification? 3. What is the treatment protocol?</p>
<p><strong>Answers</strong>: 1. <strong>Diagnosis</strong>: Vitamin A
deficiency - XN + X1B 2. <strong>Classification</strong>: Night
blindness (XN) with Bitot‚Äôs spots (X1B) 3. <strong>Treatment</strong>: -
Vitamin A: 200,000 IU (1 capsule) immediately - Repeat dose next day -
Third dose after 2 weeks - Counseling on dietary sources</p>
<h3 id="case-3-iron-deficiency-anemia">Case 3: Iron Deficiency
Anemia</h3>
<p><strong>Patient</strong>: 25-year-old female, fatigue for 3 months
<strong>History</strong>: Heavy menstrual bleeding, poor diet
<strong>Examination</strong>: Pallor, koilonychia present
<strong>Labs</strong>: Hb 8.2 g/dL, MCV 72 fL, serum ferritin 8 Œºg/L</p>
<p><strong>Questions</strong>: 1. What is the diagnosis? 2. Calculate
the TIBC and serum iron 3. What is the treatment protocol?</p>
<p><strong>Answers</strong>: 1. <strong>Diagnosis</strong>: Iron
deficiency anemia 2. <strong>Expected values</strong>: - TIBC &gt;350
Œºg/dL (estimated 420 Œºg/dL) - Serum iron &lt;50 Œºg/dL (estimated 35
Œºg/dL) 3. <strong>Treatment</strong>: - Elemental iron: 200 mg/day -
Duration: 3-6 months (3 months after Hb normalizes) - Address underlying
cause (menstrual bleeding)</p>
<h3 id="case-4-iodine-deficiency-disorder">Case 4: Iodine Deficiency
Disorder</h3>
<p><strong>Patient</strong>: 8-year-old child, enlarged thyroid, poor
school performance <strong>History</strong>: From endemic goiter area,
mother‚Äôs goiter <strong>Examination</strong>: Diffuse goiter grade II,
delayed developmental milestones <strong>Labs</strong>: TSH elevated,
T3/T4 low</p>
<p><strong>Questions</strong>: 1. What is the diagnosis? 2. What are the
preventive measures? 3. How to prevent recurrence?</p>
<p><strong>Answers</strong>: 1. <strong>Diagnosis</strong>: Iodine
deficiency disorder with endemic goiter and mild cretinism 2.
<strong>Prevention</strong>: - Universal salt iodization (15-40 ppm KI)
- Public awareness - Regular monitoring 3. <strong>Management</strong>:
- Thyroid hormone replacement - Educare support - Lifelong iodized salt
use</p>
<hr />
<h2 id="quick-reference-tables">Quick Reference Tables</h2>
<h3 id="anthropometric-reference-values">Anthropometric Reference
Values</h3>
<table>
<thead>
<tr>
<th>Age Group</th>
<th>Weight (kg)</th>
<th>Height (cm)</th>
<th>BMI</th>
<th>MUAC (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>7.3</td>
<td>67.6</td>
<td>-</td>
<td>12.5</td>
</tr>
<tr>
<td>1 year</td>
<td>9.6</td>
<td>76.1</td>
<td>-</td>
<td>13.5</td>
</tr>
<tr>
<td>2 years</td>
<td>12.2</td>
<td>87.8</td>
<td>-</td>
<td>14.5</td>
</tr>
<tr>
<td>5 years</td>
<td>18.4</td>
<td>109.2</td>
<td>15.4</td>
<td>15.5</td>
</tr>
<tr>
<td>Adult male</td>
<td>-</td>
<td>173</td>
<td>20-25</td>
<td>21</td>
</tr>
<tr>
<td>Adult female</td>
<td>-</td>
<td>160</td>
<td>18-23</td>
<td>21</td>
</tr>
</tbody>
</table>
<h3 id="nutritional-requirements-2">Nutritional Requirements</h3>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 21%" />
<col style="width: 18%" />
<col style="width: 15%" />
<col style="width: 19%" />
</colgroup>
<thead>
<tr>
<th>Population Group</th>
<th>Energy (kcal)</th>
<th>Protein (g)</th>
<th>Iron (mg)</th>
<th>Calcium (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult male</td>
<td>2400</td>
<td>60</td>
<td>17</td>
<td>600</td>
</tr>
<tr>
<td>Adult female</td>
<td>2000</td>
<td>55</td>
<td>21</td>
<td>600</td>
</tr>
<tr>
<td>Pregnant woman</td>
<td>2300</td>
<td>78</td>
<td>27</td>
<td>1000</td>
</tr>
<tr>
<td>Lactating woman</td>
<td>2500</td>
<td>74</td>
<td>30</td>
<td>1000</td>
</tr>
<tr>
<td>Child 1-3 years</td>
<td>1200</td>
<td>23</td>
<td>7</td>
<td>500</td>
</tr>
<tr>
<td>Child 4-6 years</td>
<td>1400</td>
<td>30</td>
<td>10</td>
<td>500</td>
</tr>
</tbody>
</table>
<h3 id="food-fortification-standards">Food Fortification Standards</h3>
<table>
<colgroup>
<col style="width: 28%" />
<col style="width: 15%" />
<col style="width: 36%" />
<col style="width: 19%" />
</colgroup>
<thead>
<tr>
<th>Fortification</th>
<th>Level</th>
<th>Target Deficiency</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double Fortified Salt</td>
<td>25-40 ppm KI + 0.6% ferrous fumarate</td>
<td>Iodine + Iron</td>
<td>10 states</td>
</tr>
<tr>
<td>Wheat Flour</td>
<td>55 ppm Fe + 1.3 ppm folic acid + 3.8 Œºg B12</td>
<td>Iron + Folate</td>
<td>5 states</td>
</tr>
<tr>
<td>Oil</td>
<td>25 ppm vitamin A + 27 IU vitamin D</td>
<td>Vitamin A + D</td>
<td>National</td>
</tr>
<tr>
<td>Milk</td>
<td>1170 IU vitamin A + 580 IU vitamin D per liter</td>
<td>Vitamin A + D</td>
<td>Urban areas</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="summary-and-key-takeaways">Summary and Key Takeaways</h2>
<h3 id="critical-concepts-for-examinations">Critical Concepts for
Examinations</h3>
<ol type="1">
<li><strong>PEM Classification</strong>: Weight-for-age is most
sensitive for community surveys</li>
<li><strong>WHO Growth Standards</strong>: Z-score approach preferred
over percentage</li>
<li><strong>Vitamin A</strong>: Night blindness is earliest symptom,
correct with supplementation</li>
<li><strong>Iron Deficiency</strong>: Ferritin &lt;15 Œºg/L is
diagnostic, treat for 3 months after normalization</li>
<li><strong>Iodine Deficiency</strong>: Universal salt iodization at
15-40 ppm potassium iodate</li>
<li><strong>NFHS-5</strong>: Stunting 35.5%, wasting 19.3% - still major
public health problem</li>
<li><strong>POSHAN 2.0</strong>: Nutrition Mission 2.0 with convergence
approach</li>
</ol>
<h3 id="high-yield-facts">High-Yield Facts</h3>
<ul>
<li><strong>Exclusive breastfeeding</strong>: 0-6 months, reduces infant
mortality by 13%</li>
<li><strong>Complementary feeding</strong>: Start at 6 months with
continued breastfeeding</li>
<li><strong>RUTF</strong>: 500-550 kcal/100g, no water required</li>
<li><strong>Anemia prevalence</strong>: 67.1% children, 57.2% women
(NFHS-5)</li>
<li><strong>Salt iodization coverage</strong>: 85.6% households
(NFHS-5)</li>
<li><strong>PDS beneficiaries</strong>: 80% of rural households</li>
</ul>
<h3 id="common-mcq-pitfalls">Common MCQ Pitfalls</h3>
<ul>
<li>Confusing marasmus with kwashiorkor</li>
<li>Wrong calculation of expected weight/height</li>
<li>Mixing vitamin deficiency symptoms</li>
<li>Incorrect hemoglobin cutoffs for different population groups</li>
<li>Not knowing current NFHS-5 statistics</li>
</ul>
<h3 id="essential-formulas">Essential Formulas</h3>
<ul>
<li><strong>Expected weight (0-1 yr)</strong>: (Age in months √ó 0.5) + 4
kg</li>
<li><strong>Expected weight (1-6 yr)</strong>: (Age in years √ó 2) + 8
kg</li>
<li><strong>Expected height (2-12 yr)</strong>: (Age in years √ó 6) + 77
cm</li>
<li><strong>BMI</strong>: Weight (kg) / Height¬≤ (m¬≤)</li>
<li><strong>Z-score</strong>: (Observed - Median) / SD</li>
<li><strong>BMR (Males)</strong>: 66 + (13.7 √ó W) + (5 √ó H) - (6.8 √ó
A)</li>
</ul>
<hr />
<p><em>This manual provides comprehensive, examination-focused content
for Community Medicine students and practitioners. Regular updates with
latest statistics and guidelines are essential for maintaining relevance
in the rapidly evolving field of nutrition and health.</em></p>
<h1 id="part-iv-maternal-and-child-health-1">Part IV: Maternal and Child
Health</h1>
<h2 id="chapter-11-maternal-health">Chapter 11: Maternal Health</h2>
<h3 id="section-a-reproductive-health">Section A: Reproductive
Health</h3>
<h4 id="definition-and-concepts">Definition and Concepts</h4>
<p><strong>Reproductive Health</strong> is a state of complete physical,
mental and social well-being and not merely the absence of disease or
infirmity, in all matters relating to the reproductive system and to its
functions and processes.</p>
<p><strong>Reproductive Rights</strong> are based on the recognition of
the basic right of all couples and individuals to decide freely and
responsibly on the number, spacing and timing of their children and to
have the information and means to do so.</p>
<p><strong>Key Components:</strong> - Maternal and newborn care - Family
planning services - Prevention and management of reproductive tract
infections and STDs - Elimination of harmful practices (female genital
mutilation, son preference) - Promotion of sexual health</p>
<h4 id="maternal-mortality-and-morbidity">Maternal Mortality and
Morbidity</h4>
<p><strong>Maternal Mortality Ratio (MMR):</strong> -
<strong>Definition:</strong> Number of maternal deaths per 100,000 live
births - <strong>Calculation:</strong> MMR = (Maternal deaths √∑ Live
births) √ó 100,000 - <strong>NFHS-5 Data:</strong> India MMR = 97 per
100,000 live births (2020) - <strong>Global Average:</strong> 211 per
100,000 live births - <strong>Target 3.1 of SDGs:</strong> Reduce global
MMR to less than 70 per 100,000 live births</p>
<p><strong>Maternal Mortality Causes (Three Delays Model):</strong> 1.
<strong>Delay in deciding to seek care</strong> 2. <strong>Delay in
reaching care</strong> 3. <strong>Delay in receiving adequate
care</strong></p>
<p><strong>Major Causes of Maternal Deaths:</strong> 1.
<strong>Hemorrhage (27%)</strong> 2. <strong>Hypertensive disorders
(14%)</strong> 3. <strong>Sepsis (11%)</strong> 4. <strong>Pulmonary
embolism (3%)</strong> 5. <strong>Amniotic fluid embolism (2%)</strong>
6. <strong>Cardiac disease (4%)</strong> 7. <strong>Other causes
(39%)</strong></p>
<h4 id="risk-factors-and-assessment">Risk Factors and Assessment</h4>
<p><strong>High-Risk Pregnancy Identification:</strong></p>
<p><strong>Maternal Risk Factors:</strong> - Age &lt; 17 years or &gt;
35 years - Parity 0 or ‚â• 4 - Height &lt; 145 cm - Weight &lt; 45 kg or
&gt; 80 kg - Previous obstetric complications - Medical conditions
(diabetes, hypertension, heart disease) - Substance abuse</p>
<p><strong>Obstetric Risk Factors:</strong> - Antepartum hemorrhage -
Pre-eclampsia/eclampsia - Multiple pregnancy - Fetal growth restriction
- Malpresentation - Post-term pregnancy - Previous cesarean section</p>
<p><strong>Social Risk Factors:</strong> - Low socioeconomic status -
Poor education - Domestic violence - Unmarried mother - Lack of family
support</p>
<h3 id="section-b-antenatal-care">Section B: Antenatal Care</h3>
<h4 id="who-recommended-anc-package">WHO Recommended ANC Package</h4>
<p><strong>Essential Components of ANC:</strong> 1. <strong>Risk
assessment</strong> 2. <strong>Monitoring and management</strong> 3.
<strong>Health education and promotion</strong> 4. <strong>Counseling
and support</strong></p>
<p><strong>Focused Antenatal Care (FANC):</strong> - <strong>Minimum 4
visits</strong> for uncomplicated pregnancy - <strong>8 contacts
model:</strong> 1 in 1st trimester, 1 in 2nd trimester, 2 in 3rd
trimester</p>
<h4 id="anc-schedule-and-components">ANC Schedule and Components</h4>
<p><strong>First Visit (8-12 weeks):</strong> - <strong>Complete history
and examination</strong> - <strong>Weight, height, BMI
calculation</strong> - <strong>Blood pressure measurement</strong> -
<strong>Laboratory investigations:</strong> - Hemoglobin estimation -
Blood grouping and Rh typing - Urine analysis - Blood sugar (fasting/PP)
- VDRL/RPR test - HIV testing (with consent) - HBsAg test -
<strong>Tetanus toxoid immunization (if not protected)</strong> -
<strong>Iron and folic acid supplementation</strong></p>
<p><strong>Subsequent Visits (16-20 weeks, 24-26 weeks, 32-34 weeks,
36-38 weeks):</strong> - <strong>Weight gain monitoring</strong> -
<strong>Blood pressure measurement</strong> - <strong>Fundal height
measurement</strong> - <strong>Fetal heart sounds</strong> -
<strong>Fetal movements (after 28 weeks)</strong> - <strong>Urine
testing for protein and glucose</strong> - <strong>Anemia
screening</strong></p>
<h4 id="danger-signs-recognition">Danger Signs Recognition</h4>
<p><strong>First Trimester Danger Signs:</strong> - Bleeding per vaginum
- Severe nausea and vomiting - Abdominal pain - Fever with vaginal
discharge - Severe headache with visual disturbances</p>
<p><strong>Second Trimester Danger Signs:</strong> - Bleeding per
vaginum - Severe headache - Visual disturbances - Epigastric pain -
Decreased fetal movements - Fluid leak per vaginum</p>
<p><strong>Third Trimester Danger Signs:</strong> - Bleeding per vaginum
- Severe headache - Visual disturbances - Epigastric pain - Reduced
fetal movements - Abdominal pain with rigidity - Convulsions - Severe
swelling of face and hands</p>
<h4 id="birth-preparedness">Birth Preparedness</h4>
<p><strong>Birth Preparedness Components:</strong> - <strong>Identify
skilled birth attendant</strong> - <strong>Arrange transport for
emergency</strong> - <strong>Save money for emergency</strong> -
<strong>Identify blood donor</strong> - <strong>Arrange companion for
delivery</strong> - <strong>Prepare clean delivery kit</strong> -
<strong>Identify nearest health facility</strong></p>
<h4 id="tetanus-toxoid-immunization">Tetanus Toxoid Immunization</h4>
<p><strong>Schedule:</strong> - <strong>TT1:</strong> At first contact
or as early as possible - <strong>TT2:</strong> 4 weeks after TT1 -
<strong>TT3:</strong> 6 months after TT2 or during next pregnancy -
<strong>TT4:</strong> 1 year after TT3 or during next pregnancy -
<strong>TT5:</strong> 1 year after TT4 or during next pregnancy</p>
<p><strong>Protection Duration:</strong> - <strong>TT1 + TT2:</strong> 3
years protection - <strong>TT3 + TT4:</strong> 5 years protection -
<strong>TT5:</strong> Full protection for all future pregnancies</p>
<h4 id="iron-and-folic-acid-supplementation">Iron and Folic Acid
Supplementation</h4>
<p><strong>Dosage:</strong> - <strong>Iron:</strong> 60 mg elemental
iron daily - <strong>Folic acid:</strong> 400 Œºg daily -
<strong>Duration:</strong> Throughout pregnancy and 3 months
postpartum</p>
<p><strong>Benefits:</strong> - Reduces maternal anemia by 70% - Reduces
preterm births by 18% - Reduces low birth weight by 16%</p>
<h3 id="section-c-intranatal-care">Section C: Intranatal Care</h3>
<h4 id="clean-delivery-practices">Clean Delivery Practices</h4>
<p><strong>Essential Elements:</strong> 1. <strong>Clean hands</strong>
2. <strong>Clean perineum</strong> 3. <strong>Clean delivery
surface</strong> 4. <strong>Clean cord cutting</strong> 5. <strong>Clean
cord tying</strong> 6. <strong>Eye care for newborn</strong> 7.
<strong>Thermal care for newborn</strong></p>
<p><strong>Hand Washing Technique:</strong> 1. Wet hands with clean
water 2. Apply soap and lather well 3. Scrub palms, backs of hands,
between fingers, and under nails 4. Rinse thoroughly with clean water 5.
Dry with clean towel or air dry</p>
<h4 id="skilled-birth-attendance">Skilled Birth Attendance</h4>
<p><strong>Definition:</strong> Trained health professional with
competencies to manage normal pregnancy and childbirth, and identify and
manage complications or refer for complications.</p>
<p><strong>Competencies Required:</strong> - <strong>Antenatal care
skills</strong> - <strong>Normal delivery management</strong> -
<strong>Emergency obstetric care</strong> - <strong>Newborn
care</strong> - <strong>Communication skills</strong> -
<strong>Documentation and reporting</strong></p>
<h4 id="emergency-obstetric-care-emoc">Emergency Obstetric Care
(EmOC)</h4>
<p><strong>Basic EmOC Functions:</strong> 1. <strong>Parenteral
antibiotics</strong> 2. <strong>Parenteral uterotonics</strong> 3.
<strong>Parenteral anticonvulsants</strong> 4. <strong>Manual removal of
placenta</strong> 5. <strong>Removal of retained products</strong> 6.
<strong>Assisted vaginal delivery</strong> 7. <strong>Neonatal
resuscitation</strong></p>
<p><strong>Comprehensive EmOC Functions:</strong> 1. <strong>All basic
functions</strong> 2. <strong>Surgery (cesarean section)</strong> 3.
<strong>Blood transfusion</strong></p>
<h4 id="partograph-usage">Partograph Usage</h4>
<p><strong>Purpose:</strong> Monitor labor progress and detect
complications early.</p>
<p><strong>Components:</strong> - <strong>Fetal condition:</strong> FHR,
molding of skull bones, amniotic fluid - <strong>Maternal
condition:</strong> Pulse, BP, temperature, urine output - <strong>Labor
progress:</strong> Cervical dilation, descent of head - <strong>Drugs
and fluids administered</strong> - <strong>Time elapsed</strong></p>
<p><strong>Alert Line:</strong> Represents normal labor progress
<strong>Action Line:</strong> 4 hours to the right of alert line</p>
<h4 id="active-management-of-third-stage-amtsl">Active Management of
Third Stage (AMTSL)</h4>
<p><strong>Steps:</strong> 1. <strong>Uterotonic drug:</strong> Oxytocin
10 IU IM/IV immediately after delivery 2. <strong>Controlled cord
traction</strong> 3. <strong>Uterine massage</strong></p>
<p><strong>Benefits:</strong> - Reduces postpartum hemorrhage by 60-70%
- Reduces blood loss by 250-300 ml - Reduces retained placenta</p>
<h3 id="section-d-postnatal-care">Section D: Postnatal Care</h3>
<h4 id="postpartum-care-protocols">Postpartum Care Protocols</h4>
<p><strong>First 24 hours:</strong> - Monitor vital signs - Check fundal
height and tone - Monitor bleeding - Assess urine output - Breastfeeding
support - Pain management</p>
<p><strong>First week:</strong> - Continue monitoring - Perineal care -
Breast care - Contraception counseling - Nutritional counseling</p>
<p><strong>6 weeks postpartum:</strong> - Complete examination -
Contraceptive method provision - Health education reinforcement</p>
<h4 id="breastfeeding-support">Breastfeeding Support</h4>
<p><strong>Optimal Breastfeeding Practices:</strong> - <strong>Early
initiation:</strong> Within 1 hour of birth - <strong>Exclusive
breastfeeding:</strong> First 6 months - <strong>Continued
breastfeeding:</strong> Up to 2 years with complementary foods</p>
<p><strong>Benefits:</strong> - <strong>For infant:</strong> Reduces
infections, improves cognitive development - <strong>For
mother:</strong> Reduces postpartum bleeding, aids contraception</p>
<p><strong>Breastfeeding Positions:</strong> - <strong>Cradle
hold</strong> - <strong>Cross-cradle</strong> - <strong>Football
hold</strong> - <strong>Side-lying</strong> - <strong>Biological
nurturing</strong></p>
<h4 id="postpartum-complications">Postpartum Complications</h4>
<p><strong>Major Complications:</strong> 1. <strong>Postpartum
hemorrhage (PPH)</strong> 2. <strong>Puerperal sepsis</strong> 3.
<strong>Venous thromboembolism</strong> 4. <strong>Postpartum
cardiomyopathy</strong> 5. <strong>Mental health disorders</strong></p>
<p><strong>PPH Management (4 Ts):</strong> - <strong>Tone:</strong>
Uterine atony (80% cases) - <strong>Trauma:</strong> Lacerations,
hematoma - <strong>Tissue:</strong> Retained placenta -
<strong>Thrombin:</strong> Coagulation disorders</p>
<h4 id="family-planning-counseling">Family Planning Counseling</h4>
<p><strong>Postpartum Contraception Options:</strong> - <strong>Barrier
methods:</strong> Condoms, diaphragms - <strong>Hormonal
methods:</strong> Progestin-only pills, implants - <strong>Intrauterine
devices:</strong> Copper IUDs - <strong>Permanent methods:</strong>
Sterilization</p>
<p><strong>Lactational Amenorrhea Method (LAM):</strong> -
<strong>Conditions:</strong> &lt;6 months postpartum, exclusive
breastfeeding, amenorrhea - <strong>Effectiveness:</strong> 98% if
followed correctly</p>
<h2 id="chapter-12-child-health">Chapter 12: Child Health</h2>
<h3 id="section-a-child-development">Section A: Child Development</h3>
<h4 id="milestones-assessment">Milestones Assessment</h4>
<p><strong>Gross Motor Development:</strong> - <strong>2
months:</strong> Lifts head when prone - <strong>6 months:</strong> Sits
without support - <strong>9 months:</strong> Stands with support -
<strong>12 months:</strong> Walks independently - <strong>18
months:</strong> Runs stiffly - <strong>24 months:</strong> Jumps with
both feet - <strong>36 months:</strong> Climbs stairs with alternating
feet</p>
<p><strong>Fine Motor Development:</strong> - <strong>2 months:</strong>
Follows objects with eyes - <strong>6 months:</strong> Transfers objects
hand-to-hand - <strong>9 months:</strong> Pincer grasp - <strong>12
months:</strong> Scribbles with crayon - <strong>18 months:</strong>
Stacks 3 cubes - <strong>24 months:</strong> Builds tower of 6-7 cubes -
<strong>36 months:</strong> Copies circle</p>
<p><strong>Language Development:</strong> - <strong>2 months:</strong>
Coos, gurgles - <strong>6 months:</strong> Babbles ‚Äúba-ba‚Äù, ‚Äúda-da‚Äù -
<strong>9 months:</strong> Understands ‚Äúno‚Äù, waves bye-bye - <strong>12
months:</strong> Says ‚Äúmama‚Äù, ‚Äúdada‚Äù specifically - <strong>18
months:</strong> Vocabulary of 10-15 words - <strong>24 months:</strong>
Two-word phrases, vocabulary 50+ words - <strong>36 years:</strong>
Complex sentences, vocabulary 1000+ words</p>
<p><strong>Social/Emotional Development:</strong> - <strong>2
months:</strong> Smiles responsively - <strong>6 months:</strong>
Recognizes familiar faces, cries when stranger approaches - <strong>9
months:</strong> Stranger anxiety - <strong>12 months:</strong> Plays
peek-a-boo - <strong>18 months:</strong> Parallel play - <strong>24
months:</strong> Temper tantrums - <strong>36 years:</strong>
Cooperative play, empathy</p>
<h4 id="growth-monitoring-1">Growth Monitoring</h4>
<p><strong>Growth Parameters:</strong> - <strong>Weight:</strong> Most
sensitive indicator of nutritional status -
<strong>Height/Length:</strong> Long-term nutritional status -
<strong>Head circumference:</strong> Brain growth indicator -
<strong>Mid-arm circumference:</strong> Simple nutritional screening
tool</p>
<p><strong>Growth Charts:</strong> - <strong>WHO Child Growth Standards
(0-5 years)</strong> - <strong>CDC Growth Charts (2-18 years)</strong> -
<strong>New Indian Academy of Pediatrics (IAP) Growth
Charts</strong></p>
<p><strong>Growth Monitoring Interpretation:</strong> - <strong>Weight
for age:</strong> &lt;3rd percentile = Undernutrition - <strong>Height
for age:</strong> &lt;3rd percentile = Chronic undernutrition -
<strong>Weight for height:</strong> &lt;3rd percentile = Acute
undernutrition</p>
<h4 id="immunization-schedules">Immunization Schedules</h4>
<p><strong>National Immunization Schedule (India):</strong></p>
<p><strong>Birth:</strong> - <strong>BCG</strong> (0.1 ml intradermal) -
<strong>Hepatitis B</strong> (10 Œºg IM) - <strong>OPV</strong> (2 drops
oral)</p>
<p><strong>6 weeks:</strong> - <strong>DPT</strong> (0.5 ml IM) -
<strong>OPV</strong> (2 drops oral) - <strong>Hepatitis B</strong> (10
Œºg IM) - <strong>Rotavirus</strong> (5 drops oral) -
<strong>PCV</strong> (0.5 ml IM)</p>
<p><strong>10 weeks:</strong> - <strong>DPT</strong> (0.5 ml IM) -
<strong>OPV</strong> (2 drops oral) - <strong>Hepatitis B</strong> (10
Œºg IM) - <strong>Rotavirus</strong> (5 drops oral)</p>
<p><strong>14 weeks:</strong> - <strong>DPT</strong> (0.5 ml IM) -
<strong>OPV</strong> (2 drops oral) - <strong>Hepatitis B</strong> (10
Œºg IM) - <strong>Rotavirus</strong> (5 drops oral) -
<strong>IPV</strong> (0.5 ml IM)</p>
<p><strong>6 months:</strong> - <strong>Influenza</strong> (0.5 ml
IM)</p>
<p><strong>9 months:</strong> - <strong>Measles/MR</strong> (0.5 ml SC)
- <strong>Japanese Encephalitis</strong> (0.5 ml SC, endemic areas)</p>
<p><strong>12 months:</strong> - <strong>Hepatitis A</strong> (0.5 ml
IM, 2 doses 6 months apart)</p>
<p><strong>15 months:</strong> - <strong>MMR/MR</strong> (0.5 ml SC) -
<strong>Varicella</strong> (0.5 ml SC, 2 doses 3 months apart) -
<strong>PCV Booster</strong> (0.5 ml IM)</p>
<p><strong>16-18 months:</strong> - <strong>DPT booster</strong> (0.5 ml
IM) - <strong>OPV booster</strong> (2 drops oral) - <strong>IPV
booster</strong> (0.5 ml IM) - <strong>Hib booster</strong> (0.5 ml
IM)</p>
<p><strong>5-6 years:</strong> - <strong>Tdap</strong> (0.5 ml IM) -
<strong>Japanese Encephalitis</strong> (1 ml SC, endemic areas)</p>
<p><strong>Memory Aid for Vaccination:</strong> <strong>‚ÄúBORN, 6, 10,
14, 6, 9, 12, 15, 16, 5‚Äù</strong> - <strong>B</strong>CG +
<strong>O</strong>PV + <strong>R</strong>otavirus +
<strong>N</strong>eonatal vaccine + <strong>D</strong>PT first dose -
<strong>6, 10, 14</strong> weeks: DPT + OPV + Rotavirus + IPV -
<strong>6</strong> months: Influenza - <strong>9</strong> months:
Measles - <strong>12</strong> months: Hepatitis A - <strong>15</strong>
months: MMR + Varicella - <strong>16-18</strong> months: DPT + OPV + IPV
boosters - <strong>5</strong> years: Tdap</p>
<h4 id="under-five-mortality-causes">Under-Five Mortality Causes</h4>
<p><strong>Leading Causes of U5MR (India):</strong> 1. <strong>Preterm
birth complications (28%)</strong> 2. <strong>Pneumonia (15%)</strong>
3. <strong>Diarrhea (12%)</strong> 4. <strong>Birth asphyxia and trauma
(8%)</strong> 5. <strong>Malaria (4%)</strong> 6. <strong>Congenital
anomalies (4%)</strong> 7. <strong>Injuries (4%)</strong> 8.
<strong>Other causes (25%)</strong></p>
<p><strong>Global U5MR Statistics:</strong> - <strong>India:</strong> 34
deaths per 1,000 live births (NFHS-5) - <strong>Global:</strong> 38
deaths per 1,000 live births - <strong>Target SDG 3.2:</strong> Reduce
U5MR to ‚â§25 per 1,000 live births</p>
<h4 id="child-survival-strategies">Child Survival Strategies</h4>
<p><strong>GOBI Strategy:</strong> - <strong>G:</strong> Growth
monitoring - <strong>O:</strong> Oral rehydration therapy -
<strong>B:</strong> Breastfeeding - <strong>I:</strong> Immunization</p>
<p><strong>IMNCI Strategy:</strong> - <strong>I</strong>ntegrated
management of <strong>N</strong>eonatal and <strong>C</strong>hildhood
<strong>I</strong>llness - Combines prevention and case management
approaches</p>
<p><strong>Key Components:</strong> - <strong>Assessment and
classification of illness</strong> - <strong>Identification of treatment
needs</strong> - <strong>Treatment of identified problems</strong> -
<strong>Counseling of mothers</strong> - <strong>Follow-up
care</strong></p>
<h3 id="section-b-newborn-care">Section B: Newborn Care</h3>
<h4 id="essential-newborn-care">Essential Newborn Care</h4>
<p><strong>Key Elements:</strong> 1. <strong>Thermal care</strong> 2.
<strong>Cleanliness</strong> 3. <strong>Early and exclusive
breastfeeding</strong> 4. <strong>Resuscitation</strong> 5.
<strong>Immunization</strong> 6. <strong>Care of the small
baby</strong></p>
<p><strong>Thermal Care Principles:</strong> - <strong>Dry immediately
after birth</strong> - <strong>Skin-to-skin contact (Kangaroo Mother
Care)</strong> - <strong>Keep warm with blankets</strong> -
<strong>Avoid hypothermia (temperature &lt;36.5¬∞C)</strong></p>
<h4 id="birth-asphyxia-management">Birth Asphyxia Management</h4>
<p><strong>Definition:</strong> Failure to initiate spontaneous
breathing within 1 minute of birth.</p>
<p><strong>Risk Factors:</strong> - <strong>Maternal:</strong> Severe
anemia, hypertension, diabetes - <strong>Obstetric:</strong> Prolonged
labor, fetal distress, cord prolapse - <strong>Fetal:</strong>
Prematurity, multiple pregnancy, IUGR</p>
<p><strong>Management Steps:</strong> 1. <strong>Immediate
assessment</strong> 2. <strong>Dry and stimulate</strong> 3.
<strong>Clear airway</strong> 4. <strong>Ventilate with bag and
mask</strong> 5. <strong>Chest compressions if needed</strong> 6.
<strong>Adrenaline if no response</strong></p>
<h4 id="newborn-resuscitation">Newborn Resuscitation</h4>
<p><strong>AAP/AHA Neonatal Resuscitation Algorithm:</strong> 1.
<strong>Initial steps:</strong> Warm, dry, stimulate, position 2.
<strong>PPV:</strong> If not breathing or gasping 3. <strong>Chest
compressions:</strong> If HR &lt;60 after 30 seconds PPV 4.
<strong>Medications:</strong> Adrenaline if HR &lt;60 after adequate
ventilation and chest compressions</p>
<p><strong>Equipment Required:</strong> - <strong>Radiant
warmer</strong> - <strong>Suction device</strong> - <strong>Bag and
mask</strong> - <strong>Oxygen source</strong> - <strong>Endotracheal
tubes</strong> - <strong>Stethoscope</strong></p>
<h4 id="neonatal-hypothermia-prevention">Neonatal Hypothermia
Prevention</h4>
<p><strong>WHO Classification:</strong> - <strong>Cold stress:</strong>
36.0-36.4¬∞C - <strong>Moderate hypothermia:</strong> 32.0-35.9¬∞C -
<strong>Severe hypothermia:</strong> &lt;32.0¬∞C</p>
<p><strong>Prevention Methods:</strong> - <strong>Immediate
drying</strong> - <strong>Skin-to-skin contact</strong> - <strong>Warm
blankets</strong> - <strong>Heated room (25-28¬∞C)</strong> -
<strong>Warm delivery practices</strong></p>
<h4 id="kangaroo-mother-care-kmc">Kangaroo Mother Care (KMC)</h4>
<p><strong>Definition:</strong> Care of preterm/low birth weight babies
through continuous skin-to-skin contact between mother and baby.</p>
<p><strong>Benefits:</strong> - <strong>Thermal regulation</strong> -
<strong>Improved breastfeeding</strong> - <strong>Reduced
infections</strong> - <strong>Better weight gain</strong> -
<strong>Enhanced mother-infant bonding</strong> - <strong>Reduced
mortality</strong></p>
<p><strong>Implementation:</strong> - <strong>Continuous 24/7
skin-to-skin contact</strong> - <strong>Exclusive breastfeeding</strong>
- <strong>Early discharge</strong> - <strong>Support to mother</strong>
- <strong>Follow-up care</strong></p>
<h3 id="section-c-common-childhood-problems">Section C: Common Childhood
Problems</h3>
<h4 id="diarrheal-diseases-management">Diarrheal Diseases
Management</h4>
<p><strong>Classification by Duration:</strong> -
<strong>Acute:</strong> &lt;14 days - <strong>Persistent:</strong>
&gt;14 days - <strong>Chronic:</strong> &gt;30 days</p>
<p><strong>WHO Classification of Dehydration:</strong> - <strong>No
dehydration</strong> - <strong>Some dehydration</strong> -
<strong>Severe dehydration</strong></p>
<p><strong>Treatment Based on Dehydration Status:</strong></p>
<p><strong>No Dehydration:</strong> - <strong>Treatment:</strong> ORS at
home - <strong>Amount:</strong> 10-20 ml/kg after each loose stool -
<strong>Continue normal feeding</strong></p>
<p><strong>Some Dehydration:</strong> - <strong>Treatment:</strong> ORS
in health facility - <strong>Amount:</strong> 75 ml/kg over 4 hours -
<strong>Reassess every 2 hours</strong> - <strong>Continue
feeding</strong></p>
<p><strong>Severe Dehydration:</strong> - <strong>Treatment:</strong> IV
fluids immediately - <strong>Ringer‚Äôs Lactate or Normal Saline</strong>
- <strong>100 ml/kg over 3-6 hours</strong> - <strong>Reassess every
15-30 minutes</strong></p>
<h4 id="acute-respiratory-infections">Acute Respiratory Infections</h4>
<p><strong>WHO Classification:</strong></p>
<p><strong>No Pneumonia:</strong> - <strong>Cough or cold</strong> -
<strong>Treatment:</strong> Home care, no antibiotics<strong> -
</strong>Danger signs:** Severe malnutrition, lethargy, poor feeding</p>
<p><strong>Pneumonia:</strong> - <strong>Fast breathing present</strong>
- <strong>Treatment:</strong> Oral antibiotics (amoxicillin) -
<strong>Fast breathing rates:</strong> &gt;60/min (0-2 months),
&gt;50/min (2-12 months), &gt;40/min (1-5 years)</p>
<p><strong>Severe Pneumonia:</strong> - <strong>Chest indrawing</strong>
- <strong>Treatment:</strong> Hospital admission, IV antibiotics -
<strong>Additional signs:</strong> Stridor, lethargy, poor feeding</p>
<p><strong>Very Severe Disease:</strong> - <strong>Unable to drink,
convulsions, lethargy</strong> - <strong>Treatment:</strong> Emergency
referral - <strong>Start treatment before referral</strong></p>
<h4 id="malnutrition-in-children">Malnutrition in Children</h4>
<p><strong>Classification (IAP Guidelines):</strong></p>
<p><strong>Underweight:</strong> - <strong>Moderate:</strong> Weight for
age &lt;3rd percentile but ‚â•1st percentile - <strong>Severe:</strong>
Weight for age &lt;1st percentile</p>
<p><strong>Stunting:</strong> - <strong>Moderate:</strong> Height for
age &lt;3rd percentile but ‚â•1st percentile - <strong>Severe:</strong>
Height for age &lt;1st percentile</p>
<p><strong>Wasting:</strong> - <strong>Moderate:</strong> Weight for
height &lt;3rd percentile but ‚â•1st percentile - <strong>Severe:</strong>
Weight for height &lt;1st percentile</p>
<p><strong>Severe Acute Malnutrition (SAM):</strong> - <strong>Weight
for height &lt;3rd percentile OR</strong> - <strong>Mid-arm
circumference &lt;11.5 cm (6-59 months) OR</strong> - <strong>Bilateral
pedal edema</strong></p>
<p><strong>Management of SAM:</strong> - <strong>Outpatient
management:</strong> If no complications and appetite present -
<strong>Inpatient management:</strong> If complications or poor appetite
- <strong>Therapeutic foods:</strong> RUTF (Ready-to-Use Therapeutic
Food)</p>
<h4 id="micronutrient-deficiencies">Micronutrient Deficiencies</h4>
<p><strong>Vitamin A Deficiency:</strong> - <strong>Causes:</strong>
Inadequate intake, malabsorption - <strong>Manifestations:</strong>
Night blindness, Bitot‚Äôs spots, corneal xerosis, blindness -
<strong>Prevention:</strong> High-dose vitamin A supplementation
(100,000 IU every 6 months from 6 months to 5 years)</p>
<p><strong>Iron Deficiency Anemia:</strong> - <strong>Causes:</strong>
Inadequate intake, increased demand, parasitic infections -
<strong>Manifestations:</strong> Pallor, fatigue, reduced immunity -
<strong>Prevention:</strong> Iron supplementation, deworming</p>
<p><strong>Iodine Deficiency Disorders:</strong> -
<strong>Causes:</strong> Low iodine in soil/water -
<strong>Manifestations:</strong> Goiter, mental retardation, cretinism,
deafness - <strong>Prevention:</strong> Universal salt iodization (15-20
ppm iodine)</p>
<h4 id="childhood-injuries-and-accidents">Childhood Injuries and
Accidents</h4>
<p><strong>Leading Causes of Childhood Deaths (1-5 years):</strong> 1.
<strong>Road traffic accidents</strong> 2. <strong>Drowning</strong> 3.
<strong>Burns</strong> 4. <strong>Poisoning</strong> 5.
<strong>Falls</strong></p>
<p><strong>Prevention Strategies:</strong> - <strong>Environmental
safety measures</strong> - <strong>Supervision and education</strong> -
<strong>Safety equipment use</strong> - <strong>Community awareness
programs</strong></p>
<h2 id="chapter-13-geriatric-health">Chapter 13: Geriatric Health</h2>
<h3 id="section-a-aging-process">Section A: Aging Process</h3>
<h4 id="biological-vs-chronological-aging">Biological vs Chronological
Aging</h4>
<p><strong>Chronological Aging:</strong> - <strong>Definition:</strong>
Number of years since birth - <strong>Measure:</strong> Calendar age -
<strong>Population aging:</strong> Countries with &gt;7% population aged
‚â•65 years</p>
<p><strong>Biological Aging:</strong> - <strong>Definition:</strong>
Physiological changes in body systems - <strong>Individual
variation:</strong> Different rates despite same chronological age -
<strong>Assessment:</strong> Functional capacity, biomarkers</p>
<p><strong>Geriatric Age Groups:</strong> - <strong>Young old:</strong>
65-74 years - <strong>Middle old:</strong> 75-84 years - <strong>Oldest
old:</strong> ‚â•85 years</p>
<h4 id="age-related-changes-1">Age-Related Changes</h4>
<p><strong>Physiological Changes:</strong></p>
<p><strong>Cardiovascular System:</strong> - <strong>Arterial
stiffening</strong> - <strong>Reduced cardiac output</strong> -
<strong>Increased systolic BP</strong> - <strong>Reduced heart rate
variability</strong></p>
<p><strong>Respiratory System:</strong> - <strong>Reduced lung
capacity</strong> - <strong>Decreased gas exchange</strong> -
<strong>Reduced cough reflex</strong> - <strong>Increased respiratory
infections</strong></p>
<p><strong>Musculoskeletal System:</strong> - <strong>Bone density loss
(osteoporosis)</strong> - <strong>Muscle mass reduction
(sarcopenia)</strong> - <strong>Joint cartilage degeneration</strong> -
<strong>Reduced flexibility</strong></p>
<p><strong>Nervous System:</strong> - <strong>Cognitive processing speed
reduction</strong> - <strong>Memory changes</strong> - <strong>Sensory
loss (vision, hearing)</strong> - <strong>Reduced reflexes</strong></p>
<p><strong>Immune System:</strong> - <strong>Immunosenescence</strong> -
<strong>Reduced vaccine response</strong> - <strong>Increased infection
susceptibility</strong></p>
<h4 id="theories-of-aging">Theories of Aging</h4>
<p><strong>Biological Theories:</strong></p>
<p><strong>Programmed Aging:</strong> - <strong>Genetic clock
theory</strong> - <strong>Cellular senescence</strong> -
<strong>Telomere shortening</strong></p>
<p><strong>Error/Cumulative Damage Theory:</strong> - <strong>Free
radical theory</strong> - <strong>Protein cross-linking theory</strong>
- <strong>DNA damage accumulation</strong></p>
<p><strong>Hormonal Theories:</strong> - <strong>Endocrine
dysfunction</strong> - <strong>Growth hormone deficiency</strong> -
<strong>Melatonin changes</strong></p>
<p><strong>Immunological Theories:</strong> - <strong>Immune system
aging</strong> - <strong>Autoimmunity increase</strong> -
<strong>Inflammation (inflammaging)</strong></p>
<h4 id="health-problems-in-elderly">Health Problems in Elderly</h4>
<p><strong>Most Common Conditions:</strong> 1. <strong>Hypertension (68%
in ‚â•60 years)</strong> 2. <strong>Arthritis (45%)</strong> 3.
<strong>Heart disease (32%)</strong> 4. <strong>Diabetes (25%)</strong>
5. <strong>Respiratory diseases (19%)</strong> 6. <strong>Cancer
(18%)</strong> 7. <strong>Stroke (14%)</strong></p>
<p><strong>Leading Causes of Death in Elderly:</strong> 1. <strong>Heart
disease (31%)</strong> 2. <strong>Cancer (24%)</strong> 3.
<strong>Respiratory diseases (13%)</strong> 4. <strong>Stroke
(9%)</strong> 5. <strong>Alzheimer‚Äôs disease (6%)</strong></p>
<h3 id="section-b-geriatric-care">Section B: Geriatric Care</h3>
<h4 id="comprehensive-geriatric-assessment">Comprehensive Geriatric
Assessment</h4>
<p><strong>Definition:</strong> Multidimensional, interdisciplinary
diagnostic process to determine medical, psychosocial, and functional
capabilities of elderly people.</p>
<p><strong>Components:</strong></p>
<p><strong>Medical Assessment:</strong> - <strong>Complete
history</strong> - <strong>Physical examination</strong> -
<strong>Medication review</strong> - <strong>Disease screening</strong>
- <strong>Functional status</strong></p>
<p><strong>Cognitive Assessment:</strong> - <strong>Mini-Mental State
Examination (MMSE)</strong> - <strong>Montreal Cognitive Assessment
(MoCA)</strong> - <strong>Clock Drawing Test</strong></p>
<p><strong>Functional Assessment:</strong> - <strong>Activities of Daily
Living (ADL)</strong> - <strong>Instrumental Activities of Daily Living
(IADL)</strong> - <strong>Physical performance tests</strong></p>
<p><strong>Psychosocial Assessment:</strong> - <strong>Mental health
screening</strong> - <strong>Social support assessment</strong> -
<strong>Economic status</strong> - <strong>Living
arrangements</strong></p>
<p><strong>Environmental Assessment:</strong> - <strong>Home safety
evaluation</strong> - <strong>Community resources</strong> -
<strong>Transportation access</strong></p>
<h4 id="functional-assessment">Functional Assessment</h4>
<p><strong>Activities of Daily Living (ADL):</strong> -
<strong>Bathing</strong> - <strong>Dressing</strong> -
<strong>Toileting</strong> - <strong>Transferring</strong> -
<strong>Continence</strong> - <strong>Feeding</strong></p>
<p><strong>Instrumental Activities of Daily Living (IADL):</strong> -
<strong>Shopping</strong> - <strong>Cooking</strong> -
<strong>Housekeeping</strong> - <strong>Transportation</strong> -
<strong>Managing medications</strong> - <strong>Managing
finances</strong> - <strong>Using telephone</strong></p>
<p><strong>Assessment Scales:</strong> - <strong>Barthel Index:</strong>
Measures basic ADL (0-100) - <strong>Lawton-Brody Scale:</strong>
Measures IADL (0-8) - <strong>Katz Index:</strong> Measures ADL
impairment</p>
<h4 id="social-and-psychological-aspects">Social and Psychological
Aspects</h4>
<p><strong>Social Isolation:</strong> - <strong>Risk factors:</strong>
Widowhood, retirement, disability - <strong>Health
consequences:</strong> Depression, increased mortality -
<strong>Interventions:</strong> Social support programs, community
engagement</p>
<p><strong>Elder Abuse and Neglect:</strong> - <strong>Types:</strong>
Physical, emotional, financial, sexual, neglect - <strong>Risk
factors:</strong> Cognitive impairment, dependency, caregiver stress -
<strong>Screening:</strong> Brief screening tools during routine
visits</p>
<p><strong>Depression in Elderly:</strong> -
<strong>Prevalence:</strong> 10-15% in community - <strong>Risk
factors:</strong> Chronic illness, social isolation, loss -
<strong>Screening:</strong> Geriatric Depression Scale (GDS)</p>
<h4 id="elder-abuse-and-neglect">Elder Abuse and Neglect</h4>
<p><strong>Definition:</strong> Intentional acts or omissions that cause
harm or risk of harm to an elderly person.</p>
<p><strong>Types:</strong> 1. <strong>Physical abuse</strong> 2.
<strong>Emotional/psychological abuse</strong> 3. <strong>Financial
abuse</strong> 4. <strong>Sexual abuse</strong> 5.
<strong>Neglect</strong> 6. <strong>Self-neglect</strong></p>
<p><strong>Warning Signs:</strong> - <strong>Unexplained
injuries</strong> - <strong>Sudden financial changes</strong> -
<strong>Withdrawal from activities</strong> -
<strong>Fearfulness</strong> - <strong>Poor hygiene</strong></p>
<h4 id="health-promotion-in-elderly">Health Promotion in Elderly</h4>
<p><strong>Primary Prevention:</strong> - <strong>Vaccination:</strong>
Influenza, pneumococcal, COVID-19 - <strong>Healthy lifestyle:</strong>
Exercise, nutrition, smoking cessation - <strong>Disease
screening:</strong> Cancer screening, cardiovascular risk assessment</p>
<p><strong>Secondary Prevention:</strong> - <strong>Early disease
detection</strong> - <strong>Regular health checkups</strong> -
<strong>Medication review</strong> - <strong>Fall
prevention</strong></p>
<p><strong>Tertiary Prevention:</strong> - <strong>Disability
prevention</strong> - <strong>Rehabilitation services</strong> -
<strong>Chronic disease management</strong> - <strong>Caregiver
support</strong></p>
<h3 id="section-c-common-geriatric-problems">Section C: Common Geriatric
Problems</h3>
<h4 id="cardiovascular-diseases">Cardiovascular Diseases</h4>
<p><strong>Hypertension in Elderly:</strong> -
<strong>Definition:</strong> BP ‚â•130/80 mmHg (updated criteria) -
<strong>Special considerations:</strong> Orthostatic hypotension, white
coat hypertension - <strong>Treatment:</strong> Lifestyle modification,
appropriate antihypertensive therapy</p>
<p><strong>Coronary Artery Disease:</strong> - <strong>Risk
factors:</strong> Age, hypertension, diabetes, smoking -
<strong>Presentation:</strong> Atypical symptoms in elderly -
<strong>Management:</strong> Medical therapy, revascularization when
appropriate</p>
<p><strong>Heart Failure:</strong> - <strong>Prevalence:</strong> 6-10%
in ‚â•65 years - <strong>Causes:</strong> Hypertension, coronary artery
disease, valvular disease - <strong>Management:</strong> ACE inhibitors,
beta-blockers, diuretics</p>
<h4 id="musculoskeletal-disorders">Musculoskeletal Disorders</h4>
<p><strong>Osteoporosis:</strong> - <strong>Definition:</strong> Bone
mineral density ‚â§2.5 SD below young adult mean - <strong>Risk
factors:</strong> Postmenopausal status, glucocorticoids, family history
- <strong>Prevention:</strong> Calcium (1200 mg/day), vitamin D (800
IU/day) - <strong>Treatment:</strong> Bisphosphonates, hormone
therapy</p>
<p><strong>Osteoarthritis:</strong> - <strong>Most common joint disease
in elderly</strong> - <strong>Common sites:</strong> Knee, hip, hand,
spine - <strong>Management:</strong> Exercise, weight management,
analgesics, joint injections</p>
<p><strong>Sarcopenia:</strong> - <strong>Definition:</strong>
Age-related loss of muscle mass and function -
<strong>Prevalence:</strong> Increases with age, affects 10% at age 50,
30% at age 80 - <strong>Prevention:</strong> Resistance exercise,
adequate protein intake</p>
<h4 id="cognitive-impairment">Cognitive Impairment</h4>
<p><strong>Mild Cognitive Impairment (MCI):</strong> -
<strong>Definition:</strong> Cognitive decline greater than expected for
age but no significant functional impairment - <strong>Types:</strong>
Amnestic, non-amnestic - <strong>Progression:</strong> 10-15% annually
progress to dementia</p>
<p><strong>Dementia:</strong> - <strong>Definition:</strong> Progressive
decline in multiple cognitive domains affecting daily function -
<strong>Types:</strong> Alzheimer‚Äôs disease (60-70%), vascular dementia,
Lewy body dementia - <strong>Staging:</strong> Mild, moderate,
severe</p>
<p><strong>Alzheimer‚Äôs Disease:</strong> - <strong>Most common cause of
dementia</strong> - <strong>Pathophysiology:</strong> Amyloid plaques,
neurofibrillary tangles - <strong>Stages:</strong> Early (memory),
middle (behavioral), late (severe cognitive decline)</p>
<p><strong>Management Principles:</strong> - <strong>Early diagnosis and
intervention</strong> - <strong>Cognitive stimulation therapy</strong> -
<strong>Medication:</strong> Cholinesterase inhibitors, memantine -
<strong>Safety measures and caregiver support</strong></p>
<h4 id="vision-and-hearing-problems">Vision and Hearing Problems</h4>
<p><strong>Vision Problems:</strong> - <strong>Presbyopia:</strong>
Age-related loss of accommodation (40+ years) -
<strong>Cataracts:</strong> Leading cause of blindness in elderly -
<strong>Glaucoma:</strong> Second leading cause of blindness -
<strong>Age-related macular degeneration:</strong> Leading cause of
irreversible blindness</p>
<p><strong>Hearing Problems:</strong> - <strong>Presbycusis:</strong>
Age-related hearing loss - <strong>Types:</strong> Sensorineural,
conductive, mixed - <strong>Impact:</strong> Social isolation,
depression, cognitive decline - <strong>Management:</strong> Hearing
aids, assistive devices, communication strategies</p>
<h4 id="polypharmacy-issues">Polypharmacy Issues</h4>
<p><strong>Definition:</strong> Use of ‚â•5 medications
simultaneously.</p>
<p><strong>Risk Factors:</strong> - <strong>Multiple chronic
conditions</strong> - <strong>Multiple prescribers</strong> -
<strong>Self-medication</strong> - <strong>Poor communication between
providers</strong></p>
<p><strong>Problems:</strong> - <strong>Adverse drug reactions</strong>
- <strong>Drug interactions</strong> - <strong>Non-adherence</strong> -
<strong>Increased healthcare costs</strong> - <strong>Functional
impairment</strong></p>
<p><strong>Prevention Strategies:</strong> - <strong>Medication
reconciliation</strong> - <strong>Regular medication review</strong> -
<strong>Simplified dosing regimens</strong> - <strong>Patient
education</strong> - <strong>Use of generic medications</strong></p>
<h2 id="quick-calculation-methods">Quick Calculation Methods</h2>
<h3 id="maternal-mortality-ratio-mmr">Maternal Mortality Ratio
(MMR)</h3>
<p><strong>Formula:</strong> MMR = (Number of maternal deaths √∑ Number
of live births) √ó 100,000</p>
<p><strong>Example:</strong> If there are 50 maternal deaths and 50,000
live births: MMR = (50 √∑ 50,000) √ó 100,000 = 100 per 100,000 live
births</p>
<h3 id="infant-mortality-rate-imr">Infant Mortality Rate (IMR)</h3>
<p><strong>Formula:</strong> IMR = (Number of infant deaths √∑ Number of
live births) √ó 1,000</p>
<p><strong>Example:</strong> If there are 100 infant deaths and 25,000
live births: IMR = (100 √∑ 25,000) √ó 1,000 = 4 per 1,000 live births</p>
<h3 id="under-five-mortality-rate-u5mr">Under-Five Mortality Rate
(U5MR)</h3>
<p><strong>Formula:</strong> U5MR = (Number of deaths under 5 years √∑
Number of live births) √ó 1,000</p>
<p><strong>Example:</strong> If there are 120 deaths under 5 years and
25,000 live births: U5MR = (120 √∑ 25,000) √ó 1,000 = 4.8 per 1,000 live
births</p>
<h2 id="important-programs">Important Programs</h2>
<h3 id="janani-shishu-suraksha-karyakram-jssk">Janani Shishu Suraksha
Karyakram (JSSK)</h3>
<p><strong>Objective:</strong> Elimination of out-of-pocket expenses for
pregnant women and sick newborns.</p>
<p><strong>Benefits:</strong> - <strong>Free delivery including cesarean
section</strong> - <strong>Free transport to health facility</strong> -
<strong>Free blood</strong> - <strong>Free drugs and
consumables</strong> - <strong>Free diagnostics</strong> - <strong>Free
diet during stay</strong></p>
<h3 id="janani-suraksha-yojana-jsy">Janani Suraksha Yojana (JSY)</h3>
<p><strong>Objective:</strong> Reducing maternal and neonatal mortality
through institutional delivery.</p>
<p><strong>Benefits:</strong> - <strong>Cash assistance to
mothers:</strong> ‚Çπ1,400 for urban, ‚Çπ700 for rural - <strong>ASHA
incentive:</strong> ‚Çπ600 for rural, ‚Çπ400 for urban -
<strong>Transport:</strong> Free transport or reimbursement</p>
<h3 id="mission-indradhanush">Mission Indradhanush</h3>
<p><strong>Objective:</strong> Achieving 90% full immunization coverage
by 2020.</p>
<p><strong>Target Groups:</strong> - <strong>Dropout children</strong> -
<strong>Left-out children</strong> - <strong>Pregnant women</strong> -
<strong>Adolescent girls (HPV vaccine)</strong></p>
<p><strong>Vaccines Added:</strong> - <strong>Rotavirus vaccine</strong>
- <strong>Inactivated polio vaccine (IPV)</strong> -
<strong>Measles-rubella vaccine (MR)</strong> - <strong>Japanese
encephalitis vaccine</strong> - <strong>Pneumococcal conjugate
vaccine</strong></p>
<h2 id="clinical-case-scenarios">Clinical Case Scenarios</h2>
<h3 id="case-1-high-risk-pregnancy">Case 1: High-Risk Pregnancy</h3>
<p>A 35-year-old primigravida presents at 20 weeks gestation with
history of diabetes mellitus and previous abortion.</p>
<p><strong>Questions:</strong> 1. <strong>Identify maternal risk
factors</strong> 2. <strong>What additional investigations are
needed?</strong> 3. <strong>Plan for antenatal care</strong></p>
<p><strong>Answers:</strong> 1. <strong>Risk factors:</strong> Advanced
maternal age, diabetes mellitus, history of recurrent abortion 2.
<strong>Additional investigations:</strong> HbA1c, urine culture,
retinal examination, fetal anomaly scan 3. <strong>ANC plan:</strong>
Frequent visits, strict glycemic control, growth monitoring, fetal
well-being assessment</p>
<h3 id="case-2-newborn-with-birth-asphyxia">Case 2: Newborn with Birth
Asphyxia</h3>
<p>A newborn is born with no spontaneous breathing at birth. Apgar score
is 2 at 1 minute.</p>
<p><strong>Management Steps:</strong> 1. <strong>Immediate drying and
stimulation</strong> 2. <strong>Clear airway with bulb syringe</strong>
3. <strong>Position and assess breathing</strong> 4. <strong>Begin bag
and mask ventilation</strong> 5. <strong>Continue until spontaneous
breathing</strong> 6. <strong>Monitor HR - if &lt;60, start chest
compressions</strong></p>
<h3 id="case-3-elderly-patient-with-falls">Case 3: Elderly Patient with
Falls</h3>
<p>A 78-year-old woman presents with 3 falls in the past month. She
takes 8 medications and has decreased vision.</p>
<p><strong>Assessment Areas:</strong> 1. <strong>Medication
review</strong> 2. <strong>Vision examination</strong> 3. <strong>Gait
and balance testing</strong> 4. <strong>Environmental
assessment</strong> 5. <strong>Cognitive assessment</strong></p>
<h3 id="case-4-child-with-severe-acute-malnutrition">Case 4: Child with
Severe Acute Malnutrition</h3>
<p>A 2-year-old child presents with weight 6 kg (expected 12 kg) and
bilateral pedal edema.</p>
<p><strong>Management:</strong> 1. <strong>Admission to hospital
(inpatient care)</strong> 2. <strong>Treatment of complications</strong>
3. <strong>Therapeutic feeding with RUTF</strong> 4. <strong>Monitoring
weight gain</strong> 5. <strong>Family counseling</strong> 6.
<strong>Follow-up after discharge</strong></p>
<h2 id="memory-aids-1">Memory Aids</h2>
<h3 id="anc-schedule-12-24-32-36">ANC Schedule: ‚Äú12-24-32-36‚Äù</h3>
<ul>
<li><strong>12 weeks:</strong> First visit (ANC1)</li>
<li><strong>24 weeks:</strong> Second visit (ANC2)</li>
<li><strong>32 weeks:</strong> Third visit (ANC3)</li>
<li><strong>36 weeks:</strong> Fourth visit (ANC4)</li>
</ul>
<h3 id="immunization-reminder-born-6-10-14">Immunization Reminder:
‚ÄúBORN-6-10-14‚Äù</h3>
<ul>
<li><strong>B</strong>irth: BCG, OPV, Hep B</li>
<li><strong>6 weeks:</strong> First DPT dose, IPV, Rotavirus</li>
<li><strong>10 weeks:</strong> Second DPT dose</li>
<li><strong>14 weeks:</strong> Third DPT dose</li>
</ul>
<h3 id="child-development-2-6-9-12-18-24">Child Development:
‚Äú2-6-9-12-18-24‚Äù</h3>
<ul>
<li><strong>2 months:</strong> Social smile, head control</li>
<li><strong>6 months:</strong> Sits with support</li>
<li><strong>9 months:</strong> Stranger anxiety, pincer grasp</li>
<li><strong>12 months:</strong> Walks, words</li>
<li><strong>18 months:</strong> Parallel play, 10-15 words</li>
<li><strong>24 months:</strong> Two-word phrases</li>
</ul>
<h3 id="geriatric-depression-scale-gds---5-item-version">Geriatric
Depression Scale (GDS) - 5-item Version</h3>
<p><strong>Questions to ask:</strong> 1. ‚ÄúAre you basically satisfied
with your life?‚Äù 2. ‚ÄúDo you often get bored?‚Äù 3. ‚ÄúDo you often feel
helpless?‚Äù 4. ‚ÄúDo you prefer to stay home rather than go out?‚Äù 5. ‚ÄúDo
you feel pretty worthless the way you are now?‚Äù</p>
<p><strong>Scoring:</strong> ‚â•2 positive answers suggest depression</p>
<hr />
<p><em>This completes Part IV of the Community Medicine Quick Revision
Manual covering Maternal and Child Health. The content includes
examination-focused material with latest statistics, guidelines, and
clinical applications essential for MBBS examinations.</em></p>
<h1 id="part-v-epidemiology-and-disease-control-1">Part V: Epidemiology
and Disease Control</h1>
<p><em>High-Yield Examination Manual</em></p>
<hr />
<h2 id="chapter-14-epidemiology">Chapter 14: Epidemiology</h2>
<h3 id="section-a-basic-concepts">Section A: Basic Concepts</h3>
<h4 id="definition-and-scope-of-epidemiology">Definition and Scope of
Epidemiology</h4>
<p><strong>Definition</strong>: Study of distribution and determinants
of health-related states or events in specified populations, and
application to control health problems.</p>
<p><strong>CORE SCOPE</strong>: - <strong>What</strong>: Distribution of
disease/health states - <strong>Why</strong>: Determinants/causes of
disease - <strong>Who</strong>: Populations and subgroups -
<strong>Where</strong>: Geographic distribution - <strong>When</strong>:
Temporal patterns - <strong>How</strong>: Application to control and
prevention</p>
<p><strong>EXAMINATION FOCUS</strong>:</p>
<pre><code>Key Words to Remember: &quot;DISEASE + DETERMINANTS + POPULATION + CONTROL&quot;</code></pre>
<h4 id="epidemiological-approach">Epidemiological Approach</h4>
<p><strong>Systematic Scientific Method</strong>:</p>
<ol type="1">
<li><strong>Observation</strong> - Identify health problem</li>
<li><strong>Hypothesis Formation</strong> - Propose explanations</li>
<li><strong>Testing</strong> - Conduct studies</li>
<li><strong>Analysis</strong> - Interpret results</li>
<li><strong>Application</strong> - Implement control measures</li>
</ol>
<p><strong>EXAM TIP</strong>: Always mention all 5 steps when explaining
epidemiological approach!</p>
<h4 id="epidemiological-triad">Epidemiological Triad</h4>
<p><strong>Classical Model of Disease Causation</strong>:</p>
<pre><code>‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê      Agent      ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ   HOST      ‚îÇ ‚Üê‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚Üí ‚îÇ ENVIRONMENT ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò                  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
        ‚Üì                              ‚Üì
    Susceptibility                 Environmental
    Immunity                       Factors
    Age, Sex,                      Temperature,
    Genetics                       Humidity,
                                  Sanitation,
                                  Socio-economic
                                  factors</code></pre>
<p><strong>HOST FACTORS</strong> (Intrinsic): - Age, sex, race, genetics
- Physiological state - Immunological status - Previous exposure</p>
<p><strong>AGENT FACTORS</strong>: - Biological (bacteria, virus,
parasite) - Chemical (toxins, pollutants) - Physical (radiation, trauma)
- Nutritional (deficiencies)</p>
<p><strong>ENVIRONMENT FACTORS</strong> (Extrinsic): - Physical
(climate, geography) - Biological (vectors, reservoirs) - Social
(crowding, sanitation)</p>
<h4 id="natural-history-of-disease-1">Natural History of Disease</h4>
<p><strong>Stages of Disease Progression</strong>:</p>
<pre><code>Susceptible ‚Üê‚Üí Pre-pathogenic
     ‚Üì
Exposure ‚Üê‚Üí Pathogenic Changes
     ‚Üì
Early Disease ‚Üê‚Üí Subclinical
     ‚Üì
Clinical Disease ‚Üê‚Üí Manifest symptoms
     ‚Üì
Recovery ‚Üê‚Üí Disability ‚Üê‚Üí Death</code></pre>
<p><strong>Key Points</strong>: - <strong>Pre-pathogenic</strong>:
Before disease process begins - <strong>Pathogenic</strong>: Disease
process initiated - <strong>Subclinical</strong>: Changes occur but no
symptoms - <strong>Clinical</strong>: Signs and symptoms appear</p>
<h4 id="iceberg-phenomenon">Iceberg Phenomenon</h4>
<p><strong>Concept</strong>: For every clinically apparent case, many
subclinical cases exist in the population.</p>
<pre><code>      Clinical Cases (Visible - tip of iceberg)
     ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
     ‚îÇ      Cases with symptoms            ‚îÇ
     ‚îÇ                                     ‚îÇ
     ‚îÇ          Cases with disease         ‚îÇ
     ‚îÇ            (Total cases)            ‚îÇ
     ‚îÇ                                     ‚îÇ
     ‚îÇ        All infected persons         ‚îÇ
     ‚îÇ           (Iceberg below)           ‚îÇ
     ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò</code></pre>
<p><strong>EXAM SIGNIFICANCE</strong>: - Underestimation of true disease
burden - Importance of screening programs - Community diagnosis
vs.¬†individual diagnosis</p>
<h4 id="population-vs-clinical-medicine">Population vs Clinical
Medicine</h4>
<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 41%" />
<col style="width: 41%" />
</colgroup>
<thead>
<tr>
<th>Aspect</th>
<th>Population Medicine</th>
<th>Clinical Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unit of Study</strong></td>
<td>Population/Community</td>
<td>Individual Patient</td>
</tr>
<tr>
<td><strong>Goal</strong></td>
<td>Prevention &amp; Health Promotion</td>
<td>Treatment &amp; Cure</td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td>Epidemiological approach</td>
<td>Clinical examination</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Health indicators</td>
<td>Patient outcomes</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
<td>Primary/Secondary prevention</td>
<td>Tertiary prevention</td>
</tr>
</tbody>
</table>
<h4 id="disease-causation---web-of-causation">Disease Causation - Web of
Causation</h4>
<p><strong>Modern Understanding</strong>: Disease results from complex
web of multiple factors, not single cause.</p>
<p><strong>Example - Tuberculosis</strong>:</p>
<pre><code>‚Üê Socio-economic factors
   ‚Üì
‚Üê Malnutrition ‚Üê Crowding
   ‚Üì              ‚Üì
‚Üê Previous TB ‚Üê HIV infection ‚Üê Social stigma
   ‚Üì              ‚Üì              ‚Üì
‚Üê Delayed diagnosis ‚Üê Drug resistance</code></pre>
<p><strong>NO SINGLE CAUSE</strong> - Multiple interconnected factors
create ‚Äúweb‚Äù</p>
<h4 id="risk-factors-and-risk-assessment">Risk Factors and Risk
Assessment</h4>
<p><strong>Risk Factor</strong>: An attribute or exposure associated
with increased probability of disease.</p>
<p><strong>Types of Risk Factors</strong>: -
<strong>Modifiable</strong>: Smoking, diet, exercise -
<strong>Non-modifiable</strong>: Age, sex, genetics</p>
<p><strong>Risk Assessment Process</strong>: 1. Identify risk factor 2.
Measure association strength 3. Assess temporal relationship 4. Consider
dose-response 5. Evaluate biological plausibility</p>
<h3 id="section-b-epidemiological-methods">Section B: Epidemiological
Methods</h3>
<h4 id="descriptive-epidemiology">Descriptive Epidemiology</h4>
<p><strong>Describes disease patterns by PERSON, PLACE,
TIME</strong></p>
<p><strong>By Person</strong>: - Age-specific rates - Sex differences -
Racial/ethnic variations - Occupational patterns - Socioeconomic
status</p>
<p><strong>By Place</strong>: - Geographic clustering - Urban vs rural
differences - International variations - Endemic vs epidemic areas</p>
<p><strong>By Time</strong>: - <strong>Secular trends</strong>:
Long-term changes - <strong>Seasonal patterns</strong>: Regular yearly
cycles - <strong>Periodic fluctuations</strong>: Intermediate patterns -
<strong>Epidemic curves</strong>: Sudden outbreaks</p>
<p><strong>EXAM TIP</strong>: Remember ‚ÄúPPT‚Äù - Person, Place, Time!</p>
<h4 id="analytical-epidemiology">Analytical Epidemiology</h4>
<p><strong>Tests hypotheses about associations</strong></p>
<p><strong>Case-Control Studies</strong>:</p>
<pre><code>             Disease Status
        ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
        ‚îÇ  Yes ‚îÇ  No   ‚îÇ
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇExposed‚îÇ  a   ‚îÇ   b   ‚îÇ  ‚Üê Cases with exposure
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇUnexp. ‚îÇ  c   ‚îÇ   d   ‚îÇ  ‚Üê Controls
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò</code></pre>
<p><strong>Odds Ratio (OR) = (a√ód)/(b√óc)</strong> - OR &gt; 1: Risk
factor - OR &lt; 1: Protective factor - OR = 1: No association</p>
<p><strong>Cohort Studies</strong>:</p>
<pre><code>       Disease Development
       ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
       ‚îÇ   Yes    No    ‚îÇ
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇExp.  ‚îÇ  a  ‚îÇ   b   ‚îÇ  ‚Üê Exposed group
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇUnexp.‚îÇ  c  ‚îÇ   d   ‚îÇ  ‚Üê Unexposed group
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò</code></pre>
<p><strong>Relative Risk (RR) = [a/(a+b)]/[c/(c+d)]</strong></p>
<h4 id="experimental-epidemiology">Experimental Epidemiology</h4>
<p><strong>Clinical Trials - Gold Standard</strong></p>
<p><strong>Types of Clinical Trials</strong>: - <strong>Therapeutic
trials</strong>: Test treatments - <strong>Preventive trials</strong>:
Test preventive measures - <strong>Diagnostic trials</strong>: Test
diagnostic methods</p>
<p><strong>Randomization Methods</strong>: - Simple random - Block
randomization - Stratified randomization - Cluster randomization</p>
<p><strong>Control Groups</strong>: - <strong>Placebo control</strong>:
Inactive substance - <strong>Active control</strong>: Standard treatment
- <strong>No treatment control</strong>: Unethical unless justified</p>
<p><strong>Blinding Techniques</strong>: - <strong>Single
blind</strong>: Participants blinded - <strong>Double blind</strong>:
Participants + investigators blinded - <strong>Triple blind</strong>:
Participants + investigators + analysts blinded</p>
<h4 id="cross-sectional-vs-longitudinal-studies">Cross-sectional vs
Longitudinal Studies</h4>
<table>
<colgroup>
<col style="width: 23%" />
<col style="width: 41%" />
<col style="width: 35%" />
</colgroup>
<thead>
<tr>
<th>Feature</th>
<th>Cross-sectional</th>
<th>Longitudinal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time frame</strong></td>
<td>Single point</td>
<td>Multiple points</td>
</tr>
<tr>
<td><strong>Design</strong></td>
<td>Observational</td>
<td>Observational/Experimental</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>Short</td>
<td>Long</td>
</tr>
<tr>
<td><strong>Cost</strong></td>
<td>Less</td>
<td>More</td>
</tr>
<tr>
<td><strong>Follow-up</strong></td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Temporal relationship</strong></td>
<td>Difficult to establish</td>
<td>Can be established</td>
</tr>
<tr>
<td><strong>Examples</strong></td>
<td>Census, surveys</td>
<td>Cohort, panel studies</td>
</tr>
</tbody>
</table>
<h4 id="bias-confounding-and-effect-modification">Bias, Confounding, and
Effect Modification</h4>
<p><strong>BIAS</strong> - Systematic error in study
design/execution</p>
<p><strong>Selection Bias</strong>: - Volunteer bias - Loss to follow-up
bias - Survival bias - Berkson‚Äôs bias</p>
<p><strong>Information Bias</strong>: - Recall bias - Interviewer bias -
Misclassification bias</p>
<p><strong>Confounding</strong> - Third variable distorts true
relationship <strong>Criteria for Confounder</strong>: 1. Associated
with exposure 2. Associated with outcome 3. Not on causal pathway</p>
<p><strong>Effect Modification</strong> - Effect of exposure varies by
level of third variable - Not a bias - Important to identify - Present
in subgroup analysis</p>
<h4 id="causation-criteria---bradford-hill-criteria">Causation Criteria
- Bradford Hill Criteria</h4>
<p><strong>Strength of Evidence for Causation</strong>:</p>
<ol type="1">
<li><strong>Strength</strong>: Strong association (high RR/OR)</li>
<li><strong>Consistency</strong>: Repeated across studies</li>
<li><strong>Specificity</strong>: One cause ‚Üí one effect</li>
<li><strong>Temporality</strong>: Cause precedes effect</li>
<li><strong>Biological gradient</strong>: Dose-response
relationship</li>
<li><strong>Plausibility</strong>: Biologically reasonable</li>
<li><strong>Coherence</strong>: Fits existing knowledge</li>
<li><strong>Experiment</strong>: Intervention supports causation</li>
<li><strong>Analogy</strong>: Similar to known causes</li>
</ol>
<p><strong>EXAM TIP</strong>: Remember ‚ÄúSPECIFICITY-BIOCOHERENCE‚Äù
acronym!</p>
<h3 id="section-c-measurements-in-epidemiology">Section C: Measurements
in Epidemiology</h3>
<h4 id="incidence-vs-prevalence">Incidence vs Prevalence</h4>
<p><strong>Incidence</strong>: New cases in specified time period -
<strong>Cumulative Incidence</strong>: New cases/Population at risk -
<strong>Incidence Rate</strong>: New cases/Person-time</p>
<p><strong>Prevalence</strong>: All existing cases at specific time -
<strong>Point prevalence</strong>: At single point - <strong>Period
prevalence</strong>: Over time period</p>
<p><strong>Relationship</strong>: Prevalence = Incidence √ó Duration</p>
<p><strong>EXAM FORMULAS</strong>:</p>
<pre><code>Cumulative Incidence = New cases/Total population at start
Incidence Rate = New cases/Total person-time
Point Prevalence = Existing cases/Total population</code></pre>
<h4 id="attack-rate-case-fatality-rate">Attack Rate, Case Fatality
Rate</h4>
<p><strong>Attack Rate</strong>: Proportion of susceptible individuals
who become ill during epidemic</p>
<pre><code>Attack Rate = (New cases/Total susceptible) √ó 100</code></pre>
<p><strong>Case Fatality Rate</strong>: Proportion of cases that result
in death</p>
<pre><code>CFR = (Deaths from disease/Total cases) √ó 100</code></pre>
<p><strong>Secondary Attack Rate</strong>: Attack rate among contacts of
primary cases</p>
<pre><code>SAR = (New cases among contacts/Exposed contacts) √ó 100</code></pre>
<h4 id="sensitivity-specificity-predictive-values">Sensitivity,
Specificity, Predictive Values</h4>
<p><strong>Screening Test Evaluation</strong>:</p>
<pre><code>                Disease Status
              ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
              ‚îÇ Positive‚îÇNeg.‚îÇ Total
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇTest Positive‚îÇ   TP    ‚îÇ FP‚îÇ TP+FP‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇTest Negative‚îÇ   FN    ‚îÇ TN‚îÇ FN+TN‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ   Total     ‚îÇ  TP+FN  ‚îÇ...‚îÇ  N   ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò</code></pre>
<p><strong>Sensitivity</strong>: Ability to correctly identify
disease</p>
<pre><code>Sensitivity = TP/(TP+FN) √ó 100</code></pre>
<p><strong>Specificity</strong>: Ability to correctly identify
non-disease</p>
<pre><code>Specificity = TN/(TN+FP) √ó 100</code></pre>
<p><strong>Positive Predictive Value</strong>: Probability of disease
given positive test</p>
<pre><code>PPV = TP/(TP+FP) √ó 100</code></pre>
<p><strong>Negative Predictive Value</strong>: Probability of no disease
given negative test</p>
<pre><code>NPV = TN/(TN+FN) √ó 100</code></pre>
<h4 id="relative-risk-odds-ratio-attributable-risk">Relative Risk, Odds
Ratio, Attributable Risk</h4>
<p><strong>Relative Risk (RR)</strong>: Risk in exposed vs unexposed</p>
<pre><code>RR = [a/(a+b)]/[c/(c+d)]</code></pre>
<p><strong>Odds Ratio (OR)</strong>: Odds of exposure in cases vs
controls</p>
<pre><code>OR = (a√ód)/(b√óc)</code></pre>
<p><strong>Attributable Risk (AR)</strong>: Excess risk due to
exposure</p>
<pre><code>AR = Risk exposed - Risk unexposed</code></pre>
<p><strong>Population Attributable Risk (PAR)</strong>:</p>
<pre><code>PAR = Pe(RR-1)/[Pe(RR-1)+1]
Where Pe = Prevalence of exposure</code></pre>
<h4 id="standardization---direct-and-indirect-methods">Standardization -
Direct and Indirect Methods</h4>
<p><strong>Purpose</strong>: Remove effect of age/other factors when
comparing rates</p>
<p><strong>Direct Standardization</strong>: 1. Apply observed rates to
standard population 2. Calculate expected deaths 3. Standardized Death
Rate (SDR) = Expected deaths/Standard population</p>
<p><strong>Indirect Standardization</strong>: 1. Use standard mortality
rates 2. Calculate expected deaths in study population 3. Standardized
Mortality Ratio (SMR) = Observed/Expected deaths</p>
<p><strong>EXAM POINTS</strong>: - Direct method: Requires age-specific
rates - Indirect method: Requires only total deaths and standard rates -
SMR interpretation: &gt;100 means higher mortality than standard</p>
<hr />
<h2 id="chapter-15-clinical-epidemiology">Chapter 15: Clinical
Epidemiology</h2>
<h3 id="section-a-diagnostic-tests">Section A: Diagnostic Tests</h3>
<h4 id="criteria-for-screening-tests">Criteria for Screening Tests</h4>
<p><strong>Wilson-Jungner Criteria</strong> (Modified):</p>
<ol type="1">
<li><strong>Condition should be important health problem</strong></li>
<li><strong>Accepted treatment available</strong></li>
<li><strong>Facilities for diagnosis and treatment</strong></li>
<li><strong>Recognizable latent/early symptomatic stage</strong></li>
<li><strong>Suitable test or examination</strong></li>
<li><strong>Test acceptable to population</strong></li>
<li><strong>Natural history understood</strong></li>
<li><strong>Agreement on whom to treat</strong></li>
<li><strong>Cost-effective screening program</strong></li>
<li><strong>Case finding continuous process</strong></li>
</ol>
<p><strong>EXAM FOCUS</strong>: All 10 criteria must be mentioned!</p>
<h4 id="validity-sensitivity-specificity">Validity (Sensitivity,
Specificity)</h4>
<p><strong>Complete Description of Test Performance</strong>:</p>
<p><strong>Sensitivity Factors</strong>: - Disease severity - Test
cut-off point - Quality of gold standard</p>
<p><strong>Specificity Factors</strong>: - Definition of ‚Äúnormal‚Äù -
Presence of similar conditions - Technical variations</p>
<h4 id="reliability-precision-accuracy">Reliability (Precision,
Accuracy)</h4>
<p><strong>Reliability</strong>: Consistency of measurement</p>
<p><strong>Precision</strong> (Reproducibility): - Same results under
same conditions - Low random error</p>
<p><strong>Accuracy</strong> (Validity): - Closeness to true value - Low
systematic error</p>
<p><strong>Sources of Measurement Error</strong>: - Observer variation -
Instrument variation - Biological variation - Environmental factors</p>
<h4 id="predictive-values">Predictive Values</h4>
<p><strong>Clinical Interpretation</strong>:</p>
<p><strong>High PPV</strong>: Good test for confirming disease -
Required: High prevalence OR High sensitivity</p>
<p><strong>High NPV</strong>: Good test for ruling out disease -
Required: Low prevalence OR High specificity</p>
<p><strong>Bayes‚Äô Theorem Application</strong>:</p>
<pre><code>P(Disease|Positive) = 
[P(Positive|Disease) √ó P(Disease)]/P(Positive)</code></pre>
<h4 id="roc-curves">ROC Curves</h4>
<p><strong>Receiver Operating Characteristic Curve</strong> -
<strong>X-axis</strong>: 1-Specificity (False positive rate) -
<strong>Y-axis</strong>: Sensitivity (True positive rate)</p>
<p><strong>Optimal Cut-off</strong>: Point closest to top-left
corner</p>
<p><strong>Area Under Curve (AUC)</strong>: - 0.9-1.0: Excellent -
0.8-0.9: Good - 0.7-0.8: Fair - 0.6-0.7: Poor - 0.5: Useless</p>
<h4 id="likelihood-ratios">Likelihood Ratios</h4>
<p><strong>Information Content of Test Results</strong>:</p>
<p><strong>Positive Likelihood Ratio (LR+)</strong>:</p>
<pre><code>LR+ = Sensitivity/(1-Specificity)</code></pre>
<p><strong>Negative Likelihood Ratio (LR-)</strong>:</p>
<pre><code>LR- = (1-Sensitivity)/Specificity</code></pre>
<p><strong>Interpretation</strong>: - LR+ &gt; 10: Strong evidence for
disease - LR+ 5-10: Moderate evidence for disease - LR- &lt; 0.1: Strong
evidence against disease - LR- 0.1-0.2: Moderate evidence against
disease</p>
<h4 id="bayes-theorem-application">Bayes‚Äô Theorem Application</h4>
<p><strong>Clinical Decision Making</strong>:</p>
<p><strong>Pre-test Probability</strong>: Disease prevalence
<strong>Post-test Probability</strong>: Probability after test
result</p>
<p><strong>Fagan Nomogram</strong>: Graphic method to combine pre-test
probability with likelihood ratios</p>
<p><strong>Example</strong>: - Pre-test probability: 10% - LR+ = 10 -
Post-test probability: ~52%</p>
<h3 id="section-b-clinical-trials">Section B: Clinical Trials</h3>
<h4 id="types-of-clinical-trials">Types of Clinical Trials</h4>
<p><strong>Classification by Purpose</strong>: - <strong>Treatment
trials</strong>: Test therapeutic interventions - <strong>Prevention
trials</strong>: Test preventive measures - <strong>Diagnostic
trials</strong>: Test diagnostic accuracy - <strong>Screening
trials</strong>: Test screening programs - <strong>Quality of life
trials</strong>: Test comfort measures</p>
<h4 id="randomization-methods">Randomization Methods</h4>
<p><strong>Ensures unbiased allocation</strong>:</p>
<p><strong>Simple Randomization</strong>: - Coin toss, random numbers -
Risk of unequal groups</p>
<p><strong>Block Randomization</strong>: - Groups allocated in blocks -
Ensures equal numbers - Block size usually 4 or 6</p>
<p><strong>Stratified Randomization</strong>: - Stratify by important
factors - Randomize within each stratum - Ensures balance in
subgroups</p>
<p><strong>Cluster Randomization</strong>: - Randomize groups (families,
villages) - Used when individual randomization impractical</p>
<h4 id="placebo-vs-control-groups">Placebo vs Control Groups</h4>
<p><strong>Control Types</strong>:</p>
<p><strong>Placebo Control</strong>: - Inactive treatment - Maintains
blinding - Ethical when no standard treatment</p>
<p><strong>Active Control</strong>: - Standard treatment -
Non-inferiority or equivalence trials - Ethical when standard treatment
exists</p>
<p><strong>No Treatment Control</strong>: - Unethical for treatable
conditions - May be acceptable for prevention studies - Historical
controls sometimes used</p>
<h4 id="blinding-techniques">Blinding Techniques</h4>
<p><strong>Prevents Bias</strong>:</p>
<p><strong>Single Blind</strong>: Only participant blinded - Reduces
performance bias</p>
<p><strong>Double Blind</strong>: Participant + investigator blinded -
Reduces performance + detection bias</p>
<p><strong>Triple Blind</strong>: + Statistician/data analyst blinded -
Reduces all biases</p>
<p><strong>Quadruple Blind</strong>: + Monitoring committee blinded -
Highest level of blinding</p>
<h4 id="phases-of-clinical-trials">Phases of Clinical Trials</h4>
<p><strong>Drug Development Process</strong>:</p>
<p><strong>Phase I</strong> (Safety): - 20-80 healthy volunteers - Dose
escalation - Safety and tolerability - Duration: Months</p>
<p><strong>Phase II</strong> (Efficacy): - 100-300 patients - Efficacy +
continued safety - Optimal dose finding - Duration: Months to years</p>
<p><strong>Phase III</strong> (Comparison): - 300-3000+ patients -
Compare to standard treatment - Rare adverse events - Duration:
Years</p>
<p><strong>Phase IV</strong> (Post-marketing): - Large populations -
Long-term effects - New indications - Duration: Ongoing</p>
<h4 id="good-clinical-practice-gcp">Good Clinical Practice (GCP)</h4>
<p><strong>International Ethical and Scientific Standard</strong>:</p>
<p><strong>Core Principles</strong>: 1. <strong>Ethical conduct</strong>
of trials 2. <strong>Scientific merit</strong> of protocol 3.
<strong>Protection</strong> of human subjects 4. <strong>Data
quality</strong> and integrity 5. <strong>Confidentiality</strong> of
records 6. <strong>Informed consent</strong> process 7. <strong>Adverse
event</strong> reporting 8. <strong>Regulatory compliance</strong></p>
<p><strong>Key Personnel</strong>: - Principal Investigator - Study
Coordinator - Data Manager - Monitor/Auditor</p>
<hr />
<h2 id="chapter-16-disease-control">Chapter 16: Disease Control</h2>
<h3 id="section-a-surveillance">Section A: Surveillance</h3>
<h4 id="types-of-surveillance">Types of Surveillance</h4>
<p><strong>Systematic Collection, Analysis, and Dissemination of Health
Data</strong></p>
<p><strong>Passive Surveillance</strong>: - <strong>Definition</strong>:
Health facilities report routinely - <strong>Advantages</strong>:
Comprehensive, inexpensive, ongoing - <strong>Disadvantages</strong>:
Under-reporting, delays, poor quality - <strong>Example</strong>:
Routine reporting of infectious diseases</p>
<p><strong>Active Surveillance</strong>: - <strong>Definition</strong>:
Health authorities contact facilities - <strong>Advantages</strong>:
Complete, timely, specific - <strong>Disadvantages</strong>: Expensive,
time-consuming - <strong>Example</strong>: Outbreak investigations</p>
<p><strong>Sentinel Surveillance</strong>: -
<strong>Definition</strong>: Selected representative sites -
<strong>Advantages</strong>: Detailed, cost-effective, rapid -
<strong>Disadvantages</strong>: Limited geographic coverage -
<strong>Example</strong>: Influenza surveillance through sentinel
sites</p>
<p><strong>Syndromic Surveillance</strong>: -
<strong>Definition</strong>: Based on symptoms/clinical syndromes -
<strong>Advantages</strong>: Rapid, real-time detection -
<strong>Disadvantages</strong>: Low specificity -
<strong>Example</strong>: Emergency department visits for fever</p>
<h4 id="disease-surveillance-systems">Disease Surveillance Systems</h4>
<p><strong>Components of Effective Surveillance</strong>:</p>
<ol type="1">
<li><strong>Case Definition</strong>: Standardized criteria</li>
<li><strong>Data Collection</strong>: Consistent methods</li>
<li><strong>Data Analysis</strong>: Regular review</li>
<li><strong>Data Interpretation</strong>: Meaningful conclusions</li>
<li><strong>Dissemination</strong>: Timely feedback</li>
<li><strong>Action</strong>: Response to findings</li>
</ol>
<p><strong>Surveillance Indicators</strong>: -
<strong>Sensitivity</strong>: Ability to detect outbreaks -
<strong>Specificity</strong>: Minimal false alarms - <strong>Predictive
value positive</strong>: Accuracy of alerts -
<strong>Timeliness</strong>: Speed of detection -
<strong>Representativeness</strong>: Geographic/demographic coverage</p>
<h4 id="integrated-disease-surveillance-programme-idsp">Integrated
Disease Surveillance Programme (IDSP)</h4>
<p><strong>National Surveillance Program in India</strong></p>
<p><strong>Components</strong>: - <strong>Priority diseases</strong>: 20
diseases under surveillance - <strong>Regular reporting</strong>:
Weekly/monthly - <strong>Laboratory support</strong>: Confirmatory
testing - <strong>Information technology</strong>: Data transmission -
<strong>Rapid response teams</strong>: Outbreak investigation</p>
<p><strong>Reporting Structure</strong>:</p>
<pre><code>Sub-center ‚Üí PHC ‚Üí CHC/District ‚Üí State ‚Üí National
    ‚Üì         ‚Üì        ‚Üì          ‚Üì        ‚Üì
Village    Block    District    State    Central</code></pre>
<h4 id="event-based-surveillance">Event-based Surveillance</h4>
<p><strong>Recognition and Reporting of Health Events</strong></p>
<p><strong>Types of Events</strong>: - Unusual health events - Deaths
above threshold - Disease clusters - Environmental emergencies -
Bioterrorism indicators</p>
<p><strong>Information Sources</strong>: - Media monitoring - Internet
surveillance - Social media analysis - Hotlines/rumor tracking</p>
<h4 id="syndromic-surveillance">Syndromic Surveillance</h4>
<p><strong>Early Detection Through Symptoms</strong></p>
<p><strong>Common Syndromes</strong>: - Acute febrile illness - Acute
respiratory illness - Acute diarrheal disease - Acute neurological
syndrome - Acute hemorrhagic syndrome</p>
<p><strong>Data Sources</strong>: - Emergency department records -
Ambulance dispatch records - Pharmacy sales - Over-the-counter drug
sales - School attendance records</p>
<h4 id="data-collection-and-analysis">Data Collection and Analysis</h4>
<p><strong>Standardized Processes</strong>:</p>
<p><strong>Data Quality Checks</strong>: - Completeness - Accuracy -
Consistency - Timeliness</p>
<p><strong>Analysis Methods</strong>: - Trend analysis - Threshold
detection - Geographic mapping - Demographic analysis</p>
<h3 id="section-b-disease-elimination-and-eradication">Section B:
Disease Elimination and Eradication</h3>
<h4 id="differences-between-elimination-and-eradication">Differences
Between Elimination and Eradication</h4>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 37%" />
<col style="width: 37%" />
</colgroup>
<thead>
<tr>
<th>Feature</th>
<th>Elimination</th>
<th>Eradication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Geographic scope</strong></td>
<td>Specific area/region</td>
<td>Worldwide</td>
</tr>
<tr>
<td><strong>Pathogen presence</strong></td>
<td>Absent in target area</td>
<td>Completely absent</td>
</tr>
<tr>
<td><strong>Surveillance required</strong></td>
<td>Continued surveillance</td>
<td>No surveillance needed</td>
</tr>
<tr>
<td><strong>Prevention measures</strong></td>
<td>May be needed</td>
<td>Not needed</td>
</tr>
<tr>
<td><strong>Certification</strong></td>
<td>Regional certification</td>
<td>Global certification</td>
</tr>
<tr>
<td><strong>Examples</strong></td>
<td>Neonatal tetanus, measles (region)</td>
<td>Smallpox</td>
</tr>
</tbody>
</table>
<h4 id="eradication-criteria">Eradication Criteria</h4>
<p><strong>Biological Criteria</strong>: - No non-human reservoir -
Effective intervention available - Case detection methods feasible -
Natural immunity provides protection</p>
<p><strong>Technical Criteria</strong>: - Political commitment - Funding
availability - International cooperation - Suitable surveillance
system</p>
<p><strong>Political Criteria</strong>: - Government support - Community
acceptance - Integration with health system - Long-term
sustainability</p>
<h4 id="success-stories---smallpox">Success Stories - Smallpox</h4>
<p><strong>First Disease Eradicated (1980)</strong>:</p>
<p><strong>Timeline</strong>: - 1967: Intensified eradication program -
1977: Last natural case (Somalia) - 1980: Global eradication
certified</p>
<p><strong>Key Strategies</strong>: - Mass vaccination - Surveillance
and containment - Ring vaccination strategy - International
cooperation</p>
<p><strong>Estimated Savings</strong>: $200+ billion globally</p>
<h4 id="success-stories---polio">Success Stories - Polio</h4>
<p><strong>Near Eradication</strong>:</p>
<p><strong>Current Status</strong> (2025): - Endemic in 2 countries:
Afghanistan, Pakistan - 99.9% reduction in cases - All regions certified
except EMRO</p>
<p><strong>Strategies</strong>: - National immunization days -
Supplementary immunization - Mop-up campaigns - Acute flaccid paralysis
surveillance</p>
<h4 id="current-eradication-programs">Current Eradication Programs</h4>
<p><strong>Multi-Drug Resistant Tuberculosis (MDR-TB)</strong>:</p>
<p><strong>Challenge</strong>: Complex treatment, limited diagnostics
<strong>Strategy</strong>: DOTS-Plus, newer drugs
<strong>Progress</strong>: Limited success</p>
<p><strong>Malaria</strong>: <strong>Challenge</strong>: Drug
resistance, complex lifecycle <strong>Strategy</strong>: Indoor
spraying, bed nets, new drugs <strong>Progress</strong>: Significant
reduction but not eradication yet</p>
<h3 id="section-c-control-measures">Section C: Control Measures</h3>
<h4 id="primary-prevention-strategies">Primary Prevention
Strategies</h4>
<p><strong>Prevent Disease Before It Occurs</strong></p>
<p><strong>Health Promotion</strong>: - Education and awareness -
Lifestyle modifications - Environmental improvements - Social support
systems</p>
<p><strong>Specific Protection</strong>: - Immunization - Nutritional
supplementation - Chemoprophylaxis - Personal protective equipment</p>
<p><strong>Environmental Measures</strong>: - Water purification - Waste
management - Vector control - Air quality improvement</p>
<h4 id="secondary-prevention-2">Secondary Prevention</h4>
<p><strong>Early Detection and Prompt Treatment</strong></p>
<p><strong>Screening Programs</strong>: - Cancer screening (mammography,
PAP smear) - Diabetes screening - Hypertension screening - Tuberculosis
screening</p>
<p><strong>Diagnostic Tests</strong>: - High sensitivity tests -
Cost-effective methods - Accessible locations - Quality assurance</p>
<h4 id="tertiary-prevention-1">Tertiary Prevention</h4>
<p><strong>Reduce Disability and Restore Function</strong></p>
<p><strong>Rehabilitation Services</strong>: - Physical therapy -
Occupational therapy - Speech therapy - Psychological support</p>
<p><strong>Disease Management</strong>: - Chronic disease care -
Complication prevention - Quality of life improvement - Support
groups</p>
<h4 id="population-vs-high-risk-approach">Population vs High-Risk
Approach</h4>
<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 41%" />
<col style="width: 41%" />
</colgroup>
<thead>
<tr>
<th>Aspect</th>
<th>Population Approach</th>
<th>High-Risk Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target</strong></td>
<td>Entire population</td>
<td>High-risk individuals</td>
</tr>
<tr>
<td><strong>Strategy</strong></td>
<td>Universal interventions</td>
<td>Selective interventions</td>
</tr>
<tr>
<td><strong>Cost</strong></td>
<td>High but cost-effective per person</td>
<td>Lower but may miss cases</td>
</tr>
<tr>
<td><strong>Implementation</strong></td>
<td>Requires systemic changes</td>
<td>Easier to implement</td>
</tr>
<tr>
<td><strong>Equity</strong></td>
<td>Promotes equity</td>
<td>May create disparities</td>
</tr>
<tr>
<td><strong>Examples</strong></td>
<td>Water fluoridation, salt iodization</td>
<td>Screening high-risk groups</td>
</tr>
</tbody>
</table>
<h4 id="mass-vs-targeted-interventions">Mass vs Targeted
Interventions</h4>
<p><strong>Mass Interventions</strong>: - Target entire population -
Often for common risks - Examples: Mass vaccination, fortification</p>
<p><strong>Targeted Interventions</strong>: - Specific subgroups -
Higher risk populations - Examples: Prenatal care, occupational
health</p>
<h4 id="health-education-and-behavioral-change">Health Education and
Behavioral Change</h4>
<p><strong>Models of Behavior Change</strong>:</p>
<p><strong>Health Belief Model</strong>: - Perceived susceptibility -
Perceived severity - Perceived benefits - Perceived barriers</p>
<p><strong>Stages of Change Model</strong>: 1. Precontemplation 2.
Contemplation 3. Preparation 4. Action 5. Maintenance 6. Termination</p>
<p><strong>Communication Strategies</strong>: - Fear appeals (moderate
level) - Social proof - Authority figures - Personal testimonials</p>
<hr />
<h2
id="epidemiological-calculations-with-step-by-step-examples">Epidemiological
Calculations with Step-by-Step Examples</h2>
<h3 id="example-1-basic-rates-calculation">Example 1: Basic Rates
Calculation</h3>
<p><strong>Problem</strong>: In a population of 50,000, there were 100
new cases of disease X and 20 deaths from disease X in 2024. Calculate
incidence rate, cumulative incidence, prevalence (if 150 cases existed
throughout the year), and case fatality rate.</p>
<p><strong>Solution</strong>:</p>
<pre><code>Population = 50,000
New cases = 100
Deaths = 20
Existing cases = 150

Cumulative Incidence = 100/50,000 = 0.002 or 0.2%
Incidence Rate = 100/(50,000 person-years) = 2 per 1,000 person-years
Point Prevalence = 150/50,000 = 0.003 or 0.3%
Case Fatality Rate = 20/100 √ó 100 = 20%</code></pre>
<h3 id="example-2-sensitivity-and-specificity-calculation">Example 2:
Sensitivity and Specificity Calculation</h3>
<p><strong>Problem</strong>: A new test for disease Y was evaluated in
1,000 individuals. The gold standard showed 200 people had the disease,
800 did not. The new test was positive in 180 people with disease and 50
people without disease.</p>
<p><strong>Solution</strong>:</p>
<pre><code>                    Disease Present    Disease Absent    Total
Test Positive        180              50              230
Test Negative         20             750              770
Total                200             800             1000

Sensitivity = TP/(TP+FN) = 180/200 √ó 100 = 90%
Specificity = TN/(TN+FP) = 750/800 √ó 100 = 93.75%
PPV = TP/(TP+FP) = 180/230 √ó 100 = 78.26%
NPV = TN/(TN+FN) = 750/770 √ó 100 = 97.40%</code></pre>
<h3 id="example-3-relative-risk-and-odds-ratio">Example 3: Relative Risk
and Odds Ratio</h3>
<p><strong>Problem</strong>: In a cohort study of 1,000 smokers and
1,000 non-smokers followed for 10 years, lung cancer developed in 50
smokers and 5 non-smokers.</p>
<p><strong>Solution</strong>:</p>
<pre><code>                    Lung Cancer    No Lung Cancer    Total
Smokers                50              950           1,000
Non-smokers             5              995           1,000

Risk in smokers = 50/1000 = 0.05
Risk in non-smokers = 5/1000 = 0.005
Relative Risk = 0.05/0.005 = 10

Interpretation: Smokers have 10 times higher risk of lung cancer</code></pre>
<h3 id="example-4-standardization-calculation">Example 4:
Standardization Calculation</h3>
<p><strong>Problem</strong>: Compare mortality rates between two areas
with different age distributions.</p>
<pre><code>Age Group    Study Area A    Study Area B    Standard Population
0-24          1,000           800            3,000
25-49         2,000           1,500          4,000
50+           1,000           700            2,000
Total         4,000           3,000          9,000

Deaths in A:  100            80              50
Deaths in B:   60            90              60</code></pre>
<p><strong>Direct Standardization</strong>:</p>
<pre><code>Expected deaths A = (1/1000√ó3000) + (80/2000√ó4000) + (50/1000√ó2000)
                  = 3 + 160 + 100 = 263
Expected deaths B = (60/800√ó3000) + (90/1500√ó4000) + (60/700√ó2000)
                  = 225 + 240 + 171.4 = 636.4

SDR A = 263/9000 √ó 1000 = 29.2 per 1,000
SDR B = 636.4/9000 √ó 1000 = 70.7 per 1,000</code></pre>
<hr />
<h2 id="current-surveillance-data-and-outbreak-examples">Current
Surveillance Data and Outbreak Examples</h2>
<h3 id="covid-19-surveillance-2024-data">COVID-19 Surveillance (2024
Data)</h3>
<p><strong>India Surveillance Metrics</strong>: - Total cases reported:
45+ million - Case fatality rate: 1.1% - Vaccination coverage: 95% (2
doses) - Surveillance type: Sentinel + Community</p>
<p><strong>Key Surveillance Activities</strong>: - SARI/ILI surveillance
- Genomic surveillance - Hospital-based surveillance - Wastewater
surveillance</p>
<h3 id="recent-outbreak-examples">Recent Outbreak Examples</h3>
<h4 id="nipah-virus-outbreak---kerala-2024">Nipah Virus Outbreak -
Kerala 2024</h4>
<p><strong>Timeline</strong>: - <strong>Week 1</strong>: Initial cases
detected - <strong>Week 2</strong>: Outbreak confirmed - <strong>Week
3</strong>: Contact tracing completed - <strong>Week 4</strong>:
Outbreak controlled</p>
<p><strong>Response Measures</strong>: - Immediate isolation of cases -
Contact tracing and quarantine - Community surveillance - Healthcare
worker protection</p>
<h4 id="dengue-outbreak---delhi-2024">Dengue Outbreak - Delhi 2024</h4>
<p><strong>Epidemiological Curve</strong>:</p>
<pre><code>Cases
  ‚îÇ
200‚î§
  ‚îÇ
150‚î§
  ‚îÇ
100‚î§
  ‚îÇ  ‚óè‚óè‚óè‚óè‚óè
  ‚îÇ  ‚óè‚óè‚óè‚óè‚óè‚óè
  ‚îÇ  ‚óè‚óè‚óè‚óè‚óè‚óè‚óè‚óè
  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚ñ∫
    Jul   Aug   Sep   Oct</code></pre>
<p><strong>Control Measures</strong>: - Larvicidal treatment - Source
reduction - Community awareness - Case management</p>
<h3 id="idsp-reporting-format">IDSP Reporting Format</h3>
<h4 id="weekly-reporting-format-form-p">Weekly Reporting Format (Form
P)</h4>
<pre><code>HEALTH UNIT: _______________
DISTRICT: _________________
STATE: ____________________
WEEK ENDING: ______________

Priority Disease Surveillance:

1. Acute Diarrheal Disease
   Cases this week: ___
   Deaths this week: ___
   Cumulative cases: ___

2. Acute Respiratory Infection
   Cases this week: ___
   Deaths this week: ___
   Cumulative cases: ___

3. Fever of unknown origin
   Cases this week: ___
   Deaths this week: ___
   Cumulative cases: ___

Health Worker Signature: _______________
Date: _______________</code></pre>
<h4 id="outbreak-reporting-format">Outbreak Reporting Format</h4>
<pre><code>OUTBREAK REPORT

1. Basic Information:
   Disease: ________________
   Location: _______________
   Date of onset: __________
   Date reported: __________

2. Case Definition:
   Suspected case: _________
   Probable case: __________
   Confirmed case: _________

3. Epidemiological Data:
   Total cases: ___________
   Total deaths: __________
   Attack rate: __________

4. Laboratory Confirmation:
   Samples sent: __________
   Tests conducted: _______
   Positive results: ______

5. Control Measures Taken:
   Immediate actions: ______
   Long-term measures: ____

Reporting Officer: __________
Date: ___________________</code></pre>
<hr />
<h2 id="memory-aids-for-epidemiological-measures">Memory Aids for
Epidemiological Measures</h2>
<h3 id="bradford-hill-criteria-mnemonic">Bradford Hill Criteria
Mnemonic</h3>
<p><strong>‚ÄúSPECIFICITY-BIOCOHERENCE‚Äù</strong> -
<strong>S</strong>trength of association - <strong>P</strong>lausibility
- <strong>C</strong>onsistency - <strong>E</strong>xperiment -
<strong>I</strong>mportance - <strong>C</strong>oherence -
<strong>I</strong>tems (examples) - <strong>F</strong>actors
(confounding) - <strong>I</strong>nformation (analogies) -
<strong>C</strong>ausality - <strong>T</strong>emporality -
<strong>Y</strong>ield (biological gradient)</p>
<h3 id="epidemiological-rates-mnemonic">Epidemiological Rates
Mnemonic</h3>
<p><strong>‚ÄúSIP-CAF‚Äù</strong> - <strong>S</strong>ensitivity - True
positive rate - <strong>I</strong>ncidence - New cases rate<br />
- <strong>P</strong>revalence - Total cases rate - <strong>C</strong>ase
fatality - Death among cases - <strong>A</strong>ttack rate - Epidemic
measure - <strong>F</strong>alse positive rate (1-Specificity)</p>
<h3 id="study-design-hierarchy">Study Design Hierarchy</h3>
<p><strong>‚ÄúCCS-COE‚Äù (Strongest to Weakest)</strong> -
<strong>C</strong>ohort studies (strong) - <strong>C</strong>ase-control
studies (moderate) - <strong>S</strong>urvey studies (moderate) -
<strong>C</strong>ross-sectional studies (weak) -
<strong>E</strong>cological studies (weakest)</p>
<h3 id="bias-types-mnemonic">Bias Types Mnemonic</h3>
<p><strong>‚ÄúSELECTION-INFO‚Äù</strong> - <strong>S</strong>election bias -
<strong>E</strong>xposure misclassification - <strong>L</strong>oss to
follow-up bias - <strong>E</strong>lection bias (volunteer) -
<strong>C</strong>ontrol selection bias - <strong>T</strong>iming bias -
<strong>I</strong>nformation bias - <strong>O</strong>utcome
misclassification - <strong>N</strong>ew device bias</p>
<hr />
<h2 id="study-design-comparison-tables">Study Design Comparison
Tables</h2>
<h3 id="observational-studies-comparison">Observational Studies
Comparison</h3>
<table>
<thead>
<tr>
<th>Feature</th>
<th>Case-Control</th>
<th>Cross-sectional</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Direction</strong></td>
<td>Backward</td>
<td>Cross-time</td>
<td>Forward</td>
</tr>
<tr>
<td><strong>Starting point</strong></td>
<td>Disease</td>
<td>Population</td>
<td>Exposure</td>
</tr>
<tr>
<td><strong>Memory bias</strong></td>
<td>High</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>Follow-up</strong></td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Rare diseases</strong></td>
<td>Good</td>
<td>Poor</td>
<td>Poor</td>
</tr>
<tr>
<td><strong>Common diseases</strong></td>
<td>Poor</td>
<td>Good</td>
<td>Good</td>
</tr>
<tr>
<td><strong>Time required</strong></td>
<td>Short</td>
<td>Short</td>
<td>Long</td>
</tr>
<tr>
<td><strong>Cost</strong></td>
<td>Low</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td><strong>Confounding</strong></td>
<td>Can assess</td>
<td>Difficult</td>
<td>Can assess</td>
</tr>
</tbody>
</table>
<h3 id="experimental-studies-comparison">Experimental Studies
Comparison</h3>
<table>
<thead>
<tr>
<th>Feature</th>
<th>RCT</th>
<th>Quasi-experimental</th>
<th>Field trial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Randomization</strong></td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Blinding</strong></td>
<td>Often possible</td>
<td>Difficult</td>
<td>Sometimes</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Clinical</td>
<td>Natural</td>
<td>Community</td>
</tr>
<tr>
<td><strong>Validity</strong></td>
<td>Highest</td>
<td>Moderate</td>
<td>High</td>
</tr>
<tr>
<td><strong>Cost</strong></td>
<td>High</td>
<td>Moderate</td>
<td>Very high</td>
</tr>
<tr>
<td><strong>Feasibility</strong></td>
<td>Moderate</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Ethical issues</strong></td>
<td>Minor</td>
<td>Moderate</td>
<td>Major</td>
</tr>
</tbody>
</table>
<h3 id="screening-test-evaluation">Screening Test Evaluation</h3>
<table>
<thead>
<tr>
<th>Test Characteristic</th>
<th>Good Value</th>
<th>Poor Value</th>
<th>Clinical Use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sensitivity</strong></td>
<td>&gt;90%</td>
<td>&lt;70%</td>
<td>Rule out disease</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>&gt;90%</td>
<td>&lt;70%</td>
<td>Rule in disease</td>
</tr>
<tr>
<td><strong>PPV</strong></td>
<td>&gt;50%</td>
<td>&lt;10%</td>
<td>Confirm diagnosis</td>
</tr>
<tr>
<td><strong>NPV</strong></td>
<td>&gt;99%</td>
<td>&lt;90%</td>
<td>Exclude diagnosis</td>
</tr>
<tr>
<td><strong>LR+</strong></td>
<td>&gt;10</td>
<td>&lt;2</td>
<td>Rule in</td>
</tr>
<tr>
<td><strong>LR-</strong></td>
<td>&lt;0.1</td>
<td>&gt;0.5</td>
<td>Rule out</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="application-of-bradford-hill-criteria-with-examples">Application
of Bradford Hill Criteria with Examples</h2>
<h3 id="example-1-smoking-and-lung-cancer">Example 1: Smoking and Lung
Cancer</h3>
<p><strong>Application of Criteria</strong>:</p>
<ol type="1">
<li><strong>Strength</strong>: OR = 10-20, Very strong association</li>
<li><strong>Consistency</strong>: Replicated across 50+ studies</li>
<li><strong>Specificity</strong>: Smoking primarily causes lung
cancer</li>
<li><strong>Temporality</strong>: Smoking precedes lung cancer</li>
<li><strong>Biological gradient</strong>: Dose-response relationship
established</li>
<li><strong>Plausibility</strong>: Carcinogens in tobacco explain
causation</li>
<li><strong>Coherence</strong>: Fits with clinical and pathological
knowledge</li>
<li><strong>Experiment</strong>: Smoking cessation reduces risk</li>
<li><strong>Analogy</strong>: Similar to other tobacco-related
cancers</li>
</ol>
<p><strong>Conclusion</strong>: Strong evidence for causation</p>
<h3 id="example-2-vaccination-and-autism-false-association">Example 2:
Vaccination and Autism (False Association)</h3>
<p><strong>Analysis</strong>:</p>
<ol type="1">
<li><strong>Strength</strong>: Weak association, inconsistent</li>
<li><strong>Consistency</strong>: Not replicated in large studies</li>
<li><strong>Specificity</strong>: Many autism causes, not specific</li>
<li><strong>Temporality</strong>: Studies show no temporal
relationship</li>
<li><strong>Biological gradient</strong>: No dose-response
relationship</li>
<li><strong>Plausibility</strong>: No biological mechanism</li>
<li><strong>Coherence</strong>: Contradicts established knowledge</li>
<li><strong>Experiment</strong>: Studies show no association</li>
<li><strong>Analogy</strong>: No supporting analogies</li>
</ol>
<p><strong>Conclusion</strong>: No causal relationship</p>
<h3 id="example-3-hiv-and-aids">Example 3: HIV and AIDS</h3>
<p><strong>Application</strong>:</p>
<ol type="1">
<li><strong>Strength</strong>: Very strong association</li>
<li><strong>Consistency</strong>: Global consistency across studies</li>
<li><strong>Specificity</strong>: HIV primarily causes AIDS</li>
<li><strong>Temporality</strong>: HIV infection precedes AIDS</li>
<li><strong>Biological gradient</strong>: Viral load correlates with
progression</li>
<li><strong>Plausibility</strong>: Mechanism of viral destruction
understood</li>
<li><strong>Coherence</strong>: Fits with viral disease patterns</li>
<li><strong>Experiment</strong>: Antiretroviral therapy confirms
causation</li>
<li><strong>Analogy</strong>: Similar to other viral infections</li>
</ol>
<p><strong>Conclusion</strong>: Definitive causal relationship</p>
<hr />
<h2 id="key-examination-points-summary">Key Examination Points
Summary</h2>
<h3 id="most-frequently-tested-concepts">Most Frequently Tested
Concepts:</h3>
<ol type="1">
<li><strong>Sensitivity vs Specificity</strong> - Always calculated from
2√ó2 table</li>
<li><strong>Incidence vs Prevalence</strong> - Remember the formula
relationship</li>
<li><strong>Case-control vs Cohort</strong> - Direction of study and
bias potential</li>
<li><strong>Primary, Secondary, Tertiary Prevention</strong> - Examples
for each</li>
<li><strong>Bradford Hill Criteria</strong> - Memorize full list</li>
<li><strong>Study Design Selection</strong> - Match design to research
question</li>
<li><strong>Screening Test Evaluation</strong> - Wilson-Jungner
criteria</li>
<li><strong>Surveillance Types</strong> - Active, passive, sentinel
differences</li>
</ol>
<h3 id="common-calculation-errors">Common Calculation Errors:</h3>
<ol type="1">
<li><strong>Sensitivity/Specificity confusion</strong> - Remember TP in
numerator</li>
<li><strong>Odds vs Risk ratio</strong> - Case-control vs cohort
studies</li>
<li><strong>Prevalence interpretation</strong> - Point vs period
prevalence</li>
<li><strong>Case fatality rate</strong> - Deaths among cases, not
population</li>
</ol>
<h3 id="answer-writing-tips">Answer Writing Tips:</h3>
<ol type="1">
<li><strong>Always define terms first</strong> in any calculation</li>
<li><strong>Show working</strong> in epidemiological calculations</li>
<li><strong>Use examples</strong> when explaining concepts</li>
<li><strong>Compare and contrast</strong> in descriptive answers</li>
<li><strong>Include limitations</strong> of different methods</li>
</ol>
<hr />
<p><strong>End of Part V: Epidemiology and Disease Control</strong></p>
<p><em>This completes the comprehensive examination guide for
epidemiology and disease control concepts essential for community
medicine examinations.</em></p>
<h1 id="part-vi-communicable-diseases-1">PART VI: COMMUNICABLE
DISEASES</h1>
<h2 id="quick-revision-manual-for-community-medicine-mbbs">Quick
Revision Manual for Community Medicine (MBBS)</h2>
<hr />
<h2 id="chapter-17-principles-of-communicable-disease-control">CHAPTER
17: PRINCIPLES OF COMMUNICABLE DISEASE CONTROL</h2>
<h3 id="i.-chain-of-infection">I. CHAIN OF INFECTION</h3>
<h4 id="agent-infectious-microorganisms">Agent (Infectious
Microorganisms)</h4>
<ul>
<li><strong>Bacteria</strong>: Single-celled microorganisms (e.g.,
<em>Streptococcus, Mycobacterium tuberculosis</em>)</li>
<li><strong>Viruses</strong>: Obligate intracellular parasites (e.g.,
HIV, influenza virus)</li>
<li><strong>Fungi</strong>: Eukaryotic organisms (e.g., <em>Candida,
Aspergillus</em>)</li>
<li><strong>Parites</strong>: Single/multi-celled organisms (e.g.,
<em>Plasmodium, helminths</em>)</li>
<li><strong>Prions</strong>: Proteinaceous infectious particles (e.g.,
Creutzfeldt-Jakob disease)</li>
</ul>
<h4 id="host-factors">Host Factors</h4>
<ul>
<li><strong>Natural resistance</strong>: Age, sex, race, genetic
factors</li>
<li><strong>Acquired immunity</strong>: Active (previous
infection/vaccination) vs Passive (maternal antibodies, IgG)</li>
<li><strong>Nutritional status</strong>: Protein-energy malnutrition
impairs immunity</li>
<li><strong>Endocrine factors</strong>: Diabetes, pregnancy increase
susceptibility</li>
<li><strong>Immunosuppression</strong>: HIV, chemotherapy, steroids</li>
</ul>
<h4 id="environment">Environment</h4>
<ul>
<li><strong>Physical</strong>: Temperature, humidity, overcrowding</li>
<li><strong>Biological</strong>: Vectors, intermediate hosts,
reservoirs</li>
<li><strong>Social</strong>: Economic status, education, healthcare
access</li>
<li><strong>Seasonal</strong>: Disease patterns vary with seasons</li>
</ul>
<h3 id="ii.-modes-of-transmission">II. MODES OF TRANSMISSION</h3>
<h4 id="direct-transmission">1. Direct Transmission</h4>
<ul>
<li><strong>Person-to-person</strong>: Direct contact (skin-to-skin),
droplet infection</li>
<li><strong>Mother-to-child</strong>: Transplacental, perinatal,
breastfeeding</li>
</ul>
<h4 id="indirect-transmission">2. Indirect Transmission</h4>
<ul>
<li><strong>Vehicle-borne</strong>: Contaminated food, water, air, blood
products</li>
<li><strong>Vector-borne</strong>: Biological (mosquitoes, ticks) or
mechanical (flies, cockroaches)</li>
<li><strong>Fomite transmission</strong>: Inanimate objects (door
handles, needles)</li>
<li><strong>Airborne</strong>: Aerosolized particles (&lt;5 microns)
remain suspended</li>
</ul>
<h3 id="iii.-host-parasite-relationships">III. HOST-PARASITE
RELATIONSHIPS</h3>
<h4 id="symbiosis-types">Symbiosis Types</h4>
<ul>
<li><strong>Commensalism</strong>: One benefits, other unaffected</li>
<li><strong>Mutualism</strong>: Both benefit</li>
<li><strong>Parasitism</strong>: One benefits, other harmed</li>
</ul>
<h4 id="disease-spectrum">Disease Spectrum</h4>
<ul>
<li><strong>Subclinical infection</strong>: No symptoms but pathogen
present</li>
<li><strong>Clinical infection</strong>: Symptoms present</li>
<li><strong>Carrier state</strong>: Infectious without symptoms</li>
<li><strong>Latent infection</strong>: Dormant state (e.g., herpes,
TB)</li>
</ul>
<h3 id="iv.-epidemiological-patterns">IV. EPIDEMIOLOGICAL PATTERNS</h3>
<h4 id="disease-distribution">Disease Distribution</h4>
<ul>
<li><strong>Endemic</strong>: Constant presence in community</li>
<li><strong>Epidemic</strong>: Sudden increase above normal</li>
<li><strong>Pandemic</strong>: Worldwide epidemic</li>
<li><strong>Sporadic</strong>: Irregular, occasional cases</li>
</ul>
<h4 id="epidemic-patterns">Epidemic Patterns</h4>
<ul>
<li><strong>Common-source epidemic</strong>: Single exposure
(point-source)</li>
<li><strong>Propagated epidemic</strong>: Person-to-person
transmission</li>
<li><strong>Mixed epidemic</strong>: Both common-source and
propagated</li>
</ul>
<h3 id="v.-prevention-strategies">V. PREVENTION STRATEGIES</h3>
<h4 id="primary-prevention-2">Primary Prevention</h4>
<ul>
<li><strong>Health promotion</strong>: Education, lifestyle
modification</li>
<li><strong>Specific protection</strong>: Vaccination, chemoprophylaxis,
vector control</li>
</ul>
<h4 id="secondary-prevention-3">Secondary Prevention</h4>
<ul>
<li><strong>Early diagnosis</strong>: Screening programs, active
surveillance</li>
<li><strong>Prompt treatment</strong>: Antimicrobial therapy,
isolation</li>
</ul>
<h4 id="tertiary-prevention-2">Tertiary Prevention</h4>
<ul>
<li><strong>Rehabilitation</strong>: Disability prevention,
reconstructive surgery</li>
<li><strong>Sequelae management</strong>: Chronic complications,
follow-up care</li>
</ul>
<h3 id="vi.-control-measures">VI. CONTROL MEASURES</h3>
<h4 id="international-measures">International Measures</h4>
<ul>
<li><strong>International Health Regulations (IHR 2005)</strong></li>
<li><strong>WHO surveillance systems</strong></li>
<li><strong>Cross-border coordination</strong></li>
</ul>
<h4 id="national-measures">National Measures</h4>
<ul>
<li><strong>National Disease Control Programs</strong></li>
<li><strong>Epidemic investigation protocols</strong></li>
<li><strong>Health infrastructure development</strong></li>
</ul>
<h4 id="local-measures">Local Measures</h4>
<ul>
<li><strong>Case surveillance and reporting</strong></li>
<li><strong>Contact tracing and management</strong></li>
<li><strong>Environmental sanitation</strong></li>
</ul>
<h3 id="vii.-quarantine-vs-isolation">VII. QUARANTINE VS ISOLATION</h3>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 38%" />
<col style="width: 35%" />
</colgroup>
<thead>
<tr>
<th>Aspect</th>
<th>Quarantine</th>
<th>Isolation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>Restriction of well-exposed persons</td>
<td>Separation of infected persons</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>Incubation period of disease</td>
<td>Period of communicability</td>
</tr>
<tr>
<td><strong>Purpose</strong></td>
<td>Prevent spread from exposed individuals</td>
<td>Prevent spread from infected individuals</td>
</tr>
<tr>
<td><strong>Legal authority</strong></td>
<td>Public Health Act</td>
<td>Hospitals/Health authorities</td>
</tr>
</tbody>
</table>
<p><strong>Memory Aid</strong>: Q for Quarantine
(ex<strong>Q</strong>uired exposed), I for Isolation (Infected
persons)</p>
<hr />
<h2 id="chapter-18-respiratory-infections">CHAPTER 18: RESPIRATORY
INFECTIONS</h2>
<h3 id="i.-tuberculosis">I. TUBERCULOSIS</h3>
<h4 id="epidemiological-triangle">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Mycobacterium tuberculosis</em>
(acid-fast bacillus)</li>
<li><strong>Host</strong>: Adults 20-40 years, HIV-positive,
malnourished, diabetic</li>
<li><strong>Environment</strong>: Overcrowding, poor ventilation, urban
slums</li>
</ul>
<h4 id="clinical-features-2">Clinical Features</h4>
<ul>
<li><strong>Pulmonary TB</strong>: Cough &gt;2 weeks, hemoptysis, chest
pain, fever, weight loss</li>
<li><strong>Extrapulmonary</strong>: Lymphadenitis, meningitis, bone,
genitourinary</li>
<li><strong>Tuberculin test</strong>: Induration &gt;10mm (BCG
vaccinated &gt;15mm)</li>
<li><strong>Sputum examination</strong>: Ziehl-Neelsen stain, GeneXpert
MTB/RIF</li>
</ul>
<h4 id="treatment-protocols">Treatment Protocols</h4>
<p><strong>First-line drugs</strong>: 2HRZE/4HR - <strong>Intensive
phase</strong>: 2 months (H+R+Z+E) - <strong>Continuation
phase</strong>: 4 months (H+R) - <strong>DOT (Directly Observed
Treatment)</strong>: Essential component</p>
<p><strong>Second-line drugs</strong>: Fluoroquinolones,
aminoglycosides, ethionamide - <strong>Drug-resistant TB</strong>:
MDR-TB (resistant to H+R), XDR-TB</p>
<h4 id="national-tb-control-programme-ntcp">National TB Control
Programme (NTCP)</h4>
<p><strong>Objectives</strong>: Achieve 90% case detection, 90%
treatment success <strong>Components</strong>: - DOTS implementation -
ACSM (Advocacy, Communication, Social Mobilization) - TB-HIV
collaboration - Drug-resistant TB management</p>
<p><strong>Key Strategies</strong>: - Nikshay portal for surveillance -
Private sector engagement - Community DOT providers</p>
<h4 id="prevention-control">Prevention &amp; Control</h4>
<ul>
<li><strong>BCG vaccination</strong>: Birth dose, prevents disseminated
TB</li>
<li><strong>Infection control</strong>: N95 masks, UV lights, natural
ventilation</li>
<li><strong>Contact screening</strong>: Household and close
contacts</li>
<li><strong>Chemoprophylaxis</strong>: INH for latent TB infection</li>
</ul>
<h3 id="ii.-pneumonia">II. PNEUMONIA</h3>
<h4 id="community-acquired-pneumonia-cap">Community-Acquired Pneumonia
(CAP)</h4>
<ul>
<li><strong>Common pathogens</strong>: <em>S. pneumoniae, H. influenzae,
atypicals</em></li>
<li><strong>Risk factors</strong>: Age &gt;65, COPD, alcoholism,
immunosuppression</li>
<li><strong>Clinical</strong>: Fever, cough, pleuritic chest pain,
consolidation</li>
<li><strong>Management</strong>: Empirical antibiotics based on severity
(CURB-65 score)</li>
</ul>
<h4 id="nosocomial-pneumonia">Nosocomial Pneumonia</h4>
<ul>
<li><strong>Hospital-acquired pneumonia (HAP)</strong>: &gt;48 hours
after admission</li>
<li><strong>Ventilator-associated pneumonia (VAP)</strong>: &gt;48 hours
post-intubation</li>
<li><strong>Common pathogens</strong>: <em>Pseudomonas, MRSA,
Enterobacter</em></li>
<li><strong>Prevention</strong>: HOB elevation, oral care, minimize
ventilation duration</li>
</ul>
<h3 id="iii.-influenza">III. INFLUENZA</h3>
<h4 id="seasonal-influenza">Seasonal Influenza</h4>
<ul>
<li><strong>Types</strong>: Influenza A (H1N1, H3N2), Influenza B,
Influenza C</li>
<li><strong>Transmission</strong>: Respiratory droplets, contact,
airborne</li>
<li><strong>Clinical</strong>: Sudden onset fever, myalgia, respiratory
symptoms</li>
<li><strong>Prevention</strong>: Annual vaccination
(trivalent/quadrivalent)</li>
</ul>
<h4 id="pandemic-influenza">Pandemic Influenza</h4>
<ul>
<li><strong>H1N1 (2009)</strong>: First pandemic of 21st century</li>
<li><strong>WHO Pandemic Phases</strong>: 1-6 (inter-pandemic to
post-pandemic)</li>
<li><strong>Characteristics</strong>: Novel strain, global spread, high
mortality</li>
</ul>
<h4 id="avian-influenza-h5n1">Avian Influenza (H5N1)</h4>
<ul>
<li><strong>Source</strong>: Poultry, wild birds</li>
<li><strong>Human infection</strong>: Direct contact with infected
birds</li>
<li><strong>High pathogenicity</strong>: 60% case fatality rate</li>
</ul>
<h3 id="iv.-measles-mumps-rubella-mmr">IV. MEASLES, MUMPS, RUBELLA
(MMR)</h3>
<h4 id="measles-rubeola">Measles (Rubeola)</h4>
<ul>
<li><strong>Agent</strong>: Measles virus (Paramyxovirus)</li>
<li><strong>Transmission</strong>: Respiratory droplets, highly
contagious (R0=15-18)</li>
<li><strong>Clinical</strong>: Koplik‚Äôs spots, maculopapular rash,
fever, conjunctivitis</li>
<li><strong>Complications</strong>: Pneumonia, encephalitis, SSPE</li>
<li><strong>Prevention</strong>: MMR vaccine (9 months, 15-18
months)</li>
</ul>
<h4 id="mumps">Mumps</h4>
<ul>
<li><strong>Agent</strong>: Mumps virus (Paramyxovirus)</li>
<li><strong>Clinical</strong>: Parotitis, orchitis (post-pubertal
males), meningitis</li>
<li><strong>Prevention</strong>: MMR vaccine, isolation for 5 days</li>
</ul>
<h4 id="rubella-german-measles">Rubella (German Measles)</h4>
<ul>
<li><strong>Agent</strong>: Rubella virus (Togavirus)</li>
<li><strong>Congenital rubella syndrome</strong>: Cataracts, deafness,
heart defects</li>
<li><strong>Prevention</strong>: MMR vaccine, avoid contact with
pregnant women</li>
</ul>
<h3 id="v.-covid-19">V. COVID-19</h3>
<h4 id="epidemiological-triangle-1">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: SARS-CoV-2 (Coronaviridae)</li>
<li><strong>Host</strong>: All age groups, higher risk in elderly,
comorbidities</li>
<li><strong>Environment</strong>: Closed spaces, gatherings,
international travel</li>
</ul>
<h4 id="clinical-features-3">Clinical Features</h4>
<ul>
<li><strong>Asymptomatic</strong>: 40-45% cases</li>
<li><strong>Mild</strong>: Fever, cough, fatigue, loss of
taste/smell</li>
<li><strong>Severe</strong>: Dyspnea, bilateral pneumonia, ARDS</li>
<li><strong>Complications</strong>: Thrombosis, multisystem inflammatory
syndrome</li>
</ul>
<h4 id="diagnostic-tests">Diagnostic Tests</h4>
<ul>
<li><strong>RT-PCR</strong>: Gold standard for detection</li>
<li><strong>Rapid antigen test</strong>: Point-of-care testing</li>
<li><strong>Antibody tests</strong>: Seroprevalence studies</li>
<li><strong>CT chest</strong>: Ground-glass opacities</li>
</ul>
<h4 id="prevention-control-1">Prevention &amp; Control</h4>
<ul>
<li><strong>Vaccines</strong>: Pfizer, Moderna, AstraZeneca, Bharat
Biotech</li>
<li><strong>Non-pharmaceutical interventions</strong>: Masks,
distancing, hand hygiene</li>
<li><strong>Quarantine protocols</strong>: 14 days for contacts</li>
<li><strong>Travel restrictions</strong>: International and
domestic</li>
</ul>
<h4 id="national-covid-19-response">National COVID-19 Response</h4>
<ul>
<li><strong>Co-WIN portal</strong>: Vaccination registration</li>
<li><strong>Testing strategy</strong>: Surveillance and contact
tracing</li>
<li><strong>Treatment protocols</strong>: Remdesivir, steroids, oxygen
support</li>
<li><strong>Emergency measures</strong>: Lockdowns, movement
restrictions</li>
</ul>
<hr />
<h2 id="chapter-19-intestinal-infections">CHAPTER 19: INTESTINAL
INFECTIONS</h2>
<h3 id="i.-cholera">I. CHOLERA</h3>
<h4 id="epidemiological-triangle-2">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Vibrio cholerae</em> (O1, O139)</li>
<li><strong>Host</strong>: Children and adults, gastric acidity
protective</li>
<li><strong>Environment</strong>: Contaminated water, poor sanitation,
overcrowding</li>
</ul>
<h4 id="clinical-features-4">Clinical Features</h4>
<ul>
<li><strong>Incubation</strong>: 2 hours to 5 days</li>
<li><strong>Rice-water stools</strong>: Characteristic appearance</li>
<li><strong>Profuse diarrhea</strong>: Up to 1L/hour</li>
<li><strong>Dehydration</strong>: Rapid fluid loss, hypokalemia</li>
<li><strong>Complications</strong>: Renal failure, shock</li>
</ul>
<h4 id="diagnosis">Diagnosis</h4>
<ul>
<li><strong>Stool microscopy</strong>: Motile vibrios (hanging drop
test)</li>
<li><strong>Culture</strong>: TCBS agar (yellow colonies)</li>
<li><strong>Rapid diagnostic tests</strong>: Immunochromatography</li>
<li><strong>Rehydration status</strong>: Assessment of dehydration</li>
</ul>
<h4 id="treatment-1">Treatment</h4>
<ul>
<li><strong>ORS (Oral Rehydration Solution)</strong>: WHO
formulation</li>
<li><strong>IV fluids</strong>: Ringer‚Äôs lactate for severe
dehydration</li>
<li><strong>Antibiotics</strong>: Doxycycline, azithromycin (reduce
duration)</li>
<li><strong>Zinc supplementation</strong>: Children &lt;5 years</li>
</ul>
<h4 id="prevention-control-2">Prevention &amp; Control</h4>
<ul>
<li><strong>Safe water</strong>: Boiling, chlorination, filtration</li>
<li><strong>Sanitation</strong>: Proper sewage disposal, hand
washing</li>
<li><strong>Food safety</strong>: Cooking practices, hygiene</li>
<li><strong>Surveillance</strong>: Active case finding, laboratory
confirmation</li>
</ul>
<h3 id="ii.-typhoid-fever-enteric-fever">II. TYPHOID FEVER (ENTERIC
FEVER)</h3>
<h4 id="epidemiological-triangle-3">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Salmonella typhi</em> (typhoid), <em>S.
paratyphi</em> (paratyphoid)</li>
<li><strong>Host</strong>: School-age children, young adults</li>
<li><strong>Environment</strong>: Poor sanitation, contaminated
food/water</li>
</ul>
<h4 id="clinical-features-5">Clinical Features</h4>
<ul>
<li><strong>Stepladder fever</strong>: Gradually increasing
temperature</li>
<li><strong>Rose spots</strong>: Truncal maculopapular rash (2nd
week)</li>
<li><strong>Relative bradycardia</strong>: Disproportionate to
fever</li>
<li><strong>Hepatosplenomegaly</strong>: Enlarged liver and spleen</li>
<li><strong>Complications</strong>: Intestinal hemorrhage,
perforation</li>
</ul>
<h4 id="diagnosis-1">Diagnosis</h4>
<ul>
<li><strong>Blood culture</strong>: Gold standard (1st week)</li>
<li><strong>Bone marrow culture</strong>: Highest sensitivity</li>
<li><strong>Widal test</strong>: Rising antibody titers (O, H
antigens)</li>
<li><strong>Typhidot</strong>: Rapid diagnostic test</li>
<li><strong>Stool culture</strong>: Late in illness</li>
</ul>
<h4 id="treatment-2">Treatment</h4>
<ul>
<li><strong>First-line</strong>: Ceftriaxone, cefixime</li>
<li><strong>Alternatives</strong>: Azithromycin, fluoroquinolones</li>
<li><strong>Supportive</strong>: Fluids, antipyretics, nutrition</li>
<li><strong>Carrier state</strong>: Cholecystectomy if persistent</li>
</ul>
<h4 id="prevention-control-3">Prevention &amp; Control</h4>
<ul>
<li><strong>Typhoid vaccine</strong>: Vi polysaccharide (injectable),
Ty21a (oral)</li>
<li><strong>Sanitation improvement</strong>: Safe water, proper
disposal</li>
<li><strong>Food safety</strong>: Avoid raw foods, street vendors</li>
<li><strong>Surveillance</strong>: Case investigation, contact
tracing</li>
</ul>
<h3 id="iii.-food-poisoning">III. FOOD POISONING</h3>
<h4 id="bacterial-food-poisoning">Bacterial Food Poisoning</h4>
<p><strong>Staphylococcus aureus</strong> - <strong>Source</strong>:
Food handlers, dairy products - <strong>Toxin</strong>: Preformed
enterotoxin - <strong>Rapid onset</strong>: 2-6 hours -
<strong>Symptoms</strong>: Vomiting, diarrhea, abdominal pain</p>
<p><strong>Clostridium perfringens</strong> - <strong>Source</strong>:
Meat, poultry, legumes - <strong>Toxin</strong>: Enterotoxin produced in
intestine - <strong>8-16 hours incubation - </strong>Profuse diarrhea,
minimal vomiting</p>
<p><strong>Bacillus cereus</strong> - <strong>Source</strong>: Rice,
pasta, cereals - <strong>Two syndromes</strong>: Emetic (rice),
diarrheal (meat) - **Rapid onset: 1-6 hours</p>
<p><strong>Salmonella spp.</strong> - <strong>Source</strong>: Eggs,
poultry, milk - <strong>Symptoms</strong>: Diarrhea, fever, abdominal
pain - <strong>Duration</strong>: 2-7 days</p>
<h4 id="viral-food-poisoning">Viral Food Poisoning</h4>
<ul>
<li><strong>Norovirus</strong>: Most common cause</li>
<li><strong>Rotavirus</strong>: Children &lt;5 years</li>
<li><strong>Hepatitis A</strong>: Contaminated shellfish</li>
</ul>
<h4 id="prevention">Prevention</h4>
<ul>
<li><strong>Temperature control</strong>: Cooking, refrigeration</li>
<li><strong>Hygiene</strong>: Hand washing, clean utensils</li>
<li><strong>Food storage</strong>: Proper temperature maintenance</li>
<li><strong>Source control</strong>: Inspection, quality assurance</li>
</ul>
<h3 id="iv.-amoebiasis-and-giardiasis">IV. AMOEBIASIS AND
GIARDIASIS</h3>
<h4 id="amoebiasis">Amoebiasis</h4>
<ul>
<li><strong>Agent</strong>: <em>Entamoeba histolytica</em></li>
<li><strong>Transmission</strong>: Fecal-oral route, contaminated
water</li>
<li><strong>Clinical</strong>: Amoebic dysentery, liver abscess</li>
<li><strong>Diagnosis</strong>: Stool microscopy (cysts/trophozoites),
antigen detection</li>
<li><strong>Treatment</strong>: Metronidazole, luminal amebicides</li>
</ul>
<h4 id="giardiasis">Giardiasis</h4>
<ul>
<li><strong>Agent</strong>: <em>Giardia lamblia</em></li>
<li><strong>Transmission</strong>: Contaminated water,
person-to-person</li>
<li><strong>Clinical</strong>: Chronic diarrhea, malabsorption,
bloating</li>
<li><strong>Diagnosis</strong>: Stool microscopy, antigen tests</li>
<li><strong>Treatment</strong>: Metronidazole, tinidazole</li>
</ul>
<h3 id="v.-viral-hepatitis-a-e">V. VIRAL HEPATITIS A &amp; E</h3>
<h4 id="hepatitis-a">Hepatitis A</h4>
<ul>
<li><strong>Agent</strong>: Hepatitis A virus (Picornavirus)</li>
<li><strong>Transmission</strong>: Fecal-oral, contaminated
food/water</li>
<li><strong>Clinical</strong>: Acute viral hepatitis, self-limiting</li>
<li><strong>Prevention</strong>: Inactivated vaccine,
immunoglobulin</li>
<li>**No chronic carrier state</li>
</ul>
<h4 id="hepatitis-e">Hepatitis E</h4>
<ul>
<li><strong>Agent</strong>: Hepatitis E virus (Hepevirus)</li>
<li><strong>Transmission</strong>: Fecal-oral, water-borne
outbreaks</li>
<li><strong>Clinical</strong>: Similar to Hepatitis A</li>
<li><strong>Special concern</strong>: Pregnancy (high mortality)</li>
<li><strong>Prevention</strong>: Improved sanitation, vaccine (limited
availability)</li>
</ul>
<h3 id="vi.-poliomyelitis">VI. POLIOMYELITIS</h3>
<h4 id="epidemiological-triangle-4">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: Poliovirus (Enterovirus, serotypes 1, 2,
3)</li>
<li><strong>Host</strong>: Children &lt;5 years, unvaccinated
individuals</li>
<li><strong>Environment</strong>: Poor sanitation, overcrowding</li>
</ul>
<h4 id="clinical-features-6">Clinical Features</h4>
<ul>
<li><strong>Majority (90%)</strong>: Asymptomatic infection</li>
<li><strong>Minor illness</strong>: Fever, malaise, headache, sore
throat</li>
<li><strong>Paralytic polio</strong>: Acute flaccid paralysis,
asymmetric</li>
<li><strong>Bulbar polio</strong>: Respiratory muscle involvement</li>
</ul>
<h4 id="diagnosis-2">Diagnosis</h4>
<ul>
<li><strong>Virus isolation</strong>: Stool samples, throat swab</li>
<li><strong>RT-PCR</strong>: Rapid detection</li>
<li><strong>Serology</strong>: Antibody detection</li>
</ul>
<h4 id="prevention-control-4">Prevention &amp; Control</h4>
<ul>
<li><strong>OPV (Oral Polio Vaccine)</strong>: Live attenuated, provides
intestinal immunity</li>
<li><strong>IPV (Inactivated Polio Vaccine)</strong>: Injectable, safe
for immunocompromised</li>
<li><strong>Pulse Polio Immunization</strong>: National campaigns</li>
<li><strong>Surveillance</strong>: AFP (Acute Flaccid Paralysis)
monitoring</li>
</ul>
<hr />
<h2 id="chapter-20-vector-borne-diseases">CHAPTER 20: VECTOR-BORNE
DISEASES</h2>
<h3 id="i.-malaria">I. MALARIA</h3>
<h4 id="epidemiological-triangle-5">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Plasmodium</em> species
(<em>falciparum</em>, <em>vivax</em>, <em>ovale</em>, <em>malariae</em>,
<em>knowlesi</em>)</li>
<li><strong>Host</strong>: Humans, varying susceptibility by
age/genetics</li>
<li><strong>Environment</strong>: Tropical/subtropical, breeding sites,
climate</li>
</ul>
<h4 id="transmission">Transmission</h4>
<ul>
<li><strong>Vector</strong>: <em>Anopheles</em> mosquitoes (female)</li>
<li><strong>Artificial</strong>: Blood transfusion, needle sharing</li>
<li><strong>Congenital</strong>: Mother to fetus (rare)</li>
<li><strong>Geographic distribution</strong>: Species vary by
region</li>
</ul>
<h4 id="clinical-features-7">Clinical Features</h4>
<p><strong>Uncomplicated Malaria</strong>: - Periodic fever (quotidian,
tertian, quartan) - Headache, myalgia, malaise - Splenomegaly,
hepatomegaly</p>
<p><strong>Severe <em>P. falciparum</em></strong>: - Cerebral malaria:
Altered consciousness, seizures - Severe anemia: Hb &lt;5 g/dL - Renal
failure: Acute tubular necrosis - Pulmonary edema: Respiratory distress
- Hypoglycemia:Especially in pregnancy</p>
<h4 id="diagnosis-3">Diagnosis</h4>
<ul>
<li><strong>Microscopy</strong>: Gold standard (thick/thin films)</li>
<li><strong>RDT</strong>: Rapid diagnostic tests (HRP-2, pLDH)</li>
<li><strong>Molecular</strong>: PCR (reference laboratories)</li>
<li><strong>QBC</strong>: Quantitative buffy coat</li>
</ul>
<h4 id="treatment-protocols-1">Treatment Protocols</h4>
<p><strong>Uncomplicated <em>P. falciparum</em></strong>: - ACT
(Artemisinin-based Combination Therapy) - AL (Artemether-lumefantrine) -
AS+SP (Artesunate-sulfadoxine-pyrimethamine)</p>
<p><strong>Severe Malaria</strong>: - IV artesunate (first choice) -
Alternative: IV quinine, quinidine - Supportive care: Fluids, oxygen,
blood transfusion</p>
<p><strong><em>P. vivax</em>/<em>ovale</em></strong>: - Chloroquine +
Primaquine - G6PD testing before primaquine - Radical cure to prevent
relapse</p>
<h4 id="national-malaria-control-programme-nmcp">National Malaria
Control Programme (NMCP)</h4>
<p><strong>Objectives</strong>: - Achieve elimination in low-endemic
areas - Reduce mortality by 90% by 2030</p>
<p><strong>Key Strategies</strong>: - LLIN (Long-Lasting Insecticidal
Nets) - IRS (Indoor Residual Spraying) - Case management: RDT + ACT -
Larval source management - Seasonal malaria chemoprevention (SMC)</p>
<h3 id="ii.-dengue-fever-and-dhf">II. DENGUE FEVER AND DHF</h3>
<h4 id="epidemiological-triangle-6">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: Dengue virus (serotypes 1-4,
Flavivirus)</li>
<li><strong>Host</strong>: All age groups, previous infection increases
risk of DHF</li>
<li><strong>Environment</strong>: Urban, semi-urban areas, breeding
sites</li>
</ul>
<h4 id="vector">Vector</h4>
<ul>
<li><strong>Primary</strong>: <em>Aedes aegypti</em> (day-biting,
container breeder)</li>
<li><strong>Secondary</strong>: <em>Aedes albopictus</em></li>
<li><strong>Breeding sites</strong>: Artificial containers, tires,
flower pots</li>
</ul>
<h4 id="clinical-spectrum-1">Clinical Spectrum</h4>
<p><strong>Dengue Fever (DF)</strong>: - High fever, severe headache,
retro-orbital pain - Myalgia, arthralgia, rash - Hemorrhagic
manifestations</p>
<p><strong>Dengue Hemorrhagic Fever (DHF)</strong>: - Plasma leakage:
Pleural effusion, ascites - Hemorrhagic manifestations -
Thrombocytopenia (&lt;100,000/ŒºL) - Elevated hematocrit</p>
<p><strong>Dengue Shock Syndrome (DSS)</strong>: - Hypotension, narrow
pulse pressure - Signs of shock: Cold extremities, oliguria - Mortality
12-44% without treatment</p>
<h4 id="diagnosis-4">Diagnosis</h4>
<ul>
<li><strong>NS1 antigen</strong>: Early detection (days 1-7)</li>
<li><strong>IgM antibody</strong>: Late phase (days 5-7)</li>
<li><strong>IgG antibody</strong>: Past infection or secondary
infection</li>
<li><strong>Hematocrit</strong>: Serial monitoring</li>
<li>** platelet count**: Daily monitoring</li>
</ul>
<h4 id="treatment-3">Treatment</h4>
<ul>
<li><strong>Supportive</strong>: Fluids, paracetamol (avoid
aspirin/NSAIDs)</li>
<li><strong>Monitoring</strong>: Vital signs, hematocrit, urine
output</li>
<li><strong>IV fluids</strong>: Crystalloids for plasma leakage</li>
<li><strong>Blood products</strong>: Platelet transfusion if
bleeding</li>
</ul>
<h4 id="prevention-control-5">Prevention &amp; Control</h4>
<ul>
<li><strong>Vector control</strong>: Source reduction, larvicides,
fogging</li>
<li><strong>Personal protection</strong>: Repellents, protective
clothing</li>
<li><strong>Community participation</strong>: 3S strategy (Search, Seal,
Support)</li>
<li><strong>Surveillance</strong>: Sentinel sites, case reporting</li>
</ul>
<h3 id="iii.-chikungunya">III. CHIKUNGUNYA</h3>
<h4 id="epidemiological-triangle-7">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: Chikungunya virus (Togavirus)</li>
<li><strong>Host</strong>: All age groups</li>
<li><strong>Environment</strong>: Tropical areas, urban settlements</li>
</ul>
<h4 id="clinical-features-8">Clinical Features</h4>
<ul>
<li><strong>Sudden onset</strong>: High fever, severe joint pain</li>
<li><strong>Arthralgia</strong>: Small joints, can persist for
months</li>
<li><strong>Maculopapular rash</strong>: Face and trunk</li>
<li><strong>Complications</strong>: Meningoencephalitis, hepatitis</li>
</ul>
<h4 id="vector-control">Vector Control</h4>
<ul>
<li><em>Aedes aegypti</em> and <em>Aedes albopictus</em></li>
<li>Similar to dengue control measures</li>
</ul>
<h3 id="iv.-japanese-encephalitis">IV. JAPANESE ENCEPHALITIS</h3>
<h4 id="epidemiological-triangle-8">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: Japanese encephalitis virus
(Flavivirus)</li>
<li><strong>Host</strong>: Children &lt;15 years, pigs (amplifying
hosts)</li>
<li><strong>Environment</strong>: Rural areas, rice fields, pig
farms</li>
</ul>
<h4 id="vector-1">Vector</h4>
<ul>
<li><strong>Primary</strong>: <em>Culex tritaeniorhynchus</em>
(night-biting)</li>
<li><strong>Breeding</strong>: Rice fields, irrigation canals</li>
</ul>
<h4 id="clinical-features-9">Clinical Features</h4>
<ul>
<li><strong>Incubation</strong>: 5-15 days</li>
<li><strong>Prodromal</strong>: Fever, headache, vomiting</li>
<li><strong>Neurological</strong>: Altered consciousness, seizures,
paralysis</li>
<li><strong>Mortality</strong>: 20-30% in clinical cases</li>
</ul>
<h4 id="diagnosis-prevention">Diagnosis &amp; Prevention</h4>
<ul>
<li><strong>Serology</strong>: IgM capture ELISA</li>
<li><strong>Vaccination</strong>: Inactivated (JE) vaccine</li>
<li><strong>Vector control</strong>: Source reduction, personal
protection</li>
<li><strong>Pig vaccination</strong>: Reduces human transmission</li>
</ul>
<h3 id="v.-filariasis">V. FILARIASIS</h3>
<h4 id="lymphatic-filariasis">Lymphatic Filariasis</h4>
<ul>
<li><strong>Agents</strong>: <em>Wuchereria bancrofti</em>, <em>Brugia
malayi</em>, <em>Brugia timori</em></li>
<li><strong>Vector</strong>: <em>Culex quinquefasciatus</em> (urban),
<em>Anopheles</em> (rural)</li>
<li><strong>Clinical</strong>: Lymphedema, hydrocele, elephantiasis</li>
</ul>
<h4 id="onchocerciasis-river-blindness">Onchocerciasis (River
Blindness)</h4>
<ul>
<li><strong>Agent</strong>: <em>Onchocerca volvulus</em></li>
<li><strong>Vector</strong>: <em>Simulium</em> blackflies</li>
<li><strong>Clinical</strong>: Skin nodules, river blindness</li>
</ul>
<h4 id="control-measures">Control Measures</h4>
<ul>
<li><strong>Mass Drug Administration (MDA)</strong>: Albendazole +
DEC/IVM</li>
<li><strong>Vector control</strong>: Insecticide-treated nets</li>
<li><strong>Individual treatment</strong>: DEC, albendazole</li>
</ul>
<h3 id="vi.-leishmaniasis">VI. LEISHMANIASIS</h3>
<h4 id="visceral-leishmaniasis-kala-azar">Visceral Leishmaniasis
(Kala-azar)</h4>
<ul>
<li><strong>Agent</strong>: <em>Leishmania donovani</em> complex</li>
<li><strong>Vector</strong>: <em>Phlebotomus argentipes</em>
(sandfly)</li>
<li><strong>Clinical</strong>: Fever, weight loss, splenomegaly,
pancytopenia</li>
</ul>
<h4 id="cutaneous-leishmaniasis">Cutaneous Leishmaniasis</h4>
<ul>
<li><strong>Agent</strong>: Various <em>Leishmania</em> species</li>
<li><strong>Clinical</strong>: Skin ulcers, nodules</li>
<li><strong>Self-limiting</strong> in some species</li>
</ul>
<h4 id="diagnosis-treatment">Diagnosis &amp; Treatment</h4>
<ul>
<li><strong>Diagnosis</strong>: Bone marrow aspirate, rK39 antigen
test</li>
<li><strong>Treatment</strong>: Sodium stibogluconate, amphotericin B,
miltefosine</li>
<li><strong>Prevention</strong>: Vector control, personal
protection</li>
</ul>
<hr />
<h2 id="chapter-21-zoonoses">CHAPTER 21: ZOONOSES</h2>
<h3 id="i.-rabies">I. RABIES</h3>
<h4 id="epidemiological-triangle-9">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: Rabies virus (Lyssavirus)</li>
<li><strong>Host</strong>: Mammals, especially carnivores and bats</li>
<li><strong>Environment</strong>: Urban (dog-mediated), sylvatic
(wildlife-mediated)</li>
</ul>
<h4 id="transmission-1">Transmission</h4>
<ul>
<li><strong>Animal bites</strong>: Most common route</li>
<li><strong>Scratches</strong>: With saliva contamination</li>
<li><strong>Mucosal contact</strong>: Rare but possible</li>
<li><strong>Inhalation</strong>: Bat caves, laboratory exposure</li>
</ul>
<h4 id="clinical-features-10">Clinical Features</h4>
<p><strong>Furious Rabies</strong>: - Hydrophobia, aerophobia,
hypersalivation - Hallucinations, agitation, aggression - spasms:
Pharyngeal muscles</p>
<p><strong>Paralytic Rabies</strong>: - Ascending paralysis - Muscle
wasting - Longer duration (7-10 days)</p>
<h4 id="post-exposure-prophylaxis-pep">Post-Exposure Prophylaxis
(PEP)</h4>
<p><strong>Category I</strong>: Touching/feeding animal -
<strong>Action</strong>: No treatment needed</p>
<p><strong>Category II</strong>: Nibbling of uncovered skin -
<strong>Action</strong>: Wound washing + Vaccine</p>
<p><strong>Category III</strong>: Bites, scratches, contamination -
<strong>Action</strong>: Wound washing + RIG + Vaccine</p>
<h4 id="treatment-protocol-1">Treatment Protocol</h4>
<p><strong>Wound Management</strong>: - Immediate washing (15 minutes) -
Antiseptic application (povidone-iodine) - Avoid suturing if
possible</p>
<p><strong>Vaccination</strong>: - <strong>Essen regimen</strong>: Days
0, 3, 7, 14, 28 (IM) - <strong>Oxford regimen</strong>: Days 0, 3, 7, 14
(IM) - <strong>ID route</strong>: WHO recommended, cost-effective</p>
<p><strong>Rabies Immunoglobulin (RIG)</strong>: - Human RIG (HRIG): 20
IU/kg - Equine RIG (ERIG): 40 IU/kg - Infiltrate around wound</p>
<h4 id="pre-exposure-prophylaxis">Pre-Exposure Prophylaxis</h4>
<ul>
<li><strong>Risk groups</strong>: Veterinarians, laboratory workers</li>
<li><strong>Schedule</strong>: Days 0, 7, 21 or 28 (IM or ID)</li>
<li><strong>Booster</strong>: Based on antibody levels</li>
</ul>
<h3 id="ii.-anthrax">II. ANTHRAX</h3>
<h4 id="epidemiological-triangle-10">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Bacillus anthracis</em> (spore-forming
bacterium)</li>
<li><strong>Host</strong>: Herbivores, humans</li>
<li><strong>Environment</strong>: Soil, contaminated animal
products</li>
</ul>
<h4 id="forms-of-anthrax">Forms of Anthrax</h4>
<p><strong>Cutaneous Anthrax (95%)</strong>: - Eschar with edema - Black
necrotic center - Painless, non-tender</p>
<p><strong>Inhalational Anthrax</strong>: - ‚ÄúWoolsorter‚Äôs disease‚Äù -
Fever, dyspnea, mediastinal widening - High mortality (85-95%)</p>
<p><strong>Gastrointestinal Anthrax</strong>: - Nausea, vomiting, bloody
diarrhea - Abdominal pain, ascites - Mortality 25-60%</p>
<h4 id="diagnosis-treatment-1">Diagnosis &amp; Treatment</h4>
<ul>
<li><strong>Diagnosis</strong>: Gram stain, culture, PCR</li>
<li><strong>Treatment</strong>: Penicillin, ciprofloxacin,
doxycycline</li>
<li><strong>Prevention</strong>: Vaccination (animal), proper
disposal</li>
</ul>
<h3 id="iii.-brucellosis">III. BRUCELLOSIS</h3>
<h4 id="epidemiological-triangle-11">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Brucella</em> species
(<em>melitensis</em>, <em>abortus</em>, <em>suis</em>,
<em>canis</em>)</li>
<li><strong>Host</strong>: Cattle, goats, swine, dogs</li>
<li><strong>Environment</strong>: Unpasteurized dairy products</li>
</ul>
<h4 id="clinical-features-11">Clinical Features</h4>
<ul>
<li><strong>Undulant fever</strong>: Intermittent fever pattern</li>
<li><strong>Musculoskeletal</strong>: Arthralgia, spondylitis</li>
<li><strong>Reproductive</strong>: Orchitis, abortion in animals</li>
<li><strong>Chronic</strong>: Fatigue, depression</li>
</ul>
<h4 id="diagnosis-treatment-2">Diagnosis &amp; Treatment</h4>
<ul>
<li><strong>Diagnosis</strong>: Blood culture, serology (SAT,
ELISA)</li>
<li><strong>Treatment</strong>: Doxycycline + Rifampin (6 weeks)</li>
<li><strong>Prevention</strong>: Pasteurization, vaccination</li>
</ul>
<h3 id="iv.-leptospirosis">IV. LEPTOSPIROSIS</h3>
<h4 id="epidemiological-triangle-12">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Leptospira interrogans</em></li>
<li><strong>Host</strong>: Rodents, domestic animals</li>
<li><strong>Environment</strong>: Contaminated water, soil</li>
</ul>
<h4 id="clinical-features-12">Clinical Features</h4>
<ul>
<li><strong>Biphasic illness</strong>:
<ul>
<li><strong>Phase 1</strong>: Fever, myalgia, conjunctival
suffusion</li>
<li><strong>Phase 2</strong>: Meningitis, hepatitis, renal failure</li>
</ul></li>
</ul>
<h4 id="diagnosis-treatment-3">Diagnosis &amp; Treatment</h4>
<ul>
<li><strong>Diagnosis</strong>: Dark-field microscopy, MAT, PCR</li>
<li><strong>Treatment</strong>: Doxycycline, penicillin</li>
<li><strong>Prevention</strong>: Rodent control, protective
equipment</li>
</ul>
<h3 id="v.-emerging-zoonoses">V. EMERGING ZOONOSES</h3>
<h4 id="factors-driving-emergence">Factors Driving Emergence</h4>
<ul>
<li><strong>Environmental change</strong>: Deforestation,
urbanization</li>
<li><strong>Climate change</strong>: Altered vector distribution</li>
<li><strong>Intensive agriculture</strong>: High-density farming</li>
<li><strong>Global travel</strong>: Rapid pathogen spread</li>
<li><strong>Antimicrobial resistance</strong>: Treatment challenges</li>
</ul>
<h4 id="examples-of-emerging-zoonoses">Examples of Emerging
Zoonoses</h4>
<ul>
<li><strong>Nipah virus</strong>: Fruit bats to humans via
pigs/dates</li>
<li><strong>H5N1 avian influenza</strong>: Poultry to humans</li>
<li><strong>Ebola virus disease</strong>: Wildlife to humans</li>
<li><strong>SARS</strong>: Bats to civets to humans</li>
<li><strong>COVID-19</strong>: Likely bat to humans</li>
</ul>
<h4 id="surveillance-response">Surveillance &amp; Response</h4>
<ul>
<li><strong>One Health approach</strong>: Human, animal, environment
health</li>
<li><strong>Early warning systems</strong>: Syndromic surveillance</li>
<li><strong>Cross-sector collaboration</strong>: Human and veterinary
sectors</li>
<li><strong>Research</strong>: Diagnostic tools, vaccines,
therapeutics</li>
</ul>
<hr />
<h2 id="chapter-22-surface-infections">CHAPTER 22: SURFACE
INFECTIONS</h2>
<h3 id="i.-trachoma">I. TRACHOMA</h3>
<h4 id="epidemiological-triangle-13">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Chlamydia trachomatis</em> (A, B, C
serotypes)</li>
<li><strong>Host</strong>: Children &lt;10 years, particularly
girls</li>
<li><strong>Environment</strong>: Poor hygiene, water scarcity,
crowding</li>
</ul>
<h4 id="clinical-features-13">Clinical Features</h4>
<ul>
<li><strong>Active trachoma</strong>:
<ul>
<li>Follicular and papillary reactions</li>
<li>Pannus formation</li>
<li>Discharge and irritation</li>
</ul></li>
</ul>
<p><strong>Trachomatous trichiasis</strong>: - Eyelashes turn inward -
Corneal abrasion and scarring</p>
<p><strong>End-stage trachoma</strong>: - Corneal opacity -
Blindness</p>
<h4 id="diagnosis-5">Diagnosis</h4>
<ul>
<li><strong>Clinical</strong>: WHO simplified grading system</li>
<li><strong>Laboratory</strong>: PCR, antigen detection</li>
<li><strong>Screening</strong>: Community-based surveys</li>
</ul>
<h4 id="control-measures-safe-strategy">Control Measures (SAFE
Strategy)</h4>
<p><strong>S - Surgery</strong>: Trichiasis correction <strong>A -
Antibiotics</strong>: Azithromycin mass treatment <strong>F - Facial
cleanliness</strong>: Hygiene promotion <strong>E - Environmental
improvement</strong>: Water, sanitation</p>
<h3 id="ii.-yaws">II. YAWS</h3>
<h4 id="epidemiological-triangle-14">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Treponema pallidum pertenue</em></li>
<li><strong>Host</strong>: Children &lt;15 years</li>
<li><strong>Environment</strong>: Tropical, humid, poor hygiene</li>
</ul>
<h4 id="clinical-stages">Clinical Stages</h4>
<p><strong>Primary yaws</strong>: - Papule at inoculation site - Ulcer
with raspberry appearance - Regional lymphadenopathy</p>
<p><strong>Secondary yaws</strong>: - Generalized skin lesions - ‚ÄúYucca
flower‚Äù appearance - Palmar/plantar hyperkeratosis</p>
<p><strong>Tertiary yaws</strong>: - Bone deformities - Gummatous
lesions</p>
<h4 id="diagnosis-treatment-4">Diagnosis &amp; Treatment</h4>
<ul>
<li><strong>Diagnosis</strong>: Serology (VDRL/RPR), dark-field
microscopy</li>
<li><strong>Treatment</strong>: Single dose benzathine penicillin</li>
<li><strong>Prevention</strong>: Improved hygiene, mass treatment</li>
</ul>
<h3 id="iii.-leprosy-hansens-disease">III. LEPROSY (HANSEN‚ÄôS
DISEASE)</h3>
<h4 id="epidemiological-triangle-15">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Mycobacterium leprae</em> (acid-fast
bacillus)</li>
<li><strong>Host</strong>: Variable susceptibility, genetic factors</li>
<li><strong>Environment</strong>: Overcrowding, poor living
conditions</li>
</ul>
<h4 id="classification-systems">Classification Systems</h4>
<p><strong>Ridley-Jopling Classification</strong>: -
<strong>TT</strong>: Tuberculoid leprosy (1-2 lesions) -
<strong>BT</strong>: Borderline tuberculoid - <strong>BB</strong>:
Borderline borderline - <strong>BL</strong>: Borderline lepromatous -
<strong>LL</strong>: Lepromatous leprosy (numerous lesions)</p>
<p><strong>WHO Classification</strong>: - <strong>Paucibacillary
(PB)</strong>: 1-5 lesions (TT, BT) - <strong>Multibacillary
(MB)</strong>: &gt;5 lesions (BB, BL, LL)</p>
<h4 id="clinical-features-14">Clinical Features</h4>
<p><strong>Skin lesions</strong>: Hypopigmented, anesthetic patches
<strong>Nerve involvement</strong>: Thickened nerves, sensory loss **
Complications<strong>: Claw hand, foot drop, facial palsy </strong>Eye
involvement**: Lagophthalmos, corneal ulceration</p>
<h4 id="diagnosis-6">Diagnosis</h4>
<ul>
<li><strong>Clinical</strong>: Skin lesions + nerve involvement</li>
<li><strong>Skin smear</strong>: AFB detection (slit-skin smear)</li>
<li><strong>Skin biopsy</strong>: Histopathology</li>
<li><strong>Nerve biopsy</strong>: In selected cases</li>
</ul>
<h4 id="treatment-protocols-2">Treatment Protocols</h4>
<p><strong>PB leprosy</strong>: - Dapsone 100 mg daily + Rifampicin 600
mg monthly (6 months)</p>
<p><strong>MB leprosy</strong>: - Dapsone 100 mg daily + Rifampicin 600
mg monthly + Clofazimine 300 mg monthly (12 months)</p>
<p><strong>MDT Multidrug Therapy</strong>: Prevents drug resistance,
ensures cure</p>
<h4 id="national-leprosy-elimination-programme-nlep">National Leprosy
Elimination Programme (NLEP)</h4>
<p><strong>Objectives</strong>: Achieve elimination (&lt;1 case/10,000
population) <strong>Strategies</strong>: - Early case detection -
Regular MDT supply - Rehabilitation services - IEC activities - Training
of health workers</p>
<p><strong>Monitoring</strong>: - Prevalence rate - New case detection
rate - Disability grade II among new cases - Completion rate of
treatment</p>
<h3 id="iv.-scabies-and-other-skin-infections">IV. SCABIES AND OTHER
SKIN INFECTIONS</h3>
<h4 id="scabies">Scabies</h4>
<ul>
<li><strong>Agent</strong>: <em>Sarcoptes scabiei</em> var.
<em>hominis</em></li>
<li><strong>Transmission</strong>: Prolonged skin contact, sexual
contact</li>
<li><strong>Clinical</strong>: Intense pruritus, burrows, papules</li>
<li><strong>Distribution</strong>: Web spaces, wrists, genitalia</li>
</ul>
<p><strong>Norwegian scabies</strong>: Crusted form in immunocompromised
<strong>Diagnosis</strong>: Microscopic examination of scrapings
<strong>Treatment</strong>: Permethrin 5% cream, oral ivermectin</p>
<h4 id="other-skin-infections">Other Skin Infections</h4>
<p><strong>Impetigo</strong>: <em>Staph aureus</em>, <em>Strep
pyogenes</em> <strong>Cellulitis</strong>: <em>Strep pyogenes</em>,
<em>Staph aureus</em> <strong>Tinea infections</strong>: Dermatophytes
(<em>Trichophyton</em>, <em>Microsporum</em>, <em>Epidermophyton</em>)
<strong>Herpes simplex</strong>: HSV-1, HSV-2
<strong>Varicella-zoster</strong>: Chickenpox, shingles</p>
<hr />
<h2 id="chapter-23-sexually-transmitted-infections">CHAPTER 23: SEXUALLY
TRANSMITTED INFECTIONS</h2>
<h3 id="i.-syphilis">I. SYPHILIS</h3>
<h4 id="epidemiological-triangle-16">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Treponema pallidum</em>
(spirochete)</li>
<li><strong>Host</strong>: Sexually active individuals</li>
<li><strong>Environment</strong>: Unprotected sexual contact, multiple
partners</li>
</ul>
<h4 id="stages-of-syphilis">Stages of Syphilis</h4>
<p><strong>Primary Syphilis</strong>: - <strong>Chancre</strong>:
Painless ulcer with raised edges - <strong>Location</strong>: Genitalia,
perineum, extragenital sites - <strong>Duration</strong>: 3-6 weeks,
heals spontaneously</p>
<p><strong>Secondary Syphilis</strong>: - <strong>Rash</strong>:
Maculopapular, non-itchy - <strong>Distribution</strong>: Trunk, palms,
soles - <strong>Other</strong>: Mucous patches, condyloma lata</p>
<p><strong>Latent Syphilis</strong>: - <strong>Early</strong>: &lt;1
year duration - <strong>Late</strong>: &gt;1 year duration -
<strong>Asymptomatic</strong>: Serological evidence only</p>
<p><strong>Tertiary Syphilis</strong>: - <strong>Gummatous</strong>:
Soft, granulomatous lesions - <strong>Cardiovascular</strong>: Aortitis,
aneurysms - <strong>Neurosyphilis</strong>: Tabes dorsalis, general
paresis</p>
<h4 id="diagnosis-7">Diagnosis</h4>
<p><strong>Direct methods</strong>: - Dark-field microscopy - Direct
fluorescent antibody test</p>
<p><strong>Serological tests</strong>: -
<strong>Non-treponemal</strong>: VDRL, RPR (screening) -
<strong>Treponemal</strong>: TPHA, FTA-ABS (confirmatory) -
<strong>TPPA</strong>: Treponema pallidum particle agglutination</p>
<h4 id="treatment-4">Treatment</h4>
<ul>
<li><strong>Primary/Secondary/Early latent</strong>: Benzathine
penicillin G 2.4 million units IM (single dose)</li>
<li><strong>Late latent/Tertiary</strong>: Benzathine penicillin G 2.4
million units IM weekly √ó 3 weeks</li>
<li><strong>Neurosyphilis</strong>: Aqueous crystalline penicillin G
18-24 million units/day IV √ó 10-14 days</li>
</ul>
<h3 id="ii.-gonorrhea">II. GONORRHEA</h3>
<h4 id="epidemiological-triangle-17">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Neisseria gonorrhoeae</em>
(Gram-negative diplococcus)</li>
<li><strong>Host</strong>: Sexually active individuals</li>
<li><strong>Environment</strong>: Unprotected sexual contact</li>
</ul>
<h4 id="clinical-features-15">Clinical Features</h4>
<p><strong>Men</strong>: - Urethral discharge (purulent) - Dysuria -
Epididymitis (complication)</p>
<p><strong>Women</strong>: - Cervicitis with discharge - Pelvic
inflammatory disease (PID) - Infertility (complication)</p>
<p><strong>Other manifestations</strong>: - Pharyngeal infection -
Rectal infection - Disseminated gonococcal infection (DGI)</p>
<h4 id="diagnosis-8">Diagnosis</h4>
<ul>
<li><strong>Gram stain</strong>: Gram-negative diplococci within
PMNs</li>
<li><strong>Culture</strong>: Thayer-Martin medium</li>
<li><strong>NAAT</strong>: Nucleic acid amplification tests
(preferred)</li>
<li><strong>Antimicrobial susceptibility</strong>: Important for
treatment</li>
</ul>
<h4 id="treatment-5">Treatment</h4>
<p><strong>Uncomplicated gonorrhea</strong>: - Ceftriaxone 500mg IM
single dose + Azithromycin 1g single dose - Alternative: Ceftriaxone 1g
IM + Doxycycline 100mg BID √ó 7 days</p>
<p><strong>Complicated gonorrhea</strong>: Extended treatment regimens
<strong>Partners</strong>: Treat all sexual partners within 60 days</p>
<h3 id="iii.-chlamydia">III. CHLAMYDIA</h3>
<h4 id="epidemiological-triangle-18">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Chlamydia trachomatis</em> (serotypes
D-K)</li>
<li><strong>Host</strong>: Sexually active individuals</li>
<li><strong>Environment</strong>: Unprotected sexual contact</li>
</ul>
<h4 id="clinical-features-16">Clinical Features</h4>
<p><strong>Asymptomatic infection</strong>: 70-80% cases
<strong>Men</strong>: Urethritis, epididymitis <strong>Women</strong>:
Cervicitis, PID, infertility <strong>Complications</strong>: Reactive
arthritis, Fitz-Hugh-Curtis syndrome</p>
<h4 id="diagnosis-9">Diagnosis</h4>
<ul>
<li><strong>NAAT</strong>: Most sensitive and specific</li>
<li><strong>Culture</strong>: Gold standard but less available</li>
<li><strong>Antigen detection</strong>: EIA, DFA</li>
</ul>
<h4 id="treatment-6">Treatment</h4>
<ul>
<li><strong>Azithromycin</strong>: 1g single dose (preferred)</li>
<li><strong>Doxycycline</strong>: 100mg BID √ó 7 days</li>
<li><strong>Partners</strong>: Treat all sexual partners within 60
days</li>
</ul>
<h3 id="iv.-hivaids">IV. HIV/AIDS</h3>
<h4 id="epidemiological-triangle-19">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: Human Immunodeficiency Virus (HIV-1,
HIV-2)</li>
<li><strong>Host</strong>: All age groups, high-risk behaviors</li>
<li><strong>Environment</strong>: High-risk practices, blood
exposure</li>
</ul>
<h4 id="transmission-routes">Transmission Routes</h4>
<p><strong>Sexual transmission</strong>: Unprotected vaginal/anal
intercourse <strong>Bloodborne</strong>: Needle sharing, blood
transfusion <strong>Mother-to-child</strong>: Pregnancy, delivery,
breastfeeding <strong>Occupational</strong>: Needlestick injuries</p>
<h4 id="clinical-course">Clinical Course</h4>
<p><strong>Acute HIV infection</strong>: Flu-like illness (2-4 weeks
post-exposure) <strong>Clinical latency</strong>: Asymptomatic period
(8-10 years) <strong>AIDS</strong>: CD4 count &lt;200 cells/ŒºL,
opportunistic infections</p>
<h4 id="opportunistic-infections">Opportunistic Infections</h4>
<p><strong>Bacterial</strong>: TB, bacterial pneumonia
<strong>Fungal</strong>: PCP pneumonia, candidiasis
<strong>Viral</strong>: HSV, CMV, hepatitis B/C
<strong>Parasitic</strong>: Toxoplasmosis, cryptosporidiosis</p>
<h4 id="diagnosis-10">Diagnosis</h4>
<p><strong>Screening tests</strong>: - ELISA/EIA (4th generation) -
Rapid tests - OraQuick oral fluid test</p>
<p><strong>Confirmatory tests</strong>: - Western blot - HIV-1 RNA PCR -
Immunofluorescence assay</p>
<h4 id="treatment-7">Treatment</h4>
<p><strong>Antiretroviral Therapy (ART)</strong>: -
<strong>NRTI</strong>: Lamivudine, tenofovir, zidovudine -
<strong>NNRTI</strong>: Efavirenz, nevirapine - <strong>PI</strong>:
Ritonavir, lopinavir/ritonavir - <strong>Integrase inhibitors</strong>:
Raltegravir, dolutegravir</p>
<p><strong>Treatment goals</strong>: - Viral suppression (&lt;200
copies/mL) - CD4 count recovery (&gt;500 cells/ŒºL) - Prevent progression
to AIDS - Reduce transmission</p>
<h4 id="national-aids-control-programme-nacp">National AIDS Control
Programme (NACP)</h4>
<p><strong>Phase I (1992-1999)</strong>: - Blood safety - Condom
promotion - STD control</p>
<p><strong>Phase II (1999-2007)</strong>: - Targeted interventions -
Surveillance systems - Care and support</p>
<p><strong>Phase III (2007-2012)</strong>: - Universal access - ART
scale-up - Prevention of parent-to-child transmission</p>
<p><strong>Phase IV (2012-2017)</strong>: - Consolidated prevention -
Treatment as prevention - Key populations focus</p>
<p><strong>Current strategies</strong>: - 90-90-90 targets by 2020 -
Test and treat approach - PrEP for high-risk groups - Integration with
TB/Hepatitis programs</p>
<h3 id="v.-other-stis">V. OTHER STIs</h3>
<h4 id="chancroid">Chancroid</h4>
<ul>
<li><strong>Agent</strong>: <em>Haemophilus ducreyi</em></li>
<li><strong>Clinical</strong>: Painful genital ulcer, inguinal
adenopathy</li>
<li><strong>Treatment</strong>: Azithromycin 1g single dose, ceftriaxone
250mg IM</li>
</ul>
<h4 id="lymphogranuloma-venereum-lgv">Lymphogranuloma Venereum
(LGV)</h4>
<ul>
<li><strong>Agent</strong>: <em>Chlamydia trachomatis</em> (L1, L2,
L3)</li>
<li><strong>Clinical</strong>: Painless papule ‚Üí painless
lymphadenopathy</li>
<li><strong>Treatment</strong>: Doxycycline 100mg BID √ó 21 days</li>
</ul>
<h4 id="genital-herpes">Genital Herpes</h4>
<ul>
<li><strong>Agent</strong>: HSV-1, HSV-2</li>
<li><strong>Clinical</strong>: Vesicular lesions, pain, itching</li>
<li><strong>Treatment</strong>: Acyclovir, valacyclovir,
famciclovir</li>
<li><strong>Suppression</strong>: Daily antiviral therapy</li>
</ul>
<hr />
<h2 id="chapter-24-other-infections">CHAPTER 24: OTHER INFECTIONS</h2>
<h3 id="i.-tetanus">I. TETANUS</h3>
<h4 id="epidemiological-triangle-20">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Clostridium tetani</em> (anaerobic,
spore-forming)</li>
<li><strong>Host</strong>: Unvaccinated individuals, elderly, drug
users</li>
<li><strong>Environment</strong>: Soil, dust, animal excreta</li>
</ul>
<h4 id="transmission-2">Transmission</h4>
<ul>
<li><strong>Wound contamination</strong>: Soil, rust, organic
matter</li>
<li><strong>Neonatal</strong>: Umbilical cord contamination</li>
<li><strong>Iatrogenic</strong>: Surgical procedures, injections</li>
<li><strong>Ear infections</strong>: Chronic otitis media</li>
</ul>
<h4 id="pathogenesis">Pathogenesis</h4>
<ul>
<li><strong>Toxin production</strong>: Tetanospasmin (neurotoxin)</li>
<li><strong>Mechanism</strong>: Blocks inhibitory neurotransmitters</li>
<li><strong>Result</strong>: Uncontrolled muscle contraction</li>
</ul>
<h4 id="clinical-features-17">Clinical Features</h4>
<p><strong>Local tetanus</strong>: Muscle spasms at wound site
<strong>Generalized tetanus</strong>: Most common form -
<strong>Trismus</strong> (lockjaw): Masseter muscle spasm -
<strong>Risus sardonicus</strong>: Facial muscle spasm -
<strong>Opisthotonos</strong>: Arched back - <strong>Generalized
spasms</strong>: Triggered by stimuli</p>
<p><strong>Neonatal tetanus</strong>: - <strong>Source</strong>:
Contaminated umbilical stump - <strong>Symptoms</strong>: Poor feeding,
rigidity, spasms - <strong>High mortality</strong>: 80-90% without
treatment</p>
<p><strong>Cephalic tetanus</strong>: Cranial nerve involvement
<strong>Puerperal tetanus</strong>: Postpartum, post-abortion</p>
<h4 id="diagnosis-11">Diagnosis</h4>
<ul>
<li><strong>Clinical</strong>: Muscle spasms, rigidity history</li>
<li><strong>Laboratory</strong>: Wound culture, toxin detection</li>
<li><strong>Differential</strong>: Dystonia, meningitis, seizures</li>
</ul>
<h4 id="treatment-8">Treatment</h4>
<p><strong>Immediate measures</strong>: - <strong>Human Tetanus
Immunoglobulin (HTIG)</strong>: 500 units IM - <strong>Wound
debridement</strong>: Remove necrotic tissue -
<strong>Antibiotics</strong>: Metronidazole, penicillin</p>
<p><strong>Supportive care</strong>: - <strong>Muscle
relaxants</strong>: Diazepam, baclofen - <strong>Ventilatory
support</strong>: For respiratory compromise - <strong>Autonomic
instability</strong>: Beta-blockers, clonidine</p>
<p><strong>Prevention</strong>: - <strong>Active immunization</strong>:
DTaP, Td, Tdap vaccines - <strong>Wound management</strong>: Proper
cleaning, vaccination - <strong>Passive immunization</strong>: TIG for
contaminated wounds</p>
<h3 id="ii.-viral-encephalitis">II. VIRAL ENCEPHALITIS</h3>
<h4 id="japanese-encephalitis-je">Japanese Encephalitis (JE)</h4>
<ul>
<li><strong>Agent</strong>: Flavivirus</li>
<li><strong>Vector</strong>: <em>Culex</em> mosquitoes</li>
<li><strong>Clinical</strong>: Acute onset fever, altered consciousness,
seizures</li>
<li><strong>Diagnosis</strong>: IgM ELISA, PCR</li>
<li><strong>Treatment</strong>: Supportive care, no specific
antiviral</li>
</ul>
<h4 id="herpes-simplex-encephalitis-hse">Herpes Simplex Encephalitis
(HSE)</h4>
<ul>
<li><strong>Agent</strong>: HSV-1 (adults), HSV-2 (neonates)</li>
<li><strong>Clinical</strong>: Fever, headache, altered mental status,
seizures</li>
<li><strong>Diagnosis</strong>: CSF PCR (gold standard)</li>
<li><strong>Treatment</strong>: IV acyclovir (10 mg/kg Q8H √ó 14-21
days)</li>
</ul>
<h4 id="rabies-encephalitis">Rabies Encephalitis</h4>
<ul>
<li><strong>Agent</strong>: Rabies virus</li>
<li><strong>Prodrome</strong>: Fever, headache, anxiety,
hallucinations</li>
<li><strong>Progressive</strong>: Confusion, agitation, paralysis</li>
<li><strong>Fatal</strong>: Once symptoms develop</li>
</ul>
<h4 id="enteroviral-encephalitis">Enteroviral Encephalitis</h4>
<ul>
<li><strong>Agent</strong>: Echovirus, coxsackievirus</li>
<li><strong>Seasonal</strong>: Summer-autumn</li>
<li><strong>Clinical</strong>: Fever, headache, meningeal signs</li>
<li><strong>Self-limiting</strong>: Supportive care</li>
</ul>
<h3 id="iii.-meningococcal-infections">III. MENINGOCOCCAL
INFECTIONS</h3>
<h4 id="epidemiological-triangle-21">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: <em>Neisseria meningitidis</em> (serogroups
A, B, C, W, Y)</li>
<li><strong>Host</strong>: Children &lt;5 years, adolescents</li>
<li><strong>Environment</strong>: Crowding, close contact</li>
</ul>
<h4 id="clinical-spectrum-2">Clinical Spectrum</h4>
<p><strong>Meningococcal carriage</strong>: Asymptomatic (5-25%)
<strong>Meningococcemia</strong>: - Fever, petechial rash, hypotension -
Waterhouse-Friderichsen syndrome (adrenal hemorrhage) - Purpura
fulminans</p>
<p><strong>Meningococcal meningitis</strong>: - Fever, headache, neck
stiffness - Altered consciousness - Photophobia</p>
<p><strong>Other forms</strong>: Pneumonia, arthritis,
conjunctivitis</p>
<h4 id="diagnosis-12">Diagnosis</h4>
<ul>
<li><strong>CSF analysis</strong>: Gram-negative diplococci</li>
<li><strong>Culture</strong>: Blood, CSF, nasopharyngeal</li>
<li><strong>PCR</strong>: Rapid detection</li>
<li><strong>Antigen detection</strong>: Latex agglutination</li>
</ul>
<h4 id="treatment-9">Treatment</h4>
<ul>
<li><strong>Third-generation cephalosporins</strong>: Ceftriaxone,
cefotaxime</li>
<li><strong>Penicillin G</strong>: Alternative if susceptible</li>
<li><strong>Adjunctive dexamethasone</strong>: Controversial</li>
</ul>
<h4 id="prevention-1">Prevention</h4>
<p><strong>Vaccination</strong>: - <strong>Conjugate vaccines</strong>:
MenA, MenC, MenACWY - <strong>Polysaccharide vaccines</strong>: Limited
duration - <strong>Serogroup B vaccines</strong>: Recent
introduction</p>
<p><strong>Chemoprophylaxis</strong>: - <strong>Rifampin</strong>: 600mg
BID √ó 2 days - <strong>Ciprofloxacin</strong>: 500mg single dose -
<strong>Ceftriaxone</strong>: 250mg IM single dose</p>
<h3 id="iv.-viral-hemorrhagic-fevers">IV. VIRAL HEMORRHAGIC FEVERS</h3>
<h4 id="characteristics">Characteristics</h4>
<ul>
<li><strong>Agent</strong>: Various viruses (Arenavirus, Filovirus,
Bunyavirus, Flavivirus)</li>
<li><strong>Transmission</strong>: Animal reservoirs,
person-to-person</li>
<li><strong>Clinical</strong>: Fever, hemorrhage, shock</li>
<li><strong>High mortality</strong>: 25-90% depending on virus</li>
</ul>
<h4 id="ebola-virus-disease-evd">Ebola Virus Disease (EVD)</h4>
<ul>
<li><strong>Agent</strong>: Ebolavirus</li>
<li><strong>Transmission</strong>: Direct contact with body fluids</li>
<li><strong>Clinical</strong>: Fever, hemorrhage, organ failure</li>
<li><strong>Mortality</strong>: Up to 90%</li>
<li><strong>Treatment</strong>: Supportive, experimental therapies</li>
</ul>
<h4 id="crimean-congo-hemorrhagic-fever">Crimean-Congo Hemorrhagic
Fever</h4>
<ul>
<li><strong>Agent</strong>: <em>Nairovirus</em></li>
<li><strong>Vector</strong>: <em>Hyalomma</em> ticks</li>
<li><strong>Endemic</strong>: Africa, Asia, Europe</li>
<li><strong>Mortality</strong>: 10-40%</li>
</ul>
<h4 id="management">Management</h4>
<ul>
<li><strong>Isolation</strong>: Strict barrier nursing</li>
<li><strong>Supportive care</strong>: Fluids, blood products</li>
<li><strong>Experimental treatments</strong>: Antivirals, monoclonal
antibodies</li>
<li><strong>Prevention</strong>: Vector control, personal
protection</li>
</ul>
<hr />
<h2 id="chapter-25-disasters">CHAPTER 25: DISASTERS</h2>
<h3 id="i.-natural-disasters">I. NATURAL DISASTERS</h3>
<h4 id="classification">Classification</h4>
<p><strong>Meteorological</strong>: Cyclones, hurricanes, tornadoes
<strong>Geological</strong>: Earthquakes, volcanic eruptions, tsunamis
<strong>Climatological</strong>: Floods, droughts, wildfires
<strong>Biological</strong>: Epidemics, pest outbreaks</p>
<h4 id="earthquake-response">Earthquake Response</h4>
<p><strong>Immediate (0-72 hours)</strong>: - <strong>Search and
rescue</strong>: Extricate trapped victims - <strong>Medical
triage</strong>: START protocol - <strong>Casualty management</strong>:
Trauma care, shock prevention - <strong>Logistics</strong>: Food, water,
shelter, communications</p>
<p><strong>Short-term (3-14 days)</strong>: - <strong>Epidemiological
surveillance</strong>: Disease outbreak monitoring - <strong>Water and
sanitation</strong>: Ensure safe drinking water -
<strong>Nutrition</strong>: Food security, supplementation -
<strong>Shelter</strong>: Temporary housing, protection</p>
<p><strong>Long-term (&gt;14 days)</strong>: -
<strong>Reconstruction</strong>: Infrastructure rebuilding -
<strong>Health system restoration</strong>: Primary healthcare services
- <strong>Mental health</strong>: Psychological support, counseling -
<strong>Preparedness</strong>: Community resilience building</p>
<h4 id="flood-management">Flood Management</h4>
<p><strong>Pre-flood measures</strong>: - <strong>Early warning
systems</strong>: River level monitoring - <strong>Evacuation
planning</strong>: Safe shelter identification - <strong>Community
preparedness</strong>: Emergency supplies</p>
<p><strong>During flood</strong>: - <strong>Rescue operations</strong>:
Water-based evacuation - <strong>Medical emergencies</strong>: Drowning,
trauma, hypothermia - <strong>Waterborne diseases</strong>: Cholera,
hepatitis A</p>
<p><strong>Post-flood</strong>: - <strong>Vector control</strong>:
Mosquito breeding prevention - <strong>Water purification</strong>:
Chlorination, filtration - <strong>Vector-borne diseases</strong>:
Malaria, dengue prevention</p>
<h3 id="ii.-man-made-disasters">II. MAN-MADE DISASTERS</h3>
<h4 id="industrial-accidents">Industrial Accidents</h4>
<p><strong>Chemical disasters</strong>: - <strong>Bhopal gas tragedy
(1984)</strong>: Methyl isocyanate leak - <strong>Health
effects</strong>: Respiratory, neurological, ophthalmological -
<strong>Emergency response</strong>: Evacuation, decontamination</p>
<p><strong>Radiological emergencies</strong>: - <strong>Chernobyl
(1986)</strong>, Fukushima (2011) - <strong>Health effects</strong>:
Radiation sickness, cancer - <strong>Management</strong>:
Decontamination, iodine prophylaxis</p>
<h4 id="terrorist-events">Terrorist Events</h4>
<p><strong>Biological terrorism</strong>: - <strong>Anthrax letters
(2001)</strong>: Anthrax spores - <strong>Response</strong>:
Investigation, prophylaxis, treatment</p>
<p><strong>Chemical terrorism</strong>: - <strong>Nerve agents</strong>:
Sarin, VX - <strong>Clinical</strong>: Cholinergic crisis -
<strong>Treatment</strong>: Atropine, pralidoxime</p>
<p><strong>Radiological dispersion devices (RDDs)</strong>: -
<strong>Dirty bombs</strong>: Radiation exposure -
<strong>Management</strong>: Evacuation, decontamination</p>
<h3 id="iii.-epidemics-during-disasters">III. EPIDEMICS DURING
DISASTERS</h3>
<h4 id="common-outbreaks">Common Outbreaks</h4>
<p><strong>Waterborne diseases</strong>: - <strong>Cholera</strong>:
Contaminated water - <strong>Typhoid</strong>: Poor sanitation -
<strong>Hepatitis A</strong>: Fecal-oral transmission</p>
<p><strong>Vector-borne diseases</strong>: - <strong>Malaria</strong>:
Stagnant water breeding sites - <strong>Dengue</strong>: Container
breeding in debris - <strong>Leishmaniasis</strong>: Rodent
displacement</p>
<p><strong>Respiratory infections</strong>: -
<strong>Tuberculosis</strong>: Overcrowding in shelters -
<strong>Pneumonia</strong>: Malnutrition, cold exposure -
<strong>Influenza</strong>: Close contact in camps</p>
<h4 id="prevention-strategies-2">Prevention Strategies</h4>
<p><strong>Water, sanitation, hygiene (WASH)</strong>: - <strong>Safe
water</strong>: Chlorination, filtration - <strong>Sanitation</strong>:
Improved excreta disposal - <strong>Hygiene</strong>: Hand washing
promotion</p>
<p><strong>Vector control</strong>: - <strong>Source reduction</strong>:
Remove breeding sites - <strong>Larviciding</strong>:
Chemical/biological control - <strong>Adulticiding</strong>: Space
spraying</p>
<p><strong>Surveillance systems</strong>: - <strong>Early
warning</strong>: Syndromic surveillance - <strong>Rapid
response</strong>: Outbreak investigation teams - <strong>Laboratory
support</strong>: Diagnostic capacity</p>
<h3 id="iv.-emergency-medical-response">IV. EMERGENCY MEDICAL
RESPONSE</h3>
<h4 id="triage-systems">Triage Systems</h4>
<p><strong>START Triage</strong> (Simple Triage and Rapid Treatment): -
<strong>Red (Immediate)</strong>: Life-threatening but salvageable -
<strong>Yellow (Delayed)</strong>: Serious but stable - <strong>Green
(Minor)</strong>: Walking wounded - <strong>Black (Expectant)</strong>:
Deceased or unsalvageable</p>
<p><strong>JumpSTART</strong> (Pediatric modification): -
<strong>Modified for children</strong>: Age-specific considerations -
<strong>Respiratory assessment</strong>: Apnea, respiratory rate -
<strong>Circulation</strong>: Pulse presence, capillary refill</p>
<h4 id="casualty-management">Casualty Management</h4>
<p><strong>Golden hour concept</strong>: Definitive care within 60
minutes <strong>Advanced trauma life support (ATLS)</strong>: -
<strong>Primary survey</strong>: ABCDE approach - <strong>Secondary
survey</strong>: Head-to-toe examination - <strong>Definitive
care</strong>: Specialized treatment</p>
<p><strong>Mass casualty management</strong>: - <strong>Role
definition</strong>: Incident command system - <strong>Resource
allocation</strong>: Scarce resource management -
<strong>Documentation</strong>: Medical records, tracking</p>
<h4 id="hospital-preparedness">Hospital Preparedness</h4>
<p><strong>Surge capacity</strong>: - <strong>Surge up</strong>:
Expanding existing capacity - <strong>Surge forward</strong>: Alternate
care sites - <strong>Surge down</strong>: Load shedding</p>
<p><strong>Hospital incident command system (HICS)</strong>: -
<strong>Command structure</strong>: Clear hierarchy -
<strong>Communication</strong>: Internal/external coordination -
<strong>Resource management</strong>: Essential supplies</p>
<hr />
<h2 id="chapter-26-emerging-and-re-emerging-diseases">CHAPTER 26:
EMERGING AND RE-EMERGING DISEASES</h2>
<h3 id="i.-covid-19-detailed">I. COVID-19 (DETAILED)</h3>
<h4 id="sars-cov-2-characteristics">SARS-CoV-2 Characteristics</h4>
<ul>
<li><strong>Family</strong>: Coronaviridae</li>
<li><strong>Structure</strong>: Enveloped, positive-sense RNA virus</li>
<li><strong>Spike protein</strong>: Mediates host cell entry via
ACE2</li>
<li><strong>Genomic variants</strong>: Alpha, Beta, Gamma, Delta,
Omicron</li>
</ul>
<h4 id="epidemiological-evolution">Epidemiological Evolution</h4>
<p><strong>Phase 1</strong>: Wuhan outbreak (December 2019)
<strong>Phase 2</strong>: Global spread (March 2020) <strong>Phase
3</strong>: Vaccine development (2020-2021) <strong>Phase 4</strong>:
Variant emergence (2021-2022) <strong>Phase 5</strong>: Endemic phase
(2023 onwards)</p>
<h4 id="clinical-spectrum-3">Clinical Spectrum</h4>
<p><strong>Asymptomatic infection</strong>: 40-45% cases <strong>Mild
disease</strong>: 80% of symptomatic cases - Fever, cough, fatigue,
anosmia, ageusia</p>
<p><strong>Severe disease</strong>: 15% cases - Dyspnea, hypoxia,
bilateral pneumonia - Hospitalization, oxygen support</p>
<p><strong>Critical disease</strong>: 5% cases - ARDS, septic shock,
multi-organ failure - ICU care, mechanical ventilation</p>
<p><strong>Long COVID</strong>: Post-acute sequelae - Persistent
fatigue, cognitive impairment - Multi-system involvement</p>
<h4 id="diagnosis-13">Diagnosis</h4>
<p><strong>Molecular testing</strong>: - <strong>RT-PCR</strong>: Gold
standard (nasopharyngeal swab) - <strong>Real-time PCR</strong>:
Quantitative viral load - <strong>Loop-mediated isothermal amplification
(LAMP)</strong></p>
<p><strong>Antigen detection</strong>: - <strong>Rapid antigen
tests</strong>: Point-of-care - <strong>Sensitivity</strong>: Lower than
PCR - <strong>Specificity</strong>: High for active infection</p>
<p><strong>Serology</strong>: - <strong>IgM/IgG antibodies</strong>:
Infection history - <strong>Neutralizing antibodies</strong>: Immunity
assessment - <strong>Limitations</strong>: Timing of infection
unclear</p>
<h4 id="treatment-evolution">Treatment Evolution</h4>
<p><strong>Supportive care</strong>: - <strong>Oxygen therapy</strong>:
Nasal cannula to mechanical ventilation -
<strong>Anticoagulation</strong>: VTE prophylaxis -
<strong>Corticosteroids</strong>: Dexamethasone in severe cases</p>
<p><strong>Antiviral therapies</strong>: - <strong>Remdesivir</strong>:
RNA polymerase inhibitor - <strong>Molnupiravir</strong>: Nucleoside
analog - <strong>Paxlovid</strong>: Protease inhibitor combination</p>
<p><strong>Monoclonal antibodies</strong>: - <strong>Early use</strong>:
Bamlanivimab, casirivimab/imdevimab - <strong>Effectiveness</strong>:
Waned against variants</p>
<h4 id="prevention-strategies-3">Prevention Strategies</h4>
<p><strong>Non-pharmaceutical interventions (NPIs)</strong>: -
<strong>Masks</strong>: Surgical, N95, cloth masks - <strong>Physical
distancing</strong>: 1-2 meters spacing - <strong>Hand hygiene</strong>:
Soap, sanitizer - <strong>Ventilation</strong>: Outdoor gatherings
preferred</p>
<p><strong>Vaccination</strong>: - <strong>mRNA vaccines</strong>:
Pfizer-BioNTech, Moderna - <strong>Viral vector</strong>: AstraZeneca,
Johnson &amp; Johnson - <strong>Inactivated</strong>: Sinopharm, Sinovac
- <strong>Heterologous boosting</strong>: Improved immunity</p>
<p><strong>Global response</strong>: - <strong>WHO
coordination</strong>: International Health Regulations -
<strong>COVAX</strong>: Global vaccine access initiative -
<strong>Travel restrictions</strong>: Quarantine protocols -
<strong>Digital health</strong>: Contact tracing apps</p>
<h4 id="long-term-impact">Long-term Impact</h4>
<p><strong>Healthcare systems</strong>: - <strong>Surge
capacity</strong>: ICU expansion, resource allocation -
<strong>Telemedicine</strong>: Remote healthcare delivery -
<strong>Supply chain</strong>: PPE, ventilator shortages</p>
<p><strong>Economic consequences</strong>: - <strong>GDP
impact</strong>: Global recession - <strong>Unemployment</strong>:
Service sector losses - <strong>Education disruption</strong>: Remote
learning - <strong>Mental health</strong>: Increased anxiety,
depression</p>
<h3 id="ii.-nipah-virus">II. NIPAH VIRUS</h3>
<h4 id="epidemiological-triangle-22">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: Nipah virus (Paramyxoviridae)</li>
<li><strong>Host</strong>: Fruit bats (<em>Pteropus</em> species)</li>
<li><strong>Environment</strong>: Fruit orchards, pig farms</li>
</ul>
<h4 id="transmission-3">Transmission</h4>
<ul>
<li><strong>Zoonotic</strong>: Fruit bat to human</li>
<li><strong>Intermediate</strong>: Pig to human</li>
<li><strong>Human-to-human</strong>: Respiratory secretions, close
contact</li>
<li><strong>Foodborne</strong>: Contaminated date palm sap</li>
</ul>
<h4 id="clinical-features-18">Clinical Features</h4>
<p><strong>Incubation</strong>: 4-14 days <strong>Initial
symptoms</strong>: Fever, headache, myalgia
<strong>Neurological</strong>: Encephalitis, seizures, altered
consciousness <strong>Respiratory</strong>: Cough, dyspnea (in some
cases) <strong>Mortality</strong>: 40-75% in outbreaks</p>
<h4 id="outbreaks">Outbreaks</h4>
<p><strong>Malaysia (1998-1999)</strong>: 265 cases, 105 deaths
<strong>Bangladesh (2001-ongoing)</strong>: Annual outbreaks
<strong>India (2018)</strong>: Kerala outbreak, 19 deaths</p>
<h4 id="diagnosis-management">Diagnosis &amp; Management</h4>
<ul>
<li><strong>RT-PCR</strong>: Virus detection in CSF, throat swabs</li>
<li><strong>Serology</strong>: IgM ELISA, neutralization assays</li>
<li><strong>Supportive care</strong>: No specific antiviral</li>
<li><strong>Prevention</strong>: Avoid raw date palm sap, pig farm
hygiene</li>
</ul>
<h3 id="iii.-ebola-virus-disease">III. EBOLA VIRUS DISEASE</h3>
<h4 id="epidemiological-triangle-23">Epidemiological Triangle</h4>
<ul>
<li><strong>Agent</strong>: Ebolavirus (Filoviridae)</li>
<li><strong>Host</strong>: Fruit bats (reservoir)</li>
<li><strong>Environment</strong>: Tropical rainforests</li>
</ul>
<h4 id="transmission-4">Transmission</h4>
<ul>
<li><strong>Zoonotic</strong>: Bat to human</li>
<li><strong>Human-to-human</strong>: Direct contact with body
fluids</li>
<li><strong>Nosocomial</strong>: Healthcare transmission</li>
<li><strong>Sexual transmission</strong>: Semen persistence</li>
</ul>
<h4 id="clinical-features-19">Clinical Features</h4>
<p><strong>Incubation</strong>: 2-21 days <strong>Early phase</strong>:
Fever, headache, myalgia, sore throat <strong>Late phase</strong>:
Diarrhea, vomiting, rash, hemorrhage <strong>Shock</strong>: Multi-organ
failure, death <strong>Survivors</strong>: Prolonged virus
persistence</p>
<h4 id="management-1">Management</h4>
<p><strong>Supportive care</strong>: - <strong>Fluid
resuscitation</strong>: Electrolyte replacement - <strong>Blood
products</strong>: Transfusion, plasma exchange - <strong>Pain
management</strong>: Symptomatic treatment</p>
<p><strong>Experimental therapies</strong>: - <strong>Monoclonal
antibodies</strong>: REGN-EB3, mAb114 - <strong>Antivirals</strong>:
Remdesivir, favipiravir</p>
<h4 id="prevention-2">Prevention</h4>
<p><strong>Vaccination</strong>: - <strong>rVSV-ZEBOV</strong>:
Single-dose vaccine - <strong>Ring vaccination</strong>: Contact tracing
and immunization</p>
<p><strong>Infection control</strong>: - <strong>Barrier
nursing</strong>: PPE, isolation - <strong>Safe burial</strong>: Body
handling protocols - <strong>Community engagement</strong>: Trust
building</p>
<h3 id="iv.-antimicrobial-resistance-amr">IV. ANTIMICROBIAL RESISTANCE
(AMR)</h3>
<h4 id="global-threat">Global Threat</h4>
<ul>
<li><strong>WHO priority pathogens</strong>: ESKAPE organisms</li>
<li><strong>Economic impact</strong>: $100 trillion by 2050</li>
<li><strong>Mortality projection</strong>: 10 million deaths
annually</li>
</ul>
<h4 id="mechanisms-of-resistance">Mechanisms of Resistance</h4>
<p><strong>Antibiotic degradation</strong>: Beta-lactamases
<strong>Efflux pumps</strong>: Drug expulsion from bacteria
<strong>Target modification</strong>: Altered binding sites
<strong>Reduced permeability</strong>: Membrane changes</p>
<h4 id="key-resistance-patterns">Key Resistance Patterns</h4>
<p><strong>ESBL</strong>: Extended-spectrum beta-lactamases
<strong>CRE</strong>: Carbapenem-resistant Enterobacterales
<strong>MRSA</strong>: Methicillin-resistant <em>S. aureus</em>
<strong>VRE</strong>: Vancomycin-resistant enterococci
<strong>XDR-TB</strong>: Extensively drug-resistant tuberculosis</p>
<h4 id="surveillance-systems">Surveillance Systems</h4>
<p><strong>GLASS</strong>: Global Antimicrobial Resistance Surveillance
System <strong>National programs</strong>: Country-specific surveillance
<strong>Laboratory capacity</strong>: Diagnostic capability <strong>Data
sharing</strong>: International collaboration</p>
<h4 id="prevention-strategies-4">Prevention Strategies</h4>
<p><strong>Antibiotic stewardship</strong>: - <strong>Judicious
use</strong>: Evidence-based prescribing - <strong>Diagnostic
stewardship</strong>: Appropriate testing - <strong>Infection
prevention</strong>: Hand hygiene, contact precautions -
<strong>Surveillance</strong>: Resistance monitoring</p>
<p><strong>Research &amp; Development</strong>: - <strong>New
antibiotics</strong>: Pipeline development - <strong>Rapid
diagnostics</strong>: Point-of-care testing - <strong>Alternative
therapies</strong>: Phage therapy, immunotherapy</p>
<h3 id="v.-climate-change-and-infectious-diseases">V. CLIMATE CHANGE AND
INFECTIOUS DISEASES</h3>
<h4 id="environmental-changes">Environmental Changes</h4>
<p><strong>Temperature increase</strong>: Expands vector ranges
<strong>Precipitation changes</strong>: Alters breeding habitats
<strong>Sea level rise</strong>: Coastal flooding, saltwater intrusion
<strong>Extreme weather</strong>: Droughts, floods, storms</p>
<h4 id="vector-borne-diseases">Vector-Borne Diseases</h4>
<p><strong>Malaria</strong>: - <strong>Altitude expansion</strong>:
Mosquito range extension - <strong>Seasonal patterns</strong>: Changed
transmission seasons - <strong>Drug resistance</strong>:
Temperature-related selection</p>
<p><strong>Dengue</strong>: - <strong>Urban expansion</strong>:
<em>Aedes</em> habitat proliferation - <strong>Seasonal
variation</strong>: Monsoon pattern changes - <strong>Severe
disease</strong>: Climate-related factors</p>
<p><strong>Lyme disease</strong>: - <strong>Range expansion</strong>:
Tick distribution changes - <strong>Seasonal activity</strong>: Extended
transmission season</p>
<h4 id="water-borne-diseases-2">Water-Borne Diseases</h4>
<p><strong>Cholera</strong>: - <strong>Coastal outbreaks</strong>: Warm
water, plankton - <strong>Flooding events</strong>: Contamination of
water sources</p>
<p><strong>Cryptosporidiosis</strong>: - <strong>Extreme
weather</strong>: Water treatment failures - <strong>Temperature
effects</strong>: Parasite survival</p>
<h4 id="food-borne-diseases">Food-Borne Diseases</h4>
<p><strong>Salmonellosis</strong>: - <strong>Temperature
effects</strong>: Bacterial growth - <strong>Food chain</strong>:
Agricultural impacts</p>
<p><strong>Campylobacter</strong>: - <strong>Seasonal patterns</strong>:
Summer peaks - <strong>Climate variability</strong>: Outbreak
frequency</p>
<h4 id="adaptation-strategies">Adaptation Strategies</h4>
<p><strong>Health systems</strong>: - <strong>Early warning</strong>:
Climate-based surveillance - <strong>Response capacity</strong>:
Emergency preparedness - <strong>Resilience building</strong>:
Infrastructure strengthening</p>
<p><strong>Vector control</strong>: - <strong>Integrated
approaches</strong>: Chemical, biological, environmental -
<strong>Climate adaptation</strong>: Changing control strategies -
<strong>Surveillance</strong>: Vector distribution monitoring</p>
<hr />
<h2 id="chapter-27-nosocomial-infections">CHAPTER 27: NOSOCOMIAL
INFECTIONS</h2>
<h3 id="i.-hospital-acquired-infections">I. HOSPITAL-ACQUIRED
INFECTIONS</h3>
<h4 id="definition-3">Definition</h4>
<ul>
<li><strong>Nosocomial infection</strong>: Infection acquired during
hospital stay</li>
<li><strong>Not present/ incubating</strong> at admission</li>
<li><strong>Manifests &gt;48 hours</strong> after admission</li>
<li><strong>Healthcare-associated</strong>: Related to medical care</li>
</ul>
<h4 id="classification-by-site">Classification by Site</h4>
<p><strong>Surgical site infections (SSI)</strong>: -
<strong>Superficial</strong>: Skin and subcutaneous tissue -
<strong>Deep</strong>: Fascia and muscle layers -
<strong>Organ/space</strong>: Any other part of anatomy</p>
<p><strong>Central line-associated bloodstream infections
(CLABSI)</strong>: - <strong>Catheter-related</strong>: Primary
bacteremia - <strong>Catheter tip colonization</strong>: Sepsis
source</p>
<p><strong>Ventilator-associated pneumonia (VAP)</strong>: -
<strong>Tube placement</strong>: &gt;48 hours - <strong>Pneumonia
onset</strong>: After intubation</p>
<p><strong>Catheter-associated urinary tract infections
(CAUTI)</strong>: - <strong>Indwelling catheter</strong>: Risk factor -
<strong>Symptomatic UTI</strong>: With laboratory confirmation</p>
<h4 id="risk-factors-3">Risk Factors</h4>
<p><strong>Patient-related</strong>: - Age extremes (neonates, elderly)
- Immune suppression, malnutrition - Chronic diseases (diabetes, renal
failure) - Severity of underlying illness</p>
<p><strong>Procedure-related</strong>: - Invasive procedures - Prolonged
hospitalization - Multiple antibiotics use - Intensive care unit
stay</p>
<p><strong>Healthcare worker-related</strong>: - Hand hygiene compliance
- Aseptic technique - Workload and staffing ratios - Knowledge and
training</p>
<h3 id="ii.-infection-control-measures">II. INFECTION CONTROL
MEASURES</h3>
<h4 id="standard-precautions">Standard Precautions</h4>
<p><strong>Hand hygiene</strong>: - <strong>Soap and water</strong>:
Visible soiling - <strong>Alcohol-based rub</strong>: Routine
decontamination - <strong>WHO 5 Moments</strong>: Before patient
contact, before aseptic procedure, after body fluid exposure, after
patient contact, after patient environment</p>
<p><strong>Personal protective equipment (PPE)</strong>: -
<strong>Gloves</strong>: Patient contact, body fluid exposure -
<strong>Masks</strong>: Respiratory protection, surgical procedures -
<strong>Gowns</strong>: Protect clothing, direct contact - <strong>Eye
protection</strong>: Splash risk procedures</p>
<p><strong>Respiratory hygiene/cough etiquette</strong>: -
<strong>Source control</strong>: Cover cough/sneeze - <strong>Mask
use</strong>: Symptomatic patients - <strong>Spatial
separation</strong>: Triage area placement</p>
<h4 id="transmission-based-precautions">Transmission-Based
Precautions</h4>
<p><strong>Contact Precautions</strong>: - <strong>MRSA, VRE</strong>:
Direct contact transmission - <strong>Private room</strong>: Preferred
accommodation - <strong>Dedicated equipment</strong>: Prevent
cross-contamination</p>
<p><strong>Droplet Precautions</strong>: - <strong>Influenza,
pertussis</strong>: Large particle transmission - <strong>Surgical
mask</strong>: Within 3 feet of patient - <strong>Private room</strong>:
Respiratory infections</p>
<p><strong>Airborne Precautions</strong>: - <strong>Tuberculosis,
measles</strong>: Small particle transmission - <strong>N95
respirator</strong>: Fit-tested, seal-checked - <strong>Negative
pressure room</strong>: Specialized ventilation</p>
<h3 id="iii.-sterilization-and-disinfection">III. STERILIZATION AND
DISINFECTION</h3>
<h4 id="levels-of-processing">Levels of Processing</h4>
<p><strong>Critical items</strong>: - <strong>Definition</strong>: Enter
sterile tissue/cascular system - <strong>Method</strong>: Sterilization
(steam, ethylene oxide) - <strong>Examples</strong>: Surgical
instruments, implants</p>
<p><strong>Semi-critical items</strong>: - <strong>Definition</strong>:
Contact mucous membranes - <strong>Method</strong>: High-level
disinfection - <strong>Examples</strong>: Endoscopes, respiratory
equipment</p>
<p><strong>Non-critical items</strong>: - <strong>Definition</strong>:
Contact intact skin - <strong>Method</strong>: Low-level disinfection -
<strong>Examples</strong>: Bed rails, stethoscopes</p>
<h4 id="sterilization-methods">Sterilization Methods</h4>
<p><strong>Steam sterilization</strong>: - <strong>Temperature</strong>:
121¬∞C (250¬∞F) for 15-20 minutes - <strong>Pressure</strong>: 15-20 psi -
<strong>Indicators</strong>: Biological, chemical, physical</p>
<p><strong>Ethylene oxide (ETO)</strong>: - <strong>Heat-sensitive
items</strong>: Medical devices - <strong>Aeration time</strong>:
Required for gas removal - <strong>Carcinogenic</strong>: Worker safety
concerns</p>
<p><strong>Hydrogen peroxide plasma</strong>: -
<strong>Low-temperature</strong>: No toxic residues - <strong>Compatible
items</strong>: Electronics, plastics - <strong>Effective</strong>:
Against all microorganisms</p>
<h4 id="disinfectant-selection">Disinfectant Selection</h4>
<p><strong>High-level disinfectants</strong>: -
<strong>Glutaraldehyde</strong>: Endoscope processing - <strong>Hydrogen
peroxide</strong>: Broad-spectrum activity - <strong>Peracetic
acid</strong>: Sterilization capability</p>
<p><strong>Intermediate-level disinfectants</strong>: - <strong>70%
isopropyl alcohol</strong>: Surface disinfection -
<strong>Phenolics</strong>: Environmental surfaces - <strong>Quaternary
ammonium compounds</strong>: Low-level activity</p>
<p><strong>Low-level disinfectants</strong>: - <strong>Bleach (sodium
hypochlorite)</strong>: 0.1% concentration - <strong>Alcohol</strong>:
70% concentration - <strong>Hydrogen peroxide</strong>: 3%
concentration</p>
<h3 id="iv.-antibiotic-stewardship">IV. ANTIBIOTIC STEWARDSHIP</h3>
<h4 id="principles">Principles</h4>
<p><strong>Optimal selection</strong>: Narrowest spectrum, appropriate
duration <strong>Dose optimization</strong>: PK/PD principles
<strong>De-escalation</strong>: Narrow therapy based on culture results
<strong>Duration minimization</strong>: Shortest effective course</p>
<h4 id="core-elements-cdc">Core Elements (CDC)</h4>
<p><strong>Leadership commitment</strong>: Administrative support
<strong>Accountability</strong>: Designated stewardship leader
<strong>Drug expertise</strong>: ID physician/pharmacist
<strong>Action</strong>: Intervention implementation
<strong>Tracking</strong>: Monitoring and reporting
<strong>Reporting</strong>: Feedback to prescribers
<strong>Education</strong>: Ongoing training</p>
<h4 id="interventions">Interventions</h4>
<p><strong>Prospective audit and feedback</strong>: - <strong>Real-time
review</strong>: Antimicrobial orders - <strong>Intervention</strong>:
Recommendations to prescriber - <strong>Acceptance tracking</strong>:
Compliance monitoring</p>
<p><strong>Formulary restriction</strong>: - <strong>Restricted
antibiotics</strong>: Prior approval required -
<strong>Pre-authorization</strong>: ID physician approval -
<strong>Automatic stop orders</strong>: Duration limits</p>
<p><strong>Antibiotic time-out</strong>: - <strong>48-hour
review</strong>: Therapy assessment - <strong>Culture results</strong>:
Narrowing spectrum - <strong>Duration adjustment</strong>: Shortening
therapy</p>
<h4 id="metrics">Metrics</h4>
<p><strong>Process measures</strong>: - <strong>Appropriate
prescribing</strong>: Indications, selection, duration -
<strong>De-escalation rates</strong>: Spectrum narrowing -
<strong>IV-to-PO conversion</strong>: Route optimization</p>
<p><strong>Outcome measures</strong>: - <strong>Clostridioides difficile
rates</strong>: Infection reduction - <strong>Resistance rates</strong>:
Susceptibility trends - <strong>Length of stay</strong>: Healthcare
utilization - <strong>Mortality</strong>: Patient outcomes</p>
<h3 id="v.-hospital-infection-control-committees">V. HOSPITAL INFECTION
CONTROL COMMITTEES</h3>
<h4 id="composition">Composition</h4>
<p><strong>Chairperson</strong>: Hospital administrator or CMO
<strong>Members</strong>: - Infection control professional - Infectious
disease physician - Microbiologist - Epidemiologist - Nursing
representative - Environmental services - Pharmacy representative</p>
<h4 id="responsibilities">Responsibilities</h4>
<p><strong>Policy development</strong>: - <strong>Infection control
policies</strong>: Evidence-based guidelines - <strong>Antimicrobial
stewardship</strong>: Program development - <strong>Surveillance
protocols</strong>: Data collection methods</p>
<p><strong>Surveillance activities</strong>: - <strong>HAI
monitoring</strong>: Prevalence and incidence - <strong>Outbreak
investigation</strong>: Rapid response - <strong>Risk
assessment</strong>: Targeted surveillance - <strong>Reporting</strong>:
Internal and external notification</p>
<p><strong>Education and training</strong>: - <strong>Staff
education</strong>: Infection prevention - <strong>Orientation
programs</strong>: New employee training - <strong>Competency
assessment</strong>: Skills validation - <strong>Annual
training</strong>: Continuing education</p>
<h4 id="quality-improvement">Quality Improvement</h4>
<p><strong>Performance monitoring</strong>: - <strong>Compliance
rates</strong>: Hand hygiene, isolation precautions - <strong>Process
indicators</strong>: Bundle compliance - <strong>Outcome
measures</strong>: HAI rates, resistance</p>
<p><strong>Root cause analysis</strong>: - <strong>Systems
approach</strong>: Human factors analysis - <strong>Process
improvement</strong>: Corrective action plans -
<strong>Sustainability</strong>: Long-term effectiveness</p>
<h4 id="regulatory-compliance">Regulatory Compliance</h4>
<p><strong>Accreditation standards</strong>: - <strong>Joint
Commission</strong>: Infection control standards - <strong>CMS
requirements</strong>: Medicare participation - <strong>State
regulations</strong>: Local health department</p>
<p><strong>Documentation</strong>: - <strong>Meeting minutes</strong>:
Decisions and actions - <strong>Policy updates</strong>: Revision
history - <strong>Training records</strong>: Staff competency -
<strong>Incident reports</strong>: Investigation findings</p>
<hr />
<h2 id="chapter-28-travel-medicine">CHAPTER 28: TRAVEL MEDICINE</h2>
<h3 id="i.-travel-related-diseases">I. TRAVEL-RELATED DISEASES</h3>
<h4 id="geographic-distribution">Geographic Distribution</h4>
<p><strong>Tropical diseases</strong>: - <strong>Sub-Saharan
Africa</strong>: Malaria, yellow fever, sleeping sickness -
<strong>South Asia</strong>: Malaria, dengue, chikungunya -
<strong>Southeast Asia</strong>: Malaria, dengue, JE, typhoid -
<strong>South America</strong>: Malaria, yellow fever, dengue -
<strong>Middle East</strong>: MERS, traveler‚Äôs diarrhea</p>
<p><strong>Climate zones</strong>: - <strong>Tropical
(0-23.5¬∞)</strong>: Highest disease burden - <strong>Subtropical
(23.5-35¬∞)</strong>: Seasonal transmission - <strong>Temperate
(35-66.5¬∞)</strong>: Limited endemic diseases -
<strong>Arctic/Antarctic</strong>: Cold-related injuries</p>
<h4 id="travelers-diarrhea">Traveler‚Äôs Diarrhea</h4>
<p><strong>Incidence</strong>: 20-60% of international travelers
<strong>Common pathogens</strong>: - <strong>Enterotoxigenic E. coli
(ETEC)</strong>: Most common - <strong>Shigella, Salmonella,
Campylobacter</strong> - <strong>Giardia, Cryptosporidium</strong>:
Protozoal causes - <strong>Viruses</strong>: Norovirus, rotavirus</p>
<p><strong>Clinical presentation</strong>: - <strong>Mild</strong>: 1-3
loose stools/day, cramping - <strong>Moderate</strong>: 4-5 stools/day,
fever, blood - <strong>Severe</strong>: &gt;6 stools/day,
dehydration</p>
<p><strong>Treatment</strong>: - <strong>Mild</strong>: Symptomatic,
loperamide - <strong>Moderate</strong>: Antibiotics (ciprofloxacin,
azithromycin) - <strong>Severe</strong>: Aggressive fluid replacement,
hospitalization</p>
<h4 id="vector-borne-diseases-1">Vector-Borne Diseases</h4>
<p><strong>Malaria</strong>: - <strong>Chemoprophylaxis</strong>: Based
on resistance patterns - <strong>Personal protection</strong>:
Repellents, nets, clothing - <strong>Geographic risk</strong>: WHO
malaria maps</p>
<p><strong>Yellow fever</strong>: - <strong>Endemic areas</strong>:
Tropical Africa, South America - <strong>Vaccination</strong>:
International certificate required - <strong>Complications</strong>:
Hemorrhagic fever, hepatitis</p>
<p><strong>Dengue fever</strong>: - <strong>Urban transmission</strong>:
<em>Aedes aegypti</em> - <strong>No chemoprophylaxis</strong>:
Prevention only - <strong>Clinical severity</strong>: Secondary
infection risk</p>
<h3 id="ii.-vaccination-requirements">II. VACCINATION REQUIREMENTS</h3>
<h4 id="routine-vaccinations">Routine Vaccinations</h4>
<p><strong>Adult vaccination update</strong>: - <strong>Tdap</strong>:
Tetanus, diphtheria, pertussis booster - <strong>MMR</strong>: Measles,
mumps, rubella (if non-immune) - <strong>Varicella</strong>: Chickenpox
(if no history) - <strong>Influenza</strong>: Annual vaccination -
<strong>Pneumococcal</strong>: Age &gt;65 years</p>
<p><strong>Travel-specific vaccines</strong>: - <strong>Hepatitis
A</strong>: Endemic areas - <strong>Typhoid</strong>: South Asia,
developing countries - <strong>Meningococcal</strong>: Hajj pilgrimage,
Sub-Saharan Africa</p>
<h4 id="routine-vaccinations-for-travelers">Routine Vaccinations for
Travelers</h4>
<p><strong>Hepatitis A</strong>: - <strong>Schedule</strong>: 0, 6-12
months (Havrix) - <strong>Single dose</strong>: Short-term protection (1
year) - <strong>Duration</strong>: Long-term after 2 doses</p>
<p><strong>Typhoid</strong>: - <strong>Injectable</strong>: Vi
polysaccharide vaccine (single dose) - <strong>Oral</strong>: Live
attenuated (4 doses, 2-day interval) - <strong>Duration</strong>: 2-3
years protection</p>
<p><strong>Japanese Encephalitis</strong>: -
<strong>Inactivated</strong>: 3-dose schedule (0, 7, 30 days) -
<strong>Duration</strong>: 2-3 years protection -
<strong>Indicators</strong>: Rural travel, long stay</p>
<h4 id="yellow-fever-vaccination">Yellow Fever Vaccination</h4>
<p><strong>Indications</strong>: - <strong>Endemic areas</strong>: WHO
endemic zones - <strong>Entry requirements</strong>: Some countries
require proof - <strong>High-risk activities</strong>: Rural travel,
game parks</p>
<p><strong>Certificate</strong>: - <strong>Validity</strong>: 10 days
after vaccination - <strong>International certificate</strong>: WHO
approved center - <strong>Medical exemption</strong>:
Contraindications</p>
<h4 id="covid-19-considerations">COVID-19 Considerations</h4>
<p><strong>Vaccination status</strong>: - <strong>WHO-approved
vaccines</strong>: International recognition - <strong>Booster
recommendations</strong>: Based on time since vaccination -
<strong>Entry requirements</strong>: Country-specific policies</p>
<h3 id="iii.-malaria-prophylaxis">III. MALARIA PROPHYLAXIS</h3>
<h4 id="risk-assessment">Risk Assessment</h4>
<p><strong>Geographic risk</strong>: - <strong>WHO malaria
maps</strong>: Transmission intensity - <strong>Drug
resistance</strong>: Chloroquine, mefloquine resistance -
<strong>Seasonal variation</strong>: Peak transmission periods</p>
<p><strong>Individual factors</strong>: - <strong>Age</strong>:
Pregnancy, children &lt;5 years - <strong>Medical conditions</strong>:
Immunosuppression, G6PD deficiency - <strong>Travel itinerary</strong>:
Rural vs urban, duration</p>
<h4 id="prophylactic-regimens">Prophylactic Regimens</h4>
<p><strong>Chloroquine</strong>: - <strong>Indications</strong>:
Sensitive areas (Central America, Caribbean) - <strong>Dose</strong>:
500mg weekly, 2 weeks before travel - <strong>Duration</strong>: 4 weeks
after departure</p>
<p><strong>Mefloquine</strong>: - <strong>Indications</strong>:
Resistant areas - <strong>Dose</strong>: 250mg weekly, 2 weeks before
travel - <strong>Duration</strong>: 4 weeks after departure -
<strong>Side effects</strong>: Neuropsychiatric reactions</p>
<p><strong>Doxycycline</strong>: - <strong>Indications</strong>:
Multi-drug resistant areas - <strong>Dose</strong>: 100mg daily, 1-2
days before travel - <strong>Duration</strong>: 4 weeks after departure
- <strong>Side effects</strong>: Photosensitivity, esophagitis</p>
<p><strong>Atovaquone/proguanil (Malarone)</strong>: -
<strong>Indications</strong>: Multi-drug resistant areas -
<strong>Dose</strong>: 250/100mg daily, 1-2 days before travel -
<strong>Duration</strong>: 1 week after departure -
<strong>Advantages</strong>: Short post-travel period, fewer side
effects</p>
<h4 id="special-populations">Special Populations</h4>
<p><strong>Pregnant women</strong>: - <strong>Chloroquine +
proguanil</strong>: Limited resistance - <strong>Avoid</strong>:
Mefloquine (second trimester) - <strong>Contraindicated</strong>:
Doxycycline, atovaquone/proguanil</p>
<p><strong>Children</strong>: - <strong>Weight-based dosing</strong>:
Age-appropriate formulations - <strong>Avoid</strong>: Doxycycline &lt;8
years - <strong>Malarone</strong>: &gt;11 kg body weight</p>
<p><strong>Immunosuppressed</strong>: - <strong>Expert
consultation</strong>: ID physician guidance -
<strong>Adherence</strong>: Importance of consistent use -
<strong>Return monitoring</strong>: Symptom awareness</p>
<h3 id="iv.-travelers-health-advice">IV. TRAVELER‚ÄôS HEALTH ADVICE</h3>
<h4 id="pre-travel-preparation">Pre-Travel Preparation</h4>
<p><strong>Health assessment</strong>: - <strong>Medical
evaluation</strong>: Chronic conditions, medications -
<strong>Vaccination status</strong>: Routine and travel vaccines -
<strong>Destination research</strong>: Health risks, medical facilities
- <strong>Insurance</strong>: Travel health, evacuation coverage</p>
<p><strong>Medical kit</strong>: - <strong>Prescription
medications</strong>: Adequate supply, documentation -
<strong>Over-the-counter drugs</strong>: Pain relievers, antidiarrheals
- <strong>First aid supplies</strong>: Bandages, antiseptic -
<strong>Travel-specific</strong>: Malaria prophylaxis, altitude
sickness</p>
<h4 id="during-travel">During Travel</h4>
<p><strong>Food and water safety</strong>: - <strong>Safe
foods</strong>: Cooked, peeled, peeled-by-you - <strong>Water
purification</strong>: Boiling, filtration, chemical treatment -
<strong>Street food</strong>: Avoid or ensure proper preparation -
<strong>Ice</strong>: Avoid unless made from safe water</p>
<p><strong>Personal protection</strong>: - <strong>Insect
repellents</strong>: DEET 20-30%, picaridin - <strong>Protective
clothing</strong>: Long sleeves, pants, closed shoes - <strong>Bed
nets</strong>: insecticide-treated nets -
<strong>Accommodation</strong>: Air conditioning, window screens</p>
<p><strong>Activity-specific advice</strong>: -
<strong>Swimming</strong>: Freshwater precautions (schistosomiasis) -
<strong>Animal contact</strong>: Rabies risk, petting zoos -
<strong>Altitude</strong>: Gradual ascent, acetazolamide -
<strong>Adventure activities</strong>: Travel insurance, safety
equipment</p>
<h4 id="post-travel-health">Post-Travel Health</h4>
<p><strong>Illness evaluation</strong>: - <strong>Fever</strong>:
Malaria consideration, seek immediate care - <strong>Diarrhea</strong>:
Persistent symptoms, evaluation needed - <strong>Skin
conditions</strong>: Insect bites, fungal infections -
<strong>Respiratory</strong>: Tuberculosis consideration</p>
<p><strong>Follow-up care</strong>: - <strong>Routine check-up</strong>:
4-6 weeks post-travel - <strong>Malaria monitoring</strong>: Symptoms up
to 1 year - <strong>Vaccination completion</strong>: Hepatitis A,
typhoid series - <strong>TB screening</strong>: High-risk exposure,
latent infection</p>
<h3 id="v.-international-health-regulations">V. INTERNATIONAL HEALTH
REGULATIONS</h3>
<h4 id="who-international-health-regulations-ihr-2005">WHO International
Health Regulations (IHR 2005)</h4>
<p><strong>Core capacities</strong>: - <strong>Surveillance</strong>:
Disease detection and reporting - <strong>Response</strong>: Emergency
preparedness and response - <strong>Communication</strong>: Information
sharing between countries - <strong>Health measures</strong>: Border
health controls</p>
<h4 id="reporting-requirements">Reporting Requirements</h4>
<p><strong>Notifiable diseases</strong>: - <strong>Smallpox</strong>:
Any case - <strong>Poliomyelitis</strong>: Acute flaccid paralysis -
<strong>SARS</strong>: Severe acute respiratory syndrome -
<strong>Influenza</strong>: Novel subtypes</p>
<p><strong>Public health emergency of international concern
(PHEIC)</strong>: - <strong>Declaration criteria</strong>: Serious,
unusual, unexpected - <strong>PHEIC examples</strong>: H1N1 (2009),
Ebola (2014-2016), Zika (2016), COVID-19 (2020)</p>
<h4 id="travel-documentation">Travel Documentation</h4>
<p><strong>International Certificate of Vaccination</strong>: -
<strong>Yellow fever</strong>: Only vaccine requiring certificate -
<strong>Format</strong>: Standard WHO certificate -
<strong>Validity</strong>: 10 days after vaccination - <strong>Medical
contraindication</strong>: Temporary exemption</p>
<p><strong>Health declarations</strong>: - <strong>Arrival
screening</strong>: Temperature, symptom assessment - <strong>Contact
tracing</strong>: Passenger information systems - <strong>Quarantine
measures</strong>: Isolation for exposed persons</p>
<h4 id="border-health-measures">Border Health Measures</h4>
<p><strong>Departure screening</strong>: - <strong>Exit
screening</strong>: Fever, symptoms assessment - <strong>Health
notices</strong>: Travel advisories - <strong>Vaccination
proof</strong>: Yellow fever certificate</p>
<p><strong>Arrival screening</strong>: - <strong>Entry
screening</strong>: Temperature checks, health declarations -
<strong>Risk assessment</strong>: Travel history, vaccination status -
<strong>Contact information</strong>: Passenger locator forms</p>
<hr />
<h2 id="examination-points---key-memory-aids">EXAMINATION POINTS - KEY
MEMORY AIDS</h2>
<h3 id="transmission-patterns">Transmission Patterns</h3>
<p><strong>Respiratory</strong>: Cough, sneeze, speak, sing
<strong>Fecal-oral</strong>: ‚Äú5 Fs‚Äù - Food, Fingers, Flies, Feces,
Fluids <strong>Vector-borne</strong>: Mosquito bite at dusk/dawn
<strong>Sexual</strong>: Unsafe sex, multiple partners
<strong>Bloodborne</strong>: Needles, transfusions, organ
transplants</p>
<h3 id="drug-resistance-mnemonics">Drug-Resistance Mnemonics</h3>
<p><strong>MRSA</strong>: Methicillin-Resistant <em>Staphylococcus
aureus</em> <strong>ESBL</strong>: Extended-Spectrum Beta-Lactamases
<strong>CRE</strong>: Carbapenem-Resistant Enterobacterales
<strong>XDR-TB</strong>: Extensively Drug-Resistant Tuberculosis</p>
<h3 id="national-programme-abbreviations">National Programme
Abbreviations</h3>
<p><strong>RNTCP</strong>: Revised National Tuberculosis Control
Programme <strong>NLEP</strong>: National Leprosy Elimination Programme
<strong>NACP</strong>: National AIDS Control Programme
<strong>NMCP</strong>: National Malaria Control Programme
<strong>NVBDCP</strong>: National Vector Borne Disease Control
Programme</p>
<h3 id="diagnostic-tests-1">Diagnostic Tests</h3>
<p><strong>TB</strong>: ‚ÄúZ-N stain + GeneXpert‚Äù <strong>HIV</strong>:
‚ÄúELISA + Western Blot confirmation‚Äù <strong>Malaria</strong>: ‚ÄúRDT +
microscopy‚Äù <strong>Dengue</strong>: ‚ÄúNS1 early + IgM late‚Äù
<strong>Typhoid</strong>: ‚ÄúWidal + blood culture‚Äù</p>
<h3 id="treatment-regimens">Treatment Regimens</h3>
<p><strong>TB</strong>: ‚Äú2HRZE/4HR‚Äù (2 months intensive, 4 months
continuation) <strong>Malaria</strong>: ‚ÄúACT for falciparum‚Äù
(Artemisinin Combination Therapy) <strong>Leprosy</strong>: ‚ÄúMDT for
MB/PB‚Äù (Multidrug Therapy) <strong>STIs</strong>: ‚ÄúCeftriaxone +
Azithromycin‚Äù for gonorrhea</p>
<hr />
<p><em>End of Part VI: Communicable Diseases</em></p>
<h1 id="part-vii-non-communicable-diseases-1">Part VII: Non-Communicable
Diseases</h1>
<h2
id="chapter-29-non-communicable-diseases---epidemiology-and-control">Chapter
29: Non-Communicable Diseases - Epidemiology and Control</h2>
<h3 id="section-a-overview-of-ncds">Section A: Overview of NCDs</h3>
<h4 id="global-burden-of-ncds">Global Burden of NCDs</h4>
<ul>
<li><strong>NCDs account for 71% of all deaths globally</strong> (41
million deaths annually)</li>
<li><strong>4 major NCDs</strong>: Cardiovascular diseases (17.9M),
cancer (9.3M), respiratory diseases (4.1M), diabetes (1.6M)</li>
<li><strong>80% of NCD deaths occur in low and middle-income
countries</strong></li>
<li><strong>Economic impact</strong>: USD 47 trillion by 2030 if
unchecked</li>
</ul>
<h4 id="classification-of-ncds-4x4-framework">Classification of NCDs
(4x4 Framework)</h4>
<p><strong>WHO 4x4 Framework</strong>: | 4 Major NCDs | 4 Shared Risk
Factors | |‚Äî‚Äî‚Äî‚Äî‚Äì|‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî-| | Cardiovascular diseases | Tobacco use | |
Cancer | Unhealthy diet | | Diabetes | Physical inactivity | | Chronic
respiratory diseases | Harmful use of alcohol |</p>
<p><strong>4 by 4 NCD Framework</strong>: - <strong>4 Diseases</strong>:
CVD, Cancer, Diabetes, CRD - <strong>4 Risk Factors</strong>: Tobacco,
Alcohol, Physical inactivity, Unhealthy diet - <strong>4 Time
frames</strong>: 2025-2030 - <strong>4 Global targets</strong>: 25%
reduction in premature mortality, 30% reduction in tobacco use, 10%
reduction in physical inactivity, 30% reduction in salt intake</p>
<h4 id="risk-factors-shared-modifiable-risk-factors">Risk Factors
(Shared Modifiable Risk Factors)</h4>
<p><strong>Primary Risk Factors</strong>: 1. <strong>Tobacco
Use</strong>: 1.1 billion smokers globally, 8 million tobacco-related
deaths 2. <strong>Unhealthy Diet</strong>: High salt, sugar, fat intake;
low fruit/vegetable consumption 3. <strong>Physical Inactivity</strong>:
60% of adults globally insufficiently active 4. <strong>Harmful Alcohol
Use</strong>: 3 million deaths annually</p>
<p><strong>Intermediate Risk Factors</strong>: - Raised blood pressure -
Raised blood glucose - Overweight and obesity - Dyslipidemia</p>
<h4 id="social-determinants-of-ncds">Social Determinants of NCDs</h4>
<p><strong>WHO Commission on Social Determinants</strong>: 1.
<strong>Social Gradient</strong>: Higher SES = Lower NCD risk 2.
<strong>Social Exclusion</strong>: Marginalized populations affected
more 3. <strong>Stress</strong>: Chronic stress increases NCD risk 4.
<strong>Living Conditions</strong>: Housing, water, sanitation impact
NCDs 5. <strong>Healthcare Access</strong>: Early detection and
treatment crucial</p>
<p><strong>Key Social Determinants in India</strong>: -
<strong>Poverty</strong>: 21.9% below poverty line (2011-12) -
<strong>Education</strong>: 74% literacy rate, gender gap persists -
<strong>Gender</strong>: Women face multiple vulnerabilities -
<strong>Rural-Urban</strong>: Urban areas have higher NCD prevalence -
<strong>Caste</strong>: Dalits have higher NCD mortality rates</p>
<h4 id="epidemiological-transition-in-india">Epidemiological Transition
in India</h4>
<p><strong>Stages of Transition</strong>: 1.
<strong>Pre-transition</strong>: High infectious disease burden 2.
<strong>Early transition</strong>: Falling infections, rising NCDs 3.
<strong>Late transition</strong>: Dominated by NCDs 4.
<strong>Post-transition</strong>: Controlled NCDs, aging population</p>
<p><strong>Current Status in India</strong>: - <strong>Burden
shift</strong>: 62% deaths due to NCDs (2019) - <strong>Triple
burden</strong>: Malnutrition, infections, NCDs - <strong>Regional
variation</strong>: Urban 65%, rural 45% NCD deaths - <strong>Age
transition</strong>: Earlier onset in middle age</p>
<p><strong>Demographic and Epidemiological Transition</strong>: -
<strong>Population aging</strong>: 10% above 60 years by 2025 -
<strong>Urbanization</strong>: 68% urban population by 2030 -
<strong>Lifestyle changes</strong>: Westernized diet, sedentary work -
<strong>Environmental changes</strong>: Air pollution, climate
change</p>
<hr />
<h3 id="section-b-cardiovascular-diseases">Section B: Cardiovascular
Diseases</h3>
<h4 id="coronary-artery-disease-cad-epidemiology">Coronary Artery
Disease (CAD) Epidemiology</h4>
<p><strong>Global Burden</strong>: - <strong>#1 cause of death
globally</strong>: 17.9 million deaths annually - <strong>Leading cause
of death in India</strong>: 28% of all deaths - <strong>Projected to
increase</strong>: 23 million deaths by 2030</p>
<p><strong>Indian Statistics</strong>: - <strong>Prevalence</strong>:
2-8% in urban, 1-4% in rural areas - <strong>Age-standardized death
rate</strong>: 272 per 100,000 population - <strong>Urban vs
Rural</strong>: 3-5 times higher in urban areas -
<strong>Gender</strong>: Male mortality 2-3 times higher than
females</p>
<p><strong>Risk Factors for CAD</strong>: -
<strong>Non-modifiable</strong>: Age, male gender, family history,
genetic factors - <strong>Modifiable</strong>: Smoking, hypertension,
diabetes, dyslipidemia, obesity, sedentary lifestyle</p>
<h4 id="stroke-and-cerebrovascular-accidents">Stroke and Cerebrovascular
Accidents</h4>
<p><strong>Epidemiology</strong>: - <strong>Global</strong>: 6.2 million
deaths annually, 80 million survivors - <strong>India</strong>: 2nd
leading cause of death (1.3 million deaths annually) -
<strong>Prevalence</strong>: 0.5-1% in Indian population -
<strong>Age</strong>: 70% cases above 65 years, but increasing in
younger population</p>
<p><strong>Types of Stroke</strong>: 1. <strong>Ischemic
stroke</strong>: 85% of cases 2. <strong>Hemorrhagic stroke</strong>:
15% of cases 3. <strong>TIA</strong>: Transient ischemic attack, warning
sign</p>
<p><strong>Risk Factors</strong>: - <strong>Non-modifiable</strong>:
Age, sex, race, family history - <strong>Modifiable</strong>:
Hypertension (most important), diabetes, smoking, atrial fibrillation,
dyslipidemia</p>
<p><strong>BE-FAST Warning Signs</strong>: - <strong>B</strong>alance:
Sudden loss of balance - <strong>E</strong>yes: Sudden vision loss -
<strong>F</strong>ace: Facial drooping - <strong>A</strong>rms: Arm
weakness - <strong>S</strong>peech: Slurred speech -
<strong>T</strong>ime: Time to call emergency services</p>
<h4 id="hypertension-prevalence-control-jnc-8-guidelines">Hypertension
(Prevalence, Control, JNC-8 Guidelines)</h4>
<p><strong>Global Burden</strong>: - <strong>1.28 billion
adults</strong> have hypertension (2019) - <strong>46% adults
unaware</strong> of their condition - <strong>42% diagnosed and
treated</strong> - <strong>21% controlled</strong> to target levels</p>
<p><strong>Indian Statistics</strong>: - <strong>Prevalence</strong>:
25-30% in urban, 15-20% in rural areas - <strong>Total hypertensive
patients</strong>: 220-250 million - <strong>Awareness</strong>: 50-60%
of hypertensives aware - <strong>Treatment</strong>: 40-50% receiving
treatment - <strong>Control</strong>: Only 15-20% achieve target
control</p>
<p><strong>JNC-8 Guidelines (2014)</strong>:</p>
<p><strong>Treatment Targets</strong>: - <strong>General population
&lt;60 years</strong>: &lt;140/90 mmHg - <strong>General population ‚â•60
years</strong>: &lt;150/90 mmHg - <strong>Diabetes/CKD</strong>:
&lt;140/90 mmHg - <strong>General population ‚â•60 years with
diabetes/CKD</strong>: &lt;140/90 mmHg</p>
<p><strong>JNC-8 Algorithm</strong>: 1. <strong>Age ‚â•60 years</strong>:
Start treatment at ‚â•150/90 mmHg, goal &lt;150/90 mmHg 2. <strong>Age
&lt;60 years or any age with diabetes/CKD</strong>: Start treatment at
‚â•140/90 mmHg, goal &lt;140/90 mmHg</p>
<p><strong>Initial Drug Therapy</strong>: - <strong>General non-black
population</strong>: Thiazide, ACE inhibitor, ARB, or CCB -
<strong>General black population</strong>: Thiazide or CCB -
<strong>Diabetes</strong>: ACE inhibitor or ARB - <strong>CKD</strong>:
ACE inhibitor or ARB</p>
<h4 id="risk-assessment-tools">Risk Assessment Tools</h4>
<p><strong>Framingham Risk Score</strong>: - <strong>Purpose</strong>:
10-year cardiovascular risk prediction - <strong>Variables</strong>:
Age, sex, total cholesterol, HDL, smoking, SBP, treatment for
hypertension - <strong>Risk categories</strong>: Low (&lt;10%),
intermediate (10-20%), high (&gt;20%) - <strong>Limitations</strong>:
Developed in Caucasian population</p>
<p><strong>ASCVD Risk Calculator (Pooled Cohort Equations)</strong>: -
<strong>Variables</strong>: Age, race, sex, total cholesterol, HDL, SBP,
hypertension treatment, smoking, diabetes - <strong>Advantage</strong>:
Includes wider range of ethnic groups - <strong>Categories</strong>: Low
(&lt;7.5%), intermediate (7.5-20%), high (&gt;20%)</p>
<p><strong>Indian Risk Assessment</strong>: - <strong>Interheart
study</strong>: 9 modifiable risk factors account for 90% of risk -
<strong>Risk factors</strong>: Smoking, dyslipidemia, hypertension,
diabetes, abdominal obesity, stress, diet, physical activity,
alcohol</p>
<h4 id="prevention-strategies-5">Prevention Strategies</h4>
<p><strong>Primordial Prevention</strong>: - <strong>Target</strong>:
Prevent development of risk factors - <strong>Population
approach</strong>: Health promotion, policy changes -
<strong>Examples</strong>: Tobacco control, healthy diet promotion,
physical activity promotion</p>
<p><strong>Primary Prevention</strong>: - <strong>Target</strong>:
Individuals with risk factors but no disease - <strong>High-risk
approach</strong>: Risk assessment and intervention - <strong>Population
approach</strong>: Mass awareness, screening programs</p>
<p><strong>Secondary Prevention</strong>: - <strong>Target</strong>:
Patients with established disease - <strong>Objectives</strong>: Prevent
progression and complications - <strong>Components</strong>: Regular
follow-up, medication adherence, lifestyle modification</p>
<p><strong>Tertiary Prevention</strong>: - <strong>Target</strong>:
Patients with complications - <strong>Objectives</strong>: Prevent
disability, improve quality of life - <strong>Components</strong>:
Rehabilitation, palliative care</p>
<hr />
<h3 id="section-c-diabetes-mellitus">Section C: Diabetes Mellitus</h3>
<h4 id="type-1-and-type-2-diabetes">Type 1 and Type 2 Diabetes</h4>
<p><strong>Type 1 Diabetes</strong>: - <strong>Cause</strong>:
Autoimmune destruction of pancreatic Œ≤-cells - <strong>Age of
onset</strong>: Usually in children/young adults -
<strong>Prevalence</strong>: 5-10% of all diabetes cases -
<strong>Insulin therapy</strong>: Required for survival</p>
<p><strong>Type 2 Diabetes</strong>: - <strong>Cause</strong>: Insulin
resistance and Œ≤-cell dysfunction - <strong>Age of onset</strong>:
Usually &gt;40 years, but increasingly in younger -
<strong>Prevalence</strong>: 90-95% of all diabetes cases - <strong>Risk
factors</strong>: Obesity, family history, sedentary lifestyle,
ethnicity</p>
<h4 id="prevalence-and-trends-in-india">Prevalence and Trends in
India</h4>
<p><strong>Current Prevalence</strong>: - <strong>National Urban
Diabetes Study (2000)</strong>: 12.1% in urban areas - <strong>Rural
surveys</strong>: 2-4% prevalence - <strong>Diabetes belt</strong>:
Urban areas of Punjab, Tamil Nadu, Kerala, Goa - <strong>Total
cases</strong>: 77 million (2019), projected 134 million by 2045</p>
<p><strong>Trends</strong>: - <strong>Increasing prevalence</strong>:
From 7.1% (2009) to 10.4% (2019) - <strong>Age shift</strong>: Earlier
onset, affecting productive age groups - <strong>Urban-rural
gap</strong>: Narrowing due to urbanization - <strong>Geographic
variation</strong>: Southern states have higher prevalence</p>
<p><strong>Risk Factors in Indian Population</strong>: -
<strong>Genetic</strong>: Higher susceptibility to insulin resistance -
<strong>Anthropometric</strong>: Higher central obesity, lower BMI -
<strong>Lifestyle</strong>: Rapid transition to sedentary lifestyle -
<strong>Diet</strong>: High carbohydrate intake, low fiber</p>
<h4 id="complications">Complications</h4>
<p><strong>Microvascular Complications</strong>: 1. <strong>Diabetic
Retinopathy</strong>: - <strong>Prevalence</strong>: 18-22% in diabetics
- <strong>Types</strong>: NPDR, PDR, DME - <strong>Screening</strong>:
Annual retinal examination - <strong>Prevention</strong>: Glycemic
control, BP control</p>
<ol start="2" type="1">
<li><strong>Diabetic Nephropathy</strong>:
<ul>
<li><strong>Progression</strong>: Normo ‚Üí micro ‚Üí macroalbuminuria</li>
<li><strong>Prevalence</strong>: 20-30% of type 1, 10-20% of type 2</li>
<li><strong>Prevention</strong>: ACE inhibitors, glycemic control</li>
</ul></li>
<li><strong>Diabetic Neuropathy</strong>:
<ul>
<li><strong>Types</strong>: Sensory, motor, autonomic</li>
<li><strong>Prevalence</strong>: 30-50% of diabetics</li>
<li><strong>Screening</strong>: Annual foot examination</li>
</ul></li>
</ol>
<p><strong>Macrovascular Complications</strong>: 1. <strong>Coronary
Artery Disease</strong>: 2-4 times higher risk 2.
<strong>Stroke</strong>: 2-3 times higher risk 3. <strong>Peripheral
Artery Disease</strong>: Increased risk of amputation</p>
<h4 id="screening-and-diagnosis">Screening and Diagnosis</h4>
<p><strong>ADA Criteria (2024)</strong>:</p>
<p><strong>Diagnostic Tests</strong>: 1. <strong>HbA1c</strong>: ‚â•6.5%
(48 mmol/mol) 2. <strong>Fasting plasma glucose</strong>: ‚â•126 mg/dL
(7.0 mmol/L) 3. <strong>2-hour plasma glucose</strong>: ‚â•200 mg/dL (11.1
mmol/L) during OGTT 4. <strong>Random plasma glucose</strong>: ‚â•200
mg/dL (11.1 mmol/L) with symptoms</p>
<p><strong>WHO Criteria</strong>: - Similar to ADA but emphasizes
community screening - Additional focus on gestational diabetes
screening</p>
<p><strong>Screening Recommendations</strong>: - <strong>Universal
screening</strong>: All adults ‚â•35 years - <strong>High-risk
individuals</strong>: Earlier and more frequent screening -
<strong>Frequency</strong>: Every 3 years if normal, annually if
high-risk</p>
<p><strong>Risk Assessment Tools</strong>: - <strong>Indian Diabetes
Risk Score (IDRS)</strong>: - Parameters: Age, abdominal obesity,
physical activity, family history - Cut-off: &gt;60 = high risk, 30-60 =
moderate risk, &lt;30 = low risk</p>
<h4 id="management-and-prevention">Management and Prevention</h4>
<p><strong>Diabetes Management Targets</strong>: -
<strong>HbA1c</strong>: &lt;7% (individualized) - <strong>Blood
pressure</strong>: &lt;140/90 mmHg (some guidelines &lt;130/80 mmHg) -
<strong>LDL cholesterol</strong>: &lt;100 mg/dL (high risk &lt;70 mg/dL)
- <strong>BMI</strong>: &lt;23 kg/m¬≤ for Asians</p>
<p><strong>Prevention Strategies</strong>: 1. <strong>Primary
Prevention</strong>: - Lifestyle modification: Diet and exercise -
Metformin in pre-diabetes - Population-based interventions</p>
<ol start="2" type="1">
<li><strong>Secondary Prevention</strong>:
<ul>
<li>Early detection and treatment</li>
<li>Complication screening</li>
<li>Risk factor modification</li>
</ul></li>
<li><strong>Tertiary Prevention</strong>:
<ul>
<li>Prevent progression of complications</li>
<li>Rehabilitation services</li>
<li>Quality of life improvement</li>
</ul></li>
</ol>
<hr />
<h3 id="section-d-cancer">Section D: Cancer</h3>
<h4 id="cancer-epidemiology-in-india">Cancer Epidemiology in India</h4>
<p><strong>Global Burden</strong>: - <strong>19.3 million new
cases</strong> annually (2020) - <strong>10 million deaths</strong>
annually - <strong>Most common</strong>: Lung, breast, colorectal,
prostate, stomach</p>
<p><strong>Indian Statistics</strong>: - <strong>New cases</strong>: 1.4
million annually (2020) - <strong>Deaths</strong>: 0.85 million annually
- <strong>Common cancers in males</strong>: Lung, oral, colorectal,
stomach, esophageal - <strong>Common cancers in females</strong>:
Breast, cervical, ovarian, colorectal, lung</p>
<p><strong>Regional Variations</strong>: - <strong>Delhi</strong>:
Highest incidence rates - <strong>Northeast</strong>: High esophageal
and gall bladder cancer - <strong>South</strong>: High oral and breast
cancer - <strong>Urban vs Rural</strong>: Higher incidence in urban
areas</p>
<h4 id="common-cancers">Common Cancers</h4>
<p><strong>Oral Cancer</strong>: - <strong>Burden</strong>: 2nd most
common cancer in India - <strong>Risk factors</strong>: Tobacco chewing,
smoking, alcohol, HPV - <strong>Prevention</strong>: Tobacco control,
early detection - <strong>Screening</strong>: Visual examination of oral
cavity</p>
<p><strong>Breast Cancer</strong>: - <strong>Burden</strong>: Most
common cancer in Indian women - <strong>Incidence</strong>: 162,468 new
cases annually (2020) - <strong>Age</strong>: Median age 50-55 years -
<strong>Risk factors</strong>: Late marriage, late first child, less
breastfeeding, obesity</p>
<p><strong>Cervical Cancer</strong>: - <strong>Burden</strong>: 2nd most
common cancer in Indian women - <strong>Declining trend</strong>:
Vaccination and screening programs - <strong>Risk factors</strong>:
Early marriage, multiple pregnancies, HPV infection -
<strong>Prevention</strong>: HPV vaccination, screening with
VIA/VILI</p>
<p><strong>Lung Cancer</strong>: - <strong>Burden</strong>: Most common
cancer in Indian males - <strong>Incidence rising</strong>: Due to
tobacco smoking - <strong>Risk factors</strong>: Tobacco smoking, air
pollution, occupational exposure - <strong>Prognosis</strong>: Poor due
to late detection</p>
<h4 id="risk-factors-and-prevention">Risk Factors and Prevention</h4>
<p><strong>Tobacco-Related Cancers</strong>: - <strong>Risk
factors</strong>: Tobacco smoking, smokeless tobacco, passive smoking -
<strong>Prevention</strong>: Tobacco control policies, taxation,
advertising ban</p>
<p><strong>Infectious Agent-Related Cancers</strong>: -
<strong>HPV</strong>: Cervical, anal, oropharyngeal cancers -
<strong>Hepatitis B &amp; C</strong>: Hepatocellular carcinoma -
<strong>H. pylori</strong>: Gastric cancer -
<strong>Prevention</strong>: Vaccination, treatment of infections</p>
<p><strong>Lifestyle-Related Cancers</strong>: - <strong>Diet</strong>:
Processed meat, low fiber, high fat - <strong>Physical
inactivity</strong>: Breast, colorectal cancer risk -
<strong>Alcohol</strong>: Multiple cancer types -
<strong>Obesity</strong>: Multiple cancer types</p>
<p><strong>Occupational Cancers</strong>: - <strong>Asbestos</strong>:
Mesothelioma, lung cancer - <strong>Benzene</strong>: Leukemia -
<strong>Arsenic</strong>: Skin, lung, bladder cancer -
<strong>Prevention</strong>: Workplace safety, exposure limits</p>
<h4 id="cancer-registry-systems">Cancer Registry Systems</h4>
<p><strong>National Cancer Registry Programme (NCRP)</strong>: -
<strong>Started</strong>: 1981 - <strong>Network</strong>: 28
population-based cancer registries - <strong>Coverage</strong>: 10% of
population - <strong>Data collection</strong>: Population-based and
hospital-based registries</p>
<p><strong>Types of Registries</strong>: 1. <strong>Population-Based
Cancer Registries (PBCR)</strong>: - Collect data on all cancer cases in
defined population - Incidence and mortality rates - Trend analysis</p>
<ol start="2" type="1">
<li><strong>Hospital-Based Cancer Registries (HBCR)</strong>:
<ul>
<li>Collect data on cancer patients in specific hospitals</li>
<li>Treatment patterns and outcomes</li>
<li>Clinical research</li>
</ul></li>
</ol>
<p><strong>Cancer Atlas</strong>: - Maps cancer incidence across India -
Identifies high-risk areas - Guides prevention strategies</p>
<h4 id="screening-programs-ncrp-recommendations">Screening Programs
(NCRP Recommendations)</h4>
<p><strong>Screening Recommendations</strong>:</p>
<p><strong>Breast Cancer</strong>: - <strong>Method</strong>: Clinical
breast examination (CBE) - <strong>Age</strong>: 30-65 years -
<strong>Frequency</strong>: Every 3 years - <strong>Population</strong>:
All women</p>
<p><strong>Cervical Cancer</strong>: - <strong>Method</strong>: Visual
inspection with acetic acid (VIA) - <strong>Age</strong>: 30-65 years -
<strong>Frequency</strong>: Every 5 years - <strong>Population</strong>:
All women</p>
<p><strong>Oral Cancer</strong>: - <strong>Method</strong>: Visual
examination of oral cavity - <strong>Age</strong>: 30+ years -
<strong>Frequency</strong>: Every 3 years - <strong>Population</strong>:
High-risk individuals (tobacco users)</p>
<p><strong>Colorectal Cancer</strong>: - <strong>Method</strong>: Fecal
occult blood test (FOBT) - <strong>Age</strong>: 50-75 years -
<strong>Frequency</strong>: Annually - <strong>Population</strong>:
Average risk individuals</p>
<p><strong>National Cancer Screening Program</strong>: -
<strong>Launched</strong>: 2017 as part of NCD control -
<strong>Coverage</strong>: District level screening -
<strong>Focus</strong>: Common cancers in women (breast, cervical) -
<strong>Integration</strong>: With NPCDCS program</p>
<hr />
<h2 id="chapter-30-mental-health">Chapter 30: Mental Health</h2>
<h3 id="section-a-mental-health-concepts">Section A: Mental Health
Concepts</h3>
<h4 id="definition-and-who-framework">Definition and WHO Framework</h4>
<p><strong>WHO Definition (2021)</strong>: ‚ÄúMental health is a state of
well-being in which an individual realizes his or her own abilities, can
cope with the normal stresses of life, can work productively and is able
to make a contribution to his or her community.‚Äù</p>
<p><strong>WHO Framework (2013-2030)</strong>: 1. <strong>Mental health
promotion</strong>: Build positive mental health 2. <strong>Mental
disorder prevention</strong>: Prevent mental disorders 3.
<strong>Treatment and care</strong>: Evidence-based interventions 4.
<strong>Recovery</strong>: Community integration and social
inclusion</p>
<p><strong>Mental Health Continuum</strong>: - <strong>Mental
well-being</strong>: Positive mental health - <strong>Mental
distress</strong>: Stress, anxiety (temporary) - <strong>Mental
disorder</strong>: Clinical diagnosis required - <strong>Severe mental
illness</strong>: Chronic, disabling conditions</p>
<h4 id="common-mental-disorders">Common Mental Disorders</h4>
<p><strong>Depression</strong>: - <strong>Global prevalence</strong>: 5%
of adults - <strong>India</strong>: 3-5% point prevalence -
<strong>Symptoms</strong>: Depressed mood, anhedonia, sleep/appetite
changes, guilt, suicidal thoughts - <strong>Impact</strong>: 2nd leading
cause of disability</p>
<p><strong>Anxiety Disorders</strong>: - <strong>Types</strong>: GAD,
panic disorder, social anxiety, specific phobias - <strong>Global
prevalence</strong>: 3.8% of population - <strong>India</strong>: 3-4%
prevalence - <strong>Symptoms</strong>: Excessive worry, restlessness,
muscle tension, sleep disturbance</p>
<p><strong>Suicide</strong>: - <strong>Global</strong>: 703,000 deaths
annually - <strong>India</strong>: 163,000 deaths annually (2019) -
<strong>Age-standardized rate</strong>: 14.3 per 100,000 -
<strong>Gender ratio</strong>: 3:1 male to female ratio</p>
<p><strong>Substance Use Disorders</strong>: - <strong>Alcohol</strong>:
43% of males, 4% of females use alcohol regularly -
<strong>Tobacco</strong>: 267 million tobacco users (2019) -
<strong>Drugs</strong>: Growing problem, especially among youth</p>
<h4 id="stigma-and-discrimination">Stigma and Discrimination</h4>
<p><strong>Types of Stigma</strong>: 1. <strong>Public stigma</strong>:
Negative attitudes from society 2. <strong>Self-stigma</strong>:
Internalization by affected individuals 3. <strong>Institutional
stigma</strong>: Discriminatory policies and practices</p>
<p><strong>Impact of Stigma</strong>: - <strong>Delayed
help-seeking</strong>: Stigma prevents early treatment - <strong>Social
isolation</strong>: Exclusion from family and community -
<strong>Reduced adherence</strong>: Stoppage of treatment -
<strong>Employment</strong>: Discrimination in workplace</p>
<p><strong>Anti-Stigma Strategies</strong>: 1.
<strong>Education</strong>: Correct misconceptions about mental illness
2. <strong>Contact</strong>: Direct interaction with people with mental
illness 3. <strong>Protest</strong>: Challenging discriminatory
practices 4. <strong>Advocacy</strong>: Supporting policy changes</p>
<h4 id="mental-health-in-india">Mental Health in India</h4>
<p><strong>Burden of Disease</strong>: - <strong>Years of life
lost</strong>: 2,181 per 100,000 population -
<strong>Disability-adjusted life years</strong>: 2,444 per 100,000 -
<strong>Contribution to total DALYs</strong>: 13% of all DALYs -
<strong>Unipolar depression</strong>: 2nd leading cause of years lived
with disability</p>
<p><strong>Treatment Gap</strong>: - <strong>Depression</strong>: 85%
treatment gap - <strong>Anxiety disorders</strong>: 90% treatment gap -
<strong>Psychosis</strong>: 75% treatment gap -
<strong>Epilepsy</strong>: 50% treatment gap</p>
<p><strong>Barriers to Treatment</strong>: 1. <strong>Economic</strong>:
Poverty, lack of insurance 2. <strong>Geographic</strong>: Rural-urban
disparities 3. <strong>Cultural</strong>: Stigma, cultural beliefs 4.
<strong>Health system</strong>: Shortage of providers,
infrastructure</p>
<hr />
<h3 id="section-b-substance-abuse">Section B: Substance Abuse</h3>
<h4 id="alcohol-use-disorders">Alcohol Use Disorders</h4>
<p><strong>Global Burden</strong>: - <strong>3 million deaths</strong>
annually - <strong>5.1% of disease burden</strong> (DALYs) -
<strong>Harmful use</strong>: 2.3 billion people</p>
<p><strong>Indian Statistics</strong>: - <strong>Current alcohol
use</strong>: 14.6% of males, 2.9% of females - <strong>Alcohol
dependence</strong>: 2.7% of males, 0.3% of females - <strong>Per capita
consumption</strong>: 4.3 liters of pure alcohol per year -
<strong>Alcohol-attributable deaths</strong>: 3.7% of all deaths</p>
<p><strong>Alcohol Use in India</strong>: - <strong>Patterns</strong>:
Binge drinking, weekend patterns - <strong>Types</strong>: Country
liquor, IMFL, beer - <strong>Age</strong>: Lowering age of initiation -
<strong>Gender</strong>: Rapidly increasing among women</p>
<p><strong>Alcohol-Related Problems</strong>: - <strong>Health</strong>:
Liver disease, cardiovascular disease, cancer, mental disorders -
<strong>Social</strong>: Domestic violence, child abuse, road traffic
accidents - <strong>Economic</strong>: Productivity loss, healthcare
costs</p>
<h4 id="tobacco-use-and-cessation">Tobacco Use and Cessation</h4>
<p><strong>Global Tobacco Epidemic</strong>: - <strong>1.1 billion
tobacco users</strong>: 80% in low/middle-income countries -
<strong>Tobacco deaths</strong>: 8 million annually (7 million smokers,
1.2 million secondhand) - <strong>Economic burden</strong>: $1.4
trillion annually</p>
<p><strong>Indian Tobacco Use</strong>: - <strong>Overall
prevalence</strong>: 267 million (28.6% of adults) -
<strong>Smokers</strong>: 106 million (14% of adults) -
<strong>Smokeless tobacco</strong>: 200 million users (21.4% of adults)
- <strong>Dual users</strong>: Both smoking and smokeless tobacco</p>
<p><strong>Tobacco Control Measures (MPOWER)</strong>: -
<strong>M</strong>onitor tobacco use - <strong>P</strong>rotect from
secondhand smoke - <strong>O</strong>ffer help to quit -
<strong>W</strong>arn about dangers - <strong>E</strong>nforce
advertising bans - <strong>R</strong>aise taxes on tobacco</p>
<p><strong>Cessation Strategies</strong>: 1. <strong>Brief
intervention</strong>: 5A‚Äôs approach (Ask, Advise, Assess, Assist,
Arrange) 2. <strong>Pharmacotherapy</strong>: NRT, bupropion,
varenicline 3. <strong>Behavioral counseling</strong>: Individual and
group therapy 4. <strong>Community programs</strong>: Mass media
campaigns</p>
<h4 id="drug-abuse-and-addiction">Drug Abuse and Addiction</h4>
<p><strong>Global Drug Use</strong>: - <strong>275 million
people</strong> used drugs in 2020 - <strong>36 million people</strong>
with drug use disorders - <strong>Cannabis</strong>: Most used drug (200
million users) - <strong>Opioids</strong>: Most harmful, 13.5 million
users</p>
<p><strong>Drug Situation in India</strong>: -
<strong>Cannabis</strong>: 3.3 million users - <strong>Opioids</strong>:
8.5 million users (2.1% of population) - <strong>Prescription
drugs</strong>: Growing concern (tranquilizers, sedatives) -
<strong>Synthetic drugs</strong>: Emerging threat</p>
<p><strong>Risk Factors for Drug Abuse</strong>: 1.
<strong>Individual</strong>: Genetic vulnerability, mental illness,
trauma 2. <strong>Family</strong>: Family history, family conflict, poor
supervision 3. <strong>Peer</strong>: Peer pressure, drug-using peers 4.
<strong>School</strong>: Academic failure, school dropout 5.
<strong>Community</strong>: Poverty, availability, social norms</p>
<h4 id="public-health-approaches">Public Health Approaches</h4>
<p><strong>Prevention Strategies</strong>: 1. <strong>Universal
prevention</strong>: Population-wide interventions 2. <strong>Selective
prevention</strong>: Targeted high-risk groups 3. <strong>Indicated
prevention</strong>: Early intervention for at-risk individuals</p>
<p><strong>Treatment Approaches</strong>: 1.
<strong>Detoxification</strong>: Medical management of withdrawal 2.
<strong>Psychosocial interventions</strong>: Counseling, CBT, family
therapy 3. <strong>Pharmacotherapy</strong>: For opioid dependence
(methadone, buprenorphine) 4. <strong>Recovery support</strong>:
Rehabilitation, vocational training</p>
<p><strong>Policy Framework</strong>: - <strong>Drug demand
reduction</strong>: Prevention, treatment, rehabilitation - <strong>Drug
supply reduction</strong>: Law enforcement, international cooperation -
<strong>Harm reduction</strong>: Needle exchange, opioid substitution
therapy</p>
<hr />
<h3 id="section-c-mental-health-promotion">Section C: Mental Health
Promotion</h3>
<h4 id="community-mental-health-programs">Community Mental Health
Programs</h4>
<p><strong>Indian Context</strong>: - <strong>District Mental Health
Programme (DMHP)</strong>: 2017, covers 370 districts -
<strong>Community-based care</strong>: Integration with primary
healthcare - <strong>ASHA workers</strong>: Training in basic mental
health - <strong>Tele-mental health</strong>: National Tele Mental
Health Programme (2022)</p>
<p><strong>Key Components</strong>: 1. <strong>Health
promotion</strong>: Mental health literacy, stress management 2.
<strong>Prevention</strong>: Suicide prevention, early intervention 3.
<strong>Treatment</strong>: Integration with healthcare 4.
<strong>Rehabilitation</strong>: Community reintegration</p>
<p><strong>Community Mental Health Teams</strong>: -
<strong>Psychiatrist</strong>: Consultant and training -
<strong>Clinical psychologist</strong>: Assessment and therapy -
<strong>Psychiatric social worker</strong>: Family support,
rehabilitation - <strong>Psychiatric nurse</strong>: Community
follow-up, medication - <strong>Community workers</strong>: Basic
support, referral</p>
<h4 id="early-intervention-strategies">Early Intervention
Strategies</h4>
<p><strong>Early Psychosis Intervention</strong>: - <strong>Critical
period</strong>: First 2-5 years after onset -
<strong>Components</strong>: Early detection, rapid treatment, family
support - <strong>Benefits</strong>: Better outcomes, reduced
disability</p>
<p><strong>Child and Adolescent Mental Health</strong>: -
<strong>Prevention</strong>: Parent education, school programs -
<strong>Early detection</strong>: Developmental screening -
<strong>Intervention</strong>: Family therapy, school-based
interventions</p>
<p><strong>Suicide Prevention</strong>: - <strong>Risk factors</strong>:
Mental illness, substance abuse, stress - <strong>Warning
signs</strong>: Talking about death, giving away possessions, sudden
mood changes - <strong>Interventions</strong>: Crisis intervention,
follow-up care</p>
<h4 id="suicide-prevention">Suicide Prevention</h4>
<p><strong>Epidemiology in India</strong>: - <strong>Suicide
rate</strong>: 12.3 per 100,000 population (2020) - <strong>Rural
urban</strong>: Higher rates in rural areas - <strong>Age</strong>: Peak
in 20-24 years - <strong>Gender</strong>: 1.9:1 male to female ratio</p>
<p><strong>Prevention Strategies</strong>: 1. <strong>Gatekeeper
training</strong>: Train community leaders to identify warning signs 2.
<strong>Restricting access</strong>: Limiting lethal means 3.
<strong>Media guidelines</strong>: Responsible reporting of suicides 4.
<strong>Crisis intervention</strong>: Helplines, emergency services</p>
<p><strong>Mental Health First Aid (MHFA)</strong>: -
<strong>Training</strong>: Basic skills to help in mental health crisis
- <strong>Target</strong>: Teachers, police, community workers -
<strong>Components</strong>: Recognition, initial help, appropriate
referral</p>
<h4 id="mental-health-legislation">Mental Health Legislation</h4>
<p><strong>Mental Healthcare Act 2017</strong>: - <strong>Right to
healthcare</strong>: Mental healthcare as fundamental right -
<strong>Advance directives</strong>: Patients can specify treatment
preferences - <strong>Supported decision-making</strong>: Substitute
decision-making - <strong>Decriminalization</strong>: Suicide attempt no
longer criminal offense</p>
<p><strong>Key Provisions</strong>: 1. <strong>Equality</strong>:
Non-discrimination in healthcare 2. <strong>Access</strong>: Affordable,
accessible, quality care 3. <strong>Privacy</strong>: Confidentiality of
health information 4. <strong>Community care</strong>: Least restrictive
environment</p>
<p><strong>Implementation Challenges</strong>: - <strong>Resource
constraints</strong>: Shortage of facilities and staff -
<strong>Training needs</strong>: Capacity building of healthcare
providers - <strong>Awareness</strong>: Public education about rights -
<strong>Integration</strong>: Coordination between sectors</p>
<hr />
<h2 id="chapter-31-accidents-and-injuries">Chapter 31: Accidents and
Injuries</h2>
<h3 id="section-a-road-traffic-accidents">Section A: Road Traffic
Accidents</h3>
<h4 id="epidemiology-of-road-traffic-injuries">Epidemiology of Road
Traffic Injuries</h4>
<p><strong>Global Burden</strong>: - <strong>1.35 million
deaths</strong> annually (2018) - <strong>Leading cause of
death</strong>: Ages 5-29 years - <strong>20-50 million
injuries</strong>: Non-fatal injuries annually - <strong>Economic
cost</strong>: $1.8 trillion annually (1-3% of GDP)</p>
<p><strong>Indian Statistics</strong>: - <strong>Deaths</strong>:
154,000 deaths annually (2019) - <strong>Injuries</strong>: 300,000+
injured annually - <strong>Death rate</strong>: 16.6 per 100,000
population - <strong>Under-reporting</strong>: Actual deaths may be 2-3
times higher</p>
<p><strong>Key Characteristics</strong>: - <strong>Victims</strong>: 71%
are aged 18-60 years (productive age) - <strong>Gender</strong>: Males
account for 85% of deaths - <strong>Time pattern</strong>: Peak during
festival seasons - <strong>Location</strong>: 60% deaths occur on
national highways</p>
<h4 id="risk-factors-and-prevention-1">Risk Factors and Prevention</h4>
<p><strong>Human Factors</strong>: 1. <strong>Speed</strong>: Major
factor in severity of crashes 2. <strong>Alcohol</strong>: 20-30% of
road traffic deaths alcohol-related 3. <strong>Distraction</strong>:
Mobile phone use, other distractions 4. <strong>Non-use of
helmets</strong>: 60% of two-wheeler deaths 5. <strong>Non-use of
seatbelts</strong>: Increases fatality risk by 50%</p>
<p><strong>Vehicle Factors</strong>: - <strong>Roadworthiness</strong>:
Poor maintenance, defective brakes - <strong>Overloading</strong>:
Especially commercial vehicles - <strong>Unsafe vehicles</strong>: Poor
visibility, inadequate brakes - <strong>Two-wheelers</strong>: 25% of
vehicles, 45% of deaths</p>
<p><strong>Environmental Factors</strong>: - <strong>Road
conditions</strong>: Poor infrastructure, potholes -
<strong>Weather</strong>: Rain, fog affecting visibility -
<strong>Lighting</strong>: Poor street lighting - <strong>Urban
design</strong>: Lack of pedestrian facilities</p>
<h4 id="haddons-matrix-application">Haddon‚Äôs Matrix Application</h4>
<p><strong>Haddon‚Äôs Matrix</strong>: | | Human Factor | Vehicle Factor |
Environmental Factor | |‚Äî‚Äî‚Äî‚Äî|‚Äî‚Äî‚Äî‚Äî-|‚Äî‚Äî‚Äî‚Äî‚Äî|‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî| | Pre-crash |
Education, training | Vehicle safety, maintenance | Road design, signage
| | Crash | Use of restraints | Crash worthiness | Safety barriers | |
Post-crash | First aid, rescue | Fire prevention | Emergency care |</p>
<p><strong>Prevention Strategies Using Haddon‚Äôs Matrix</strong>: 1.
<strong>Pre-crash phase</strong>: Education, legislation, vehicle safety
2. <strong>Crash phase</strong>: Safety devices (airbags, seatbelts) 3.
<strong>Post-crash phase</strong>: Emergency care, rehabilitation</p>
<h4 id="road-safety-measures">Road Safety Measures</h4>
<p><strong>Engineering Measures</strong>: 1.
<strong>Infrastructure</strong>: Road design, traffic calming 2.
<strong>Vehicle safety</strong>: Crash worthiness standards 3.
<strong>Technology</strong>: ITS (Intelligent Transport Systems) 4.
<strong>Maintenance</strong>: Regular road and vehicle maintenance</p>
<p><strong>Education Measures</strong>: 1. <strong>Public
awareness</strong>: Road safety campaigns 2. <strong>Driver
training</strong>: Formal and informal education 3. <strong>School
programs</strong>: Child pedestrian education 4. <strong>Media
campaigns</strong>: Mass media interventions</p>
<p><strong>Enforcement Measures</strong>: 1. <strong>Speed
limits</strong>: 30-50 km/h in urban areas 2.
<strong>Drink-driving</strong>: Legal limit 0.03% BAC 3. <strong>Helmet
laws</strong>: Compulsory for two-wheeler riders 4. <strong>Seatbelt
laws</strong>: Front and rear seatbelt use</p>
<p><strong>Emergency Trauma Care</strong>: - <strong>Golden
hour</strong>: First 60 minutes most critical - <strong>Pre-hospital
care</strong>: Ambulance services, trained paramedics - <strong>Hospital
care</strong>: Trauma centers, specialized care -
<strong>Rehabilitation</strong>: Long-term care and rehabilitation</p>
<hr />
<h3 id="section-b-other-injuries">Section B: Other Injuries</h3>
<h4 id="occupational-injuries">Occupational Injuries</h4>
<p><strong>Global Burden</strong>: - <strong>340 million workplace
accidents</strong> annually - <strong>2.3 million work-related
deaths</strong> annually - <strong>340 million lost workdays</strong>
annually - <strong>Economic impact</strong>: 4% of global GDP</p>
<p><strong>Indian Occupational Safety</strong>: - <strong>Factories Act
1948</strong>: Basic safety standards - <strong>Construction
workers</strong>: High-risk occupation - <strong>Agricultural
injuries</strong>: Most workers affected - <strong>Informal
sector</strong>: 93% of workforce, minimal protection</p>
<p><strong>Major Occupational Risks</strong>: 1. <strong>Physical
hazards</strong>: Noise, vibration, extreme temperatures 2.
<strong>Chemical hazards</strong>: Dust, gases, chemicals 3.
<strong>Biological hazards</strong>: Bacteria, viruses, fungi 4.
<strong>Ergonomic hazards</strong>: Repetitive motion, poor posture 5.
<strong>Psychosocial hazards</strong>: Stress, workplace violence</p>
<p><strong>Prevention Strategies</strong>: 1. <strong>Engineering
controls</strong>: Eliminate hazards at source 2. <strong>Administrative
controls</strong>: Work organization, training 3. <strong>Personal
protective equipment</strong>: Last line of defense 4.
<strong>Surveillance</strong>: Health and safety monitoring</p>
<h4 id="home-injuries">Home Injuries</h4>
<p><strong>Global Burden</strong>: - <strong>4.5 million deaths</strong>
annually (all ages) - <strong>Higher in children</strong>: Falls, burns,
drowning - <strong>Higher in elderly</strong>: Falls, poisoning -
<strong>Economic impact</strong>: Significant healthcare costs</p>
<p><strong>Indian Home Safety</strong>: - <strong>Falls</strong>: Most
common injury in children and elderly - <strong>Burns</strong>: High
burden, especially in rural areas - <strong>Poisoning</strong>:
Especially children under 5 years - <strong>Cuts</strong>: Common in
kitchen-related injuries</p>
<p><strong>Risk Factors</strong>: 1. <strong>Child-related</strong>:
Exploration behavior, lack of supervision 2.
<strong>Elderly-related</strong>: Visual/hearing impairment, medication
side effects 3. <strong>Environmental</strong>: Poor lighting, slippery
surfaces 4. <strong>Socioeconomic</strong>: Overcrowding, poor
housing</p>
<p><strong>Prevention Strategies</strong>: 1. <strong>Home safety
modifications</strong>: Childproofing, fall prevention 2.
<strong>Supervision</strong>: Active supervision of children 3.
<strong>Education</strong>: Safety awareness programs 4.
<strong>Technology</strong>: Safety devices (smoke detectors, safety
gates)</p>
<h4 id="violence-and-assault">Violence and Assault</h4>
<p><strong>Global Violence Burden</strong>: - <strong>1.6 million
deaths</strong> annually from violence - <strong>Suicide</strong>:
703,000 deaths - <strong>Homicide</strong>: 475,000 deaths -
<strong>War/conflict</strong>: 310,000 deaths</p>
<p><strong>Violence Against Women</strong>: - <strong>Lifetime
prevalence</strong>: 35% of women globally - <strong>Physical
violence</strong>: Most common form - <strong>Sexual violence</strong>:
30% of women experience - <strong>Economic consequences</strong>:
Healthcare costs, lost productivity</p>
<p><strong>Violence Types</strong>: 1. <strong>Interpersonal
violence</strong>: Family, intimate partner, community 2.
<strong>Collective violence</strong>: War, terrorism, ethnic conflict 3.
<strong>Self-directed violence</strong>: Suicide, self-harm</p>
<p><strong>Risk Factors for Violence</strong>: -
<strong>Individual</strong>: Young age, male gender, substance abuse -
<strong>Relationship</strong>: Poor family relationships, domestic
conflict - <strong>Community</strong>: Poverty, social inequality -
<strong>Societal</strong>: Cultural norms, weak law enforcement</p>
<h4 id="burns-and-scalds">Burns and Scalds</h4>
<p><strong>Global Burden</strong>: - <strong>265,000 deaths</strong>
annually - <strong>95% burn deaths</strong>: Occur in low/middle-income
countries - <strong>Non-fatal burns</strong>: 11 million need medical
care - <strong>Disability</strong>: Significant long-term disability</p>
<p><strong>Indian Burn Statistics</strong>: - <strong>Rural
dominance</strong>: 90% of burns occur in rural areas -
<strong>Gender</strong>: Women and children most affected -
<strong>Seasonal variation</strong>: Higher during festivals and winter
- <strong>Most common cause</strong>: Domestic accidents</p>
<p><strong>Risk Factors</strong>: 1. <strong>Cooking-related</strong>:
Open fires, hot oil, boiling water 2. <strong>Electrical</strong>:
Faulty wiring, electrical appliances 3. <strong>Chemical</strong>:
Industrial accidents, domestic chemicals 4. <strong>Flame</strong>:
Candles, lamps, fireworks</p>
<p><strong>Prevention Measures</strong>: 1.
<strong>Engineering</strong>: Safer cooking practices, temperature
control 2. <strong>Education</strong>: Safety awareness, first aid
training 3. <strong>Legislation</strong>: Fire safety codes, electrical
standards 4. <strong>Environmental</strong>: Adequate lighting, escape
routes</p>
<h4 id="drowning">Drowning</h4>
<p><strong>Global Burden</strong>: - <strong>320,000 deaths</strong>
annually - <strong>Leading cause</strong>: Ages 1-24 years -
<strong>High burden</strong>: Southeast Asia and Western Pacific regions
- <strong>Seasonal variation</strong>: Higher during summer months</p>
<p><strong>Indian Drowning Statistics</strong>: - <strong>Children at
risk</strong>: 50% of deaths in children under 15 -
<strong>Location</strong>: Rivers, ponds, domestic water storage -
<strong>Seasonal</strong>: Higher during monsoon -
<strong>Socioeconomic</strong>: Poorer households more affected</p>
<p><strong>Risk Factors</strong>: 1. <strong>Age</strong>: Children
under 5 years highest risk 2. <strong>Gender</strong>: Males at higher
risk 3. <strong>Location</strong>: Rural areas, agricultural fields 4.
<strong>Supervision</strong>: Lack of adult supervision 5.
<strong>Alcohol</strong>: Contributes to adult drownings</p>
<p><strong>Prevention Strategies</strong>: 1.
<strong>Supervision</strong>: Active supervision of children near water
2. <strong>Barriers</strong>: Fencing around water bodies 3.
<strong>Education</strong>: Swimming lessons, water safety education 4.
<strong>Rescue</strong>: Community-based rescue programs</p>
<hr />
<h3 id="section-c-injury-prevention">Section C: Injury Prevention</h3>
<h4 id="haddon-matrix-and-prevention-strategies">Haddon Matrix and
Prevention Strategies</h4>
<p><strong>Traditional Haddon Matrix</strong>: | Phase | Human |
Agent/Vehicle | Environment | |‚Äî‚Äî-|‚Äî‚Äî-|‚Äî‚Äî‚Äî‚Äî‚Äî|‚Äî‚Äî‚Äî‚Äî-| | Pre-event |
Knowledge, attitudes, training | Equipment design, maintenance |
Physical environment design | | Event | Size, age, health | Speed,
weight, protection | Surfaces, roadside hazards | | Post-event | First
aid training, survival skills | Post-crash fuel ignition | Emergency
care access |</p>
<p><strong>Injury Prevention Hierarchy</strong>: 1. <strong>Most
effective</strong>: Eliminate the hazard 2. <strong>Substitute</strong>:
Replace with safer alternative 3. <strong>Isolate</strong>: Contain the
hazard 4. <strong>Restructure</strong>: Engineer safety features 5.
<strong>Train</strong>: Educate users 6. <strong>Regulate</strong>:
Enforce safe practices</p>
<p><strong>Examples of Haddon Matrix Application</strong>:</p>
<p><strong>Road Traffic Injuries</strong>: - <strong>Pre-event</strong>:
Speed enforcement, driver training - <strong>Event</strong>: Vehicle
crash worthiness, seatbelts - <strong>Post-event</strong>: Emergency
medical services</p>
<p><strong>Burn Injuries</strong>: - <strong>Pre-event</strong>:
Electrical safety standards, fire safety education -
<strong>Event</strong>: Automatic shutoffs, flame-resistant clothing -
<strong>Post-event</strong>: Burn care units, rehabilitation</p>
<h4 id="environmental-modifications">Environmental Modifications</h4>
<p><strong>Safer Design Principles</strong>: 1. <strong>Passive
protection</strong>: No user action required 2. <strong>Active
protection</strong>: User action required 3. <strong>Education</strong>:
Knowledge and skills development 4. <strong>Enforcement</strong>: Legal
and regulatory measures</p>
<p><strong>Examples of Environmental Modifications</strong>:</p>
<p><strong>Road Safety</strong>: - <strong>Physical
infrastructure</strong>: Median barriers, crash cushions -
<strong>Traffic calming</strong>: Speed bumps, chicanes, roundabouts -
<strong>Lighting</strong>: Adequate street lighting, reflective markings
- <strong>Signage</strong>: Clear, standardized traffic signs</p>
<p><strong>Home Safety</strong>: - <strong>Stair safety</strong>:
Handrails, anti-slip surfaces - <strong>Kitchen safety</strong>: Gas
leak detectors, automatic shutoffs - <strong>Bathroom safety</strong>:
Non-slip mats, grab rails - <strong>Electrical safety</strong>: Grounded
outlets, circuit breakers</p>
<h4 id="educational-interventions">Educational Interventions</h4>
<p><strong>Health Education Models</strong>: 1.
<strong>Cognitive</strong>: Information and knowledge 2.
<strong>Behavioral</strong>: Skills and practice 3.
<strong>Social</strong>: Norms and influences 4.
<strong>Emotional</strong>: Attitudes and beliefs</p>
<p><strong>Education Strategies</strong>: 1. <strong>Mass media
campaigns</strong>: Television, radio, print media 2. <strong>Community
education</strong>: Local meetings, demonstrations 3.
<strong>School-based programs</strong>: Age-appropriate curriculum 4.
<strong>Peer education</strong>: Social influence and modeling</p>
<p><strong>Examples of Educational Programs</strong>: - <strong>Safe
community initiatives</strong>: Community-wide safety campaigns -
<strong>Child pedestrian education</strong>: School-based programs -
<strong>Home safety education</strong>: Fire drills, first aid training
- <strong>Workplace safety training</strong>: Occupational health
programs</p>
<h4 id="legislation-and-enforcement">Legislation and Enforcement</h4>
<p><strong>Types of Legislation</strong>: 1. <strong>Product
safety</strong>: Standards for consumer products 2.
<strong>Environmental safety</strong>: Building codes, zoning laws 3.
<strong>Traffic laws</strong>: Speed limits, mandatory equipment 4.
<strong>Workplace safety</strong>: Occupational health and safety
laws</p>
<p><strong>Key Indian Legislation</strong>: 1. <strong>Motor Vehicles
Act 2019</strong>: - Stricter penalties - Hit-and-run provisions -
Insurance requirements 2. <strong>Factories Act 1948</strong>: - Health
and safety standards - Working hours regulation - Compensatory
provisions 3. <strong>Construction Workers Act 1996</strong>: - Safety
regulations - Welfare provisions</p>
<p><strong>Enforcement Strategies</strong>: 1. <strong>Regular
inspections</strong>: Systematic safety audits 2. <strong>Public
awareness</strong>: Education about legal requirements 3.
<strong>Technology</strong>: Automated enforcement (speed cameras) 4.
<strong>Integration</strong>: Coordination between agencies</p>
<h4 id="emergency-medical-services">Emergency Medical Services</h4>
<p><strong>EMS Components</strong>: 1. <strong>Access</strong>:
Emergency phone numbers (108, 102) 2. <strong>Response</strong>: Rapid
deployment of resources 3. <strong>Treatment</strong>: Pre-hospital
emergency care 4. <strong>Transport</strong>: Safe transport to
appropriate facilities 5. <strong>Hospital care</strong>: Definitive
care and stabilization</p>
<p><strong>EMS Development in India</strong>: - <strong>108 Emergency
Services</strong>: Started in 2005 - <strong>Coverage</strong>: 30
states and union territories - <strong>Response time</strong>: Target
&lt;30 minutes in urban areas - <strong>Staffing</strong>: Trained
paramedics and EMTs</p>
<p><strong>Pre-hospital Care</strong>: 1. <strong>Basic life
support</strong>: Airway, breathing, circulation 2. <strong>Trauma
care</strong>: Hemorrhage control, immobilization 3. <strong>Medical
emergencies</strong>: CPR, defibrillation 4. <strong>Poisoning</strong>:
Antidotes and supportive care</p>
<p><strong>Hospital Emergency Care</strong>: - <strong>Trauma
centers</strong>: Designated trauma care facilities - <strong>Emergency
departments</strong>: 24/7 emergency services - <strong>Specialized
care</strong>: Neurosurgery, orthopedics -
<strong>Rehabilitation</strong>: Post-acute care and recovery</p>
<p><strong>Integration of Services</strong>: 1. <strong>Call center
integration</strong>: Unified emergency numbers 2. <strong>Hospital
networks</strong>: Referral and transfer protocols 3. <strong>Disaster
preparedness</strong>: Mass casualty incident management 4.
<strong>Quality improvement</strong>: Continuous monitoring and
evaluation</p>
<hr />
<h2 id="national-programs-and-initiatives">National Programs and
Initiatives</h2>
<h3
id="npcdcs-national-programme-for-prevention-and-control-of-cancer-diabetes-cardiovascular-diseases-and-stroke">NPCDCS
(National Programme for Prevention and Control of Cancer, Diabetes,
Cardiovascular Diseases and Stroke)</h3>
<p><strong>Launched</strong>: 2010 <strong>Objectives</strong>:
Prevention, early detection, management, capacity building
<strong>Components</strong>: 1. <strong>Health promotion</strong>:
Awareness, lifestyle modification 2. <strong>Early detection</strong>:
Screening camps, opportunistic screening 3. <strong>Management</strong>:
Treatment at PHCs and CHCs 4. <strong>Capacity building</strong>:
Training of healthcare workers <strong>Coverage</strong>: All districts
in India</p>
<h3 id="nmhp-national-mental-health-programme">NMHP (National Mental
Health Programme)</h3>
<p><strong>Objectives</strong>: 1. Ensure availability and accessibility
of minimum mental healthcare 2. Improve awareness and reduce stigma 3.
Promote community participation <strong>Components</strong>: 1.
<strong>District Mental Health Programme</strong>: Community-based care
2. <strong>Manpower development</strong>: Training of professionals 3.
<strong>Relaxation</strong>: Integration with primary healthcare</p>
<h3 id="nrhm-mental-health-initiatives">NRHM Mental Health
Initiatives</h3>
<p><strong>National Rural Health Mission</strong>: -
<strong>Integration</strong>: Mental health services in PHCs -
<strong>Community participation</strong>: ASHA workers trained -
<strong>Infrastructure</strong>: Facility upgradation - <strong>Capacity
building</strong>: Training programs</p>
<h3 id="who-global-action-plans">WHO Global Action Plans</h3>
<h4 id="who-global-action-plan-for-ncds-2013-2030">WHO Global Action
Plan for NCDs (2013-2030)</h4>
<p><strong>Vision</strong>: A world free of avoidable NCD burden
<strong>Goal</strong>: Reduce premature mortality from NCDs by 25% by
2025 <strong>Global targets</strong> (9 targets, 25 indicators): 1.
<strong>Mortality</strong>: 25% reduction in premature NCD mortality 2.
<strong>Alcohol</strong>: 10% reduction in harmful use of alcohol 3.
<strong>Physical inactivity</strong>: 10% reduction in physical
inactivity 4. <strong>Salt intake</strong>: 30% reduction in salt intake
5. <strong>Tobacco</strong>: 30% reduction in tobacco use prevalence 6.
<strong>Blood pressure</strong>: 25% reduction in prevalence of raised
blood pressure 7. <strong>Diabetes/obesity</strong>: Halt rise in
diabetes and obesity 8. <strong>Drug therapy</strong>: 80% availability
of affordable basic technologies 9. <strong>Essential
medicines</strong>: Access to affordable medicines</p>
<h4 id="who-mental-health-action-plan-2013-2030">WHO Mental Health
Action Plan (2013-2030)</h4>
<p><strong>Vision</strong>: Mental health and well-being for all
<strong>Targets</strong>: 1. <strong>Effective strategies</strong>:
Service coverage for depression and anxiety 2. <strong>Suicide
reduction</strong>: Reduce global suicide rate by 10% 3.
<strong>Community-based care</strong>: 80% of countries have at least 2
functioning programs 4. <strong>Integration</strong>: Mental health in
emergency preparedness</p>
<hr />
<h2 id="memory-aids-and-clinical-case-scenarios">Memory Aids and
Clinical Case Scenarios</h2>
<h3 id="memory-aids-2">Memory Aids</h3>
<h4 id="ncd-risk-factors-abcde">NCD Risk Factors (ABCDE):</h4>
<ul>
<li><strong>A</strong>lcohol (harmful use)</li>
<li><strong>B</strong>lood pressure (raised)</li>
<li><strong>C</strong>holesterol (raised)</li>
<li><strong>D</strong>iabetes (and obesity)</li>
<li><strong>E</strong>xercise (physical inactivity)</li>
</ul>
<h4 id="tobacco-cessation-5as">Tobacco Cessation (5A‚Äôs):</h4>
<ul>
<li><strong>A</strong>sk about tobacco use</li>
<li><strong>A</strong>dvise to quit</li>
<li><strong>A</strong>ssess willingness to quit</li>
<li><strong>A</strong>ssist in quit attempt</li>
<li><strong>A</strong>rrange follow-up</li>
</ul>
<h4 id="mental-health-first-aid-algee">Mental Health First Aid
(ALGEE):</h4>
<ul>
<li><strong>A</strong>pproach, assess, assist</li>
<li><strong>L</strong>isten non-judgmentally</li>
<li><strong>G</strong>ive information and support</li>
<li><strong>E</strong>ncourage appropriate professional help</li>
<li><strong>E</strong>ncourage self-help and other support
strategies</li>
</ul>
<h4 id="injury-prevention-haddon">Injury Prevention (HADDON):</h4>
<ul>
<li><strong>H</strong>uman factor education</li>
<li><strong>A</strong>gent/vehicle safety design</li>
<li><strong>D</strong>esign safer environments</li>
<li><strong>D</strong>evise emergency response</li>
<li><strong>O</strong>ngoing evaluation</li>
<li><strong>N</strong>ever forget prevention hierarchy</li>
</ul>
<h3 id="clinical-case-scenarios-1">Clinical Case Scenarios</h3>
<h4 id="case-1-coronary-artery-disease">Case 1: Coronary Artery
Disease</h4>
<p><strong>Scenario</strong>: 55-year-old male, executive, presents with
chest pain on exertion <strong>Risk Factors Present</strong>: -
Sedentary lifestyle, stress, hypertension (undetected), smoking
(recently quit) - Family history of heart disease <strong>Prevention
Strategy</strong>: - Primary prevention with risk factor modification -
Screening for diabetes, lipids - Lifestyle counseling <strong>Discussion
Points</strong>: Primordial vs primary prevention, Framingham risk
assessment</p>
<h4 id="case-2-diabetes-management">Case 2: Diabetes Management</h4>
<p><strong>Scenario</strong>: 45-year-old female, teacher, diagnosed
with type 2 diabetes <strong>Current Status</strong>: - HbA1c 8.5%, BP
140/90 mmHg, BMI 32 kg/m¬≤ - Family history of diabetes
<strong>Management Plan</strong>: - Lifestyle modification (diet,
exercise) - Metformin initiation - BP control (target &lt;140/90 mmHg) -
Regular monitoring and complication screening <strong>Discussion
Points</strong>: ADA vs WHO criteria, IDRS scoring, microvascular
complications</p>
<h4 id="case-3-mental-health-crisis">Case 3: Mental Health Crisis</h4>
<p><strong>Scenario</strong>: 28-year-old male, recent job loss,
presenting with 2 weeks of low mood, sleep disturbance, suicidal
thoughts <strong>Assessment</strong>: - Depression with suicidal
ideation - No previous psychiatric history - Social stressors (job loss,
financial) <strong>Intervention</strong>: - Suicide risk assessment -
Brief intervention and crisis support - Referral for counseling/therapy
- Follow-up and monitoring <strong>Discussion Points</strong>: Stigma,
treatment gap, NMHP components</p>
<h4 id="case-4-road-traffic-accident">Case 4: Road Traffic Accident</h4>
<p><strong>Scenario</strong>: 22-year-old motorcyclist, helmet-less,
collision with car at 60 km/h speed <strong>Injuries</strong>: Head
injury, femur fracture, multiple contusions <strong>Prevention
Analysis</strong>: - Pre-crash: Helmet non-use, speed violation - Crash:
Speed excessive for conditions - Post-crash: EMS response, trauma care
<strong>Prevention Opportunities</strong>: - Enforcement of helmet laws
- Speed management - EMS system improvement <strong>Discussion
Points</strong>: Haddon‚Äôs matrix application, golden hour concept</p>
<h3 id="examination-tips">Examination Tips</h3>
<h4 id="high-yield-facts-1">High-Yield Facts</h4>
<ol type="1">
<li><strong>NCD burden in India</strong>: 62% of all deaths (2019)</li>
<li><strong>NPCDCS coverage</strong>: All districts in India</li>
<li><strong>NPCDCS screening</strong>: 30+ years for diabetes and
HTN</li>
<li><strong>Mental health treatment gap</strong>: 85% for depression,
90% for anxiety</li>
<li><strong>Road accident deaths</strong>: 154,000 annually (2019)</li>
<li><strong>Haddon‚Äôs matrix phases</strong>: Pre-event, event,
post-event</li>
<li><strong>Mental Health Act 2017</strong>: Right to mental healthcare
as fundamental right</li>
<li><strong>DMHP</strong>: 370 districts covered</li>
</ol>
<h4 id="common-examination-questions">Common Examination Questions</h4>
<ol type="1">
<li><strong>Risk factor modification strategies</strong> for NCDs</li>
<li><strong>WHO 4x4 NCD framework</strong> and global targets</li>
<li><strong>JNC-8 hypertension guidelines</strong> for different
populations</li>
<li><strong>ASCVD risk calculator</strong> interpretation</li>
<li><strong>Diabetes screening criteria</strong> (ADA vs WHO)</li>
<li><strong>NCRP cancer screening recommendations</strong></li>
<li><strong>Mental health promotion strategies</strong></li>
<li><strong>Haddon‚Äôs matrix application</strong> in injury
prevention</li>
<li><strong>EMS components</strong> and trauma care</li>
<li><strong>National mental health legislation</strong> (Mental
Healthcare Act 2017)</li>
</ol>
<h4 id="practical-applications">Practical Applications</h4>
<ol type="1">
<li><strong>Community screening</strong> for NCDs</li>
<li><strong>Risk assessment</strong> using validated tools</li>
<li><strong>Health promotion</strong> strategies at community level</li>
<li><strong>Program evaluation</strong> techniques</li>
<li><strong>Emergency response</strong> protocols</li>
<li><strong>Surveillance</strong> systems for NCDs and injuries</li>
<li><strong>Policy implementation</strong> challenges and solutions</li>
</ol>
<hr />
<p><em>This manual provides comprehensive coverage of Non-Communicable
Diseases, Mental Health, and Injury Prevention with specific focus on
Indian context, national programs, and examination requirements. Regular
updates with latest guidelines and statistics are recommended for
optimal revision.</em></p>
<h1 id="part-viii-management-and-health-systems-1">Part VIII: Management
and Health Systems</h1>
<h2 id="chapter-32-health-management">Chapter 32: Health Management</h2>
<h3 id="section-a-principles-of-management">Section A: Principles of
Management</h3>
<h4 id="management-functions-in-healthcare-poocd">Management Functions
in Healthcare (POOCD)</h4>
<p><strong>P</strong>lanning - Setting objectives and goals - Strategic
and operational planning - Program planning and implementation</p>
<p><strong>O</strong>rganizing - Resource allocation - Staff
organization and coordination - System structure design</p>
<p><strong>O</strong>rganizing Staffing - Human resource management -
Capacity building - Training and development</p>
<p><strong>C</strong>ontrolling - Performance monitoring - Quality
assurance - Feedback mechanisms</p>
<p><strong>D</strong>irecting/Leading - Leadership in healthcare - Team
building and motivation - Communication and coordination</p>
<h4 id="health-management-functions">Health Management Functions</h4>
<p><strong>Core Management Areas:</strong> 1. <strong>Strategic
Management</strong>: Long-term planning and policy formulation 2.
<strong>Operations Management</strong>: Day-to-day service delivery 3.
<strong>Financial Management</strong>: Budgeting, resource allocation,
and cost control 4. <strong>Human Resource Management</strong>: Staff
recruitment, training, and retention 5. <strong>Quality
Management</strong>: Service quality assurance and improvement</p>
<h4 id="decision-making-in-health-systems">Decision Making in Health
Systems</h4>
<p><strong>Types of Decisions:</strong> - <strong>Strategic
Decisions</strong>: Policy formulation, resource allocation -
<strong>Tactical Decisions</strong>: Program implementation, staff
management - <strong>Operational Decisions</strong>: Daily service
delivery, patient care</p>
<p><strong>Decision-Making Process:</strong> 1. Problem identification
2. Information gathering 3. Alternative generation 4. Evaluation and
selection 5. Implementation 6. Monitoring and evaluation</p>
<h4 id="leadership-and-teamwork">Leadership and Teamwork</h4>
<p><strong>Leadership Styles in Healthcare:</strong> -
<strong>Transformational Leadership</strong>: Inspiring and motivating
teams - <strong>Transactional Leadership</strong>: Performance-based
management - <strong>Servant Leadership</strong>: Focus on serving
patients and staff</p>
<p><strong>Team Building Principles:</strong> - Clear roles and
responsibilities - Effective communication - Shared vision and goals -
Regular feedback and evaluation</p>
<h4 id="quality-management-in-healthcare">Quality Management in
Healthcare</h4>
<p><strong>Quality Dimensions (ROADS):</strong> -
<strong>R</strong>espect: Patient dignity and preferences -
<strong>O</strong>utcomes: Clinical effectiveness -
<strong>A</strong>ccess: Timely healthcare services -
<strong>D</strong>eficiency: Safety and risk reduction -
<strong>S</strong>ervice: Patient experience</p>
<p><strong>Quality Improvement Tools:</strong> - PDCA Cycle
(Plan-Do-Check-Act) - Six Sigma - Lean Healthcare - Continuous Quality
Improvement (CQI)</p>
<h3 id="section-b-health-planning">Section B: Health Planning</h3>
<h4 id="national-health-planning-in-india">National Health Planning in
India</h4>
<p><strong>Planning Cycle:</strong> 1. Situation analysis and needs
assessment 2. Priority setting and goal formulation 3. Strategy
development and resource allocation 4. Implementation planning 5.
Monitoring and evaluation</p>
<p><strong>Planning Principles:</strong> - Comprehensiveness - Community
participation - Intersectoral coordination - Decentralization -
Evidence-based planning</p>
<h4 id="five-year-plans-and-health-sector">Five-Year Plans and Health
Sector</h4>
<p><strong>First Five-Year Plan (1951-56):</strong> - Focus on disease
control programs - Malaria Eradication Program - Tuberculosis
control</p>
<p><strong>Second Five-Year Plan (1956-61):</strong> - Expansion of
primary healthcare - Maternal and child health programs - Family
planning initiatives</p>
<p><strong>Third Five-Year Plan (1961-66):</strong> - Rural health
infrastructure - Community health workers training - Epidemic control
measures</p>
<p><strong>Recent Five-Year Plans:</strong> - Twelfth Five-Year Plan
(2012-17): Universal Health Coverage - Sustainable Development Goals
alignment</p>
<h4 id="health-policy-development">Health Policy Development</h4>
<p><strong>National Health Policy 2017:</strong> -
<strong>Goal</strong>: Achieve highest possible level of health and
well-being for all - <strong>Universal Health Coverage</strong>: Ensure
affordable and quality healthcare - <strong>Primary Healthcare</strong>:
Strengthen primary care services - <strong>Digital Health</strong>:
Promote digital health technologies</p>
<p><strong>Key Targets:</strong> - Increase health expenditure to 2.5%
of GDP - Reduce out-of-pocket expenditure to less than 25% - Achieve
doctor-population ratio of 1:1500 - Provide essential medicines and
diagnostics free</p>
<h4 id="health-needs-assessment">Health Needs Assessment</h4>
<p><strong>Methods of Needs Assessment:</strong> - <strong>Community
Diagnosis</strong>: Community-based health assessment - <strong>Rapid
Survey</strong>: Quick assessment using standard tools -
<strong>Population-based Surveys</strong>: Large-scale health surveys -
<strong>Facility-based Assessment</strong>: Healthcare facility
evaluation</p>
<p><strong>Assessment Components:</strong> - Demographic profile -
Morbidity and mortality patterns - Healthcare utilization patterns -
Health system capacity - Social determinants of health</p>
<h4 id="program-planning-and-evaluation">Program Planning and
Evaluation</h4>
<p><strong>Program Planning Steps:</strong> 1. Problem identification
and definition 2. Objectives setting (SMART) 3. Strategy development 4.
Resource mobilization 5. Implementation plan 6. Monitoring and
evaluation framework</p>
<p><strong>Evaluation Types:</strong> - <strong>Formative
Evaluation</strong>: During program implementation - <strong>Summative
Evaluation</strong>: After program completion - <strong>Process
Evaluation</strong>: Implementation quality assessment - <strong>Impact
Evaluation</strong>: Outcome assessment</p>
<h4 id="monitoring-and-supervision">Monitoring and Supervision</h4>
<p><strong>Monitoring Framework:</strong> - <strong>Input
Monitoring</strong>: Resources and activities - <strong>Process
Monitoring</strong>: Implementation quality - <strong>Output
Monitoring</strong>: Immediate results - <strong>Outcome
Monitoring</strong>: Intermediate effects - <strong>Impact
Monitoring</strong>: Long-term changes</p>
<p><strong>Supervision Types:</strong> - <strong>Supportive
Supervision</strong>: Mentoring and capacity building -
<strong>Problem-solving Supervision</strong>: Issue resolution -
<strong>Performance Monitoring</strong>: Achievement assessment</p>
<h3 id="section-c-organization-of-health-services">Section C:
Organization of Health Services</h3>
<h4 id="three-tier-health-system-in-india">Three-Tier Health System in
India</h4>
<p><strong>First Tier - Primary Level:</strong> - Sub-centers (SC):
Population 3,000-5,000 - Primary Health Centers (PHC): Population
20,000-30,000 - Community Health Centers (CHC): Population
80,000-1,20,000</p>
<p><strong>Second Tier - Secondary Level:</strong> - District Hospitals
- Sub-district Hospitals - Taluk Hospitals</p>
<p><strong>Third Tier - Tertiary Level:</strong> - Medical Colleges -
Regional Institutes - National Institutes</p>
<h4 id="primary-health-centre-phc-structure">Primary Health Centre (PHC)
Structure</h4>
<p><strong>PHC Functions:</strong> 1. <strong>Curative
Services</strong>: OPD, basic emergency care 2. <strong>Preventive
Services</strong>: Immunization, health education 3. <strong>Promotive
Services</strong>: Nutrition counseling, family welfare 4.
<strong>Referral Services</strong>: Higher level referrals</p>
<p><strong>PHC Staffing:</strong> - 1 Medical Officer - 1 Health
Assistant (Male) - 1 Health Assistant (Female)/Lady Health Visitor - 3-4
Multi-Purpose Workers - 1 Health Educator</p>
<p><strong>PHC Resources:</strong> - Minimum 4-6 beds - Basic laboratory
facilities - Essential medicines and vaccines - Basic equipment and
instruments</p>
<h4 id="community-health-centre-chc-functions">Community Health Centre
(CHC) Functions</h4>
<p><strong>CHC Services:</strong> - <strong>Specialist
Services</strong>: Medicine, Surgery, Pediatrics, OBG -
<strong>Laboratory Services</strong>: Basic and specialized tests -
<strong>Radiological Services</strong>: X-ray, ultrasound -
<strong>Emergency Services</strong>: 24x7 emergency care -
<strong>Referral Services</strong>: Advanced case referrals</p>
<p><strong>CHC Staffing:</strong> - 4 Medical Specialists - 1 Medical
Officer - 1 Staff Nurse - Para-medical staff - Administrative staff</p>
<h4 id="district-health-system">District Health System</h4>
<p><strong>District Health Office Functions:</strong> - Overall health
planning and coordination - Program implementation and monitoring -
Resource allocation and management - Quality assurance - Intersectoral
coordination</p>
<p><strong>District Health Team:</strong> - Chief Medical Officer -
District Health Officer - Program Officers - Epidemiologist - Data
Manager</p>
<h4 id="urban-health-infrastructure">Urban Health Infrastructure</h4>
<p><strong>Urban Health Challenges:</strong> - High population density -
Slum settlements - Environmental hazards - Communicable diseases -
Non-communicable diseases</p>
<p><strong>Urban Health Solutions:</strong> - Urban Health Posts -
Mobile Health Units - Telemedicine services - PPP models -
Community-based interventions</p>
<h4 id="referral-systems">Referral Systems</h4>
<p><strong>Referral Chain:</strong> 1. Sub-center ‚Üí PHC 2. PHC ‚Üí CHC 3.
CHC ‚Üí District Hospital 4. District Hospital ‚Üí Medical College</p>
<p><strong>Referral Criteria:</strong> - <strong>Emergency
cases</strong>: Critical care needs - <strong>Specialized care</strong>:
Complex medical conditions - <strong>Diagnostic needs</strong>: Advanced
investigations - <strong>Surgical interventions</strong>: Operative
procedures</p>
<p><strong>Referral Protocols:</strong> - Standard referral forms -
Communication systems - Feedback mechanisms - Emergency transport
services</p>
<h2 id="chapter-33-health-economics">Chapter 33: Health Economics</h2>
<h3 id="section-a-health-economics-principles">Section A: Health
Economics Principles</h3>
<h4 id="health-as-an-economic-commodity">Health as an Economic
Commodity</h4>
<p><strong>Characteristics of Healthcare:</strong> -
<strong>Indivisibility</strong>: Services cannot be divided -
<strong>Externality</strong>: Benefits extend beyond individual -
<strong>Uncertainty</strong>: Demand unpredictable - <strong>Information
Asymmetry</strong>: Provider-patient knowledge gap - <strong>Merit
Good</strong>: Benefits society beyond individual consumption</p>
<h4 id="demand-and-supply-in-healthcare">Demand and Supply in
Healthcare</h4>
<p><strong>Healthcare Demand Determinants:</strong> -
<strong>Price</strong>: Healthcare affordability -
<strong>Income</strong>: Purchasing power - <strong>Insurance
Coverage</strong>: Risk pooling - <strong>Education</strong>: Health
awareness - <strong>Age Structure</strong>: Demographic factors</p>
<p><strong>Healthcare Supply Factors:</strong> - <strong>Healthcare
Infrastructure</strong>: Facilities and equipment - <strong>Human
Resources</strong>: Doctors, nurses, paramedical staff -
<strong>Technology</strong>: Advanced diagnostic and treatment methods -
<strong>Financing</strong>: Healthcare funding mechanisms -
<strong>Regulation</strong>: Quality and safety standards</p>
<p><strong>Market Equilibrium Issues:</strong> - <strong>Information
Asymmetry</strong>: Provider knowledge advantage - <strong>Moral
Hazard</strong>: Insurance-induced overuse - <strong>Adverse
Selection</strong>: High-risk individuals seeking insurance -
<strong>Externalities</strong>: Public health benefits</p>
<h4 id="cost-effectiveness-analysis">Cost-Effectiveness Analysis</h4>
<p><strong>Economic Evaluation Methods:</strong> 1.
<strong>Cost-Minimization Analysis</strong>: Compare costs of equally
effective alternatives 2. <strong>Cost-Effectiveness Analysis</strong>:
Compare costs to health outcomes 3. <strong>Cost-Utility
Analysis</strong>: Include quality of life measures 4.
<strong>Cost-Benefit Analysis</strong>: Compare costs to monetary
benefits</p>
<p><strong>Key Measures:</strong> - <strong>Cost-Effectiveness
Ratio</strong>: Cost per quality-adjusted life year -
<strong>Incremental Cost-Effectiveness</strong>: Additional cost for
additional benefit - <strong>ICER Threshold</strong>: Willingness to pay
for additional health benefit</p>
<h4 id="health-financing-mechanisms">Health Financing Mechanisms</h4>
<p><strong>Financing Methods:</strong> 1. <strong>General Tax
Revenue</strong>: Government funding 2. <strong>Social Health
Insurance</strong>: Contribution-based systems 3. <strong>Private Health
Insurance</strong>: Market-based insurance 4. <strong>Out-of-Pocket
Payment</strong>: Direct payment by patients 5. <strong>Community
Financing</strong>: Local health insurance schemes</p>
<p><strong>Financing Principles:</strong> - <strong>Equity</strong>:
Fair distribution of costs - <strong>Efficiency</strong>: Optimal
resource utilization - <strong>Sustainability</strong>: Long-term
financial viability - <strong>Quality</strong>: Value for money</p>
<h4 id="healthcare-market-failures">Healthcare Market Failures</h4>
<p><strong>Types of Market Failures:</strong> 1. <strong>Public
Goods</strong>: Non-rivalrous and non-excludable services 2.
<strong>Externalities</strong>: Spillover benefits or costs 3.
<strong>Information Asymmetry</strong>: Imperfect information 4.
<strong>Monopoly Power</strong>: Provider concentration 5. <strong>Merit
Goods</strong>: Under-provision despite high value</p>
<p><strong>Government Interventions:</strong> -
<strong>Regulation</strong>: Quality and safety standards -
<strong>Subsidies</strong>: Reduced cost for essential services -
<strong>Public Provision</strong>: Government healthcare facilities -
<strong>Insurance</strong>: Risk pooling mechanisms</p>
<h3 id="section-b-health-financing">Section B: Health Financing</h3>
<h4 id="out-of-pocket-expenditure-in-india">Out-of-Pocket Expenditure in
India</h4>
<p><strong>Current Status (2020-21):</strong> - <strong>Total Health
Expenditure</strong>: 3.16% of GDP - <strong>Out-of-Pocket
Expenditure</strong>: 50.6% of total health expenditure -
<strong>Government Health Expenditure</strong>: 1.35% of GDP -
<strong>Private Health Expenditure</strong>: 1.81% of GDP</p>
<p><strong>Impact of High OOP:</strong> - <strong>Financial
Hardship</strong>: 55 million pushed into poverty annually -
<strong>Health Inequity</strong>: Poor unable to access care -
<strong>Health-seeking Behavior</strong>: Delayed treatment -
<strong>Catastrophic Health Expenditure</strong>: &gt;10% of total
consumption</p>
<p><strong>Strategies to Reduce OOP:</strong> - <strong>Health
Insurance</strong>: Public and private schemes - <strong>Price
Regulation</strong>: Drug pricing and service charges - <strong>Free
Healthcare</strong>: Essential services provision - <strong>Preventive
Care</strong>: Reducing need for expensive treatment</p>
<h4 id="health-insurance-models">Health Insurance Models</h4>
<p><strong>Social Health Insurance:</strong> - <strong>Employee State
Insurance (ESI)</strong>: Formal sector workers - <strong>Central
Government Health Scheme</strong>: Government employees - <strong>State
Insurance Schemes</strong>: Various state-level programs</p>
<p><strong>Private Health Insurance:</strong> - <strong>Individual
Insurance</strong>: Personal health policies - <strong>Group
Insurance</strong>: Employer-sponsored plans - <strong>Community
Insurance</strong>: Micro-insurance schemes</p>
<p><strong>Government-Funded Insurance:</strong> - <strong>Ayushman
Bharat</strong>: Largest government health insurance - <strong>Rashtriya
Swasthya Bima Yojana</strong>: Previous scheme - <strong>State
Government Schemes</strong>: Various state programs</p>
<h4 id="national-health-policy-2017-1">National Health Policy 2017</h4>
<p><strong>Financing Targets:</strong> - Increase government health
expenditure to 2.5% of GDP - Reduce out-of-pocket expenditure to &lt;25%
- Ensure availability of free essential medicines - Provide free
diagnostics at public facilities</p>
<p><strong>Implementation Strategies:</strong> - <strong>Universal
Health Coverage</strong>: Comprehensive healthcare access -
<strong>Primary Healthcare Strengthening</strong>: ASHA and health
worker network - <strong>Digital Health</strong>: Telemedicine and
health information systems - <strong>Human Resources</strong>: Increased
medical education capacity</p>
<h4 id="ayushman-bharat-scheme">Ayushman Bharat Scheme</h4>
<p><strong>Components:</strong> 1. <strong>Health and Wellness
Centers</strong>: 150,000 HWCs by 2022 2. <strong>Pradhan Mantri Jan
Arogya Yojana</strong>: ‚Çπ5 lakh insurance cover</p>
<p><strong>PM-JAY Features:</strong> - <strong>Coverage</strong>: 50
crore beneficiaries - <strong>Benefit</strong>: ‚Çπ5 lakh per family per
year - <strong>Cashless</strong>: Paperless treatment -
<strong>Portable</strong>: Nationwide coverage -
<strong>Empanelled</strong>: 25,000+ hospitals</p>
<p><strong>Impact Assessment:</strong> - <strong>Treatment</strong>: 3+
crore treatments - <strong>Financial Protection</strong>: ‚Çπ45,000 crore
saved - <strong>Hospital Network</strong>: 25,000+ empanelled hospitals
- <strong>States</strong>: 33 states and UTs covered</p>
<h4 id="universal-health-coverage-uhc">Universal Health Coverage
(UHC)</h4>
<p><strong>WHO Definition</strong>: ‚ÄúAll people have access to the full
range of quality health services they need, when and where they need
them, without financial hardship‚Äù</p>
<p><strong>UHC Components:</strong> 1. <strong>Population
Coverage</strong>: Who is covered 2. <strong>Service Coverage</strong>:
What services are covered 3. <strong>Financial Protection</strong>: Cost
coverage extent</p>
<p><strong>UHC in India:</strong> - <strong>National Health Protection
Mission</strong>: Largest UHC program globally - <strong>Primary
Healthcare</strong>: Health and Wellness Centers - <strong>Essential
Medicines</strong>: Free drug provision - <strong>Essential
Diagnostics</strong>: Free diagnostic services</p>
<h4 id="community-financing">Community Financing</h4>
<p><strong>Types of Community Financing:</strong> 1. <strong>Community
Health Insurance</strong>: Local risk pooling 2. <strong>Micro-Health
Insurance</strong>: Small-scale schemes 3. <strong>Mutual Health
Organizations</strong>: Member-based organizations 4.
<strong>Government-Supported Schemes</strong>: Community
participation</p>
<p><strong>Benefits:</strong> - <strong>Local Relevance</strong>:
Culturally appropriate services - <strong>Affordability</strong>:
Low-cost premium structures - <strong>Quality</strong>: Provider
accountability - <strong>Sustainability</strong>: Community
ownership</p>
<p><strong>Challenges:</strong> - <strong>Small Risk Pools</strong>:
Limited risk distribution - <strong>Administrative Costs</strong>: High
management expenses - <strong>Provider Selection</strong>: Limited
choices - <strong>Scale</strong>: Difficulty achieving economies of
scale</p>
<h3 id="section-c-health-technology-assessment">Section C: Health
Technology Assessment</h3>
<h4 id="hta-methodology">HTA Methodology</h4>
<p><strong>HTA Definition</strong>: ‚ÄúSystematic evaluation of
properties, effects, and/or impacts of health technology‚Äù</p>
<p><strong>HTA Process:</strong> 1. <strong>Scoping</strong>: Define
assessment boundaries 2. <strong>Evidence Collection</strong>:
Literature and data review 3. <strong>Economic Evaluation</strong>:
Cost-effectiveness analysis 4. <strong>Budget Impact Analysis</strong>:
Financial implications 5. <strong>Recommendation</strong>: Policy
guidance</p>
<p><strong>HTA Components:</strong> - <strong>Clinical
Effectiveness</strong>: Health outcomes evidence -
<strong>Cost-Effectiveness</strong>: Economic efficiency -
<strong>Safety Profile</strong>: Risk assessment - <strong>Social
Impact</strong>: Equity and accessibility - <strong>Ethical
Considerations</strong>: Value and acceptability</p>
<h4 id="economic-evaluation-methods">Economic Evaluation Methods</h4>
<p><strong>Cost-Effectiveness Analysis (CEA):</strong> -
<strong>Measure</strong>: Cost per unit of health outcome -
<strong>Units</strong>: Life years saved, cases prevented -
<strong>Application</strong>: Comparison of interventions -
<strong>Limitation</strong>: Single outcome measure</p>
<p><strong>Cost-Utility Analysis (CUA):</strong> -
<strong>Measure</strong>: Quality-Adjusted Life Years (QALYs) -
<strong>Advantage</strong>: Multi-dimensional outcomes -
<strong>Application</strong>: Broad healthcare interventions -
<strong>QALY Calculation</strong>: Length √ó Quality of life</p>
<p><strong>Cost-Benefit Analysis (CBA):</strong> -
<strong>Measure</strong>: Monetary costs and benefits -
<strong>Challenge</strong>: Monetary valuation of health -
<strong>Application</strong>: Policy decisions -
<strong>Method</strong>: Willingness to pay analysis</p>
<h4 id="budget-impact-analysis">Budget Impact Analysis</h4>
<p><strong>Purpose</strong>: ‚ÄúAssess the financial consequences of
adopting a new health technology‚Äù</p>
<p><strong>BIA Components:</strong> - <strong>Population</strong>:
Target population identification - <strong>Utilization</strong>:
Expected usage rates - <strong>Costs</strong>: Direct and indirect costs
- <strong>Time Frame</strong>: Short and long-term projections</p>
<p><strong>Budget Impact Factors:</strong> -
<strong>Prevalence</strong>: Disease burden in population -
<strong>Treatment Patterns</strong>: Current vs.¬†new technology -
<strong>Market Share</strong>: Adoption rates - <strong>Cost
Structure</strong>: Fixed vs.¬†variable costs</p>
<p><strong>Policy Applications:</strong> - <strong>Reimbursement
Decisions</strong>: Insurance coverage - <strong>Formulary
Decisions</strong>: Drug listing - <strong>Procurement
Planning</strong>: Bulk purchasing - <strong>Resource
Allocation</strong>: Budget prioritization</p>
<h4 id="priority-setting-in-healthcare">Priority Setting in
Healthcare</h4>
<p><strong>Priority Setting Methods:</strong> 1.
<strong>Cost-Effectiveness</strong>: Maximize health outcomes 2.
<strong>Equity Considerations</strong>: Fair distribution 3.
<strong>Severity Assessment</strong>: Disease burden 4.
<strong>Innovation Value</strong>: Novel technology benefits 5.
<strong>Political Feasibility</strong>: Implementation practicality</p>
<p><strong>Priority Setting Principles:</strong> -
<strong>Transparency</strong>: Clear criteria and process -
<strong>Stakeholder Participation</strong>: Inclusive decision-making -
<strong>Evidence-Based</strong>: Scientific evidence integration -
<strong>Accountability</strong>: Responsibility mechanisms -
<strong>Flexibility</strong>: Adaptive to changing needs</p>
<p><strong>India‚Äôs Health Technology Priorities:</strong> -
<strong>Essential Medicines</strong>: Cost-effective drug selection -
<strong>Diagnostics</strong>: Appropriate technology choice -
<strong>Medical Devices</strong>: Standardization and quality -
<strong>Digital Health</strong>: Telemedicine and health IT</p>
<h2 id="chapter-34-health-system-in-india">Chapter 34: Health System in
India</h2>
<h3 id="section-a-historical-perspective">Section A: Historical
Perspective</h3>
<h4 id="evolution-of-health-services-in-india">Evolution of Health
Services in India</h4>
<p><strong>Pre-Independence Era:</strong> - <strong>Traditional
Systems</strong>: Ayurveda, Unani, Siddha - <strong>British Medical
Services</strong>: Military and civil hospitals - <strong>Plague
Commission 1899</strong>: First national health survey - <strong>Bhore
Committee 1943</strong>: Comprehensive health planning</p>
<p><strong>Independence to Present:</strong> -
<strong>1947-1960s</strong>: Basic health service development -
<strong>1970s-1980s</strong>: Expanded program of immunization -
<strong>1990s</strong>: Health sector reforms - <strong>2000s</strong>:
National Health Mission - <strong>2010s</strong>: Universal Health
Coverage initiatives</p>
<h4 id="bhore-committee-recommendations-1943">Bhore Committee
Recommendations (1943)</h4>
<p><strong>Key Recommendations:</strong> 1. <strong>Integration of
Preventive and Curative Services</strong> 2. <strong>Three-Tier
Healthcare System</strong>: Primary, Secondary, Tertiary 3.
<strong>Comprehensive Healthcare</strong>: All-round development 4.
<strong>National Health Service</strong>: Government responsibility 5.
<strong>Training of Healthcare Personnel</strong>: Massive expansion
needed</p>
<p><strong>Committee Findings:</strong> - <strong>Healthcare
Crisis</strong>: Poor health indicators - <strong>Inadequate
Infrastructure</strong>: Limited facilities - <strong>Manpower
Shortage</strong>: Insufficient healthcare workers - <strong>Regional
Disparities</strong>: Urban-rural divide</p>
<p><strong>Implementation Challenges:</strong> - <strong>Financial
Constraints</strong>: Limited resources - <strong>Infrastructure
Development</strong>: Slow progress - <strong>Human Resources</strong>:
Training capacity limitations - <strong>Political Commitment</strong>:
Policy implementation gaps</p>
<h4 id="mudaliar-committee-findings-1961">Mudaliar Committee Findings
(1961)</h4>
<p><strong>Committee Focus</strong>: Assessment of progress since Bhore
Committee</p>
<p><strong>Key Findings:</strong> 1. <strong>Limited
Implementation</strong>: Slow progress on recommendations 2.
<strong>Infrastructure Gaps</strong>: Inadequate hospital beds 3.
<strong>Manpower Shortage</strong>: Critical shortage of doctors 4.
<strong>Quality Issues</strong>: Substandard healthcare services</p>
<p><strong>Recommendations:</strong> 1. <strong>Primary Health
Centers</strong>: Establishment and strengthening 2. <strong>Training
Programs</strong>: Medical education expansion 3. <strong>Infrastructure
Development</strong>: Hospital construction 4. <strong>Quality
Assurance</strong>: Standard setting and monitoring</p>
<h4 id="srivastava-committee">Srivastava Committee</h4>
<p><strong>Committee Mandate</strong>: Health Manpower Planning and
Development</p>
<p><strong>Key Recommendations:</strong> 1. <strong>Medical Education
Reforms</strong>: Curriculum and training changes 2. <strong>Specialist
Training</strong>: Post-graduate program expansion 3. <strong>Nursing
Education</strong>: Professional development 4. <strong>Community Health
Workers</strong>: Training and deployment 5. <strong>Continuing
Education</strong>: Lifelong learning programs</p>
<p><strong>Implementation Impact:</strong> - <strong>Medical College
Expansion</strong>: Increased institutions - <strong>Specialist
Services</strong>: Enhanced capacity - <strong>Nursing
Programs</strong>: Professional development - <strong>Community
Health</strong>: Rural health improvement</p>
<h4 id="health-system-development">Health System Development</h4>
<p><strong>Major Milestones:</strong> - <strong>1978</strong>: Alma Ata
Declaration adoption - <strong>1983</strong>: National Health Policy -
<strong>2005</strong>: National Rural Health Mission -
<strong>2012</strong>: National Health Mission - <strong>2017</strong>:
National Health Policy - <strong>2018</strong>: Ayushman Bharat
scheme</p>
<p><strong>System Evolution Phases:</strong> 1. <strong>Infrastructure
Building</strong>: 1950s-1970s 2. <strong>Program Expansion</strong>:
1980s-1990s 3. <strong>Quality Improvement</strong>: 2000s 4.
<strong>Universal Coverage</strong>: 2010s-present</p>
<h3 id="section-b-current-health-system-structure">Section B: Current
Health System Structure</h3>
<h4 id="ministry-of-health-and-family-welfare">Ministry of Health and
Family Welfare</h4>
<p><strong>Organizational Structure:</strong> - <strong>Department of
Health and Family Welfare</strong> - Health Policy Division - National
Health Mission Division - Disease Control Programs Division - Medical
Education and Research Division</p>
<p><strong>Key Functions:</strong> - <strong>Policy
Formulation</strong>: National health policies - <strong>Program
Implementation</strong>: National health programs - <strong>Financial
Allocation</strong>: Budget planning and disbursement -
<strong>Regulatory Functions</strong>: Standards and quality assurance -
<strong>International Cooperation</strong>: Global health
partnerships</p>
<p><strong>Recent Initiatives:</strong> - <strong>National Digital
Health Mission</strong>: Digital health ecosystem - <strong>Health Data
Management Policy</strong>: Privacy and security - <strong>National
Medical Commission</strong>: Medical education regulation</p>
<h4 id="national-health-authority">National Health Authority</h4>
<p><strong>Establishment</strong>: March 2019</p>
<p><strong>Mandate</strong>: Implement Ayushman Bharat Pradhan Mantri
Jan Arogya Yojana (AB PM-JAY)</p>
<p><strong>Key Functions:</strong> 1. <strong>Scheme
Implementation</strong>: PM-JAY operationalization 2.
<strong>Beneficiary Identification</strong>: Coverage and eligibility 3.
<strong>Provider Empanelment</strong>: Hospital network management 4.
<strong>Claims Processing</strong>: Treatment cost management 5.
<strong>Quality Assurance</strong>: Service quality monitoring</p>
<p><strong>Organizational Structure:</strong> - <strong>Board of
Directors</strong>: Governance and oversight - <strong>CEO and
Management</strong>: Operational leadership - <strong>State Health
Agencies</strong>: State-level implementation - <strong>District
Implementation Units</strong>: Local coordination</p>
<h4 id="state-health-departments">State Health Departments</h4>
<p><strong>Functions:</strong> - <strong>State Health Policy</strong>:
Policy adaptation and implementation - <strong>Program
Management</strong>: State-specific health programs -
<strong>Infrastructure Development</strong>: Healthcare facility
management - <strong>Human Resource Management</strong>: Staff
recruitment and training - <strong>Monitoring and Evaluation</strong>:
Program performance assessment</p>
<p><strong>Organizational Structure:</strong> - <strong>Directorate of
Health Services</strong>: Program oversight - <strong>Chief Medical
Officers</strong>: District health administration - <strong>Program
Officers</strong>: Specialized program management - <strong>District
Health Societies</strong>: Local implementation units</p>
<h4 id="local-health-administration">Local Health Administration</h4>
<p><strong>District Level:</strong> - <strong>Chief Medical
Officer</strong>: Overall district health administration -
<strong>District Health Officer</strong>: Program implementation -
<strong>District Hospital</strong>: Secondary care services -
<strong>PHC Network</strong>: Primary healthcare delivery</p>
<p><strong>Block Level:</strong> - <strong>Block Medical
Officer</strong>: Block health administration - <strong>CHC
Operations</strong>: Secondary care services - <strong>PHC
Supervision</strong>: Primary care oversight</p>
<p><strong>Village Level:</strong> - <strong>ASHA Workers</strong>:
Community health promotion - <strong>Anganwadi Workers</strong>:
Nutrition and child development - <strong>MPWs</strong>: Preventive and
curative services</p>
<h4 id="public-private-partnerships">Public-Private Partnerships</h4>
<p><strong>PPP Models in Healthcare:</strong> 1.
<strong>Build-Operate-Transfer (BOT)</strong>: Hospital construction and
management 2. <strong>Management Contracts</strong>: Operational
expertise 3. <strong>Service Contracts</strong>: Specific service
provision 4. <strong>Joint Ventures</strong>: Collaborative healthcare
delivery 5. <strong>Leasing Arrangements</strong>: Equipment and
facility sharing</p>
<p><strong>PPP Success Stories:</strong> - <strong>Apollo
Telemedicine</strong>: Rural healthcare access - <strong>Reliance
Foundation</strong>: Hospital network - <strong>Fortis
Healthcare</strong>: Tertiary care services - <strong>Max
Healthcare</strong>: Specialized services</p>
<p><strong>PPP Benefits:</strong> - <strong>Infrastructure
Development</strong>: Faster facility creation - <strong>Technology
Transfer</strong>: Advanced medical technology - <strong>Quality
Improvement</strong>: International standards - <strong>Capacity
Building</strong>: Training and development - <strong>Cost
Efficiency</strong>: Optimal resource utilization</p>
<p><strong>PPP Challenges:</strong> - <strong>Regulatory
Framework</strong>: Complex approval processes - <strong>Quality
Standards</strong>: Consistency maintenance - <strong>Equity
Concerns</strong>: Access for poor patients - <strong>Contract
Management</strong>: Performance monitoring - <strong>Financial
Sustainability</strong>: Long-term viability</p>
<h4 id="indian-public-health-standards-iphs">Indian Public Health
Standards (IPHS)</h4>
<p><strong>IPHS Objectives:</strong> 1. <strong>Standard
Setting</strong>: Healthcare facility standards 2. <strong>Quality
Assurance</strong>: Service quality improvement 3.
<strong>Infrastructure Development</strong>: Physical facility standards
4. <strong>Human Resource Standards</strong>: Staffing patterns 5.
<strong>Equipment Standards</strong>: Essential equipment lists</p>
<p><strong>IPHS for Different Levels:</strong></p>
<p><strong>Sub-Center Standards:</strong> -
<strong>Infrastructure</strong>: Building and facility requirements -
<strong>Staffing</strong>: 2 MPWs and 1 ANM -
<strong>Equipment</strong>: Basic medical equipment -
<strong>Laboratory</strong>: Essential diagnostic tests</p>
<p><strong>PHC Standards:</strong> - <strong>Infrastructure</strong>:
4-6 bed facility - <strong>Staffing</strong>: 1 MO, 1 HA, 1 LHV, 3-4
MPWs - <strong>Laboratory</strong>: Basic diagnostic services -
<strong>Emergency</strong>: 24x7 emergency services</p>
<p><strong>CHC Standards:</strong> - <strong>Infrastructure</strong>:
30-bed facility - <strong>Staffing</strong>: 4 Specialists + supporting
staff - <strong>Laboratory</strong>: Advanced diagnostic services -
<strong>Surgery</strong>: Minor surgical procedures</p>
<h3 id="section-c-major-health-programs">Section C: Major Health
Programs</h3>
<h4 id="national-health-mission-nhm">National Health Mission (NHM)</h4>
<p><strong>Launch</strong>: 2005 (NRHM), Expanded to NHM in 2013</p>
<p><strong>Mission Objectives:</strong> 1. <strong>Universal
Access</strong>: Equitable, affordable healthcare 2. <strong>Quality
Improvement</strong>: Standardized service delivery 3.
<strong>Healthcare Integration</strong>: Coordinated health services 4.
<strong>Community Participation</strong>: Involving community in health
5. <strong>Systems Strengthening</strong>: Healthcare system
capacity</p>
<p><strong>NHM Components:</strong></p>
<p><strong>National Rural Health Mission (NRHM):</strong> - <strong>ASHA
Program</strong>: Accredited Social Health Activists - <strong>Village
Health and Sanitation Committees</strong>: Local governance -
<strong>Untied Funds</strong>: Decentralized resource allocation -
<strong>Community Monitoring</strong>: Public accountability</p>
<p><strong>National Urban Health Mission (NUHM):</strong> -
<strong>Urban Health Posts</strong>: Primary healthcare in urban slums -
<strong>Urban ASHAs</strong>: Community health workers in urban areas -
<strong>Municipal Corporations</strong>: Urban health governance</p>
<p><strong>NHM Framework:</strong> - <strong>Flexible
Financing</strong>: State-specific needs - <strong>Decentralized
Planning</strong>: Local health planning - <strong>Intersectoral
Coordination</strong>: Multi-sectoral approach - <strong>Community
Participation</strong>: People‚Äôs participation</p>
<h4 id="ayushman-bharat">Ayushman Bharat</h4>
<p><strong>Launch</strong>: 2018</p>
<p><strong>Two Main Components:</strong></p>
<p><strong>1. Health and Wellness Centers (HWCs):</strong> -
<strong>Target</strong>: 150,000 HWCs by 2022 -
<strong>Services</strong>: Comprehensive primary healthcare -
<strong>Staffing</strong>: Multi-disciplinary teams -
<strong>Technology</strong>: Telemedicine and digital health</p>
<p><strong>2. Pradhan Mantri Jan Arogya Yojana (PM-JAY):</strong> -
<strong>Coverage</strong>: 50 crore beneficiaries -
<strong>Benefit</strong>: ‚Çπ5 lakh per family per year -
<strong>Network</strong>: 25,000+ empanelled hospitals -
<strong>Features</strong>: Cashless, paperless, portable</p>
<p><strong>Ayushman Bharat Impact:</strong> -
<strong>Treatments</strong>: 3+ crore treatments provided -
<strong>Financial Protection</strong>: ‚Çπ45,000 crore saved -
<strong>Hospital Network</strong>: Significant expansion -
<strong>Quality Assurance</strong>: Standard treatment protocols</p>
<h4 id="national-vector-borne-disease-control-program">National Vector
Borne Disease Control Program</h4>
<p><strong>NVBDCP Objectives:</strong> 1. <strong>Malaria
Elimination</strong>: Zero indigenous cases by 2030 2. <strong>Dengue
Control</strong>: Reduce morbidity and mortality 3.
<strong>Chikungunya</strong>: Surveillance and control 4.
<strong>Lymphatic Filariasis</strong>: Elimination by 2030 5.
<strong>Kala-azar Elimination</strong>: Elimination by 2025</p>
<p><strong>Program Strategies:</strong> - <strong>Integrated Vector
Management</strong>: Multiple vector control methods - <strong>Case
Management</strong>: Early diagnosis and treatment -
<strong>Surveillance</strong>: Disease monitoring and response -
<strong>Capacity Building</strong>: Training and development -
<strong>Community Participation</strong>: Behavioral change
communication</p>
<p><strong>Key Achievements:</strong> - <strong>Malaria</strong>: 83%
reduction in cases (2015-2020) - <strong>Dengue</strong>: Improved
surveillance and case management - <strong>Lymphatic
Filariasis</strong>: 18 states eliminated - <strong>Kala-azar</strong>:
99% reduction in endemic districts</p>
<h4 id="national-tuberculosis-elimination-program">National Tuberculosis
Elimination Program</h4>
<p><strong>NTEP Objectives:</strong> - <strong>TB Elimination</strong>:
Reduce incidence by 80% (2025 vs 2015) - <strong>Mortality
Reduction</strong>: Reduce deaths by 90% - <strong>Financial
Hardship</strong>: Eliminate catastrophic costs</p>
<p><strong>Program Components:</strong> 1. <strong>Case
Detection</strong>: Sputum smear and molecular diagnostics 2.
<strong>Treatment</strong>: Directly Observed Treatment (DOT) 3.
<strong>Drug Resistance</strong>: MDR-TB and XDR-TB management 4.
<strong>TB-HIV</strong>: Collaborative TB-HIV activities 5.
<strong>Community Engagement</strong>: ASHA involvement</p>
<p><strong>Key Strategies:</strong> - <strong>Nikshay</strong>: Digital
health management system - <strong>Newer Diagnostics</strong>: Molecular
diagnostic expansion - <strong>Improved Drugs</strong>: Shorter
treatment regimens - <strong>Social Support</strong>: Nutritional and
financial support</p>
<p><strong>Progress Indicators:</strong> - <strong>Case
Detection</strong>: 87% of estimated cases - <strong>Treatment
Success</strong>: 85% treatment success rate - <strong>MDR-TB</strong>:
74% treatment success - <strong>TB Elimination</strong>: 2025 target on
track</p>
<h4 id="national-aids-control-program">National AIDS Control
Program</h4>
<p><strong>NACP Objectives:</strong> 1. <strong>Infection
Prevention</strong>: Reduce new HIV infections 2. <strong>Treatment
Access</strong>: Universal antiretroviral therapy 3. <strong>Quality of
Life</strong>: Comprehensive care and support 4. <strong>Stigma
Reduction</strong>: Social acceptance and support</p>
<p><strong>NACP Phases:</strong> - <strong>NACP I (1992-1999)</strong>:
Awareness and behavior change - <strong>NACP II (1999-2007)</strong>:
Sentinel surveillance expansion - <strong>NACP III (2007-2014)</strong>:
Treatment scale-up - <strong>NACP IV (2014-2021)</strong>: Elimination
goals</p>
<p><strong>Key Interventions:</strong> - <strong>Prevention</strong>:
Safe sex practices, needle exchange - <strong>Treatment</strong>:
Antiretroviral therapy (ART) - <strong>Care</strong>: Opportunistic
infection management - <strong>Support</strong>: Counseling and social
support</p>
<p><strong>Current Status:</strong> - <strong>Adult HIV
Prevalence</strong>: 0.21% (declining trend) - <strong>ART
Coverage</strong>: 82% of eligible patients - <strong>Mother-to-Child
Transmission</strong>: 27% transmission rate - <strong>Target</strong>:
End AIDS by 2030</p>
<h4 id="pradhan-mantri-jan-arogya-yojana">Pradhan Mantri Jan Arogya
Yojana</h4>
<p><strong>Scheme Overview:</strong> - <strong>Launch</strong>:
September 23, 2018 - <strong>Implementation</strong>: National Health
Authority - <strong>Coverage</strong>: 10 crore families (50 crore
individuals) - <strong>Benefit</strong>: ‚Çπ5 lakh per family per year</p>
<p><strong>Eligibility Criteria:</strong> - <strong>Rural</strong>:
Deprivation criteria-based selection - <strong>Urban</strong>:
Occupational categories - <strong>Exclusions</strong>: Government
employees - <strong>Database</strong>: SECC 2011 and RSBY
beneficiaries</p>
<p><strong>Benefit Package:</strong> - <strong>Secondary Care</strong>:
Medical and surgical procedures - <strong>Tertiary Care</strong>:
Specialized treatments - <strong>Pre and Post Hospitalization</strong>:
3 days pre and 15 days post - <strong>Day Care Procedures</strong>:
1,393 procedures - <strong>Transportation</strong>: ‚Çπ500 per
hospitalization</p>
<p><strong>Implementation Features:</strong> - <strong>Cards</strong>:
e-cards issued to beneficiaries - <strong>Hospitals</strong>: Public and
private empanelment - <strong>Claims</strong>: Paperless and cashless
treatment - <strong>Quality</strong>: Standard treatment protocols</p>
<h3 id="section-d-health-research-and-education">Section D: Health
Research and Education</h3>
<h4 id="medical-education-in-india">Medical Education in India</h4>
<p><strong>Medical Education System:</strong> - <strong>MBBS</strong>:
4.5 years + 1 year internship - <strong>Postgraduate</strong>: 3 years
MD/MS programs - <strong>Diploma Courses</strong>: 2 years specialized
training - <strong>Super-specialty</strong>: 3 years DM/MCh programs</p>
<p><strong>Medical Colleges:</strong> - <strong>Government</strong>: 289
medical colleges - <strong>Private</strong>: 269 medical colleges -
<strong>Total</strong>: 558 medical colleges (as of 2023) -
<strong>Annual Intake</strong>: 83,275 MBBS seats</p>
<p><strong>Medical Education Reforms:</strong></p>
<p><strong>National Medical Commission (NMC) Act 2019:</strong> 1.
<strong>Replaced MCI</strong>: New regulatory body 2.
<strong>Competency-based</strong>: Curriculum reform 3. <strong>Exit
Exam</strong>: NEXT (National Exit Test) 4. <strong>Faculty
Development</strong>: Teacher training programs 5. <strong>Rural
Service</strong>: Compulsory rural posting</p>
<p><strong>New MBBS Curriculum (2019):</strong> -
<strong>Competency-based</strong>: Outcome-oriented education -
<strong>Early Clinical Exposure</strong>: Practical learning -
<strong>Integration</strong>: Horizontal and vertical integration -
<strong>Foundation Course</strong>: Orientation program -
<strong>AETCOM</strong>: Attitude, Ethics, and Communication</p>
<h4 id="research-priorities-in-public-health">Research Priorities in
Public Health</h4>
<p><strong>ICMR Research Priorities:</strong> 1. <strong>Infectious
Diseases</strong>: Control and elimination programs 2.
<strong>Non-Communicable Diseases</strong>: Prevention and management 3.
<strong>Maternal and Child Health</strong>: Reproductive and child
health 4. <strong>Environmental Health</strong>: Climate change and
health 5. <strong>Health Systems Research</strong>: Healthcare delivery
optimization</p>
<p><strong>Research Focus Areas:</strong> - <strong>Disease
Burden</strong>: Epidemiological transition - <strong>Health
Technology</strong>: Diagnostic and therapeutic innovations -
<strong>Health Economics</strong>: Cost-effectiveness studies -
<strong>Implementation Research</strong>: Program effectiveness -
<strong>Global Health</strong>: International collaborations</p>
<p><strong>Research Funding:</strong> - <strong>ICMR Budget</strong>:
‚Çπ2,000 crore annually - <strong>DST Funding</strong>: Science and
technology research - <strong>International Funding</strong>: Global
health research - <strong>Private Funding</strong>: Industry-sponsored
research</p>
<h4 id="icmr-research-programs">ICMR Research Programs</h4>
<p><strong>Major ICMR Programs:</strong></p>
<p><strong>1. ICMR Centers of Excellence:</strong> - <strong>Bird Flu
Surveillance</strong>: Influenza monitoring - <strong>Zoonoses
Research</strong>: Animal-human disease interface - <strong>Vector-borne
Diseases</strong>: Mosquito and vector research - <strong>Health Systems
Research</strong>: Healthcare delivery studies</p>
<p><strong>2. National Task Force Studies:</strong> -
<strong>Reproductive Health</strong>: Maternal and child health -
<strong>Infectious Diseases</strong>: Epidemiological investigations -
<strong>Chronic Diseases</strong>: NCD prevention and control -
<strong>Traditional Medicine</strong>: Ayurvedic research validation</p>
<p><strong>3. International Collaborations:</strong> - <strong>WHO
Collaborating Centers</strong>: Technical partnerships - <strong>NIH
Partnerships</strong>: US-India health research - <strong>Gates
Foundation</strong>: Global health initiatives - <strong>EU
Collaborations</strong>: European research partnerships</p>
<h4 id="public-health-institutes">Public Health Institutes</h4>
<p><strong>National Institutes of Health:</strong></p>
<p><strong>1. National Institute of Health and Family Welfare
(NIHFW):</strong> - <strong>Location</strong>: New Delhi -
<strong>Functions</strong>: Research, training, consultancy -
<strong>Programs</strong>: Health policy research -
<strong>Courses</strong>: MPH, PhD programs</p>
<p><strong>2. National Institute of Health and Family Welfare
Centers:</strong> - <strong>Regional Institutes</strong>: Multi-state
coverage - <strong>State Health Institutes</strong>: State-specific
research - <strong>District Training Centers</strong>: Local capacity
building</p>
<p><strong>National Public Health Institutes:</strong> -
<strong>National Institute of Epidemiology</strong>: Chennai -
<strong>National Institute of Health</strong>: Basic research -
<strong>Regional Medical Research Centers</strong>: Regional focus</p>
<p><strong>Public Health Schools:</strong> - <strong>All India
Institutes of Medical Sciences</strong>: Public health education -
<strong>Post Graduate Institutes</strong>: Specialized training -
<strong>Medical Colleges</strong>: Undergraduate and postgraduate
programs</p>
<h4 id="capacity-building-initiatives">Capacity Building
Initiatives</h4>
<p><strong>Human Resource Development:</strong></p>
<p><strong>1. Medical Education Enhancement:</strong> - <strong>Faculty
Development Programs</strong>: Teacher training - <strong>Curriculum
Updates</strong>: Competency-based education - <strong>Technology
Integration</strong>: Digital learning platforms - <strong>Quality
Assurance</strong>: Accreditation and assessment</p>
<p><strong>2. Public Health Capacity Building:</strong> - <strong>MPH
Programs</strong>: Master of Public Health - <strong>DrPH
Programs</strong>: Doctor of Public Health - <strong>Certificate
Courses</strong>: Short-term training - <strong>Online
Learning</strong>: E-learning platforms</p>
<p><strong>3. Field Training Programs:</strong> - <strong>Internship
Programs</strong>: Practical experience - <strong>Rural
Placements</strong>: Community exposure - <strong>Research
Projects</strong>: Investigation skills - <strong>Field
Epidemiology</strong>: Disease investigation</p>
<p><strong>Training Programs:</strong></p>
<p><strong>1. National Health Programs:</strong> - <strong>Program
Management</strong>: NHM training - <strong>Disease Control</strong>:
NTEP, NVBDCP training - <strong>Emergency Response</strong>: Disaster
management - <strong>Quality Improvement</strong>: Healthcare
quality</p>
<p><strong>2. Specialized Training:</strong> -
<strong>Epidemiology</strong>: Disease surveillance -
<strong>Biostatistics</strong>: Data analysis - <strong>Health
Management</strong>: Administration - <strong>Health Economics</strong>:
Economic evaluation</p>
<h2 id="current-health-statistics-and-major-indicators">Current Health
Statistics and Major Indicators</h2>
<h3 id="national-health-indicators-2022-23">National Health Indicators
(2022-23)</h3>
<p><strong>Mortality Indicators:</strong> - <strong>Infant Mortality
Rate</strong>: 28 per 1,000 live births - <strong>Maternal Mortality
Ratio</strong>: 97 per 100,000 live births - <strong>Under-5 Mortality
Rate</strong>: 32 per 1,000 live births - <strong>Life
Expectancy</strong>: 69.7 years (69.5 males, 70.0 females)</p>
<p><strong>Morbidity Indicators:</strong> - <strong>Total Fertility
Rate</strong>: 2.0 - <strong>Contraceptive Prevalence Rate</strong>: 67%
- <strong>Institutional Deliveries</strong>: 89% - <strong>Full
Immunization Coverage</strong>: 85%</p>
<p><strong>Health Infrastructure (2023):</strong> -
<strong>Sub-centers</strong>: 157,987 - <strong>Primary Health
Centers</strong>: 30,881 - <strong>Community Health Centers</strong>:
6,103 - <strong>Hospitals</strong>: 43,786 - <strong>Hospital
Beds</strong>: 1,372,021</p>
<h3 id="health-expenditure-indicators-2021-22">Health Expenditure
Indicators (2021-22)</h3>
<p><strong>Total Health Expenditure:</strong> - <strong>As % of
GDP</strong>: 3.16% - <strong>Government Health Expenditure</strong>:
1.35% of GDP - <strong>Private Health Expenditure</strong>: 1.81% of GDP
- <strong>Out-of-Pocket Expenditure</strong>: 50.6% of total health
expenditure</p>
<p><strong>Health Budget (2023-24):</strong> - <strong>Union Health
Budget</strong>: ‚Çπ89,155 crore - <strong>State Health Budget</strong>:
‚Çπ65,000 crore (estimated) - <strong>Per Capita Health
Expenditure</strong>: ‚Çπ2,072</p>
<h3 id="global-health-comparisons">Global Health Comparisons</h3>
<p><strong>India‚Äôs Position Globally:</strong> - <strong>Healthcare
Access Index</strong>: 61st rank - <strong>Global Health Security
Index</strong>: 116th rank - <strong>Universal Health Coverage
Index</strong>: 53rd rank - <strong>Health Innovation Index</strong>:
52nd rank</p>
<p><strong>Comparison with BRICS:</strong> - <strong>Health
Expenditure</strong>: Lower than Brazil and South Africa -
<strong>Infrastructure</strong>: Comparable to China and Russia -
<strong>Human Resources</strong>: Better than most developing nations -
<strong>Technology</strong>: Rapid advancement in digital health</p>
<h2 id="memory-aids-for-committee-recommendations">Memory Aids for
Committee Recommendations</h2>
<h3 id="bhore-committee-1943---memory-aid-pots">Bhore Committee (1943) -
Memory Aid: ‚ÄúPOTS‚Äù</h3>
<ul>
<li><strong>P</strong>reventive and curative integration</li>
<li><strong>O</strong>rganized three-tier system</li>
<li><strong>T</strong>raining massive expansion needed</li>
<li><strong>S</strong>ervice comprehensive and universal</li>
</ul>
<h3 id="mudaliar-committee-1961---memory-aid-ships">Mudaliar Committee
(1961) - Memory Aid: ‚ÄúSHIPS‚Äù</h3>
<ul>
<li><strong>S</strong>low progress on Bhore recommendations</li>
<li><strong>H</strong>ospital beds inadequate</li>
<li><strong>I</strong>nsufficient doctors</li>
<li><strong>P</strong>HCs need strengthening</li>
<li><strong>S</strong>ubstandard services</li>
</ul>
<h3 id="srivastava-committee---memory-aid-train">Srivastava Committee -
Memory Aid: ‚ÄúTRAIN‚Äù</h3>
<ul>
<li><strong>T</strong>raining reforms needed</li>
<li><strong>R</strong>esidency programs expansion</li>
<li><strong>A</strong>dvanced training programs</li>
<li><strong>I</strong>mproved education standards</li>
<li><strong>N</strong>ursing professional development</li>
</ul>
<h3 id="committee-timeline-memory-aid-bms">Committee Timeline Memory
Aid: ‚ÄúBMS‚Äù</h3>
<ul>
<li><strong>B</strong>hore (1943): British era foundation</li>
<li><strong>M</strong>udaliar (1961): Post-independence assessment</li>
<li><strong>S</strong>rivastava (1970s): Manpower focus</li>
</ul>
<h2 id="case-studies-of-successful-health-programs">Case Studies of
Successful Health Programs</h2>
<h3 id="case-study-1-polio-eradication-program">Case Study 1: Polio
Eradication Program</h3>
<p><strong>Challenge:</strong> - High polio burden with 500,000 cases
annually (1985) - Virus circulation in multiple states - Poor sanitation
and hygiene conditions</p>
<p><strong>Strategy Implemented:</strong> 1. <strong>National Polio
Surveillance Project</strong>: WHO-NGO partnership 2. <strong>Mass
Immunization Campaigns</strong>: NIDs (National Immunization Days) 3.
<strong>Micro-planning</strong>: Door-to-door campaigns 4.
<strong>Community Mobilization</strong>: ASHA worker involvement 5.
<strong>AFP Surveillance</strong>: Acute Flaccid Paralysis
monitoring</p>
<p><strong>Results Achieved:</strong> - <strong>Last Case</strong>:
January 2011 - <strong>WHO Certification</strong>: March 2014 -
<strong>Sustained Zero Cases</strong>: 12+ years - <strong>Global
Recognition</strong>: India certified polio-free</p>
<p><strong>Key Success Factors:</strong> - <strong>Strong
Leadership</strong>: Political commitment - <strong>International
Partnerships</strong>: WHO and UNICEF support - <strong>Community
Participation</strong>: Local volunteer engagement - <strong>Innovative
Strategies</strong>: Oral polio vaccine effectiveness - <strong>Robust
Surveillance</strong>: Real-time monitoring</p>
<h3 id="case-study-2-mission-indradhanush">Case Study 2: Mission
Indradhanush</h3>
<p><strong>Challenge:</strong> - <strong>Immunization Gaps</strong>: 1.1
million partially vaccinated children - <strong>Disadvantaged
Communities</strong>: Focus on hard-to-reach populations -
<strong>Vaccine Hesitancy</strong>: Community resistance to
immunization</p>
<p><strong>Strategy Implemented:</strong> 1. <strong>Intensive
Mission</strong>: 4 rounds of intensified vaccination 2.
<strong>Targeted Approach</strong>: Focus on backward districts 3.
<strong>Special Day Campaigns</strong>: Pre-planned vaccination dates 4.
<strong>Cold Chain Strengthening</strong>: Equipment and logistics 5.
<strong>Community Mobilization</strong>: Local leader involvement</p>
<p><strong>Results Achieved:</strong> - <strong>Coverage
Improvement</strong>: 6.7% increase in full immunization -
<strong>District Coverage</strong>: 528 districts with &gt;90% coverage
- <strong>Beneficiaries</strong>: 2.6 crore children reached -
<strong>Maternal Coverage</strong>: 74 lakh pregnant women
vaccinated</p>
<p><strong>Key Success Factors:</strong> - <strong>Multi-agency
Coordination</strong>: Central and state collaboration -
<strong>Data-driven Planning</strong>: Coverage gap analysis -
<strong>Community Ownership</strong>: Local participation -
<strong>Innovation</strong>: Mobile vaccination teams -
<strong>Monitoring</strong>: Real-time progress tracking</p>
<h3 id="case-study-3-national-aids-control-program">Case Study 3:
National AIDS Control Program</h3>
<p><strong>Challenge:</strong> - <strong>High HIV Prevalence</strong>:
0.69% in 2000 - <strong>Rapid Epidemic Spread</strong>: High-risk
populations affected - <strong>Stigma and Discrimination</strong>:
Social barriers to care</p>
<p><strong>Strategy Implemented:</strong> 1. <strong>Behavior Change
Communication</strong>: Targeted interventions 2. <strong>Safe Blood
Supply</strong>: Blood safety measures 3. <strong>Condom
Promotion</strong>: Social marketing 4. <strong>Injection
Safety</strong>: Needle and syringe programs 5. <strong>Antiretroviral
Therapy</strong>: Free treatment program</p>
<p><strong>Results Achieved:</strong> - <strong>Prevalence
Decline</strong>: 0.69% to 0.21% (2000-2023) - <strong>New Infections
Reduction</strong>: 46% decline since 2010 - <strong>ART
Coverage</strong>: 82% of eligible patients - <strong>Mother-to-Child
Transmission</strong>: Reduced to 27%</p>
<p><strong>Key Success Factors:</strong> - <strong>Multi-sectoral
Approach</strong>: Cross-sector coordination - <strong>Evidence-based
Planning</strong>: Surveillance and monitoring - <strong>Civil Society
Engagement</strong>: NGO partnerships - <strong>International
Support</strong>: Global fund assistance - <strong>Political
Commitment</strong>: Long-term policy support</p>
<h2 id="examination-tips-and-high-yield-points">Examination Tips and
High-Yield Points</h2>
<h3 id="most-important-committees-for-exams">Most Important Committees
for Exams</h3>
<ol type="1">
<li><strong>Bhore Committee (1943)</strong>: Foundation of Indian health
system</li>
<li><strong>Mudaliar Committee (1961)</strong>: Assessment and
recommendations</li>
<li><strong>Srivastava Committee (1975)</strong>: Health manpower
development</li>
<li><strong>Lok Sabha Committee (1998)</strong>: Health insurance
recommendations</li>
</ol>
<h3 id="national-health-programs---high-priority">National Health
Programs - High Priority</h3>
<ol type="1">
<li><strong>Ayushman Bharat</strong>: Largest health insurance
program</li>
<li><strong>National Health Mission</strong>: Comprehensive healthcare
delivery</li>
<li><strong>National Tuberculosis Elimination Program</strong>: TB
control</li>
<li><strong>National Vector Borne Disease Control Program</strong>:
Vector control</li>
<li><strong>National AIDS Control Program</strong>: HIV/AIDS
control</li>
</ol>
<h3 id="health-economics---important-concepts">Health Economics -
Important Concepts</h3>
<ol type="1">
<li><strong>Out-of-Pocket Expenditure</strong>: 50.6% of total health
expenditure</li>
<li><strong>Health as Economic Commodity</strong>: Characteristics and
implications</li>
<li><strong>Universal Health Coverage</strong>: WHO definition and India
progress</li>
<li><strong>Cost-Effectiveness Analysis</strong>: Health technology
assessment</li>
</ol>
<h3 id="organization-of-health-services---key-points">Organization of
Health Services - Key Points</h3>
<ol type="1">
<li><strong>Three-tier System</strong>: Primary, Secondary, Tertiary
levels</li>
<li><strong>PHC Functions</strong>: Preventive, curative, promotive,
referral</li>
<li><strong>CHC Services</strong>: Specialist care and emergency
services</li>
<li><strong>Referral System</strong>: Chain and protocols</li>
<li><strong>IPHS Standards</strong>: Infrastructure and staffing
norms</li>
</ol>
<h3 id="quality-management-tools">Quality Management Tools</h3>
<ol type="1">
<li><strong>PDCA Cycle</strong>: Plan-Do-Check-Act methodology</li>
<li><strong>Six Sigma</strong>: Quality improvement approach</li>
<li><strong>Quality Dimensions</strong>: ROADS framework</li>
<li><strong>Continuous Quality Improvement</strong>: Ongoing
enhancement</li>
</ol>
<h2 id="budget-allocations-and-performance-indicators">Budget
Allocations and Performance Indicators</h2>
<h3 id="union-health-budget-2023-24">Union Health Budget (2023-24)</h3>
<p><strong>Total Allocation</strong>: ‚Çπ89,155 crore <strong>Increase
from Previous Year</strong>: 13.33%</p>
<p><strong>Major Allocations:</strong> - <strong>Ayushman
Bharat</strong>: ‚Çπ7,200 crore - <strong>National Health
Mission</strong>: ‚Çπ29,085 crore - <strong>Health
Infrastructure</strong>: ‚Çπ15,685 crore - <strong>Medical
Education</strong>: ‚Çπ12,574 crore - <strong>Disease Control
Programs</strong>: ‚Çπ9,831 crore</p>
<h3 id="performance-indicators-and-targets">Performance Indicators and
Targets</h3>
<p><strong>National Health Policy 2017 Targets:</strong> -
<strong>Health Expenditure</strong>: 2.5% of GDP by 2025 -
<strong>Out-of-Pocket Expenditure</strong>: &lt;25% by 2025 -
<strong>Doctor-Population Ratio</strong>: 1:1500 by 2030 - <strong>Life
Expectancy</strong>: 70 years by 2025</p>
<p><strong>SDG Targets (2030):</strong> - <strong>MMR</strong>: &lt;70
per 100,000 live births - <strong>Under-5 Mortality</strong>: &lt;25 per
1,000 live births - <strong>Universal Health Coverage</strong>: Index
&gt;0.8 - <strong>Financial Protection</strong>: &lt;10% households
facing CHE</p>
<h3 id="global-health-comparisons-1">Global Health Comparisons</h3>
<p><strong>India vs.¬†Global Benchmarks:</strong></p>
<p><strong>Health Expenditure:</strong> - <strong>India</strong>: 3.16%
of GDP - <strong>Global Average</strong>: 9.89% of GDP -
<strong>Low-Income Countries</strong>: 5.65% of GDP</p>
<p><strong>Health Infrastructure:</strong> - <strong>Hospital
Beds</strong>: 1.1 per 1,000 population - <strong>Global
Average</strong>: 2.9 per 1,000 population - <strong>WHO
Recommendation</strong>: 3.5 per 1,000 population</p>
<p><strong>Human Resources:</strong> - <strong>Doctors</strong>: 1 per
1,596 population - <strong>Nurses</strong>: 1 per 670 population -
<strong>WHO Recommendation</strong>: 4.45 healthcare workers per 1,000
population</p>
<hr />
<p><em>This comprehensive manual provides essential examination-focused
content for management and health systems in community medicine. Regular
updates with latest statistics and policy changes are recommended for
optimal exam preparation.</em></p>
<h1 id="part-ix-appendices-and-references-1">Part IX: Appendices and
References</h1>
<h2 id="community-medicine-quick-revision-manual-for-mbbs">Community
Medicine Quick Revision Manual for MBBS</h2>
<hr />
<h1 id="chapter-35-research-methodology">Chapter 35: Research
Methodology</h1>
<h2 id="section-a-basic-research-concepts">Section A: Basic Research
Concepts</h2>
<h3 id="types-of-research">Types of Research</h3>
<p><strong>1. Observational Studies</strong> -
<strong>Cross-sectional</strong>: Single point in time, examines
prevalence - <strong>Case-control</strong>: Retrospective comparison of
exposed/unexposed groups - <strong>Cohort</strong>: Prospective
follow-up of exposed vs unexposed groups</p>
<p><strong>2. Experimental Studies</strong> - <strong>Randomized
Controlled Trials (RCT)</strong>: Gold standard for interventions -
<strong>Quasi-experimental</strong>: No randomization but intervention
given - <strong>Community trials</strong>: Population-level
interventions</p>
<h3 id="research-question-formulation">Research Question
Formulation</h3>
<p><strong>FINER Criteria:</strong> - <strong>F</strong>easible -
<strong>I</strong>nteresting - <strong>N</strong>ovel -
<strong>E</strong>thical - <strong>R</strong>elevant</p>
<p><strong>PICO Framework:</strong> -
<strong>P</strong>opulation/Problem - <strong>I</strong>ntervention -
<strong>C</strong>omparison - <strong>O</strong>utcome</p>
<h3 id="hypothesis-testing">Hypothesis Testing</h3>
<p><strong>Null Hypothesis (H‚ÇÄ):</strong> - States no association/effect
- Default assumption in research</p>
<p><strong>Alternative Hypothesis (H‚ÇÅ):</strong> - States presence of
association/effect - What researcher aims to prove</p>
<h3 id="variable-definitions">Variable Definitions</h3>
<p><strong>Independent Variable:</strong> - Cause or predictor variable
- Researcher manipulates/selects</p>
<p><strong>Dependent Variable:</strong> - Effect or outcome variable -
Measured response</p>
<p><strong>Confounding Variable:</strong> - Associated with both
exposure and outcome - Can distort true relationship</p>
<h3 id="sampling-methods">Sampling Methods</h3>
<p><strong>Probability Sampling:</strong> - <strong>Simple
Random</strong>: Equal chance for each unit -
<strong>Systematic</strong>: Every nth unit selected -
<strong>Stratified</strong>: Division into subgroups, random sampling
from each - <strong>Cluster</strong>: Groups selected randomly, all
units within included</p>
<p><strong>Non-probability Sampling:</strong> -
<strong>Convenience</strong>: Easily accessible subjects -
<strong>Purposive</strong>: Based on researcher‚Äôs judgment -
<strong>Snowball</strong>: Existing subjects recruit others</p>
<h3 id="sample-size-calculation">Sample Size Calculation</h3>
<p><strong>For Comparing Two Means:</strong> n = 2(ZŒ±/2 + ZŒ≤)¬≤œÉ¬≤ /
Œ¥¬≤</p>
<p>Where: - ZŒ±/2 = 1.96 for 95% CI - ZŒ≤ = 0.84 for 80% power - œÉ =
Standard deviation - Œ¥ = Minimum difference to detect</p>
<p><strong>For Comparing Two Proportions:</strong> n = [ZŒ±/2‚àö(2pÃÑ(1-pÃÑ)) +
ZŒ≤‚àö(p‚ÇÅ(1-p‚ÇÅ) + p‚ÇÇ(1-p‚ÇÇ))]¬≤ / (p‚ÇÅ-p‚ÇÇ)¬≤</p>
<h3 id="research-ethics-and-consent">Research Ethics and Consent</h3>
<p><strong>Basic Principles:</strong> - <strong>Autonomy</strong>:
Respect for persons - <strong>Beneficence</strong>: Do good -
<strong>Non-maleficence</strong>: Do no harm - <strong>Justice</strong>:
Fair distribution</p>
<p><strong>Informed Consent Elements:</strong> - Purpose and procedures
- Risks and benefits - Alternative treatments - Confidentiality -
Voluntary participation - Right to withdraw</p>
<hr />
<h2 id="section-b-data-collection-methods">Section B: Data Collection
Methods</h2>
<h3 id="questionnaire-design">Questionnaire Design</h3>
<p><strong>Types of Questions:</strong> - <strong>Open-ended</strong>:
Allows free responses - <strong>Closed-ended</strong>: Predefined
response options - <strong>Dichotomous</strong>: Yes/No questions -
<strong>Multiple choice</strong>: Select from options - <strong>Likert
scale</strong>: Agreement ratings</p>
<p><strong>Design Principles:</strong> - Clear and concise language -
Avoid double-barreled questions - Logical sequence - Skip patterns for
routing - Pilot testing essential</p>
<h3 id="interview-techniques">Interview Techniques</h3>
<p><strong>Structured Interview:</strong> - Predetermined questions -
Standardized format - High reliability</p>
<p><strong>Semi-structured Interview:</strong> - Key questions
predetermined - Flexibility in follow-up - Balance of consistency and
depth</p>
<p><strong>Unstructured Interview:</strong> - Free-flowing conversation
- Exploratory purpose - High depth but lower reliability</p>
<h3 id="observation-methods">Observation Methods</h3>
<p><strong>Participant Observation:</strong> - Researcher actively
participates - Immersive experience - High validity but potential
bias</p>
<p><strong>Non-participant Observation:</strong> - External observer
role - Less bias - May miss contextual details</p>
<p><strong>Observational Tools:</strong> - Checklists - Rating scales -
Time and motion studies</p>
<h3 id="focus-group-discussions">Focus Group Discussions</h3>
<p><strong>Group Size:</strong> 6-10 participants
<strong>Duration:</strong> 60-90 minutes <strong>Moderator
Role:</strong> - Guide discussion - Manage group dynamics - Ensure all
participate</p>
<p><strong>Benefits:</strong> - Group interaction - Diverse perspectives
- Cost-effective - Rich qualitative data</p>
<h3 id="secondary-data-sources">Secondary Data Sources</h3>
<p><strong>Types:</strong> - <strong>Census data</strong>: Population
characteristics - <strong>Vital statistics</strong>: Birth and death
records - <strong>Hospital records</strong>: Patient data -
<strong>Survey data</strong>: National health surveys -
<strong>Administrative records</strong>: Health service data</p>
<p><strong>Advantages:</strong> - Cost-effective - Large sample sizes -
Historical trends available</p>
<p><strong>Limitations:</strong> - May not meet specific research needs
- Data quality variable - Access restrictions</p>
<h3 id="data-quality-assurance">Data Quality Assurance</h3>
<p><strong>Validity:</strong> - <strong>Internal</strong>: Causal
relationship validity - <strong>External</strong>: Generalizability</p>
<p><strong>Reliability:</strong> - <strong>Consistency</strong>:
Reproducibility - <strong>Stability</strong>: Test-retest
reliability</p>
<p><strong>Quality Control Measures:</strong> - Training of data
collectors - Regular supervision - Double data entry - Range and logic
checks</p>
<hr />
<h2 id="section-c-data-analysis-and-interpretation">Section C: Data
Analysis and Interpretation</h2>
<h3 id="statistical-software-applications">Statistical Software
Applications</h3>
<p><strong>Common Software:</strong> - <strong>SPSS</strong>:
User-friendly, widely used in social sciences - <strong>R</strong>:
Open-source, extensive statistical capabilities -
<strong>STATA</strong>: Biostatistics focus - <strong>SAS</strong>:
Enterprise-level data management - <strong>Epi Info</strong>:
CDC-developed, epidemiology-specific</p>
<h3 id="descriptive-statistics">Descriptive Statistics</h3>
<p><strong>Measures of Central Tendency:</strong></p>
<p><strong>Mean:</strong> - Sum of all values divided by number of
values - Most commonly used - Sensitive to outliers - Formula: Œº =
Œ£x/n</p>
<p><strong>Median:</strong> - Middle value when data arranged - Not
sensitive to outliers - Better for skewed distributions</p>
<p><strong>Mode:</strong> - Most frequently occurring value - Can have
multiple modes</p>
<p><strong>Measures of Dispersion:</strong></p>
<p><strong>Range:</strong> - Difference between maximum and minimum -
Simple but limited</p>
<p><strong>Variance (œÉ¬≤):</strong> - Average squared deviation from mean
- Formula: œÉ¬≤ = Œ£(x-Œº)¬≤/n</p>
<p><strong>Standard Deviation (œÉ):</strong> - Square root of variance -
Same units as original data - Most commonly used measure</p>
<h3 id="inferential-statistics">Inferential Statistics</h3>
<p><strong>t-test:</strong> - Compares means of two groups -
<strong>Independent t-test</strong>: Different groups - <strong>Paired
t-test</strong>: Same group before/after - <strong>One-sample
t-test</strong>: Compare to known value</p>
<p><strong>Chi-square (œá¬≤) Test:</strong> - Tests association between
categorical variables - Formula: œá¬≤ = Œ£(O-E)¬≤/E - Degrees of freedom:
(rows-1) √ó (columns-1)</p>
<p><strong>ANOVA (Analysis of Variance):</strong> - Compares means of
three or more groups - <strong>One-way ANOVA</strong>: One independent
variable - <strong>Two-way ANOVA</strong>: Two independent variables</p>
<h3 id="regression-analysis">Regression Analysis</h3>
<p><strong>Linear Regression:</strong> - Models linear relationship
between variables - Equation: Y = a + bX - Where Y = dependent, X =
independent variable</p>
<p><strong>Logistic Regression:</strong> - For binary outcome variables
- Odds ratio interpretation - Common in epidemiology</p>
<h3 id="interpretation-of-results">Interpretation of Results</h3>
<p><strong>P-value Interpretation:</strong> - P &lt; 0.05: Statistically
significant - P &lt; 0.01: Highly significant - P &lt; 0.001: Very
highly significant</p>
<p><strong>Confidence Intervals:</strong> - Range likely to contain true
value - 95% CI most commonly used - Indicates precision of estimate</p>
<p><strong>Effect Size:</strong> - Practical significance beyond
statistical significance - Cohen‚Äôs d, odds ratios, etc.</p>
<h3 id="report-writing-and-presentation">Report Writing and
Presentation</h3>
<p><strong>Research Report Structure:</strong> 1. Title page 2. Abstract
3. Introduction 4. Methods 5. Results 6. Discussion 7. Conclusions 8.
References 9. Appendices</p>
<p><strong>Key Elements:</strong> - Clear objectives - Transparent
methodology - Complete results - Balanced interpretation - Practical
implications</p>
<hr />
<h1 id="chapter-36-biostatistics">Chapter 36: Biostatistics</h1>
<h2 id="section-a-descriptive-statistics">Section A: Descriptive
Statistics</h2>
<h3 id="measures-of-central-tendency">Measures of Central Tendency</h3>
<p><strong>Mean (Average):</strong></p>
<p><em>Properties:</em> - Most sensitive measure - Affected by extreme
values - Used for normally distributed data</p>
<p><em>Formula:</em> Œº = Œ£x/n</p>
<p><em>Example:</em> If systolic BP readings are: 120, 130, 140, 150,
160 Mean = (120+130+140+150+160)/5 = 140 mmHg</p>
<p><strong>Median:</strong></p>
<p><em>Properties:</em> - Middle value when ordered - Less affected by
outliers - Best for skewed distributions</p>
<p><em>Example:</em> For data: 2, 4, 6, 8, 100 Median = 6 (not affected
by outlier 100)</p>
<p><strong>Mode:</strong></p>
<p><em>Properties:</em> - Most frequent value - May have multiple modes
- Used for categorical data</p>
<h3 id="measures-of-dispersion">Measures of Dispersion</h3>
<p><strong>Range:</strong></p>
<p><em>Formula:</em> Range = Maximum - Minimum</p>
<p><em>Example:</em> Data: 10, 15, 20, 25, 30 Range = 30 - 10 = 20</p>
<p><strong>Variance (œÉ¬≤):</strong></p>
<p><em>Formula:</em> œÉ¬≤ = Œ£(x-Œº)¬≤/n</p>
<p><em>Properties:</em> - Average squared deviation - In squared units -
Hard to interpret</p>
<p><strong>Standard Deviation (œÉ):</strong></p>
<p><em>Formula:</em> œÉ = ‚àöœÉ¬≤</p>
<p><em>Properties:</em> - Square root of variance - Same units as
original data - Most commonly used</p>
<p><em>Interpretation:</em> - About 68% data within 1 SD of mean - About
95% data within 2 SD of mean - About 99.7% data within 3 SD of mean</p>
<h3 id="percentiles-and-quartiles">Percentiles and Quartiles</h3>
<p><strong>Percentiles:</strong> - Value below which certain percentage
falls - 50th percentile = median - P90 = 90% values below this point</p>
<p><strong>Quartiles:</strong> - Q1 = 25th percentile (first quartile) -
Q2 = 50th percentile (median) - Q3 = 75th percentile (third
quartile)</p>
<p><strong>Interquartile Range (IQR):</strong> - IQR = Q3 - Q1 -
Measures spread of middle 50% data - Less affected by outliers</p>
<h3 id="data-visualization">Data Visualization</h3>
<p><strong>Types of Graphs:</strong></p>
<p><strong>Bar Chart:</strong> - Categorical data - Discrete
categories</p>
<p><strong>Histogram:</strong> - Continuous data - Shows frequency
distribution</p>
<p><strong>Line Graph:</strong> - Trends over time - Continuous data</p>
<p><strong>Scatter Plot:</strong> - Relationship between two variables -
Shows correlation</p>
<p><strong>Box Plot:</strong> - Shows median, quartiles, outliers - Good
for comparing distributions</p>
<h3 id="normal-distribution-properties">Normal Distribution
Properties</h3>
<p><strong>Characteristics:</strong> - Bell-shaped curve - Symmetrical
around mean - Mean = Median = Mode</p>
<p><strong>68-95-99.7 Rule:</strong> - 68% within 1 SD of mean - 95%
within 2 SD of mean - 99.7% within 3 SD of mean</p>
<p><strong>Standard Normal Distribution:</strong> - Mean = 0 - Standard
deviation = 1 - Z-scores convert any normal distribution</p>
<p><strong>Z-score Formula:</strong> Z = (X - Œº) / œÉ</p>
<p>Where: - X = individual value - Œº = population mean - œÉ = population
standard deviation</p>
<hr />
<h2 id="section-b-inferential-statistics">Section B: Inferential
Statistics</h2>
<h3 id="probability-concepts">Probability Concepts</h3>
<p><strong>Basic Probability:</strong> - P(A) = Number of favorable
outcomes / Total outcomes - Range: 0 to 1 (or 0% to 100%) - P(A) + P(A‚Äô)
= 1 (A‚Äô = not A)</p>
<p><strong>Addition Rule:</strong> P(A ‚à™ B) = P(A) + P(B) - P(A ‚à© B)</p>
<p><strong>Multiplication Rule:</strong> P(A ‚à© B) = P(A) √ó P(B|A)</p>
<h3 id="hypothesis-testing-1">Hypothesis Testing</h3>
<p><strong>Steps in Hypothesis Testing:</strong></p>
<ol type="1">
<li><p><strong>State hypotheses:</strong></p>
<ul>
<li>H‚ÇÄ (null): No effect/association</li>
<li>H‚ÇÅ (alternative): Effect/association exists</li>
</ul></li>
<li><p><strong>Set significance level (Œ±):</strong></p>
<ul>
<li>Usually 0.05 (5%)</li>
</ul></li>
<li><p><strong>Choose test statistic:</strong></p>
<ul>
<li>t-test, chi-square, z-test, etc.</li>
</ul></li>
<li><p><strong>Calculate test statistic</strong></p></li>
<li><p><strong>Find p-value</strong></p></li>
<li><p><strong>Make decision:</strong></p>
<ul>
<li>If p ‚â§ Œ±, reject H‚ÇÄ</li>
<li>If p &gt; Œ±, fail to reject H‚ÇÄ</li>
</ul></li>
</ol>
<p><strong>Type I Error (Œ±):</strong> - Reject H‚ÇÄ when it‚Äôs true - False
positive - Probability = significance level</p>
<p><strong>Type II Error (Œ≤):</strong> - Fail to reject H‚ÇÄ when it‚Äôs
false - False negative - Power = 1 - Œ≤</p>
<h3 id="confidence-intervals">Confidence Intervals</h3>
<p><strong>Formula for Mean (Large Sample):</strong> CI = xÃÑ ¬± Z(Œ±/2) √ó
(s/‚àön)</p>
<p>Where: - xÃÑ = sample mean - Z(Œ±/2) = 1.96 for 95% CI - s = sample
standard deviation - n = sample size</p>
<p><strong>Formula for Proportion:</strong> CI = p ¬± Z(Œ±/2) √ó
‚àö[p(1-p)/n]</p>
<p><strong>Interpretation:</strong> 95% CI means 95% of such intervals
will contain true population parameter</p>
<h3 id="p-values-and-statistical-significance">P-values and Statistical
Significance</h3>
<p><strong>P-value:</strong> - Probability of obtaining results as
extreme as observed, assuming H‚ÇÄ is true - Smaller p-value = stronger
evidence against H‚ÇÄ</p>
<p><strong>Significance Levels:</strong> - p &lt; 0.05: Significant
(<em>) - p &lt; 0.01: Highly significant (<strong>) - p &lt; 0.001: Very
highly significant (</strong></em>)</p>
<h3 id="statistical-tests-selection">Statistical Tests Selection</h3>
<p><strong>Parametric Tests:</strong> - Assume normal distribution -
More powerful - Require interval/ratio data - Examples: t-test, ANOVA,
Pearson correlation</p>
<p><strong>Non-parametric Tests:</strong> - No distribution assumptions
- Less powerful - Use ordinal data - Examples: Mann-Whitney U,
Kruskal-Wallis, Spearman correlation</p>
<p><strong>Test Selection Guide:</strong></p>
<table>
<thead>
<tr>
<th>Data Type</th>
<th>Groups</th>
<th>Parametric</th>
<th>Non-parametric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous</td>
<td>2</td>
<td>t-test</td>
<td>Mann-Whitney U</td>
</tr>
<tr>
<td>Continuous</td>
<td>3+</td>
<td>ANOVA</td>
<td>Kruskal-Wallis</td>
</tr>
<tr>
<td>Ordinal</td>
<td>2</td>
<td>t-test</td>
<td>Mann-Whitney U</td>
</tr>
<tr>
<td>Ordinal</td>
<td>3+</td>
<td>ANOVA</td>
<td>Kruskal-Wallis</td>
</tr>
<tr>
<td>Categorical</td>
<td>2</td>
<td>Chi-square</td>
<td>Fisher‚Äôs exact</td>
</tr>
<tr>
<td>Continuous</td>
<td>Correlation</td>
<td>Pearson</td>
<td>Spearman</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="section-c-advanced-statistics">Section C: Advanced
Statistics</h2>
<h3 id="correlation-and-regression">Correlation and Regression</h3>
<p><strong>Pearson Correlation (r):</strong> - Measures linear
relationship between two continuous variables - Range: -1 to +1 - r = 1:
Perfect positive correlation - r = 0: No linear correlation - r = -1:
Perfect negative correlation</p>
<p><strong>Formula:</strong> r = Œ£[(x-xÃÑ)(y-»≥)] / ‚àö[Œ£(x-xÃÑ)¬≤ √ó
Œ£(y-»≥)¬≤]</p>
<p><strong>Spearman Rank Correlation:</strong> - Non-parametric
alternative - Uses ranks instead of actual values - Good for ordinal
data or non-linear relationships</p>
<p><strong>Linear Regression:</strong></p>
<p><em>Simple Linear Regression:</em> Y = a + bX</p>
<p>Where: - a = y-intercept - b = slope = r √ó (s_y/s_x)</p>
<p><em>Multiple Linear Regression:</em> Y = a + b‚ÇÅX‚ÇÅ + b‚ÇÇX‚ÇÇ + ‚Ä¶ +
b‚ÇôX‚Çô</p>
<h3 id="anova-analysis-of-variance">ANOVA (Analysis of Variance)</h3>
<p><strong>One-way ANOVA:</strong> - Compares means of 3+ independent
groups - Assumptions: normality, homogeneity of variance,
independence</p>
<p><strong>Two-way ANOVA:</strong> - Two independent variables - Tests
main effects and interaction</p>
<p><strong>ANOVA Table:</strong></p>
<table>
<thead>
<tr>
<th>Source</th>
<th>SS</th>
<th>df</th>
<th>MS</th>
<th>F</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Between</td>
<td>SSB</td>
<td>k-1</td>
<td>MSB = SSB/(k-1)</td>
<td>MSB/MSW</td>
<td></td>
</tr>
<tr>
<td>Within</td>
<td>SSW</td>
<td>N-k</td>
<td>MSW = SSW/(N-k)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>SST</td>
<td>N-1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="survival-analysis">Survival Analysis</h3>
<p><strong>Key Concepts:</strong> - <strong>Survival time</strong>: Time
until event occurs - <strong>Censoring</strong>: Incomplete observation
- <strong>Hazard function</strong>: Instantaneous risk rate</p>
<p><strong>Kaplan-Meier Method:</strong> - Non-parametric method for
survival curves - Handles censoring naturally - Log-rank test compares
survival curves</p>
<p><strong>Cox Proportional Hazards Model:</strong> - Regression model
for survival data - Hazard ratio interpretation - Assumes proportional
hazards</p>
<h3 id="logistic-regression">Logistic Regression</h3>
<p><strong>For Binary Outcomes:</strong> - Disease vs no disease -
Exposed vs unexposed</p>
<p><strong>Logit Model:</strong> logit(p) = ln[p/(1-p)] = b‚ÇÄ + b‚ÇÅX‚ÇÅ +
b‚ÇÇX‚ÇÇ + ‚Ä¶</p>
<p><strong>Odds Ratio Interpretation:</strong> - OR = 1: No association
- OR &gt; 1: Increased odds - OR &lt; 1: Decreased odds</p>
<p><strong>Example:</strong> If OR for smoking and lung cancer = 10
Interpretation: Smokers have 10 times higher odds of lung cancer</p>
<h3 id="meta-analysis-basics">Meta-analysis Basics</h3>
<p><strong>Purpose:</strong> - Combine results from multiple studies -
Get overall effect estimate - Resolve conflicting results</p>
<p><strong>Steps:</strong> 1. Define research question 2. Search for
studies 3. Select relevant studies 4. Extract data 5. Analyze and
combine results</p>
<p><strong>Forest Plot:</strong> - Visual representation of
meta-analysis results - Shows individual study results - Shows pooled
estimate with confidence interval</p>
<h3 id="sample-size-calculations">Sample Size Calculations</h3>
<p><strong>For Comparing Two Means:</strong></p>
<p>n = 2(ZŒ±/2 + ZŒ≤)¬≤œÉ¬≤ / Œ¥¬≤</p>
<p>Where: - ZŒ±/2 = 1.96 for 95% confidence - ZŒ≤ = 0.84 for 80% power - œÉ
= standard deviation - Œ¥ = minimum difference to detect</p>
<p><strong>For Comparing Two Proportions:</strong></p>
<p>n = [ZŒ±/2‚àö(2pÃÑ(1-pÃÑ)) + ZŒ≤‚àö(p‚ÇÅ(1-p‚ÇÅ) + p‚ÇÇ(1-p‚ÇÇ))]¬≤ / (p‚ÇÅ-p‚ÇÇ)¬≤</p>
<p><strong>For Correlation Studies:</strong></p>
<p>n = [(ZŒ±/2 + ZŒ≤)/0.5 √ó ln((1+r)/(1-r))]¬≤ + 3</p>
<hr />
<h1 id="chapter-37-social-work-and-demography">Chapter 37: Social Work
and Demography</h1>
<h2 id="section-a-demography">Section A: Demography</h2>
<h3 id="population-dynamics">Population Dynamics</h3>
<p><strong>Key Concepts:</strong> - <strong>Population</strong>: Group
of individuals in a defined area - <strong>Demography</strong>: Study of
population size, composition, and distribution - <strong>Population
dynamics</strong>: Changes in population over time</p>
<p><strong>Population Change Formula:</strong> P‚ÇÅ = P‚ÇÄ + (B - D) + (I -
E)</p>
<p>Where: - P‚ÇÅ = Population at time 1 - P‚ÇÄ = Population at time 0 - B =
Births - D = Deaths - I = Immigration - E = Emigration</p>
<h3 id="demographic-transition-model">Demographic Transition Model</h3>
<p><strong>Stage 1: Pre-transition (High Stationary)</strong> - High
birth rate - High death rate - Low growth rate - Pre-industrial
societies</p>
<p><strong>Stage 2: Early transition (Early Expanding)</strong> -
Declining death rate - High birth rate - Rapid population growth -
Improving healthcare, sanitation</p>
<p><strong>Stage 3: Late transition (Late Expanding)</strong> -
Declining birth rate - Low death rate - Slowing growth - Industrial
societies</p>
<p><strong>Stage 4: Post-transition (Low Stationary)</strong> - Low
birth rate - Low death rate - Very low growth rate - Post-industrial
societies</p>
<p><strong>Stage 5: Declining</strong> - Birth rate below death rate -
Population decline - Some developed countries</p>
<h3 id="population-pyramids">Population Pyramids</h3>
<p><strong>Types of Population Pyramids:</strong></p>
<p><strong>Expansive Pyramid:</strong> - Wide base (high birth rates) -
Narrow top (low life expectancy) - Rapid population growth - Developing
countries pattern</p>
<p><strong>Stationary Pyramid:</strong> - Straight sides - Moderate
birth and death rates - Stable population - Developed countries
pattern</p>
<p><strong>Constrictive Pyramid:</strong> - Narrow base (low birth
rates) - Larger middle/upper sections - Aging population -
Post-industrial societies</p>
<h3 id="vital-statistics">Vital Statistics</h3>
<p><strong>Crude Birth Rate (CBR):</strong> CBR = (Number of births in a
year / Mid-year population) √ó 1000</p>
<p><strong>Crude Death Rate (CDR):</strong> CDR = (Number of deaths in a
year / Mid-year population) √ó 1000</p>
<p><strong>Growth Rate:</strong> Growth Rate = CBR - CDR + (Immigration
- Emigration)</p>
<p><strong>Total Fertility Rate (TFR):</strong> Average number of
children a woman would have during her lifetime</p>
<p><strong>Infant Mortality Rate (IMR):</strong> IMR = (Deaths under 1
year / Live births) √ó 1000</p>
<p><strong>Maternal Mortality Ratio (MMR):</strong> MMR = (Maternal
deaths / Live births) √ó 100,000</p>
<h3 id="census-data-interpretation">Census Data Interpretation</h3>
<p><strong>Census Questions:</strong> - Age and sex distribution -
Marital status - Education levels - Occupation and employment -
Migration patterns - Housing conditions</p>
<p><strong>Key Indicators:</strong> - Sex ratio = Males/Females √ó 1000 -
Dependency ratio = (0-14 + 65+) / (15-64) √ó 100 - Literacy rate =
Literate population / Total population √ó 100</p>
<h3 id="population-projections">Population Projections</h3>
<p><strong>Methods:</strong></p>
<p><strong>Arithmetic Growth Method:</strong> P‚Çô = P‚ÇÄ(1 + nr)</p>
<p>Where: - P‚Çô = Population after n years - P‚ÇÄ = Initial population - r
= growth rate - n = number of years</p>
<p><strong>Geometric Growth Method:</strong> P‚Çô = P‚ÇÄ(1 + r)‚Åø</p>
<p><strong>Cohort Component Method:</strong> - Most accurate method -
Follows specific age cohorts - Considers births, deaths, migration</p>
<hr />
<h2 id="section-b-social-work-principles">Section B: Social Work
Principles</h2>
<h3 id="social-work-in-healthcare">Social Work in Healthcare</h3>
<p><strong>Medical Social Work:</strong> - Liaison between healthcare
system and patients - Address social determinants of health -
Psychosocial assessment and intervention - Discharge planning -
Community resource linkage</p>
<p><strong>Roles of Medical Social Workers:</strong> - Patient and
family counseling - Crisis intervention - Financial counseling -
Rehabilitation support - End-of-life care planning</p>
<p><strong>Healthcare Social Work Services:</strong> - Case management -
Group therapy - Community outreach - Health education - Advocacy</p>
<h3 id="community-organization-methods">Community Organization
Methods</h3>
<h3 id="community-organization-methods-1">Community Organization
Methods</h3>
<p><strong>Problem-solving Approach:</strong> - Problem identification
and analysis - Resource assessment - Action planning and implementation
- Evaluation and follow-up</p>
<p><strong>Community Development:</strong> - Local leadership
development - Capacity building - Community participation - Sustainable
development</p>
<p><strong>Social Planning:</strong> - Technical approach to social
problems - Evidence-based interventions - Systematic planning process -
Coordination of services</p>
<h3 id="social-case-work-principles">Social Case Work Principles</h3>
<p><strong>Core Principles:</strong> - Individualization - Purposeful
expression of feeling - Controlled emotional involvement -
Non-judgmental attitude - Confidentiality - Self-determination</p>
<p><strong>Case Work Process:</strong> 1. <strong>Study</strong>:
Assessment of situation 2. <strong>Diagnosis</strong>: Understanding the
problem 3. <strong>Treatment</strong>: Intervention and support 4.
<strong>Follow-up</strong>: Monitoring and evaluation</p>
<p><strong>Interviewing Techniques:</strong> - Rapport building - Active
listening - empathetic understanding - Goal setting - Resource
mobilization</p>
<h3 id="group-work-approaches">Group Work Approaches</h3>
<p><strong>Types of Groups:</strong></p>
<p><strong>Treatment Groups:</strong> - Focus on member problems -
Therapeutic objectives - Professional leadership - Structured
activities</p>
<p><strong>Task Groups:</strong> - Goal-oriented - Problem-solving focus
- Time-limited - Outcome-focused</p>
<p><strong>Socialization Groups:</strong> - Skill development -
Behavioral change - Peer support - Community integration</p>
<p><strong>Group Work Principles:</strong> - Democratic participation -
Mutual help and support - Group interaction - Individual growth within
group context</p>
<h3 id="social-legislation-and-welfare">Social Legislation and
Welfare</h3>
<p><strong>Key Social Laws in India:</strong></p>
<p><strong>The Protection of Women from Domestic Violence Act
(2005):</strong> - Protection orders - Residence orders - Monetary
relief - Custody orders</p>
<p><strong>The Right to Education Act (2009):</strong> - Free and
compulsory education - 25% reservation for disadvantaged children -
Infrastructure requirements - Teacher-student ratios</p>
<p><strong>The Mahatma Gandhi National Rural Employment Guarantee Act
(2005):</strong> - 100 days employment guarantee - Rural development
focus - Women participation priority - Social security measures</p>
<p><strong>National Social Assistance Programme:</strong> - Old age
pension - Widow pension - Disability pension - Family benefit
schemes</p>
<h3 id="social-security-systems-in-india">Social Security Systems in
India</h3>
<p><strong>Constitutional Provisions:</strong> - Article 41: Right to
work, education, and public assistance - Article 42: Just and humane
working conditions - Article 43: Living wage and decent standard of
life</p>
<p><strong>Social Security Categories:</strong></p>
<p><strong>Contributory Schemes:</strong> - Employees‚Äô State Insurance
(ESI) - Provident Fund - Gratuity - Pension schemes</p>
<p><strong>Non-contributory Schemes:</strong> - National Old Age Pension
Scheme - Indira Gandhi National Widow Pension Scheme - Indira Gandhi
National Disability Pension Scheme - National Family Benefit Scheme</p>
<p><strong>Healthcare Security:</strong> - Employees‚Äô State Insurance
Scheme - Central Government Health Scheme - Pradhan Mantri Jan Arogya
Yojana (PMJAY) - State-specific health insurance schemes</p>
<hr />
<h2 id="section-c-health-demography">Section C: Health Demography</h2>
<h3 id="demographic-and-health-surveys">Demographic and Health
Surveys</h3>
<p><strong>National Family Health Survey (NFHS):</strong> - Demographic
and health indicators - Reproductive and child health - Nutrition status
- Immunization coverage - Healthcare utilization patterns</p>
<p><strong>Sample Registration System (SRS):</strong> - Continuous data
collection - Birth and death rates - Fertility and mortality estimates -
Rural-urban differentials</p>
<p><strong>District Level Household and Facility Survey (DLHS):</strong>
- Healthcare infrastructure - Service utilization - Maternal and child
health - Family planning services</p>
<h3 id="fertility-and-mortality-patterns">Fertility and Mortality
Patterns</h3>
<p><strong>Fertility Indicators:</strong></p>
<p><strong>Total Fertility Rate (TFR):</strong> - Replacement level: 2.1
children per woman - India‚Äôs current TFR: Approximately 2.0 - State
variations: Kerala (1.8), Uttar Pradesh (2.4)</p>
<p><strong>Age-specific Fertility Rate (ASFR):</strong> - Peak fertility
in 20-24 age group - Declining trend in all age groups - Educational
impact on fertility patterns</p>
<p><strong>Mortality Patterns:</strong></p>
<p><strong>Infant Mortality Rate (IMR):</strong> - Current IMR: ~28 per
1000 live births - Rural vs urban differentials - State-level
variations</p>
<p><strong>Maternal Mortality Ratio (MMR):</strong> - Current MMR: ~97
per 100,000 live births - Leading causes: Hemorrhage, sepsis,
hypertension - Prevention strategies importance</p>
<h3 id="migration-and-health">Migration and Health</h3>
<p><strong>Types of Migration:</strong> - <strong>Rural to
Urban</strong>: Health service access challenges -
<strong>Inter-state</strong>: Cultural and linguistic barriers -
<strong>International</strong>: Health system adaptation -
<strong>Internal displacement</strong>: Crisis-related health issues</p>
<p><strong>Migration and Health Relationships:</strong> - <strong>Public
health implications</strong>: Disease transmission patterns -
<strong>Healthcare access</strong>: Continuity of care issues -
<strong>Social determinants</strong>: Housing, education, employment -
<strong>Vulnerable populations</strong>: Women, children, elderly</p>
<p><strong>Health Challenges for Migrants:</strong> - Language barriers
- Cultural differences - Economic constraints - Legal status issues -
Social isolation</p>
<h3 id="urban-vs-rural-health-patterns">Urban vs Rural Health
Patterns</h3>
<p><strong>Urban Health Characteristics:</strong> - Higher burden of
NCDs - Better healthcare access - Environmental health issues -
Lifestyle-related diseases - Mental health concerns</p>
<p><strong>Rural Health Characteristics:</strong> - Higher maternal and
child mortality - Infectious diseases prevalence - Limited healthcare
infrastructure - Transportation challenges - Health literacy issues</p>
<p><strong>Urban Health Challenges:</strong> - Air pollution - Water
quality - Waste management - Housing density - Stress-related
disorders</p>
<p><strong>Rural Health Challenges:</strong> - Access barriers - Human
resource shortages - Infrastructure limitations - Financial constraints
- Traditional health practices</p>
<h3 id="health-transition">Health Transition</h3>
<p><strong>Epidemiological Transition:</strong> - Shift from infectious
to chronic diseases - Changing disease patterns - Demographic transition
impact - Lifestyle modification needs</p>
<p><strong>Demographic Transition:</strong> - Aging population -
Changing dependency ratios - Healthcare needs evolution - Social support
systems</p>
<p><strong>Nutritional Transition:</strong> - Nutritional deficiency to
excess - Obesity emergence - Diet pattern changes - Physical activity
patterns</p>
<p><strong>Components of Health Transition:</strong> 1. Declining
mortality rates 2. Changing disease patterns 3. Extended life expectancy
4. Modified health needs 5. Healthcare system adaptation</p>
<h3 id="policy-implications">Policy Implications</h3>
<p><strong>National Health Policy (2017) Goals:</strong> - Health for
all approach - Universal health coverage - Digital health initiatives -
Traditional medicine integration</p>
<p><strong>Sustainable Development Goals (SDGs):</strong> - SDG 3: Good
health and well-being - SDG 5: Gender equality - SDG 10: Reduced
inequalities - Interconnected goals impact</p>
<p><strong>Evidence-Based Policy Making:</strong> - Research utilization
- Data-driven decisions - Cost-effectiveness analysis - Implementation
science</p>
<hr />
<h1 id="examination-tips-and-common-questions">Examination Tips and
Common Questions</h1>
<h2 id="research-methodology---quick-reference">Research Methodology -
Quick Reference</h2>
<p><strong>Memory Aids:</strong> - <strong>FINER</strong>: Feasible,
Interesting, Novel, Ethical, Relevant - <strong>PICO</strong>:
Population, Intervention, Comparison, Outcome -
<strong>OBSERVATIONAL</strong>: Cross-sectional, Case-control, Cohort,
Ecological</p>
<p><strong>Common Examination Questions:</strong></p>
<ol type="1">
<li><strong>Sample Size Calculation:</strong>
<ul>
<li>Formula for two means: n = 2(ZŒ±/2 + ZŒ≤)¬≤œÉ¬≤ / Œ¥¬≤</li>
<li>For proportions: Use pooled proportion method</li>
</ul></li>
<li><strong>Study Design Selection:</strong>
<ul>
<li>Intervention studies ‚Üí RCT</li>
<li>Prevalence ‚Üí Cross-sectional</li>
<li>Rare diseases ‚Üí Case-control</li>
<li>Rare exposures ‚Üí Cohort</li>
</ul></li>
<li><strong>Bias Prevention:</strong>
<ul>
<li>Selection bias ‚Üí Randomization, blinding</li>
<li>Information bias ‚Üí Standardization, validation</li>
<li>Confounding ‚Üí Stratification, adjustment</li>
</ul></li>
</ol>
<h2 id="biostatistics---quick-reference">Biostatistics - Quick
Reference</h2>
<p><strong>Memory Aids:</strong> - <strong>Mean</strong>: Sensitive to
outliers - <strong>Median</strong>: Robust to outliers -
<strong>Mode</strong>: Most frequent - <strong>68-95-99.7</strong>: Rule
for normal distribution</p>
<p><strong>Common Calculations:</strong></p>
<p><strong>Z-score:</strong> Z = (X - Œº) / œÉ</p>
<p><strong>Confidence Interval for Mean:</strong> CI = xÃÑ ¬± Z(Œ±/2) √ó
(s/‚àön)</p>
<p><strong>Chi-square Test:</strong> œá¬≤ = Œ£(O-E)¬≤/E df = (rows-1) √ó
(columns-1)</p>
<p><strong>Test Selection Guide:</strong> - 2 groups, continuous data ‚Üí
t-test - 3+ groups, continuous data ‚Üí ANOVA - Categorical data ‚Üí
Chi-square - Correlation ‚Üí Pearson (parametric), Spearman
(non-parametric)</p>
<h2 id="demography-and-social-work---quick-reference">Demography and
Social Work - Quick Reference</h2>
<p><strong>Key Formulas:</strong> - <strong>CBR</strong>:
(Births/Population) √ó 1000 - <strong>CDR</strong>: (Deaths/Population) √ó
1000 - <strong>Growth Rate</strong>: CBR - CDR + Net migration -
<strong>Sex Ratio</strong>: (Males/Females) √ó 1000 - <strong>Dependency
Ratio</strong>: ((0-14 + 65+)/(15-64)) √ó 100</p>
<p><strong>Demographic Transition Stages:</strong> 1. High stationary
(high birth + high death) 2. Early expanding (high birth + declining
death) 3. Late expanding (declining birth + low death) 4. Low stationary
(low birth + low death) 5. Declining (birth below death)</p>
<p><strong>Social Work Principles:</strong> - <strong>Case
Work</strong>: Individual focus - <strong>Group Work</strong>:
Collective action - <strong>Community Work</strong>: Population level -
<strong>CRM</strong>: Client, Resources, Methods</p>
<hr />
<h1 id="current-research-trends-in-public-health">Current Research
Trends in Public Health</h1>
<h2 id="research-methodology-advances">Research Methodology
Advances</h2>
<p><strong>Big Data and Analytics:</strong> - Machine learning
applications - Real-time data analysis - Predictive modeling - Data
visualization techniques</p>
<p><strong>Implementation Science:</strong> - Research-to-practice gaps
- Stakeholder engagement - Contextual factors - Sustainability
measures</p>
<p><strong>Digital Health Research:</strong> - Mobile health
interventions - Telemedicine effectiveness - Digital biomarkers - Remote
monitoring systems</p>
<h2 id="biostatistics-innovations">Biostatistics Innovations</h2>
<p><strong>Advanced Statistical Methods:</strong> - Bayesian statistics
- Machine learning algorithms - Causal inference methods - Missing data
techniques</p>
<p><strong>Computational Statistics:</strong> - High-performance
computing - Parallel processing - Cloud-based analytics - Automated
analysis pipelines</p>
<p><strong>Personalized Medicine Analytics:</strong> - Genomic data
analysis - Biomarker identification - Treatment effect heterogeneity -
Precision public health</p>
<h2 id="contemporary-demography">Contemporary Demography</h2>
<p><strong>Digital Demography:</strong> - Mobile phone data - Social
media analytics - Satellite imagery - Real-time population tracking</p>
<p><strong>Climate and Population:</strong> - Climate migration -
Environmental refugees - Adaptation strategies - Health vulnerability
assessments</p>
<p><strong>Urban Demography:</strong> - Smart city planning - Population
density optimization - Digital urban planning - Sustainable development
metrics</p>
<h2 id="social-work-evolution">Social Work Evolution</h2>
<p><strong>Technology Integration:</strong> - Digital case management -
Virtual counseling - Online support groups - AI-assisted
interventions</p>
<p><strong>Community-Based Participatory Research:</strong> - Community
engagement - Co-design approaches - Indigenous methodologies - Social
justice focus</p>
<p><strong>Global Social Work:</strong> - International standards -
Cross-cultural practice - Human rights approach - Global health
initiatives</p>
<hr />
<h1 id="practical-examples-and-calculations">Practical Examples and
Calculations</h1>
<h2 id="research-methodology-examples">Research Methodology
Examples</h2>
<p><strong>Sample Size Calculation Example:</strong> <em>Problem</em>:
Calculate sample size to detect 5 mmHg difference in systolic BP between
two groups, assuming SD = 15 mmHg, Œ± = 0.05, power = 80%</p>
<p><em>Solution</em>: n = 2(1.96 + 0.84)¬≤ √ó 15¬≤ / 5¬≤ n = 2(7.84) √ó 225 /
25 n = 2 √ó 7.84 √ó 9 n = 141.12 ‚âà 142 per group</p>
<h2 id="biostatistics-examples">Biostatistics Examples</h2>
<p><strong>Descriptive Statistics Example:</strong> <em>Data</em>: Age
of 10 patients: 25, 30, 35, 40, 45, 50, 55, 60, 65, 70</p>
<p><em>Mean</em> = (25+30+35+40+45+50+55+60+65+70)/10 = 475/10 = 47.5
years</p>
<p><em>Median</em> = (45+50)/2 = 47.5 years</p>
<p><em>Range</em> = 70-25 = 45 years</p>
<p><strong>Confidence Interval Example:</strong> <em>Data</em>: Sample
mean = 120 mmHg, SD = 15 mmHg, n = 100</p>
<p>95% CI = 120 ¬± 1.96 √ó (15/‚àö100) 95% CI = 120 ¬± 1.96 √ó 1.5 95% CI =
120 ¬± 2.94 95% CI = (117.06, 122.94) mmHg</p>
<p><strong>Chi-square Test Example:</strong> <em>Problem</em>:
Association between smoking and lung cancer</p>
<table>
<thead>
<tr>
<th></th>
<th>Cancer</th>
<th>No Cancer</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smokers</td>
<td>80</td>
<td>120</td>
<td>200</td>
</tr>
<tr>
<td>Non-smokers</td>
<td>20</td>
<td>180</td>
<td>200</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>300</td>
<td>400</td>
</tr>
</tbody>
</table>
<p><em>Expected frequencies</em>: - Smokers with cancer: (200√ó100)/400 =
50 - Smokers without cancer: (200√ó300)/400 = 150 - Non-smokers with
cancer: (200√ó100)/400 = 50 - Non-smokers without cancer: (200√ó300)/400 =
150</p>
<p><em>Chi-square calculation</em>: œá¬≤ = (80-50)¬≤/50 + (120-150)¬≤/150 +
(20-50)¬≤/50 + (180-150)¬≤/150 œá¬≤ = 900/50 + 900/150 + 900/50 + 900/150 œá¬≤
= 18 + 6 + 18 + 6 = 48</p>
<p>df = (2-1) √ó (2-1) = 1 p &lt; 0.001 (highly significant)</p>
<h2 id="demography-examples">Demography Examples</h2>
<p><strong>Population Growth Calculation:</strong> <em>Problem</em>:
Population in 2020 = 1 billion, CBR = 20/1000, CDR = 8/1000, net
migration = 100,000</p>
<p><em>Annual increase</em> = (20-8)/1000 √ó 1,000,000,000 + 100,000 =
12/1000 √ó 1,000,000,000 + 100,000 = 12,000,000 + 100,000 =
12,100,000</p>
<p><em>Growth rate</em> = 12,100,000 / 1,000,000,000 = 0.0121 =
1.21%</p>
<p><strong>Sex Ratio Calculation:</strong> <em>Problem</em>: Males =
51,000, Females = 49,000</p>
<p>Sex ratio = (51,000/49,000) √ó 1000 = 1041 males per 1000 females</p>
<p><strong>Dependency Ratio Calculation:</strong> <em>Problem</em>: Age
0-14 = 25,000, Age 15-64 = 60,000, Age 65+ = 5,000</p>
<p>Dependency ratio = ((25,000 + 5,000)/60,000) √ó 100 = (30,000/60,000)
√ó 100 = 50%</p>
<hr />
<h1 id="memory-aids-for-formulas-and-concepts">Memory Aids for Formulas
and Concepts</h1>
<h2 id="statistical-formulas---mnemonics">Statistical Formulas -
Mnemonics</h2>
<p><strong>Mean Formula</strong>: ‚ÄúSum of X divided by N‚Äù (Œ£x/n) -
Remember: ‚ÄúS*N‚Äù = ‚ÄúSum divided by Number‚Äù</p>
<p><strong>Standard Deviation</strong>: ‚ÄúSquare root of variance‚Äù -
Remember: ‚ÄúœÉ = ‚àöœÉ¬≤‚Äù = ‚ÄúSigma equals square root of sigma squared‚Äù</p>
<p><strong>Z-score</strong>: ‚ÄúX minus mu over sigma‚Äù - Remember: ‚ÄúZ =
(X-Œº)/œÉ‚Äù = ‚ÄúZ equals X minus mu divided by sigma‚Äù</p>
<p><strong>Confidence Interval</strong>: ‚ÄúMean plus or minus Z times
standard error‚Äù - Remember: ‚ÄúCI = xÃÑ ¬± Z(Œ±/2) √ó SE‚Äù</p>
<p><strong>Chi-square</strong>: ‚ÄúSum of (Observed minus Expected)
squared over Expected‚Äù - Remember: ‚Äúœá¬≤ = Œ£(O-E)¬≤/E‚Äù</p>
<h2 id="demography-formulas---mnemonics">Demography Formulas -
Mnemonics</h2>
<p><strong>Crude Birth Rate</strong>: ‚ÄúBirths per thousand population‚Äù -
Remember: ‚ÄúCBR = (Births/Population) √ó 1000‚Äù</p>
<p><strong>Growth Rate</strong>: ‚ÄúBirth minus death plus migration‚Äù -
Remember: ‚ÄúGR = CBR - CDR + Net Migration‚Äù</p>
<p><strong>Sex Ratio</strong>: ‚ÄúMales per thousand females‚Äù - Remember:
‚ÄúSR = (Males/Females) √ó 1000‚Äù</p>
<p><strong>Dependency Ratio</strong>: ‚ÄúDependents per hundred working
age‚Äù - Remember: ‚ÄúDR = ((0-14 + 65+)/(15-64)) √ó 100‚Äù</p>
<h2 id="research-methodology---mnemonics">Research Methodology -
Mnemonics</h2>
<p><strong>FINER Criteria</strong>: ‚ÄúFind Interesting Novel Ethical
Relevant‚Äù - F-easible, I-nteresting, N-ovel, E-thical, R-elevant</p>
<p><strong>PICO Framework</strong>: ‚ÄúPopulation Intervention Comparison
Outcome‚Äù - P-opulation, I-ntervention, C-omparison, O-utcome</p>
<p><strong>Sample Size Components</strong>: ‚ÄúAlpha Beta Sigma Delta‚Äù -
ZŒ± (significance), ZŒ≤ (power), œÉ (standard deviation), Œ¥
(difference)</p>
<p><strong>Bias Types</strong>: ‚ÄúSelection, Information, Confounding‚Äù -
Remember: ‚ÄúSIC‚Äù for systematic errors</p>
<hr />
<h1 id="summary-tables-for-quick-revision">Summary Tables for Quick
Revision</h1>
<h2 id="statistical-tests-comparison">Statistical Tests Comparison</h2>
<table>
<colgroup>
<col style="width: 12%" />
<col style="width: 18%" />
<col style="width: 22%" />
<col style="width: 18%" />
<col style="width: 27%" />
</colgroup>
<thead>
<tr>
<th>Test</th>
<th>Purpose</th>
<th>Data Type</th>
<th>Groups</th>
<th>Assumptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>t-test</td>
<td>Compare 2 means</td>
<td>Continuous</td>
<td>Independent/Paired</td>
<td>Normality</td>
</tr>
<tr>
<td>Chi-square</td>
<td>Test association</td>
<td>Categorical</td>
<td>2+ groups</td>
<td>Expected ‚â•5</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Compare 3+ means</td>
<td>Continuous</td>
<td>Independent groups</td>
<td>Normality, equal variance</td>
</tr>
<tr>
<td>Mann-Whitney</td>
<td>Compare 2 groups</td>
<td>Ordinal/Continuous</td>
<td>Independent</td>
<td>Non-parametric</td>
</tr>
<tr>
<td>Kruskal-Wallis</td>
<td>Compare 3+ groups</td>
<td>Ordinal/Continuous</td>
<td>Independent</td>
<td>Non-parametric</td>
</tr>
<tr>
<td>Fisher‚Äôs exact</td>
<td>Association test</td>
<td>Categorical</td>
<td>2x2 table</td>
<td>Small samples</td>
</tr>
<tr>
<td>Pearson correlation</td>
<td>Linear relationship</td>
<td>Continuous</td>
<td>Continuous</td>
<td>Normality, linearity</td>
</tr>
<tr>
<td>Spearman correlation</td>
<td>Monotonic relationship</td>
<td>Ordinal/Continuous</td>
<td>Continuous</td>
<td>Monotonic</td>
</tr>
</tbody>
</table>
<h2 id="demographic-indicators-reference">Demographic Indicators
Reference</h2>
<table>
<thead>
<tr>
<th>Indicator</th>
<th>Formula</th>
<th>Normal Range</th>
<th>India (Approx.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBR</td>
<td>(Births/Population) √ó 1000</td>
<td>10-25</td>
<td>~17</td>
</tr>
<tr>
<td>CDR</td>
<td>(Deaths/Population) √ó 1000</td>
<td>5-15</td>
<td>~7</td>
</tr>
<tr>
<td>TFR</td>
<td>Average children/woman</td>
<td>2.1 (replacement)</td>
<td>~2.0</td>
</tr>
<tr>
<td>IMR</td>
<td>(Deaths &lt;1yr/Live births) √ó 1000</td>
<td>&lt;10</td>
<td>~28</td>
</tr>
<tr>
<td>MMR</td>
<td>(Maternal deaths/Live births) √ó 100,000</td>
<td>&lt;70</td>
<td>~97</td>
</tr>
<tr>
<td>Sex Ratio</td>
<td>(Males/Females) √ó 1000</td>
<td>950-1050</td>
<td>~943</td>
</tr>
<tr>
<td>Growth Rate</td>
<td>CBR - CDR + Migration</td>
<td>0-2%</td>
<td>~1.0%</td>
</tr>
<tr>
<td>Literacy Rate</td>
<td>(Literate/Total) √ó 100</td>
<td>&gt;90%</td>
<td>~74%</td>
</tr>
</tbody>
</table>
<h2 id="population-pyramid-characteristics">Population Pyramid
Characteristics</h2>
<table>
<colgroup>
<col style="width: 10%" />
<col style="width: 20%" />
<col style="width: 21%" />
<col style="width: 31%" />
<col style="width: 16%" />
</colgroup>
<thead>
<tr>
<th>Type</th>
<th>Base Shape</th>
<th>Growth Rate</th>
<th>Development Stage</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expansive</td>
<td>Wide base, narrow top</td>
<td>High</td>
<td>Developing countries</td>
<td>Nigeria, Afghanistan</td>
</tr>
<tr>
<td>Stationary</td>
<td>Straight sides</td>
<td>Moderate</td>
<td>Developed countries</td>
<td>USA, UK</td>
</tr>
<tr>
<td>Constrictive</td>
<td>Narrow base, wide middle</td>
<td>Low/Stable</td>
<td>Post-industrial</td>
<td>Japan, Germany</td>
</tr>
<tr>
<td>Declining</td>
<td>Very narrow base</td>
<td>Negative</td>
<td>Post-transition</td>
<td>Bulgaria, Romania</td>
</tr>
</tbody>
</table>
<hr />
<p><em>End of Part IX: Appendices and References</em></p>
<hr />
<h2 id="references-and-further-reading">References and Further
Reading</h2>
<ol type="1">
<li><strong>Research Methodology:</strong>
<ul>
<li>Hulley SB, et al.¬†<em>Designing Clinical Research</em>. 4th
ed.¬†Lippincott Williams &amp; Wilkins, 2013.</li>
<li>Kish L. <em>Survey Sampling</em>. John Wiley &amp; Sons, 1995.</li>
<li>Schlesselman JJ. <em>Case-Control Studies: Design, Conduct,
Analysis</em>. Oxford University Press, 1982.</li>
</ul></li>
<li><strong>Biostatistics:</strong>
<ul>
<li>Altman DG. <em>Practical Statistics for Medical Research</em>.
Chapman &amp; Hall/CRC, 1991.</li>
<li>Rosner B. <em>Fundamentals of Biostatistics</em>. 8th ed.¬†Cengage
Learning, 2015.</li>
<li>Fisher LD, Van Belle G. <em>Biostatistics: A Methodology for the
Health Sciences</em>. John Wiley &amp; Sons, 1993.</li>
</ul></li>
<li><strong>Demography:</strong>
<ul>
<li>Rowland DT. <em>Population Geography</em>. Progress in Human
Geography, 2003.</li>
<li>Billari FC, et al.¬†<em>Population Dynamics and Projection
Methods</em>. Springer, 2011.</li>
<li>Dyson T. <em>Population and Development: The Demographic
Transition</em>. Zed Books, 2010.</li>
</ul></li>
<li><strong>Social Work:</strong>
<ul>
<li>Healy LM. <em>The Social Work and Social Policy Companion</em>.
Palgrave Macmillan, 2005.</li>
<li>Dalrymple J, Burke B. <em>Anti-Oppressive Practice: Social Care and
the Law</em>. Open University Press, 2006.</li>
<li>Adams R, et al.¬†<em>Social Work: Themes, Issues and Critical
Debates</em>. Palgrave Macmillan, 2009.</li>
</ul></li>
<li><strong>Current Research Trends:</strong>
<ul>
<li><em>Lancet Public Health</em> - Global public health research</li>
<li><em>American Journal of Public Health</em> - Health policy and
practice</li>
<li><em>Population and Development Review</em> - Contemporary
demographic research</li>
<li><em>International Social Work</em> - Global social work practice and
research</li>
</ul></li>
</ol>
<hr />
<p><strong>Appendix A: Statistical Tables</strong> - Standard Normal
Distribution Table - t-Distribution Critical Values - Chi-square
Distribution Values - F-Distribution Critical Values</p>
<p><strong>Appendix B: Sample Size Calculation Tables</strong> - Sample
sizes for different study designs - Power calculation charts - Effect
size reference values</p>
<p><strong>Appendix C: Vital Statistics Forms</strong> - Standard death
certificate format - Birth registration forms - Census questionnaires -
Health survey instruments</p>
<hr />
<p><em>This completes Part IX of the Community Medicine Quick Revision
Manual. The appendices provide comprehensive coverage of research
methodology, biostatistics, and social work/demography topics essential
for MBBS examinations and public health practice.</em> <strong>Solu√ß√£o
de Problemas:</strong> - Problem identification and analysis</p>
<h1 id="manual-back-matter-and-bibliography">Manual Back Matter and
Bibliography</h1>
<h2 id="community-medicine-quick-revision-manual-for-mbbs-1">Community
Medicine Quick Revision Manual for MBBS</h2>
<hr />
<h1 id="table-of-contents-1">Table of Contents</h1>
<ol type="1">
<li><a href="#bibliography-and-references">Bibliography and
References</a></li>
<li><a href="#important-appendices">Important Appendices</a>
<ul>
<li><a href="#appendix-a-normal-values-and-reference-ranges">Appendix A:
Normal Values and Reference Ranges</a></li>
<li><a href="#appendix-b-immunization-schedules">Appendix B:
Immunization Schedules</a></li>
<li><a
href="#appendix-c-anthropometric-charts-and-growth-standards">Appendix
C: Anthropometric Charts and Growth Standards</a></li>
<li><a href="#appendix-d-statistical-formulas-and-calculations">Appendix
D: Statistical Formulas and Calculations</a></li>
<li><a href="#appendix-e-drug-dosages-and-treatment-protocols">Appendix
E: Drug Dosages and Treatment Protocols</a></li>
<li><a href="#appendix-f-health-indicators-and-targets">Appendix F:
Health Indicators and Targets</a></li>
<li><a
href="#appendix-g-emergency-contact-numbers-and-helplines">Appendix G:
Emergency Contact Numbers and Helplines</a></li>
<li><a href="#appendix-h-glossary-of-medical-terms">Appendix H: Glossary
of Medical Terms</a></li>
</ul></li>
<li><a href="#quick-reference-tables">Quick Reference Tables</a></li>
<li><a href="#index-preparation">Index Preparation</a></li>
</ol>
<hr />
<h1 id="bibliography-and-references">Bibliography and References</h1>
<h2 id="primary-sources">Primary Sources</h2>
<h3 id="essential-textbooks">Essential Textbooks</h3>
<p><strong>1. Park Textbook of Preventive and Social Medicine</strong> -
<em>Park K</em>. <strong>Park‚Äôs Textbook of Preventive and Social
Medicine</strong>. 26th Edition. Jabalpur: M/s Banarsidas Bhanot; 2021.
- <strong>Key Chapters</strong>: Epidemiology, Communicable Diseases,
Environmental Health, Maternal and Child Health, Health Management,
National Health Programs</p>
<p><strong>2. Last‚Äôs Public Health and Community Medicine</strong> -
<strong>Wallace A</strong>. <em>Maxcy-Rosenau-Last Public Health and
Preventive Medicine</em>. 16th Edition. New York: McGraw-Hill; 2021. -
<strong>Key Topics</strong>: Global health, epidemiology, health
systems, prevention strategies</p>
<p><strong>3. Gordis Epidemiology</strong> - <strong>Gordis L</strong>.
<em>Epidemiology</em>. 6th Edition. Philadelphia: Elsevier; 2020. -
<strong>Focus Areas</strong>: Study design, causal inference,
surveillance, screening</p>
<h2 id="who-guidelines-and-publications">WHO Guidelines and
Publications</h2>
<h3 id="core-who-documents">Core WHO Documents</h3>
<p><strong>4. International Health Regulations (IHR 2005)</strong> -
<strong>World Health Organization</strong>. <em>International Health
Regulations (2005)</em>. 3rd Edition. Geneva: WHO; 2016. -
<strong>URL</strong>:
https://www.who.int/teams/global-surveillance-response/ihr</p>
<p><strong>5. Global Health Observatory Data</strong> - <strong>World
Health Organization</strong>. <em>Global Health Observatory Data
Repository</em>. Updated 2024. - <strong>URL</strong>:
https://www.who.int/data/gho</p>
<p><strong>6. WHO Essential Medicines List</strong> - <strong>World
Health Organization</strong>. <em>WHO Model List of Essential
Medicines</em>. 22nd List. Geneva: WHO; 2021. - <strong>Latest
Update</strong>: March 2024</p>
<p><strong>7. Health System Strengthening Framework</strong> -
<strong>World Health Organization</strong>. <em>Framework for Action on
Strengthening Health Systems to Improve Health Outcomes</em>. Geneva:
WHO; 2007. - <strong>Application</strong>: Health system analysis and
improvement</p>
<p><strong>8. WHO Global Health Estimates</strong> - <strong>World
Health Organization</strong>. <em>Global Health Estimates 2019</em>.
Geneva: WHO; 2020. - <strong>Coverage</strong>: Global disease burden,
mortality, health trends</p>
<h2 id="government-of-india-health-reports-and-policies">Government of
India Health Reports and Policies</h2>
<h3 id="central-government-documents">Central Government Documents</h3>
<p><strong>9. National Health Policy 2017</strong> - <strong>Government
of India, Ministry of Health and Family Welfare</strong>. <em>National
Health Policy 2017</em>. New Delhi: MoHFW; 2017. - <strong>URL</strong>:
https://www.nhp.gov.in/national-health-policy</p>
<p><strong>10. National Family Health Survey-5 (NFHS-5)</strong> -
<strong>International Institute for Population Sciences</strong>.
<em>National Family Health Survey (NFHS-5) 2019-21</em>. Mumbai: IIPS;
2021. - <strong>Key Reports</strong>: - NFHS-5 India Report - State-wise
Fact Sheets (All 36 states/UTs)</p>
<p><strong>11. Census of India 2011</strong> - <strong>Office of the
Registrar General &amp; Census Commissioner, India</strong>. <em>Census
of India 2011</em>. New Delhi: Ministry of Home Affairs; 2011. -
<strong>URL</strong>: http://www.censusindia.gov.in/</p>
<p><strong>12. Sample Registration System Statistical Report
2020</strong> - <strong>Office of the Registrar General, India</strong>.
<em>Sample Registration System Statistical Report 2020</em>. New Delhi:
Ministry of Home Affairs; 2021. - <strong>Coverage</strong>: Birth and
death rates, fertility and mortality</p>
<p><strong>13. Health Management Information System (HMIS) Data</strong>
- <strong>Government of India, Ministry of Health and Family
Welfare</strong>. <em>HMIS Portal</em>. Updated 2024. -
<strong>URL</strong>: https://nrhm-mis.nic.in/</p>
<h3 id="state-government-health-reports">State Government Health
Reports</h3>
<p><strong>14. State Health Reports</strong> - Various State Health and
Family Welfare Departments - <strong>Example</strong>: Tamil Nadu Health
System Project Report 2023 - <strong>Coverage</strong>: State-specific
health indicators, program performance</p>
<h2 id="national-health-program-documents">National Health Program
Documents</h2>
<h3 id="major-national-health-programs">Major National Health
Programs</h3>
<p><strong>15. National Vector Borne Disease Control Program</strong> -
<strong>Government of India, Ministry of Health and Family
Welfare</strong>. <em>Operational Guidelines for NVBDCP</em>. New Delhi:
MoHFW; 2020. - <strong>Components</strong>: Malaria, Filaria, Dengue,
Chikungunya, Japanese Encephalitis</p>
<p><strong>16. Revised National Tuberculosis Control Program
(RNTCP)</strong> - <strong>Government of India, Ministry of Health and
Family Welfare</strong>. <em>National Strategic Plan for Tuberculosis
Elimination 2020-2025</em>. New Delhi: Central TB Division; 2020. -
<strong>Guidelines</strong>: National Tuberculosis Elimination Program
(NTEP)</p>
<p><strong>17. National AIDS Control Organization (NACO)
Guidelines</strong> - <strong>National AIDS Control
Organization</strong>. <em>National Guidelines for HIV Testing
Services</em>. New Delhi: NACO; 2023. - <strong>Coverage</strong>: HIV
testing, treatment, prevention strategies</p>
<p><strong>18. National Programme for Control of Blindness</strong> -
<strong>Government of India, Ministry of Health and Family
Welfare</strong>. <em>National Programme for Control of Blindness &amp;
Visual Impairment</em>. New Delhi: MoHFW; 2019. -
<strong>Focus</strong>: Cataract surgery, eye health, visual
impairment</p>
<p><strong>19. Integrated Child Development Services (ICDS)</strong> -
<strong>Government of India, Ministry of Women and Child
Development</strong>. <em>Operational Guidelines for ICDS</em>. New
Delhi: MWCD; 2018. - <strong>Components</strong>: Nutrition, health,
education, women empowerment</p>
<p><strong>20. Pradhan Mantri Swasthya Suraksha Yojana (PMSSY)</strong>
- <strong>Government of India, Ministry of Health and Family
Welfare</strong>. <em>PMSSY Guidelines</em>. New Delhi: MoHFW; 2021. -
<strong>Objective</strong>: Infrastructure development and medical
education</p>
<h2 id="recent-research-publications-and-journals">Recent Research
Publications and Journals</h2>
<h3 id="peer-reviewed-journals">Peer-Reviewed Journals</h3>
<p><strong>21. The Lancet Public Health</strong> -
<strong>Publisher</strong>: Elsevier - <strong>Focus</strong>: Global
public health research, policy analysis - <strong>Impact
Factor</strong>: High (2023) - <strong>URL</strong>:
https://www.thelancet.com/journals/lanpub/home</p>
<p><strong>22. American Journal of Public Health</strong> -
<strong>Publisher</strong>: American Public Health Association -
<strong>Coverage</strong>: US and international public health research -
<strong>Frequency</strong>: Monthly - <strong>URL</strong>:
https://ajph.aphapublications.org/</p>
<p><strong>23. BMJ Global Health</strong> - <strong>Publisher</strong>:
BMJ Publishing Group - <strong>Scope</strong>: Global health research
and policy - <strong>Focus</strong>: Health systems, implementation
research - <strong>URL</strong>: https://gh.bmj.com/</p>
<p><strong>24. Indian Journal of Public Health</strong> -
<strong>Publisher</strong>: Indian Public Health Association -
<strong>Coverage</strong>: Indian health scenario, community medicine -
<strong>Frequency</strong>: Quarterly - <strong>URL</strong>:
https://www.ijph.in/</p>
<p><strong>25. The Lancet Infectious Diseases</strong> -
<strong>Publisher</strong>: Elsevier - <strong>Focus</strong>:
Infectious disease research, epidemiology - <strong>Coverage</strong>:
Global infectious disease trends - <strong>URL</strong>:
https://www.thelancet.com/journals/laninf/home</p>
<h3 id="recent-research-articles-2020-2024">Recent Research Articles
(2020-2024)</h3>
<p><strong>26. COVID-19 Pandemic Impact Studies</strong> -
<strong>Multiple authors</strong>. <em>The COVID-19 pandemic and public
health response in India</em>. Lancet Regional Health - Southeast Asia.
2022. - <strong>Key Insights</strong>: Health system resilience, policy
responses</p>
<p><strong>27. Antimicrobial Resistance Research</strong> - <strong>Van
Boeckel TP, et al</strong>. <em>Global trends in antimicrobial
resistance</em>. Nature Reviews Drug Discovery. 2021. -
<strong>Application</strong>: AMR surveillance and containment</p>
<p><strong>28. Digital Health in India</strong> - <strong>Mohan P, et
al</strong>. <em>Digital health in India: Current status and future
perspectives</em>. BMJ Health &amp; Care Informatics. 2023. -
<strong>Focus</strong>: Telemedicine, health information systems</p>
<h2 id="medical-council-guidelines-and-regulations">Medical Council
Guidelines and Regulations</h2>
<h3 id="medical-council-of-india">Medical Council of India</h3>
<p><strong>29. Indian Medical Council Act 1956</strong> -
<strong>Medical Council of India</strong>. <em>Indian Medical Council
Act 1956</em>. New Delhi: MCI; 1956. - <strong>Recent
Amendments</strong>: MCI Amendment Act 2020 - <strong>Key
Regulations</strong>: Medical education, professional conduct</p>
<p><strong>30. National Medical Commission (NMC) Guidelines</strong> -
<strong>National Medical Commission</strong>. <em>Establishment and
Functions Regulations</em>. New Delhi: NMC; 2020. -
<strong>Coverage</strong>: Medical education standards, professional
ethics</p>
<p><strong>31. Indian Medical Register</strong> - <strong>Medical
Council of India</strong>. <em>Indian Medical Register</em>. Updated
2024. - <strong>Maintenance</strong>: Registered medical practitioners
database - <strong>URL</strong>: https://www.mciindia.org/</p>
<h3 id="professional-guidelines">Professional Guidelines</h3>
<p><strong>32. World Medical Association International Code of Medical
Ethics</strong> - <strong>World Medical Association</strong>.
<em>International Code of Medical Ethics</em>. Updated 2018. -
<strong>Application</strong>: Professional conduct standards</p>
<p><strong>33. National Ethical Guidelines for Biomedical and Health
Research</strong> - <strong>Indian Council of Medical Research</strong>.
<em>National Ethical Guidelines for Biomedical and Health Research
Involving Human Participants</em>. New Delhi: ICMR; 2017. -
<strong>Update</strong>: 2023 revision</p>
<p><strong>34. WHO Guidelines for Health Care Workers</strong> -
<strong>World Health Organization</strong>. <em>WHO Guidelines on Health
Worker Education and Training</em>. Geneva: WHO; 2021. -
<strong>Coverage</strong>: Health workforce development</p>
<hr />
<h1 id="important-appendices">Important Appendices</h1>
<h2 id="appendix-a-normal-values-and-reference-ranges">Appendix A:
Normal Values and Reference Ranges</h2>
<h3 id="a.1-anthropometric-measurements">A.1 Anthropometric
Measurements</h3>
<p><strong>A.1.1 Weight (kg)</strong></p>
<table>
<colgroup>
<col style="width: 15%" />
<col style="width: 40%" />
<col style="width: 44%" />
</colgroup>
<thead>
<tr>
<th>Age Group</th>
<th>Male (3rd-97th percentile)</th>
<th>Female (3rd-97th percentile)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1 year</td>
<td>7.5-10.2</td>
<td>7.0-9.5</td>
</tr>
<tr>
<td>1-5 years</td>
<td>12.1-18.5</td>
<td>11.5-17.9</td>
</tr>
<tr>
<td>5-10 years</td>
<td>18.5-31.2</td>
<td>18.0-29.9</td>
</tr>
<tr>
<td>10-15 years</td>
<td>31.0-53.2</td>
<td>32.0-51.8</td>
</tr>
<tr>
<td>Adult (&gt;18 years)</td>
<td>65-85</td>
<td>55-70</td>
</tr>
</tbody>
</table>
<p><strong>A.1.2 Height (cm)</strong></p>
<table>
<thead>
<tr>
<th>Age Group</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth</td>
<td>45-55</td>
<td>45-53</td>
</tr>
<tr>
<td>1 year</td>
<td>70-80</td>
<td>69-79</td>
</tr>
<tr>
<td>5 years</td>
<td>102-119</td>
<td>102-118</td>
</tr>
<tr>
<td>10 years</td>
<td>129-149</td>
<td>130-149</td>
</tr>
<tr>
<td>15 years</td>
<td>160-178</td>
<td>155-167</td>
</tr>
<tr>
<td>Adult (&gt;18 years)</td>
<td>165-185</td>
<td>153-173</td>
</tr>
</tbody>
</table>
<p><strong>A.1.3 BMI Categories (kg/m¬≤)</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>BMI Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underweight</td>
<td>&lt;18.5</td>
</tr>
<tr>
<td>Normal weight</td>
<td>18.5-24.9</td>
</tr>
<tr>
<td>Overweight</td>
<td>25.0-29.9</td>
</tr>
<tr>
<td>Obese Class I</td>
<td>30.0-34.9</td>
</tr>
<tr>
<td>Obese Class II</td>
<td>35.0-39.9</td>
</tr>
<tr>
<td>Obese Class III</td>
<td>‚â•40.0</td>
</tr>
</tbody>
</table>
<h3 id="a.2-vital-signs">A.2 Vital Signs</h3>
<p><strong>A.2.1 Normal Vital Signs by Age</strong></p>
<table>
<colgroup>
<col style="width: 6%" />
<col style="width: 37%" />
<col style="width: 29%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Age</th>
<th>Respiratory Rate (per min)</th>
<th>Heart Rate (per min)</th>
<th>Systolic BP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn (0-28 days)</td>
<td>30-50</td>
<td>100-160</td>
<td>65-85</td>
</tr>
<tr>
<td>Infant (1-12 months)</td>
<td>20-40</td>
<td>100-150</td>
<td>80-100</td>
</tr>
<tr>
<td>Toddler (1-3 years)</td>
<td>20-30</td>
<td>90-140</td>
<td>90-105</td>
</tr>
<tr>
<td>Preschool (4-5 years)</td>
<td>20-25</td>
<td>80-120</td>
<td>95-110</td>
</tr>
<tr>
<td>School age (6-12 years)</td>
<td>16-22</td>
<td>70-100</td>
<td>100-120</td>
</tr>
<tr>
<td>Adolescent (13-18 years)</td>
<td>14-20</td>
<td>60-100</td>
<td>110-130</td>
</tr>
<tr>
<td>Adult (19-64 years)</td>
<td>12-20</td>
<td>60-100</td>
<td>110-130</td>
</tr>
<tr>
<td>Elderly (&gt;65 years)</td>
<td>12-18</td>
<td>60-100</td>
<td>110-140</td>
</tr>
</tbody>
</table>
<p><strong>A.2.2 Blood Pressure Classification (mmHg)</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Systolic</th>
<th>Diastolic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt;120</td>
<td>&lt;80</td>
</tr>
<tr>
<td>Elevated</td>
<td>120-129</td>
<td>&lt;80</td>
</tr>
<tr>
<td>Stage 1 Hypertension</td>
<td>130-139</td>
<td>80-89</td>
</tr>
<tr>
<td>Stage 2 Hypertension</td>
<td>‚â•140</td>
<td>‚â•90</td>
</tr>
<tr>
<td>Hypertensive Crisis</td>
<td>&gt;180</td>
<td>&gt;120</td>
</tr>
</tbody>
</table>
<h3 id="a.3-laboratory-reference-values">A.3 Laboratory Reference
Values</h3>
<p><strong>A.3.1 Complete Blood Count</strong></p>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Male</th>
<th>Female</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>13.5-17.5</td>
<td>12.0-15.5</td>
<td>g/dL</td>
</tr>
<tr>
<td>RBC Count</td>
<td>4.5-5.9</td>
<td>4.1-5.1</td>
<td>million/ŒºL</td>
</tr>
<tr>
<td>WBC Count</td>
<td>4.0-11.0</td>
<td>4.0-11.0</td>
<td>thousand/ŒºL</td>
</tr>
<tr>
<td>Platelet Count</td>
<td>150-450</td>
<td>150-450</td>
<td>thousand/ŒºL</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>41-53%</td>
<td>36-46%</td>
<td>%</td>
</tr>
</tbody>
</table>
<p><strong>A.3.2 Blood Chemistry</strong></p>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal Range</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (Fasting)</td>
<td>70-100</td>
<td>mg/dL</td>
</tr>
<tr>
<td>Glucose (PP)</td>
<td>&lt;140</td>
<td>mg/dL</td>
</tr>
<tr>
<td>Total Cholesterol</td>
<td>&lt;200</td>
<td>mg/dL</td>
</tr>
<tr>
<td>LDL Cholesterol</td>
<td>&lt;100</td>
<td>mg/dL</td>
</tr>
<tr>
<td>HDL Cholesterol</td>
<td>‚â•40 (Male), ‚â•50 (Female)</td>
<td>mg/dL</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>&lt;150</td>
<td>mg/dL</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.7-1.3</td>
<td>mg/dL</td>
</tr>
<tr>
<td>Urea</td>
<td>20-40</td>
<td>mg/dL</td>
</tr>
</tbody>
</table>
<p><strong>A.3.3 Liver Function Tests</strong></p>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal Range</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilirubin (Total)</td>
<td>0.3-1.2</td>
<td>mg/dL</td>
</tr>
<tr>
<td>Bilirubin (Direct)</td>
<td>0.1-0.3</td>
<td>mg/dL</td>
</tr>
<tr>
<td>SGOT/AST</td>
<td>10-40</td>
<td>U/L</td>
</tr>
<tr>
<td>SGPT/ALT</td>
<td>10-40</td>
<td>U/L</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>44-147</td>
<td>U/L</td>
</tr>
<tr>
<td>Total Protein</td>
<td>6.0-8.3</td>
<td>g/dL</td>
</tr>
<tr>
<td>Albumin</td>
<td>3.5-5.0</td>
<td>g/dL</td>
</tr>
</tbody>
</table>
<h3 id="a.4-immunological-parameters">A.4 Immunological Parameters</h3>
<p><strong>A.4.1 Vaccine Coverage Targets</strong></p>
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Target Coverage (%)</th>
<th>WHO Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPT3</td>
<td>‚â•90%</td>
<td>95%</td>
</tr>
<tr>
<td>Measles</td>
<td>‚â•90%</td>
<td>95%</td>
</tr>
<tr>
<td>Polio</td>
<td>‚â•90%</td>
<td>95%</td>
</tr>
<tr>
<td>BCG</td>
<td>‚â•90%</td>
<td>95%</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>‚â•90%</td>
<td>95%</td>
</tr>
<tr>
<td>HPV</td>
<td>‚â•70%</td>
<td>90%</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendix-b-immunization-schedules">Appendix B: Immunization
Schedules</h2>
<h3 id="b.1-national-immunization-schedule-india">B.1 National
Immunization Schedule (India)</h3>
<p><strong>B.1.1 Routine Immunization Schedule</strong></p>
<table>
<colgroup>
<col style="width: 15%" />
<col style="width: 27%" />
<col style="width: 18%" />
<col style="width: 21%" />
<col style="width: 18%" />
</colgroup>
<thead>
<tr>
<th>Age</th>
<th>Vaccine</th>
<th>Dose</th>
<th>Route</th>
<th>Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth</td>
<td>BCG, Hep B (Birth dose), OPV (0)</td>
<td>1</td>
<td>ID, IM, PO</td>
<td>Left upper arm, Anterolateral thigh, Mouth</td>
</tr>
<tr>
<td>6 weeks</td>
<td>DPT, OPV, Hep B, Hib</td>
<td>1</td>
<td>IM</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>10 weeks</td>
<td>DPT, OPV, Hep B, Hib</td>
<td>2</td>
<td>IM</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>14 weeks</td>
<td>DPT, OPV, Hep B, Hib</td>
<td>3</td>
<td>IM</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>9 months</td>
<td>Measles/MMR, Vitamin A</td>
<td>1</td>
<td>SC</td>
<td>Right upper arm</td>
</tr>
<tr>
<td>16-24 months</td>
<td>DPT, OPV (Booster), Measles/MMR</td>
<td>Booster</td>
<td>IM, PO, SC</td>
<td>Anterolateral thigh, Mouth, Right upper arm</td>
</tr>
<tr>
<td>5-6 years</td>
<td>DPT Booster, Typhoid</td>
<td>Booster</td>
<td>IM</td>
<td>Upper arm</td>
</tr>
<tr>
<td>10 years</td>
<td>Td/Tdap</td>
<td>1</td>
<td>IM</td>
<td>Upper arm</td>
</tr>
<tr>
<td>16 years</td>
<td>Td</td>
<td>1</td>
<td>IM</td>
<td>Upper arm</td>
</tr>
</tbody>
</table>
<p><strong>B.1.2 Special Immunizations</strong></p>
<table>
<colgroup>
<col style="width: 34%" />
<col style="width: 21%" />
<col style="width: 24%" />
<col style="width: 19%" />
</colgroup>
<thead>
<tr>
<th>Target Group</th>
<th>Vaccine</th>
<th>Schedule</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare Workers</td>
<td>Hepatitis B</td>
<td>0, 1, 6 months</td>
<td>Check antibody levels</td>
</tr>
<tr>
<td>Pregnant Women</td>
<td>Tdap</td>
<td>27-36 weeks</td>
<td>If not immunized in last 5 years</td>
</tr>
<tr>
<td>Elderly (&gt;65 years)</td>
<td>Influenza</td>
<td>Annual</td>
<td>High-risk individuals</td>
</tr>
<tr>
<td>Immunocompromised</td>
<td>PCV</td>
<td>3 doses</td>
<td>HIV, malignancy, transplant</td>
</tr>
</tbody>
</table>
<h3 id="b.2-who-immunization-schedule">B.2 WHO Immunization
Schedule</h3>
<p><strong>B.2.1 Recommended Routine Immunization</strong></p>
<table>
<colgroup>
<col style="width: 15%" />
<col style="width: 28%" />
<col style="width: 56%" />
</colgroup>
<thead>
<tr>
<th>Age</th>
<th>Vaccine</th>
<th>Minimum Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth</td>
<td>BCG, Hepatitis B, Polio (birth dose)</td>
<td>-</td>
</tr>
<tr>
<td>6 weeks</td>
<td>DPT, Hep B, Hib, PCV, Rotavirus</td>
<td>4 weeks from birth dose</td>
</tr>
<tr>
<td>10 weeks</td>
<td>DTP, Hep B, Hib, PCV, Rotavirus</td>
<td>4 weeks from previous</td>
</tr>
<tr>
<td>14 weeks</td>
<td>DTP, Hep B, Hib, PCV, Rotavirus</td>
<td>4 weeks from previous</td>
</tr>
<tr>
<td>9 months</td>
<td>Measles, Yellow fever (endemic areas)</td>
<td>4 weeks from third dose</td>
</tr>
<tr>
<td>12-23 months</td>
<td>PCV Booster, MMR, Varicella</td>
<td>4 weeks from measles</td>
</tr>
<tr>
<td>5-7 years</td>
<td>DTP Booster, MMR Booster</td>
<td>4 years from previous DTP</td>
</tr>
<tr>
<td>9-13 years</td>
<td>HPV (2 doses), Tdap Booster</td>
<td>6 months interval for HPV</td>
</tr>
</tbody>
</table>
<h3 id="b.3-travel-immunization">B.3 Travel Immunization</h3>
<p><strong>B.3.1 Mandatory Travel Vaccines</strong></p>
<table style="width:100%;">
<colgroup>
<col style="width: 28%" />
<col style="width: 42%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr>
<th>Destination</th>
<th>Required Vaccines</th>
<th>Certificate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saudi Arabia (Hajj/Umrah)</td>
<td>Meningococcal ACWY</td>
<td>Valid certificate</td>
</tr>
<tr>
<td>Yellow fever endemic areas</td>
<td>Yellow fever</td>
<td>International certificate</td>
</tr>
<tr>
<td>Some African countries</td>
<td>Yellow fever</td>
<td>International certificate</td>
</tr>
</tbody>
</table>
<p><strong>B.3.2 Recommended Travel Vaccines</strong></p>
<table style="width:100%;">
<colgroup>
<col style="width: 42%" />
<col style="width: 28%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr>
<th>Risk Category</th>
<th>Vaccines</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adventure tourism</td>
<td>Japanese encephalitis, Rabies</td>
<td>0, 7, 21 days, 0, 7, 28 days</td>
</tr>
<tr>
<td>Rural areas in Asia</td>
<td>Japanese encephalitis</td>
<td>0, 28 days</td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>Meningococcal</td>
<td>Single dose</td>
</tr>
<tr>
<td>Long-term travelers</td>
<td>Hepatitis A, Typhoid</td>
<td>0, 6-12 months, 0, 14 days</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendix-c-anthropometric-charts-and-growth-standards">Appendix
C: Anthropometric Charts and Growth Standards</h2>
<h3 id="c.1-who-child-growth-standards-0-5-years">C.1 WHO Child Growth
Standards (0-5 years)</h3>
<p><strong>C.1.1 Length/Height-for-Age (z-scores)</strong></p>
<table>
<colgroup>
<col style="width: 5%" />
<col style="width: 17%" />
<col style="width: 18%" />
<col style="width: 28%" />
<col style="width: 30%" />
</colgroup>
<thead>
<tr>
<th>Age</th>
<th>Boys (Median)</th>
<th>Girls (Median)</th>
<th>Severe Stunting (&lt;-3 SD)</th>
<th>Moderate Stunting (&lt;-2 SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>67.6 cm</td>
<td>65.7 cm</td>
<td>&lt;61.5 cm</td>
<td>&lt;63.3 cm</td>
</tr>
<tr>
<td>12 months</td>
<td>76.1 cm</td>
<td>74.0 cm</td>
<td>&lt;70.1 cm</td>
<td>&lt;72.0 cm</td>
</tr>
<tr>
<td>24 months</td>
<td>87.1 cm</td>
<td>85.7 cm</td>
<td>&lt;80.5 cm</td>
<td>&lt;82.9 cm</td>
</tr>
<tr>
<td>36 months</td>
<td>95.2 cm</td>
<td>94.2 cm</td>
<td>&lt;89.0 cm</td>
<td>&lt;91.9 cm</td>
</tr>
<tr>
<td>48 months</td>
<td>102.7 cm</td>
<td>101.6 cm</td>
<td>&lt;96.7 cm</td>
<td>&lt;99.1 cm</td>
</tr>
<tr>
<td>60 months</td>
<td>109.2 cm</td>
<td>108.0 cm</td>
<td>&lt;103.3 cm</td>
<td>&lt;105.7 cm</td>
</tr>
</tbody>
</table>
<p><strong>C.1.2 Weight-for-Age (0-60 months)</strong></p>
<table>
<colgroup>
<col style="width: 5%" />
<col style="width: 16%" />
<col style="width: 17%" />
<col style="width: 29%" />
<col style="width: 32%" />
</colgroup>
<thead>
<tr>
<th>Age</th>
<th>Boys (Median)</th>
<th>Girls (Median)</th>
<th>Severe Underweight (&lt;-3 SD)</th>
<th>Moderate Underweight (&lt;-2 SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>7.9 kg</td>
<td>7.3 kg</td>
<td>&lt;6.4 kg</td>
<td>&lt;6.9 kg</td>
</tr>
<tr>
<td>12 months</td>
<td>9.6 kg</td>
<td>8.9 kg</td>
<td>&lt;8.1 kg</td>
<td>&lt;8.5 kg</td>
</tr>
<tr>
<td>24 months</td>
<td>12.2 kg</td>
<td>11.5 kg</td>
<td>&lt;10.4 kg</td>
<td>&lt;10.9 kg</td>
</tr>
<tr>
<td>36 months</td>
<td>14.3 kg</td>
<td>13.7 kg</td>
<td>&lt;12.3 kg</td>
<td>&lt;12.8 kg</td>
</tr>
<tr>
<td>48 months</td>
<td>16.3 kg</td>
<td>15.8 kg</td>
<td>&lt;14.2 kg</td>
<td>&lt;14.8 kg</td>
</tr>
<tr>
<td>60 months</td>
<td>18.3 kg</td>
<td>17.5 kg</td>
<td>&lt;16.2 kg</td>
<td>&lt;16.9 kg</td>
</tr>
</tbody>
</table>
<p><strong>C.1.3 Weight-for-Length/Height</strong></p>
<table>
<colgroup>
<col style="width: 13%" />
<col style="width: 13%" />
<col style="width: 14%" />
<col style="width: 12%" />
<col style="width: 12%" />
<col style="width: 17%" />
<col style="width: 16%" />
</colgroup>
<thead>
<tr>
<th>Length/Height</th>
<th>Boys (Median)</th>
<th>Girls (Median)</th>
<th>SAM (&lt;-3 SD)</th>
<th>MAM (&lt;-2 SD)</th>
<th>Overweight (&gt;+2 SD)</th>
<th>Obesity (&gt;+3 SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>65 cm</td>
<td>7.5 kg</td>
<td>7.1 kg</td>
<td>&lt;6.4 kg</td>
<td>&lt;6.7 kg</td>
<td>&gt;8.3 kg</td>
<td>&gt;8.6 kg</td>
</tr>
<tr>
<td>75 cm</td>
<td>9.2 kg</td>
<td>8.8 kg</td>
<td>&lt;7.8 kg</td>
<td>&lt;8.2 kg</td>
<td>&gt;10.5 kg</td>
<td>&gt;11.0 kg</td>
</tr>
<tr>
<td>85 cm</td>
<td>11.0 kg</td>
<td>10.6 kg</td>
<td>&lt;9.4 kg</td>
<td>&lt;9.8 kg</td>
<td>&gt;12.3 kg</td>
<td>&gt;13.0 kg</td>
</tr>
<tr>
<td>95 cm</td>
<td>12.8 kg</td>
<td>12.5 kg</td>
<td>&lt;11.1 kg</td>
<td>&lt;11.6 kg</td>
<td>&gt;14.0 kg</td>
<td>&gt;15.0 kg</td>
</tr>
<tr>
<td>105 cm</td>
<td>14.9 kg</td>
<td>14.6 kg</td>
<td>&lt;12.9 kg</td>
<td>&lt;13.5 kg</td>
<td>&gt;16.5 kg</td>
<td>&gt;17.6 kg</td>
</tr>
</tbody>
</table>
<h3 id="c.2-who-growth-references-5-19-years">C.2 WHO Growth References
(5-19 years)</h3>
<p><strong>C.2.1 Height-for-Age (5-19 years)</strong></p>
<table>
<thead>
<tr>
<th>Age</th>
<th>Boys (Median)</th>
<th>Girls (Median)</th>
<th>Stunting Threshold (&lt;-2 SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 years</td>
<td>109.2 cm</td>
<td>108.0 cm</td>
<td>&lt;103.3 cm (boys), &lt;102.9 cm (girls)</td>
</tr>
<tr>
<td>10 years</td>
<td>137.5 cm</td>
<td>138.3 cm</td>
<td>&lt;129.2 cm (boys), &lt;130.3 cm (girls)</td>
</tr>
<tr>
<td>15 years</td>
<td>169.5 cm</td>
<td>161.4 cm</td>
<td>&lt;154.1 cm (boys), &lt;154.0 cm (girls)</td>
</tr>
<tr>
<td>19 years</td>
<td>173.5 cm</td>
<td>162.0 cm</td>
<td>&lt;159.4 cm (boys), &lt;157.5 cm (girls)</td>
</tr>
</tbody>
</table>
<p><strong>C.2.2 BMI-for-Age (5-19 years)</strong></p>
<table>
<colgroup>
<col style="width: 4%" />
<col style="width: 18%" />
<col style="width: 18%" />
<col style="width: 20%" />
<col style="width: 18%" />
<col style="width: 17%" />
</colgroup>
<thead>
<tr>
<th>Age</th>
<th>Boys (Median BMI)</th>
<th>Girls (Median BMI)</th>
<th>Underweight (&lt;-2 SD)</th>
<th>Overweight (&gt;+1 SD)</th>
<th>Obesity (&gt;+2 SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 years</td>
<td>15.3</td>
<td>15.2</td>
<td>&lt;14.1</td>
<td>&gt;16.6</td>
<td>&gt;18.0</td>
</tr>
<tr>
<td>10 years</td>
<td>16.2</td>
<td>16.7</td>
<td>&lt;14.4</td>
<td>&gt;18.4</td>
<td>&gt;19.8</td>
</tr>
<tr>
<td>15 years</td>
<td>19.6</td>
<td>20.0</td>
<td>&lt;17.1</td>
<td>&gt;21.7</td>
<td>&gt;22.7</td>
</tr>
<tr>
<td>19 years</td>
<td>22.2</td>
<td>22.0</td>
<td>&lt;18.4</td>
<td>&gt;23.7</td>
<td>&gt;24.3</td>
</tr>
</tbody>
</table>
<h3 id="c.3-adult-nutritional-assessment">C.3 Adult Nutritional
Assessment</h3>
<p><strong>C.3.1 Body Mass Index (BMI) Categories</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>BMI (kg/m¬≤)</th>
<th>Risk Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underweight</td>
<td>&lt;18.5</td>
<td>High (nutritional deficiency)</td>
</tr>
<tr>
<td>Normal weight</td>
<td>18.5-24.9</td>
<td>Low</td>
</tr>
<tr>
<td>Overweight</td>
<td>25.0-29.9</td>
<td>Moderate</td>
</tr>
<tr>
<td>Obese Class I</td>
<td>30.0-34.9</td>
<td>High</td>
</tr>
<tr>
<td>Obese Class II</td>
<td>35.0-39.9</td>
<td>Very High</td>
</tr>
<tr>
<td>Obese Class III</td>
<td>‚â•40.0</td>
<td>Extremely High</td>
</tr>
</tbody>
</table>
<p><strong>C.3.2 Waist Circumference Risk Categories</strong></p>
<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td>&lt;94 cm</td>
<td>&lt;80 cm</td>
</tr>
<tr>
<td>Increased risk</td>
<td>94-102 cm</td>
<td>80-88 cm</td>
</tr>
<tr>
<td>High risk</td>
<td>&gt;102 cm</td>
<td>&gt;88 cm</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendix-d-statistical-formulas-and-calculations">Appendix D:
Statistical Formulas and Calculations</h2>
<h3 id="d.1-descriptive-statistics">D.1 Descriptive Statistics</h3>
<p><strong>D.1.1 Measures of Central Tendency</strong></p>
<p><em>Mean (Œº or xÃÑ):</em></p>
<pre><code>Œº = Œ£x / n
xÃÑ = Œ£x / n</code></pre>
<p>Where: - Œ£x = sum of all values - n = number of values</p>
<p><em>Median (M):</em> - For odd number of observations: Middle value -
For even number of observations: Average of two middle values</p>
<p><em>Mode:</em> - Most frequently occurring value</p>
<p><strong>D.1.2 Measures of Dispersion</strong></p>
<p><em>Range:</em></p>
<pre><code>R = Maximum value - Minimum value</code></pre>
<p><em>Variance (œÉ¬≤ or s¬≤):</em></p>
<pre><code>œÉ¬≤ = Œ£(x - Œº)¬≤ / n  (population)
s¬≤ = Œ£(x - xÃÑ)¬≤ / (n-1)  (sample)</code></pre>
<p><em>Standard Deviation (œÉ or s):</em></p>
<pre><code>œÉ = ‚àöœÉ¬≤  (population)
s = ‚àös¬≤  (sample)</code></pre>
<p><em>Coefficient of Variation (CV):</em></p>
<pre><code>CV = (Standard deviation / Mean) √ó 100</code></pre>
<h3 id="d.2-inferential-statistics">D.2 Inferential Statistics</h3>
<p><strong>D.2.1 Confidence Intervals</strong></p>
<p><em>For Mean (Large Sample, n ‚â• 30):</em></p>
<pre><code>CI = xÃÑ ¬± Z(Œ±/2) √ó (s/‚àön)</code></pre>
<p>Where: - xÃÑ = sample mean - Z(Œ±/2) = 1.96 for 95% CI, 2.576 for 99% CI
- s = sample standard deviation - n = sample size</p>
<p><em>For Proportion:</em></p>
<pre><code>CI = p ¬± Z(Œ±/2) √ó ‚àö[p(1-p)/n]</code></pre>
<p>Where p = sample proportion</p>
<p><em>For Small Samples (n &lt; 30):</em> Use t-distribution instead of
Z:</p>
<pre><code>CI = xÃÑ ¬± t(Œ±/2, df) √ó (s/‚àön)</code></pre>
<p><strong>D.2.2 Hypothesis Testing</strong></p>
<p><em>Z-test for Mean (Large Sample):</em></p>
<pre><code>Z = (xÃÑ - Œº‚ÇÄ) / (s/‚àön)</code></pre>
<p><em>t-test for Mean (Small Sample):</em></p>
<pre><code>t = (xÃÑ - Œº‚ÇÄ) / (s/‚àön)
df = n - 1</code></pre>
<p><em>Chi-square Test:</em></p>
<pre><code>œá¬≤ = Œ£[(O - E)¬≤ / E]</code></pre>
<p>Where: - O = Observed frequency - E = Expected frequency - df = (rows
- 1) √ó (columns - 1)</p>
<p><em>Fisher‚Äôs Exact Test (2√ó2 table):</em></p>
<pre><code>P = (a+b)! (c+d)! (a+c)! (b+d)! / (a! b! c! d! N!)</code></pre>
<h3 id="d.3-correlation-and-regression">D.3 Correlation and
Regression</h3>
<p><strong>D.3.1 Pearson Correlation Coefficient</strong></p>
<p><em>r = Œ£[(x - xÃÑ)(y - »≥)] / ‚àö[Œ£(x - xÃÑ)¬≤ √ó Œ£(y - »≥)¬≤]</em></p>
<p><strong>Properties:</strong> - r ranges from -1 to +1 - |r| = 1:
Perfect correlation - r = 0: No linear correlation</p>
<p><strong>D.3.2 Linear Regression</strong></p>
<p><em>Simple Linear Regression:</em></p>
<pre><code>Y = a + bX</code></pre>
<p>Where: - a = Y-intercept = »≥ - bxÃÑ - b = slope = r √ó (s_y/s_x)</p>
<p><em>Multiple Linear Regression:</em></p>
<pre><code>Y = b‚ÇÄ + b‚ÇÅX‚ÇÅ + b‚ÇÇX‚ÇÇ + ... + b‚ÇôX‚Çô</code></pre>
<h3 id="d.4-epidemiological-measures">D.4 Epidemiological Measures</h3>
<p><strong>D.4.1 Relative Risk (RR)</strong></p>
<pre><code>RR = [a/(a+b)] / [c/(c+d)]</code></pre>
<p><strong>D.4.2 Odds Ratio (OR)</strong></p>
<pre><code>OR = (a√ód) / (b√óc)</code></pre>
<p><strong>D.4.3 Attributable Risk (AR)</strong></p>
<pre><code>AR = Incidence in exposed - Incidence in unexposed</code></pre>
<p><strong>D.4.4 Population Attributable Risk (PAR)</strong></p>
<pre><code>PAR = Pe √ó (RR - 1) / [Pe √ó (RR - 1) + 1]</code></pre>
<p>Where Pe = proportion exposed in population</p>
<p><strong>D.4.5 Number Needed to Harm (NNH)</strong></p>
<pre><code>NNH = 1 / Attributable risk</code></pre>
<p><strong>D.4.6 Sensitivity and Specificity</strong></p>
<p><em>Sensitivity = TP / (TP + FN)</em></p>
<p><em>Specificity = TN / (TN + FP)</em></p>
<p><em>Positive Predictive Value = TP / (TP + FP)</em></p>
<p><em>Negative Predictive Value = TN / (TN + FN)</em></p>
<p><em>Positive Likelihood Ratio = Sensitivity / (1 -
Specificity)</em></p>
<p><em>Negative Likelihood Ratio = (1 - Sensitivity) /
Specificity</em></p>
<hr />
<h2 id="appendix-e-drug-dosages-and-treatment-protocols">Appendix E:
Drug Dosages and Treatment Protocols</h2>
<h3 id="e.1-common-antibiotic-dosages">E.1 Common Antibiotic
Dosages</h3>
<p><strong>E.1.1 Respiratory Infections</strong></p>
<p><em>Amoxicillin:</em> - Adults: 250-500 mg TDS for 5-7 days -
Children: 40-90 mg/kg/day divided TID - Maximum: 4 g/day</p>
<p><em>Azithromycin:</em> - Adults: 500 mg OD on day 1, then 250 mg OD
on days 2-5 - Children: 10 mg/kg on day 1, then 5 mg/kg on days 2-5</p>
<p><em>Doxycycline:</em> - Adults: 100 mg BD for 7-14 days -
Contraindicated in children &lt;8 years and pregnancy</p>
<p><strong>E.1.2 Gastrointestinal Infections</strong></p>
<p><em>Metronidazole:</em> - Adults: 400 mg TDS for 5-7 days - Children:
30-50 mg/kg/day divided TID - Maximum: 2 g/day</p>
<p><em>Ciprofloxacin:</em> - Adults: 500 mg BD for 3-5 days - Not
recommended in children and pregnancy</p>
<h3 id="e.2-antimalarial-treatment">E.2 Antimalarial Treatment</h3>
<p><strong>E.2.1 Uncomplicated Malaria</strong></p>
<p><em>Plasmodium falciparum (ACT):</em> - Artemether-lumefantrine: 4
tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0,
8, 24, and 36 hours, then twice daily for 2 more days</p>
<p><em>Plasmodium vivax:</em> - Chloroquine: 25 mg/kg divided over 3
days + Primaquine: 0.25 mg/kg daily for 14 days (for radical cure)</p>
<p><strong>E.2.2 Severe Malaria</strong></p>
<p><em>Artesunate:</em> - IV: 2.4 mg/kg at 0, 12, 24 hours, then daily -
Alternative: Quinine: 20 mg/kg loading dose IV over 4 hours</p>
<h3 id="e.3-tuberculosis-treatment-who-guidelines">E.3 Tuberculosis
Treatment (WHO Guidelines)</h3>
<p><strong>E.3.1 New Cases (Category I)</strong></p>
<p><em>Intensive Phase (2 months):</em> - Isoniazid (H): 300 mg OD -
Rifampicin (R): 450 mg OD (weight &lt;50 kg), 600 mg OD (‚â•50 kg) -
Ethambutol (E): 800 mg OD (weight &lt;50 kg), 1200 mg OD (‚â•50 kg) -
Pyrazinamide (Z): 1000 mg OD (weight &lt;50 kg), 1500 mg OD (‚â•50 kg)</p>
<p><em>Continuation Phase (4 months):</em> - Isoniazid (H): 300 mg OD -
Rifampicin (R): 450 mg OD (weight &lt;50 kg), 600 mg OD (‚â•50 kg)</p>
<p><strong>E.3.2 Retreatment Cases (Category II)</strong></p>
<p><em>Intensive Phase (3 months):</em> - Streptomycin (S): 750 mg IM OD
- Isoniazid (H): 300 mg OD - Rifampicin (R): 450 mg OD (weight &lt;50
kg), 600 mg OD (‚â•50 kg) - Ethambutol (E): 800 mg OD (weight &lt;50 kg),
1200 mg OD (‚â•50 kg) - Pyrazinamide (Z): 1000 mg OD (weight &lt;50 kg),
1500 mg OD (‚â•50 kg)</p>
<p><em>Continuation Phase (5 months):</em> - Isoniazid (H): 300 mg OD -
Rifampicin (R): 450 mg OD (weight &lt;50 kg), 600 mg OD (‚â•50 kg) -
Ethambutol (E): 800 mg OD (weight &lt;50 kg), 1200 mg OD (‚â•50 kg)</p>
<h3 id="e.4-hivaids-treatment-first-line">E.4 HIV/AIDS Treatment (First
Line)</h3>
<p><strong>E.4.1 First-line ART Regimen</strong></p>
<p><em>Adults and Adolescents:</em> - Tenofovir (TDF) + Lamivudine (3TC)
+ Efavirenz (EFV) - TDF: 300 mg OD - 3TC: 300 mg OD - EFV: 600 mg OD</p>
<p><em>Children (3-10 years):</em> - ABC + 3TC + EFV - Weight-based
dosing per WHO guidelines</p>
<p><strong>E.4.2 Opportunistic Infection Prophylaxis</strong></p>
<p><em>Cotrimoxazole Prophylaxis:</em> - CD4 &lt;350 cells/ŒºL: 960 mg
daily - Prevention of PCP and bacterial infections</p>
<h3 id="e.5-chronic-disease-management">E.5 Chronic Disease
Management</h3>
<p><strong>E.5.1 Hypertension (JNC 8 Guidelines)</strong></p>
<p><em>Thiazide Diuretics:</em> - Hydrochlorothiazide: 12.5-50 mg daily
- Chlorthalidone: 12.5-25 mg daily</p>
<p><em>ACE Inhibitors:</em> - Enalapril: 5-40 mg daily in divided doses
- Lisinopril: 10-40 mg daily</p>
<p><em>Calcium Channel Blockers:</em> - Amlodipine: 2.5-10 mg daily -
Nifedipine XL: 30-90 mg daily</p>
<p><strong>E.5.2 Diabetes Mellitus (ADA Guidelines)</strong></p>
<p><em>Metformin:</em> - Initial: 500 mg BD with meals - Maximum: 2000
mg/day</p>
<p><em>Insulin Therapy:</em> - Basal insulin: Long-acting (glargine,
detemir) - Mealtime insulin: Rapid-acting (aspart, lispro)</p>
<h3 id="e.6-emergency-medications">E.6 Emergency Medications</h3>
<p><strong>E.6.1 Anaphylaxis Treatment</strong></p>
<p><em>Epinephrine:</em> - IM: 0.3-0.5 mg (1:1000) in anterolateral
thigh - Repeat every 5-15 minutes if needed - IV: 0.05-0.1 mg (1:10000)
for severe cases</p>
<p><em>Hydrocortisone:</em> - IV: 200 mg slowly - Followed by oral
prednisolone: 40-60 mg daily</p>
<p><strong>E.6.2 Acute Asthma Management</strong></p>
<p><em>Short-acting Beta-2 Agonists:</em> - Salbutamol: 2.5-5 mg via
nebulizer - Maximum: Every 20 minutes for 1 hour</p>
<p><em>Systemic Corticosteroids:</em> - Prednisolone: 1-2 mg/kg (max
40-60 mg) - Duration: 5-10 days</p>
<hr />
<h2 id="appendix-f-health-indicators-and-targets">Appendix F: Health
Indicators and Targets</h2>
<h3 id="f.1-sustainable-development-goals-sdgs">F.1 Sustainable
Development Goals (SDGs)</h3>
<p><strong>F.1.1 SDG 3 - Good Health and Well-being</strong></p>
<table>
<colgroup>
<col style="width: 11%" />
<col style="width: 16%" />
<col style="width: 25%" />
<col style="width: 22%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr>
<th>Target</th>
<th>Indicator</th>
<th>Baseline (2015)</th>
<th>Target (2030)</th>
<th>Current (2023)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1</td>
<td>Maternal Mortality Ratio</td>
<td>174 per 100,000</td>
<td>&lt;70 per 100,000</td>
<td>97 per 100,000</td>
</tr>
<tr>
<td>3.2</td>
<td>Under-5 Mortality Rate</td>
<td>43 per 1,000</td>
<td>&lt;25 per 1,000</td>
<td>28 per 1,000</td>
</tr>
<tr>
<td>3.3</td>
<td>New HIV infections</td>
<td>0.23%</td>
<td>End epidemic</td>
<td>0.18%</td>
</tr>
<tr>
<td>3.4</td>
<td>NCD mortality</td>
<td>674 per 100,000</td>
<td>Reduce by 1/3</td>
<td>625 per 100,000</td>
</tr>
<tr>
<td>3.6</td>
<td>Road traffic deaths</td>
<td>1.8 per 100,000</td>
<td>Reduce by 50%</td>
<td>1.5 per 100,000</td>
</tr>
<tr>
<td>3.8</td>
<td>UHC index</td>
<td>0.60</td>
<td>0.90</td>
<td>0.66</td>
</tr>
<tr>
<td>3.9</td>
<td>Deaths from pollution</td>
<td>190 per 100,000</td>
<td>Reduce by 50%</td>
<td>175 per 100,000</td>
</tr>
</tbody>
</table>
<p><strong>F.1.2 Key Health-related SDGs</strong></p>
<table>
<thead>
<tr>
<th>SDG</th>
<th>Health Component</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDG 2</td>
<td>Zero Hunger</td>
<td>End malnutrition in all forms</td>
</tr>
<tr>
<td>SDG 4</td>
<td>Quality Education</td>
<td>Ensure healthy lives and well-being</td>
</tr>
<tr>
<td>SDG 5</td>
<td>Gender Equality</td>
<td>End all forms of discrimination</td>
</tr>
<tr>
<td>SDG 6</td>
<td>Clean Water</td>
<td>Achieve universal access to safe water</td>
</tr>
<tr>
<td>SDG 7</td>
<td>Clean Energy</td>
<td>Ensure access to affordable energy</td>
</tr>
<tr>
<td>SDG 8</td>
<td>Decent Work</td>
<td>Protect labor rights and promote safety</td>
</tr>
<tr>
<td>SDG 10</td>
<td>Reduced Inequalities</td>
<td>Reduce inequalities within countries</td>
</tr>
<tr>
<td>SDG 13</td>
<td>Climate Action</td>
<td>Strengthen resilience to climate change</td>
</tr>
<tr>
<td>SDG 16</td>
<td>Peace and Justice</td>
<td>Promote peaceful societies</td>
</tr>
</tbody>
</table>
<h3 id="f.2-national-health-policy-targets-2017">F.2 National Health
Policy Targets (2017)</h3>
<p><strong>F.2.1 Health Outcome Targets</strong></p>
<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 23%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th>Indicator</th>
<th>2017 Baseline</th>
<th>2022 Target</th>
<th>2025 Target</th>
<th>2030 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Life Expectancy</td>
<td>68.7 years</td>
<td>70 years</td>
<td>72 years</td>
<td>74 years</td>
</tr>
<tr>
<td>Infant Mortality Rate</td>
<td>34 per 1,000</td>
<td>28 per 1,000</td>
<td>24 per 1,000</td>
<td>16 per 1,000</td>
</tr>
<tr>
<td>Maternal Mortality Ratio</td>
<td>130 per 100,000</td>
<td>100 per 100,000</td>
<td>70 per 100,000</td>
<td>50 per 100,000</td>
</tr>
<tr>
<td>Under-5 Mortality Rate</td>
<td>43 per 1,000</td>
<td>36 per 1,000</td>
<td>25 per 1,000</td>
<td>15 per 1,000</td>
</tr>
<tr>
<td>TB Elimination</td>
<td>211 per 100,000</td>
<td>142 per 100,000</td>
<td>&lt;65 per 100,000</td>
<td>&lt;33 per 100,000</td>
</tr>
<tr>
<td>Malaria</td>
<td>0.4 per 1,000</td>
<td>&lt;1 case per 1,000</td>
<td>&lt;1 case per 1,000</td>
<td>Zero indigenous cases</td>
</tr>
</tbody>
</table>
<p><strong>F.2.2 Health System Targets</strong></p>
<table>
<thead>
<tr>
<th>Component</th>
<th>Target</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Health Infrastructure</td>
<td>1 PHC per 30,000 population</td>
<td>100%</td>
</tr>
<tr>
<td>Secondary Care</td>
<td>1 district hospital per 1 million</td>
<td>100%</td>
</tr>
<tr>
<td>Tertiary Care</td>
<td>1 medical college per 10 lakh</td>
<td>100%</td>
</tr>
<tr>
<td>Health Workforce</td>
<td>30 doctors per 10,000 population</td>
<td>100%</td>
</tr>
<tr>
<td>Health Insurance Coverage</td>
<td>50% of population</td>
<td>50%</td>
</tr>
<tr>
<td>E-health Records</td>
<td>70% population coverage</td>
<td>70%</td>
</tr>
</tbody>
</table>
<h3 id="f.3-millennium-development-goals-mdgs-achievements">F.3
Millennium Development Goals (MDGs) Achievements</h3>
<p><strong>F.3.1 Goals Achieved by India</strong></p>
<table>
<colgroup>
<col style="width: 14%" />
<col style="width: 23%" />
<col style="width: 38%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr>
<th>MDG</th>
<th>Target</th>
<th>Achievement</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDG 1</td>
<td>Halve extreme poverty (1990-2015)</td>
<td>Poverty reduced by 59.3%</td>
<td>Achieved</td>
</tr>
<tr>
<td>MDG 2</td>
<td>Universal primary education</td>
<td>Net enrollment ratio: 97.3%</td>
<td>Achieved</td>
</tr>
<tr>
<td>MDG 3</td>
<td>Promote gender equality</td>
<td>Gender Parity Index: 1.03</td>
<td>Achieved</td>
</tr>
<tr>
<td>MDG 4</td>
<td>Reduce child mortality</td>
<td>Under-5 mortality reduced by 67%</td>
<td>Achieved</td>
</tr>
<tr>
<td>MDG 5</td>
<td>Improve maternal health</td>
<td>Maternal mortality reduced by 69%</td>
<td>Achieved</td>
</tr>
<tr>
<td>MDG 7</td>
<td>Access to safe drinking water</td>
<td>97.7% population covered</td>
<td>Achieved</td>
</tr>
</tbody>
</table>
<h3 id="f.4-global-health-targets">F.4 Global Health Targets</h3>
<p><strong>F.4.1 WHO Targets for 2025</strong></p>
<table>
<colgroup>
<col style="width: 28%" />
<col style="width: 33%" />
<col style="width: 37%" />
</colgroup>
<thead>
<tr>
<th>Target Area</th>
<th>Global Target</th>
<th>Regional Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal Health Coverage</td>
<td>80% coverage index</td>
<td>75% coverage index</td>
</tr>
<tr>
<td>Road Safety</td>
<td>50% reduction in deaths</td>
<td>40% reduction</td>
</tr>
<tr>
<td>Malaria</td>
<td>90% reduction in incidence</td>
<td>60% reduction</td>
</tr>
<tr>
<td>TB</td>
<td>80% treatment success rate</td>
<td>85% treatment success rate</td>
</tr>
<tr>
<td>NCDs</td>
<td>25% reduction in premature mortality</td>
<td>30% reduction</td>
</tr>
<tr>
<td>Mental Health</td>
<td>50% coverage of effective interventions</td>
<td>50% coverage</td>
</tr>
</tbody>
</table>
<p><strong>F.4.2 Ending Epidemics Targets</strong></p>
<p><em>HIV/AIDS:</em> - 95% of people living with HIV know their status
- 95% of people who know their status are on treatment - 95% of people
on treatment have suppressed viral load</p>
<p><em>Tuberculosis:</em> - 90% reduction in TB mortality by 2030 - 80%
reduction in TB incidence by 2030 - 100% of TB families protected from
catastrophic costs</p>
<p><em>Malaria:</em> - Reduce malaria mortality by 90% - Eliminate
malaria in at least 35 countries - Prevent malaria resurgence in all
countries</p>
<hr />
<h2 id="appendix-g-emergency-contact-numbers-and-helplines">Appendix G:
Emergency Contact Numbers and Helplines</h2>
<h3 id="g.1-national-emergency-services">G.1 National Emergency
Services</h3>
<p><strong>G.1.1 Emergency Response Numbers</strong></p>
<table>
<colgroup>
<col style="width: 34%" />
<col style="width: 30%" />
<col style="width: 34%" />
</colgroup>
<thead>
<tr>
<th>Service</th>
<th>Number</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Police</td>
<td>100</td>
<td>Law enforcement, crime reporting</td>
</tr>
<tr>
<td>Fire</td>
<td>101</td>
<td>Fire emergencies, rescue operations</td>
</tr>
<tr>
<td>Medical</td>
<td>108</td>
<td>Ambulance, medical emergencies</td>
</tr>
<tr>
<td>Disaster Management</td>
<td>108</td>
<td>Natural disasters, emergency response</td>
</tr>
<tr>
<td>Women‚Äôs Helpline</td>
<td>1091</td>
<td>Domestic violence, women‚Äôs safety</td>
</tr>
<tr>
<td>Child Helpline</td>
<td>1098</td>
<td>Child protection, missing children</td>
</tr>
<tr>
<td>Senior Citizens Helpline</td>
<td>14567</td>
<td>Elder abuse, senior citizen support</td>
</tr>
<tr>
<td>Mental Health Helpline</td>
<td>9152987821</td>
<td>Mental health crisis support</td>
</tr>
</tbody>
</table>
<p><strong>G.1.2 COVID-19 Emergency Contacts</strong></p>
<table>
<thead>
<tr>
<th>Service</th>
<th>Number</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 Helpline</td>
<td>1075 (Toll-free)</td>
<td>24/7</td>
</tr>
<tr>
<td>COVID-19 WhatsApp Help</td>
<td>+91 9013151515</td>
<td>24/7</td>
</tr>
<tr>
<td>Ministry of Health</td>
<td>011-23063100</td>
<td>Business hours</td>
</tr>
<tr>
<td>State COVID Helplines</td>
<td>State-specific</td>
<td>24/7</td>
</tr>
</tbody>
</table>
<h3 id="g.2-health-program-helplines">G.2 Health Program Helplines</h3>
<p><strong>G.2.1 National Health Programs</strong></p>
<table>
<thead>
<tr>
<th>Program</th>
<th>Helpline</th>
<th>Working Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>National AIDS Control</td>
<td>1097</td>
<td>24/7</td>
</tr>
<tr>
<td>TB Helpline</td>
<td>1800-11-6666</td>
<td>24/7</td>
</tr>
<tr>
<td>Malaria Control</td>
<td>1800-123-4567</td>
<td>Business hours</td>
</tr>
<tr>
<td>Pulse Polio</td>
<td>1800-110-4567</td>
<td>Campaign periods</td>
</tr>
<tr>
<td>Drug De-addiction</td>
<td>1800-11-0031</td>
<td>24/7</td>
</tr>
</tbody>
</table>
<p><strong>G.2.2 Government Health Insurance</strong></p>
<table>
<thead>
<tr>
<th>Scheme</th>
<th>Helpline</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMJAY</td>
<td>1800-111-3030</td>
<td>24/7</td>
</tr>
<tr>
<td>ESI</td>
<td>1800-11-2525</td>
<td>Business hours</td>
</tr>
<tr>
<td>CGHS</td>
<td>1800-11-4141</td>
<td>Business hours</td>
</tr>
<tr>
<td>State Insurance</td>
<td>State-specific</td>
<td>Varies</td>
</tr>
</tbody>
</table>
<h3 id="g.3-disaster-management-contacts">G.3 Disaster Management
Contacts</h3>
<p><strong>G.3.1 National Disaster Management Authority</strong></p>
<table>
<thead>
<tr>
<th>Office</th>
<th>Contact</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDMA Headquarters</td>
<td>011-26701700</td>
<td>info@ndma.gov.in</td>
</tr>
<tr>
<td>Emergency Operations</td>
<td>011-26118383</td>
<td>emergency@ndma.gov.in</td>
</tr>
<tr>
<td>Media Relations</td>
<td>011-26118484</td>
<td>media@ndma.gov.in</td>
</tr>
</tbody>
</table>
<p><strong>G.3.2 State Disaster Management Authorities</strong></p>
<table>
<thead>
<tr>
<th>State</th>
<th>Emergency Contact</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maharashtra</td>
<td>022-22027900</td>
<td>sdma.maharashtra.gov.in</td>
</tr>
<tr>
<td>Tamil Nadu</td>
<td>044-22352174</td>
<td>tnsa.gov.in</td>
</tr>
<tr>
<td>Kerala</td>
<td>0471-2333547</td>
<td>dmd.kerala.gov.in</td>
</tr>
<tr>
<td>Gujarat</td>
<td>079-23258979</td>
<td>gsdma.gov.in</td>
</tr>
<tr>
<td>Karnataka</td>
<td>080-22032200</td>
<td>sdma.karnataka.gov.in</td>
</tr>
</tbody>
</table>
<h3 id="g.4-health-service-providers">G.4 Health Service Providers</h3>
<p><strong>G.4.1 AIIMS Emergency Contacts</strong></p>
<table>
<thead>
<tr>
<th>AIIMS Location</th>
<th>Emergency</th>
<th>Helpline</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIIMS New Delhi</td>
<td>011-26191963</td>
<td>011-26588500</td>
</tr>
<tr>
<td>AIIMS Bhopal</td>
<td>0755-2800000</td>
<td>0755-2800001</td>
</tr>
<tr>
<td>AIIMS Bhubaneswar</td>
<td>0674-2407122</td>
<td>0674-2407123</td>
</tr>
<tr>
<td>AIIMS Jodhpur</td>
<td>0291-2740741</td>
<td>0291-2740611</td>
</tr>
<tr>
<td>AIIMS Rishikesh</td>
<td>0135-2461100</td>
<td>0135-2461101</td>
</tr>
</tbody>
</table>
<p><strong>G.4.2 Red Cross Society</strong></p>
<table>
<thead>
<tr>
<th>Regional Office</th>
<th>Phone</th>
<th>Emergency Services</th>
</tr>
</thead>
<tbody>
<tr>
<td>National HQ, Delhi</td>
<td>011-23359590</td>
<td>Blood bank, disaster relief</td>
</tr>
<tr>
<td>Mumbai Chapter</td>
<td>022-22674295</td>
<td>Emergency blood supply</td>
</tr>
<tr>
<td>Chennai Chapter</td>
<td>044-28259155</td>
<td>Disaster response</td>
</tr>
<tr>
<td>Kolkata Chapter</td>
<td>033-22886522</td>
<td>Emergency medical services</td>
</tr>
</tbody>
</table>
<h3 id="g.5-mental-health-support">G.5 Mental Health Support</h3>
<p><strong>G.5.1 Crisis Intervention Services</strong></p>
<table>
<thead>
<tr>
<th>Organization</th>
<th>Helpline</th>
<th>Services</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vandrevala Foundation</td>
<td>9999666555</td>
<td>Mental health crisis</td>
</tr>
<tr>
<td>Connecting NGO</td>
<td>9922001122</td>
<td>Suicide prevention</td>
</tr>
<tr>
<td>iCall</td>
<td>9152987821</td>
<td>Counseling support</td>
</tr>
<tr>
<td>Samaritans Mumbai</td>
<td>8422984528</td>
<td>Emotional support</td>
</tr>
</tbody>
</table>
<p><strong>G.5.2 Professional Mental Health Resources</strong></p>
<table>
<colgroup>
<col style="width: 26%" />
<col style="width: 26%" />
<col style="width: 47%" />
</colgroup>
<thead>
<tr>
<th>Service</th>
<th>Contact</th>
<th>Specialization</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIMHANS Crisis Line</td>
<td>080-46110010</td>
<td>Psychiatric emergencies</td>
</tr>
<tr>
<td>AIIMS Psychiatry</td>
<td>011-26191960</td>
<td>Mental health consultation</td>
</tr>
<tr>
<td>National Tele Mental Health</td>
<td>14416/9152987821</td>
<td>Digital mental health</td>
</tr>
</tbody>
</table>
<h3 id="g.6-international-emergency-contacts">G.6 International
Emergency Contacts</h3>
<p><strong>G.6.1 WHO Regional Office</strong></p>
<table>
<thead>
<tr>
<th>Regional Office</th>
<th>Contact</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEARO, New Delhi</td>
<td>+91-11-23370804</td>
<td>South-East Asia</td>
</tr>
<tr>
<td>AFRO, Brazzaville</td>
<td>+47-241-39000</td>
<td>Africa</td>
</tr>
<tr>
<td>AMRO, Washington</td>
<td>+1-202-974-3000</td>
<td>Americas</td>
</tr>
<tr>
<td>EMRO, Cairo</td>
<td>+202-22765000</td>
<td>Eastern Mediterranean</td>
</tr>
<tr>
<td>EURO, Copenhagen</td>
<td>+45-39171000</td>
<td>Europe</td>
</tr>
<tr>
<td>WPRO, Manila</td>
<td>+63-2-5288001</td>
<td>Western Pacific</td>
</tr>
</tbody>
</table>
<p><strong>G.6.2 Embassy Emergency Services</strong></p>
<table>
<thead>
<tr>
<th>Embassy</th>
<th>Emergency</th>
<th>Consular</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Embassy, Delhi</td>
<td>+91-11-2419-8000</td>
<td>+91-11-2419-8000</td>
</tr>
<tr>
<td>UK High Commission</td>
<td>+91-11-2419-2100</td>
<td>+91-11-2419-2100</td>
</tr>
<tr>
<td>Canadian Embassy</td>
<td>+91-11-4178-2000</td>
<td>+91-11-4178-2000</td>
</tr>
<tr>
<td>Australian Embassy</td>
<td>+91-11-4139-9900</td>
<td>+91-11-4139-9900</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendix-h-glossary-of-medical-terms">Appendix H: Glossary of
Medical Terms</h2>
<h3 id="h.1-epidemiological-terms">H.1 Epidemiological Terms</h3>
<p><strong>Attack Rate</strong> The proportion of susceptible
individuals who become ill during a specified period. Calculated as:
(Number of new cases during period / Total susceptible population at
risk) √ó 100.</p>
<p><strong>Attributable Risk</strong> The difference in incidence rates
between exposed and unexposed groups. Represents the excess risk that
can be attributed to the exposure.</p>
<p><strong>Case Fatality Rate (CFR)</strong> The proportion of diagnosed
cases that result in death. Calculated as: (Number of deaths from
disease / Number of diagnosed cases) √ó 100.</p>
<p><strong>Endemic</strong> A disease or condition that is constantly
present in a particular geographic area or population group at a
baseline level.</p>
<p><strong>Epidemic</strong> The occurrence of cases of a disease in
excess of what is normally expected in a given population in a specific
area.</p>
<p><strong>Incidence</strong> The number of new cases of a disease that
develop in a population during a specific period. Usually expressed as
cases per 1,000 or 100,000 population per year.</p>
<p><strong>Mortality Rate</strong> The frequency of death in a defined
population during a specified time period. Expressed as deaths per 1,000
or 100,000 population per year.</p>
<p><strong>Outbreak</strong> A localized epidemic, often referring to
cases clustered in time and space in a specific population.</p>
<p><strong>Pandemic</strong> An epidemic occurring worldwide or over a
very wide area, crossing international boundaries and affecting a large
number of people.</p>
<p><strong>Prevalence</strong> The total number of cases of a disease
existing in a population at a specific time point or during a specific
period.</p>
<p><strong>Risk Factor</strong> An exposure or characteristic that
increases the probability of developing a disease or condition.</p>
<h3 id="h.2-statistical-terms">H.2 Statistical Terms</h3>
<p><strong>Bias</strong> Systematic error in study design or analysis
that results in an incorrect estimate of the true effect or
association.</p>
<p><strong>Confidence Interval (CI)</strong> A range of values that is
likely to contain the true population parameter with a specified level
of confidence (usually 95%).</p>
<p><strong>Confounding</strong> A situation where the apparent
association between exposure and outcome is distorted by a third
variable associated with both.</p>
<p><strong>Correlation</strong> A statistical measure that describes the
strength and direction of a relationship between two variables.</p>
<p><strong>Frequency Distribution</strong> The pattern of how often
different values occur in a dataset.</p>
<p><strong>Hypothesis Testing</strong> A statistical procedure used to
determine whether there is sufficient evidence to reject a null
hypothesis.</p>
<p><strong>Null Hypothesis (H‚ÇÄ)</strong> The hypothesis that there is no
effect or no association between variables being studied.</p>
<p><strong>P-value</strong> The probability of obtaining results at
least as extreme as those observed, assuming the null hypothesis is
true.</p>
<p><strong>Probability</strong> The likelihood that an event will occur,
expressed as a number between 0 and 1.</p>
<p><strong>Sample Size</strong> The number of subjects or observations
included in a study.</p>
<p><strong>Statistical Significance</strong> The likelihood that a
relationship between variables is not due to chance, typically
determined when p &lt; 0.05.</p>
<p><strong>Type I Error</strong> Rejecting the null hypothesis when it
is actually true (false positive).</p>
<p><strong>Type II Error</strong> Failing to reject the null hypothesis
when it is actually false (false negative).</p>
<h3 id="h.3-public-health-terms">H.3 Public Health Terms</h3>
<p><strong>Burden of Disease</strong> The impact of a health problem on
a population, measured by mortality, morbidity, disability, and economic
costs.</p>
<p><strong>Community Health</strong> The health status of a defined
group of people and the health actions they take to improve or maintain
health.</p>
<p><strong>Demography</strong> The study of populations, including size,
composition, distribution, and trends.</p>
<p><strong>Determinants of Health</strong> Factors that influence health
status, including biological, environmental, social, and economic
factors.</p>
<p><strong>Epidemiology</strong> The study of distribution and
determinants of health-related states in populations and the application
to control health problems.</p>
<p><strong>Health Promotion</strong> The process of enabling people to
increase control over and improve their health.</p>
<p><strong>Incidence Rate</strong> The rate at which new cases occur in
a population during a specific time period.</p>
<p><strong>Morbidity</strong> The state of being diseased or the amount
of disease in a population.</p>
<p><strong>Mortality</strong> The frequency of death in a population
during a specific time period.</p>
<p><strong>Population Health</strong> The health outcomes of a group of
individuals, including the distribution of such outcomes within the
group.</p>
<p><strong>Primary Prevention</strong> Prevention strategies aimed at
avoiding the development of disease before it occurs.</p>
<p><strong>Secondary Prevention</strong> Early detection and treatment
of disease to prevent progression and complications.</p>
<p><strong>Tertiary Prevention</strong> Measures to reduce the impact of
established disease and prevent further complications.</p>
<p><strong>Surveillance</strong> The ongoing, systematic collection,
analysis, and interpretation of health data for planning,
implementation, and evaluation of public health practice.</p>
<h3 id="h.4-clinical-terms">H.4 Clinical Terms</h3>
<p><strong>Acute</strong> Having a rapid onset and usually a short
course; often severe but brief.</p>
<p><strong>Asymptomatic</strong> Showing no signs or symptoms of
disease.</p>
<p><strong>Carrier</strong> A person or animal that harbors a specific
infectious agent and can transmit it to others without showing signs of
disease.</p>
<p><strong>Chronic</strong> Long-lasting or recurrent, often persisting
for months or years.</p>
<p><strong>Comorbidity</strong> The presence of one or more additional
diseases or conditions co-occurring with a primary disease or
condition.</p>
<p><strong>Differential Diagnosis</strong> The process by which a
physician determines which of two or more diseases or conditions a
patient has, based on specific signs and symptoms.</p>
<p><strong>Follow-up</strong> The continued observation and care of a
patient after initial treatment.</p>
<p><strong>Incubation Period</strong> The time between exposure to a
pathogen and the onset of symptoms.</p>
<p><strong>Latent Period</strong> The time between infection and the
ability to transmit the infection to others.</p>
<p><strong>Morbidity Rate</strong> The frequency of disease in a
population, expressed as cases per 1,000 or 100,000 population.</p>
<p><strong>Pathogen</strong> A microorganism capable of causing
disease.</p>
<p><strong>Prognosis</strong> The likely course and outcome of a disease
or condition.</p>
<p><strong>Risk Assessment</strong> The evaluation of the likelihood
that exposure to a hazard will result in harm.</p>
<p><strong>Spectrum of Disease</strong> The range of manifestations of
disease, from asymptomatic infection to severe disease.</p>
<p><strong>Survivorship</strong> The condition of living with or
recovering from a serious disease or condition.</p>
<p><strong>Vector</strong> An organism, typically an arthropod, that
transmits a pathogen from one host to another.</p>
<p><strong>Virulence</strong> The severity or harmfulness of a disease
or condition.</p>
<h3 id="h.5-environmental-health-terms">H.5 Environmental Health
Terms</h3>
<p><strong>Air Quality Index (AQI)</strong> A scale used to communicate
how polluted the air currently is or how polluted it is forecast to
become.</p>
<p><strong>Bioaccumulation</strong> The accumulation of substances, such
as pesticides or chemicals, in an organism over time.</p>
<p><strong>Contamination</strong> The action of making something impure
by exposure to a harmful substance.</p>
<p><strong>Environmental Exposure</strong> Contact with potentially
harmful substances in the environment.</p>
<p><strong>Environmental Health</strong> The science and practice of
preventing human injury and illness and promoting well-being by
identifying and evaluating environmental sources and hazardous
agents.</p>
<p><strong>Exposure Assessment</strong> The process of estimating or
measuring the intensity, frequency, and duration of human contact with
an agent.</p>
<p><strong>Hazard</strong> A biological, chemical, or physical agent
that is reasonably likely to cause harm under some circumstances.</p>
<p><strong>Pollution</strong> The presence in the environment of a
substance or condition that causes harm.</p>
<p><strong>Risk Assessment</strong> The process of evaluating the
potential risks associated with a hazard.</p>
<p><strong>Sanitation</strong> The provision of facilities and services
for the safe disposal of human waste and the maintenance of hygienic
conditions.</p>
<p><strong>Waste Management</strong> The collection, transport,
processing, recycling, or disposal of waste materials.</p>
<p><strong>Water Quality</strong> The physical, chemical, biological,
and radiological characteristics of water.</p>
<hr />
<h1 id="quick-reference-tables-1">Quick Reference Tables</h1>
<h2 id="key-health-statistics-of-india-nfhs-5">Key Health Statistics of
India (NFHS-5)</h2>
<h3 id="demographic-indicators-1">Demographic Indicators</h3>
<table>
<colgroup>
<col style="width: 34%" />
<col style="width: 21%" />
<col style="width: 25%" />
<col style="width: 18%" />
</colgroup>
<thead>
<tr>
<th>Indicator</th>
<th>Value</th>
<th>Source</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population</td>
<td>1,210.9 million</td>
<td>Census 2011</td>
<td>2021 (Projected)</td>
</tr>
<tr>
<td>Birth Rate</td>
<td>19.5 per 1,000</td>
<td>SRS 2020</td>
<td>2020</td>
</tr>
<tr>
<td>Death Rate</td>
<td>6.0 per 1,000</td>
<td>SRS 2020</td>
<td>2020</td>
</tr>
<tr>
<td>Total Fertility Rate</td>
<td>2.0 children per woman</td>
<td>NFHS-5</td>
<td>2019-21</td>
</tr>
<tr>
<td>Infant Mortality Rate</td>
<td>28 per 1,000 live births</td>
<td>SRS 2020</td>
<td>2020</td>
</tr>
<tr>
<td>Maternal Mortality Ratio</td>
<td>97 per 100,000 live births</td>
<td>SRS 2017-19</td>
<td>2019</td>
</tr>
<tr>
<td>Under-5 Mortality Rate</td>
<td>32 per 1,000 live births</td>
<td>NFHS-5</td>
<td>2019-21</td>
</tr>
<tr>
<td>Life Expectancy</td>
<td>70.2 years</td>
<td>SRS 2018-20</td>
<td>2020</td>
</tr>
<tr>
<td>Sex Ratio (M:F)</td>
<td>943:1000</td>
<td>Census 2011</td>
<td>2011</td>
</tr>
<tr>
<td>Literacy Rate</td>
<td>74.4%</td>
<td>Census 2011</td>
<td>2011</td>
</tr>
</tbody>
</table>
<h3 id="health-outcome-indicators">Health Outcome Indicators</h3>
<table>
<thead>
<tr>
<th>Condition</th>
<th>Prevalence</th>
<th>Burden Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>10.3%</td>
<td>2nd highest globally</td>
</tr>
<tr>
<td>Hypertension</td>
<td>26.5%</td>
<td>Growing concern</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>45.3% per 100,000</td>
<td>Leading cause of death</td>
</tr>
<tr>
<td>Cancer</td>
<td>111 per 100,000</td>
<td>7th highest globally</td>
</tr>
<tr>
<td>Mental Health Disorders</td>
<td>10.6%</td>
<td>Underestimated</td>
</tr>
<tr>
<td>Respiratory Diseases</td>
<td>39.5%</td>
<td>Air pollution impact</td>
</tr>
<tr>
<td>Malnutrition</td>
<td>35.5% children under 5</td>
<td>Stunting prevalent</td>
</tr>
</tbody>
</table>
<h2 id="maternal-and-child-health-indicators">Maternal and Child Health
Indicators</h2>
<h3 id="maternal-health-nfhs-5">Maternal Health (NFHS-5)</h3>
<table>
<thead>
<tr>
<th>Indicator</th>
<th>Rural</th>
<th>Urban</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antenatal Care (4+ visits)</td>
<td>65.5%</td>
<td>86.8%</td>
<td>71.6%</td>
</tr>
<tr>
<td>Institutional Delivery</td>
<td>78.0%</td>
<td>96.8%</td>
<td>83.7%</td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>81.8%</td>
<td>97.8%</td>
<td>85.9%</td>
</tr>
<tr>
<td>Postnatal Care (within 2 days)</td>
<td>68.0%</td>
<td>83.0%</td>
<td>72.2%</td>
</tr>
<tr>
<td>Full Antenatal Care</td>
<td>36.8%</td>
<td>55.4%</td>
<td>42.0%</td>
</tr>
<tr>
<td>C-section Delivery</td>
<td>13.4%</td>
<td>40.1%</td>
<td>21.0%</td>
</tr>
</tbody>
</table>
<h3 id="child-health-nfhs-5">Child Health (NFHS-5)</h3>
<table>
<thead>
<tr>
<th>Indicator</th>
<th>Value</th>
<th>WHO Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Immunization (12-23 months)</td>
<td>76.4%</td>
<td>90%</td>
</tr>
<tr>
<td>Birth Weight &lt;2.5 kg</td>
<td>18.7%</td>
<td>&lt;10%</td>
</tr>
<tr>
<td>Stunting (under 5 years)</td>
<td>35.5%</td>
<td>&lt;20%</td>
</tr>
<tr>
<td>Wasting (under 5 years)</td>
<td>19.3%</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Underweight (under 5 years)</td>
<td>32.1%</td>
<td>&lt;15%</td>
</tr>
<tr>
<td>Exclusive Breastfeeding (0-6 months)</td>
<td>63.7%</td>
<td>&gt;70%</td>
</tr>
<tr>
<td>Minimum Dietary Diversity</td>
<td>21.0%</td>
<td>&gt;50%</td>
</tr>
</tbody>
</table>
<h2 id="disease-burden-statistics">Disease Burden Statistics</h2>
<h3 id="leading-causes-of-death-2021">Leading Causes of Death
(2021)</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Cause</th>
<th>Deaths (millions)</th>
<th>% of Total Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cardiovascular Diseases</td>
<td>6.2</td>
<td>32%</td>
</tr>
<tr>
<td>2</td>
<td>Respiratory Diseases</td>
<td>3.5</td>
<td>18%</td>
</tr>
<tr>
<td>3</td>
<td>Cancer</td>
<td>2.8</td>
<td>14%</td>
</tr>
<tr>
<td>4</td>
<td>Diabetes</td>
<td>1.6</td>
<td>8%</td>
</tr>
<tr>
<td>5</td>
<td>Digestive Diseases</td>
<td>1.2</td>
<td>6%</td>
</tr>
<tr>
<td>6</td>
<td>Tuberculosis</td>
<td>0.8</td>
<td>4%</td>
</tr>
<tr>
<td>7</td>
<td>Suicide</td>
<td>0.7</td>
<td>3.5%</td>
</tr>
<tr>
<td>8</td>
<td>Road Traffic Injuries</td>
<td>0.6</td>
<td>3%</td>
</tr>
<tr>
<td>9</td>
<td>Maternal Conditions</td>
<td>0.5</td>
<td>2.5%</td>
</tr>
<tr>
<td>10</td>
<td>Malaria</td>
<td>0.3</td>
<td>1.5%</td>
</tr>
</tbody>
</table>
<h3 id="communicable-disease-burden">Communicable Disease Burden</h3>
<table>
<thead>
<tr>
<th>Disease</th>
<th>Annual Cases</th>
<th>Case Fatality Rate</th>
<th>Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuberculosis</td>
<td>2.64 million</td>
<td>4.5%</td>
<td>Declining</td>
</tr>
<tr>
<td>Malaria</td>
<td>4.9 million</td>
<td>0.1%</td>
<td>Declining</td>
</tr>
<tr>
<td>Dengue</td>
<td>1.1 million</td>
<td>1.5%</td>
<td>Increasing</td>
</tr>
<tr>
<td>Chikungunya</td>
<td>2.4 million</td>
<td>&lt;0.1%</td>
<td>Increasing</td>
</tr>
<tr>
<td>Japanese Encephalitis</td>
<td>4,000</td>
<td>20%</td>
<td>Declining</td>
</tr>
<tr>
<td>Acute Diarrheal Disease</td>
<td>25 million</td>
<td>0.2%</td>
<td>Stable</td>
</tr>
<tr>
<td>Acute Respiratory Infection</td>
<td>78 million</td>
<td>0.3%</td>
<td>Stable</td>
</tr>
<tr>
<td>Viral Hepatitis</td>
<td>1.5 million</td>
<td>1.8%</td>
<td>Stable</td>
</tr>
</tbody>
</table>
<h2 id="health-program-coverage-data">Health Program Coverage Data</h2>
<h3 id="national-health-programs-performance-2022-23">National Health
Programs Performance (2022-23)</h3>
<table>
<thead>
<tr>
<th>Program</th>
<th>Target Population</th>
<th>Coverage Achieved</th>
<th>Key Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRHM</td>
<td>1.3 billion</td>
<td>85%</td>
<td>Improved PHC infrastructure</td>
</tr>
<tr>
<td>NTEP</td>
<td>2.6 million</td>
<td>82%</td>
<td>TB case detection improved</td>
</tr>
<tr>
<td>NVBDCP</td>
<td>1.1 billion</td>
<td>78%</td>
<td>Malaria incidence reduced 60%</td>
</tr>
<tr>
<td>NACP</td>
<td>2.4 million</td>
<td>71%</td>
<td>Viral suppression 85%</td>
</tr>
<tr>
<td>NCD Program</td>
<td>650 million</td>
<td>45%</td>
<td>Early detection improved</td>
</tr>
<tr>
<td>UHC Initiative</td>
<td>1.3 billion</td>
<td>52%</td>
<td>Financial protection expanded</td>
</tr>
</tbody>
</table>
<h3 id="health-infrastructure-2">Health Infrastructure</h3>
<table>
<thead>
<tr>
<th>Type</th>
<th>Current</th>
<th>Requirement</th>
<th>Gap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sub Centers</td>
<td>160,000</td>
<td>180,000</td>
<td>20,000</td>
</tr>
<tr>
<td>Primary Health Centers</td>
<td>25,000</td>
<td>35,000</td>
<td>10,000</td>
</tr>
<tr>
<td>Community Health Centers</td>
<td>5,000</td>
<td>6,000</td>
<td>1,000</td>
</tr>
<tr>
<td>District Hospitals</td>
<td>1,200</td>
<td>1,500</td>
<td>300</td>
</tr>
<tr>
<td>Medical Colleges</td>
<td>595</td>
<td>750</td>
<td>155</td>
</tr>
</tbody>
</table>
<h2 id="global-health-comparisons-2">Global Health Comparisons</h2>
<h3 id="india-vs-global-averages-2022">India vs Global Averages
(2022)</h3>
<table>
<thead>
<tr>
<th>Indicator</th>
<th>India</th>
<th>Global Average</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Life Expectancy</td>
<td>70.2 years</td>
<td>73.3 years</td>
<td>125/195</td>
</tr>
<tr>
<td>Infant Mortality</td>
<td>28 per 1,000</td>
<td>29 per 1,000</td>
<td>132/195</td>
</tr>
<tr>
<td>Maternal Mortality</td>
<td>97 per 100,000</td>
<td>211 per 100,000</td>
<td>114/185</td>
</tr>
<tr>
<td>Under-5 Mortality</td>
<td>32 per 1,000</td>
<td>38 per 1,000</td>
<td>127/195</td>
</tr>
<tr>
<td>Total Health Expenditure</td>
<td>3.0% GDP</td>
<td>9.9% GDP</td>
<td>172/183</td>
</tr>
<tr>
<td>Per Capita Health Expenditure</td>
<td>$63</td>
<td>$1,064</td>
<td>174/183</td>
</tr>
<tr>
<td>Physicians per 1,000</td>
<td>0.86</td>
<td>1.55</td>
<td>147/184</td>
</tr>
<tr>
<td>Hospital Beds per 1,000</td>
<td>0.53</td>
<td>2.95</td>
<td>162/186</td>
</tr>
<tr>
<td>Vaccination Coverage (DTP3)</td>
<td>85%</td>
<td>86%</td>
<td>109/195</td>
</tr>
</tbody>
</table>
<h3 id="comparison-with-brics-countries-2022">Comparison with BRICS
Countries (2022)</h3>
<table>
<thead>
<tr>
<th>Country</th>
<th>Life Expectancy</th>
<th>IMR</th>
<th>MMR</th>
<th>Health Expenditure (% GDP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil</td>
<td>75.9 years</td>
<td>13</td>
<td>60</td>
<td>9.2%</td>
</tr>
<tr>
<td>Russia</td>
<td>72.6 years</td>
<td>5</td>
<td>17</td>
<td>5.3%</td>
</tr>
<tr>
<td>India</td>
<td>70.2 years</td>
<td>28</td>
<td>97</td>
<td>3.0%</td>
</tr>
<tr>
<td>China</td>
<td>78.0 years</td>
<td>7</td>
<td>29</td>
<td>5.2%</td>
</tr>
<tr>
<td>South Africa</td>
<td>64.1 years</td>
<td>32</td>
<td>119</td>
<td>8.3%</td>
</tr>
</tbody>
</table>
<h3 id="health-system-performance-index">Health System Performance
Index</h3>
<table>
<thead>
<tr>
<th>Country</th>
<th>Overall Score</th>
<th>Access</th>
<th>Quality</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thailand</td>
<td>75.3</td>
<td>80.2</td>
<td>67.4</td>
<td>78.2</td>
</tr>
<tr>
<td>China</td>
<td>72.6</td>
<td>76.3</td>
<td>66.1</td>
<td>75.4</td>
</tr>
<tr>
<td>Brazil</td>
<td>69.8</td>
<td>71.2</td>
<td>65.3</td>
<td>72.9</td>
</tr>
<tr>
<td>India</td>
<td>48.4</td>
<td>52.1</td>
<td>41.3</td>
<td>51.8</td>
</tr>
<tr>
<td>South Africa</td>
<td>45.1</td>
<td>48.7</td>
<td>39.6</td>
<td>46.9</td>
</tr>
</tbody>
</table>
<hr />
<h1 id="index-preparation">Index Preparation</h1>
<h2 id="alphabetical-index-of-important-terms">Alphabetical Index of
Important Terms</h2>
<h3 id="a">A</h3>
<ul>
<li><strong>Attack Rate</strong>: H.1, D.4</li>
<li><strong>Attributable Risk</strong>: D.4, H.1</li>
<li><strong>Anthropometry</strong>: C.1-C.3, Appendix C</li>
<li><strong>Antenatal Care</strong>: F.2, Maternal Health Table</li>
<li><strong>Antimicrobial Resistance</strong>: Recent Research, E.1</li>
<li><strong>Apparent Prevalence</strong>: E.1</li>
<li><strong>AQI</strong>: H.5</li>
</ul>
<h3 id="b">B</h3>
<ul>
<li><strong>BMI Categories</strong>: A.3.1, C.3.1</li>
<li><strong>Bias</strong>: D.2, H.2</li>
<li><strong>Birth Rate</strong>: Demography Section, Quick
Reference</li>
<li><strong>Burden of Disease</strong>: H.3</li>
<li><strong>Bootstrap Method</strong>: Advanced Statistics</li>
</ul>
<h3 id="c">C</h3>
<ul>
<li><strong>CFR (Case Fatality Rate)</strong>: D.4, H.1</li>
<li><strong>Chi-square Test</strong>: D.2.2, D.4</li>
<li><strong>Chronic Disease</strong>: F.2, Disease Burden</li>
<li><strong>Confidence Interval</strong>: D.2, H.2</li>
<li><strong>Community Health</strong>: H.3</li>
<li><strong>Confounding</strong>: D.2, H.2</li>
<li><strong>Correlation</strong>: D.3, H.2</li>
<li><strong>Crude Birth Rate</strong>: Demography Examples, Appendix
D</li>
</ul>
<h3 id="d">D</h3>
<ul>
<li><strong>Death Rate</strong>: Demography Section, Quick
Reference</li>
<li><strong>Demographic Transition</strong>: Demography Section</li>
<li><strong>Descriptive Statistics</strong>: D.1, Appendix D</li>
<li><strong>Disease Burden</strong>: Disease Burden Statistics</li>
<li><strong>Disaster Management</strong>: Appendix G</li>
<li><strong>Drug Resistance</strong>: E.1, Tuberculosis Treatment</li>
</ul>
<h3 id="e">E</h3>
<ul>
<li><strong>Endemic</strong>: H.1</li>
<li><strong>Epidemic</strong>: H.1</li>
<li><strong>Epidemiological Transition</strong>: Demography Section</li>
<li><strong>Epidemiology</strong>: H.3</li>
<li><strong>Emergency Contacts</strong>: Appendix G</li>
<li><strong>Evidence-Based Medicine</strong>: Section B References</li>
</ul>
<h3 id="f">F</h3>
<ul>
<li><strong>Fertility Rate</strong>: Demography Section, Quick
Reference</li>
<li><strong>Fisher‚Äôs Exact Test</strong>: D.2.2</li>
<li><strong>Focus Groups</strong>: Research Methodology</li>
</ul>
<h3 id="g">G</h3>
<ul>
<li><strong>Global Health</strong>: References, Quick Reference
Tables</li>
<li><strong>Growth Standards</strong>: Appendix C, WHO Growth
References</li>
<li><strong>Growth Monitoring</strong>: Appendix C</li>
</ul>
<h3 id="h">H</h3>
<ul>
<li><strong>Health Indicators</strong>: Appendix F, Quick Reference</li>
<li><strong>Health Transition</strong>: Demography Section</li>
<li><strong>Health Systems</strong>: Management Section, References</li>
<li><strong>Helplines</strong>: Appendix G</li>
<li><strong>Hypothesis Testing</strong>: D.2, Appendix D</li>
</ul>
<h3 id="i">I</h3>
<ul>
<li><strong>IMR</strong>: Appendix F, Quick Reference Tables</li>
<li><strong>Incidence</strong>: H.1, D.4</li>
<li><strong>Incidence Rate</strong>: H.3</li>
<li><strong>Incubation Period</strong>: H.4</li>
<li><strong>Immunization Schedule</strong>: Appendix B</li>
<li><strong>Index Construction</strong>: This Index Section</li>
</ul>
<h3 id="l">L</h3>
<ul>
<li><strong>Life Expectancy</strong>: Demography Section, Quick
Reference</li>
<li><strong>Likelihood Ratio</strong>: D.4</li>
<li><strong>Longitudinal Study</strong>: Research Methodology</li>
</ul>
<h3 id="m">M</h3>
<ul>
<li><strong>Malnutrition</strong>: Child Health, Disease Burden</li>
<li><strong>Maternal Health</strong>: Appendix F, Maternal Health
Table</li>
<li><strong>MDGs</strong>: Appendix F</li>
<li><strong>Mortality Rate</strong>: H.1, Demography Section</li>
<li><strong>MMR</strong>: Appendix F, Quick Reference Tables</li>
</ul>
<h3 id="n">N</h3>
<ul>
<li><strong>NFHS</strong>: References, Quick Reference Tables</li>
<li><strong>NCDs</strong>: Disease Burden, Appendix F</li>
<li><strong>Normal Values</strong>: Appendix A</li>
<li><strong>Null Hypothesis</strong>: D.2, H.2</li>
</ul>
<h3 id="o">O</h3>
<ul>
<li><strong>Odds Ratio</strong>: D.4, H.1</li>
<li><strong>Outbreak</strong>: H.1</li>
<li><strong>Outcomes</strong>: Health System Performance</li>
</ul>
<h3 id="p">P</h3>
<ul>
<li><strong>Pandemic</strong>: H.1</li>
<li><strong>Population Health</strong>: H.3</li>
<li><strong>Prevalence</strong>: H.1</li>
<li><strong>Primary Prevention</strong>: H.3</li>
<li><strong>Probability</strong>: D.2, H.2</li>
<li><strong>Public Health</strong>: H.3</li>
</ul>
<h3 id="q">Q</h3>
<ul>
<li><strong>Quality Indicators</strong>: Health System Performance</li>
<li><strong>Quartiles</strong>: Biostatistics, Appendix D</li>
<li><strong>Questionnaire Design</strong>: Research Methodology</li>
</ul>
<h3 id="r">R</h3>
<ul>
<li><strong>Randomized Controlled Trial</strong>: Research
Methodology</li>
<li><strong>Relative Risk</strong>: D.4, H.1</li>
<li><strong>Research Methodology</strong>: Part IX References</li>
<li><strong>Risk Assessment</strong>: H.4</li>
<li><strong>Risk Factor</strong>: H.1</li>
</ul>
<h3 id="s">S</h3>
<ul>
<li><strong>Sample Size</strong>: Research Methodology, Appendix D</li>
<li><strong>SDG</strong>: Appendix F</li>
<li><strong>Secondary Prevention</strong>: H.3</li>
<li><strong>Sensitivity</strong>: D.4</li>
<li><strong>Social Work</strong>: Part IX Section C</li>
<li><strong>Specificity</strong>: D.4</li>
<li><strong>Standard Deviation</strong>: D.1, Appendix D</li>
<li><strong>Statistical Significance</strong>: H.2</li>
<li><strong>Surveillance</strong>: H.3</li>
</ul>
<h3 id="t">T</h3>
<ul>
<li><strong>Tertiary Prevention</strong>: H.3</li>
<li><strong>t-test</strong>: D.2, Appendix D</li>
<li><strong>TB Treatment</strong>: E.3</li>
<li><strong>Tuberculosis</strong>: Disease Burden, Appendix E</li>
<li><strong>Travel Medicine</strong>: Appendix B</li>
</ul>
<h3 id="u">U</h3>
<ul>
<li><strong>Under-5 Mortality</strong>: Appendix F, Child Health</li>
<li><strong>Universal Health Coverage</strong>: SDG, Appendix F</li>
</ul>
<h3 id="v">V</h3>
<ul>
<li><strong>Vaccination</strong>: Appendix B, Child Health</li>
<li><strong>Vector</strong>: H.4</li>
<li><strong>Virulence</strong>: H.4</li>
<li><strong>Vital Statistics</strong>: Demography Section</li>
</ul>
<h3 id="w">W</h3>
<ul>
<li><strong>WHO Guidelines</strong>: References, Appendices</li>
<li><strong>Wasting</strong>: Appendix C, Child Health</li>
</ul>
<h2 id="index-of-diseases-and-conditions">Index of Diseases and
Conditions</h2>
<h3 id="communicable-diseases-1">Communicable Diseases</h3>
<ul>
<li><strong>Tuberculosis</strong>: D.4, Disease Burden, E.3</li>
<li><strong>Malaria</strong>: Disease Burden, E.2</li>
<li><strong>Dengue</strong>: Disease Burden, E.2</li>
<li><strong>HIV/AIDS</strong>: Disease Burden, E.4</li>
<li><strong>COVID-19</strong>: G.1, Emergency Contacts</li>
<li><strong>Acute Respiratory Infections</strong>: Disease Burden</li>
<li><strong>Diarrheal Diseases</strong>: Disease Burden, E.1</li>
<li><strong>Viral Hepatitis</strong>: Disease Burden</li>
<li><strong>Japanese Encephalitis</strong>: Disease Burden, Appendix
B</li>
<li><strong>Chikungunya</strong>: Disease Burden</li>
<li><strong>Filariasis</strong>: Disease Burden</li>
<li><strong>Leprosy</strong>: Disease Burden</li>
</ul>
<h3 id="non-communicable-diseases-1">Non-Communicable Diseases</h3>
<ul>
<li><strong>Diabetes Mellitus</strong>: Disease Burden, E.5</li>
<li><strong>Hypertension</strong>: Disease Burden, E.5</li>
<li><strong>Cardiovascular Diseases</strong>: Disease Burden, Quick
Reference</li>
<li><strong>Cancer</strong>: Disease Burden, Quick Reference</li>
<li><strong>Stroke</strong>: Disease Burden</li>
<li><strong>COPD</strong>: Disease Burden</li>
<li><strong>Mental Health Disorders</strong>: Disease Burden</li>
<li><strong>Obesity</strong>: Disease Burden, C.3</li>
<li><strong>Kidney Disease</strong>: Disease Burden</li>
</ul>
<h3 id="maternal-and-child-health-conditions">Maternal and Child Health
Conditions</h3>
<ul>
<li><strong>Maternal Mortality</strong>: Appendix F, Quick
Reference</li>
<li><strong>Neonatal Mortality</strong>: Child Health</li>
<li><strong>Low Birth Weight</strong>: Child Health</li>
<li><strong>Stunting</strong>: Child Health, C.1</li>
<li><strong>Wasting</strong>: Child Health, C.1</li>
<li><strong>Undernutrition</strong>: Child Health, Disease Burden</li>
<li><strong>Anemia</strong>: Child Health, Maternal Health</li>
</ul>
<h3 id="other-health-conditions">Other Health Conditions</h3>
<ul>
<li><strong>Road Traffic Injuries</strong>: Disease Burden, Appendix
F</li>
<li><strong>Suicide</strong>: Disease Burden, G.5</li>
<li><strong>Poisoning</strong>: Emergency Management</li>
<li><strong>Burns</strong>: Emergency Management</li>
<li><strong>Mental Health Crisis</strong>: G.5, Mental Health
Support</li>
</ul>
<h2 id="index-of-programs-and-policies">Index of Programs and
Policies</h2>
<h3 id="national-health-programs">National Health Programs</h3>
<ul>
<li><strong>National Vector Borne Disease Control Program</strong>: H.1,
References</li>
<li><strong>Revised National Tuberculosis Control Program</strong>: H.1,
References</li>
<li><strong>National AIDS Control Program</strong>: H.1, References</li>
<li><strong>National Programme for Control of Blindness</strong>:
H.1</li>
<li><strong>Integrated Child Development Services</strong>: H.1</li>
<li><strong>Pradhan Mantri Swasthya Suraksha Yojana</strong>: H.1</li>
<li><strong>Pradhan Mantri Jan Arogya Yojana</strong>: References,
G.2</li>
<li><strong>National Health Mission</strong>: H.1, Program Coverage</li>
<li><strong>National Urban Health Mission</strong>: References</li>
<li><strong>National Rural Health Mission</strong>: References</li>
</ul>
<h3 id="international-programs">International Programs</h3>
<ul>
<li><strong>Sustainable Development Goals</strong>: Appendix F,
References</li>
<li><strong>Millennium Development Goals</strong>: Appendix F</li>
<li><strong>Global Fund</strong>: References</li>
<li><strong>GAVI Alliance</strong>: References</li>
<li><strong>COVAX</strong>: References</li>
</ul>
<h3 id="health-insurance-schemes">Health Insurance Schemes</h3>
<ul>
<li><strong>Employees‚Äô State Insurance</strong>: References, G.2</li>
<li><strong>Central Government Health Scheme</strong>: References,
G.2</li>
<li><strong>Rashtriya Swasthya Bima Yojana</strong>: References</li>
<li><strong>State-specific Insurance Schemes</strong>: References</li>
</ul>
<h3 id="government-policies">Government Policies</h3>
<ul>
<li><strong>National Health Policy 2017</strong>: References, Appendix
F</li>
<li><strong>National Population Policy</strong>: References</li>
<li><strong>National Health Mission</strong>: References</li>
<li><strong>Digital Health Mission</strong>: References</li>
</ul>
<h2 id="index-of-statistical-measures">Index of Statistical
Measures</h2>
<h3 id="descriptive-statistics-1">Descriptive Statistics</h3>
<ul>
<li><strong>Mean</strong>: D.1.1, Appendix D</li>
<li><strong>Median</strong>: D.1.1, Appendix D</li>
<li><strong>Mode</strong>: D.1.1, Appendix D</li>
<li><strong>Standard Deviation</strong>: D.1.2, Appendix D</li>
<li><strong>Variance</strong>: D.1.2, Appendix D</li>
<li><strong>Range</strong>: D.1.2, Appendix D</li>
<li><strong>Coefficient of Variation</strong>: D.1.2</li>
<li><strong>Quartiles</strong>: Biostatistics, Appendix D</li>
<li><strong>Percentiles</strong>: Appendix D</li>
<li><strong>Z-score</strong>: Appendix D</li>
</ul>
<h3 id="inferential-statistics-1">Inferential Statistics</h3>
<ul>
<li><strong>Confidence Intervals</strong>: D.2.1, Appendix D</li>
<li><strong>Hypothesis Testing</strong>: D.2.2, Appendix D</li>
<li><strong>P-value</strong>: H.2, Appendix D</li>
<li><strong>Type I Error</strong>: H.2, Appendix D</li>
<li><strong>Type II Error</strong>: H.2, Appendix D</li>
<li><strong>Power</strong>: Appendix D</li>
</ul>
<h3 id="hypothesis-tests">Hypothesis Tests</h3>
<ul>
<li><strong>t-test</strong>: D.2, Appendix D</li>
<li><strong>Chi-square Test</strong>: D.2.2, Appendix D</li>
<li><strong>Fisher‚Äôs Exact Test</strong>: D.2.2</li>
<li><strong>Mann-Whitney U Test</strong>: Appendix D</li>
<li><strong>Kruskal-Wallis Test</strong>: Appendix D</li>
<li><strong>ANOVA</strong>: D.3, Appendix D</li>
</ul>
<h3 id="correlation-and-regression-1">Correlation and Regression</h3>
<ul>
<li><strong>Pearson Correlation</strong>: D.3.1, Appendix D</li>
<li><strong>Spearman Correlation</strong>: D.3.1</li>
<li><strong>Linear Regression</strong>: D.3.2, Appendix D</li>
<li><strong>Multiple Regression</strong>: D.3.2</li>
</ul>
<h3 id="epidemiological-measures">Epidemiological Measures</h3>
<ul>
<li><strong>Relative Risk</strong>: D.4, Appendix D</li>
<li><strong>Odds Ratio</strong>: D.4, Appendix D</li>
<li><strong>Attributable Risk</strong>: D.4, Appendix D</li>
<li><strong>Population Attributable Risk</strong>: D.4</li>
<li><strong>Sensitivity</strong>: D.4, Appendix D</li>
<li><strong>Specificity</strong>: D.4, Appendix D</li>
<li><strong>Positive Predictive Value</strong>: D.4</li>
<li><strong>Negative Predictive Value</strong>: D.4</li>
<li><strong>Likelihood Ratios</strong>: D.4</li>
<li><strong>Number Needed to Harm</strong>: D.4</li>
</ul>
<hr />
<p><em>This Manual Back Matter and Bibliography provides comprehensive
reference material for the Community Medicine Quick Revision Manual,
supporting all aspects of preventive and social medicine education and
practice.</em></p>
<p><strong>Document Information:</strong> - Version: 1.0 - Date:
November 2024 - Authors: Community Medicine Education Committee -
Purpose: Quick Reference Guide for MBBS Students and Practitioners -
Coverage: Complete Bibliography, Appendices, and Reference Tables</p>
</body>
</html>
